bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags sequence	text stringlengths 5 72.4k	tokens sequence	types sequence
Prior is a Temporal, chemotherapy or radiotherapy is a Scope, within 2 weeks prior is a Temporal, entering the study is a Reference_point, not is a Negation, recovered is a Condition, adverse events is a Condition, agents is a Drug, more than 2 weeks earlier is a Temporal, Systemic steroids is a Drug, not is a Negation, stabilized is a Qualifier, ≥ 5 days is a Temporal, ≤10 mg / day is a Multiplier, prednisone is a Drug, prior to is a Temporal, start of the study drugs is a Reference_point, other investigational agents is a Drug, History is a Observation, allergic reactions is a Condition, TGR-1202 or carfilzomib is a Scope, Uncontrolled is a Qualifier, inter - current illness is a Condition, Pregnant is a Condition, women is a Person, Nursing is a Condition, women is a Person, Current is a Temporal, malignancy is a Condition, history of a prior is a Observation, malignancy is a Condition, Hepatitis A is a Condition, Hepatitis B is a Condition, Hepatitis C is a Condition	NCT02867618_exc_task1	Sentence: 1. Prior Therapy Exposure to chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier. Systemic steroids that have not been stabilized (≥ 5 days) to the equivalent of ≤10 mg/day prednisone prior to the start of the study drugs. No other investigational agents are allowed. 2. History of allergic reactions to TGR-1202 or carfilzomib 3. Uncontrolled inter-current illness 4. Pregnant women 5. Nursing women 6. Current malignancy or history of a prior malignancy 7. Patient known to be Human Immunodeficiency Virus (HIV)-positive 8. Active Hepatitis A, Hepatitis B, or Hepatitis C infection Instructions: please typing these entity words according to sentence: Prior, chemotherapy or radiotherapy, within 2 weeks prior, entering the study, not, recovered, adverse events, agents, more than 2 weeks earlier, Systemic steroids, not, stabilized, ≥ 5 days, ≤10 mg / day, prednisone, prior to, start of the study drugs, other investigational agents, History, allergic reactions, TGR-1202 or carfilzomib, Uncontrolled, inter - current illness, Pregnant, women, Nursing, women, Current, malignancy, history of a prior, malignancy, Hepatitis A, Hepatitis B, Hepatitis C Options: Temporal, Condition, Qualifier, Person, Observation, Multiplier, Reference_point, Negation, Scope, Drug	[ "O", "O", "B-Temporal", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Reference_point", "I-Reference_point", "I-Reference_point", "O", "O", "O", "O", "B-Negation", "B-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Drug", "I-Drug", "O", "O", "B-Negation", "O", "B-Qualifier", "O", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "B-Drug", "B-Temporal", "I-Temporal", "O", "B-Reference_point", "I-Reference_point", "I-Reference_point", "I-Reference_point", "I-Reference_point", "O", "O", "B-Drug", "I-Drug", "I-Drug", "O", "O", "O", "O", "O", "O", "B-Observation", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Condition", "B-Person", "O", "O", "O", "B-Condition", "B-Person", "O", "O", "O", "B-Temporal", "B-Condition", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "B-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Condition", "I-Condition", "O", "O" ]	1. Prior Therapy Exposure to chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier. Systemic steroids that have not been stabilized (≥ 5 days) to the equivalent of ≤10 mg/day prednisone prior to the start of the study drugs. No other investigational agents are allowed. 2. History of allergic reactions to TGR-1202 or carfilzomib 3. Uncontrolled inter-current illness 4. Pregnant women 5. Nursing women 6. Current malignancy or history of a prior malignancy 7. Patient known to be Human Immunodeficiency Virus (HIV)-positive 8. Active Hepatitis A, Hepatitis B, or Hepatitis C infection	[ "1", ".", "Prior", "Therapy", "Exposure", "to", "chemotherapy", "or", "radiotherapy", "within", "2", "weeks", "prior", "to", "entering", "the", "study", "or", "those", "who", "have", "not", "recovered", "from", "adverse", "events", "due", "to", "agents", "administered", "more", "than", "2", "weeks", "earlier", ".", "Systemic", "steroids", "that", "have", "not", "been", "stabilized", "(", "≥", "5", "days", ")", "to", "the", "equivalent", "of", "≤10", "mg", "/", "day", "prednisone", "prior", "to", "the", "start", "of", "the", "study", "drugs", ".", "No", "other", "investigational", "agents", "are", "allowed", ".", "\n", "2", ".", "History", "of", "allergic", "reactions", "to", "TGR-1202", "or", "carfilzomib", "\n", "3", ".", "Uncontrolled", "inter", "-", "current", "illness", "\n", "4", ".", "Pregnant", "women", "\n", "5", ".", "Nursing", "women", "\n", "6", ".", "Current", "malignancy", "or", "history", "of", "a", "prior", "malignancy", "\n", "7", ".", "Patient", "known", "to", "be", "Human", "Immunodeficiency", "Virus", "(", "HIV)-positive", "\n", "8", ".", "Active", "Hepatitis", "A", ",", "Hepatitis", "B", ",", "or", "Hepatitis", "C", "infection", " \n \n" ]	[ "Measurement", "Scope", "Drug", "Temporal", "Reference_point", "Condition", "Observation", "Procedure", "Qualifier", "Multiplier", "Value", "Person", "Negation" ]
Prior, chemotherapy or radiotherapy, within 2 weeks prior, entering the study, not, recovered, adverse events, agents, more than 2 weeks earlier, Systemic steroids, not, stabilized, ≥ 5 days, ≤10 mg / day, prednisone, prior to, start of the study drugs, other investigational agents, History, allergic reactions, TGR-1202 or carfilzomib, Uncontrolled, inter - current illness, Pregnant, women, Nursing, women, Current, malignancy, history of a prior, malignancy, Hepatitis A, Hepatitis B, Hepatitis C	NCT02867618_exc_task2	Sentence: 1. Prior Therapy Exposure to chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier. Systemic steroids that have not been stabilized (≥ 5 days) to the equivalent of ≤10 mg/day prednisone prior to the start of the study drugs. No other investigational agents are allowed. 2. History of allergic reactions to TGR-1202 or carfilzomib 3. Uncontrolled inter-current illness 4. Pregnant women 5. Nursing women 6. Current malignancy or history of a prior malignancy 7. Patient known to be Human Immunodeficiency Virus (HIV)-positive 8. Active Hepatitis A, Hepatitis B, or Hepatitis C infection Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Temporal", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Reference_point", "I-Reference_point", "I-Reference_point", "O", "O", "O", "O", "B-Negation", "B-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Drug", "I-Drug", "O", "O", "B-Negation", "O", "B-Qualifier", "O", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "B-Drug", "B-Temporal", "I-Temporal", "O", "B-Reference_point", "I-Reference_point", "I-Reference_point", "I-Reference_point", "I-Reference_point", "O", "O", "B-Drug", "I-Drug", "I-Drug", "O", "O", "O", "O", "O", "O", "B-Observation", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Condition", "B-Person", "O", "O", "O", "B-Condition", "B-Person", "O", "O", "O", "B-Temporal", "B-Condition", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "B-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Condition", "I-Condition", "O", "O" ]	1. Prior Therapy Exposure to chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier. Systemic steroids that have not been stabilized (≥ 5 days) to the equivalent of ≤10 mg/day prednisone prior to the start of the study drugs. No other investigational agents are allowed. 2. History of allergic reactions to TGR-1202 or carfilzomib 3. Uncontrolled inter-current illness 4. Pregnant women 5. Nursing women 6. Current malignancy or history of a prior malignancy 7. Patient known to be Human Immunodeficiency Virus (HIV)-positive 8. Active Hepatitis A, Hepatitis B, or Hepatitis C infection	[ "1", ".", "Prior", "Therapy", "Exposure", "to", "chemotherapy", "or", "radiotherapy", "within", "2", "weeks", "prior", "to", "entering", "the", "study", "or", "those", "who", "have", "not", "recovered", "from", "adverse", "events", "due", "to", "agents", "administered", "more", "than", "2", "weeks", "earlier", ".", "Systemic", "steroids", "that", "have", "not", "been", "stabilized", "(", "≥", "5", "days", ")", "to", "the", "equivalent", "of", "≤10", "mg", "/", "day", "prednisone", "prior", "to", "the", "start", "of", "the", "study", "drugs", ".", "No", "other", "investigational", "agents", "are", "allowed", ".", "\n", "2", ".", "History", "of", "allergic", "reactions", "to", "TGR-1202", "or", "carfilzomib", "\n", "3", ".", "Uncontrolled", "inter", "-", "current", "illness", "\n", "4", ".", "Pregnant", "women", "\n", "5", ".", "Nursing", "women", "\n", "6", ".", "Current", "malignancy", "or", "history", "of", "a", "prior", "malignancy", "\n", "7", ".", "Patient", "known", "to", "be", "Human", "Immunodeficiency", "Virus", "(", "HIV)-positive", "\n", "8", ".", "Active", "Hepatitis", "A", ",", "Hepatitis", "B", ",", "or", "Hepatitis", "C", "infection", " \n \n" ]	[ "Measurement", "Scope", "Drug", "Temporal", "Reference_point", "Condition", "Observation", "Procedure", "Qualifier", "Multiplier", "Value", "Person", "Negation" ]
patients is an umlsterm, hemodynamics is an umlsterm, rest is an umlsterm, exercise is an umlsterm, myocardial infarction is an umlsterm, left - heart is an umlsterm, catheterizations is an umlsterm, catheterization is an umlsterm, ventricular function is an umlsterm, patient is an umlsterm, PTCA is an umlsterm, surgery is an umlsterm, hemodynamics is an umlsterm, rest is an umlsterm, exercise is an umlsterm, exercise tolerance is an umlsterm, ventricular function is an umlsterm, hemodynamics is an umlsterm, patients is an umlsterm, pressures is an umlsterm, exercise is an umlsterm, control is an umlsterm, exercise tolerance is an umlsterm, Ventricular function is an umlsterm, Measurement is an umlsterm, hemodynamics is an umlsterm, rest is an umlsterm, exercise is an umlsterm, future is an umlsterm, patient is an umlsterm	ZfuerKardiologie.70860485.eng.abstr_task0	Sentence: In 123 consecutive patients pulmonary hemodynamics at rest and during exercise were measured 7-10 days after acute myocardial infarction and systemic thrombolysis . Right- and left-heart catheterizations were performed at the same session and repeated after 6 months . We investigated if right-heart catheterization could predict the number of stenotic or occluded coronaries , the angiographic ventricular function andor , most important , if the patient would profit from revascularization by PTCA or coronary surgery . Results : 1 ) Pulmonary hemodynamics at rest and during exercise did not correlate to the number of stenotic or occluded coronaries , but exercise tolerance did . 2 ) Correlation between ventricular function and pulmonary hemodynamics was weak . 3 ) Only patients with pathologically elevated pulmonary pressures at exercise showed profit from revascularization ( increase of ejection fraction > 5% at control ) . This profit was closely correlated to the angiographic extent of ventricular damage . Consequences from our results : Individual exercise tolerance can easily be measured non-invasively . Ventricular function can be measured non-invasively as well as by echocardiography . Measurement of pulmonary hemodynamics at rest and during exercise does not contribute to planning the future management of the postinfarction patient and does not replace coronarography when indicated by clinical or non-invasive parameters . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In 123 consecutive patients pulmonary hemodynamics at rest and during exercise were measured 7-10 days after acute myocardial infarction and systemic thrombolysis . Right- and left-heart catheterizations were performed at the same session and repeated after 6 months . We investigated if right-heart catheterization could predict the number of stenotic or occluded coronaries , the angiographic ventricular function andor , most important , if the patient would profit from revascularization by PTCA or coronary surgery . Results : 1 ) Pulmonary hemodynamics at rest and during exercise did not correlate to the number of stenotic or occluded coronaries , but exercise tolerance did . 2 ) Correlation between ventricular function and pulmonary hemodynamics was weak . 3 ) Only patients with pathologically elevated pulmonary pressures at exercise showed profit from revascularization ( increase of ejection fraction > 5% at control ) . This profit was closely correlated to the angiographic extent of ventricular damage . Consequences from our results : Individual exercise tolerance can easily be measured non-invasively . Ventricular function can be measured non-invasively as well as by echocardiography . Measurement of pulmonary hemodynamics at rest and during exercise does not contribute to planning the future management of the postinfarction patient and does not replace coronarography when indicated by clinical or non-invasive parameters .	[ "In", "123", "consecutive", "patients", "pulmonary", "hemodynamics", "at", "rest", "and", "during", "exercise", "were", "measured", "7", "-", "10", "days", "after", "acute", "myocardial", "infarction", "and", "systemic", "thrombolysis", ".", "Right-", "and", "left", "-", "heart", "catheterizations", "were", "performed", "at", "the", "same", "session", "and", "repeated", "after", "6", "months", ".", "We", "investigated", "if", "right", "-", "heart", "catheterization", "could", "predict", "the", "number", "of", "stenotic", "or", "occluded", "coronaries", ",", "the", "angiographic", "ventricular", "function", "andor", ",", "most", "important", ",", "if", "the", "patient", "would", "profit", "from", "revascularization", "by", "PTCA", "or", "coronary", "surgery", ".", "Results", ":", "1", ")", "Pulmonary", "hemodynamics", "at", "rest", "and", "during", "exercise", "did", "not", "correlate", "to", "the", "number", "of", "stenotic", "or", "occluded", "coronaries", ",", "but", "exercise", "tolerance", "did", ".", "2", ")", "Correlation", "between", "ventricular", "function", "and", "pulmonary", "hemodynamics", "was", "weak", ".", "3", ")", "Only", "patients", "with", "pathologically", "elevated", "pulmonary", "pressures", "at", "exercise", "showed", "profit", "from", "revascularization", "(", "increase", "of", "ejection", "fraction", ">", "5", "%", "at", "control", ")", ".", "This", "profit", "was", "closely", "correlated", "to", "the", "angiographic", "extent", "of", "ventricular", "damage", ".", "Consequences", "from", "our", "results", ":", "Individual", "exercise", "tolerance", "can", "easily", "be", "measured", "non", "-", "invasively", ".", "Ventricular", "function", "can", "be", "measured", "non", "-", "invasively", "as", "well", "as", "by", "echocardiography", ".", "Measurement", "of", "pulmonary", "hemodynamics", "at", "rest", "and", "during", "exercise", "does", "not", "contribute", "to", "planning", "the", "future", "management", "of", "the", "postinfarction", "patient", "and", "does", "not", "replace", "coronarography", "when", "indicated", "by", "clinical", "or", "non", "-", "invasive", "parameters", "." ]	[ "umlsterm" ]
patients is an umlsterm, hemodynamics is an umlsterm, rest is an umlsterm, exercise is an umlsterm, myocardial infarction is an umlsterm, left - heart is an umlsterm, catheterizations is an umlsterm, catheterization is an umlsterm, ventricular function is an umlsterm, patient is an umlsterm, PTCA is an umlsterm, surgery is an umlsterm, hemodynamics is an umlsterm, rest is an umlsterm, exercise is an umlsterm, exercise tolerance is an umlsterm, ventricular function is an umlsterm, hemodynamics is an umlsterm, patients is an umlsterm, pressures is an umlsterm, exercise is an umlsterm, control is an umlsterm, exercise tolerance is an umlsterm, Ventricular function is an umlsterm, Measurement is an umlsterm, hemodynamics is an umlsterm, rest is an umlsterm, exercise is an umlsterm, future is an umlsterm, patient is an umlsterm	ZfuerKardiologie.70860485.eng.abstr_task1	Sentence: In 123 consecutive patients pulmonary hemodynamics at rest and during exercise were measured 7-10 days after acute myocardial infarction and systemic thrombolysis . Right- and left-heart catheterizations were performed at the same session and repeated after 6 months . We investigated if right-heart catheterization could predict the number of stenotic or occluded coronaries , the angiographic ventricular function andor , most important , if the patient would profit from revascularization by PTCA or coronary surgery . Results : 1 ) Pulmonary hemodynamics at rest and during exercise did not correlate to the number of stenotic or occluded coronaries , but exercise tolerance did . 2 ) Correlation between ventricular function and pulmonary hemodynamics was weak . 3 ) Only patients with pathologically elevated pulmonary pressures at exercise showed profit from revascularization ( increase of ejection fraction > 5% at control ) . This profit was closely correlated to the angiographic extent of ventricular damage . Consequences from our results : Individual exercise tolerance can easily be measured non-invasively . Ventricular function can be measured non-invasively as well as by echocardiography . Measurement of pulmonary hemodynamics at rest and during exercise does not contribute to planning the future management of the postinfarction patient and does not replace coronarography when indicated by clinical or non-invasive parameters . Instructions: please typing these entity words according to sentence: patients, hemodynamics, rest, exercise, myocardial infarction, left - heart, catheterizations, catheterization, ventricular function, patient, PTCA, surgery, hemodynamics, rest, exercise, exercise tolerance, ventricular function, hemodynamics, patients, pressures, exercise, control, exercise tolerance, Ventricular function, Measurement, hemodynamics, rest, exercise, future, patient Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In 123 consecutive patients pulmonary hemodynamics at rest and during exercise were measured 7-10 days after acute myocardial infarction and systemic thrombolysis . Right- and left-heart catheterizations were performed at the same session and repeated after 6 months . We investigated if right-heart catheterization could predict the number of stenotic or occluded coronaries , the angiographic ventricular function andor , most important , if the patient would profit from revascularization by PTCA or coronary surgery . Results : 1 ) Pulmonary hemodynamics at rest and during exercise did not correlate to the number of stenotic or occluded coronaries , but exercise tolerance did . 2 ) Correlation between ventricular function and pulmonary hemodynamics was weak . 3 ) Only patients with pathologically elevated pulmonary pressures at exercise showed profit from revascularization ( increase of ejection fraction > 5% at control ) . This profit was closely correlated to the angiographic extent of ventricular damage . Consequences from our results : Individual exercise tolerance can easily be measured non-invasively . Ventricular function can be measured non-invasively as well as by echocardiography . Measurement of pulmonary hemodynamics at rest and during exercise does not contribute to planning the future management of the postinfarction patient and does not replace coronarography when indicated by clinical or non-invasive parameters .	[ "In", "123", "consecutive", "patients", "pulmonary", "hemodynamics", "at", "rest", "and", "during", "exercise", "were", "measured", "7", "-", "10", "days", "after", "acute", "myocardial", "infarction", "and", "systemic", "thrombolysis", ".", "Right-", "and", "left", "-", "heart", "catheterizations", "were", "performed", "at", "the", "same", "session", "and", "repeated", "after", "6", "months", ".", "We", "investigated", "if", "right", "-", "heart", "catheterization", "could", "predict", "the", "number", "of", "stenotic", "or", "occluded", "coronaries", ",", "the", "angiographic", "ventricular", "function", "andor", ",", "most", "important", ",", "if", "the", "patient", "would", "profit", "from", "revascularization", "by", "PTCA", "or", "coronary", "surgery", ".", "Results", ":", "1", ")", "Pulmonary", "hemodynamics", "at", "rest", "and", "during", "exercise", "did", "not", "correlate", "to", "the", "number", "of", "stenotic", "or", "occluded", "coronaries", ",", "but", "exercise", "tolerance", "did", ".", "2", ")", "Correlation", "between", "ventricular", "function", "and", "pulmonary", "hemodynamics", "was", "weak", ".", "3", ")", "Only", "patients", "with", "pathologically", "elevated", "pulmonary", "pressures", "at", "exercise", "showed", "profit", "from", "revascularization", "(", "increase", "of", "ejection", "fraction", ">", "5", "%", "at", "control", ")", ".", "This", "profit", "was", "closely", "correlated", "to", "the", "angiographic", "extent", "of", "ventricular", "damage", ".", "Consequences", "from", "our", "results", ":", "Individual", "exercise", "tolerance", "can", "easily", "be", "measured", "non", "-", "invasively", ".", "Ventricular", "function", "can", "be", "measured", "non", "-", "invasively", "as", "well", "as", "by", "echocardiography", ".", "Measurement", "of", "pulmonary", "hemodynamics", "at", "rest", "and", "during", "exercise", "does", "not", "contribute", "to", "planning", "the", "future", "management", "of", "the", "postinfarction", "patient", "and", "does", "not", "replace", "coronarography", "when", "indicated", "by", "clinical", "or", "non", "-", "invasive", "parameters", "." ]	[ "umlsterm" ]
patients, hemodynamics, rest, exercise, myocardial infarction, left - heart, catheterizations, catheterization, ventricular function, patient, PTCA, surgery, hemodynamics, rest, exercise, exercise tolerance, ventricular function, hemodynamics, patients, pressures, exercise, control, exercise tolerance, Ventricular function, Measurement, hemodynamics, rest, exercise, future, patient	ZfuerKardiologie.70860485.eng.abstr_task2	Sentence: In 123 consecutive patients pulmonary hemodynamics at rest and during exercise were measured 7-10 days after acute myocardial infarction and systemic thrombolysis . Right- and left-heart catheterizations were performed at the same session and repeated after 6 months . We investigated if right-heart catheterization could predict the number of stenotic or occluded coronaries , the angiographic ventricular function andor , most important , if the patient would profit from revascularization by PTCA or coronary surgery . Results : 1 ) Pulmonary hemodynamics at rest and during exercise did not correlate to the number of stenotic or occluded coronaries , but exercise tolerance did . 2 ) Correlation between ventricular function and pulmonary hemodynamics was weak . 3 ) Only patients with pathologically elevated pulmonary pressures at exercise showed profit from revascularization ( increase of ejection fraction > 5% at control ) . This profit was closely correlated to the angiographic extent of ventricular damage . Consequences from our results : Individual exercise tolerance can easily be measured non-invasively . Ventricular function can be measured non-invasively as well as by echocardiography . Measurement of pulmonary hemodynamics at rest and during exercise does not contribute to planning the future management of the postinfarction patient and does not replace coronarography when indicated by clinical or non-invasive parameters . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In 123 consecutive patients pulmonary hemodynamics at rest and during exercise were measured 7-10 days after acute myocardial infarction and systemic thrombolysis . Right- and left-heart catheterizations were performed at the same session and repeated after 6 months . We investigated if right-heart catheterization could predict the number of stenotic or occluded coronaries , the angiographic ventricular function andor , most important , if the patient would profit from revascularization by PTCA or coronary surgery . Results : 1 ) Pulmonary hemodynamics at rest and during exercise did not correlate to the number of stenotic or occluded coronaries , but exercise tolerance did . 2 ) Correlation between ventricular function and pulmonary hemodynamics was weak . 3 ) Only patients with pathologically elevated pulmonary pressures at exercise showed profit from revascularization ( increase of ejection fraction > 5% at control ) . This profit was closely correlated to the angiographic extent of ventricular damage . Consequences from our results : Individual exercise tolerance can easily be measured non-invasively . Ventricular function can be measured non-invasively as well as by echocardiography . Measurement of pulmonary hemodynamics at rest and during exercise does not contribute to planning the future management of the postinfarction patient and does not replace coronarography when indicated by clinical or non-invasive parameters .	[ "In", "123", "consecutive", "patients", "pulmonary", "hemodynamics", "at", "rest", "and", "during", "exercise", "were", "measured", "7", "-", "10", "days", "after", "acute", "myocardial", "infarction", "and", "systemic", "thrombolysis", ".", "Right-", "and", "left", "-", "heart", "catheterizations", "were", "performed", "at", "the", "same", "session", "and", "repeated", "after", "6", "months", ".", "We", "investigated", "if", "right", "-", "heart", "catheterization", "could", "predict", "the", "number", "of", "stenotic", "or", "occluded", "coronaries", ",", "the", "angiographic", "ventricular", "function", "andor", ",", "most", "important", ",", "if", "the", "patient", "would", "profit", "from", "revascularization", "by", "PTCA", "or", "coronary", "surgery", ".", "Results", ":", "1", ")", "Pulmonary", "hemodynamics", "at", "rest", "and", "during", "exercise", "did", "not", "correlate", "to", "the", "number", "of", "stenotic", "or", "occluded", "coronaries", ",", "but", "exercise", "tolerance", "did", ".", "2", ")", "Correlation", "between", "ventricular", "function", "and", "pulmonary", "hemodynamics", "was", "weak", ".", "3", ")", "Only", "patients", "with", "pathologically", "elevated", "pulmonary", "pressures", "at", "exercise", "showed", "profit", "from", "revascularization", "(", "increase", "of", "ejection", "fraction", ">", "5", "%", "at", "control", ")", ".", "This", "profit", "was", "closely", "correlated", "to", "the", "angiographic", "extent", "of", "ventricular", "damage", ".", "Consequences", "from", "our", "results", ":", "Individual", "exercise", "tolerance", "can", "easily", "be", "measured", "non", "-", "invasively", ".", "Ventricular", "function", "can", "be", "measured", "non", "-", "invasively", "as", "well", "as", "by", "echocardiography", ".", "Measurement", "of", "pulmonary", "hemodynamics", "at", "rest", "and", "during", "exercise", "does", "not", "contribute", "to", "planning", "the", "future", "management", "of", "the", "postinfarction", "patient", "and", "does", "not", "replace", "coronarography", "when", "indicated", "by", "clinical", "or", "non", "-", "invasive", "parameters", "." ]	[ "umlsterm" ]
Patienten is an umlsterm, Arterien is an umlsterm, Patienten is an umlsterm, wachsende is an umlsterm, Patienten is an umlsterm, Erwachsenenalter is an umlsterm, Schwangerschaft is an umlsterm, Patienten is an umlsterm, Literatursuche is an umlsterm, MEDLINE is an umlsterm, Schwangerschaften is an umlsterm, Schwangerschaften is an umlsterm, Komplikationen is an umlsterm, Fruehaborten is an umlsterm, Fehlgeburt is an umlsterm, Abort is an umlsterm, Kinder is an umlsterm, Komplikationen is an umlsterm, Muettern is an umlsterm, therapiebeduerftige is an umlsterm, koerperlichen Leistungsfaehigkeit is an umlsterm, Komplikationen is an umlsterm, Patienten is an umlsterm, Tachykardien is an umlsterm, Prognose is an umlsterm, Muetter is an umlsterm, Kinder is an umlsterm	ZfuerKardiologie.70860945.ger.abstr_task0	Sentence: Hintergrund : Patienten nach atrialen Umkehroperationen ( Mustard- oder Senning-Operation ) zur Korrektur einer Transposition der grossen Arterien ( TGA ) unterscheiden sich in einem wesentlichen Punkt von anderen Patienten mit kongenitalen Vitien : Der anatomisch rechte ( vorne gelegene ) Ventrikel fungiert bei ihnen als Systemventrikel . Da eine wachsende Zahl derart operierter Patienten das Erwachsenenalter erreicht , gewinnt die Frage , ob eine Schwangerschaft fuer die so operierten Patientinnen wegen der dabei auftretenden , ausgepraegten haemodynamischen Veraenderungen eine Gefaehrdung darstellt , zunehmende Bedeutung . Patienten : Initiiert durch die Vorstellung einer schwangeren Patientin in unserer Klinik konnten durch Literatursuche in MEDLINE weitere 26 Kasuistiken ueber Schwangerschaften nach Mustard-Operation identifiziert werden . Bei den somit insgesamt 27 Patientinnen wurde ueber 39 Schwangerschaften berichtet . Fetale Komplikationen : Es kam zu drei Fruehaborten im 1. Trimenon und einer Fehlgeburt in der 23. Schwangerschaftswoche . Weiterhin wurde ein elektiver Abort im 1. Trimenon durchgefuehrt . 35 Kinder ( ein Zwillingspaar ) wurden lebend geboren ohne kardiovaskulaere Fehlbildungen . Muetterliche Komplikationen : Von den Muettern verstarb keine . Acht Patientinnen entwickelten eine therapiebeduerftige Herzinsuffizienz , wobei alle drei Patientinnen mit vormals komplexer TGA ( zusaetzliche andere kardiale Fehlbildungen ) betroffen waren . Von diesen erholten sich vier Patientinnen innerhalb der Nachbeobachtungszeit , die anderen vier Patientinnen zeigten eine anhaltende Verschlechterung ihrer koerperlichen Leistungsfaehigkeit oder klinische Zeichen einer Herzinsuffizienz . Als weitere Komplikationen kam es bei fuenf Patienten zu supraventrikulaeren Tachykardien und bei 22% der Patientinnen zu einer Hypertonie/Prae-Eklampsie . Schlussfolgerung : Zusammenfassend zeigt sich eine gute Prognose fuer Muetter nach Mustard-Operation und ihre Kinder , ein intensives und spezielles Monitoring vorausgesetzt . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	Hintergrund : Patienten nach atrialen Umkehroperationen ( Mustard- oder Senning-Operation ) zur Korrektur einer Transposition der grossen Arterien ( TGA ) unterscheiden sich in einem wesentlichen Punkt von anderen Patienten mit kongenitalen Vitien : Der anatomisch rechte ( vorne gelegene ) Ventrikel fungiert bei ihnen als Systemventrikel . Da eine wachsende Zahl derart operierter Patienten das Erwachsenenalter erreicht , gewinnt die Frage , ob eine Schwangerschaft fuer die so operierten Patientinnen wegen der dabei auftretenden , ausgepraegten haemodynamischen Veraenderungen eine Gefaehrdung darstellt , zunehmende Bedeutung . Patienten : Initiiert durch die Vorstellung einer schwangeren Patientin in unserer Klinik konnten durch Literatursuche in MEDLINE weitere 26 Kasuistiken ueber Schwangerschaften nach Mustard-Operation identifiziert werden . Bei den somit insgesamt 27 Patientinnen wurde ueber 39 Schwangerschaften berichtet . Fetale Komplikationen : Es kam zu drei Fruehaborten im 1. Trimenon und einer Fehlgeburt in der 23. Schwangerschaftswoche . Weiterhin wurde ein elektiver Abort im 1. Trimenon durchgefuehrt . 35 Kinder ( ein Zwillingspaar ) wurden lebend geboren ohne kardiovaskulaere Fehlbildungen . Muetterliche Komplikationen : Von den Muettern verstarb keine . Acht Patientinnen entwickelten eine therapiebeduerftige Herzinsuffizienz , wobei alle drei Patientinnen mit vormals komplexer TGA ( zusaetzliche andere kardiale Fehlbildungen ) betroffen waren . Von diesen erholten sich vier Patientinnen innerhalb der Nachbeobachtungszeit , die anderen vier Patientinnen zeigten eine anhaltende Verschlechterung ihrer koerperlichen Leistungsfaehigkeit oder klinische Zeichen einer Herzinsuffizienz . Als weitere Komplikationen kam es bei fuenf Patienten zu supraventrikulaeren Tachykardien und bei 22% der Patientinnen zu einer Hypertonie/Prae-Eklampsie . Schlussfolgerung : Zusammenfassend zeigt sich eine gute Prognose fuer Muetter nach Mustard-Operation und ihre Kinder , ein intensives und spezielles Monitoring vorausgesetzt .	[ "Hintergrund", ":", "Patienten", "nach", "atrialen", "Umkehroperationen", "(", "Mustard-", "oder", "Senning", "-", "Operation", ")", "zur", "Korrektur", "einer", "Transposition", "der", "grossen", "Arterien", "(", "TGA", ")", "unterscheiden", "sich", "in", "einem", "wesentlichen", "Punkt", "von", "anderen", "Patienten", "mit", "kongenitalen", "Vitien", ":", "Der", "anatomisch", "rechte", "(", "vorne", "gelegene", ")", "Ventrikel", "fungiert", "bei", "ihnen", "als", "Systemventrikel", ".", "Da", "eine", "wachsende", "Zahl", "derart", "operierter", "Patienten", "das", "Erwachsenenalter", "erreicht", ",", "gewinnt", "die", "Frage", ",", "ob", "eine", "Schwangerschaft", "fuer", "die", "so", "operierten", "Patientinnen", "wegen", "der", "dabei", "auftretenden", ",", "ausgepraegten", "haemodynamischen", "Veraenderungen", "eine", "Gefaehrdung", "darstellt", ",", "zunehmende", "Bedeutung", ".", "Patienten", ":", "Initiiert", "durch", "die", "Vorstellung", "einer", "schwangeren", "Patientin", "in", "unserer", "Klinik", "konnten", "durch", "Literatursuche", "in", "MEDLINE", "weitere", "26", "Kasuistiken", "ueber", "Schwangerschaften", "nach", "Mustard", "-", "Operation", "identifiziert", "werden", ".", "Bei", "den", "somit", "insgesamt", "27", "Patientinnen", "wurde", "ueber", "39", "Schwangerschaften", "berichtet", ".", "Fetale", "Komplikationen", ":", "Es", "kam", "zu", "drei", "Fruehaborten", "im", "1", ".", "Trimenon", "und", "einer", "Fehlgeburt", "in", "der", "23", ".", "Schwangerschaftswoche", ".", "Weiterhin", "wurde", "ein", "elektiver", "Abort", "im", "1", ".", "Trimenon", "durchgefuehrt", ".", "35", "Kinder", "(", "ein", "Zwillingspaar", ")", "wurden", "lebend", "geboren", "ohne", "kardiovaskulaere", "Fehlbildungen", ".", "Muetterliche", "Komplikationen", ":", "Von", "den", "Muettern", "verstarb", "keine", ".", "Acht", "Patientinnen", "entwickelten", "eine", "therapiebeduerftige", "Herzinsuffizienz", ",", "wobei", "alle", "drei", "Patientinnen", "mit", "vormals", "komplexer", "TGA", "(", "zusaetzliche", "andere", "kardiale", "Fehlbildungen", ")", "betroffen", "waren", ".", "Von", "diesen", "erholten", "sich", "vier", "Patientinnen", "innerhalb", "der", "Nachbeobachtungszeit", ",", "die", "anderen", "vier", "Patientinnen", "zeigten", "eine", "anhaltende", "Verschlechterung", "ihrer", "koerperlichen", "Leistungsfaehigkeit", "oder", "klinische", "Zeichen", "einer", "Herzinsuffizienz", ".", "Als", "weitere", "Komplikationen", "kam", "es", "bei", "fuenf", "Patienten", "zu", "supraventrikulaeren", "Tachykardien", "und", "bei", "22", "%", "der", "Patientinnen", "zu", "einer", "Hypertonie", "/", "Prae", "-", "Eklampsie", ".", "Schlussfolgerung", ":", "Zusammenfassend", "zeigt", "sich", "eine", "gute", "Prognose", "fuer", "Muetter", "nach", "Mustard", "-", "Operation", "und", "ihre", "Kinder", ",", "ein", "intensives", "und", "spezielles", "Monitoring", "vorausgesetzt", "." ]	[ "umlsterm" ]
Patienten is an umlsterm, Arterien is an umlsterm, Patienten is an umlsterm, wachsende is an umlsterm, Patienten is an umlsterm, Erwachsenenalter is an umlsterm, Schwangerschaft is an umlsterm, Patienten is an umlsterm, Literatursuche is an umlsterm, MEDLINE is an umlsterm, Schwangerschaften is an umlsterm, Schwangerschaften is an umlsterm, Komplikationen is an umlsterm, Fruehaborten is an umlsterm, Fehlgeburt is an umlsterm, Abort is an umlsterm, Kinder is an umlsterm, Komplikationen is an umlsterm, Muettern is an umlsterm, therapiebeduerftige is an umlsterm, koerperlichen Leistungsfaehigkeit is an umlsterm, Komplikationen is an umlsterm, Patienten is an umlsterm, Tachykardien is an umlsterm, Prognose is an umlsterm, Muetter is an umlsterm, Kinder is an umlsterm	ZfuerKardiologie.70860945.ger.abstr_task1	Sentence: Hintergrund : Patienten nach atrialen Umkehroperationen ( Mustard- oder Senning-Operation ) zur Korrektur einer Transposition der grossen Arterien ( TGA ) unterscheiden sich in einem wesentlichen Punkt von anderen Patienten mit kongenitalen Vitien : Der anatomisch rechte ( vorne gelegene ) Ventrikel fungiert bei ihnen als Systemventrikel . Da eine wachsende Zahl derart operierter Patienten das Erwachsenenalter erreicht , gewinnt die Frage , ob eine Schwangerschaft fuer die so operierten Patientinnen wegen der dabei auftretenden , ausgepraegten haemodynamischen Veraenderungen eine Gefaehrdung darstellt , zunehmende Bedeutung . Patienten : Initiiert durch die Vorstellung einer schwangeren Patientin in unserer Klinik konnten durch Literatursuche in MEDLINE weitere 26 Kasuistiken ueber Schwangerschaften nach Mustard-Operation identifiziert werden . Bei den somit insgesamt 27 Patientinnen wurde ueber 39 Schwangerschaften berichtet . Fetale Komplikationen : Es kam zu drei Fruehaborten im 1. Trimenon und einer Fehlgeburt in der 23. Schwangerschaftswoche . Weiterhin wurde ein elektiver Abort im 1. Trimenon durchgefuehrt . 35 Kinder ( ein Zwillingspaar ) wurden lebend geboren ohne kardiovaskulaere Fehlbildungen . Muetterliche Komplikationen : Von den Muettern verstarb keine . Acht Patientinnen entwickelten eine therapiebeduerftige Herzinsuffizienz , wobei alle drei Patientinnen mit vormals komplexer TGA ( zusaetzliche andere kardiale Fehlbildungen ) betroffen waren . Von diesen erholten sich vier Patientinnen innerhalb der Nachbeobachtungszeit , die anderen vier Patientinnen zeigten eine anhaltende Verschlechterung ihrer koerperlichen Leistungsfaehigkeit oder klinische Zeichen einer Herzinsuffizienz . Als weitere Komplikationen kam es bei fuenf Patienten zu supraventrikulaeren Tachykardien und bei 22% der Patientinnen zu einer Hypertonie/Prae-Eklampsie . Schlussfolgerung : Zusammenfassend zeigt sich eine gute Prognose fuer Muetter nach Mustard-Operation und ihre Kinder , ein intensives und spezielles Monitoring vorausgesetzt . Instructions: please typing these entity words according to sentence: Patienten, Arterien, Patienten, wachsende, Patienten, Erwachsenenalter, Schwangerschaft, Patienten, Literatursuche, MEDLINE, Schwangerschaften, Schwangerschaften, Komplikationen, Fruehaborten, Fehlgeburt, Abort, Kinder, Komplikationen, Muettern, therapiebeduerftige, koerperlichen Leistungsfaehigkeit, Komplikationen, Patienten, Tachykardien, Prognose, Muetter, Kinder Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	Hintergrund : Patienten nach atrialen Umkehroperationen ( Mustard- oder Senning-Operation ) zur Korrektur einer Transposition der grossen Arterien ( TGA ) unterscheiden sich in einem wesentlichen Punkt von anderen Patienten mit kongenitalen Vitien : Der anatomisch rechte ( vorne gelegene ) Ventrikel fungiert bei ihnen als Systemventrikel . Da eine wachsende Zahl derart operierter Patienten das Erwachsenenalter erreicht , gewinnt die Frage , ob eine Schwangerschaft fuer die so operierten Patientinnen wegen der dabei auftretenden , ausgepraegten haemodynamischen Veraenderungen eine Gefaehrdung darstellt , zunehmende Bedeutung . Patienten : Initiiert durch die Vorstellung einer schwangeren Patientin in unserer Klinik konnten durch Literatursuche in MEDLINE weitere 26 Kasuistiken ueber Schwangerschaften nach Mustard-Operation identifiziert werden . Bei den somit insgesamt 27 Patientinnen wurde ueber 39 Schwangerschaften berichtet . Fetale Komplikationen : Es kam zu drei Fruehaborten im 1. Trimenon und einer Fehlgeburt in der 23. Schwangerschaftswoche . Weiterhin wurde ein elektiver Abort im 1. Trimenon durchgefuehrt . 35 Kinder ( ein Zwillingspaar ) wurden lebend geboren ohne kardiovaskulaere Fehlbildungen . Muetterliche Komplikationen : Von den Muettern verstarb keine . Acht Patientinnen entwickelten eine therapiebeduerftige Herzinsuffizienz , wobei alle drei Patientinnen mit vormals komplexer TGA ( zusaetzliche andere kardiale Fehlbildungen ) betroffen waren . Von diesen erholten sich vier Patientinnen innerhalb der Nachbeobachtungszeit , die anderen vier Patientinnen zeigten eine anhaltende Verschlechterung ihrer koerperlichen Leistungsfaehigkeit oder klinische Zeichen einer Herzinsuffizienz . Als weitere Komplikationen kam es bei fuenf Patienten zu supraventrikulaeren Tachykardien und bei 22% der Patientinnen zu einer Hypertonie/Prae-Eklampsie . Schlussfolgerung : Zusammenfassend zeigt sich eine gute Prognose fuer Muetter nach Mustard-Operation und ihre Kinder , ein intensives und spezielles Monitoring vorausgesetzt .	[ "Hintergrund", ":", "Patienten", "nach", "atrialen", "Umkehroperationen", "(", "Mustard-", "oder", "Senning", "-", "Operation", ")", "zur", "Korrektur", "einer", "Transposition", "der", "grossen", "Arterien", "(", "TGA", ")", "unterscheiden", "sich", "in", "einem", "wesentlichen", "Punkt", "von", "anderen", "Patienten", "mit", "kongenitalen", "Vitien", ":", "Der", "anatomisch", "rechte", "(", "vorne", "gelegene", ")", "Ventrikel", "fungiert", "bei", "ihnen", "als", "Systemventrikel", ".", "Da", "eine", "wachsende", "Zahl", "derart", "operierter", "Patienten", "das", "Erwachsenenalter", "erreicht", ",", "gewinnt", "die", "Frage", ",", "ob", "eine", "Schwangerschaft", "fuer", "die", "so", "operierten", "Patientinnen", "wegen", "der", "dabei", "auftretenden", ",", "ausgepraegten", "haemodynamischen", "Veraenderungen", "eine", "Gefaehrdung", "darstellt", ",", "zunehmende", "Bedeutung", ".", "Patienten", ":", "Initiiert", "durch", "die", "Vorstellung", "einer", "schwangeren", "Patientin", "in", "unserer", "Klinik", "konnten", "durch", "Literatursuche", "in", "MEDLINE", "weitere", "26", "Kasuistiken", "ueber", "Schwangerschaften", "nach", "Mustard", "-", "Operation", "identifiziert", "werden", ".", "Bei", "den", "somit", "insgesamt", "27", "Patientinnen", "wurde", "ueber", "39", "Schwangerschaften", "berichtet", ".", "Fetale", "Komplikationen", ":", "Es", "kam", "zu", "drei", "Fruehaborten", "im", "1", ".", "Trimenon", "und", "einer", "Fehlgeburt", "in", "der", "23", ".", "Schwangerschaftswoche", ".", "Weiterhin", "wurde", "ein", "elektiver", "Abort", "im", "1", ".", "Trimenon", "durchgefuehrt", ".", "35", "Kinder", "(", "ein", "Zwillingspaar", ")", "wurden", "lebend", "geboren", "ohne", "kardiovaskulaere", "Fehlbildungen", ".", "Muetterliche", "Komplikationen", ":", "Von", "den", "Muettern", "verstarb", "keine", ".", "Acht", "Patientinnen", "entwickelten", "eine", "therapiebeduerftige", "Herzinsuffizienz", ",", "wobei", "alle", "drei", "Patientinnen", "mit", "vormals", "komplexer", "TGA", "(", "zusaetzliche", "andere", "kardiale", "Fehlbildungen", ")", "betroffen", "waren", ".", "Von", "diesen", "erholten", "sich", "vier", "Patientinnen", "innerhalb", "der", "Nachbeobachtungszeit", ",", "die", "anderen", "vier", "Patientinnen", "zeigten", "eine", "anhaltende", "Verschlechterung", "ihrer", "koerperlichen", "Leistungsfaehigkeit", "oder", "klinische", "Zeichen", "einer", "Herzinsuffizienz", ".", "Als", "weitere", "Komplikationen", "kam", "es", "bei", "fuenf", "Patienten", "zu", "supraventrikulaeren", "Tachykardien", "und", "bei", "22", "%", "der", "Patientinnen", "zu", "einer", "Hypertonie", "/", "Prae", "-", "Eklampsie", ".", "Schlussfolgerung", ":", "Zusammenfassend", "zeigt", "sich", "eine", "gute", "Prognose", "fuer", "Muetter", "nach", "Mustard", "-", "Operation", "und", "ihre", "Kinder", ",", "ein", "intensives", "und", "spezielles", "Monitoring", "vorausgesetzt", "." ]	[ "umlsterm" ]
Patienten, Arterien, Patienten, wachsende, Patienten, Erwachsenenalter, Schwangerschaft, Patienten, Literatursuche, MEDLINE, Schwangerschaften, Schwangerschaften, Komplikationen, Fruehaborten, Fehlgeburt, Abort, Kinder, Komplikationen, Muettern, therapiebeduerftige, koerperlichen Leistungsfaehigkeit, Komplikationen, Patienten, Tachykardien, Prognose, Muetter, Kinder	ZfuerKardiologie.70860945.ger.abstr_task2	Sentence: Hintergrund : Patienten nach atrialen Umkehroperationen ( Mustard- oder Senning-Operation ) zur Korrektur einer Transposition der grossen Arterien ( TGA ) unterscheiden sich in einem wesentlichen Punkt von anderen Patienten mit kongenitalen Vitien : Der anatomisch rechte ( vorne gelegene ) Ventrikel fungiert bei ihnen als Systemventrikel . Da eine wachsende Zahl derart operierter Patienten das Erwachsenenalter erreicht , gewinnt die Frage , ob eine Schwangerschaft fuer die so operierten Patientinnen wegen der dabei auftretenden , ausgepraegten haemodynamischen Veraenderungen eine Gefaehrdung darstellt , zunehmende Bedeutung . Patienten : Initiiert durch die Vorstellung einer schwangeren Patientin in unserer Klinik konnten durch Literatursuche in MEDLINE weitere 26 Kasuistiken ueber Schwangerschaften nach Mustard-Operation identifiziert werden . Bei den somit insgesamt 27 Patientinnen wurde ueber 39 Schwangerschaften berichtet . Fetale Komplikationen : Es kam zu drei Fruehaborten im 1. Trimenon und einer Fehlgeburt in der 23. Schwangerschaftswoche . Weiterhin wurde ein elektiver Abort im 1. Trimenon durchgefuehrt . 35 Kinder ( ein Zwillingspaar ) wurden lebend geboren ohne kardiovaskulaere Fehlbildungen . Muetterliche Komplikationen : Von den Muettern verstarb keine . Acht Patientinnen entwickelten eine therapiebeduerftige Herzinsuffizienz , wobei alle drei Patientinnen mit vormals komplexer TGA ( zusaetzliche andere kardiale Fehlbildungen ) betroffen waren . Von diesen erholten sich vier Patientinnen innerhalb der Nachbeobachtungszeit , die anderen vier Patientinnen zeigten eine anhaltende Verschlechterung ihrer koerperlichen Leistungsfaehigkeit oder klinische Zeichen einer Herzinsuffizienz . Als weitere Komplikationen kam es bei fuenf Patienten zu supraventrikulaeren Tachykardien und bei 22% der Patientinnen zu einer Hypertonie/Prae-Eklampsie . Schlussfolgerung : Zusammenfassend zeigt sich eine gute Prognose fuer Muetter nach Mustard-Operation und ihre Kinder , ein intensives und spezielles Monitoring vorausgesetzt . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	Hintergrund : Patienten nach atrialen Umkehroperationen ( Mustard- oder Senning-Operation ) zur Korrektur einer Transposition der grossen Arterien ( TGA ) unterscheiden sich in einem wesentlichen Punkt von anderen Patienten mit kongenitalen Vitien : Der anatomisch rechte ( vorne gelegene ) Ventrikel fungiert bei ihnen als Systemventrikel . Da eine wachsende Zahl derart operierter Patienten das Erwachsenenalter erreicht , gewinnt die Frage , ob eine Schwangerschaft fuer die so operierten Patientinnen wegen der dabei auftretenden , ausgepraegten haemodynamischen Veraenderungen eine Gefaehrdung darstellt , zunehmende Bedeutung . Patienten : Initiiert durch die Vorstellung einer schwangeren Patientin in unserer Klinik konnten durch Literatursuche in MEDLINE weitere 26 Kasuistiken ueber Schwangerschaften nach Mustard-Operation identifiziert werden . Bei den somit insgesamt 27 Patientinnen wurde ueber 39 Schwangerschaften berichtet . Fetale Komplikationen : Es kam zu drei Fruehaborten im 1. Trimenon und einer Fehlgeburt in der 23. Schwangerschaftswoche . Weiterhin wurde ein elektiver Abort im 1. Trimenon durchgefuehrt . 35 Kinder ( ein Zwillingspaar ) wurden lebend geboren ohne kardiovaskulaere Fehlbildungen . Muetterliche Komplikationen : Von den Muettern verstarb keine . Acht Patientinnen entwickelten eine therapiebeduerftige Herzinsuffizienz , wobei alle drei Patientinnen mit vormals komplexer TGA ( zusaetzliche andere kardiale Fehlbildungen ) betroffen waren . Von diesen erholten sich vier Patientinnen innerhalb der Nachbeobachtungszeit , die anderen vier Patientinnen zeigten eine anhaltende Verschlechterung ihrer koerperlichen Leistungsfaehigkeit oder klinische Zeichen einer Herzinsuffizienz . Als weitere Komplikationen kam es bei fuenf Patienten zu supraventrikulaeren Tachykardien und bei 22% der Patientinnen zu einer Hypertonie/Prae-Eklampsie . Schlussfolgerung : Zusammenfassend zeigt sich eine gute Prognose fuer Muetter nach Mustard-Operation und ihre Kinder , ein intensives und spezielles Monitoring vorausgesetzt .	[ "Hintergrund", ":", "Patienten", "nach", "atrialen", "Umkehroperationen", "(", "Mustard-", "oder", "Senning", "-", "Operation", ")", "zur", "Korrektur", "einer", "Transposition", "der", "grossen", "Arterien", "(", "TGA", ")", "unterscheiden", "sich", "in", "einem", "wesentlichen", "Punkt", "von", "anderen", "Patienten", "mit", "kongenitalen", "Vitien", ":", "Der", "anatomisch", "rechte", "(", "vorne", "gelegene", ")", "Ventrikel", "fungiert", "bei", "ihnen", "als", "Systemventrikel", ".", "Da", "eine", "wachsende", "Zahl", "derart", "operierter", "Patienten", "das", "Erwachsenenalter", "erreicht", ",", "gewinnt", "die", "Frage", ",", "ob", "eine", "Schwangerschaft", "fuer", "die", "so", "operierten", "Patientinnen", "wegen", "der", "dabei", "auftretenden", ",", "ausgepraegten", "haemodynamischen", "Veraenderungen", "eine", "Gefaehrdung", "darstellt", ",", "zunehmende", "Bedeutung", ".", "Patienten", ":", "Initiiert", "durch", "die", "Vorstellung", "einer", "schwangeren", "Patientin", "in", "unserer", "Klinik", "konnten", "durch", "Literatursuche", "in", "MEDLINE", "weitere", "26", "Kasuistiken", "ueber", "Schwangerschaften", "nach", "Mustard", "-", "Operation", "identifiziert", "werden", ".", "Bei", "den", "somit", "insgesamt", "27", "Patientinnen", "wurde", "ueber", "39", "Schwangerschaften", "berichtet", ".", "Fetale", "Komplikationen", ":", "Es", "kam", "zu", "drei", "Fruehaborten", "im", "1", ".", "Trimenon", "und", "einer", "Fehlgeburt", "in", "der", "23", ".", "Schwangerschaftswoche", ".", "Weiterhin", "wurde", "ein", "elektiver", "Abort", "im", "1", ".", "Trimenon", "durchgefuehrt", ".", "35", "Kinder", "(", "ein", "Zwillingspaar", ")", "wurden", "lebend", "geboren", "ohne", "kardiovaskulaere", "Fehlbildungen", ".", "Muetterliche", "Komplikationen", ":", "Von", "den", "Muettern", "verstarb", "keine", ".", "Acht", "Patientinnen", "entwickelten", "eine", "therapiebeduerftige", "Herzinsuffizienz", ",", "wobei", "alle", "drei", "Patientinnen", "mit", "vormals", "komplexer", "TGA", "(", "zusaetzliche", "andere", "kardiale", "Fehlbildungen", ")", "betroffen", "waren", ".", "Von", "diesen", "erholten", "sich", "vier", "Patientinnen", "innerhalb", "der", "Nachbeobachtungszeit", ",", "die", "anderen", "vier", "Patientinnen", "zeigten", "eine", "anhaltende", "Verschlechterung", "ihrer", "koerperlichen", "Leistungsfaehigkeit", "oder", "klinische", "Zeichen", "einer", "Herzinsuffizienz", ".", "Als", "weitere", "Komplikationen", "kam", "es", "bei", "fuenf", "Patienten", "zu", "supraventrikulaeren", "Tachykardien", "und", "bei", "22", "%", "der", "Patientinnen", "zu", "einer", "Hypertonie", "/", "Prae", "-", "Eklampsie", ".", "Schlussfolgerung", ":", "Zusammenfassend", "zeigt", "sich", "eine", "gute", "Prognose", "fuer", "Muetter", "nach", "Mustard", "-", "Operation", "und", "ihre", "Kinder", ",", "ein", "intensives", "und", "spezielles", "Monitoring", "vorausgesetzt", "." ]	[ "umlsterm" ]
Natural products is an umlsterm, derivatives is an umlsterm, clinical research is an umlsterm, drugs is an umlsterm, plants is an umlsterm, developments is an umlsterm, screening is an umlsterm, techniques is an umlsterm, marine is an umlsterm, origin is an umlsterm, methods is an umlsterm, natural products is an umlsterm, use is an umlsterm, research is an umlsterm, natural products is an umlsterm	DerGynaekologe.00330006.eng.abstr_task0	Sentence: Natural products and their derivatives are well established in clinical research and for medical applications . There are excellent drugs available from various plants and microorganisms . Recent developments in the different screening techniques have accelerated the discovery of new compounds . Furthermore , the investigation of compounds of marine origin , which have been more difficult to obtain , has become possible . With the help of combinatorial methods , natural products can be modified to optimize their use for medical applications . Due to the enormous medical potential , modern research on natural products will also be important in the next century . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Natural products and their derivatives are well established in clinical research and for medical applications . There are excellent drugs available from various plants and microorganisms . Recent developments in the different screening techniques have accelerated the discovery of new compounds . Furthermore , the investigation of compounds of marine origin , which have been more difficult to obtain , has become possible . With the help of combinatorial methods , natural products can be modified to optimize their use for medical applications . Due to the enormous medical potential , modern research on natural products will also be important in the next century .	[ "Natural", "products", "and", "their", "derivatives", "are", "well", "established", "in", "clinical", "research", "and", "for", "medical", "applications", ".", "There", "are", "excellent", "drugs", "available", "from", "various", "plants", "and", "microorganisms", ".", "Recent", "developments", "in", "the", "different", "screening", "techniques", "have", "accelerated", "the", "discovery", "of", "new", "compounds", ".", "Furthermore", ",", "the", "investigation", "of", "compounds", "of", "marine", "origin", ",", "which", "have", "been", "more", "difficult", "to", "obtain", ",", "has", "become", "possible", ".", "With", "the", "help", "of", "combinatorial", "methods", ",", "natural", "products", "can", "be", "modified", "to", "optimize", "their", "use", "for", "medical", "applications", ".", "Due", "to", "the", "enormous", "medical", "potential", ",", "modern", "research", "on", "natural", "products", "will", "also", "be", "important", "in", "the", "next", "century", "." ]	[ "umlsterm" ]
Natural products is an umlsterm, derivatives is an umlsterm, clinical research is an umlsterm, drugs is an umlsterm, plants is an umlsterm, developments is an umlsterm, screening is an umlsterm, techniques is an umlsterm, marine is an umlsterm, origin is an umlsterm, methods is an umlsterm, natural products is an umlsterm, use is an umlsterm, research is an umlsterm, natural products is an umlsterm	DerGynaekologe.00330006.eng.abstr_task1	Sentence: Natural products and their derivatives are well established in clinical research and for medical applications . There are excellent drugs available from various plants and microorganisms . Recent developments in the different screening techniques have accelerated the discovery of new compounds . Furthermore , the investigation of compounds of marine origin , which have been more difficult to obtain , has become possible . With the help of combinatorial methods , natural products can be modified to optimize their use for medical applications . Due to the enormous medical potential , modern research on natural products will also be important in the next century . Instructions: please typing these entity words according to sentence: Natural products, derivatives, clinical research, drugs, plants, developments, screening, techniques, marine, origin, methods, natural products, use, research, natural products Options: umlsterm	[ "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Natural products and their derivatives are well established in clinical research and for medical applications . There are excellent drugs available from various plants and microorganisms . Recent developments in the different screening techniques have accelerated the discovery of new compounds . Furthermore , the investigation of compounds of marine origin , which have been more difficult to obtain , has become possible . With the help of combinatorial methods , natural products can be modified to optimize their use for medical applications . Due to the enormous medical potential , modern research on natural products will also be important in the next century .	[ "Natural", "products", "and", "their", "derivatives", "are", "well", "established", "in", "clinical", "research", "and", "for", "medical", "applications", ".", "There", "are", "excellent", "drugs", "available", "from", "various", "plants", "and", "microorganisms", ".", "Recent", "developments", "in", "the", "different", "screening", "techniques", "have", "accelerated", "the", "discovery", "of", "new", "compounds", ".", "Furthermore", ",", "the", "investigation", "of", "compounds", "of", "marine", "origin", ",", "which", "have", "been", "more", "difficult", "to", "obtain", ",", "has", "become", "possible", ".", "With", "the", "help", "of", "combinatorial", "methods", ",", "natural", "products", "can", "be", "modified", "to", "optimize", "their", "use", "for", "medical", "applications", ".", "Due", "to", "the", "enormous", "medical", "potential", ",", "modern", "research", "on", "natural", "products", "will", "also", "be", "important", "in", "the", "next", "century", "." ]	[ "umlsterm" ]
Natural products, derivatives, clinical research, drugs, plants, developments, screening, techniques, marine, origin, methods, natural products, use, research, natural products	DerGynaekologe.00330006.eng.abstr_task2	Sentence: Natural products and their derivatives are well established in clinical research and for medical applications . There are excellent drugs available from various plants and microorganisms . Recent developments in the different screening techniques have accelerated the discovery of new compounds . Furthermore , the investigation of compounds of marine origin , which have been more difficult to obtain , has become possible . With the help of combinatorial methods , natural products can be modified to optimize their use for medical applications . Due to the enormous medical potential , modern research on natural products will also be important in the next century . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Natural products and their derivatives are well established in clinical research and for medical applications . There are excellent drugs available from various plants and microorganisms . Recent developments in the different screening techniques have accelerated the discovery of new compounds . Furthermore , the investigation of compounds of marine origin , which have been more difficult to obtain , has become possible . With the help of combinatorial methods , natural products can be modified to optimize their use for medical applications . Due to the enormous medical potential , modern research on natural products will also be important in the next century .	[ "Natural", "products", "and", "their", "derivatives", "are", "well", "established", "in", "clinical", "research", "and", "for", "medical", "applications", ".", "There", "are", "excellent", "drugs", "available", "from", "various", "plants", "and", "microorganisms", ".", "Recent", "developments", "in", "the", "different", "screening", "techniques", "have", "accelerated", "the", "discovery", "of", "new", "compounds", ".", "Furthermore", ",", "the", "investigation", "of", "compounds", "of", "marine", "origin", ",", "which", "have", "been", "more", "difficult", "to", "obtain", ",", "has", "become", "possible", ".", "With", "the", "help", "of", "combinatorial", "methods", ",", "natural", "products", "can", "be", "modified", "to", "optimize", "their", "use", "for", "medical", "applications", ".", "Due", "to", "the", "enormous", "medical", "potential", ",", "modern", "research", "on", "natural", "products", "will", "also", "be", "important", "in", "the", "next", "century", "." ]	[ "umlsterm" ]
bladder is an umlsterm, drainage is an umlsterm, technique is an umlsterm, pancreas transplants is an umlsterm, transplants is an umlsterm, United States is an umlsterm, contrast is an umlsterm, pancreas transplants is an umlsterm, Eurotransplant is an umlsterm, community is an umlsterm, grafts is an umlsterm, June is an umlsterm, October is an umlsterm, graft is an umlsterm, function is an umlsterm, pancreas is an umlsterm, kidney is an umlsterm, grafts is an umlsterm, standard is an umlsterm, procedure is an umlsterm, patients is an umlsterm, insulin - dependent diabetes mellitus is an umlsterm, end - stage renal disease is an umlsterm, Germany is an umlsterm	DerChirurg.60671002.eng.abstr_task0	Sentence: Sinde the introduction of the bladder drainage technique , the number of pancreas transplants performed has now reached 1000/year worldwide . Most of these transplants have been performed in the United States . In contrast , the number of pancreas transplants performed in the Eurotransplant community has remained at a low level for several years . The results of a consecutive series of 20 simultaneous pancreas/kidney grafts ( SPK ) performed between June 1994 and October 1995 demonstrate that high graft function rates of 83.5 % for pancreas and kidney grafts can be achieved . Therefore SPK can be recommended as a standard procedure for patients with insulin-dependent diabetes mellitus and end-stage renal disease in Germany , too . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]	Sinde the introduction of the bladder drainage technique , the number of pancreas transplants performed has now reached 1000/year worldwide . Most of these transplants have been performed in the United States . In contrast , the number of pancreas transplants performed in the Eurotransplant community has remained at a low level for several years . The results of a consecutive series of 20 simultaneous pancreas/kidney grafts ( SPK ) performed between June 1994 and October 1995 demonstrate that high graft function rates of 83.5 % for pancreas and kidney grafts can be achieved . Therefore SPK can be recommended as a standard procedure for patients with insulin-dependent diabetes mellitus and end-stage renal disease in Germany , too .	[ "Sinde", "the", "introduction", "of", "the", "bladder", "drainage", "technique", ",", "the", "number", "of", "pancreas", "transplants", "performed", "has", "now", "reached", "1000", "/", "year", "worldwide", ".", "Most", "of", "these", "transplants", "have", "been", "performed", "in", "the", "United", "States", ".", "In", "contrast", ",", "the", "number", "of", "pancreas", "transplants", "performed", "in", "the", "Eurotransplant", "community", "has", "remained", "at", "a", "low", "level", "for", "several", "years", ".", "The", "results", "of", "a", "consecutive", "series", "of", "20", "simultaneous", "pancreas", "/", "kidney", "grafts", "(", "SPK", ")", "performed", "between", "June", "1994", "and", "October", "1995", "demonstrate", "that", "high", "graft", "function", "rates", "of", "83.5", "%", "for", "pancreas", "and", "kidney", "grafts", "can", "be", "achieved", ".", "Therefore", "SPK", "can", "be", "recommended", "as", "a", "standard", "procedure", "for", "patients", "with", "insulin", "-", "dependent", "diabetes", "mellitus", "and", "end", "-", "stage", "renal", "disease", "in", "Germany", ",", "too", "." ]	[ "umlsterm" ]
bladder is an umlsterm, drainage is an umlsterm, technique is an umlsterm, pancreas transplants is an umlsterm, transplants is an umlsterm, United States is an umlsterm, contrast is an umlsterm, pancreas transplants is an umlsterm, Eurotransplant is an umlsterm, community is an umlsterm, grafts is an umlsterm, June is an umlsterm, October is an umlsterm, graft is an umlsterm, function is an umlsterm, pancreas is an umlsterm, kidney is an umlsterm, grafts is an umlsterm, standard is an umlsterm, procedure is an umlsterm, patients is an umlsterm, insulin - dependent diabetes mellitus is an umlsterm, end - stage renal disease is an umlsterm, Germany is an umlsterm	DerChirurg.60671002.eng.abstr_task1	Sentence: Sinde the introduction of the bladder drainage technique , the number of pancreas transplants performed has now reached 1000/year worldwide . Most of these transplants have been performed in the United States . In contrast , the number of pancreas transplants performed in the Eurotransplant community has remained at a low level for several years . The results of a consecutive series of 20 simultaneous pancreas/kidney grafts ( SPK ) performed between June 1994 and October 1995 demonstrate that high graft function rates of 83.5 % for pancreas and kidney grafts can be achieved . Therefore SPK can be recommended as a standard procedure for patients with insulin-dependent diabetes mellitus and end-stage renal disease in Germany , too . Instructions: please typing these entity words according to sentence: bladder, drainage, technique, pancreas transplants, transplants, United States, contrast, pancreas transplants, Eurotransplant, community, grafts, June, October, graft, function, pancreas, kidney, grafts, standard, procedure, patients, insulin - dependent diabetes mellitus, end - stage renal disease, Germany Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]	Sinde the introduction of the bladder drainage technique , the number of pancreas transplants performed has now reached 1000/year worldwide . Most of these transplants have been performed in the United States . In contrast , the number of pancreas transplants performed in the Eurotransplant community has remained at a low level for several years . The results of a consecutive series of 20 simultaneous pancreas/kidney grafts ( SPK ) performed between June 1994 and October 1995 demonstrate that high graft function rates of 83.5 % for pancreas and kidney grafts can be achieved . Therefore SPK can be recommended as a standard procedure for patients with insulin-dependent diabetes mellitus and end-stage renal disease in Germany , too .	[ "Sinde", "the", "introduction", "of", "the", "bladder", "drainage", "technique", ",", "the", "number", "of", "pancreas", "transplants", "performed", "has", "now", "reached", "1000", "/", "year", "worldwide", ".", "Most", "of", "these", "transplants", "have", "been", "performed", "in", "the", "United", "States", ".", "In", "contrast", ",", "the", "number", "of", "pancreas", "transplants", "performed", "in", "the", "Eurotransplant", "community", "has", "remained", "at", "a", "low", "level", "for", "several", "years", ".", "The", "results", "of", "a", "consecutive", "series", "of", "20", "simultaneous", "pancreas", "/", "kidney", "grafts", "(", "SPK", ")", "performed", "between", "June", "1994", "and", "October", "1995", "demonstrate", "that", "high", "graft", "function", "rates", "of", "83.5", "%", "for", "pancreas", "and", "kidney", "grafts", "can", "be", "achieved", ".", "Therefore", "SPK", "can", "be", "recommended", "as", "a", "standard", "procedure", "for", "patients", "with", "insulin", "-", "dependent", "diabetes", "mellitus", "and", "end", "-", "stage", "renal", "disease", "in", "Germany", ",", "too", "." ]	[ "umlsterm" ]
bladder, drainage, technique, pancreas transplants, transplants, United States, contrast, pancreas transplants, Eurotransplant, community, grafts, June, October, graft, function, pancreas, kidney, grafts, standard, procedure, patients, insulin - dependent diabetes mellitus, end - stage renal disease, Germany	DerChirurg.60671002.eng.abstr_task2	Sentence: Sinde the introduction of the bladder drainage technique , the number of pancreas transplants performed has now reached 1000/year worldwide . Most of these transplants have been performed in the United States . In contrast , the number of pancreas transplants performed in the Eurotransplant community has remained at a low level for several years . The results of a consecutive series of 20 simultaneous pancreas/kidney grafts ( SPK ) performed between June 1994 and October 1995 demonstrate that high graft function rates of 83.5 % for pancreas and kidney grafts can be achieved . Therefore SPK can be recommended as a standard procedure for patients with insulin-dependent diabetes mellitus and end-stage renal disease in Germany , too . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]	Sinde the introduction of the bladder drainage technique , the number of pancreas transplants performed has now reached 1000/year worldwide . Most of these transplants have been performed in the United States . In contrast , the number of pancreas transplants performed in the Eurotransplant community has remained at a low level for several years . The results of a consecutive series of 20 simultaneous pancreas/kidney grafts ( SPK ) performed between June 1994 and October 1995 demonstrate that high graft function rates of 83.5 % for pancreas and kidney grafts can be achieved . Therefore SPK can be recommended as a standard procedure for patients with insulin-dependent diabetes mellitus and end-stage renal disease in Germany , too .	[ "Sinde", "the", "introduction", "of", "the", "bladder", "drainage", "technique", ",", "the", "number", "of", "pancreas", "transplants", "performed", "has", "now", "reached", "1000", "/", "year", "worldwide", ".", "Most", "of", "these", "transplants", "have", "been", "performed", "in", "the", "United", "States", ".", "In", "contrast", ",", "the", "number", "of", "pancreas", "transplants", "performed", "in", "the", "Eurotransplant", "community", "has", "remained", "at", "a", "low", "level", "for", "several", "years", ".", "The", "results", "of", "a", "consecutive", "series", "of", "20", "simultaneous", "pancreas", "/", "kidney", "grafts", "(", "SPK", ")", "performed", "between", "June", "1994", "and", "October", "1995", "demonstrate", "that", "high", "graft", "function", "rates", "of", "83.5", "%", "for", "pancreas", "and", "kidney", "grafts", "can", "be", "achieved", ".", "Therefore", "SPK", "can", "be", "recommended", "as", "a", "standard", "procedure", "for", "patients", "with", "insulin", "-", "dependent", "diabetes", "mellitus", "and", "end", "-", "stage", "renal", "disease", "in", "Germany", ",", "too", "." ]	[ "umlsterm" ]
RNF-5 is a Protein, PAT-3 is a Protein, beta - integrin is a Protein, UNC-95 is a Protein, RNF-5 is a Protein, RNF-5 is a Protein, UNC-95 is a Protein, RNF-5 is a Protein, unc-95 is a Protein, RNF-5 is a Protein	483_task0	Sentence: Molting-specific downregulation of C. elegans body-wall muscle attachment sites: the role of RNF-5 E3 ligase. Repeated molting of the cuticula is an integral part of arthropod and nematode development. Shedding of the old cuticle takes place on the surface of hypodermal cells, which are also responsible for secretion and synthesis of a new cuticle. Here, we use the model nematode Caenorhabditis elegans to show that muscle cells, laying beneath and mechanically linked to the hypodermis, play an important role during molting. We followed the molecular composition and distribution of integrin mediated adhesion structures called dense bodies (DB), which indirectly connect muscles to the hypodermis. We found the concentration of two DB proteins (PAT-3/beta-integrin and UNC-95) to decrease during the quiescent phase of molting, concomitant with an apparent increase in lateral movement of the DB. We show that levels of the E3-ligase RNF-5 increase specifically during molting, and that RNF-5 acts to ubiquitinate the DB protein UNC-95. Persistent high levels of RNF-5 driven by a heatshock or unc-95 promoter lead to failure of ecdysis, and in non-molting worms to a progressive detachment of the cuticle from the hypodermis. These observations indicate that increased DB dynamics characterizes the lethargus phase of molting in parallel to decreased levels of DB components and that temporal expression of RNF-5 contributes to an efficient molting process. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]	Molting-specific downregulation of C. elegans body-wall muscle attachment sites: the role of RNF-5 E3 ligase. Repeated molting of the cuticula is an integral part of arthropod and nematode development. Shedding of the old cuticle takes place on the surface of hypodermal cells, which are also responsible for secretion and synthesis of a new cuticle. Here, we use the model nematode Caenorhabditis elegans to show that muscle cells, laying beneath and mechanically linked to the hypodermis, play an important role during molting. We followed the molecular composition and distribution of integrin mediated adhesion structures called dense bodies (DB), which indirectly connect muscles to the hypodermis. We found the concentration of two DB proteins (PAT-3/beta-integrin and UNC-95) to decrease during the quiescent phase of molting, concomitant with an apparent increase in lateral movement of the DB. We show that levels of the E3-ligase RNF-5 increase specifically during molting, and that RNF-5 acts to ubiquitinate the DB protein UNC-95. Persistent high levels of RNF-5 driven by a heatshock or unc-95 promoter lead to failure of ecdysis, and in non-molting worms to a progressive detachment of the cuticle from the hypodermis. These observations indicate that increased DB dynamics characterizes the lethargus phase of molting in parallel to decreased levels of DB components and that temporal expression of RNF-5 contributes to an efficient molting process.	[ "Molting", "-", "specific", "downregulation", "of", "C.", "elegans", "body", "-", "wall", "muscle", "attachment", "sites", ":", "the", "role", "of", "RNF-5", "E3", "ligase", ".", "\n", "Repeated", "molting", "of", "the", "cuticula", "is", "an", "integral", "part", "of", "arthropod", "and", "nematode", "development", ".", "Shedding", "of", "the", "old", "cuticle", "takes", "place", "on", "the", "surface", "of", "hypodermal", "cells", ",", "which", "are", "also", "responsible", "for", "secretion", "and", "synthesis", "of", "a", "new", "cuticle", ".", "Here", ",", "we", "use", "the", "model", "nematode", "Caenorhabditis", "elegans", "to", "show", "that", "muscle", "cells", ",", "laying", "beneath", "and", "mechanically", "linked", "to", "the", "hypodermis", ",", "play", "an", "important", "role", "during", "molting", ".", "We", "followed", "the", "molecular", "composition", "and", "distribution", "of", "integrin", "mediated", "adhesion", "structures", "called", "dense", "bodies", "(", "DB", ")", ",", "which", "indirectly", "connect", "muscles", "to", "the", "hypodermis", ".", "We", "found", "the", "concentration", "of", "two", "DB", "proteins", "(", "PAT-3", "/", "beta", "-", "integrin", "and", "UNC-95", ")", "to", "decrease", "during", "the", "quiescent", "phase", "of", "molting", ",", "concomitant", "with", "an", "apparent", "increase", "in", "lateral", "movement", "of", "the", "DB", ".", "We", "show", "that", "levels", "of", "the", "E3-ligase", "RNF-5", "increase", "specifically", "during", "molting", ",", "and", "that", "RNF-5", "acts", "to", "ubiquitinate", "the", "DB", "protein", "UNC-95", ".", "Persistent", "high", "levels", "of", "RNF-5", "driven", "by", "a", "heatshock", "or", "unc-95", "promoter", "lead", "to", "failure", "of", "ecdysis", ",", "and", "in", "non", "-", "molting", "worms", "to", "a", "progressive", "detachment", "of", "the", "cuticle", "from", "the", "hypodermis", ".", "These", "observations", "indicate", "that", "increased", "DB", "dynamics", "characterizes", "the", "lethargus", "phase", "of", "molting", "in", "parallel", "to", "decreased", "levels", "of", "DB", "components", "and", "that", "temporal", "expression", "of", "RNF-5", "contributes", "to", "an", "efficient", "molting", "process", ".", "\n" ]	[ "Protein" ]
RNF-5 is a Protein, PAT-3 is a Protein, beta - integrin is a Protein, UNC-95 is a Protein, RNF-5 is a Protein, RNF-5 is a Protein, UNC-95 is a Protein, RNF-5 is a Protein, unc-95 is a Protein, RNF-5 is a Protein	483_task1	Sentence: Molting-specific downregulation of C. elegans body-wall muscle attachment sites: the role of RNF-5 E3 ligase. Repeated molting of the cuticula is an integral part of arthropod and nematode development. Shedding of the old cuticle takes place on the surface of hypodermal cells, which are also responsible for secretion and synthesis of a new cuticle. Here, we use the model nematode Caenorhabditis elegans to show that muscle cells, laying beneath and mechanically linked to the hypodermis, play an important role during molting. We followed the molecular composition and distribution of integrin mediated adhesion structures called dense bodies (DB), which indirectly connect muscles to the hypodermis. We found the concentration of two DB proteins (PAT-3/beta-integrin and UNC-95) to decrease during the quiescent phase of molting, concomitant with an apparent increase in lateral movement of the DB. We show that levels of the E3-ligase RNF-5 increase specifically during molting, and that RNF-5 acts to ubiquitinate the DB protein UNC-95. Persistent high levels of RNF-5 driven by a heatshock or unc-95 promoter lead to failure of ecdysis, and in non-molting worms to a progressive detachment of the cuticle from the hypodermis. These observations indicate that increased DB dynamics characterizes the lethargus phase of molting in parallel to decreased levels of DB components and that temporal expression of RNF-5 contributes to an efficient molting process. Instructions: please typing these entity words according to sentence: RNF-5, PAT-3, beta - integrin, UNC-95, RNF-5, RNF-5, UNC-95, RNF-5, unc-95, RNF-5 Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]	Molting-specific downregulation of C. elegans body-wall muscle attachment sites: the role of RNF-5 E3 ligase. Repeated molting of the cuticula is an integral part of arthropod and nematode development. Shedding of the old cuticle takes place on the surface of hypodermal cells, which are also responsible for secretion and synthesis of a new cuticle. Here, we use the model nematode Caenorhabditis elegans to show that muscle cells, laying beneath and mechanically linked to the hypodermis, play an important role during molting. We followed the molecular composition and distribution of integrin mediated adhesion structures called dense bodies (DB), which indirectly connect muscles to the hypodermis. We found the concentration of two DB proteins (PAT-3/beta-integrin and UNC-95) to decrease during the quiescent phase of molting, concomitant with an apparent increase in lateral movement of the DB. We show that levels of the E3-ligase RNF-5 increase specifically during molting, and that RNF-5 acts to ubiquitinate the DB protein UNC-95. Persistent high levels of RNF-5 driven by a heatshock or unc-95 promoter lead to failure of ecdysis, and in non-molting worms to a progressive detachment of the cuticle from the hypodermis. These observations indicate that increased DB dynamics characterizes the lethargus phase of molting in parallel to decreased levels of DB components and that temporal expression of RNF-5 contributes to an efficient molting process.	[ "Molting", "-", "specific", "downregulation", "of", "C.", "elegans", "body", "-", "wall", "muscle", "attachment", "sites", ":", "the", "role", "of", "RNF-5", "E3", "ligase", ".", "\n", "Repeated", "molting", "of", "the", "cuticula", "is", "an", "integral", "part", "of", "arthropod", "and", "nematode", "development", ".", "Shedding", "of", "the", "old", "cuticle", "takes", "place", "on", "the", "surface", "of", "hypodermal", "cells", ",", "which", "are", "also", "responsible", "for", "secretion", "and", "synthesis", "of", "a", "new", "cuticle", ".", "Here", ",", "we", "use", "the", "model", "nematode", "Caenorhabditis", "elegans", "to", "show", "that", "muscle", "cells", ",", "laying", "beneath", "and", "mechanically", "linked", "to", "the", "hypodermis", ",", "play", "an", "important", "role", "during", "molting", ".", "We", "followed", "the", "molecular", "composition", "and", "distribution", "of", "integrin", "mediated", "adhesion", "structures", "called", "dense", "bodies", "(", "DB", ")", ",", "which", "indirectly", "connect", "muscles", "to", "the", "hypodermis", ".", "We", "found", "the", "concentration", "of", "two", "DB", "proteins", "(", "PAT-3", "/", "beta", "-", "integrin", "and", "UNC-95", ")", "to", "decrease", "during", "the", "quiescent", "phase", "of", "molting", ",", "concomitant", "with", "an", "apparent", "increase", "in", "lateral", "movement", "of", "the", "DB", ".", "We", "show", "that", "levels", "of", "the", "E3-ligase", "RNF-5", "increase", "specifically", "during", "molting", ",", "and", "that", "RNF-5", "acts", "to", "ubiquitinate", "the", "DB", "protein", "UNC-95", ".", "Persistent", "high", "levels", "of", "RNF-5", "driven", "by", "a", "heatshock", "or", "unc-95", "promoter", "lead", "to", "failure", "of", "ecdysis", ",", "and", "in", "non", "-", "molting", "worms", "to", "a", "progressive", "detachment", "of", "the", "cuticle", "from", "the", "hypodermis", ".", "These", "observations", "indicate", "that", "increased", "DB", "dynamics", "characterizes", "the", "lethargus", "phase", "of", "molting", "in", "parallel", "to", "decreased", "levels", "of", "DB", "components", "and", "that", "temporal", "expression", "of", "RNF-5", "contributes", "to", "an", "efficient", "molting", "process", ".", "\n" ]	[ "Protein" ]
RNF-5, PAT-3, beta - integrin, UNC-95, RNF-5, RNF-5, UNC-95, RNF-5, unc-95, RNF-5	483_task2	Sentence: Molting-specific downregulation of C. elegans body-wall muscle attachment sites: the role of RNF-5 E3 ligase. Repeated molting of the cuticula is an integral part of arthropod and nematode development. Shedding of the old cuticle takes place on the surface of hypodermal cells, which are also responsible for secretion and synthesis of a new cuticle. Here, we use the model nematode Caenorhabditis elegans to show that muscle cells, laying beneath and mechanically linked to the hypodermis, play an important role during molting. We followed the molecular composition and distribution of integrin mediated adhesion structures called dense bodies (DB), which indirectly connect muscles to the hypodermis. We found the concentration of two DB proteins (PAT-3/beta-integrin and UNC-95) to decrease during the quiescent phase of molting, concomitant with an apparent increase in lateral movement of the DB. We show that levels of the E3-ligase RNF-5 increase specifically during molting, and that RNF-5 acts to ubiquitinate the DB protein UNC-95. Persistent high levels of RNF-5 driven by a heatshock or unc-95 promoter lead to failure of ecdysis, and in non-molting worms to a progressive detachment of the cuticle from the hypodermis. These observations indicate that increased DB dynamics characterizes the lethargus phase of molting in parallel to decreased levels of DB components and that temporal expression of RNF-5 contributes to an efficient molting process. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]	Molting-specific downregulation of C. elegans body-wall muscle attachment sites: the role of RNF-5 E3 ligase. Repeated molting of the cuticula is an integral part of arthropod and nematode development. Shedding of the old cuticle takes place on the surface of hypodermal cells, which are also responsible for secretion and synthesis of a new cuticle. Here, we use the model nematode Caenorhabditis elegans to show that muscle cells, laying beneath and mechanically linked to the hypodermis, play an important role during molting. We followed the molecular composition and distribution of integrin mediated adhesion structures called dense bodies (DB), which indirectly connect muscles to the hypodermis. We found the concentration of two DB proteins (PAT-3/beta-integrin and UNC-95) to decrease during the quiescent phase of molting, concomitant with an apparent increase in lateral movement of the DB. We show that levels of the E3-ligase RNF-5 increase specifically during molting, and that RNF-5 acts to ubiquitinate the DB protein UNC-95. Persistent high levels of RNF-5 driven by a heatshock or unc-95 promoter lead to failure of ecdysis, and in non-molting worms to a progressive detachment of the cuticle from the hypodermis. These observations indicate that increased DB dynamics characterizes the lethargus phase of molting in parallel to decreased levels of DB components and that temporal expression of RNF-5 contributes to an efficient molting process.	[ "Molting", "-", "specific", "downregulation", "of", "C.", "elegans", "body", "-", "wall", "muscle", "attachment", "sites", ":", "the", "role", "of", "RNF-5", "E3", "ligase", ".", "\n", "Repeated", "molting", "of", "the", "cuticula", "is", "an", "integral", "part", "of", "arthropod", "and", "nematode", "development", ".", "Shedding", "of", "the", "old", "cuticle", "takes", "place", "on", "the", "surface", "of", "hypodermal", "cells", ",", "which", "are", "also", "responsible", "for", "secretion", "and", "synthesis", "of", "a", "new", "cuticle", ".", "Here", ",", "we", "use", "the", "model", "nematode", "Caenorhabditis", "elegans", "to", "show", "that", "muscle", "cells", ",", "laying", "beneath", "and", "mechanically", "linked", "to", "the", "hypodermis", ",", "play", "an", "important", "role", "during", "molting", ".", "We", "followed", "the", "molecular", "composition", "and", "distribution", "of", "integrin", "mediated", "adhesion", "structures", "called", "dense", "bodies", "(", "DB", ")", ",", "which", "indirectly", "connect", "muscles", "to", "the", "hypodermis", ".", "We", "found", "the", "concentration", "of", "two", "DB", "proteins", "(", "PAT-3", "/", "beta", "-", "integrin", "and", "UNC-95", ")", "to", "decrease", "during", "the", "quiescent", "phase", "of", "molting", ",", "concomitant", "with", "an", "apparent", "increase", "in", "lateral", "movement", "of", "the", "DB", ".", "We", "show", "that", "levels", "of", "the", "E3-ligase", "RNF-5", "increase", "specifically", "during", "molting", ",", "and", "that", "RNF-5", "acts", "to", "ubiquitinate", "the", "DB", "protein", "UNC-95", ".", "Persistent", "high", "levels", "of", "RNF-5", "driven", "by", "a", "heatshock", "or", "unc-95", "promoter", "lead", "to", "failure", "of", "ecdysis", ",", "and", "in", "non", "-", "molting", "worms", "to", "a", "progressive", "detachment", "of", "the", "cuticle", "from", "the", "hypodermis", ".", "These", "observations", "indicate", "that", "increased", "DB", "dynamics", "characterizes", "the", "lethargus", "phase", "of", "molting", "in", "parallel", "to", "decreased", "levels", "of", "DB", "components", "and", "that", "temporal", "expression", "of", "RNF-5", "contributes", "to", "an", "efficient", "molting", "process", ".", "\n" ]	[ "Protein" ]
octamer - DNA is a Entity, Oct-1 is a Protein, Oct-2 is a Protein, ' octamer ' sequence is a Entity, ATGCAAAT is a Entity, ATTTGCAT is a Entity, immunoglobulin genes is a Entity, housekeeping genes is a Entity, Oct-2A is a Protein, Oct-1 is a Protein, octamer site is a Entity, interleukin-1 is a Entity, MHC class II genes is a Entity, octamer sequence is a Entity, promoter is a Entity, octamer is a Entity, octamer is a Entity, octamer DNA sequence is a Entity, Oct-1 is a Protein, Oct-2A is a Protein, Oct-1 is a Protein, Oct-2A is a Protein, Oct-1 is a Protein, Oct-2A is a Protein, Oct-1 is a Protein, Oct-2A is a Protein, N - Oct-3 is a Protein, lymphocyte - specific promoter is a Entity, Oct-2A is a Protein, N - Oct-3 is a Protein	266_task0	Sentence: Astrocytes and glioblastoma cells express novel octamer-DNA binding proteins distinct from the ubiquitous Oct-1 and B cell type Oct-2 proteins. The 'octamer' sequence, ATGCAAAT or its complement ATTTGCAT, is a key element for the transcriptional regulation of immunoglobulin genes in B-lymphocytes as well as a number of housekeeping genes in all cell types. In lymphocytes, the octamer-binding protein Oct-2A and variants thereof are thought to contribute to the B-cell specific gene expression, while the ubiquitous protein Oct-1 seems to control general octamer site-dependent transcription. Various other genes, for example interleukin-1 and MHC class II genes, contain an octamer sequence in the promoter and are expressed in cells of both the immune and nervous systems. This prompted us to analyze the octamer-binding proteins in the latter cells. Using the electrophoretic mobility shift assay, at least six novel octamer binding proteins were detected in nuclear extracts of cultured mouse astrocytes. These proteins are differentially expressed in human glioblastoma and neuroblastoma cell lines. The nervous system-derived (N-Oct) proteins bound to the octamer DNA sequence in a manner which is indistinguishable from the Oct-1 and Oct-2A proteins. The relationship of the N-Oct proteins to Oct-1 and Oct-2A was analyzed by proteolytic clipping bandshift assays and by their reactivity towards antisera raised against recombinant Oct-1 and Oct-2A proteins. On the basis of these assays, all N-Oct-factors were found to be distinct from the ubiquitous Oct-1 and the lymphoid-specific Oct-2A proteins. In melanoma cells that contain the N-Oct-3 factor, a transfected lymphocyte-specific promoter was neither activated nor was it repressed upon contransfection with an Oct-2A expression vector. We therefore speculate that N-Oct-3 and other N-Oct factors have a specific role in gene expression in cells of the nervous system. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Astrocytes and glioblastoma cells express novel octamer-DNA binding proteins distinct from the ubiquitous Oct-1 and B cell type Oct-2 proteins. The 'octamer' sequence, ATGCAAAT or its complement ATTTGCAT, is a key element for the transcriptional regulation of immunoglobulin genes in B-lymphocytes as well as a number of housekeeping genes in all cell types. In lymphocytes, the octamer-binding protein Oct-2A and variants thereof are thought to contribute to the B-cell specific gene expression, while the ubiquitous protein Oct-1 seems to control general octamer site-dependent transcription. Various other genes, for example interleukin-1 and MHC class II genes, contain an octamer sequence in the promoter and are expressed in cells of both the immune and nervous systems. This prompted us to analyze the octamer-binding proteins in the latter cells. Using the electrophoretic mobility shift assay, at least six novel octamer binding proteins were detected in nuclear extracts of cultured mouse astrocytes. These proteins are differentially expressed in human glioblastoma and neuroblastoma cell lines. The nervous system-derived (N-Oct) proteins bound to the octamer DNA sequence in a manner which is indistinguishable from the Oct-1 and Oct-2A proteins. The relationship of the N-Oct proteins to Oct-1 and Oct-2A was analyzed by proteolytic clipping bandshift assays and by their reactivity towards antisera raised against recombinant Oct-1 and Oct-2A proteins. On the basis of these assays, all N-Oct-factors were found to be distinct from the ubiquitous Oct-1 and the lymphoid-specific Oct-2A proteins. In melanoma cells that contain the N-Oct-3 factor, a transfected lymphocyte-specific promoter was neither activated nor was it repressed upon contransfection with an Oct-2A expression vector. We therefore speculate that N-Oct-3 and other N-Oct factors have a specific role in gene expression in cells of the nervous system.	[ "Astrocytes", "and", "glioblastoma", "cells", "express", "novel", "octamer", "-", "DNA", "binding", "proteins", "distinct", "from", "the", "ubiquitous", "Oct-1", "and", "B", "cell", "type", "Oct-2", "proteins", ".", "\n", "The", "'", "octamer", "'", "sequence", ",", "ATGCAAAT", "or", "its", "complement", "ATTTGCAT", ",", "is", "a", "key", "element", "for", "the", "transcriptional", "regulation", "of", "immunoglobulin", "genes", "in", "B", "-", "lymphocytes", "as", "well", "as", "a", "number", "of", "housekeeping", "genes", "in", "all", "cell", "types", ".", "In", "lymphocytes", ",", "the", "octamer", "-", "binding", "protein", "Oct-2A", "and", "variants", "thereof", "are", "thought", "to", "contribute", "to", "the", "B", "-", "cell", "specific", "gene", "expression", ",", "while", "the", "ubiquitous", "protein", "Oct-1", "seems", "to", "control", "general", "octamer", "site", "-", "dependent", "transcription", ".", "Various", "other", "genes", ",", "for", "example", "interleukin-1", "and", "MHC", "class", "II", "genes", ",", "contain", "an", "octamer", "sequence", "in", "the", "promoter", "and", "are", "expressed", "in", "cells", "of", "both", "the", "immune", "and", "nervous", "systems", ".", "This", "prompted", "us", "to", "analyze", "the", "octamer", "-", "binding", "proteins", "in", "the", "latter", "cells", ".", "Using", "the", "electrophoretic", "mobility", "shift", "assay", ",", "at", "least", "six", "novel", "octamer", "binding", "proteins", "were", "detected", "in", "nuclear", "extracts", "of", "cultured", "mouse", "astrocytes", ".", "These", "proteins", "are", "differentially", "expressed", "in", "human", "glioblastoma", "and", "neuroblastoma", "cell", "lines", ".", "The", "nervous", "system", "-", "derived", "(", "N", "-", "Oct", ")", "proteins", "bound", "to", "the", "octamer", "DNA", "sequence", "in", "a", "manner", "which", "is", "indistinguishable", "from", "the", "Oct-1", "and", "Oct-2A", "proteins", ".", "The", "relationship", "of", "the", "N", "-", "Oct", "proteins", "to", "Oct-1", "and", "Oct-2A", "was", "analyzed", "by", "proteolytic", "clipping", "bandshift", "assays", "and", "by", "their", "reactivity", "towards", "antisera", "raised", "against", "recombinant", "Oct-1", "and", "Oct-2A", "proteins", ".", "On", "the", "basis", "of", "these", "assays", ",", "all", "N", "-", "Oct", "-", "factors", "were", "found", "to", "be", "distinct", "from", "the", "ubiquitous", "Oct-1", "and", "the", "lymphoid", "-", "specific", "Oct-2A", "proteins", ".", "In", "melanoma", "cells", "that", "contain", "the", "N", "-", "Oct-3", "factor", ",", "a", "transfected", "lymphocyte", "-", "specific", "promoter", "was", "neither", "activated", "nor", "was", "it", "repressed", "upon", "contransfection", "with", "an", "Oct-2A", "expression", "vector", ".", "We", "therefore", "speculate", "that", "N", "-", "Oct-3", "and", "other", "N", "-", "Oct", "factors", "have", "a", "specific", "role", "in", "gene", "expression", "in", "cells", "of", "the", "nervous", "system", ".", "\n" ]	[ "Entity", "Protein" ]
octamer - DNA is a Entity, Oct-1 is a Protein, Oct-2 is a Protein, ' octamer ' sequence is a Entity, ATGCAAAT is a Entity, ATTTGCAT is a Entity, immunoglobulin genes is a Entity, housekeeping genes is a Entity, Oct-2A is a Protein, Oct-1 is a Protein, octamer site is a Entity, interleukin-1 is a Entity, MHC class II genes is a Entity, octamer sequence is a Entity, promoter is a Entity, octamer is a Entity, octamer is a Entity, octamer DNA sequence is a Entity, Oct-1 is a Protein, Oct-2A is a Protein, Oct-1 is a Protein, Oct-2A is a Protein, Oct-1 is a Protein, Oct-2A is a Protein, Oct-1 is a Protein, Oct-2A is a Protein, N - Oct-3 is a Protein, lymphocyte - specific promoter is a Entity, Oct-2A is a Protein, N - Oct-3 is a Protein	266_task1	Sentence: Astrocytes and glioblastoma cells express novel octamer-DNA binding proteins distinct from the ubiquitous Oct-1 and B cell type Oct-2 proteins. The 'octamer' sequence, ATGCAAAT or its complement ATTTGCAT, is a key element for the transcriptional regulation of immunoglobulin genes in B-lymphocytes as well as a number of housekeeping genes in all cell types. In lymphocytes, the octamer-binding protein Oct-2A and variants thereof are thought to contribute to the B-cell specific gene expression, while the ubiquitous protein Oct-1 seems to control general octamer site-dependent transcription. Various other genes, for example interleukin-1 and MHC class II genes, contain an octamer sequence in the promoter and are expressed in cells of both the immune and nervous systems. This prompted us to analyze the octamer-binding proteins in the latter cells. Using the electrophoretic mobility shift assay, at least six novel octamer binding proteins were detected in nuclear extracts of cultured mouse astrocytes. These proteins are differentially expressed in human glioblastoma and neuroblastoma cell lines. The nervous system-derived (N-Oct) proteins bound to the octamer DNA sequence in a manner which is indistinguishable from the Oct-1 and Oct-2A proteins. The relationship of the N-Oct proteins to Oct-1 and Oct-2A was analyzed by proteolytic clipping bandshift assays and by their reactivity towards antisera raised against recombinant Oct-1 and Oct-2A proteins. On the basis of these assays, all N-Oct-factors were found to be distinct from the ubiquitous Oct-1 and the lymphoid-specific Oct-2A proteins. In melanoma cells that contain the N-Oct-3 factor, a transfected lymphocyte-specific promoter was neither activated nor was it repressed upon contransfection with an Oct-2A expression vector. We therefore speculate that N-Oct-3 and other N-Oct factors have a specific role in gene expression in cells of the nervous system. Instructions: please typing these entity words according to sentence: octamer - DNA, Oct-1, Oct-2, ' octamer ' sequence, ATGCAAAT, ATTTGCAT, immunoglobulin genes, housekeeping genes, Oct-2A, Oct-1, octamer site, interleukin-1, MHC class II genes, octamer sequence, promoter, octamer, octamer, octamer DNA sequence, Oct-1, Oct-2A, Oct-1, Oct-2A, Oct-1, Oct-2A, Oct-1, Oct-2A, N - Oct-3, lymphocyte - specific promoter, Oct-2A, N - Oct-3 Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Astrocytes and glioblastoma cells express novel octamer-DNA binding proteins distinct from the ubiquitous Oct-1 and B cell type Oct-2 proteins. The 'octamer' sequence, ATGCAAAT or its complement ATTTGCAT, is a key element for the transcriptional regulation of immunoglobulin genes in B-lymphocytes as well as a number of housekeeping genes in all cell types. In lymphocytes, the octamer-binding protein Oct-2A and variants thereof are thought to contribute to the B-cell specific gene expression, while the ubiquitous protein Oct-1 seems to control general octamer site-dependent transcription. Various other genes, for example interleukin-1 and MHC class II genes, contain an octamer sequence in the promoter and are expressed in cells of both the immune and nervous systems. This prompted us to analyze the octamer-binding proteins in the latter cells. Using the electrophoretic mobility shift assay, at least six novel octamer binding proteins were detected in nuclear extracts of cultured mouse astrocytes. These proteins are differentially expressed in human glioblastoma and neuroblastoma cell lines. The nervous system-derived (N-Oct) proteins bound to the octamer DNA sequence in a manner which is indistinguishable from the Oct-1 and Oct-2A proteins. The relationship of the N-Oct proteins to Oct-1 and Oct-2A was analyzed by proteolytic clipping bandshift assays and by their reactivity towards antisera raised against recombinant Oct-1 and Oct-2A proteins. On the basis of these assays, all N-Oct-factors were found to be distinct from the ubiquitous Oct-1 and the lymphoid-specific Oct-2A proteins. In melanoma cells that contain the N-Oct-3 factor, a transfected lymphocyte-specific promoter was neither activated nor was it repressed upon contransfection with an Oct-2A expression vector. We therefore speculate that N-Oct-3 and other N-Oct factors have a specific role in gene expression in cells of the nervous system.	[ "Astrocytes", "and", "glioblastoma", "cells", "express", "novel", "octamer", "-", "DNA", "binding", "proteins", "distinct", "from", "the", "ubiquitous", "Oct-1", "and", "B", "cell", "type", "Oct-2", "proteins", ".", "\n", "The", "'", "octamer", "'", "sequence", ",", "ATGCAAAT", "or", "its", "complement", "ATTTGCAT", ",", "is", "a", "key", "element", "for", "the", "transcriptional", "regulation", "of", "immunoglobulin", "genes", "in", "B", "-", "lymphocytes", "as", "well", "as", "a", "number", "of", "housekeeping", "genes", "in", "all", "cell", "types", ".", "In", "lymphocytes", ",", "the", "octamer", "-", "binding", "protein", "Oct-2A", "and", "variants", "thereof", "are", "thought", "to", "contribute", "to", "the", "B", "-", "cell", "specific", "gene", "expression", ",", "while", "the", "ubiquitous", "protein", "Oct-1", "seems", "to", "control", "general", "octamer", "site", "-", "dependent", "transcription", ".", "Various", "other", "genes", ",", "for", "example", "interleukin-1", "and", "MHC", "class", "II", "genes", ",", "contain", "an", "octamer", "sequence", "in", "the", "promoter", "and", "are", "expressed", "in", "cells", "of", "both", "the", "immune", "and", "nervous", "systems", ".", "This", "prompted", "us", "to", "analyze", "the", "octamer", "-", "binding", "proteins", "in", "the", "latter", "cells", ".", "Using", "the", "electrophoretic", "mobility", "shift", "assay", ",", "at", "least", "six", "novel", "octamer", "binding", "proteins", "were", "detected", "in", "nuclear", "extracts", "of", "cultured", "mouse", "astrocytes", ".", "These", "proteins", "are", "differentially", "expressed", "in", "human", "glioblastoma", "and", "neuroblastoma", "cell", "lines", ".", "The", "nervous", "system", "-", "derived", "(", "N", "-", "Oct", ")", "proteins", "bound", "to", "the", "octamer", "DNA", "sequence", "in", "a", "manner", "which", "is", "indistinguishable", "from", "the", "Oct-1", "and", "Oct-2A", "proteins", ".", "The", "relationship", "of", "the", "N", "-", "Oct", "proteins", "to", "Oct-1", "and", "Oct-2A", "was", "analyzed", "by", "proteolytic", "clipping", "bandshift", "assays", "and", "by", "their", "reactivity", "towards", "antisera", "raised", "against", "recombinant", "Oct-1", "and", "Oct-2A", "proteins", ".", "On", "the", "basis", "of", "these", "assays", ",", "all", "N", "-", "Oct", "-", "factors", "were", "found", "to", "be", "distinct", "from", "the", "ubiquitous", "Oct-1", "and", "the", "lymphoid", "-", "specific", "Oct-2A", "proteins", ".", "In", "melanoma", "cells", "that", "contain", "the", "N", "-", "Oct-3", "factor", ",", "a", "transfected", "lymphocyte", "-", "specific", "promoter", "was", "neither", "activated", "nor", "was", "it", "repressed", "upon", "contransfection", "with", "an", "Oct-2A", "expression", "vector", ".", "We", "therefore", "speculate", "that", "N", "-", "Oct-3", "and", "other", "N", "-", "Oct", "factors", "have", "a", "specific", "role", "in", "gene", "expression", "in", "cells", "of", "the", "nervous", "system", ".", "\n" ]	[ "Entity", "Protein" ]
octamer - DNA, Oct-1, Oct-2, ' octamer ' sequence, ATGCAAAT, ATTTGCAT, immunoglobulin genes, housekeeping genes, Oct-2A, Oct-1, octamer site, interleukin-1, MHC class II genes, octamer sequence, promoter, octamer, octamer, octamer DNA sequence, Oct-1, Oct-2A, Oct-1, Oct-2A, Oct-1, Oct-2A, Oct-1, Oct-2A, N - Oct-3, lymphocyte - specific promoter, Oct-2A, N - Oct-3	266_task2	Sentence: Astrocytes and glioblastoma cells express novel octamer-DNA binding proteins distinct from the ubiquitous Oct-1 and B cell type Oct-2 proteins. The 'octamer' sequence, ATGCAAAT or its complement ATTTGCAT, is a key element for the transcriptional regulation of immunoglobulin genes in B-lymphocytes as well as a number of housekeeping genes in all cell types. In lymphocytes, the octamer-binding protein Oct-2A and variants thereof are thought to contribute to the B-cell specific gene expression, while the ubiquitous protein Oct-1 seems to control general octamer site-dependent transcription. Various other genes, for example interleukin-1 and MHC class II genes, contain an octamer sequence in the promoter and are expressed in cells of both the immune and nervous systems. This prompted us to analyze the octamer-binding proteins in the latter cells. Using the electrophoretic mobility shift assay, at least six novel octamer binding proteins were detected in nuclear extracts of cultured mouse astrocytes. These proteins are differentially expressed in human glioblastoma and neuroblastoma cell lines. The nervous system-derived (N-Oct) proteins bound to the octamer DNA sequence in a manner which is indistinguishable from the Oct-1 and Oct-2A proteins. The relationship of the N-Oct proteins to Oct-1 and Oct-2A was analyzed by proteolytic clipping bandshift assays and by their reactivity towards antisera raised against recombinant Oct-1 and Oct-2A proteins. On the basis of these assays, all N-Oct-factors were found to be distinct from the ubiquitous Oct-1 and the lymphoid-specific Oct-2A proteins. In melanoma cells that contain the N-Oct-3 factor, a transfected lymphocyte-specific promoter was neither activated nor was it repressed upon contransfection with an Oct-2A expression vector. We therefore speculate that N-Oct-3 and other N-Oct factors have a specific role in gene expression in cells of the nervous system. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Astrocytes and glioblastoma cells express novel octamer-DNA binding proteins distinct from the ubiquitous Oct-1 and B cell type Oct-2 proteins. The 'octamer' sequence, ATGCAAAT or its complement ATTTGCAT, is a key element for the transcriptional regulation of immunoglobulin genes in B-lymphocytes as well as a number of housekeeping genes in all cell types. In lymphocytes, the octamer-binding protein Oct-2A and variants thereof are thought to contribute to the B-cell specific gene expression, while the ubiquitous protein Oct-1 seems to control general octamer site-dependent transcription. Various other genes, for example interleukin-1 and MHC class II genes, contain an octamer sequence in the promoter and are expressed in cells of both the immune and nervous systems. This prompted us to analyze the octamer-binding proteins in the latter cells. Using the electrophoretic mobility shift assay, at least six novel octamer binding proteins were detected in nuclear extracts of cultured mouse astrocytes. These proteins are differentially expressed in human glioblastoma and neuroblastoma cell lines. The nervous system-derived (N-Oct) proteins bound to the octamer DNA sequence in a manner which is indistinguishable from the Oct-1 and Oct-2A proteins. The relationship of the N-Oct proteins to Oct-1 and Oct-2A was analyzed by proteolytic clipping bandshift assays and by their reactivity towards antisera raised against recombinant Oct-1 and Oct-2A proteins. On the basis of these assays, all N-Oct-factors were found to be distinct from the ubiquitous Oct-1 and the lymphoid-specific Oct-2A proteins. In melanoma cells that contain the N-Oct-3 factor, a transfected lymphocyte-specific promoter was neither activated nor was it repressed upon contransfection with an Oct-2A expression vector. We therefore speculate that N-Oct-3 and other N-Oct factors have a specific role in gene expression in cells of the nervous system.	[ "Astrocytes", "and", "glioblastoma", "cells", "express", "novel", "octamer", "-", "DNA", "binding", "proteins", "distinct", "from", "the", "ubiquitous", "Oct-1", "and", "B", "cell", "type", "Oct-2", "proteins", ".", "\n", "The", "'", "octamer", "'", "sequence", ",", "ATGCAAAT", "or", "its", "complement", "ATTTGCAT", ",", "is", "a", "key", "element", "for", "the", "transcriptional", "regulation", "of", "immunoglobulin", "genes", "in", "B", "-", "lymphocytes", "as", "well", "as", "a", "number", "of", "housekeeping", "genes", "in", "all", "cell", "types", ".", "In", "lymphocytes", ",", "the", "octamer", "-", "binding", "protein", "Oct-2A", "and", "variants", "thereof", "are", "thought", "to", "contribute", "to", "the", "B", "-", "cell", "specific", "gene", "expression", ",", "while", "the", "ubiquitous", "protein", "Oct-1", "seems", "to", "control", "general", "octamer", "site", "-", "dependent", "transcription", ".", "Various", "other", "genes", ",", "for", "example", "interleukin-1", "and", "MHC", "class", "II", "genes", ",", "contain", "an", "octamer", "sequence", "in", "the", "promoter", "and", "are", "expressed", "in", "cells", "of", "both", "the", "immune", "and", "nervous", "systems", ".", "This", "prompted", "us", "to", "analyze", "the", "octamer", "-", "binding", "proteins", "in", "the", "latter", "cells", ".", "Using", "the", "electrophoretic", "mobility", "shift", "assay", ",", "at", "least", "six", "novel", "octamer", "binding", "proteins", "were", "detected", "in", "nuclear", "extracts", "of", "cultured", "mouse", "astrocytes", ".", "These", "proteins", "are", "differentially", "expressed", "in", "human", "glioblastoma", "and", "neuroblastoma", "cell", "lines", ".", "The", "nervous", "system", "-", "derived", "(", "N", "-", "Oct", ")", "proteins", "bound", "to", "the", "octamer", "DNA", "sequence", "in", "a", "manner", "which", "is", "indistinguishable", "from", "the", "Oct-1", "and", "Oct-2A", "proteins", ".", "The", "relationship", "of", "the", "N", "-", "Oct", "proteins", "to", "Oct-1", "and", "Oct-2A", "was", "analyzed", "by", "proteolytic", "clipping", "bandshift", "assays", "and", "by", "their", "reactivity", "towards", "antisera", "raised", "against", "recombinant", "Oct-1", "and", "Oct-2A", "proteins", ".", "On", "the", "basis", "of", "these", "assays", ",", "all", "N", "-", "Oct", "-", "factors", "were", "found", "to", "be", "distinct", "from", "the", "ubiquitous", "Oct-1", "and", "the", "lymphoid", "-", "specific", "Oct-2A", "proteins", ".", "In", "melanoma", "cells", "that", "contain", "the", "N", "-", "Oct-3", "factor", ",", "a", "transfected", "lymphocyte", "-", "specific", "promoter", "was", "neither", "activated", "nor", "was", "it", "repressed", "upon", "contransfection", "with", "an", "Oct-2A", "expression", "vector", ".", "We", "therefore", "speculate", "that", "N", "-", "Oct-3", "and", "other", "N", "-", "Oct", "factors", "have", "a", "specific", "role", "in", "gene", "expression", "in", "cells", "of", "the", "nervous", "system", ".", "\n" ]	[ "Entity", "Protein" ]
Wound healing is an umlsterm, growth factors is an umlsterm, Economic aspects is an umlsterm, wound healing is an umlsterm, Germany is an umlsterm, patients is an umlsterm, chronic venous insufficiency is an umlsterm, ulcers is an umlsterm, bacterial infection is an umlsterm, ulcers is an umlsterm, bacteria is an umlsterm, antibiotic is an umlsterm, treatment is an umlsterm, wound healing is an umlsterm, in vitro is an umlsterm, antiseptic is an umlsterm, function is an umlsterm, cultures is an umlsterm, fibroblasts is an umlsterm, antiseptic is an umlsterm, growth is an umlsterm, fibroblasts is an umlsterm, solution is an umlsterm, antiseptic is an umlsterm, growth is an umlsterm, fibroblasts is an umlsterm, treatment is an umlsterm, radiation is an umlsterm, antiseptic is an umlsterm	DerHautarzt.50460319.eng.abstr_task0	Sentence: Wound healing represents a dynamic process of increasing scientific interest , especially with the detection of the different growth factors . Economic aspects are also of importance in the investigation of substances used for wound healing . In Germany 25% of all patients ( ca. 1 million ) with severe chronic venous insufficiency have crural ulcers . The influence of bacterial infection of crural ulcers is controversial . There is no doubt that the quantity of bacteria is of importance . Local antibiotic treatment is difficult , as most of the substances used are known to inhibit wound healing . In vivo and in vitro investigations showed , that chiniofon-containing antiseptic has a bacteriostatic function . Additionally it was shown , using cultures of fibroblasts , that chiniofon-containing antiseptic does not inhibit the growth of fibroblasts , whereas PVP-iodine solution , a widely used antiseptic , clearly reduces the growth of fibroblasts . The good clinical results in the treatment of acute and chronic radiation damage indicate that chiniofon-containing antiseptic may have antiflammatory activity . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]	Wound healing represents a dynamic process of increasing scientific interest , especially with the detection of the different growth factors . Economic aspects are also of importance in the investigation of substances used for wound healing . In Germany 25% of all patients ( ca. 1 million ) with severe chronic venous insufficiency have crural ulcers . The influence of bacterial infection of crural ulcers is controversial . There is no doubt that the quantity of bacteria is of importance . Local antibiotic treatment is difficult , as most of the substances used are known to inhibit wound healing . In vivo and in vitro investigations showed , that chiniofon-containing antiseptic has a bacteriostatic function . Additionally it was shown , using cultures of fibroblasts , that chiniofon-containing antiseptic does not inhibit the growth of fibroblasts , whereas PVP-iodine solution , a widely used antiseptic , clearly reduces the growth of fibroblasts . The good clinical results in the treatment of acute and chronic radiation damage indicate that chiniofon-containing antiseptic may have antiflammatory activity .	[ "Wound", "healing", "represents", "a", "dynamic", "process", "of", "increasing", "scientific", "interest", ",", "especially", "with", "the", "detection", "of", "the", "different", "growth", "factors", ".", "Economic", "aspects", "are", "also", "of", "importance", "in", "the", "investigation", "of", "substances", "used", "for", "wound", "healing", ".", "In", "Germany", "25", "%", "of", "all", "patients", "(", "ca", ".", "1", "million", ")", "with", "severe", "chronic", "venous", "insufficiency", "have", "crural", "ulcers", ".", "The", "influence", "of", "bacterial", "infection", "of", "crural", "ulcers", "is", "controversial", ".", "There", "is", "no", "doubt", "that", "the", "quantity", "of", "bacteria", "is", "of", "importance", ".", "Local", "antibiotic", "treatment", "is", "difficult", ",", "as", "most", "of", "the", "substances", "used", "are", "known", "to", "inhibit", "wound", "healing", ".", "In", "vivo", "and", "in", "vitro", "investigations", "showed", ",", "that", "chiniofon", "-", "containing", "antiseptic", "has", "a", "bacteriostatic", "function", ".", "Additionally", "it", "was", "shown", ",", "using", "cultures", "of", "fibroblasts", ",", "that", "chiniofon", "-", "containing", "antiseptic", "does", "not", "inhibit", "the", "growth", "of", "fibroblasts", ",", "whereas", "PVP", "-", "iodine", "solution", ",", "a", "widely", "used", "antiseptic", ",", "clearly", "reduces", "the", "growth", "of", "fibroblasts", ".", "The", "good", "clinical", "results", "in", "the", "treatment", "of", "acute", "and", "chronic", "radiation", "damage", "indicate", "that", "chiniofon", "-", "containing", "antiseptic", "may", "have", "antiflammatory", "activity", "." ]	[ "umlsterm" ]
Wound healing is an umlsterm, growth factors is an umlsterm, Economic aspects is an umlsterm, wound healing is an umlsterm, Germany is an umlsterm, patients is an umlsterm, chronic venous insufficiency is an umlsterm, ulcers is an umlsterm, bacterial infection is an umlsterm, ulcers is an umlsterm, bacteria is an umlsterm, antibiotic is an umlsterm, treatment is an umlsterm, wound healing is an umlsterm, in vitro is an umlsterm, antiseptic is an umlsterm, function is an umlsterm, cultures is an umlsterm, fibroblasts is an umlsterm, antiseptic is an umlsterm, growth is an umlsterm, fibroblasts is an umlsterm, solution is an umlsterm, antiseptic is an umlsterm, growth is an umlsterm, fibroblasts is an umlsterm, treatment is an umlsterm, radiation is an umlsterm, antiseptic is an umlsterm	DerHautarzt.50460319.eng.abstr_task1	Sentence: Wound healing represents a dynamic process of increasing scientific interest , especially with the detection of the different growth factors . Economic aspects are also of importance in the investigation of substances used for wound healing . In Germany 25% of all patients ( ca. 1 million ) with severe chronic venous insufficiency have crural ulcers . The influence of bacterial infection of crural ulcers is controversial . There is no doubt that the quantity of bacteria is of importance . Local antibiotic treatment is difficult , as most of the substances used are known to inhibit wound healing . In vivo and in vitro investigations showed , that chiniofon-containing antiseptic has a bacteriostatic function . Additionally it was shown , using cultures of fibroblasts , that chiniofon-containing antiseptic does not inhibit the growth of fibroblasts , whereas PVP-iodine solution , a widely used antiseptic , clearly reduces the growth of fibroblasts . The good clinical results in the treatment of acute and chronic radiation damage indicate that chiniofon-containing antiseptic may have antiflammatory activity . Instructions: please typing these entity words according to sentence: Wound healing, growth factors, Economic aspects, wound healing, Germany, patients, chronic venous insufficiency, ulcers, bacterial infection, ulcers, bacteria, antibiotic, treatment, wound healing, in vitro, antiseptic, function, cultures, fibroblasts, antiseptic, growth, fibroblasts, solution, antiseptic, growth, fibroblasts, treatment, radiation, antiseptic Options: umlsterm	[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]	Wound healing represents a dynamic process of increasing scientific interest , especially with the detection of the different growth factors . Economic aspects are also of importance in the investigation of substances used for wound healing . In Germany 25% of all patients ( ca. 1 million ) with severe chronic venous insufficiency have crural ulcers . The influence of bacterial infection of crural ulcers is controversial . There is no doubt that the quantity of bacteria is of importance . Local antibiotic treatment is difficult , as most of the substances used are known to inhibit wound healing . In vivo and in vitro investigations showed , that chiniofon-containing antiseptic has a bacteriostatic function . Additionally it was shown , using cultures of fibroblasts , that chiniofon-containing antiseptic does not inhibit the growth of fibroblasts , whereas PVP-iodine solution , a widely used antiseptic , clearly reduces the growth of fibroblasts . The good clinical results in the treatment of acute and chronic radiation damage indicate that chiniofon-containing antiseptic may have antiflammatory activity .	[ "Wound", "healing", "represents", "a", "dynamic", "process", "of", "increasing", "scientific", "interest", ",", "especially", "with", "the", "detection", "of", "the", "different", "growth", "factors", ".", "Economic", "aspects", "are", "also", "of", "importance", "in", "the", "investigation", "of", "substances", "used", "for", "wound", "healing", ".", "In", "Germany", "25", "%", "of", "all", "patients", "(", "ca", ".", "1", "million", ")", "with", "severe", "chronic", "venous", "insufficiency", "have", "crural", "ulcers", ".", "The", "influence", "of", "bacterial", "infection", "of", "crural", "ulcers", "is", "controversial", ".", "There", "is", "no", "doubt", "that", "the", "quantity", "of", "bacteria", "is", "of", "importance", ".", "Local", "antibiotic", "treatment", "is", "difficult", ",", "as", "most", "of", "the", "substances", "used", "are", "known", "to", "inhibit", "wound", "healing", ".", "In", "vivo", "and", "in", "vitro", "investigations", "showed", ",", "that", "chiniofon", "-", "containing", "antiseptic", "has", "a", "bacteriostatic", "function", ".", "Additionally", "it", "was", "shown", ",", "using", "cultures", "of", "fibroblasts", ",", "that", "chiniofon", "-", "containing", "antiseptic", "does", "not", "inhibit", "the", "growth", "of", "fibroblasts", ",", "whereas", "PVP", "-", "iodine", "solution", ",", "a", "widely", "used", "antiseptic", ",", "clearly", "reduces", "the", "growth", "of", "fibroblasts", ".", "The", "good", "clinical", "results", "in", "the", "treatment", "of", "acute", "and", "chronic", "radiation", "damage", "indicate", "that", "chiniofon", "-", "containing", "antiseptic", "may", "have", "antiflammatory", "activity", "." ]	[ "umlsterm" ]
Wound healing, growth factors, Economic aspects, wound healing, Germany, patients, chronic venous insufficiency, ulcers, bacterial infection, ulcers, bacteria, antibiotic, treatment, wound healing, in vitro, antiseptic, function, cultures, fibroblasts, antiseptic, growth, fibroblasts, solution, antiseptic, growth, fibroblasts, treatment, radiation, antiseptic	DerHautarzt.50460319.eng.abstr_task2	Sentence: Wound healing represents a dynamic process of increasing scientific interest , especially with the detection of the different growth factors . Economic aspects are also of importance in the investigation of substances used for wound healing . In Germany 25% of all patients ( ca. 1 million ) with severe chronic venous insufficiency have crural ulcers . The influence of bacterial infection of crural ulcers is controversial . There is no doubt that the quantity of bacteria is of importance . Local antibiotic treatment is difficult , as most of the substances used are known to inhibit wound healing . In vivo and in vitro investigations showed , that chiniofon-containing antiseptic has a bacteriostatic function . Additionally it was shown , using cultures of fibroblasts , that chiniofon-containing antiseptic does not inhibit the growth of fibroblasts , whereas PVP-iodine solution , a widely used antiseptic , clearly reduces the growth of fibroblasts . The good clinical results in the treatment of acute and chronic radiation damage indicate that chiniofon-containing antiseptic may have antiflammatory activity . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]	Wound healing represents a dynamic process of increasing scientific interest , especially with the detection of the different growth factors . Economic aspects are also of importance in the investigation of substances used for wound healing . In Germany 25% of all patients ( ca. 1 million ) with severe chronic venous insufficiency have crural ulcers . The influence of bacterial infection of crural ulcers is controversial . There is no doubt that the quantity of bacteria is of importance . Local antibiotic treatment is difficult , as most of the substances used are known to inhibit wound healing . In vivo and in vitro investigations showed , that chiniofon-containing antiseptic has a bacteriostatic function . Additionally it was shown , using cultures of fibroblasts , that chiniofon-containing antiseptic does not inhibit the growth of fibroblasts , whereas PVP-iodine solution , a widely used antiseptic , clearly reduces the growth of fibroblasts . The good clinical results in the treatment of acute and chronic radiation damage indicate that chiniofon-containing antiseptic may have antiflammatory activity .	[ "Wound", "healing", "represents", "a", "dynamic", "process", "of", "increasing", "scientific", "interest", ",", "especially", "with", "the", "detection", "of", "the", "different", "growth", "factors", ".", "Economic", "aspects", "are", "also", "of", "importance", "in", "the", "investigation", "of", "substances", "used", "for", "wound", "healing", ".", "In", "Germany", "25", "%", "of", "all", "patients", "(", "ca", ".", "1", "million", ")", "with", "severe", "chronic", "venous", "insufficiency", "have", "crural", "ulcers", ".", "The", "influence", "of", "bacterial", "infection", "of", "crural", "ulcers", "is", "controversial", ".", "There", "is", "no", "doubt", "that", "the", "quantity", "of", "bacteria", "is", "of", "importance", ".", "Local", "antibiotic", "treatment", "is", "difficult", ",", "as", "most", "of", "the", "substances", "used", "are", "known", "to", "inhibit", "wound", "healing", ".", "In", "vivo", "and", "in", "vitro", "investigations", "showed", ",", "that", "chiniofon", "-", "containing", "antiseptic", "has", "a", "bacteriostatic", "function", ".", "Additionally", "it", "was", "shown", ",", "using", "cultures", "of", "fibroblasts", ",", "that", "chiniofon", "-", "containing", "antiseptic", "does", "not", "inhibit", "the", "growth", "of", "fibroblasts", ",", "whereas", "PVP", "-", "iodine", "solution", ",", "a", "widely", "used", "antiseptic", ",", "clearly", "reduces", "the", "growth", "of", "fibroblasts", ".", "The", "good", "clinical", "results", "in", "the", "treatment", "of", "acute", "and", "chronic", "radiation", "damage", "indicate", "that", "chiniofon", "-", "containing", "antiseptic", "may", "have", "antiflammatory", "activity", "." ]	[ "umlsterm" ]
Insulin - like growth factor-1 is a Genes & Molecular Sequences, Fas is a Genes & Molecular Sequences, phosphatidylinositol-3 kinase is a Genes & Molecular Sequences	11504_task0	Sentence: Insulin-like growth factor-1 delays Fas-mediated apoptosis in human neutrophils through the phosphatidylinositol-3 kinase pathway. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Genes & Molecular Sequences	[ "B-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "O", "B-Genes & Molecular Sequences", "O", "O", "O", "O", "O", "O", "O", "O", "B-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "O", "O" ]	Insulin-like growth factor-1 delays Fas-mediated apoptosis in human neutrophils through the phosphatidylinositol-3 kinase pathway.	[ "Insulin", "-", "like", "growth", "factor-1", "delays", "Fas", "-", "mediated", "apoptosis", "in", "human", "neutrophils", "through", "the", "phosphatidylinositol-3", "kinase", "pathway", "." ]	[ "Genes & Molecular Sequences", "Chemicals & Drugs", "" ]
Insulin - like growth factor-1 is a Genes & Molecular Sequences, Fas is a Genes & Molecular Sequences, phosphatidylinositol-3 kinase is a Genes & Molecular Sequences	11504_task1	Sentence: Insulin-like growth factor-1 delays Fas-mediated apoptosis in human neutrophils through the phosphatidylinositol-3 kinase pathway. Instructions: please typing these entity words according to sentence: Insulin - like growth factor-1, Fas, phosphatidylinositol-3 kinase Options: Genes & Molecular Sequences	[ "B-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "O", "B-Genes & Molecular Sequences", "O", "O", "O", "O", "O", "O", "O", "O", "B-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "O", "O" ]	Insulin-like growth factor-1 delays Fas-mediated apoptosis in human neutrophils through the phosphatidylinositol-3 kinase pathway.	[ "Insulin", "-", "like", "growth", "factor-1", "delays", "Fas", "-", "mediated", "apoptosis", "in", "human", "neutrophils", "through", "the", "phosphatidylinositol-3", "kinase", "pathway", "." ]	[ "Genes & Molecular Sequences", "Chemicals & Drugs", "" ]
Insulin - like growth factor-1, Fas, phosphatidylinositol-3 kinase	11504_task2	Sentence: Insulin-like growth factor-1 delays Fas-mediated apoptosis in human neutrophils through the phosphatidylinositol-3 kinase pathway. Instructions: please extract entity words from the input sentence	[ "B-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "O", "B-Genes & Molecular Sequences", "O", "O", "O", "O", "O", "O", "O", "O", "B-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "O", "O" ]	Insulin-like growth factor-1 delays Fas-mediated apoptosis in human neutrophils through the phosphatidylinositol-3 kinase pathway.	[ "Insulin", "-", "like", "growth", "factor-1", "delays", "Fas", "-", "mediated", "apoptosis", "in", "human", "neutrophils", "through", "the", "phosphatidylinositol-3", "kinase", "pathway", "." ]	[ "Genes & Molecular Sequences", "Chemicals & Drugs", "" ]
Arterien is an umlsterm, Kalksalzen is an umlsterm, Arterien is an umlsterm, unteren Extremitaet is an umlsterm, Beckenarterien is an umlsterm, Bauchaorta is an umlsterm, Herzkranzarterien is an umlsterm	ZfuerKardiologie.80870928.ger.abstr_task0	Sentence: Mediakalzinose MK ) ( ist eine Erkrankung der Arterien vom muskulaeren Typ , die durch eine zunehmende Ablagerung von Kalksalzen in der mittleren Gefaesswandschicht , der Media , charakterisiert ist . Am haeufigsten erkranken die Arterien der unteren Extremitaet , wobei ein ausgedehnter Befall mit Einbeziehung der Beckenarterien und der Bauchaorta nicht ungewoehnlich ist . Eine systemische Ausbreitung der MK mit Beteiligung der Herzkranzarterien wurde ebenfalls beschrieben , ist jedoch nach heutiger Auffassung selten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Mediakalzinose MK ) ( ist eine Erkrankung der Arterien vom muskulaeren Typ , die durch eine zunehmende Ablagerung von Kalksalzen in der mittleren Gefaesswandschicht , der Media , charakterisiert ist . Am haeufigsten erkranken die Arterien der unteren Extremitaet , wobei ein ausgedehnter Befall mit Einbeziehung der Beckenarterien und der Bauchaorta nicht ungewoehnlich ist . Eine systemische Ausbreitung der MK mit Beteiligung der Herzkranzarterien wurde ebenfalls beschrieben , ist jedoch nach heutiger Auffassung selten .	[ "Mediakalzinose", "MK", ")", "(", "ist", "eine", "Erkrankung", "der", "Arterien", "vom", "muskulaeren", "Typ", ",", "die", "durch", "eine", "zunehmende", "Ablagerung", "von", "Kalksalzen", "in", "der", "mittleren", "Gefaesswandschicht", ",", "der", "Media", ",", "charakterisiert", "ist", ".", "Am", "haeufigsten", "erkranken", "die", "Arterien", "der", "unteren", "Extremitaet", ",", "wobei", "ein", "ausgedehnter", "Befall", "mit", "Einbeziehung", "der", "Beckenarterien", "und", "der", "Bauchaorta", "nicht", "ungewoehnlich", "ist", ".", "Eine", "systemische", "Ausbreitung", "der", "MK", "mit", "Beteiligung", "der", "Herzkranzarterien", "wurde", "ebenfalls", "beschrieben", ",", "ist", "jedoch", "nach", "heutiger", "Auffassung", "selten", "." ]	[ "umlsterm" ]
Arterien is an umlsterm, Kalksalzen is an umlsterm, Arterien is an umlsterm, unteren Extremitaet is an umlsterm, Beckenarterien is an umlsterm, Bauchaorta is an umlsterm, Herzkranzarterien is an umlsterm	ZfuerKardiologie.80870928.ger.abstr_task1	Sentence: Mediakalzinose MK ) ( ist eine Erkrankung der Arterien vom muskulaeren Typ , die durch eine zunehmende Ablagerung von Kalksalzen in der mittleren Gefaesswandschicht , der Media , charakterisiert ist . Am haeufigsten erkranken die Arterien der unteren Extremitaet , wobei ein ausgedehnter Befall mit Einbeziehung der Beckenarterien und der Bauchaorta nicht ungewoehnlich ist . Eine systemische Ausbreitung der MK mit Beteiligung der Herzkranzarterien wurde ebenfalls beschrieben , ist jedoch nach heutiger Auffassung selten . Instructions: please typing these entity words according to sentence: Arterien, Kalksalzen, Arterien, unteren Extremitaet, Beckenarterien, Bauchaorta, Herzkranzarterien Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Mediakalzinose MK ) ( ist eine Erkrankung der Arterien vom muskulaeren Typ , die durch eine zunehmende Ablagerung von Kalksalzen in der mittleren Gefaesswandschicht , der Media , charakterisiert ist . Am haeufigsten erkranken die Arterien der unteren Extremitaet , wobei ein ausgedehnter Befall mit Einbeziehung der Beckenarterien und der Bauchaorta nicht ungewoehnlich ist . Eine systemische Ausbreitung der MK mit Beteiligung der Herzkranzarterien wurde ebenfalls beschrieben , ist jedoch nach heutiger Auffassung selten .	[ "Mediakalzinose", "MK", ")", "(", "ist", "eine", "Erkrankung", "der", "Arterien", "vom", "muskulaeren", "Typ", ",", "die", "durch", "eine", "zunehmende", "Ablagerung", "von", "Kalksalzen", "in", "der", "mittleren", "Gefaesswandschicht", ",", "der", "Media", ",", "charakterisiert", "ist", ".", "Am", "haeufigsten", "erkranken", "die", "Arterien", "der", "unteren", "Extremitaet", ",", "wobei", "ein", "ausgedehnter", "Befall", "mit", "Einbeziehung", "der", "Beckenarterien", "und", "der", "Bauchaorta", "nicht", "ungewoehnlich", "ist", ".", "Eine", "systemische", "Ausbreitung", "der", "MK", "mit", "Beteiligung", "der", "Herzkranzarterien", "wurde", "ebenfalls", "beschrieben", ",", "ist", "jedoch", "nach", "heutiger", "Auffassung", "selten", "." ]	[ "umlsterm" ]
Arterien, Kalksalzen, Arterien, unteren Extremitaet, Beckenarterien, Bauchaorta, Herzkranzarterien	ZfuerKardiologie.80870928.ger.abstr_task2	Sentence: Mediakalzinose MK ) ( ist eine Erkrankung der Arterien vom muskulaeren Typ , die durch eine zunehmende Ablagerung von Kalksalzen in der mittleren Gefaesswandschicht , der Media , charakterisiert ist . Am haeufigsten erkranken die Arterien der unteren Extremitaet , wobei ein ausgedehnter Befall mit Einbeziehung der Beckenarterien und der Bauchaorta nicht ungewoehnlich ist . Eine systemische Ausbreitung der MK mit Beteiligung der Herzkranzarterien wurde ebenfalls beschrieben , ist jedoch nach heutiger Auffassung selten . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Mediakalzinose MK ) ( ist eine Erkrankung der Arterien vom muskulaeren Typ , die durch eine zunehmende Ablagerung von Kalksalzen in der mittleren Gefaesswandschicht , der Media , charakterisiert ist . Am haeufigsten erkranken die Arterien der unteren Extremitaet , wobei ein ausgedehnter Befall mit Einbeziehung der Beckenarterien und der Bauchaorta nicht ungewoehnlich ist . Eine systemische Ausbreitung der MK mit Beteiligung der Herzkranzarterien wurde ebenfalls beschrieben , ist jedoch nach heutiger Auffassung selten .	[ "Mediakalzinose", "MK", ")", "(", "ist", "eine", "Erkrankung", "der", "Arterien", "vom", "muskulaeren", "Typ", ",", "die", "durch", "eine", "zunehmende", "Ablagerung", "von", "Kalksalzen", "in", "der", "mittleren", "Gefaesswandschicht", ",", "der", "Media", ",", "charakterisiert", "ist", ".", "Am", "haeufigsten", "erkranken", "die", "Arterien", "der", "unteren", "Extremitaet", ",", "wobei", "ein", "ausgedehnter", "Befall", "mit", "Einbeziehung", "der", "Beckenarterien", "und", "der", "Bauchaorta", "nicht", "ungewoehnlich", "ist", ".", "Eine", "systemische", "Ausbreitung", "der", "MK", "mit", "Beteiligung", "der", "Herzkranzarterien", "wurde", "ebenfalls", "beschrieben", ",", "ist", "jedoch", "nach", "heutiger", "Auffassung", "selten", "." ]	[ "umlsterm" ]
Mepyramine is a CHEMICAL, histamine H1 receptor is a GENE-N, rat and human P450 2D is a GENE-N	7853212_task0	Sentence: Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, CHEMICAL	[ "B-CHEMICAL", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O" ]	Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms.	[ "Mepyramine", ",", "a", "histamine", "H1", "receptor", "antagonist", ",", "inhibits", "the", "metabolic", "activity", "of", "rat", "and", "human", "P450", "2D", "forms", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
Mepyramine is a CHEMICAL, histamine H1 receptor is a GENE-N, rat and human P450 2D is a GENE-N	7853212_task1	Sentence: Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms. Instructions: please typing these entity words according to sentence: Mepyramine, histamine H1 receptor, rat and human P450 2D Options: GENE-N, CHEMICAL	[ "B-CHEMICAL", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O" ]	Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms.	[ "Mepyramine", ",", "a", "histamine", "H1", "receptor", "antagonist", ",", "inhibits", "the", "metabolic", "activity", "of", "rat", "and", "human", "P450", "2D", "forms", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
Mepyramine, histamine H1 receptor, rat and human P450 2D	7853212_task2	Sentence: Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms. Instructions: please extract entity words from the input sentence	[ "B-CHEMICAL", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O" ]	Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms.	[ "Mepyramine", ",", "a", "histamine", "H1", "receptor", "antagonist", ",", "inhibits", "the", "metabolic", "activity", "of", "rat", "and", "human", "P450", "2D", "forms", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
Monoamine Oxidase A is a GENE-Y, Harmaline is a CHEMICAL, 5-Methoxy - N , N - Dimethyltryptamine is a CHEMICAL, CYP2D6 is a GENE-Y, 5-Methoxy - N , N - dimethyltryptamine is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, 5-MEO is a CHEMICAL, indolealkylamines is a CHEMICAL, monoamine oxidase A is a GENE-Y, MAO - A is a GENE-Y, harmaline is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, harmaline is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, CYP2D6 is a GENE-Y, harmaline is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, O is a CHEMICAL, bufotenine is a CHEMICAL, MAO - A is a GENE-Y, harmaline is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, harmaline is a CHEMICAL, CYP2D6 is a GENE-Y, Harmaline is a CHEMICAL, bufotenine is a CHEMICAL, CYP2D6 is a GENE-Y, harmaline is a CHEMICAL, bufotenine is a CHEMICAL, harmaline is a CHEMICAL, bufotenine is a CHEMICAL, CYP2D6 is a GENE-Y, 5-MeO - DMT is a CHEMICAL, harmaline is a CHEMICAL, harmaline is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, bufotenine is a CHEMICAL, CYP2D6 is a GENE-Y, harmaline is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, CYP2D6 is a GENE-Y	6196_task0	Sentence: Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name "5-MEO") is a newer designer drug belonging to a group of naturally occurring indolealkylamines. Our recent study has demonstrated that coadministration of monoamine oxidase A (MAO-A) inhibitor harmaline (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine. This study is aimed at delineating harmaline and 5-MeO-DMT pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of CYP2D6 that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine. Our data revealed that inhibition of MAO-A-mediated metabolic elimination by harmaline (2, 5, and 15 mg/kg) led to a sharp increase in systemic and cerebral exposure to 5-MeO-DMT (2 and 10 mg/kg) at all dose combinations. A more pronounced effect on 5-MeO-DMT PK was associated with greater exposure to harmaline in wild-type mice than CYP2D6-humanized (Tg-CYP2D6) mice. Harmaline (5 mg/kg) also increased blood and brain bufotenine concentrations that were generally higher in Tg-CYP2D6 mice. Surprisingly, greater harmaline dose (15 mg/kg) reduced bufotenine levels. The in vivo inhibitory effect of harmaline on CYP2D6-catalyzed bufotenine formation was confirmed by in vitro study using purified CYP2D6. Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models. This PK model may be further employed to predict harmaline and 5-MeO-DMT PK interactions at various doses, define the impact of CYP2D6 status, and drive harmaline-5-MeO-DMT pharmacodynamics. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL	[ "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name "5-MEO") is a newer designer drug belonging to a group of naturally occurring indolealkylamines. Our recent study has demonstrated that coadministration of monoamine oxidase A (MAO-A) inhibitor harmaline (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine. This study is aimed at delineating harmaline and 5-MeO-DMT pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of CYP2D6 that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine. Our data revealed that inhibition of MAO-A-mediated metabolic elimination by harmaline (2, 5, and 15 mg/kg) led to a sharp increase in systemic and cerebral exposure to 5-MeO-DMT (2 and 10 mg/kg) at all dose combinations. A more pronounced effect on 5-MeO-DMT PK was associated with greater exposure to harmaline in wild-type mice than CYP2D6-humanized (Tg-CYP2D6) mice. Harmaline (5 mg/kg) also increased blood and brain bufotenine concentrations that were generally higher in Tg-CYP2D6 mice. Surprisingly, greater harmaline dose (15 mg/kg) reduced bufotenine levels. The in vivo inhibitory effect of harmaline on CYP2D6-catalyzed bufotenine formation was confirmed by in vitro study using purified CYP2D6. Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models. This PK model may be further employed to predict harmaline and 5-MeO-DMT PK interactions at various doses, define the impact of CYP2D6 status, and drive harmaline-5-MeO-DMT pharmacodynamics.	[ "Pharmacokinetic", "Interactions", "between", "Monoamine", "Oxidase", "A", "Inhibitor", "Harmaline", "and", "5-Methoxy", "-", "N", ",", "N", "-", "Dimethyltryptamine", ",", "and", "the", "Impact", "of", "CYP2D6", "Status", ".", "\n", "5-Methoxy", "-", "N", ",", "N", "-", "dimethyltryptamine", "(", "5-MeO", "-", "DMT", "or", "street", "name", "\"", "5-MEO", "\"", ")", "is", "a", "newer", "designer", "drug", "belonging", "to", "a", "group", "of", "naturally", "occurring", "indolealkylamines", ".", "Our", "recent", "study", "has", "demonstrated", "that", "coadministration", "of", "monoamine", "oxidase", "A", "(", "MAO", "-", "A", ")", "inhibitor", "harmaline", "(", "5", "mg", "/", "kg", ")", "increases", "systemic", "exposure", "to", "5-MeO", "-", "DMT", "(", "2", "mg", "/", "kg", ")", "and", "active", "metabolite", "bufotenine", ".", "This", "study", "is", "aimed", "at", "delineating", "harmaline", "and", "5-MeO", "-", "DMT", "pharmacokinetic", "(", "PK", ")", "interactions", "at", "multiple", "dose", "levels", ",", "as", "well", "as", "the", "impact", "of", "CYP2D6", "that", "affects", "harmaline", "PK", "and", "determines", "5-MeO", "-", "DMT", "O", "-", "demethylation", "to", "produce", "bufotenine", ".", "Our", "data", "revealed", "that", "inhibition", "of", "MAO", "-", "A", "-", "mediated", "metabolic", "elimination", "by", "harmaline", "(", "2", ",", "5", ",", "and", "15", "mg", "/", "kg", ")", "led", "to", "a", "sharp", "increase", "in", "systemic", "and", "cerebral", "exposure", "to", "5-MeO", "-", "DMT", "(", "2", "and", "10", "mg", "/", "kg", ")", "at", "all", "dose", "combinations", ".", "A", "more", "pronounced", "effect", "on", "5-MeO", "-", "DMT", "PK", "was", "associated", "with", "greater", "exposure", "to", "harmaline", "in", "wild", "-", "type", "mice", "than", "CYP2D6-humanized", "(", "Tg", "-", "CYP2D6", ")", "mice", ".", "Harmaline", "(", "5", "mg", "/", "kg", ")", "also", "increased", "blood", "and", "brain", "bufotenine", "concentrations", "that", "were", "generally", "higher", "in", "Tg", "-", "CYP2D6", "mice", ".", "Surprisingly", ",", "greater", "harmaline", "dose", "(", "15", "mg", "/", "kg", ")", "reduced", "bufotenine", "levels", ".", "The", "in", "vivo", "inhibitory", "effect", "of", "harmaline", "on", "CYP2D6-catalyzed", "bufotenine", "formation", "was", "confirmed", "by", "in", "vitro", "study", "using", "purified", "CYP2D6", ".", "Given", "these", "findings", ",", "a", "unified", "PK", "model", "including", "the", "inhibition", "of", "MAO", "-", "A-", "and", "CYP2D6-catalyzed", "5-MeO", "-", "DMT", "metabolism", "by", "harmaline", "was", "developed", "to", "describe", "blood", "harmaline", ",", "5-MeO", "-", "DMT", ",", "and", "bufotenine", "PK", "profiles", "in", "both", "wild", "-", "type", "and", "Tg", "-", "CYP2D6", "mouse", "models", ".", "This", "PK", "model", "may", "be", "further", "employed", "to", "predict", "harmaline", "and", "5-MeO", "-", "DMT", "PK", "interactions", "at", "various", "doses", ",", "define", "the", "impact", "of", "CYP2D6", "status", ",", "and", "drive", "harmaline-5-MeO", "-", "DMT", "pharmacodynamics", "." ]	[ "CHEMICAL", "GENE-Y" ]
Monoamine Oxidase A is a GENE-Y, Harmaline is a CHEMICAL, 5-Methoxy - N , N - Dimethyltryptamine is a CHEMICAL, CYP2D6 is a GENE-Y, 5-Methoxy - N , N - dimethyltryptamine is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, 5-MEO is a CHEMICAL, indolealkylamines is a CHEMICAL, monoamine oxidase A is a GENE-Y, MAO - A is a GENE-Y, harmaline is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, harmaline is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, CYP2D6 is a GENE-Y, harmaline is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, O is a CHEMICAL, bufotenine is a CHEMICAL, MAO - A is a GENE-Y, harmaline is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, harmaline is a CHEMICAL, CYP2D6 is a GENE-Y, Harmaline is a CHEMICAL, bufotenine is a CHEMICAL, CYP2D6 is a GENE-Y, harmaline is a CHEMICAL, bufotenine is a CHEMICAL, harmaline is a CHEMICAL, bufotenine is a CHEMICAL, CYP2D6 is a GENE-Y, 5-MeO - DMT is a CHEMICAL, harmaline is a CHEMICAL, harmaline is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, bufotenine is a CHEMICAL, CYP2D6 is a GENE-Y, harmaline is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, CYP2D6 is a GENE-Y	6196_task1	Sentence: Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name "5-MEO") is a newer designer drug belonging to a group of naturally occurring indolealkylamines. Our recent study has demonstrated that coadministration of monoamine oxidase A (MAO-A) inhibitor harmaline (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine. This study is aimed at delineating harmaline and 5-MeO-DMT pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of CYP2D6 that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine. Our data revealed that inhibition of MAO-A-mediated metabolic elimination by harmaline (2, 5, and 15 mg/kg) led to a sharp increase in systemic and cerebral exposure to 5-MeO-DMT (2 and 10 mg/kg) at all dose combinations. A more pronounced effect on 5-MeO-DMT PK was associated with greater exposure to harmaline in wild-type mice than CYP2D6-humanized (Tg-CYP2D6) mice. Harmaline (5 mg/kg) also increased blood and brain bufotenine concentrations that were generally higher in Tg-CYP2D6 mice. Surprisingly, greater harmaline dose (15 mg/kg) reduced bufotenine levels. The in vivo inhibitory effect of harmaline on CYP2D6-catalyzed bufotenine formation was confirmed by in vitro study using purified CYP2D6. Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models. This PK model may be further employed to predict harmaline and 5-MeO-DMT PK interactions at various doses, define the impact of CYP2D6 status, and drive harmaline-5-MeO-DMT pharmacodynamics. Instructions: please typing these entity words according to sentence: Monoamine Oxidase A, Harmaline, 5-Methoxy - N , N - Dimethyltryptamine, CYP2D6, 5-Methoxy - N , N - dimethyltryptamine, 5-MeO - DMT, 5-MEO, indolealkylamines, monoamine oxidase A, MAO - A, harmaline, 5-MeO - DMT, harmaline, 5-MeO - DMT, CYP2D6, harmaline, 5-MeO - DMT, O, bufotenine, MAO - A, harmaline, 5-MeO - DMT, 5-MeO - DMT, harmaline, CYP2D6, Harmaline, bufotenine, CYP2D6, harmaline, bufotenine, harmaline, bufotenine, CYP2D6, 5-MeO - DMT, harmaline, harmaline, 5-MeO - DMT, bufotenine, CYP2D6, harmaline, 5-MeO - DMT, CYP2D6 Options: GENE-Y, CHEMICAL	[ "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name "5-MEO") is a newer designer drug belonging to a group of naturally occurring indolealkylamines. Our recent study has demonstrated that coadministration of monoamine oxidase A (MAO-A) inhibitor harmaline (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine. This study is aimed at delineating harmaline and 5-MeO-DMT pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of CYP2D6 that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine. Our data revealed that inhibition of MAO-A-mediated metabolic elimination by harmaline (2, 5, and 15 mg/kg) led to a sharp increase in systemic and cerebral exposure to 5-MeO-DMT (2 and 10 mg/kg) at all dose combinations. A more pronounced effect on 5-MeO-DMT PK was associated with greater exposure to harmaline in wild-type mice than CYP2D6-humanized (Tg-CYP2D6) mice. Harmaline (5 mg/kg) also increased blood and brain bufotenine concentrations that were generally higher in Tg-CYP2D6 mice. Surprisingly, greater harmaline dose (15 mg/kg) reduced bufotenine levels. The in vivo inhibitory effect of harmaline on CYP2D6-catalyzed bufotenine formation was confirmed by in vitro study using purified CYP2D6. Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models. This PK model may be further employed to predict harmaline and 5-MeO-DMT PK interactions at various doses, define the impact of CYP2D6 status, and drive harmaline-5-MeO-DMT pharmacodynamics.	[ "Pharmacokinetic", "Interactions", "between", "Monoamine", "Oxidase", "A", "Inhibitor", "Harmaline", "and", "5-Methoxy", "-", "N", ",", "N", "-", "Dimethyltryptamine", ",", "and", "the", "Impact", "of", "CYP2D6", "Status", ".", "\n", "5-Methoxy", "-", "N", ",", "N", "-", "dimethyltryptamine", "(", "5-MeO", "-", "DMT", "or", "street", "name", "\"", "5-MEO", "\"", ")", "is", "a", "newer", "designer", "drug", "belonging", "to", "a", "group", "of", "naturally", "occurring", "indolealkylamines", ".", "Our", "recent", "study", "has", "demonstrated", "that", "coadministration", "of", "monoamine", "oxidase", "A", "(", "MAO", "-", "A", ")", "inhibitor", "harmaline", "(", "5", "mg", "/", "kg", ")", "increases", "systemic", "exposure", "to", "5-MeO", "-", "DMT", "(", "2", "mg", "/", "kg", ")", "and", "active", "metabolite", "bufotenine", ".", "This", "study", "is", "aimed", "at", "delineating", "harmaline", "and", "5-MeO", "-", "DMT", "pharmacokinetic", "(", "PK", ")", "interactions", "at", "multiple", "dose", "levels", ",", "as", "well", "as", "the", "impact", "of", "CYP2D6", "that", "affects", "harmaline", "PK", "and", "determines", "5-MeO", "-", "DMT", "O", "-", "demethylation", "to", "produce", "bufotenine", ".", "Our", "data", "revealed", "that", "inhibition", "of", "MAO", "-", "A", "-", "mediated", "metabolic", "elimination", "by", "harmaline", "(", "2", ",", "5", ",", "and", "15", "mg", "/", "kg", ")", "led", "to", "a", "sharp", "increase", "in", "systemic", "and", "cerebral", "exposure", "to", "5-MeO", "-", "DMT", "(", "2", "and", "10", "mg", "/", "kg", ")", "at", "all", "dose", "combinations", ".", "A", "more", "pronounced", "effect", "on", "5-MeO", "-", "DMT", "PK", "was", "associated", "with", "greater", "exposure", "to", "harmaline", "in", "wild", "-", "type", "mice", "than", "CYP2D6-humanized", "(", "Tg", "-", "CYP2D6", ")", "mice", ".", "Harmaline", "(", "5", "mg", "/", "kg", ")", "also", "increased", "blood", "and", "brain", "bufotenine", "concentrations", "that", "were", "generally", "higher", "in", "Tg", "-", "CYP2D6", "mice", ".", "Surprisingly", ",", "greater", "harmaline", "dose", "(", "15", "mg", "/", "kg", ")", "reduced", "bufotenine", "levels", ".", "The", "in", "vivo", "inhibitory", "effect", "of", "harmaline", "on", "CYP2D6-catalyzed", "bufotenine", "formation", "was", "confirmed", "by", "in", "vitro", "study", "using", "purified", "CYP2D6", ".", "Given", "these", "findings", ",", "a", "unified", "PK", "model", "including", "the", "inhibition", "of", "MAO", "-", "A-", "and", "CYP2D6-catalyzed", "5-MeO", "-", "DMT", "metabolism", "by", "harmaline", "was", "developed", "to", "describe", "blood", "harmaline", ",", "5-MeO", "-", "DMT", ",", "and", "bufotenine", "PK", "profiles", "in", "both", "wild", "-", "type", "and", "Tg", "-", "CYP2D6", "mouse", "models", ".", "This", "PK", "model", "may", "be", "further", "employed", "to", "predict", "harmaline", "and", "5-MeO", "-", "DMT", "PK", "interactions", "at", "various", "doses", ",", "define", "the", "impact", "of", "CYP2D6", "status", ",", "and", "drive", "harmaline-5-MeO", "-", "DMT", "pharmacodynamics", "." ]	[ "CHEMICAL", "GENE-Y" ]
Monoamine Oxidase A, Harmaline, 5-Methoxy - N , N - Dimethyltryptamine, CYP2D6, 5-Methoxy - N , N - dimethyltryptamine, 5-MeO - DMT, 5-MEO, indolealkylamines, monoamine oxidase A, MAO - A, harmaline, 5-MeO - DMT, harmaline, 5-MeO - DMT, CYP2D6, harmaline, 5-MeO - DMT, O, bufotenine, MAO - A, harmaline, 5-MeO - DMT, 5-MeO - DMT, harmaline, CYP2D6, Harmaline, bufotenine, CYP2D6, harmaline, bufotenine, harmaline, bufotenine, CYP2D6, 5-MeO - DMT, harmaline, harmaline, 5-MeO - DMT, bufotenine, CYP2D6, harmaline, 5-MeO - DMT, CYP2D6	6196_task2	Sentence: Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name "5-MEO") is a newer designer drug belonging to a group of naturally occurring indolealkylamines. Our recent study has demonstrated that coadministration of monoamine oxidase A (MAO-A) inhibitor harmaline (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine. This study is aimed at delineating harmaline and 5-MeO-DMT pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of CYP2D6 that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine. Our data revealed that inhibition of MAO-A-mediated metabolic elimination by harmaline (2, 5, and 15 mg/kg) led to a sharp increase in systemic and cerebral exposure to 5-MeO-DMT (2 and 10 mg/kg) at all dose combinations. A more pronounced effect on 5-MeO-DMT PK was associated with greater exposure to harmaline in wild-type mice than CYP2D6-humanized (Tg-CYP2D6) mice. Harmaline (5 mg/kg) also increased blood and brain bufotenine concentrations that were generally higher in Tg-CYP2D6 mice. Surprisingly, greater harmaline dose (15 mg/kg) reduced bufotenine levels. The in vivo inhibitory effect of harmaline on CYP2D6-catalyzed bufotenine formation was confirmed by in vitro study using purified CYP2D6. Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models. This PK model may be further employed to predict harmaline and 5-MeO-DMT PK interactions at various doses, define the impact of CYP2D6 status, and drive harmaline-5-MeO-DMT pharmacodynamics. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name "5-MEO") is a newer designer drug belonging to a group of naturally occurring indolealkylamines. Our recent study has demonstrated that coadministration of monoamine oxidase A (MAO-A) inhibitor harmaline (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine. This study is aimed at delineating harmaline and 5-MeO-DMT pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of CYP2D6 that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine. Our data revealed that inhibition of MAO-A-mediated metabolic elimination by harmaline (2, 5, and 15 mg/kg) led to a sharp increase in systemic and cerebral exposure to 5-MeO-DMT (2 and 10 mg/kg) at all dose combinations. A more pronounced effect on 5-MeO-DMT PK was associated with greater exposure to harmaline in wild-type mice than CYP2D6-humanized (Tg-CYP2D6) mice. Harmaline (5 mg/kg) also increased blood and brain bufotenine concentrations that were generally higher in Tg-CYP2D6 mice. Surprisingly, greater harmaline dose (15 mg/kg) reduced bufotenine levels. The in vivo inhibitory effect of harmaline on CYP2D6-catalyzed bufotenine formation was confirmed by in vitro study using purified CYP2D6. Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models. This PK model may be further employed to predict harmaline and 5-MeO-DMT PK interactions at various doses, define the impact of CYP2D6 status, and drive harmaline-5-MeO-DMT pharmacodynamics.	[ "Pharmacokinetic", "Interactions", "between", "Monoamine", "Oxidase", "A", "Inhibitor", "Harmaline", "and", "5-Methoxy", "-", "N", ",", "N", "-", "Dimethyltryptamine", ",", "and", "the", "Impact", "of", "CYP2D6", "Status", ".", "\n", "5-Methoxy", "-", "N", ",", "N", "-", "dimethyltryptamine", "(", "5-MeO", "-", "DMT", "or", "street", "name", "\"", "5-MEO", "\"", ")", "is", "a", "newer", "designer", "drug", "belonging", "to", "a", "group", "of", "naturally", "occurring", "indolealkylamines", ".", "Our", "recent", "study", "has", "demonstrated", "that", "coadministration", "of", "monoamine", "oxidase", "A", "(", "MAO", "-", "A", ")", "inhibitor", "harmaline", "(", "5", "mg", "/", "kg", ")", "increases", "systemic", "exposure", "to", "5-MeO", "-", "DMT", "(", "2", "mg", "/", "kg", ")", "and", "active", "metabolite", "bufotenine", ".", "This", "study", "is", "aimed", "at", "delineating", "harmaline", "and", "5-MeO", "-", "DMT", "pharmacokinetic", "(", "PK", ")", "interactions", "at", "multiple", "dose", "levels", ",", "as", "well", "as", "the", "impact", "of", "CYP2D6", "that", "affects", "harmaline", "PK", "and", "determines", "5-MeO", "-", "DMT", "O", "-", "demethylation", "to", "produce", "bufotenine", ".", "Our", "data", "revealed", "that", "inhibition", "of", "MAO", "-", "A", "-", "mediated", "metabolic", "elimination", "by", "harmaline", "(", "2", ",", "5", ",", "and", "15", "mg", "/", "kg", ")", "led", "to", "a", "sharp", "increase", "in", "systemic", "and", "cerebral", "exposure", "to", "5-MeO", "-", "DMT", "(", "2", "and", "10", "mg", "/", "kg", ")", "at", "all", "dose", "combinations", ".", "A", "more", "pronounced", "effect", "on", "5-MeO", "-", "DMT", "PK", "was", "associated", "with", "greater", "exposure", "to", "harmaline", "in", "wild", "-", "type", "mice", "than", "CYP2D6-humanized", "(", "Tg", "-", "CYP2D6", ")", "mice", ".", "Harmaline", "(", "5", "mg", "/", "kg", ")", "also", "increased", "blood", "and", "brain", "bufotenine", "concentrations", "that", "were", "generally", "higher", "in", "Tg", "-", "CYP2D6", "mice", ".", "Surprisingly", ",", "greater", "harmaline", "dose", "(", "15", "mg", "/", "kg", ")", "reduced", "bufotenine", "levels", ".", "The", "in", "vivo", "inhibitory", "effect", "of", "harmaline", "on", "CYP2D6-catalyzed", "bufotenine", "formation", "was", "confirmed", "by", "in", "vitro", "study", "using", "purified", "CYP2D6", ".", "Given", "these", "findings", ",", "a", "unified", "PK", "model", "including", "the", "inhibition", "of", "MAO", "-", "A-", "and", "CYP2D6-catalyzed", "5-MeO", "-", "DMT", "metabolism", "by", "harmaline", "was", "developed", "to", "describe", "blood", "harmaline", ",", "5-MeO", "-", "DMT", ",", "and", "bufotenine", "PK", "profiles", "in", "both", "wild", "-", "type", "and", "Tg", "-", "CYP2D6", "mouse", "models", ".", "This", "PK", "model", "may", "be", "further", "employed", "to", "predict", "harmaline", "and", "5-MeO", "-", "DMT", "PK", "interactions", "at", "various", "doses", ",", "define", "the", "impact", "of", "CYP2D6", "status", ",", "and", "drive", "harmaline-5-MeO", "-", "DMT", "pharmacodynamics", "." ]	[ "CHEMICAL", "GENE-Y" ]
perfluoroalkyl acid is a CHEMICAL	23567314_task0	Sentence: Evaluation of perfluoroalkyl acid activity using primary mouse and human hepatocytes. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL	[ "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]	Evaluation of perfluoroalkyl acid activity using primary mouse and human hepatocytes.	[ "Evaluation", "of", "perfluoroalkyl", "acid", "activity", "using", "primary", "mouse", "and", "human", "hepatocytes", "." ]	[ "GENE-Y", "CHEMICAL" ]
perfluoroalkyl acid is a CHEMICAL	23567314_task1	Sentence: Evaluation of perfluoroalkyl acid activity using primary mouse and human hepatocytes. Instructions: please typing these entity words according to sentence: perfluoroalkyl acid Options: CHEMICAL	[ "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]	Evaluation of perfluoroalkyl acid activity using primary mouse and human hepatocytes.	[ "Evaluation", "of", "perfluoroalkyl", "acid", "activity", "using", "primary", "mouse", "and", "human", "hepatocytes", "." ]	[ "GENE-Y", "CHEMICAL" ]
perfluoroalkyl acid	23567314_task2	Sentence: Evaluation of perfluoroalkyl acid activity using primary mouse and human hepatocytes. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]	Evaluation of perfluoroalkyl acid activity using primary mouse and human hepatocytes.	[ "Evaluation", "of", "perfluoroalkyl", "acid", "activity", "using", "primary", "mouse", "and", "human", "hepatocytes", "." ]	[ "GENE-Y", "CHEMICAL" ]
Irene is a NOMBRE_SUJETO_ASISTENCIA, Martinez Alejandre is a NOMBRE_SUJETO_ASISTENCIA, 4356456 is a ID_SUJETO_ASISTENCIA, 06 52839679 56 is a ID_ASEGURAMIENTO, Pamplona is a TERRITORIO, 31256 is a TERRITORIO, 21/04/1992 is a FECHAS, España is a PAIS, 26 años is a EDAD_SUJETO_ASISTENCIA, 08/06/2018 is a FECHAS, Francisco Javier Repáraz Padrós is a NOMBRE_PERSONAL_SANITARIO, 31 31 25402 is a ID_TITULACION_PERSONAL_SANITARIO, 26 años is a EDAD_SUJETO_ASISTENCIA, Francisco Javier Repáraz Padrós is a NOMBRE_PERSONAL_SANITARIO, Hospital de Navarra is a HOSPITAL, Irunlarrea , 3 is a CALLE, 31008 is a TERRITORIO, Pamplona is a TERRITORIO, 848422206 is a NUMERO_TELEFONO, repamapr@hotmail.com is a CORREO_ELECTRONICO	407_task0	Sentence: Datos del paciente. Nombre: Irene. Apellidos: Martinez Alejandre. NHC: 4356456. NASS: 06 52839679 56. Domicilio: Calle Las Lomas, 13, 7C. Localidad/ Provincia: Pamplona. CP: 31256. Datos asistenciales. Fecha de nacimiento: 21/04/1992. País de nacimiento: España. Edad: 26 años Sexo: M. Fecha de Ingreso: 08/06/2018. Médico:Francisco Javier Repáraz Padrós NºCol: 31 31 25402. Informe clínico del paciente: paciente de 26 años que acude a consulta por dolor en la muñeca derecha de 7 años de evolución sin antecedente traumático. El dolor en reposo era de carácter leve, pero aumentaba con la actividad manual y especialmente con la extensión forzada de la muñeca. No mejoraba con tratamiento médico sintomático. La interlínea articular radiocarpiana dorsal y el polo proximal del escafoides eran dolorosos a la palpación. No se apreciaba tumoración palpable. La movilidad de la muñeca presentaba una ligera limitación en los últimos grados de flexión y extensión. La imagen radiológica mostraba una lesión radiolucente, bien definida, ovalada, localizada en el tercio medio-dorsal del escafoides. En la TAC se apreciaba la localización excéntrica dorsal de la lesión y un punteado compatible con calcificaciones. En la RM destacaban signos de marcado edema óseo en el escafoides, excepto en su tercio distal y sinovitis adyacente. Con el diagnóstico de sospecha de una lesión benigna (encondroma, ganglión intraóseo) se decidió el tratamiento quirúrgico de la lesión. Éste se realizó mediante una vía de abordaje dorsal del escafoides. Tras la apertura de la cápsula articular se expuso la cara dorsal de la epífisis distal del radio y del escafoides, apreciándose en el tercio medio de este último una tumoración de aspecto nacarado y coloración rojo vinosa que ocupaba la cresta dorsal del hueso navicular. Se realizó un legrado exhaustivo de la lesión y relleno del defecto con injerto óseo esponjoso de cresta iliaca. El material remitido estaba formado por islotes de matriz cartilaginosa rodeados por un tejido celular abundante constituido por células pseudo-condroblásticas. Dichas células eran redondeadas u ovoides con núcleos hipercromáticos, un citoplasma claro o moderadamente eosinófilo y una membrana plasmática nítida. El pleomorfismo celular era mínimo y el índice mitótico muy bajo. Algunas células contenían hierro. Entre las células pseudocondroblásticas se encontraban abundantes células gigantes de tipo osteoclástico. En algunas áreas había zonas de calcificación irregular. Se observaban además algunas áreas de transformación quística que asemejaban quistes aneurismáticos. El diagnóstico anatomopatológico fue condroblastoma de escafoides carpiano. Tras el tratamiento quirúrgico se inmovilizó la muñeca con una férula antebraquial durante 3 semanas y posteriormente la paciente fue remitida al Servicio de Rehabilitación. En la revisión efectuada a los 3 meses se apreció una recuperación completa de la movilidad de la muñeca e imagen radiológica de consolidación ósea del autoinjerto de cresta iliaca. Dos años después del tratamiento quirúrgico no hay evidencia de recidiva y persiste una desaparición completa del dolor con movilidad de la muñeca similar a la contralateral, así como una imagen radiológica del escafoides totalmente normalizada. Responsable clínico: Francisco Javier Repáraz Padrós Servicio de Cirugía Ortopédica y Traumatología Hospital de Navarra Irunlarrea, 3 31008 Pamplona Tfno. 848422206 E-mail: repamapr@hotmail.com Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, ID_SUJETO_ASISTENCIA, FECHAS, NUMERO_TELEFONO, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "O", "B-NUMERO_TELEFONO", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Datos del paciente. Nombre: Irene. Apellidos: Martinez Alejandre. NHC: 4356456. NASS: 06 52839679 56. Domicilio: Calle Las Lomas, 13, 7C. Localidad/ Provincia: Pamplona. CP: 31256. Datos asistenciales. Fecha de nacimiento: 21/04/1992. País de nacimiento: España. Edad: 26 años Sexo: M. Fecha de Ingreso: 08/06/2018. Médico:Francisco Javier Repáraz Padrós NºCol: 31 31 25402. Informe clínico del paciente: paciente de 26 años que acude a consulta por dolor en la muñeca derecha de 7 años de evolución sin antecedente traumático. El dolor en reposo era de carácter leve, pero aumentaba con la actividad manual y especialmente con la extensión forzada de la muñeca. No mejoraba con tratamiento médico sintomático. La interlínea articular radiocarpiana dorsal y el polo proximal del escafoides eran dolorosos a la palpación. No se apreciaba tumoración palpable. La movilidad de la muñeca presentaba una ligera limitación en los últimos grados de flexión y extensión. La imagen radiológica mostraba una lesión radiolucente, bien definida, ovalada, localizada en el tercio medio-dorsal del escafoides. En la TAC se apreciaba la localización excéntrica dorsal de la lesión y un punteado compatible con calcificaciones. En la RM destacaban signos de marcado edema óseo en el escafoides, excepto en su tercio distal y sinovitis adyacente. Con el diagnóstico de sospecha de una lesión benigna (encondroma, ganglión intraóseo) se decidió el tratamiento quirúrgico de la lesión. Éste se realizó mediante una vía de abordaje dorsal del escafoides. Tras la apertura de la cápsula articular se expuso la cara dorsal de la epífisis distal del radio y del escafoides, apreciándose en el tercio medio de este último una tumoración de aspecto nacarado y coloración rojo vinosa que ocupaba la cresta dorsal del hueso navicular. Se realizó un legrado exhaustivo de la lesión y relleno del defecto con injerto óseo esponjoso de cresta iliaca. El material remitido estaba formado por islotes de matriz cartilaginosa rodeados por un tejido celular abundante constituido por células pseudo-condroblásticas. Dichas células eran redondeadas u ovoides con núcleos hipercromáticos, un citoplasma claro o moderadamente eosinófilo y una membrana plasmática nítida. El pleomorfismo celular era mínimo y el índice mitótico muy bajo. Algunas células contenían hierro. Entre las células pseudocondroblásticas se encontraban abundantes células gigantes de tipo osteoclástico. En algunas áreas había zonas de calcificación irregular. Se observaban además algunas áreas de transformación quística que asemejaban quistes aneurismáticos. El diagnóstico anatomopatológico fue condroblastoma de escafoides carpiano. Tras el tratamiento quirúrgico se inmovilizó la muñeca con una férula antebraquial durante 3 semanas y posteriormente la paciente fue remitida al Servicio de Rehabilitación. En la revisión efectuada a los 3 meses se apreció una recuperación completa de la movilidad de la muñeca e imagen radiológica de consolidación ósea del autoinjerto de cresta iliaca. Dos años después del tratamiento quirúrgico no hay evidencia de recidiva y persiste una desaparición completa del dolor con movilidad de la muñeca similar a la contralateral, así como una imagen radiológica del escafoides totalmente normalizada. Responsable clínico: Francisco Javier Repáraz Padrós Servicio de Cirugía Ortopédica y Traumatología Hospital de Navarra Irunlarrea, 3 31008 Pamplona Tfno. 848422206 E-mail: repamapr@hotmail.com	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", " ", "Irene", ".", "\n", "Apellidos", ":", "Martinez", "Alejandre", ".", "\n", "NHC", ":", "4356456", ".", "\n", "NASS", ":", "06", "52839679", "56", ".", "\n", "Domicilio", ":", "Calle", "Las", "Lomas", ",", "13", ",", "7C.", "\n", "Localidad/", "Provincia", ":", "Pamplona", ".", "\n", "CP", ":", "31256", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "21/04/1992", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "26", "años", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "08/06/2018", ".", "\n", "Médico", ":", "Francisco", "Javier", "Repáraz", "Padrós", " ", "NºCol", ":", "31", "31", "25402", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "paciente", "de", "26", "años", "que", "acude", "a", "consulta", "por", "dolor", "en", "la", "muñeca", "derecha", "de", "7", "años", "de", "evolución", "sin", "antecedente", "traumático", ".", "El", "dolor", "en", "reposo", "era", "de", "carácter", "leve", ",", "pero", "aumentaba", "con", "la", "actividad", "manual", "y", "especialmente", "con", "la", "extensión", "forzada", "de", "la", "muñeca", ".", "No", "mejoraba", "con", "tratamiento", "médico", "sintomático", ".", "\n", "La", "interlínea", "articular", "radiocarpiana", "dorsal", "y", "el", "polo", "proximal", "del", "escafoides", "eran", "dolorosos", "a", "la", "palpación", ".", "No", "se", "apreciaba", "tumoración", "palpable", ".", "La", "movilidad", "de", "la", "muñeca", "presentaba", "una", "ligera", "limitación", "en", "los", "últimos", "grados", "de", "flexión", "y", "extensión", ".", "\n", "La", "imagen", "radiológica", "mostraba", "una", "lesión", "radiolucente", ",", "bien", "definida", ",", "ovalada", ",", "localizada", "en", "el", "tercio", "medio", "-", "dorsal", "del", "escafoides", ".", "En", "la", "TAC", "se", "apreciaba", "la", "localización", "excéntrica", "dorsal", "de", "la", "lesión", "y", "un", "punteado", "compatible", "con", "calcificaciones", ".", "En", "la", "RM", "destacaban", "signos", "de", "marcado", "edema", "óseo", "en", "el", "escafoides", ",", "excepto", "en", "su", "tercio", "distal", "y", "sinovitis", "adyacente", ".", "Con", "el", "diagnóstico", "de", "sospecha", "de", "una", "lesión", "benigna", "(", "encondroma", ",", "ganglión", "intraóseo", ")", "se", "decidió", "el", "tratamiento", "quirúrgico", "de", "la", "lesión", ".", "Éste", "se", "realizó", "mediante", "una", "vía", "de", "abordaje", "dorsal", "del", "escafoides", ".", "Tras", "la", "apertura", "de", "la", "cápsula", "articular", "se", "expuso", "la", "cara", "dorsal", "de", "la", "epífisis", "distal", "del", "radio", "y", "del", "escafoides", ",", "apreciándose", "en", "el", "tercio", "medio", "de", "este", "último", "una", "tumoración", "de", "aspecto", "nacarado", "y", "coloración", "rojo", "vinosa", "que", "ocupaba", "la", "cresta", "dorsal", "del", "hueso", "navicular", ".", "Se", "realizó", "un", "legrado", "exhaustivo", "de", "la", "lesión", "y", "relleno", "del", "defecto", "con", "injerto", "óseo", "esponjoso", "de", "cresta", "iliaca", ".", "\n", "El", "material", "remitido", "estaba", "formado", "por", "islotes", "de", "matriz", "cartilaginosa", "rodeados", "por", "un", "tejido", "celular", "abundante", "constituido", "por", "células", "pseudo", "-", "condroblásticas", ".", "Dichas", "células", "eran", "redondeadas", "u", "ovoides", "con", "núcleos", "hipercromáticos", ",", "un", "citoplasma", "claro", "o", "moderadamente", "eosinófilo", "y", "una", "membrana", "plasmática", "nítida", ".", "El", "pleomorfismo", "celular", "era", "mínimo", "y", "el", "índice", "mitótico", "muy", "bajo", ".", "Algunas", "células", "contenían", "hierro", ".", "Entre", "las", "células", "pseudocondroblásticas", "se", "encontraban", "abundantes", "células", "gigantes", "de", "tipo", "osteoclástico", ".", "En", "algunas", "áreas", "había", "zonas", "de", "calcificación", "irregular", ".", "Se", "observaban", "además", "algunas", "áreas", "de", "transformación", "quística", "que", "asemejaban", "quistes", "aneurismáticos", ".", "El", "diagnóstico", "anatomopatológico", "fue", "condroblastoma", "de", "escafoides", "carpiano", ".", "\n", "Tras", "el", "tratamiento", "quirúrgico", "se", "inmovilizó", "la", "muñeca", "con", "una", "férula", "antebraquial", "durante", "3", "semanas", "y", "posteriormente", "la", "paciente", "fue", "remitida", "al", "Servicio", "de", "Rehabilitación", ".", "En", "la", "revisión", "efectuada", "a", "los", "3", "meses", "se", "apreció", "una", "recuperación", "completa", "de", "la", "movilidad", "de", "la", "muñeca", "e", "imagen", "radiológica", "de", "consolidación", "ósea", "del", "autoinjerto", "de", "cresta", "iliaca", ".", "\n", "Dos", "años", "después", "del", "tratamiento", "quirúrgico", "no", "hay", "evidencia", "de", "recidiva", "y", "persiste", "una", "desaparición", "completa", "del", "dolor", "con", "movilidad", "de", "la", "muñeca", "similar", "a", "la", "contralateral", ",", "así", "como", "una", "imagen", "radiológica", "del", "escafoides", "totalmente", "normalizada", ".", "\n", "Responsable", "clínico", ":", "Francisco", "Javier", "Repáraz", "Padrós", "Servicio", "de", "Cirugía", "Ortopédica", "y", "Traumatología", "Hospital", "de", "Navarra", "Irunlarrea", ",", "3", "31008", "Pamplona", "Tfno", ".", "848422206", "E", "-", "mail", ":", "repamapr@hotmail.com", "\n" ]	[ "NOMBRE_PERSONAL_SANITARIO", "CALLE", "CORREO_ELECTRONICO", "HOSPITAL", "NOMBRE_SUJETO_ASISTENCIA", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "NUMERO_TELEFONO", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]
Irene is a NOMBRE_SUJETO_ASISTENCIA, Martinez Alejandre is a NOMBRE_SUJETO_ASISTENCIA, 4356456 is a ID_SUJETO_ASISTENCIA, 06 52839679 56 is a ID_ASEGURAMIENTO, Pamplona is a TERRITORIO, 31256 is a TERRITORIO, 21/04/1992 is a FECHAS, España is a PAIS, 26 años is a EDAD_SUJETO_ASISTENCIA, 08/06/2018 is a FECHAS, Francisco Javier Repáraz Padrós is a NOMBRE_PERSONAL_SANITARIO, 31 31 25402 is a ID_TITULACION_PERSONAL_SANITARIO, 26 años is a EDAD_SUJETO_ASISTENCIA, Francisco Javier Repáraz Padrós is a NOMBRE_PERSONAL_SANITARIO, Hospital de Navarra is a HOSPITAL, Irunlarrea , 3 is a CALLE, 31008 is a TERRITORIO, Pamplona is a TERRITORIO, 848422206 is a NUMERO_TELEFONO, repamapr@hotmail.com is a CORREO_ELECTRONICO	407_task1	Sentence: Datos del paciente. Nombre: Irene. Apellidos: Martinez Alejandre. NHC: 4356456. NASS: 06 52839679 56. Domicilio: Calle Las Lomas, 13, 7C. Localidad/ Provincia: Pamplona. CP: 31256. Datos asistenciales. Fecha de nacimiento: 21/04/1992. País de nacimiento: España. Edad: 26 años Sexo: M. Fecha de Ingreso: 08/06/2018. Médico:Francisco Javier Repáraz Padrós NºCol: 31 31 25402. Informe clínico del paciente: paciente de 26 años que acude a consulta por dolor en la muñeca derecha de 7 años de evolución sin antecedente traumático. El dolor en reposo era de carácter leve, pero aumentaba con la actividad manual y especialmente con la extensión forzada de la muñeca. No mejoraba con tratamiento médico sintomático. La interlínea articular radiocarpiana dorsal y el polo proximal del escafoides eran dolorosos a la palpación. No se apreciaba tumoración palpable. La movilidad de la muñeca presentaba una ligera limitación en los últimos grados de flexión y extensión. La imagen radiológica mostraba una lesión radiolucente, bien definida, ovalada, localizada en el tercio medio-dorsal del escafoides. En la TAC se apreciaba la localización excéntrica dorsal de la lesión y un punteado compatible con calcificaciones. En la RM destacaban signos de marcado edema óseo en el escafoides, excepto en su tercio distal y sinovitis adyacente. Con el diagnóstico de sospecha de una lesión benigna (encondroma, ganglión intraóseo) se decidió el tratamiento quirúrgico de la lesión. Éste se realizó mediante una vía de abordaje dorsal del escafoides. Tras la apertura de la cápsula articular se expuso la cara dorsal de la epífisis distal del radio y del escafoides, apreciándose en el tercio medio de este último una tumoración de aspecto nacarado y coloración rojo vinosa que ocupaba la cresta dorsal del hueso navicular. Se realizó un legrado exhaustivo de la lesión y relleno del defecto con injerto óseo esponjoso de cresta iliaca. El material remitido estaba formado por islotes de matriz cartilaginosa rodeados por un tejido celular abundante constituido por células pseudo-condroblásticas. Dichas células eran redondeadas u ovoides con núcleos hipercromáticos, un citoplasma claro o moderadamente eosinófilo y una membrana plasmática nítida. El pleomorfismo celular era mínimo y el índice mitótico muy bajo. Algunas células contenían hierro. Entre las células pseudocondroblásticas se encontraban abundantes células gigantes de tipo osteoclástico. En algunas áreas había zonas de calcificación irregular. Se observaban además algunas áreas de transformación quística que asemejaban quistes aneurismáticos. El diagnóstico anatomopatológico fue condroblastoma de escafoides carpiano. Tras el tratamiento quirúrgico se inmovilizó la muñeca con una férula antebraquial durante 3 semanas y posteriormente la paciente fue remitida al Servicio de Rehabilitación. En la revisión efectuada a los 3 meses se apreció una recuperación completa de la movilidad de la muñeca e imagen radiológica de consolidación ósea del autoinjerto de cresta iliaca. Dos años después del tratamiento quirúrgico no hay evidencia de recidiva y persiste una desaparición completa del dolor con movilidad de la muñeca similar a la contralateral, así como una imagen radiológica del escafoides totalmente normalizada. Responsable clínico: Francisco Javier Repáraz Padrós Servicio de Cirugía Ortopédica y Traumatología Hospital de Navarra Irunlarrea, 3 31008 Pamplona Tfno. 848422206 E-mail: repamapr@hotmail.com Instructions: please typing these entity words according to sentence: Irene, Martinez Alejandre, 4356456, 06 52839679 56, Pamplona, 31256, 21/04/1992, España, 26 años, 08/06/2018, Francisco Javier Repáraz Padrós, 31 31 25402, 26 años, Francisco Javier Repáraz Padrós, Hospital de Navarra, Irunlarrea , 3, 31008, Pamplona, 848422206, repamapr@hotmail.com Options: TERRITORIO, ID_SUJETO_ASISTENCIA, FECHAS, NUMERO_TELEFONO, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "O", "B-NUMERO_TELEFONO", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Datos del paciente. Nombre: Irene. Apellidos: Martinez Alejandre. NHC: 4356456. NASS: 06 52839679 56. Domicilio: Calle Las Lomas, 13, 7C. Localidad/ Provincia: Pamplona. CP: 31256. Datos asistenciales. Fecha de nacimiento: 21/04/1992. País de nacimiento: España. Edad: 26 años Sexo: M. Fecha de Ingreso: 08/06/2018. Médico:Francisco Javier Repáraz Padrós NºCol: 31 31 25402. Informe clínico del paciente: paciente de 26 años que acude a consulta por dolor en la muñeca derecha de 7 años de evolución sin antecedente traumático. El dolor en reposo era de carácter leve, pero aumentaba con la actividad manual y especialmente con la extensión forzada de la muñeca. No mejoraba con tratamiento médico sintomático. La interlínea articular radiocarpiana dorsal y el polo proximal del escafoides eran dolorosos a la palpación. No se apreciaba tumoración palpable. La movilidad de la muñeca presentaba una ligera limitación en los últimos grados de flexión y extensión. La imagen radiológica mostraba una lesión radiolucente, bien definida, ovalada, localizada en el tercio medio-dorsal del escafoides. En la TAC se apreciaba la localización excéntrica dorsal de la lesión y un punteado compatible con calcificaciones. En la RM destacaban signos de marcado edema óseo en el escafoides, excepto en su tercio distal y sinovitis adyacente. Con el diagnóstico de sospecha de una lesión benigna (encondroma, ganglión intraóseo) se decidió el tratamiento quirúrgico de la lesión. Éste se realizó mediante una vía de abordaje dorsal del escafoides. Tras la apertura de la cápsula articular se expuso la cara dorsal de la epífisis distal del radio y del escafoides, apreciándose en el tercio medio de este último una tumoración de aspecto nacarado y coloración rojo vinosa que ocupaba la cresta dorsal del hueso navicular. Se realizó un legrado exhaustivo de la lesión y relleno del defecto con injerto óseo esponjoso de cresta iliaca. El material remitido estaba formado por islotes de matriz cartilaginosa rodeados por un tejido celular abundante constituido por células pseudo-condroblásticas. Dichas células eran redondeadas u ovoides con núcleos hipercromáticos, un citoplasma claro o moderadamente eosinófilo y una membrana plasmática nítida. El pleomorfismo celular era mínimo y el índice mitótico muy bajo. Algunas células contenían hierro. Entre las células pseudocondroblásticas se encontraban abundantes células gigantes de tipo osteoclástico. En algunas áreas había zonas de calcificación irregular. Se observaban además algunas áreas de transformación quística que asemejaban quistes aneurismáticos. El diagnóstico anatomopatológico fue condroblastoma de escafoides carpiano. Tras el tratamiento quirúrgico se inmovilizó la muñeca con una férula antebraquial durante 3 semanas y posteriormente la paciente fue remitida al Servicio de Rehabilitación. En la revisión efectuada a los 3 meses se apreció una recuperación completa de la movilidad de la muñeca e imagen radiológica de consolidación ósea del autoinjerto de cresta iliaca. Dos años después del tratamiento quirúrgico no hay evidencia de recidiva y persiste una desaparición completa del dolor con movilidad de la muñeca similar a la contralateral, así como una imagen radiológica del escafoides totalmente normalizada. Responsable clínico: Francisco Javier Repáraz Padrós Servicio de Cirugía Ortopédica y Traumatología Hospital de Navarra Irunlarrea, 3 31008 Pamplona Tfno. 848422206 E-mail: repamapr@hotmail.com	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", " ", "Irene", ".", "\n", "Apellidos", ":", "Martinez", "Alejandre", ".", "\n", "NHC", ":", "4356456", ".", "\n", "NASS", ":", "06", "52839679", "56", ".", "\n", "Domicilio", ":", "Calle", "Las", "Lomas", ",", "13", ",", "7C.", "\n", "Localidad/", "Provincia", ":", "Pamplona", ".", "\n", "CP", ":", "31256", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "21/04/1992", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "26", "años", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "08/06/2018", ".", "\n", "Médico", ":", "Francisco", "Javier", "Repáraz", "Padrós", " ", "NºCol", ":", "31", "31", "25402", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "paciente", "de", "26", "años", "que", "acude", "a", "consulta", "por", "dolor", "en", "la", "muñeca", "derecha", "de", "7", "años", "de", "evolución", "sin", "antecedente", "traumático", ".", "El", "dolor", "en", "reposo", "era", "de", "carácter", "leve", ",", "pero", "aumentaba", "con", "la", "actividad", "manual", "y", "especialmente", "con", "la", "extensión", "forzada", "de", "la", "muñeca", ".", "No", "mejoraba", "con", "tratamiento", "médico", "sintomático", ".", "\n", "La", "interlínea", "articular", "radiocarpiana", "dorsal", "y", "el", "polo", "proximal", "del", "escafoides", "eran", "dolorosos", "a", "la", "palpación", ".", "No", "se", "apreciaba", "tumoración", "palpable", ".", "La", "movilidad", "de", "la", "muñeca", "presentaba", "una", "ligera", "limitación", "en", "los", "últimos", "grados", "de", "flexión", "y", "extensión", ".", "\n", "La", "imagen", "radiológica", "mostraba", "una", "lesión", "radiolucente", ",", "bien", "definida", ",", "ovalada", ",", "localizada", "en", "el", "tercio", "medio", "-", "dorsal", "del", "escafoides", ".", "En", "la", "TAC", "se", "apreciaba", "la", "localización", "excéntrica", "dorsal", "de", "la", "lesión", "y", "un", "punteado", "compatible", "con", "calcificaciones", ".", "En", "la", "RM", "destacaban", "signos", "de", "marcado", "edema", "óseo", "en", "el", "escafoides", ",", "excepto", "en", "su", "tercio", "distal", "y", "sinovitis", "adyacente", ".", "Con", "el", "diagnóstico", "de", "sospecha", "de", "una", "lesión", "benigna", "(", "encondroma", ",", "ganglión", "intraóseo", ")", "se", "decidió", "el", "tratamiento", "quirúrgico", "de", "la", "lesión", ".", "Éste", "se", "realizó", "mediante", "una", "vía", "de", "abordaje", "dorsal", "del", "escafoides", ".", "Tras", "la", "apertura", "de", "la", "cápsula", "articular", "se", "expuso", "la", "cara", "dorsal", "de", "la", "epífisis", "distal", "del", "radio", "y", "del", "escafoides", ",", "apreciándose", "en", "el", "tercio", "medio", "de", "este", "último", "una", "tumoración", "de", "aspecto", "nacarado", "y", "coloración", "rojo", "vinosa", "que", "ocupaba", "la", "cresta", "dorsal", "del", "hueso", "navicular", ".", "Se", "realizó", "un", "legrado", "exhaustivo", "de", "la", "lesión", "y", "relleno", "del", "defecto", "con", "injerto", "óseo", "esponjoso", "de", "cresta", "iliaca", ".", "\n", "El", "material", "remitido", "estaba", "formado", "por", "islotes", "de", "matriz", "cartilaginosa", "rodeados", "por", "un", "tejido", "celular", "abundante", "constituido", "por", "células", "pseudo", "-", "condroblásticas", ".", "Dichas", "células", "eran", "redondeadas", "u", "ovoides", "con", "núcleos", "hipercromáticos", ",", "un", "citoplasma", "claro", "o", "moderadamente", "eosinófilo", "y", "una", "membrana", "plasmática", "nítida", ".", "El", "pleomorfismo", "celular", "era", "mínimo", "y", "el", "índice", "mitótico", "muy", "bajo", ".", "Algunas", "células", "contenían", "hierro", ".", "Entre", "las", "células", "pseudocondroblásticas", "se", "encontraban", "abundantes", "células", "gigantes", "de", "tipo", "osteoclástico", ".", "En", "algunas", "áreas", "había", "zonas", "de", "calcificación", "irregular", ".", "Se", "observaban", "además", "algunas", "áreas", "de", "transformación", "quística", "que", "asemejaban", "quistes", "aneurismáticos", ".", "El", "diagnóstico", "anatomopatológico", "fue", "condroblastoma", "de", "escafoides", "carpiano", ".", "\n", "Tras", "el", "tratamiento", "quirúrgico", "se", "inmovilizó", "la", "muñeca", "con", "una", "férula", "antebraquial", "durante", "3", "semanas", "y", "posteriormente", "la", "paciente", "fue", "remitida", "al", "Servicio", "de", "Rehabilitación", ".", "En", "la", "revisión", "efectuada", "a", "los", "3", "meses", "se", "apreció", "una", "recuperación", "completa", "de", "la", "movilidad", "de", "la", "muñeca", "e", "imagen", "radiológica", "de", "consolidación", "ósea", "del", "autoinjerto", "de", "cresta", "iliaca", ".", "\n", "Dos", "años", "después", "del", "tratamiento", "quirúrgico", "no", "hay", "evidencia", "de", "recidiva", "y", "persiste", "una", "desaparición", "completa", "del", "dolor", "con", "movilidad", "de", "la", "muñeca", "similar", "a", "la", "contralateral", ",", "así", "como", "una", "imagen", "radiológica", "del", "escafoides", "totalmente", "normalizada", ".", "\n", "Responsable", "clínico", ":", "Francisco", "Javier", "Repáraz", "Padrós", "Servicio", "de", "Cirugía", "Ortopédica", "y", "Traumatología", "Hospital", "de", "Navarra", "Irunlarrea", ",", "3", "31008", "Pamplona", "Tfno", ".", "848422206", "E", "-", "mail", ":", "repamapr@hotmail.com", "\n" ]	[ "NOMBRE_PERSONAL_SANITARIO", "CALLE", "CORREO_ELECTRONICO", "HOSPITAL", "NOMBRE_SUJETO_ASISTENCIA", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "NUMERO_TELEFONO", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]
Irene, Martinez Alejandre, 4356456, 06 52839679 56, Pamplona, 31256, 21/04/1992, España, 26 años, 08/06/2018, Francisco Javier Repáraz Padrós, 31 31 25402, 26 años, Francisco Javier Repáraz Padrós, Hospital de Navarra, Irunlarrea , 3, 31008, Pamplona, 848422206, repamapr@hotmail.com	407_task2	Sentence: Datos del paciente. Nombre: Irene. Apellidos: Martinez Alejandre. NHC: 4356456. NASS: 06 52839679 56. Domicilio: Calle Las Lomas, 13, 7C. Localidad/ Provincia: Pamplona. CP: 31256. Datos asistenciales. Fecha de nacimiento: 21/04/1992. País de nacimiento: España. Edad: 26 años Sexo: M. Fecha de Ingreso: 08/06/2018. Médico:Francisco Javier Repáraz Padrós NºCol: 31 31 25402. Informe clínico del paciente: paciente de 26 años que acude a consulta por dolor en la muñeca derecha de 7 años de evolución sin antecedente traumático. El dolor en reposo era de carácter leve, pero aumentaba con la actividad manual y especialmente con la extensión forzada de la muñeca. No mejoraba con tratamiento médico sintomático. La interlínea articular radiocarpiana dorsal y el polo proximal del escafoides eran dolorosos a la palpación. No se apreciaba tumoración palpable. La movilidad de la muñeca presentaba una ligera limitación en los últimos grados de flexión y extensión. La imagen radiológica mostraba una lesión radiolucente, bien definida, ovalada, localizada en el tercio medio-dorsal del escafoides. En la TAC se apreciaba la localización excéntrica dorsal de la lesión y un punteado compatible con calcificaciones. En la RM destacaban signos de marcado edema óseo en el escafoides, excepto en su tercio distal y sinovitis adyacente. Con el diagnóstico de sospecha de una lesión benigna (encondroma, ganglión intraóseo) se decidió el tratamiento quirúrgico de la lesión. Éste se realizó mediante una vía de abordaje dorsal del escafoides. Tras la apertura de la cápsula articular se expuso la cara dorsal de la epífisis distal del radio y del escafoides, apreciándose en el tercio medio de este último una tumoración de aspecto nacarado y coloración rojo vinosa que ocupaba la cresta dorsal del hueso navicular. Se realizó un legrado exhaustivo de la lesión y relleno del defecto con injerto óseo esponjoso de cresta iliaca. El material remitido estaba formado por islotes de matriz cartilaginosa rodeados por un tejido celular abundante constituido por células pseudo-condroblásticas. Dichas células eran redondeadas u ovoides con núcleos hipercromáticos, un citoplasma claro o moderadamente eosinófilo y una membrana plasmática nítida. El pleomorfismo celular era mínimo y el índice mitótico muy bajo. Algunas células contenían hierro. Entre las células pseudocondroblásticas se encontraban abundantes células gigantes de tipo osteoclástico. En algunas áreas había zonas de calcificación irregular. Se observaban además algunas áreas de transformación quística que asemejaban quistes aneurismáticos. El diagnóstico anatomopatológico fue condroblastoma de escafoides carpiano. Tras el tratamiento quirúrgico se inmovilizó la muñeca con una férula antebraquial durante 3 semanas y posteriormente la paciente fue remitida al Servicio de Rehabilitación. En la revisión efectuada a los 3 meses se apreció una recuperación completa de la movilidad de la muñeca e imagen radiológica de consolidación ósea del autoinjerto de cresta iliaca. Dos años después del tratamiento quirúrgico no hay evidencia de recidiva y persiste una desaparición completa del dolor con movilidad de la muñeca similar a la contralateral, así como una imagen radiológica del escafoides totalmente normalizada. Responsable clínico: Francisco Javier Repáraz Padrós Servicio de Cirugía Ortopédica y Traumatología Hospital de Navarra Irunlarrea, 3 31008 Pamplona Tfno. 848422206 E-mail: repamapr@hotmail.com Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "O", "B-NUMERO_TELEFONO", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Datos del paciente. Nombre: Irene. Apellidos: Martinez Alejandre. NHC: 4356456. NASS: 06 52839679 56. Domicilio: Calle Las Lomas, 13, 7C. Localidad/ Provincia: Pamplona. CP: 31256. Datos asistenciales. Fecha de nacimiento: 21/04/1992. País de nacimiento: España. Edad: 26 años Sexo: M. Fecha de Ingreso: 08/06/2018. Médico:Francisco Javier Repáraz Padrós NºCol: 31 31 25402. Informe clínico del paciente: paciente de 26 años que acude a consulta por dolor en la muñeca derecha de 7 años de evolución sin antecedente traumático. El dolor en reposo era de carácter leve, pero aumentaba con la actividad manual y especialmente con la extensión forzada de la muñeca. No mejoraba con tratamiento médico sintomático. La interlínea articular radiocarpiana dorsal y el polo proximal del escafoides eran dolorosos a la palpación. No se apreciaba tumoración palpable. La movilidad de la muñeca presentaba una ligera limitación en los últimos grados de flexión y extensión. La imagen radiológica mostraba una lesión radiolucente, bien definida, ovalada, localizada en el tercio medio-dorsal del escafoides. En la TAC se apreciaba la localización excéntrica dorsal de la lesión y un punteado compatible con calcificaciones. En la RM destacaban signos de marcado edema óseo en el escafoides, excepto en su tercio distal y sinovitis adyacente. Con el diagnóstico de sospecha de una lesión benigna (encondroma, ganglión intraóseo) se decidió el tratamiento quirúrgico de la lesión. Éste se realizó mediante una vía de abordaje dorsal del escafoides. Tras la apertura de la cápsula articular se expuso la cara dorsal de la epífisis distal del radio y del escafoides, apreciándose en el tercio medio de este último una tumoración de aspecto nacarado y coloración rojo vinosa que ocupaba la cresta dorsal del hueso navicular. Se realizó un legrado exhaustivo de la lesión y relleno del defecto con injerto óseo esponjoso de cresta iliaca. El material remitido estaba formado por islotes de matriz cartilaginosa rodeados por un tejido celular abundante constituido por células pseudo-condroblásticas. Dichas células eran redondeadas u ovoides con núcleos hipercromáticos, un citoplasma claro o moderadamente eosinófilo y una membrana plasmática nítida. El pleomorfismo celular era mínimo y el índice mitótico muy bajo. Algunas células contenían hierro. Entre las células pseudocondroblásticas se encontraban abundantes células gigantes de tipo osteoclástico. En algunas áreas había zonas de calcificación irregular. Se observaban además algunas áreas de transformación quística que asemejaban quistes aneurismáticos. El diagnóstico anatomopatológico fue condroblastoma de escafoides carpiano. Tras el tratamiento quirúrgico se inmovilizó la muñeca con una férula antebraquial durante 3 semanas y posteriormente la paciente fue remitida al Servicio de Rehabilitación. En la revisión efectuada a los 3 meses se apreció una recuperación completa de la movilidad de la muñeca e imagen radiológica de consolidación ósea del autoinjerto de cresta iliaca. Dos años después del tratamiento quirúrgico no hay evidencia de recidiva y persiste una desaparición completa del dolor con movilidad de la muñeca similar a la contralateral, así como una imagen radiológica del escafoides totalmente normalizada. Responsable clínico: Francisco Javier Repáraz Padrós Servicio de Cirugía Ortopédica y Traumatología Hospital de Navarra Irunlarrea, 3 31008 Pamplona Tfno. 848422206 E-mail: repamapr@hotmail.com	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", " ", "Irene", ".", "\n", "Apellidos", ":", "Martinez", "Alejandre", ".", "\n", "NHC", ":", "4356456", ".", "\n", "NASS", ":", "06", "52839679", "56", ".", "\n", "Domicilio", ":", "Calle", "Las", "Lomas", ",", "13", ",", "7C.", "\n", "Localidad/", "Provincia", ":", "Pamplona", ".", "\n", "CP", ":", "31256", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "21/04/1992", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "26", "años", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "08/06/2018", ".", "\n", "Médico", ":", "Francisco", "Javier", "Repáraz", "Padrós", " ", "NºCol", ":", "31", "31", "25402", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "paciente", "de", "26", "años", "que", "acude", "a", "consulta", "por", "dolor", "en", "la", "muñeca", "derecha", "de", "7", "años", "de", "evolución", "sin", "antecedente", "traumático", ".", "El", "dolor", "en", "reposo", "era", "de", "carácter", "leve", ",", "pero", "aumentaba", "con", "la", "actividad", "manual", "y", "especialmente", "con", "la", "extensión", "forzada", "de", "la", "muñeca", ".", "No", "mejoraba", "con", "tratamiento", "médico", "sintomático", ".", "\n", "La", "interlínea", "articular", "radiocarpiana", "dorsal", "y", "el", "polo", "proximal", "del", "escafoides", "eran", "dolorosos", "a", "la", "palpación", ".", "No", "se", "apreciaba", "tumoración", "palpable", ".", "La", "movilidad", "de", "la", "muñeca", "presentaba", "una", "ligera", "limitación", "en", "los", "últimos", "grados", "de", "flexión", "y", "extensión", ".", "\n", "La", "imagen", "radiológica", "mostraba", "una", "lesión", "radiolucente", ",", "bien", "definida", ",", "ovalada", ",", "localizada", "en", "el", "tercio", "medio", "-", "dorsal", "del", "escafoides", ".", "En", "la", "TAC", "se", "apreciaba", "la", "localización", "excéntrica", "dorsal", "de", "la", "lesión", "y", "un", "punteado", "compatible", "con", "calcificaciones", ".", "En", "la", "RM", "destacaban", "signos", "de", "marcado", "edema", "óseo", "en", "el", "escafoides", ",", "excepto", "en", "su", "tercio", "distal", "y", "sinovitis", "adyacente", ".", "Con", "el", "diagnóstico", "de", "sospecha", "de", "una", "lesión", "benigna", "(", "encondroma", ",", "ganglión", "intraóseo", ")", "se", "decidió", "el", "tratamiento", "quirúrgico", "de", "la", "lesión", ".", "Éste", "se", "realizó", "mediante", "una", "vía", "de", "abordaje", "dorsal", "del", "escafoides", ".", "Tras", "la", "apertura", "de", "la", "cápsula", "articular", "se", "expuso", "la", "cara", "dorsal", "de", "la", "epífisis", "distal", "del", "radio", "y", "del", "escafoides", ",", "apreciándose", "en", "el", "tercio", "medio", "de", "este", "último", "una", "tumoración", "de", "aspecto", "nacarado", "y", "coloración", "rojo", "vinosa", "que", "ocupaba", "la", "cresta", "dorsal", "del", "hueso", "navicular", ".", "Se", "realizó", "un", "legrado", "exhaustivo", "de", "la", "lesión", "y", "relleno", "del", "defecto", "con", "injerto", "óseo", "esponjoso", "de", "cresta", "iliaca", ".", "\n", "El", "material", "remitido", "estaba", "formado", "por", "islotes", "de", "matriz", "cartilaginosa", "rodeados", "por", "un", "tejido", "celular", "abundante", "constituido", "por", "células", "pseudo", "-", "condroblásticas", ".", "Dichas", "células", "eran", "redondeadas", "u", "ovoides", "con", "núcleos", "hipercromáticos", ",", "un", "citoplasma", "claro", "o", "moderadamente", "eosinófilo", "y", "una", "membrana", "plasmática", "nítida", ".", "El", "pleomorfismo", "celular", "era", "mínimo", "y", "el", "índice", "mitótico", "muy", "bajo", ".", "Algunas", "células", "contenían", "hierro", ".", "Entre", "las", "células", "pseudocondroblásticas", "se", "encontraban", "abundantes", "células", "gigantes", "de", "tipo", "osteoclástico", ".", "En", "algunas", "áreas", "había", "zonas", "de", "calcificación", "irregular", ".", "Se", "observaban", "además", "algunas", "áreas", "de", "transformación", "quística", "que", "asemejaban", "quistes", "aneurismáticos", ".", "El", "diagnóstico", "anatomopatológico", "fue", "condroblastoma", "de", "escafoides", "carpiano", ".", "\n", "Tras", "el", "tratamiento", "quirúrgico", "se", "inmovilizó", "la", "muñeca", "con", "una", "férula", "antebraquial", "durante", "3", "semanas", "y", "posteriormente", "la", "paciente", "fue", "remitida", "al", "Servicio", "de", "Rehabilitación", ".", "En", "la", "revisión", "efectuada", "a", "los", "3", "meses", "se", "apreció", "una", "recuperación", "completa", "de", "la", "movilidad", "de", "la", "muñeca", "e", "imagen", "radiológica", "de", "consolidación", "ósea", "del", "autoinjerto", "de", "cresta", "iliaca", ".", "\n", "Dos", "años", "después", "del", "tratamiento", "quirúrgico", "no", "hay", "evidencia", "de", "recidiva", "y", "persiste", "una", "desaparición", "completa", "del", "dolor", "con", "movilidad", "de", "la", "muñeca", "similar", "a", "la", "contralateral", ",", "así", "como", "una", "imagen", "radiológica", "del", "escafoides", "totalmente", "normalizada", ".", "\n", "Responsable", "clínico", ":", "Francisco", "Javier", "Repáraz", "Padrós", "Servicio", "de", "Cirugía", "Ortopédica", "y", "Traumatología", "Hospital", "de", "Navarra", "Irunlarrea", ",", "3", "31008", "Pamplona", "Tfno", ".", "848422206", "E", "-", "mail", ":", "repamapr@hotmail.com", "\n" ]	[ "NOMBRE_PERSONAL_SANITARIO", "CALLE", "CORREO_ELECTRONICO", "HOSPITAL", "NOMBRE_SUJETO_ASISTENCIA", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "NUMERO_TELEFONO", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]
PEBP2 alpha A is a Protein, PEBP2 alpha B is a Protein, PEBP2 alpha B is a Protein, AML1 is a Protein, PEBP2 alpha A is a Protein, AML1 / PEBP2 alpha B is a Protein, CD4 is a Protein, CD4 is a Protein, AML1 / PEBP2 alpha B is a Protein, AML1 / PEBP2 alpha B is a Protein	7862157_task0	Sentence: Expression of the Runt domain-encoding PEBP2 alpha genes in T cells during thymic development. The PEBP2 alpha A and PEBP2 alpha B genes encode the DNA-binding subunit of a murine transcription factor, PEBP2, which is implicated as a T-cell-specific transcriptional regulator. These two related genes share the evolutionarily conserved region encoding the Runt domain. PEBP2 alpha B is the murine counterpart of human AML1, which is located at the breakpoints of the 8;21 and 3;21 chromosome translocations associated with acute myeloid leukemia. Northern (RNA) blots of various adult mouse tissues revealed that the levels of expression of both genes were most prominent in the thymus. Furthermore, transcripts of PEBP2 alpha A and mouse AML1/PEBP2 alpha B were detected in T lymphocytes in the thymuses from day 16 embryos and newborns, as well as 4-week-old adult mice, by in situ hybridization. The expression of the genes persisted in peripheral lymph nodes of adult mice. The transcripts were detected in all the CD4- CD8-, CD4+ CD8+, CD4+ CD8-, and CD4- CD8+ cell populations. The results indicated that both genes are expressed in T cells throughout their development, supporting the notion that PEBP2 is a T-cell-specific transcription factor. Transcripts of mouse AML1/PEBP2 alpha B were also detected in day 12 fetal hematopoietic liver and in the bone marrow cells of newborn mice. The implication of mouse AML1/PEBP2 alpha B expression in hematopoietic cells other than those of T-cell lineage is discussed in relation to myeloid leukemogenesis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Expression of the Runt domain-encoding PEBP2 alpha genes in T cells during thymic development. The PEBP2 alpha A and PEBP2 alpha B genes encode the DNA-binding subunit of a murine transcription factor, PEBP2, which is implicated as a T-cell-specific transcriptional regulator. These two related genes share the evolutionarily conserved region encoding the Runt domain. PEBP2 alpha B is the murine counterpart of human AML1, which is located at the breakpoints of the 8;21 and 3;21 chromosome translocations associated with acute myeloid leukemia. Northern (RNA) blots of various adult mouse tissues revealed that the levels of expression of both genes were most prominent in the thymus. Furthermore, transcripts of PEBP2 alpha A and mouse AML1/PEBP2 alpha B were detected in T lymphocytes in the thymuses from day 16 embryos and newborns, as well as 4-week-old adult mice, by in situ hybridization. The expression of the genes persisted in peripheral lymph nodes of adult mice. The transcripts were detected in all the CD4- CD8-, CD4+ CD8+, CD4+ CD8-, and CD4- CD8+ cell populations. The results indicated that both genes are expressed in T cells throughout their development, supporting the notion that PEBP2 is a T-cell-specific transcription factor. Transcripts of mouse AML1/PEBP2 alpha B were also detected in day 12 fetal hematopoietic liver and in the bone marrow cells of newborn mice. The implication of mouse AML1/PEBP2 alpha B expression in hematopoietic cells other than those of T-cell lineage is discussed in relation to myeloid leukemogenesis.	[ "Expression", "of", "the", "Runt", "domain", "-", "encoding", "PEBP2", "alpha", "genes", "in", "T", "cells", "during", "thymic", "development", ".", "\n", "The", "PEBP2", "alpha", "A", "and", "PEBP2", "alpha", "B", "genes", "encode", "the", "DNA", "-", "binding", "subunit", "of", "a", "murine", "transcription", "factor", ",", "PEBP2", ",", "which", "is", "implicated", "as", "a", "T", "-", "cell", "-", "specific", "transcriptional", "regulator", ".", "These", "two", "related", "genes", "share", "the", "evolutionarily", "conserved", "region", "encoding", "the", "Runt", "domain", ".", "PEBP2", "alpha", "B", "is", "the", "murine", "counterpart", "of", "human", "AML1", ",", "which", "is", "located", "at", "the", "breakpoints", "of", "the", "8;21", "and", "3;21", "chromosome", "translocations", "associated", "with", "acute", "myeloid", "leukemia", ".", "Northern", "(", "RNA", ")", "blots", "of", "various", "adult", "mouse", "tissues", "revealed", "that", "the", "levels", "of", "expression", "of", "both", "genes", "were", "most", "prominent", "in", "the", "thymus", ".", "Furthermore", ",", "transcripts", "of", "PEBP2", "alpha", "A", "and", "mouse", "AML1", "/", "PEBP2", "alpha", "B", "were", "detected", "in", "T", "lymphocytes", "in", "the", "thymuses", "from", "day", "16", "embryos", "and", "newborns", ",", "as", "well", "as", "4-week", "-", "old", "adult", "mice", ",", "by", "in", "situ", "hybridization", ".", "The", "expression", "of", "the", "genes", "persisted", "in", "peripheral", "lymph", "nodes", "of", "adult", "mice", ".", "The", "transcripts", "were", "detected", "in", "all", "the", "CD4-", "CD8-", ",", "CD4", "+", "CD8", "+", ",", "CD4", "+", "CD8-", ",", "and", "CD4-", "CD8", "+", "cell", "populations", ".", "The", "results", "indicated", "that", "both", "genes", "are", "expressed", "in", "T", "cells", "throughout", "their", "development", ",", "supporting", "the", "notion", "that", "PEBP2", "is", "a", "T", "-", "cell", "-", "specific", "transcription", "factor", ".", "Transcripts", "of", "mouse", "AML1", "/", "PEBP2", "alpha", "B", "were", "also", "detected", "in", "day", "12", "fetal", "hematopoietic", "liver", "and", "in", "the", "bone", "marrow", "cells", "of", "newborn", "mice", ".", "The", "implication", "of", "mouse", "AML1", "/", "PEBP2", "alpha", "B", "expression", "in", "hematopoietic", "cells", "other", "than", "those", "of", "T", "-", "cell", "lineage", "is", "discussed", "in", "relation", "to", "myeloid", "leukemogenesis", "." ]	[ "Protein" ]
PEBP2 alpha A is a Protein, PEBP2 alpha B is a Protein, PEBP2 alpha B is a Protein, AML1 is a Protein, PEBP2 alpha A is a Protein, AML1 / PEBP2 alpha B is a Protein, CD4 is a Protein, CD4 is a Protein, AML1 / PEBP2 alpha B is a Protein, AML1 / PEBP2 alpha B is a Protein	7862157_task1	Sentence: Expression of the Runt domain-encoding PEBP2 alpha genes in T cells during thymic development. The PEBP2 alpha A and PEBP2 alpha B genes encode the DNA-binding subunit of a murine transcription factor, PEBP2, which is implicated as a T-cell-specific transcriptional regulator. These two related genes share the evolutionarily conserved region encoding the Runt domain. PEBP2 alpha B is the murine counterpart of human AML1, which is located at the breakpoints of the 8;21 and 3;21 chromosome translocations associated with acute myeloid leukemia. Northern (RNA) blots of various adult mouse tissues revealed that the levels of expression of both genes were most prominent in the thymus. Furthermore, transcripts of PEBP2 alpha A and mouse AML1/PEBP2 alpha B were detected in T lymphocytes in the thymuses from day 16 embryos and newborns, as well as 4-week-old adult mice, by in situ hybridization. The expression of the genes persisted in peripheral lymph nodes of adult mice. The transcripts were detected in all the CD4- CD8-, CD4+ CD8+, CD4+ CD8-, and CD4- CD8+ cell populations. The results indicated that both genes are expressed in T cells throughout their development, supporting the notion that PEBP2 is a T-cell-specific transcription factor. Transcripts of mouse AML1/PEBP2 alpha B were also detected in day 12 fetal hematopoietic liver and in the bone marrow cells of newborn mice. The implication of mouse AML1/PEBP2 alpha B expression in hematopoietic cells other than those of T-cell lineage is discussed in relation to myeloid leukemogenesis. Instructions: please typing these entity words according to sentence: PEBP2 alpha A, PEBP2 alpha B, PEBP2 alpha B, AML1, PEBP2 alpha A, AML1 / PEBP2 alpha B, CD4, CD4, AML1 / PEBP2 alpha B, AML1 / PEBP2 alpha B Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Expression of the Runt domain-encoding PEBP2 alpha genes in T cells during thymic development. The PEBP2 alpha A and PEBP2 alpha B genes encode the DNA-binding subunit of a murine transcription factor, PEBP2, which is implicated as a T-cell-specific transcriptional regulator. These two related genes share the evolutionarily conserved region encoding the Runt domain. PEBP2 alpha B is the murine counterpart of human AML1, which is located at the breakpoints of the 8;21 and 3;21 chromosome translocations associated with acute myeloid leukemia. Northern (RNA) blots of various adult mouse tissues revealed that the levels of expression of both genes were most prominent in the thymus. Furthermore, transcripts of PEBP2 alpha A and mouse AML1/PEBP2 alpha B were detected in T lymphocytes in the thymuses from day 16 embryos and newborns, as well as 4-week-old adult mice, by in situ hybridization. The expression of the genes persisted in peripheral lymph nodes of adult mice. The transcripts were detected in all the CD4- CD8-, CD4+ CD8+, CD4+ CD8-, and CD4- CD8+ cell populations. The results indicated that both genes are expressed in T cells throughout their development, supporting the notion that PEBP2 is a T-cell-specific transcription factor. Transcripts of mouse AML1/PEBP2 alpha B were also detected in day 12 fetal hematopoietic liver and in the bone marrow cells of newborn mice. The implication of mouse AML1/PEBP2 alpha B expression in hematopoietic cells other than those of T-cell lineage is discussed in relation to myeloid leukemogenesis.	[ "Expression", "of", "the", "Runt", "domain", "-", "encoding", "PEBP2", "alpha", "genes", "in", "T", "cells", "during", "thymic", "development", ".", "\n", "The", "PEBP2", "alpha", "A", "and", "PEBP2", "alpha", "B", "genes", "encode", "the", "DNA", "-", "binding", "subunit", "of", "a", "murine", "transcription", "factor", ",", "PEBP2", ",", "which", "is", "implicated", "as", "a", "T", "-", "cell", "-", "specific", "transcriptional", "regulator", ".", "These", "two", "related", "genes", "share", "the", "evolutionarily", "conserved", "region", "encoding", "the", "Runt", "domain", ".", "PEBP2", "alpha", "B", "is", "the", "murine", "counterpart", "of", "human", "AML1", ",", "which", "is", "located", "at", "the", "breakpoints", "of", "the", "8;21", "and", "3;21", "chromosome", "translocations", "associated", "with", "acute", "myeloid", "leukemia", ".", "Northern", "(", "RNA", ")", "blots", "of", "various", "adult", "mouse", "tissues", "revealed", "that", "the", "levels", "of", "expression", "of", "both", "genes", "were", "most", "prominent", "in", "the", "thymus", ".", "Furthermore", ",", "transcripts", "of", "PEBP2", "alpha", "A", "and", "mouse", "AML1", "/", "PEBP2", "alpha", "B", "were", "detected", "in", "T", "lymphocytes", "in", "the", "thymuses", "from", "day", "16", "embryos", "and", "newborns", ",", "as", "well", "as", "4-week", "-", "old", "adult", "mice", ",", "by", "in", "situ", "hybridization", ".", "The", "expression", "of", "the", "genes", "persisted", "in", "peripheral", "lymph", "nodes", "of", "adult", "mice", ".", "The", "transcripts", "were", "detected", "in", "all", "the", "CD4-", "CD8-", ",", "CD4", "+", "CD8", "+", ",", "CD4", "+", "CD8-", ",", "and", "CD4-", "CD8", "+", "cell", "populations", ".", "The", "results", "indicated", "that", "both", "genes", "are", "expressed", "in", "T", "cells", "throughout", "their", "development", ",", "supporting", "the", "notion", "that", "PEBP2", "is", "a", "T", "-", "cell", "-", "specific", "transcription", "factor", ".", "Transcripts", "of", "mouse", "AML1", "/", "PEBP2", "alpha", "B", "were", "also", "detected", "in", "day", "12", "fetal", "hematopoietic", "liver", "and", "in", "the", "bone", "marrow", "cells", "of", "newborn", "mice", ".", "The", "implication", "of", "mouse", "AML1", "/", "PEBP2", "alpha", "B", "expression", "in", "hematopoietic", "cells", "other", "than", "those", "of", "T", "-", "cell", "lineage", "is", "discussed", "in", "relation", "to", "myeloid", "leukemogenesis", "." ]	[ "Protein" ]
PEBP2 alpha A, PEBP2 alpha B, PEBP2 alpha B, AML1, PEBP2 alpha A, AML1 / PEBP2 alpha B, CD4, CD4, AML1 / PEBP2 alpha B, AML1 / PEBP2 alpha B	7862157_task2	Sentence: Expression of the Runt domain-encoding PEBP2 alpha genes in T cells during thymic development. The PEBP2 alpha A and PEBP2 alpha B genes encode the DNA-binding subunit of a murine transcription factor, PEBP2, which is implicated as a T-cell-specific transcriptional regulator. These two related genes share the evolutionarily conserved region encoding the Runt domain. PEBP2 alpha B is the murine counterpart of human AML1, which is located at the breakpoints of the 8;21 and 3;21 chromosome translocations associated with acute myeloid leukemia. Northern (RNA) blots of various adult mouse tissues revealed that the levels of expression of both genes were most prominent in the thymus. Furthermore, transcripts of PEBP2 alpha A and mouse AML1/PEBP2 alpha B were detected in T lymphocytes in the thymuses from day 16 embryos and newborns, as well as 4-week-old adult mice, by in situ hybridization. The expression of the genes persisted in peripheral lymph nodes of adult mice. The transcripts were detected in all the CD4- CD8-, CD4+ CD8+, CD4+ CD8-, and CD4- CD8+ cell populations. The results indicated that both genes are expressed in T cells throughout their development, supporting the notion that PEBP2 is a T-cell-specific transcription factor. Transcripts of mouse AML1/PEBP2 alpha B were also detected in day 12 fetal hematopoietic liver and in the bone marrow cells of newborn mice. The implication of mouse AML1/PEBP2 alpha B expression in hematopoietic cells other than those of T-cell lineage is discussed in relation to myeloid leukemogenesis. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Expression of the Runt domain-encoding PEBP2 alpha genes in T cells during thymic development. The PEBP2 alpha A and PEBP2 alpha B genes encode the DNA-binding subunit of a murine transcription factor, PEBP2, which is implicated as a T-cell-specific transcriptional regulator. These two related genes share the evolutionarily conserved region encoding the Runt domain. PEBP2 alpha B is the murine counterpart of human AML1, which is located at the breakpoints of the 8;21 and 3;21 chromosome translocations associated with acute myeloid leukemia. Northern (RNA) blots of various adult mouse tissues revealed that the levels of expression of both genes were most prominent in the thymus. Furthermore, transcripts of PEBP2 alpha A and mouse AML1/PEBP2 alpha B were detected in T lymphocytes in the thymuses from day 16 embryos and newborns, as well as 4-week-old adult mice, by in situ hybridization. The expression of the genes persisted in peripheral lymph nodes of adult mice. The transcripts were detected in all the CD4- CD8-, CD4+ CD8+, CD4+ CD8-, and CD4- CD8+ cell populations. The results indicated that both genes are expressed in T cells throughout their development, supporting the notion that PEBP2 is a T-cell-specific transcription factor. Transcripts of mouse AML1/PEBP2 alpha B were also detected in day 12 fetal hematopoietic liver and in the bone marrow cells of newborn mice. The implication of mouse AML1/PEBP2 alpha B expression in hematopoietic cells other than those of T-cell lineage is discussed in relation to myeloid leukemogenesis.	[ "Expression", "of", "the", "Runt", "domain", "-", "encoding", "PEBP2", "alpha", "genes", "in", "T", "cells", "during", "thymic", "development", ".", "\n", "The", "PEBP2", "alpha", "A", "and", "PEBP2", "alpha", "B", "genes", "encode", "the", "DNA", "-", "binding", "subunit", "of", "a", "murine", "transcription", "factor", ",", "PEBP2", ",", "which", "is", "implicated", "as", "a", "T", "-", "cell", "-", "specific", "transcriptional", "regulator", ".", "These", "two", "related", "genes", "share", "the", "evolutionarily", "conserved", "region", "encoding", "the", "Runt", "domain", ".", "PEBP2", "alpha", "B", "is", "the", "murine", "counterpart", "of", "human", "AML1", ",", "which", "is", "located", "at", "the", "breakpoints", "of", "the", "8;21", "and", "3;21", "chromosome", "translocations", "associated", "with", "acute", "myeloid", "leukemia", ".", "Northern", "(", "RNA", ")", "blots", "of", "various", "adult", "mouse", "tissues", "revealed", "that", "the", "levels", "of", "expression", "of", "both", "genes", "were", "most", "prominent", "in", "the", "thymus", ".", "Furthermore", ",", "transcripts", "of", "PEBP2", "alpha", "A", "and", "mouse", "AML1", "/", "PEBP2", "alpha", "B", "were", "detected", "in", "T", "lymphocytes", "in", "the", "thymuses", "from", "day", "16", "embryos", "and", "newborns", ",", "as", "well", "as", "4-week", "-", "old", "adult", "mice", ",", "by", "in", "situ", "hybridization", ".", "The", "expression", "of", "the", "genes", "persisted", "in", "peripheral", "lymph", "nodes", "of", "adult", "mice", ".", "The", "transcripts", "were", "detected", "in", "all", "the", "CD4-", "CD8-", ",", "CD4", "+", "CD8", "+", ",", "CD4", "+", "CD8-", ",", "and", "CD4-", "CD8", "+", "cell", "populations", ".", "The", "results", "indicated", "that", "both", "genes", "are", "expressed", "in", "T", "cells", "throughout", "their", "development", ",", "supporting", "the", "notion", "that", "PEBP2", "is", "a", "T", "-", "cell", "-", "specific", "transcription", "factor", ".", "Transcripts", "of", "mouse", "AML1", "/", "PEBP2", "alpha", "B", "were", "also", "detected", "in", "day", "12", "fetal", "hematopoietic", "liver", "and", "in", "the", "bone", "marrow", "cells", "of", "newborn", "mice", ".", "The", "implication", "of", "mouse", "AML1", "/", "PEBP2", "alpha", "B", "expression", "in", "hematopoietic", "cells", "other", "than", "those", "of", "T", "-", "cell", "lineage", "is", "discussed", "in", "relation", "to", "myeloid", "leukemogenesis", "." ]	[ "Protein" ]
Amphotericin B is a Intervention_Pharmacological, children is a Participant_Age, malignant disease : is a Participant_Condition, amphotericin B administered in dextrose is a Intervention_Pharmacological, lipid emulsion is a Intervention_Pharmacological, amphotericin B ( AmB ) is a Intervention_Pharmacological, AmB infused in lipid emulsion is a Intervention_Pharmacological, 82 is a Participant_Sample-size, pharmacokinetics of AmB is a Outcome_Physical, AmB in dextrose is a Intervention_Pharmacological, AmB in lipid emulsion is a Intervention_Pharmacological, concentration of AmB in plasma is a Outcome_Physical, clearance ( CL ) of AmB in dextrose is a Outcome_Physical, steady - state volume of distribution for AmB is a Outcome_Physical, safety and tolerance is a Outcome_Other	1014_task0	Sentence: Amphotericin B in children with malignant disease : a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion . In a prospective , randomized clinical trial , the toxicity of 1 mg of amphotericin B ( AmB ) per kg of body weight per day infused in 5 % dextrose was compared with that of AmB infused in lipid emulsion in children with malignant disease . In an analysis of 82 children who received a full course of 6 days or more of AmB ( 117 courses ) , it was shown that there were significant increases in plasma urea and creatinine concentrations and in potassium requirement after 6 days of therapy with both AmB infused in dextrose and AmB infused in lipid emulsion , with there being no difference between the two methods of AmB administration . An intent-to-treat comparison of the numbers of courses affected by acute toxicity ( fever , rigors ) and chronic toxicity ( nephrotoxicity ) also indicated that there was no significant difference between AmB infused in dextrose ( 78 courses ) and AmB infused in lipid emulsion ( 84 courses ) . The pharmacokinetics of AmB were investigated in 20 children who received AmB in dextrose and 15 children who received AmB in lipid emulsion . Blood samples were collected up to 24 h after administration of the first dose , and the concentration of AmB in plasma was analyzed by a high-performance liquid chromatography assay . The clearance ( CL ) of AmB in dextrose ( 0.039 +/- 0.016 liter . h-1 . kg-1 ) was significantly lower ( P < 0.005 ) than the CL of AmB in lipid emulsion ( 0.062 +/- 0 . 024 liter . h-1 . kg-1 ) . The steady-state volume of distribution for AmB in dextrose ( 0.83 +/- 0.33 liter . kg-1 ) was also significantly lower ( P < 0.005 ) than that for AmB in lipid emulsion ( 1.47 +/- 0.77 liter . kg-1 ) . Although AmB in lipid emulsion is apparently cleared faster and distributes more widely than AmB in dextrose , this study did not reveal any significant advantage with respect to safety and tolerance in the administration of AmB in lipid emulsion compared to its administration in dextrose in children with malignant disease . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Other	[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Amphotericin B in children with malignant disease : a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion . In a prospective , randomized clinical trial , the toxicity of 1 mg of amphotericin B ( AmB ) per kg of body weight per day infused in 5 % dextrose was compared with that of AmB infused in lipid emulsion in children with malignant disease . In an analysis of 82 children who received a full course of 6 days or more of AmB ( 117 courses ) , it was shown that there were significant increases in plasma urea and creatinine concentrations and in potassium requirement after 6 days of therapy with both AmB infused in dextrose and AmB infused in lipid emulsion , with there being no difference between the two methods of AmB administration . An intent-to-treat comparison of the numbers of courses affected by acute toxicity ( fever , rigors ) and chronic toxicity ( nephrotoxicity ) also indicated that there was no significant difference between AmB infused in dextrose ( 78 courses ) and AmB infused in lipid emulsion ( 84 courses ) . The pharmacokinetics of AmB were investigated in 20 children who received AmB in dextrose and 15 children who received AmB in lipid emulsion . Blood samples were collected up to 24 h after administration of the first dose , and the concentration of AmB in plasma was analyzed by a high-performance liquid chromatography assay . The clearance ( CL ) of AmB in dextrose ( 0.039 +/- 0.016 liter . h-1 . kg-1 ) was significantly lower ( P < 0.005 ) than the CL of AmB in lipid emulsion ( 0.062 +/- 0 . 024 liter . h-1 . kg-1 ) . The steady-state volume of distribution for AmB in dextrose ( 0.83 +/- 0.33 liter . kg-1 ) was also significantly lower ( P < 0.005 ) than that for AmB in lipid emulsion ( 1.47 +/- 0.77 liter . kg-1 ) . Although AmB in lipid emulsion is apparently cleared faster and distributes more widely than AmB in dextrose , this study did not reveal any significant advantage with respect to safety and tolerance in the administration of AmB in lipid emulsion compared to its administration in dextrose in children with malignant disease .	[ "Amphotericin", "B", "in", "children", "with", "malignant", "disease", ":", "a", "comparison", "of", "the", "toxicities", "and", "pharmacokinetics", "of", "amphotericin", "B", "administered", "in", "dextrose", "versus", "lipid", "emulsion", ".", "In", "a", "prospective", ",", "randomized", "clinical", "trial", ",", "the", "toxicity", "of", "1", "mg", "of", "amphotericin", "B", "(", "AmB", ")", "per", "kg", "of", "body", "weight", "per", "day", "infused", "in", "5", "%", "dextrose", "was", "compared", "with", "that", "of", "AmB", "infused", "in", "lipid", "emulsion", "in", "children", "with", "malignant", "disease", ".", "In", "an", "analysis", "of", "82", "children", "who", "received", "a", "full", "course", "of", "6", "days", "or", "more", "of", "AmB", "(", "117", "courses", ")", ",", "it", "was", "shown", "that", "there", "were", "significant", "increases", "in", "plasma", "urea", "and", "creatinine", "concentrations", "and", "in", "potassium", "requirement", "after", "6", "days", "of", "therapy", "with", "both", "AmB", "infused", "in", "dextrose", "and", "AmB", "infused", "in", "lipid", "emulsion", ",", "with", "there", "being", "no", "difference", "between", "the", "two", "methods", "of", "AmB", "administration", ".", "An", "intent", "-", "to", "-", "treat", "comparison", "of", "the", "numbers", "of", "courses", "affected", "by", "acute", "toxicity", "(", "fever", ",", "rigors", ")", "and", "chronic", "toxicity", "(", "nephrotoxicity", ")", "also", "indicated", "that", "there", "was", "no", "significant", "difference", "between", "AmB", "infused", "in", "dextrose", "(", "78", "courses", ")", "and", "AmB", "infused", "in", "lipid", "emulsion", "(", "84", "courses", ")", ".", "The", "pharmacokinetics", "of", "AmB", "were", "investigated", "in", "20", "children", "who", "received", "AmB", "in", "dextrose", "and", "15", "children", "who", "received", "AmB", "in", "lipid", "emulsion", ".", "Blood", "samples", "were", "collected", "up", "to", "24", "h", "after", "administration", "of", "the", "first", "dose", ",", "and", "the", "concentration", "of", "AmB", "in", "plasma", "was", "analyzed", "by", "a", "high", "-", "performance", "liquid", "chromatography", "assay", ".", "The", "clearance", "(", "CL", ")", "of", "AmB", "in", "dextrose", "(", "0.039", "+", "/-", "0.016", "liter", ".", "h-1", ".", "kg-1", ")", "was", "significantly", "lower", "(", "P", "<", "0.005", ")", "than", "the", "CL", "of", "AmB", "in", "lipid", "emulsion", "(", "0.062", "+", "/-", "0", ".", "024", "liter", ".", "h-1", ".", "kg-1", ")", ".", "The", "steady", "-", "state", "volume", "of", "distribution", "for", "AmB", "in", "dextrose", "(", "0.83", "+", "/-", "0.33", "liter", ".", "kg-1", ")", "was", "also", "significantly", "lower", "(", "P", "<", "0.005", ")", "than", "that", "for", "AmB", "in", "lipid", "emulsion", "(", "1.47", "+", "/-", "0.77", "liter", ".", "kg-1", ")", ".", "Although", "AmB", "in", "lipid", "emulsion", "is", "apparently", "cleared", "faster", "and", "distributes", "more", "widely", "than", "AmB", "in", "dextrose", ",", "this", "study", "did", "not", "reveal", "any", "significant", "advantage", "with", "respect", "to", "safety", "and", "tolerance", "in", "the", "administration", "of", "AmB", "in", "lipid", "emulsion", "compared", "to", "its", "administration", "in", "dextrose", "in", "children", "with", "malignant", "disease", "." ]	[ "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Other", "Participant_Condition", "Participant_Age", "Participant_Sample-size" ]
Amphotericin B is a Intervention_Pharmacological, children is a Participant_Age, malignant disease : is a Participant_Condition, amphotericin B administered in dextrose is a Intervention_Pharmacological, lipid emulsion is a Intervention_Pharmacological, amphotericin B ( AmB ) is a Intervention_Pharmacological, AmB infused in lipid emulsion is a Intervention_Pharmacological, 82 is a Participant_Sample-size, pharmacokinetics of AmB is a Outcome_Physical, AmB in dextrose is a Intervention_Pharmacological, AmB in lipid emulsion is a Intervention_Pharmacological, concentration of AmB in plasma is a Outcome_Physical, clearance ( CL ) of AmB in dextrose is a Outcome_Physical, steady - state volume of distribution for AmB is a Outcome_Physical, safety and tolerance is a Outcome_Other	1014_task1	Sentence: Amphotericin B in children with malignant disease : a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion . In a prospective , randomized clinical trial , the toxicity of 1 mg of amphotericin B ( AmB ) per kg of body weight per day infused in 5 % dextrose was compared with that of AmB infused in lipid emulsion in children with malignant disease . In an analysis of 82 children who received a full course of 6 days or more of AmB ( 117 courses ) , it was shown that there were significant increases in plasma urea and creatinine concentrations and in potassium requirement after 6 days of therapy with both AmB infused in dextrose and AmB infused in lipid emulsion , with there being no difference between the two methods of AmB administration . An intent-to-treat comparison of the numbers of courses affected by acute toxicity ( fever , rigors ) and chronic toxicity ( nephrotoxicity ) also indicated that there was no significant difference between AmB infused in dextrose ( 78 courses ) and AmB infused in lipid emulsion ( 84 courses ) . The pharmacokinetics of AmB were investigated in 20 children who received AmB in dextrose and 15 children who received AmB in lipid emulsion . Blood samples were collected up to 24 h after administration of the first dose , and the concentration of AmB in plasma was analyzed by a high-performance liquid chromatography assay . The clearance ( CL ) of AmB in dextrose ( 0.039 +/- 0.016 liter . h-1 . kg-1 ) was significantly lower ( P < 0.005 ) than the CL of AmB in lipid emulsion ( 0.062 +/- 0 . 024 liter . h-1 . kg-1 ) . The steady-state volume of distribution for AmB in dextrose ( 0.83 +/- 0.33 liter . kg-1 ) was also significantly lower ( P < 0.005 ) than that for AmB in lipid emulsion ( 1.47 +/- 0.77 liter . kg-1 ) . Although AmB in lipid emulsion is apparently cleared faster and distributes more widely than AmB in dextrose , this study did not reveal any significant advantage with respect to safety and tolerance in the administration of AmB in lipid emulsion compared to its administration in dextrose in children with malignant disease . Instructions: please typing these entity words according to sentence: Amphotericin B, children, malignant disease :, amphotericin B administered in dextrose, lipid emulsion, amphotericin B ( AmB ), AmB infused in lipid emulsion, 82, pharmacokinetics of AmB, AmB in dextrose, AmB in lipid emulsion, concentration of AmB in plasma, clearance ( CL ) of AmB in dextrose, steady - state volume of distribution for AmB, safety and tolerance Options: Intervention_Pharmacological, Participant_Condition, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Other	[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Amphotericin B in children with malignant disease : a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion . In a prospective , randomized clinical trial , the toxicity of 1 mg of amphotericin B ( AmB ) per kg of body weight per day infused in 5 % dextrose was compared with that of AmB infused in lipid emulsion in children with malignant disease . In an analysis of 82 children who received a full course of 6 days or more of AmB ( 117 courses ) , it was shown that there were significant increases in plasma urea and creatinine concentrations and in potassium requirement after 6 days of therapy with both AmB infused in dextrose and AmB infused in lipid emulsion , with there being no difference between the two methods of AmB administration . An intent-to-treat comparison of the numbers of courses affected by acute toxicity ( fever , rigors ) and chronic toxicity ( nephrotoxicity ) also indicated that there was no significant difference between AmB infused in dextrose ( 78 courses ) and AmB infused in lipid emulsion ( 84 courses ) . The pharmacokinetics of AmB were investigated in 20 children who received AmB in dextrose and 15 children who received AmB in lipid emulsion . Blood samples were collected up to 24 h after administration of the first dose , and the concentration of AmB in plasma was analyzed by a high-performance liquid chromatography assay . The clearance ( CL ) of AmB in dextrose ( 0.039 +/- 0.016 liter . h-1 . kg-1 ) was significantly lower ( P < 0.005 ) than the CL of AmB in lipid emulsion ( 0.062 +/- 0 . 024 liter . h-1 . kg-1 ) . The steady-state volume of distribution for AmB in dextrose ( 0.83 +/- 0.33 liter . kg-1 ) was also significantly lower ( P < 0.005 ) than that for AmB in lipid emulsion ( 1.47 +/- 0.77 liter . kg-1 ) . Although AmB in lipid emulsion is apparently cleared faster and distributes more widely than AmB in dextrose , this study did not reveal any significant advantage with respect to safety and tolerance in the administration of AmB in lipid emulsion compared to its administration in dextrose in children with malignant disease .	[ "Amphotericin", "B", "in", "children", "with", "malignant", "disease", ":", "a", "comparison", "of", "the", "toxicities", "and", "pharmacokinetics", "of", "amphotericin", "B", "administered", "in", "dextrose", "versus", "lipid", "emulsion", ".", "In", "a", "prospective", ",", "randomized", "clinical", "trial", ",", "the", "toxicity", "of", "1", "mg", "of", "amphotericin", "B", "(", "AmB", ")", "per", "kg", "of", "body", "weight", "per", "day", "infused", "in", "5", "%", "dextrose", "was", "compared", "with", "that", "of", "AmB", "infused", "in", "lipid", "emulsion", "in", "children", "with", "malignant", "disease", ".", "In", "an", "analysis", "of", "82", "children", "who", "received", "a", "full", "course", "of", "6", "days", "or", "more", "of", "AmB", "(", "117", "courses", ")", ",", "it", "was", "shown", "that", "there", "were", "significant", "increases", "in", "plasma", "urea", "and", "creatinine", "concentrations", "and", "in", "potassium", "requirement", "after", "6", "days", "of", "therapy", "with", "both", "AmB", "infused", "in", "dextrose", "and", "AmB", "infused", "in", "lipid", "emulsion", ",", "with", "there", "being", "no", "difference", "between", "the", "two", "methods", "of", "AmB", "administration", ".", "An", "intent", "-", "to", "-", "treat", "comparison", "of", "the", "numbers", "of", "courses", "affected", "by", "acute", "toxicity", "(", "fever", ",", "rigors", ")", "and", "chronic", "toxicity", "(", "nephrotoxicity", ")", "also", "indicated", "that", "there", "was", "no", "significant", "difference", "between", "AmB", "infused", "in", "dextrose", "(", "78", "courses", ")", "and", "AmB", "infused", "in", "lipid", "emulsion", "(", "84", "courses", ")", ".", "The", "pharmacokinetics", "of", "AmB", "were", "investigated", "in", "20", "children", "who", "received", "AmB", "in", "dextrose", "and", "15", "children", "who", "received", "AmB", "in", "lipid", "emulsion", ".", "Blood", "samples", "were", "collected", "up", "to", "24", "h", "after", "administration", "of", "the", "first", "dose", ",", "and", "the", "concentration", "of", "AmB", "in", "plasma", "was", "analyzed", "by", "a", "high", "-", "performance", "liquid", "chromatography", "assay", ".", "The", "clearance", "(", "CL", ")", "of", "AmB", "in", "dextrose", "(", "0.039", "+", "/-", "0.016", "liter", ".", "h-1", ".", "kg-1", ")", "was", "significantly", "lower", "(", "P", "<", "0.005", ")", "than", "the", "CL", "of", "AmB", "in", "lipid", "emulsion", "(", "0.062", "+", "/-", "0", ".", "024", "liter", ".", "h-1", ".", "kg-1", ")", ".", "The", "steady", "-", "state", "volume", "of", "distribution", "for", "AmB", "in", "dextrose", "(", "0.83", "+", "/-", "0.33", "liter", ".", "kg-1", ")", "was", "also", "significantly", "lower", "(", "P", "<", "0.005", ")", "than", "that", "for", "AmB", "in", "lipid", "emulsion", "(", "1.47", "+", "/-", "0.77", "liter", ".", "kg-1", ")", ".", "Although", "AmB", "in", "lipid", "emulsion", "is", "apparently", "cleared", "faster", "and", "distributes", "more", "widely", "than", "AmB", "in", "dextrose", ",", "this", "study", "did", "not", "reveal", "any", "significant", "advantage", "with", "respect", "to", "safety", "and", "tolerance", "in", "the", "administration", "of", "AmB", "in", "lipid", "emulsion", "compared", "to", "its", "administration", "in", "dextrose", "in", "children", "with", "malignant", "disease", "." ]	[ "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Other", "Participant_Condition", "Participant_Age", "Participant_Sample-size" ]
Amphotericin B, children, malignant disease :, amphotericin B administered in dextrose, lipid emulsion, amphotericin B ( AmB ), AmB infused in lipid emulsion, 82, pharmacokinetics of AmB, AmB in dextrose, AmB in lipid emulsion, concentration of AmB in plasma, clearance ( CL ) of AmB in dextrose, steady - state volume of distribution for AmB, safety and tolerance	1014_task2	Sentence: Amphotericin B in children with malignant disease : a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion . In a prospective , randomized clinical trial , the toxicity of 1 mg of amphotericin B ( AmB ) per kg of body weight per day infused in 5 % dextrose was compared with that of AmB infused in lipid emulsion in children with malignant disease . In an analysis of 82 children who received a full course of 6 days or more of AmB ( 117 courses ) , it was shown that there were significant increases in plasma urea and creatinine concentrations and in potassium requirement after 6 days of therapy with both AmB infused in dextrose and AmB infused in lipid emulsion , with there being no difference between the two methods of AmB administration . An intent-to-treat comparison of the numbers of courses affected by acute toxicity ( fever , rigors ) and chronic toxicity ( nephrotoxicity ) also indicated that there was no significant difference between AmB infused in dextrose ( 78 courses ) and AmB infused in lipid emulsion ( 84 courses ) . The pharmacokinetics of AmB were investigated in 20 children who received AmB in dextrose and 15 children who received AmB in lipid emulsion . Blood samples were collected up to 24 h after administration of the first dose , and the concentration of AmB in plasma was analyzed by a high-performance liquid chromatography assay . The clearance ( CL ) of AmB in dextrose ( 0.039 +/- 0.016 liter . h-1 . kg-1 ) was significantly lower ( P < 0.005 ) than the CL of AmB in lipid emulsion ( 0.062 +/- 0 . 024 liter . h-1 . kg-1 ) . The steady-state volume of distribution for AmB in dextrose ( 0.83 +/- 0.33 liter . kg-1 ) was also significantly lower ( P < 0.005 ) than that for AmB in lipid emulsion ( 1.47 +/- 0.77 liter . kg-1 ) . Although AmB in lipid emulsion is apparently cleared faster and distributes more widely than AmB in dextrose , this study did not reveal any significant advantage with respect to safety and tolerance in the administration of AmB in lipid emulsion compared to its administration in dextrose in children with malignant disease . Instructions: please extract entity words from the input sentence	[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Amphotericin B in children with malignant disease : a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion . In a prospective , randomized clinical trial , the toxicity of 1 mg of amphotericin B ( AmB ) per kg of body weight per day infused in 5 % dextrose was compared with that of AmB infused in lipid emulsion in children with malignant disease . In an analysis of 82 children who received a full course of 6 days or more of AmB ( 117 courses ) , it was shown that there were significant increases in plasma urea and creatinine concentrations and in potassium requirement after 6 days of therapy with both AmB infused in dextrose and AmB infused in lipid emulsion , with there being no difference between the two methods of AmB administration . An intent-to-treat comparison of the numbers of courses affected by acute toxicity ( fever , rigors ) and chronic toxicity ( nephrotoxicity ) also indicated that there was no significant difference between AmB infused in dextrose ( 78 courses ) and AmB infused in lipid emulsion ( 84 courses ) . The pharmacokinetics of AmB were investigated in 20 children who received AmB in dextrose and 15 children who received AmB in lipid emulsion . Blood samples were collected up to 24 h after administration of the first dose , and the concentration of AmB in plasma was analyzed by a high-performance liquid chromatography assay . The clearance ( CL ) of AmB in dextrose ( 0.039 +/- 0.016 liter . h-1 . kg-1 ) was significantly lower ( P < 0.005 ) than the CL of AmB in lipid emulsion ( 0.062 +/- 0 . 024 liter . h-1 . kg-1 ) . The steady-state volume of distribution for AmB in dextrose ( 0.83 +/- 0.33 liter . kg-1 ) was also significantly lower ( P < 0.005 ) than that for AmB in lipid emulsion ( 1.47 +/- 0.77 liter . kg-1 ) . Although AmB in lipid emulsion is apparently cleared faster and distributes more widely than AmB in dextrose , this study did not reveal any significant advantage with respect to safety and tolerance in the administration of AmB in lipid emulsion compared to its administration in dextrose in children with malignant disease .	[ "Amphotericin", "B", "in", "children", "with", "malignant", "disease", ":", "a", "comparison", "of", "the", "toxicities", "and", "pharmacokinetics", "of", "amphotericin", "B", "administered", "in", "dextrose", "versus", "lipid", "emulsion", ".", "In", "a", "prospective", ",", "randomized", "clinical", "trial", ",", "the", "toxicity", "of", "1", "mg", "of", "amphotericin", "B", "(", "AmB", ")", "per", "kg", "of", "body", "weight", "per", "day", "infused", "in", "5", "%", "dextrose", "was", "compared", "with", "that", "of", "AmB", "infused", "in", "lipid", "emulsion", "in", "children", "with", "malignant", "disease", ".", "In", "an", "analysis", "of", "82", "children", "who", "received", "a", "full", "course", "of", "6", "days", "or", "more", "of", "AmB", "(", "117", "courses", ")", ",", "it", "was", "shown", "that", "there", "were", "significant", "increases", "in", "plasma", "urea", "and", "creatinine", "concentrations", "and", "in", "potassium", "requirement", "after", "6", "days", "of", "therapy", "with", "both", "AmB", "infused", "in", "dextrose", "and", "AmB", "infused", "in", "lipid", "emulsion", ",", "with", "there", "being", "no", "difference", "between", "the", "two", "methods", "of", "AmB", "administration", ".", "An", "intent", "-", "to", "-", "treat", "comparison", "of", "the", "numbers", "of", "courses", "affected", "by", "acute", "toxicity", "(", "fever", ",", "rigors", ")", "and", "chronic", "toxicity", "(", "nephrotoxicity", ")", "also", "indicated", "that", "there", "was", "no", "significant", "difference", "between", "AmB", "infused", "in", "dextrose", "(", "78", "courses", ")", "and", "AmB", "infused", "in", "lipid", "emulsion", "(", "84", "courses", ")", ".", "The", "pharmacokinetics", "of", "AmB", "were", "investigated", "in", "20", "children", "who", "received", "AmB", "in", "dextrose", "and", "15", "children", "who", "received", "AmB", "in", "lipid", "emulsion", ".", "Blood", "samples", "were", "collected", "up", "to", "24", "h", "after", "administration", "of", "the", "first", "dose", ",", "and", "the", "concentration", "of", "AmB", "in", "plasma", "was", "analyzed", "by", "a", "high", "-", "performance", "liquid", "chromatography", "assay", ".", "The", "clearance", "(", "CL", ")", "of", "AmB", "in", "dextrose", "(", "0.039", "+", "/-", "0.016", "liter", ".", "h-1", ".", "kg-1", ")", "was", "significantly", "lower", "(", "P", "<", "0.005", ")", "than", "the", "CL", "of", "AmB", "in", "lipid", "emulsion", "(", "0.062", "+", "/-", "0", ".", "024", "liter", ".", "h-1", ".", "kg-1", ")", ".", "The", "steady", "-", "state", "volume", "of", "distribution", "for", "AmB", "in", "dextrose", "(", "0.83", "+", "/-", "0.33", "liter", ".", "kg-1", ")", "was", "also", "significantly", "lower", "(", "P", "<", "0.005", ")", "than", "that", "for", "AmB", "in", "lipid", "emulsion", "(", "1.47", "+", "/-", "0.77", "liter", ".", "kg-1", ")", ".", "Although", "AmB", "in", "lipid", "emulsion", "is", "apparently", "cleared", "faster", "and", "distributes", "more", "widely", "than", "AmB", "in", "dextrose", ",", "this", "study", "did", "not", "reveal", "any", "significant", "advantage", "with", "respect", "to", "safety", "and", "tolerance", "in", "the", "administration", "of", "AmB", "in", "lipid", "emulsion", "compared", "to", "its", "administration", "in", "dextrose", "in", "children", "with", "malignant", "disease", "." ]	[ "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Other", "Participant_Condition", "Participant_Age", "Participant_Sample-size" ]
homocysteine is a compound, MTHFR is a protein, folate is a compound, cobalamin is a compound	DS.d1330_task0	Sentence: Total plasma homocysteine level, MTHFR C677T polymorphism, inherited abnormalities of the natural anticoagulant system as well as plasma folate and cobalamin levels were determined. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "O", "O", "B-compound", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "B-compound", "O", "O", "O", "O" ]	Total plasma homocysteine level, MTHFR C677T polymorphism, inherited abnormalities of the natural anticoagulant system as well as plasma folate and cobalamin levels were determined.	[ "Total", "plasma", "homocysteine", "level", ",", "MTHFR", "C677", "T", "polymorphism", ",", "inherited", "abnormalities", "of", "the", "natural", "anticoagulant", "system", "as", "well", "as", "plasma", "folate", "and", "cobalamin", "levels", "were", "determined", "." ]	[ "compound", "protein" ]
homocysteine is a compound, MTHFR is a protein, folate is a compound, cobalamin is a compound	DS.d1330_task1	Sentence: Total plasma homocysteine level, MTHFR C677T polymorphism, inherited abnormalities of the natural anticoagulant system as well as plasma folate and cobalamin levels were determined. Instructions: please typing these entity words according to sentence: homocysteine, MTHFR, folate, cobalamin Options: compound, protein	[ "O", "O", "B-compound", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "B-compound", "O", "O", "O", "O" ]	Total plasma homocysteine level, MTHFR C677T polymorphism, inherited abnormalities of the natural anticoagulant system as well as plasma folate and cobalamin levels were determined.	[ "Total", "plasma", "homocysteine", "level", ",", "MTHFR", "C677", "T", "polymorphism", ",", "inherited", "abnormalities", "of", "the", "natural", "anticoagulant", "system", "as", "well", "as", "plasma", "folate", "and", "cobalamin", "levels", "were", "determined", "." ]	[ "compound", "protein" ]
homocysteine, MTHFR, folate, cobalamin	DS.d1330_task2	Sentence: Total plasma homocysteine level, MTHFR C677T polymorphism, inherited abnormalities of the natural anticoagulant system as well as plasma folate and cobalamin levels were determined. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-compound", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "B-compound", "O", "O", "O", "O" ]	Total plasma homocysteine level, MTHFR C677T polymorphism, inherited abnormalities of the natural anticoagulant system as well as plasma folate and cobalamin levels were determined.	[ "Total", "plasma", "homocysteine", "level", ",", "MTHFR", "C677", "T", "polymorphism", ",", "inherited", "abnormalities", "of", "the", "natural", "anticoagulant", "system", "as", "well", "as", "plasma", "folate", "and", "cobalamin", "levels", "were", "determined", "." ]	[ "compound", "protein" ]
Vitamin C is a CHEMICAL, diethylmaleate is a CHEMICAL, L - cystine is a CHEMICAL	12498985_task0	Sentence: Vitamin C inhibits diethylmaleate-induced L-cystine transport in human vascular smooth muscle cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL	[ "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]	Vitamin C inhibits diethylmaleate-induced L-cystine transport in human vascular smooth muscle cells.	[ "Vitamin", "C", "inhibits", "diethylmaleate", "-", "induced", "L", "-", "cystine", "transport", "in", "human", "vascular", "smooth", "muscle", "cells", "." ]	[ "GENE-Y", "CHEMICAL", "GENE-N" ]
Vitamin C is a CHEMICAL, diethylmaleate is a CHEMICAL, L - cystine is a CHEMICAL	12498985_task1	Sentence: Vitamin C inhibits diethylmaleate-induced L-cystine transport in human vascular smooth muscle cells. Instructions: please typing these entity words according to sentence: Vitamin C, diethylmaleate, L - cystine Options: CHEMICAL	[ "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]	Vitamin C inhibits diethylmaleate-induced L-cystine transport in human vascular smooth muscle cells.	[ "Vitamin", "C", "inhibits", "diethylmaleate", "-", "induced", "L", "-", "cystine", "transport", "in", "human", "vascular", "smooth", "muscle", "cells", "." ]	[ "GENE-Y", "CHEMICAL", "GENE-N" ]
Vitamin C, diethylmaleate, L - cystine	12498985_task2	Sentence: Vitamin C inhibits diethylmaleate-induced L-cystine transport in human vascular smooth muscle cells. Instructions: please extract entity words from the input sentence	[ "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]	Vitamin C inhibits diethylmaleate-induced L-cystine transport in human vascular smooth muscle cells.	[ "Vitamin", "C", "inhibits", "diethylmaleate", "-", "induced", "L", "-", "cystine", "transport", "in", "human", "vascular", "smooth", "muscle", "cells", "." ]	[ "GENE-Y", "CHEMICAL", "GENE-N" ]
Jun oncogene family members is a DNA_family_or_group, glucocorticoid receptor - dependent transcription is an other_name	83922_task0	Sentence: Cell-specific bifunctional role of Jun oncogene family members on glucocorticoid receptor-dependent transcription. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA_family_or_group, other_name	[ "O", "O", "O", "O", "O", "O", "B-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O" ]	Cell-specific bifunctional role of Jun oncogene family members on glucocorticoid receptor-dependent transcription.	[ "Cell", "-", "specific", "bifunctional", "role", "of", "Jun", "oncogene", "family", "members", "on", "glucocorticoid", "receptor", "-", "dependent", "transcription", "." ]	[ "other_name", "DNA_molecule", "(OR DNA_molecule DNA_molecule DNA_molecule)", "other_organic_compound", "(OR protein_domain_or_region protein_domain_or_region)", "protein_molecule", "DNA_family_or_group", "DNA_domain_or_region", "virus", "protein_family_or_group", "protein_domain_or_region", "cell_line", "", "cell_type" ]
Jun oncogene family members is a DNA_family_or_group, glucocorticoid receptor - dependent transcription is an other_name	83922_task1	Sentence: Cell-specific bifunctional role of Jun oncogene family members on glucocorticoid receptor-dependent transcription. Instructions: please typing these entity words according to sentence: Jun oncogene family members, glucocorticoid receptor - dependent transcription Options: DNA_family_or_group, other_name	[ "O", "O", "O", "O", "O", "O", "B-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O" ]	Cell-specific bifunctional role of Jun oncogene family members on glucocorticoid receptor-dependent transcription.	[ "Cell", "-", "specific", "bifunctional", "role", "of", "Jun", "oncogene", "family", "members", "on", "glucocorticoid", "receptor", "-", "dependent", "transcription", "." ]	[ "other_name", "DNA_molecule", "(OR DNA_molecule DNA_molecule DNA_molecule)", "other_organic_compound", "(OR protein_domain_or_region protein_domain_or_region)", "protein_molecule", "DNA_family_or_group", "DNA_domain_or_region", "virus", "protein_family_or_group", "protein_domain_or_region", "cell_line", "", "cell_type" ]
Jun oncogene family members, glucocorticoid receptor - dependent transcription	83922_task2	Sentence: Cell-specific bifunctional role of Jun oncogene family members on glucocorticoid receptor-dependent transcription. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O" ]	Cell-specific bifunctional role of Jun oncogene family members on glucocorticoid receptor-dependent transcription.	[ "Cell", "-", "specific", "bifunctional", "role", "of", "Jun", "oncogene", "family", "members", "on", "glucocorticoid", "receptor", "-", "dependent", "transcription", "." ]	[ "other_name", "DNA_molecule", "(OR DNA_molecule DNA_molecule DNA_molecule)", "other_organic_compound", "(OR protein_domain_or_region protein_domain_or_region)", "protein_molecule", "DNA_family_or_group", "DNA_domain_or_region", "virus", "protein_family_or_group", "protein_domain_or_region", "cell_line", "", "cell_type" ]
aldo - keto reductases is a GENE-N, NF - E2-related factor 2 is a GENE-Y, NRF2 is a GENE-Y, Nrf2 is a GENE-Y, human NRF2 promoter is a GENE-N, NRF2 is a GENE-Y, NRF2 is a GENE-Y, NRF2 is a GENE-Y, NRF2 is a GENE-Y, NRF2 is a GENE-Y, NRF2 is a GENE-Y, sulforaphane is a CHEMICAL, tert - butylhydroquinone is a CHEMICAL, cinnamic aldehyde is a CHEMICAL, hydrogen peroxide is a CHEMICAL, aldo - keto reductase ( AKR ) 1C1 is a GENE-Y, AKRs is a GENE-N, KEAP1 is a GENE-Y, NRF2 is a GENE-Y, AKR1A1 , 1B1 , 1B10 , 1C1 , 1C2 , and 1C3 is a GENE-N, NRF2 is a GENE-Y, AKRs is a GENE-N, NRF2 is a GENE-Y, sulforaphane is a CHEMICAL, AKR1B1 , 1B10 , 1C1 , 1C2 , and 1C3 is a GENE-N, sulforaphane is a CHEMICAL, AKR1C1 is a GENE-Y, AKR1C1 is a GENE-Y, NRF2 is a GENE-Y, AKRs is a GENE-N, NRF2 is a GENE-Y	8099_task0	Sentence: Identification of aldo-keto reductases as NRF2-target marker genes in human cells. Transcription factor NF-E2-related factor 2 (NRF2) plays a crucial role in the cellular defense against oxidative/electrophilic stress by up-regulating multiple antioxidant genes. Numerous studies with genetically modified animals have demonstrated that Nrf2 is a sensitivity determining factor upon the exposure to environmental chemicals including carcinogens. Moreover, recent studies have demonstrated that polymorphism in the human NRF2 promoter is associated with higher risks for developing acute lung injury, gastric mucosal inflammation, and nephritis. Therefore, the identification of reliable and effective human target genes of NRF2 may allow the monitoring of NRF2 activity and to predict individual sensitivity to environmental stress-induced damage. For this purpose, we investigated genes that are tightly controlled by NRF2 to establish markers for NRF2 activity in human cells. Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments. Accordantly, the basal and inducible expressions of AKRs were significantly attenuated in NRF2-silenced HK-2 cells. Whereas, cells with stable KEAP1 knockdown, which causes a modest NRF2 activation, demonstrated substantially increased levels of AKR1A1, 1B1, 1B10, 1C1, 1C2, and 1C3. Secondly, the linkage between NRF2 and the AKRs was confirmed in human monocytic leukemia cell line U937, which can be a model of peripherally available blood cells. The treatment of U937 cells with NRF2 inducers including sulforaphane effectively elevated the expression of AKR1B1, 1B10, 1C1, 1C2, and 1C3. Whereas, the levels of both the basal and sulforaphane-inducible expression of AKR1C1 were significantly reduced in NRF2-silenced stable U937 cells compared to the control cells. Similarly, the inducible expression of AKR1C1 was observed in another human monocytic leukemia cell line THP-1 as well as in human primary blood CD14(+) monocytes. In conclusion, together with the high inducibility and NRF2 dependency shown in renal epithelial cells as well as in peripherally available blood cells, current findings suggest that AKRs can be utilized as a marker of NRF2 activity in human cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N, CHEMICAL	[ "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O" ]	Identification of aldo-keto reductases as NRF2-target marker genes in human cells. Transcription factor NF-E2-related factor 2 (NRF2) plays a crucial role in the cellular defense against oxidative/electrophilic stress by up-regulating multiple antioxidant genes. Numerous studies with genetically modified animals have demonstrated that Nrf2 is a sensitivity determining factor upon the exposure to environmental chemicals including carcinogens. Moreover, recent studies have demonstrated that polymorphism in the human NRF2 promoter is associated with higher risks for developing acute lung injury, gastric mucosal inflammation, and nephritis. Therefore, the identification of reliable and effective human target genes of NRF2 may allow the monitoring of NRF2 activity and to predict individual sensitivity to environmental stress-induced damage. For this purpose, we investigated genes that are tightly controlled by NRF2 to establish markers for NRF2 activity in human cells. Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments. Accordantly, the basal and inducible expressions of AKRs were significantly attenuated in NRF2-silenced HK-2 cells. Whereas, cells with stable KEAP1 knockdown, which causes a modest NRF2 activation, demonstrated substantially increased levels of AKR1A1, 1B1, 1B10, 1C1, 1C2, and 1C3. Secondly, the linkage between NRF2 and the AKRs was confirmed in human monocytic leukemia cell line U937, which can be a model of peripherally available blood cells. The treatment of U937 cells with NRF2 inducers including sulforaphane effectively elevated the expression of AKR1B1, 1B10, 1C1, 1C2, and 1C3. Whereas, the levels of both the basal and sulforaphane-inducible expression of AKR1C1 were significantly reduced in NRF2-silenced stable U937 cells compared to the control cells. Similarly, the inducible expression of AKR1C1 was observed in another human monocytic leukemia cell line THP-1 as well as in human primary blood CD14(+) monocytes. In conclusion, together with the high inducibility and NRF2 dependency shown in renal epithelial cells as well as in peripherally available blood cells, current findings suggest that AKRs can be utilized as a marker of NRF2 activity in human cells.	[ "Identification", "of", "aldo", "-", "keto", "reductases", "as", "NRF2-target", "marker", "genes", "in", "human", "cells", ".", "\n", "Transcription", "factor", "NF", "-", "E2-related", "factor", "2", "(", "NRF2", ")", "plays", "a", "crucial", "role", "in", "the", "cellular", "defense", "against", "oxidative", "/", "electrophilic", "stress", "by", "up", "-", "regulating", "multiple", "antioxidant", "genes", ".", "Numerous", "studies", "with", "genetically", "modified", "animals", "have", "demonstrated", "that", "Nrf2", "is", "a", "sensitivity", "determining", "factor", "upon", "the", "exposure", "to", "environmental", "chemicals", "including", "carcinogens", ".", "Moreover", ",", "recent", "studies", "have", "demonstrated", "that", "polymorphism", "in", "the", "human", "NRF2", "promoter", "is", "associated", "with", "higher", "risks", "for", "developing", "acute", "lung", "injury", ",", "gastric", "mucosal", "inflammation", ",", "and", "nephritis", ".", "Therefore", ",", "the", "identification", "of", "reliable", "and", "effective", "human", "target", "genes", "of", "NRF2", "may", "allow", "the", "monitoring", "of", "NRF2", "activity", "and", "to", "predict", "individual", "sensitivity", "to", "environmental", "stress", "-", "induced", "damage", ".", "For", "this", "purpose", ",", "we", "investigated", "genes", "that", "are", "tightly", "controlled", "by", "NRF2", "to", "establish", "markers", "for", "NRF2", "activity", "in", "human", "cells", ".", "Firstly", ",", "in", "the", "normal", "human", "renal", "epithelial", "HK-2", "cells", ",", "the", "measurement", "of", "the", "expression", "of", "30", "previously", "reported", "NRF2", "target", "genes", "in", "response", "to", "NRF2", "inducers", "(", "sulforaphane", ",", "tert", "-", "butylhydroquinone", ",", "cinnamic", "aldehyde", ",", "and", "hydrogen", "peroxide", ")", "showed", "that", "the", "aldo", "-", "keto", "reductase", "(", "AKR", ")", "1C1", "is", "highly", "inducible", "by", "all", "treatments", ".", "Accordantly", ",", "the", "basal", "and", "inducible", "expressions", "of", "AKRs", "were", "significantly", "attenuated", "in", "NRF2-silenced", "HK-2", "cells", ".", "Whereas", ",", "cells", "with", "stable", "KEAP1", "knockdown", ",", "which", "causes", "a", "modest", "NRF2", "activation", ",", "demonstrated", "substantially", "increased", "levels", "of", "AKR1A1", ",", "1B1", ",", "1B10", ",", "1C1", ",", "1C2", ",", "and", "1C3", ".", "Secondly", ",", "the", "linkage", "between", "NRF2", "and", "the", "AKRs", "was", "confirmed", "in", "human", "monocytic", "leukemia", "cell", "line", "U937", ",", "which", "can", "be", "a", "model", "of", "peripherally", "available", "blood", "cells", ".", "The", "treatment", "of", "U937", "cells", "with", "NRF2", "inducers", "including", "sulforaphane", "effectively", "elevated", "the", "expression", "of", "AKR1B1", ",", "1B10", ",", "1C1", ",", "1C2", ",", "and", "1C3", ".", "Whereas", ",", "the", "levels", "of", "both", "the", "basal", "and", "sulforaphane", "-", "inducible", "expression", "of", "AKR1C1", "were", "significantly", "reduced", "in", "NRF2-silenced", "stable", "U937", "cells", "compared", "to", "the", "control", "cells", ".", "Similarly", ",", "the", "inducible", "expression", "of", "AKR1C1", "was", "observed", "in", "another", "human", "monocytic", "leukemia", "cell", "line", "THP-1", "as", "well", "as", "in", "human", "primary", "blood", "CD14(+", ")", "monocytes", ".", "In", "conclusion", ",", "together", "with", "the", "high", "inducibility", "and", "NRF2", "dependency", "shown", "in", "renal", "epithelial", "cells", "as", "well", "as", "in", "peripherally", "available", "blood", "cells", ",", "current", "findings", "suggest", "that", "AKRs", "can", "be", "utilized", "as", "a", "marker", "of", "NRF2", "activity", "in", "human", "cells", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
aldo - keto reductases is a GENE-N, NF - E2-related factor 2 is a GENE-Y, NRF2 is a GENE-Y, Nrf2 is a GENE-Y, human NRF2 promoter is a GENE-N, NRF2 is a GENE-Y, NRF2 is a GENE-Y, NRF2 is a GENE-Y, NRF2 is a GENE-Y, NRF2 is a GENE-Y, NRF2 is a GENE-Y, sulforaphane is a CHEMICAL, tert - butylhydroquinone is a CHEMICAL, cinnamic aldehyde is a CHEMICAL, hydrogen peroxide is a CHEMICAL, aldo - keto reductase ( AKR ) 1C1 is a GENE-Y, AKRs is a GENE-N, KEAP1 is a GENE-Y, NRF2 is a GENE-Y, AKR1A1 , 1B1 , 1B10 , 1C1 , 1C2 , and 1C3 is a GENE-N, NRF2 is a GENE-Y, AKRs is a GENE-N, NRF2 is a GENE-Y, sulforaphane is a CHEMICAL, AKR1B1 , 1B10 , 1C1 , 1C2 , and 1C3 is a GENE-N, sulforaphane is a CHEMICAL, AKR1C1 is a GENE-Y, AKR1C1 is a GENE-Y, NRF2 is a GENE-Y, AKRs is a GENE-N, NRF2 is a GENE-Y	8099_task1	Sentence: Identification of aldo-keto reductases as NRF2-target marker genes in human cells. Transcription factor NF-E2-related factor 2 (NRF2) plays a crucial role in the cellular defense against oxidative/electrophilic stress by up-regulating multiple antioxidant genes. Numerous studies with genetically modified animals have demonstrated that Nrf2 is a sensitivity determining factor upon the exposure to environmental chemicals including carcinogens. Moreover, recent studies have demonstrated that polymorphism in the human NRF2 promoter is associated with higher risks for developing acute lung injury, gastric mucosal inflammation, and nephritis. Therefore, the identification of reliable and effective human target genes of NRF2 may allow the monitoring of NRF2 activity and to predict individual sensitivity to environmental stress-induced damage. For this purpose, we investigated genes that are tightly controlled by NRF2 to establish markers for NRF2 activity in human cells. Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments. Accordantly, the basal and inducible expressions of AKRs were significantly attenuated in NRF2-silenced HK-2 cells. Whereas, cells with stable KEAP1 knockdown, which causes a modest NRF2 activation, demonstrated substantially increased levels of AKR1A1, 1B1, 1B10, 1C1, 1C2, and 1C3. Secondly, the linkage between NRF2 and the AKRs was confirmed in human monocytic leukemia cell line U937, which can be a model of peripherally available blood cells. The treatment of U937 cells with NRF2 inducers including sulforaphane effectively elevated the expression of AKR1B1, 1B10, 1C1, 1C2, and 1C3. Whereas, the levels of both the basal and sulforaphane-inducible expression of AKR1C1 were significantly reduced in NRF2-silenced stable U937 cells compared to the control cells. Similarly, the inducible expression of AKR1C1 was observed in another human monocytic leukemia cell line THP-1 as well as in human primary blood CD14(+) monocytes. In conclusion, together with the high inducibility and NRF2 dependency shown in renal epithelial cells as well as in peripherally available blood cells, current findings suggest that AKRs can be utilized as a marker of NRF2 activity in human cells. Instructions: please typing these entity words according to sentence: aldo - keto reductases, NF - E2-related factor 2, NRF2, Nrf2, human NRF2 promoter, NRF2, NRF2, NRF2, NRF2, NRF2, NRF2, sulforaphane, tert - butylhydroquinone, cinnamic aldehyde, hydrogen peroxide, aldo - keto reductase ( AKR ) 1C1, AKRs, KEAP1, NRF2, AKR1A1 , 1B1 , 1B10 , 1C1 , 1C2 , and 1C3, NRF2, AKRs, NRF2, sulforaphane, AKR1B1 , 1B10 , 1C1 , 1C2 , and 1C3, sulforaphane, AKR1C1, AKR1C1, NRF2, AKRs, NRF2 Options: GENE-Y, GENE-N, CHEMICAL	[ "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O" ]	Identification of aldo-keto reductases as NRF2-target marker genes in human cells. Transcription factor NF-E2-related factor 2 (NRF2) plays a crucial role in the cellular defense against oxidative/electrophilic stress by up-regulating multiple antioxidant genes. Numerous studies with genetically modified animals have demonstrated that Nrf2 is a sensitivity determining factor upon the exposure to environmental chemicals including carcinogens. Moreover, recent studies have demonstrated that polymorphism in the human NRF2 promoter is associated with higher risks for developing acute lung injury, gastric mucosal inflammation, and nephritis. Therefore, the identification of reliable and effective human target genes of NRF2 may allow the monitoring of NRF2 activity and to predict individual sensitivity to environmental stress-induced damage. For this purpose, we investigated genes that are tightly controlled by NRF2 to establish markers for NRF2 activity in human cells. Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments. Accordantly, the basal and inducible expressions of AKRs were significantly attenuated in NRF2-silenced HK-2 cells. Whereas, cells with stable KEAP1 knockdown, which causes a modest NRF2 activation, demonstrated substantially increased levels of AKR1A1, 1B1, 1B10, 1C1, 1C2, and 1C3. Secondly, the linkage between NRF2 and the AKRs was confirmed in human monocytic leukemia cell line U937, which can be a model of peripherally available blood cells. The treatment of U937 cells with NRF2 inducers including sulforaphane effectively elevated the expression of AKR1B1, 1B10, 1C1, 1C2, and 1C3. Whereas, the levels of both the basal and sulforaphane-inducible expression of AKR1C1 were significantly reduced in NRF2-silenced stable U937 cells compared to the control cells. Similarly, the inducible expression of AKR1C1 was observed in another human monocytic leukemia cell line THP-1 as well as in human primary blood CD14(+) monocytes. In conclusion, together with the high inducibility and NRF2 dependency shown in renal epithelial cells as well as in peripherally available blood cells, current findings suggest that AKRs can be utilized as a marker of NRF2 activity in human cells.	[ "Identification", "of", "aldo", "-", "keto", "reductases", "as", "NRF2-target", "marker", "genes", "in", "human", "cells", ".", "\n", "Transcription", "factor", "NF", "-", "E2-related", "factor", "2", "(", "NRF2", ")", "plays", "a", "crucial", "role", "in", "the", "cellular", "defense", "against", "oxidative", "/", "electrophilic", "stress", "by", "up", "-", "regulating", "multiple", "antioxidant", "genes", ".", "Numerous", "studies", "with", "genetically", "modified", "animals", "have", "demonstrated", "that", "Nrf2", "is", "a", "sensitivity", "determining", "factor", "upon", "the", "exposure", "to", "environmental", "chemicals", "including", "carcinogens", ".", "Moreover", ",", "recent", "studies", "have", "demonstrated", "that", "polymorphism", "in", "the", "human", "NRF2", "promoter", "is", "associated", "with", "higher", "risks", "for", "developing", "acute", "lung", "injury", ",", "gastric", "mucosal", "inflammation", ",", "and", "nephritis", ".", "Therefore", ",", "the", "identification", "of", "reliable", "and", "effective", "human", "target", "genes", "of", "NRF2", "may", "allow", "the", "monitoring", "of", "NRF2", "activity", "and", "to", "predict", "individual", "sensitivity", "to", "environmental", "stress", "-", "induced", "damage", ".", "For", "this", "purpose", ",", "we", "investigated", "genes", "that", "are", "tightly", "controlled", "by", "NRF2", "to", "establish", "markers", "for", "NRF2", "activity", "in", "human", "cells", ".", "Firstly", ",", "in", "the", "normal", "human", "renal", "epithelial", "HK-2", "cells", ",", "the", "measurement", "of", "the", "expression", "of", "30", "previously", "reported", "NRF2", "target", "genes", "in", "response", "to", "NRF2", "inducers", "(", "sulforaphane", ",", "tert", "-", "butylhydroquinone", ",", "cinnamic", "aldehyde", ",", "and", "hydrogen", "peroxide", ")", "showed", "that", "the", "aldo", "-", "keto", "reductase", "(", "AKR", ")", "1C1", "is", "highly", "inducible", "by", "all", "treatments", ".", "Accordantly", ",", "the", "basal", "and", "inducible", "expressions", "of", "AKRs", "were", "significantly", "attenuated", "in", "NRF2-silenced", "HK-2", "cells", ".", "Whereas", ",", "cells", "with", "stable", "KEAP1", "knockdown", ",", "which", "causes", "a", "modest", "NRF2", "activation", ",", "demonstrated", "substantially", "increased", "levels", "of", "AKR1A1", ",", "1B1", ",", "1B10", ",", "1C1", ",", "1C2", ",", "and", "1C3", ".", "Secondly", ",", "the", "linkage", "between", "NRF2", "and", "the", "AKRs", "was", "confirmed", "in", "human", "monocytic", "leukemia", "cell", "line", "U937", ",", "which", "can", "be", "a", "model", "of", "peripherally", "available", "blood", "cells", ".", "The", "treatment", "of", "U937", "cells", "with", "NRF2", "inducers", "including", "sulforaphane", "effectively", "elevated", "the", "expression", "of", "AKR1B1", ",", "1B10", ",", "1C1", ",", "1C2", ",", "and", "1C3", ".", "Whereas", ",", "the", "levels", "of", "both", "the", "basal", "and", "sulforaphane", "-", "inducible", "expression", "of", "AKR1C1", "were", "significantly", "reduced", "in", "NRF2-silenced", "stable", "U937", "cells", "compared", "to", "the", "control", "cells", ".", "Similarly", ",", "the", "inducible", "expression", "of", "AKR1C1", "was", "observed", "in", "another", "human", "monocytic", "leukemia", "cell", "line", "THP-1", "as", "well", "as", "in", "human", "primary", "blood", "CD14(+", ")", "monocytes", ".", "In", "conclusion", ",", "together", "with", "the", "high", "inducibility", "and", "NRF2", "dependency", "shown", "in", "renal", "epithelial", "cells", "as", "well", "as", "in", "peripherally", "available", "blood", "cells", ",", "current", "findings", "suggest", "that", "AKRs", "can", "be", "utilized", "as", "a", "marker", "of", "NRF2", "activity", "in", "human", "cells", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
aldo - keto reductases, NF - E2-related factor 2, NRF2, Nrf2, human NRF2 promoter, NRF2, NRF2, NRF2, NRF2, NRF2, NRF2, sulforaphane, tert - butylhydroquinone, cinnamic aldehyde, hydrogen peroxide, aldo - keto reductase ( AKR ) 1C1, AKRs, KEAP1, NRF2, AKR1A1 , 1B1 , 1B10 , 1C1 , 1C2 , and 1C3, NRF2, AKRs, NRF2, sulforaphane, AKR1B1 , 1B10 , 1C1 , 1C2 , and 1C3, sulforaphane, AKR1C1, AKR1C1, NRF2, AKRs, NRF2	8099_task2	Sentence: Identification of aldo-keto reductases as NRF2-target marker genes in human cells. Transcription factor NF-E2-related factor 2 (NRF2) plays a crucial role in the cellular defense against oxidative/electrophilic stress by up-regulating multiple antioxidant genes. Numerous studies with genetically modified animals have demonstrated that Nrf2 is a sensitivity determining factor upon the exposure to environmental chemicals including carcinogens. Moreover, recent studies have demonstrated that polymorphism in the human NRF2 promoter is associated with higher risks for developing acute lung injury, gastric mucosal inflammation, and nephritis. Therefore, the identification of reliable and effective human target genes of NRF2 may allow the monitoring of NRF2 activity and to predict individual sensitivity to environmental stress-induced damage. For this purpose, we investigated genes that are tightly controlled by NRF2 to establish markers for NRF2 activity in human cells. Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments. Accordantly, the basal and inducible expressions of AKRs were significantly attenuated in NRF2-silenced HK-2 cells. Whereas, cells with stable KEAP1 knockdown, which causes a modest NRF2 activation, demonstrated substantially increased levels of AKR1A1, 1B1, 1B10, 1C1, 1C2, and 1C3. Secondly, the linkage between NRF2 and the AKRs was confirmed in human monocytic leukemia cell line U937, which can be a model of peripherally available blood cells. The treatment of U937 cells with NRF2 inducers including sulforaphane effectively elevated the expression of AKR1B1, 1B10, 1C1, 1C2, and 1C3. Whereas, the levels of both the basal and sulforaphane-inducible expression of AKR1C1 were significantly reduced in NRF2-silenced stable U937 cells compared to the control cells. Similarly, the inducible expression of AKR1C1 was observed in another human monocytic leukemia cell line THP-1 as well as in human primary blood CD14(+) monocytes. In conclusion, together with the high inducibility and NRF2 dependency shown in renal epithelial cells as well as in peripherally available blood cells, current findings suggest that AKRs can be utilized as a marker of NRF2 activity in human cells. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O" ]	Identification of aldo-keto reductases as NRF2-target marker genes in human cells. Transcription factor NF-E2-related factor 2 (NRF2) plays a crucial role in the cellular defense against oxidative/electrophilic stress by up-regulating multiple antioxidant genes. Numerous studies with genetically modified animals have demonstrated that Nrf2 is a sensitivity determining factor upon the exposure to environmental chemicals including carcinogens. Moreover, recent studies have demonstrated that polymorphism in the human NRF2 promoter is associated with higher risks for developing acute lung injury, gastric mucosal inflammation, and nephritis. Therefore, the identification of reliable and effective human target genes of NRF2 may allow the monitoring of NRF2 activity and to predict individual sensitivity to environmental stress-induced damage. For this purpose, we investigated genes that are tightly controlled by NRF2 to establish markers for NRF2 activity in human cells. Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments. Accordantly, the basal and inducible expressions of AKRs were significantly attenuated in NRF2-silenced HK-2 cells. Whereas, cells with stable KEAP1 knockdown, which causes a modest NRF2 activation, demonstrated substantially increased levels of AKR1A1, 1B1, 1B10, 1C1, 1C2, and 1C3. Secondly, the linkage between NRF2 and the AKRs was confirmed in human monocytic leukemia cell line U937, which can be a model of peripherally available blood cells. The treatment of U937 cells with NRF2 inducers including sulforaphane effectively elevated the expression of AKR1B1, 1B10, 1C1, 1C2, and 1C3. Whereas, the levels of both the basal and sulforaphane-inducible expression of AKR1C1 were significantly reduced in NRF2-silenced stable U937 cells compared to the control cells. Similarly, the inducible expression of AKR1C1 was observed in another human monocytic leukemia cell line THP-1 as well as in human primary blood CD14(+) monocytes. In conclusion, together with the high inducibility and NRF2 dependency shown in renal epithelial cells as well as in peripherally available blood cells, current findings suggest that AKRs can be utilized as a marker of NRF2 activity in human cells.	[ "Identification", "of", "aldo", "-", "keto", "reductases", "as", "NRF2-target", "marker", "genes", "in", "human", "cells", ".", "\n", "Transcription", "factor", "NF", "-", "E2-related", "factor", "2", "(", "NRF2", ")", "plays", "a", "crucial", "role", "in", "the", "cellular", "defense", "against", "oxidative", "/", "electrophilic", "stress", "by", "up", "-", "regulating", "multiple", "antioxidant", "genes", ".", "Numerous", "studies", "with", "genetically", "modified", "animals", "have", "demonstrated", "that", "Nrf2", "is", "a", "sensitivity", "determining", "factor", "upon", "the", "exposure", "to", "environmental", "chemicals", "including", "carcinogens", ".", "Moreover", ",", "recent", "studies", "have", "demonstrated", "that", "polymorphism", "in", "the", "human", "NRF2", "promoter", "is", "associated", "with", "higher", "risks", "for", "developing", "acute", "lung", "injury", ",", "gastric", "mucosal", "inflammation", ",", "and", "nephritis", ".", "Therefore", ",", "the", "identification", "of", "reliable", "and", "effective", "human", "target", "genes", "of", "NRF2", "may", "allow", "the", "monitoring", "of", "NRF2", "activity", "and", "to", "predict", "individual", "sensitivity", "to", "environmental", "stress", "-", "induced", "damage", ".", "For", "this", "purpose", ",", "we", "investigated", "genes", "that", "are", "tightly", "controlled", "by", "NRF2", "to", "establish", "markers", "for", "NRF2", "activity", "in", "human", "cells", ".", "Firstly", ",", "in", "the", "normal", "human", "renal", "epithelial", "HK-2", "cells", ",", "the", "measurement", "of", "the", "expression", "of", "30", "previously", "reported", "NRF2", "target", "genes", "in", "response", "to", "NRF2", "inducers", "(", "sulforaphane", ",", "tert", "-", "butylhydroquinone", ",", "cinnamic", "aldehyde", ",", "and", "hydrogen", "peroxide", ")", "showed", "that", "the", "aldo", "-", "keto", "reductase", "(", "AKR", ")", "1C1", "is", "highly", "inducible", "by", "all", "treatments", ".", "Accordantly", ",", "the", "basal", "and", "inducible", "expressions", "of", "AKRs", "were", "significantly", "attenuated", "in", "NRF2-silenced", "HK-2", "cells", ".", "Whereas", ",", "cells", "with", "stable", "KEAP1", "knockdown", ",", "which", "causes", "a", "modest", "NRF2", "activation", ",", "demonstrated", "substantially", "increased", "levels", "of", "AKR1A1", ",", "1B1", ",", "1B10", ",", "1C1", ",", "1C2", ",", "and", "1C3", ".", "Secondly", ",", "the", "linkage", "between", "NRF2", "and", "the", "AKRs", "was", "confirmed", "in", "human", "monocytic", "leukemia", "cell", "line", "U937", ",", "which", "can", "be", "a", "model", "of", "peripherally", "available", "blood", "cells", ".", "The", "treatment", "of", "U937", "cells", "with", "NRF2", "inducers", "including", "sulforaphane", "effectively", "elevated", "the", "expression", "of", "AKR1B1", ",", "1B10", ",", "1C1", ",", "1C2", ",", "and", "1C3", ".", "Whereas", ",", "the", "levels", "of", "both", "the", "basal", "and", "sulforaphane", "-", "inducible", "expression", "of", "AKR1C1", "were", "significantly", "reduced", "in", "NRF2-silenced", "stable", "U937", "cells", "compared", "to", "the", "control", "cells", ".", "Similarly", ",", "the", "inducible", "expression", "of", "AKR1C1", "was", "observed", "in", "another", "human", "monocytic", "leukemia", "cell", "line", "THP-1", "as", "well", "as", "in", "human", "primary", "blood", "CD14(+", ")", "monocytes", ".", "In", "conclusion", ",", "together", "with", "the", "high", "inducibility", "and", "NRF2", "dependency", "shown", "in", "renal", "epithelial", "cells", "as", "well", "as", "in", "peripherally", "available", "blood", "cells", ",", "current", "findings", "suggest", "that", "AKRs", "can", "be", "utilized", "as", "a", "marker", "of", "NRF2", "activity", "in", "human", "cells", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
proliferating cell nuclear antigen is a Protein, HLTF is a Protein, SHPRH is a Protein, proliferating cell nuclear antigen is a Protein, PCNA is a Protein, SHPRH is a Protein, Rad5 is a Protein, HLTF is a Protein, RAD5 is a Protein, HLTF is a Protein, SHPRH is a Protein, Rad5 is a Protein, PCNA is a Protein, Rad5 is a Protein, HLTF is a Protein, UBC13 is a Protein, PCNA is a Protein, SHPRH is a Protein, SHPRH is a Protein, HLTF is a Protein, Hltf is a Protein, HLTF is a Protein, SHPRH is a Protein, Rad5 is a Protein, PCNA is a Protein	333_task0	Sentence: Polyubiquitination of proliferating cell nuclear antigen by HLTF and SHPRH prevents genomic instability from stalled replication forks. Chronic stalling of DNA replication forks caused by DNA damage can lead to genomic instability. Cells have evolved lesion bypass pathways such as postreplication repair (PRR) to resolve these arrested forks. In yeast, one branch of PRR involves proliferating cell nuclear antigen (PCNA) polyubiquitination mediated by the Rad5-Ubc13-Mms2 complex that allows bypass of DNA lesion by a template-switching mechanism. Previously, we identified human SHPRH as a functional homologue of yeast Rad5 and revealed the existence of RAD5-like pathway in human cells. Here we report the identification of HLTF as a second RAD5 homologue in human cells. HLTF, like SHPRH, shares a unique domain architecture with Rad5 and promotes lysine 63-linked polyubiquitination of PCNA. Similar to yeast Rad5, HLTF is able to interact with UBC13 and PCNA, as well as SHPRH; and the reduction of either SHPRH or HLTF expression enhances spontaneous mutagenesis. Moreover, Hltf-deficient mouse embryonic fibroblasts show elevated chromosome breaks and fusions after methyl methane sulfonate treatment. Our results suggest that HLTF and SHPRH are functional homologues of yeast Rad5 that cooperatively mediate PCNA polyubiquitination and maintain genomic stability. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O" ]	Polyubiquitination of proliferating cell nuclear antigen by HLTF and SHPRH prevents genomic instability from stalled replication forks. Chronic stalling of DNA replication forks caused by DNA damage can lead to genomic instability. Cells have evolved lesion bypass pathways such as postreplication repair (PRR) to resolve these arrested forks. In yeast, one branch of PRR involves proliferating cell nuclear antigen (PCNA) polyubiquitination mediated by the Rad5-Ubc13-Mms2 complex that allows bypass of DNA lesion by a template-switching mechanism. Previously, we identified human SHPRH as a functional homologue of yeast Rad5 and revealed the existence of RAD5-like pathway in human cells. Here we report the identification of HLTF as a second RAD5 homologue in human cells. HLTF, like SHPRH, shares a unique domain architecture with Rad5 and promotes lysine 63-linked polyubiquitination of PCNA. Similar to yeast Rad5, HLTF is able to interact with UBC13 and PCNA, as well as SHPRH; and the reduction of either SHPRH or HLTF expression enhances spontaneous mutagenesis. Moreover, Hltf-deficient mouse embryonic fibroblasts show elevated chromosome breaks and fusions after methyl methane sulfonate treatment. Our results suggest that HLTF and SHPRH are functional homologues of yeast Rad5 that cooperatively mediate PCNA polyubiquitination and maintain genomic stability.	[ "Polyubiquitination", "of", "proliferating", "cell", "nuclear", "antigen", "by", "HLTF", "and", "SHPRH", "prevents", "genomic", "instability", "from", "stalled", "replication", "forks", ".", "\n", "Chronic", "stalling", "of", "DNA", "replication", "forks", "caused", "by", "DNA", "damage", "can", "lead", "to", "genomic", "instability", ".", "Cells", "have", "evolved", "lesion", "bypass", "pathways", "such", "as", "postreplication", "repair", "(", "PRR", ")", "to", "resolve", "these", "arrested", "forks", ".", "In", "yeast", ",", "one", "branch", "of", "PRR", "involves", "proliferating", "cell", "nuclear", "antigen", "(", "PCNA", ")", "polyubiquitination", "mediated", "by", "the", "Rad5-Ubc13-Mms2", "complex", "that", "allows", "bypass", "of", "DNA", "lesion", "by", "a", "template", "-", "switching", "mechanism", ".", "Previously", ",", "we", "identified", "human", "SHPRH", "as", "a", "functional", "homologue", "of", "yeast", "Rad5", "and", "revealed", "the", "existence", "of", "RAD5-like", "pathway", "in", "human", "cells", ".", "Here", "we", "report", "the", "identification", "of", "HLTF", "as", "a", "second", "RAD5", "homologue", "in", "human", "cells", ".", "HLTF", ",", "like", "SHPRH", ",", "shares", "a", "unique", "domain", "architecture", "with", "Rad5", "and", "promotes", "lysine", "63-linked", "polyubiquitination", "of", "PCNA", ".", "Similar", "to", "yeast", "Rad5", ",", "HLTF", "is", "able", "to", "interact", "with", "UBC13", "and", "PCNA", ",", "as", "well", "as", "SHPRH", ";", "and", "the", "reduction", "of", "either", "SHPRH", "or", "HLTF", "expression", "enhances", "spontaneous", "mutagenesis", ".", "Moreover", ",", "Hltf", "-", "deficient", "mouse", "embryonic", "fibroblasts", "show", "elevated", "chromosome", "breaks", "and", "fusions", "after", "methyl", "methane", "sulfonate", "treatment", ".", "Our", "results", "suggest", "that", "HLTF", "and", "SHPRH", "are", "functional", "homologues", "of", "yeast", "Rad5", "that", "cooperatively", "mediate", "PCNA", "polyubiquitination", "and", "maintain", "genomic", "stability", ".", "\n" ]	[ "Protein" ]
proliferating cell nuclear antigen is a Protein, HLTF is a Protein, SHPRH is a Protein, proliferating cell nuclear antigen is a Protein, PCNA is a Protein, SHPRH is a Protein, Rad5 is a Protein, HLTF is a Protein, RAD5 is a Protein, HLTF is a Protein, SHPRH is a Protein, Rad5 is a Protein, PCNA is a Protein, Rad5 is a Protein, HLTF is a Protein, UBC13 is a Protein, PCNA is a Protein, SHPRH is a Protein, SHPRH is a Protein, HLTF is a Protein, Hltf is a Protein, HLTF is a Protein, SHPRH is a Protein, Rad5 is a Protein, PCNA is a Protein	333_task1	Sentence: Polyubiquitination of proliferating cell nuclear antigen by HLTF and SHPRH prevents genomic instability from stalled replication forks. Chronic stalling of DNA replication forks caused by DNA damage can lead to genomic instability. Cells have evolved lesion bypass pathways such as postreplication repair (PRR) to resolve these arrested forks. In yeast, one branch of PRR involves proliferating cell nuclear antigen (PCNA) polyubiquitination mediated by the Rad5-Ubc13-Mms2 complex that allows bypass of DNA lesion by a template-switching mechanism. Previously, we identified human SHPRH as a functional homologue of yeast Rad5 and revealed the existence of RAD5-like pathway in human cells. Here we report the identification of HLTF as a second RAD5 homologue in human cells. HLTF, like SHPRH, shares a unique domain architecture with Rad5 and promotes lysine 63-linked polyubiquitination of PCNA. Similar to yeast Rad5, HLTF is able to interact with UBC13 and PCNA, as well as SHPRH; and the reduction of either SHPRH or HLTF expression enhances spontaneous mutagenesis. Moreover, Hltf-deficient mouse embryonic fibroblasts show elevated chromosome breaks and fusions after methyl methane sulfonate treatment. Our results suggest that HLTF and SHPRH are functional homologues of yeast Rad5 that cooperatively mediate PCNA polyubiquitination and maintain genomic stability. Instructions: please typing these entity words according to sentence: proliferating cell nuclear antigen, HLTF, SHPRH, proliferating cell nuclear antigen, PCNA, SHPRH, Rad5, HLTF, RAD5, HLTF, SHPRH, Rad5, PCNA, Rad5, HLTF, UBC13, PCNA, SHPRH, SHPRH, HLTF, Hltf, HLTF, SHPRH, Rad5, PCNA Options: Protein	[ "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O" ]	Polyubiquitination of proliferating cell nuclear antigen by HLTF and SHPRH prevents genomic instability from stalled replication forks. Chronic stalling of DNA replication forks caused by DNA damage can lead to genomic instability. Cells have evolved lesion bypass pathways such as postreplication repair (PRR) to resolve these arrested forks. In yeast, one branch of PRR involves proliferating cell nuclear antigen (PCNA) polyubiquitination mediated by the Rad5-Ubc13-Mms2 complex that allows bypass of DNA lesion by a template-switching mechanism. Previously, we identified human SHPRH as a functional homologue of yeast Rad5 and revealed the existence of RAD5-like pathway in human cells. Here we report the identification of HLTF as a second RAD5 homologue in human cells. HLTF, like SHPRH, shares a unique domain architecture with Rad5 and promotes lysine 63-linked polyubiquitination of PCNA. Similar to yeast Rad5, HLTF is able to interact with UBC13 and PCNA, as well as SHPRH; and the reduction of either SHPRH or HLTF expression enhances spontaneous mutagenesis. Moreover, Hltf-deficient mouse embryonic fibroblasts show elevated chromosome breaks and fusions after methyl methane sulfonate treatment. Our results suggest that HLTF and SHPRH are functional homologues of yeast Rad5 that cooperatively mediate PCNA polyubiquitination and maintain genomic stability.	[ "Polyubiquitination", "of", "proliferating", "cell", "nuclear", "antigen", "by", "HLTF", "and", "SHPRH", "prevents", "genomic", "instability", "from", "stalled", "replication", "forks", ".", "\n", "Chronic", "stalling", "of", "DNA", "replication", "forks", "caused", "by", "DNA", "damage", "can", "lead", "to", "genomic", "instability", ".", "Cells", "have", "evolved", "lesion", "bypass", "pathways", "such", "as", "postreplication", "repair", "(", "PRR", ")", "to", "resolve", "these", "arrested", "forks", ".", "In", "yeast", ",", "one", "branch", "of", "PRR", "involves", "proliferating", "cell", "nuclear", "antigen", "(", "PCNA", ")", "polyubiquitination", "mediated", "by", "the", "Rad5-Ubc13-Mms2", "complex", "that", "allows", "bypass", "of", "DNA", "lesion", "by", "a", "template", "-", "switching", "mechanism", ".", "Previously", ",", "we", "identified", "human", "SHPRH", "as", "a", "functional", "homologue", "of", "yeast", "Rad5", "and", "revealed", "the", "existence", "of", "RAD5-like", "pathway", "in", "human", "cells", ".", "Here", "we", "report", "the", "identification", "of", "HLTF", "as", "a", "second", "RAD5", "homologue", "in", "human", "cells", ".", "HLTF", ",", "like", "SHPRH", ",", "shares", "a", "unique", "domain", "architecture", "with", "Rad5", "and", "promotes", "lysine", "63-linked", "polyubiquitination", "of", "PCNA", ".", "Similar", "to", "yeast", "Rad5", ",", "HLTF", "is", "able", "to", "interact", "with", "UBC13", "and", "PCNA", ",", "as", "well", "as", "SHPRH", ";", "and", "the", "reduction", "of", "either", "SHPRH", "or", "HLTF", "expression", "enhances", "spontaneous", "mutagenesis", ".", "Moreover", ",", "Hltf", "-", "deficient", "mouse", "embryonic", "fibroblasts", "show", "elevated", "chromosome", "breaks", "and", "fusions", "after", "methyl", "methane", "sulfonate", "treatment", ".", "Our", "results", "suggest", "that", "HLTF", "and", "SHPRH", "are", "functional", "homologues", "of", "yeast", "Rad5", "that", "cooperatively", "mediate", "PCNA", "polyubiquitination", "and", "maintain", "genomic", "stability", ".", "\n" ]	[ "Protein" ]
proliferating cell nuclear antigen, HLTF, SHPRH, proliferating cell nuclear antigen, PCNA, SHPRH, Rad5, HLTF, RAD5, HLTF, SHPRH, Rad5, PCNA, Rad5, HLTF, UBC13, PCNA, SHPRH, SHPRH, HLTF, Hltf, HLTF, SHPRH, Rad5, PCNA	333_task2	Sentence: Polyubiquitination of proliferating cell nuclear antigen by HLTF and SHPRH prevents genomic instability from stalled replication forks. Chronic stalling of DNA replication forks caused by DNA damage can lead to genomic instability. Cells have evolved lesion bypass pathways such as postreplication repair (PRR) to resolve these arrested forks. In yeast, one branch of PRR involves proliferating cell nuclear antigen (PCNA) polyubiquitination mediated by the Rad5-Ubc13-Mms2 complex that allows bypass of DNA lesion by a template-switching mechanism. Previously, we identified human SHPRH as a functional homologue of yeast Rad5 and revealed the existence of RAD5-like pathway in human cells. Here we report the identification of HLTF as a second RAD5 homologue in human cells. HLTF, like SHPRH, shares a unique domain architecture with Rad5 and promotes lysine 63-linked polyubiquitination of PCNA. Similar to yeast Rad5, HLTF is able to interact with UBC13 and PCNA, as well as SHPRH; and the reduction of either SHPRH or HLTF expression enhances spontaneous mutagenesis. Moreover, Hltf-deficient mouse embryonic fibroblasts show elevated chromosome breaks and fusions after methyl methane sulfonate treatment. Our results suggest that HLTF and SHPRH are functional homologues of yeast Rad5 that cooperatively mediate PCNA polyubiquitination and maintain genomic stability. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O" ]	Polyubiquitination of proliferating cell nuclear antigen by HLTF and SHPRH prevents genomic instability from stalled replication forks. Chronic stalling of DNA replication forks caused by DNA damage can lead to genomic instability. Cells have evolved lesion bypass pathways such as postreplication repair (PRR) to resolve these arrested forks. In yeast, one branch of PRR involves proliferating cell nuclear antigen (PCNA) polyubiquitination mediated by the Rad5-Ubc13-Mms2 complex that allows bypass of DNA lesion by a template-switching mechanism. Previously, we identified human SHPRH as a functional homologue of yeast Rad5 and revealed the existence of RAD5-like pathway in human cells. Here we report the identification of HLTF as a second RAD5 homologue in human cells. HLTF, like SHPRH, shares a unique domain architecture with Rad5 and promotes lysine 63-linked polyubiquitination of PCNA. Similar to yeast Rad5, HLTF is able to interact with UBC13 and PCNA, as well as SHPRH; and the reduction of either SHPRH or HLTF expression enhances spontaneous mutagenesis. Moreover, Hltf-deficient mouse embryonic fibroblasts show elevated chromosome breaks and fusions after methyl methane sulfonate treatment. Our results suggest that HLTF and SHPRH are functional homologues of yeast Rad5 that cooperatively mediate PCNA polyubiquitination and maintain genomic stability.	[ "Polyubiquitination", "of", "proliferating", "cell", "nuclear", "antigen", "by", "HLTF", "and", "SHPRH", "prevents", "genomic", "instability", "from", "stalled", "replication", "forks", ".", "\n", "Chronic", "stalling", "of", "DNA", "replication", "forks", "caused", "by", "DNA", "damage", "can", "lead", "to", "genomic", "instability", ".", "Cells", "have", "evolved", "lesion", "bypass", "pathways", "such", "as", "postreplication", "repair", "(", "PRR", ")", "to", "resolve", "these", "arrested", "forks", ".", "In", "yeast", ",", "one", "branch", "of", "PRR", "involves", "proliferating", "cell", "nuclear", "antigen", "(", "PCNA", ")", "polyubiquitination", "mediated", "by", "the", "Rad5-Ubc13-Mms2", "complex", "that", "allows", "bypass", "of", "DNA", "lesion", "by", "a", "template", "-", "switching", "mechanism", ".", "Previously", ",", "we", "identified", "human", "SHPRH", "as", "a", "functional", "homologue", "of", "yeast", "Rad5", "and", "revealed", "the", "existence", "of", "RAD5-like", "pathway", "in", "human", "cells", ".", "Here", "we", "report", "the", "identification", "of", "HLTF", "as", "a", "second", "RAD5", "homologue", "in", "human", "cells", ".", "HLTF", ",", "like", "SHPRH", ",", "shares", "a", "unique", "domain", "architecture", "with", "Rad5", "and", "promotes", "lysine", "63-linked", "polyubiquitination", "of", "PCNA", ".", "Similar", "to", "yeast", "Rad5", ",", "HLTF", "is", "able", "to", "interact", "with", "UBC13", "and", "PCNA", ",", "as", "well", "as", "SHPRH", ";", "and", "the", "reduction", "of", "either", "SHPRH", "or", "HLTF", "expression", "enhances", "spontaneous", "mutagenesis", ".", "Moreover", ",", "Hltf", "-", "deficient", "mouse", "embryonic", "fibroblasts", "show", "elevated", "chromosome", "breaks", "and", "fusions", "after", "methyl", "methane", "sulfonate", "treatment", ".", "Our", "results", "suggest", "that", "HLTF", "and", "SHPRH", "are", "functional", "homologues", "of", "yeast", "Rad5", "that", "cooperatively", "mediate", "PCNA", "polyubiquitination", "and", "maintain", "genomic", "stability", ".", "\n" ]	[ "Protein" ]
tumoración is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, carcinoma ductal infiltrante is a MORFOLOGIA_NEOPLASIA, metástasis por carcinoma ductal is a MORFOLOGIA_NEOPLASIA, metastásica is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, células tumorales is a MORFOLOGIA_NEOPLASIA, micrometástasis is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, proliferacion epitelial neoplásica is a MORFOLOGIA_NEOPLASIA, carcinoma infiltrante is a MORFOLOGIA_NEOPLASIA, ypM0 is a MORFOLOGIA_NEOPLASIA, Progresión pulmonar is a MORFOLOGIA_NEOPLASIA, enfermedad hepática is a MORFOLOGIA_NEOPLASIA, Progresión de enfermedad ganglionar y hepática is a MORFOLOGIA_NEOPLASIA, enfermedad cerebral is a MORFOLOGIA_NEOPLASIA, metastásica is a MORFOLOGIA_NEOPLASIA	299_task0	Sentence: Anamnesis Nuestra paciente, una mujer de 48 años, consulta en febrero del 2013 por notarse nodulación en mama derecha con eritema asociado. La paciente no presentaba antecedentes médico-quirúrgicos de interés y no tenía hábitos tóxicos. En el estudio diagnóstico se realizan: ecografía mamaria que evidencia un nódulo hipoecoico de 22 cm en el cuadrante súperoexterno (CSE) de la mama derecha, engrosamiento difuso de piel y adenopatías axilares; mamografía que evidencia tumoración de 32cm en CSE de mama derecha. Se amplía el estudio con una RMN que destaca engrosamiento cutáneo de la piel con retracción asociada, encontrándose el volumen tumoral CSE pero con proyecciones espiculadas y nodulares que se extienden por todo el tejido mamario. Se realiza una biopsia por aguja gruesa (BAG) del nódulo mamario que evidencia un carcinoma ductal infiltrante de mama con receptores de estrógenos (+) y de progesterona (++) positivos, HER 2 negativo. La biopsia de la adenoapatía axilar revela metástasis por carcinoma ductal. Tras descartarse enfermedad metastásica en el estudio de extensión se decide administrar quimioterapia neoadyuvante según el esquema TAC (docetaxel, adriamicina, ciclofosfamida) por 4 ciclos. Posteriormente, se realiza una mastectomía radical modificada de mama derecha. El estudio de anatomía patológica muestra un foco tumoral de 21x23 mm, infiltración subareolar por células tumorales sueltas y 2 micrometástasis en 14 adenopatáis resecadas, los bordes quirúrgicos estaban libres de infiltración tumoral. A la visión microscópica se evidencia un tejido de proliferacion epitelial neoplásica constituida por un área escasamente nodular con proliferación de células cuboideas, frecuentes mitosis con abundante celularidad inflamatoria, positivas para CK5/6 pero negativas para CK14, débil expresión del receptor de estrógeno (Hsocre 10/300, Allred 3/8 en 10% de células), ausencia de receptores de progresterona (Hscore 0/300 y Allred 0/8) y una alta expresión de Ki67 (50% en áreas periféricas), expresión de Her2 negativa. Se trata por lo tanto de un carcinoma infiltrante de mama ypT4d ypN1 mic ypM0 RE+ RP- Her2 - ki67 50% fenotipo luminal B. Se completa el tratamiento adyuvante con TAC x 2 y con radioterapia externa hasta una dosis total de 50 Gy, tratamiento que finaliza en octubre del 2013. La paciente presenta posteriormente la siguiente evolución de enfermedad recibiendo los siguientes tratamientos de enfermedad avanzada: Noviembre del 2014: Progresión pulmonar, hepática y ósea: Placlitaxel-Bevacizumab x 6 ciclos + Zolendronato terminando en abril del 2015 por progresión de enfermedad. Mayo del 2015: Progresión de enfermedad hepática: Capecitabina - Zolendronato Noviembre del 2015: Progresión de enfermedad ganglionar y hepática: Exemestano-everolimus + Zolendronato. Diciembre del 2015: Progresión de enfermedad cerebral: Recibe radioterapia holocraneal (4 sesiones de 500cGy por sesión) y se inicia tratamiento con Navelbina que comienza el 22 de enero del 2016. La paciente no recibe el día + 8 del 2º ciclo por síndrome febril. EPISODIO ACTUAL: La paciente acude a hospital de Día el 27 de febrero del 2016 por presentar fiebre resistente a antibioterapia oral con levofloxacino. Asocia cefalea y náuseas de una semana de evolución, además de episodios de desorientación temporo-espacial de unos dos meses de evolución pero que han aumentado en frecuencia en los últimos días. La paciente se encontraba hemodinámicamente estable y a la exploración física y neurológica no destacaba ningún hallazgo salvo la desorientación temporo-espacial. Exploración física La paciente se encontraba hemodinámicamente estable y a la exploración física y neurológica no destacaba ningún hallazgo salvo desorientación temporo-espacial. No existían signos de rigidez nucal. Pruebas complementarias Se realiza una analítica al ingreso donde destaca: GGT 219 U/l, LDH 2276 U/l (previo 1660), Hb 11 g/dl, CEA 2,7 ng/ml, Ca 15.3 1088 U/ml (previa 1038), siendo el resto de parámetros del hemograma, bioquímica y coagulación dentro de la normalidad. Se realizan radiografías de tórax y abdomen sin hallazgos de interés, se serian hemocultivos siendo todos negativos, urinocultivos negativos y cultivo de punta de catéter PICC negativo. Ante sospecha de encefalitis se inicia tratamiento antibiótico con ceftriaxona, vancomicina, aciclovir y ganciclovir con escaso beneficio. Se realiza una punción lumbar que muestra un líquido cefaloraquídeo (LCR) claro y transparente y como únicos hallazgos evidencia una pleocitosis linfocitaria de 10 células/ul y una proteinorraquia de 75 mg/dl. Se realiza una serología de sangre periférica que muestra negatividad para Borrelia, CMV, VHS 1 y 2, VEB, VZV y VHH6 negativos. Se solicita una resonancia magnética nuclear (RMN) cerebral que evidencia un extenso cambio de señal que afecta al córtex temporal y perisilviano bilateral, aunque de predominio derecho, que no se modifica tras la administración de contraste paramagnético (14 ml de gadolinio). No se advierten captaciones anómalas que sugieran afectación metastásica. Imágenes compatibles con encefalitis límbica. Se estudió la autoinmunidad de algunos anticuerpos antineuronales (anti-Yo, Ri, Hu, Tr, NMO, NMDA, MAG, VGCC y anti-islotes de Langerhans), siendo todos negativos. Diagnóstico Encefalitis límbica paraneoplásica Tratamiento Ante la sospecha de encefalitis límbica paraneoplásica se decide comenzar el tratamiento específico antes de la confirmación diagnóstica. Se administra metilpredinosolona en bolos de un gramo durante 5 días, descartándose la plasmaféresis por el estado general de la paciente, y ante la escasa mejoría se administran posteriormente inmunoglubulinas 0,4 g/kg de peso durante 3 días. Se planteó el inicio de una nueva línea de tratamiento específica contra su enfermedad de base, sin embargo no fue posible iniciar nuevo tratamiento con quimioterapia debido a un importante deterioro clínico y rápida afectación del estado general. Evolución La paciente presentó una evolución desfavorable a pesar del tratamiento administrado y falleció posteriormente con buen control de síntomas. Ya habiendo fallecido la paciente, se evidenció en el proteinograma del LCR la presencia de bandas oligoclonales que apoyan el diagnóstico de encefalitis límbica paraneoplásica. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Nuestra paciente, una mujer de 48 años, consulta en febrero del 2013 por notarse nodulación en mama derecha con eritema asociado. La paciente no presentaba antecedentes médico-quirúrgicos de interés y no tenía hábitos tóxicos. En el estudio diagnóstico se realizan: ecografía mamaria que evidencia un nódulo hipoecoico de 22 cm en el cuadrante súperoexterno (CSE) de la mama derecha, engrosamiento difuso de piel y adenopatías axilares; mamografía que evidencia tumoración de 32cm en CSE de mama derecha. Se amplía el estudio con una RMN que destaca engrosamiento cutáneo de la piel con retracción asociada, encontrándose el volumen tumoral CSE pero con proyecciones espiculadas y nodulares que se extienden por todo el tejido mamario. Se realiza una biopsia por aguja gruesa (BAG) del nódulo mamario que evidencia un carcinoma ductal infiltrante de mama con receptores de estrógenos (+) y de progesterona (++) positivos, HER 2 negativo. La biopsia de la adenoapatía axilar revela metástasis por carcinoma ductal. Tras descartarse enfermedad metastásica en el estudio de extensión se decide administrar quimioterapia neoadyuvante según el esquema TAC (docetaxel, adriamicina, ciclofosfamida) por 4 ciclos. Posteriormente, se realiza una mastectomía radical modificada de mama derecha. El estudio de anatomía patológica muestra un foco tumoral de 21x23 mm, infiltración subareolar por células tumorales sueltas y 2 micrometástasis en 14 adenopatáis resecadas, los bordes quirúrgicos estaban libres de infiltración tumoral. A la visión microscópica se evidencia un tejido de proliferacion epitelial neoplásica constituida por un área escasamente nodular con proliferación de células cuboideas, frecuentes mitosis con abundante celularidad inflamatoria, positivas para CK5/6 pero negativas para CK14, débil expresión del receptor de estrógeno (Hsocre 10/300, Allred 3/8 en 10% de células), ausencia de receptores de progresterona (Hscore 0/300 y Allred 0/8) y una alta expresión de Ki67 (50% en áreas periféricas), expresión de Her2 negativa. Se trata por lo tanto de un carcinoma infiltrante de mama ypT4d ypN1 mic ypM0 RE+ RP- Her2 - ki67 50% fenotipo luminal B. Se completa el tratamiento adyuvante con TAC x 2 y con radioterapia externa hasta una dosis total de 50 Gy, tratamiento que finaliza en octubre del 2013. La paciente presenta posteriormente la siguiente evolución de enfermedad recibiendo los siguientes tratamientos de enfermedad avanzada: Noviembre del 2014: Progresión pulmonar, hepática y ósea: Placlitaxel-Bevacizumab x 6 ciclos + Zolendronato terminando en abril del 2015 por progresión de enfermedad. Mayo del 2015: Progresión de enfermedad hepática: Capecitabina - Zolendronato Noviembre del 2015: Progresión de enfermedad ganglionar y hepática: Exemestano-everolimus + Zolendronato. Diciembre del 2015: Progresión de enfermedad cerebral: Recibe radioterapia holocraneal (4 sesiones de 500cGy por sesión) y se inicia tratamiento con Navelbina que comienza el 22 de enero del 2016. La paciente no recibe el día + 8 del 2º ciclo por síndrome febril. EPISODIO ACTUAL: La paciente acude a hospital de Día el 27 de febrero del 2016 por presentar fiebre resistente a antibioterapia oral con levofloxacino. Asocia cefalea y náuseas de una semana de evolución, además de episodios de desorientación temporo-espacial de unos dos meses de evolución pero que han aumentado en frecuencia en los últimos días. La paciente se encontraba hemodinámicamente estable y a la exploración física y neurológica no destacaba ningún hallazgo salvo la desorientación temporo-espacial. Exploración física La paciente se encontraba hemodinámicamente estable y a la exploración física y neurológica no destacaba ningún hallazgo salvo desorientación temporo-espacial. No existían signos de rigidez nucal. Pruebas complementarias Se realiza una analítica al ingreso donde destaca: GGT 219 U/l, LDH 2276 U/l (previo 1660), Hb 11 g/dl, CEA 2,7 ng/ml, Ca 15.3 1088 U/ml (previa 1038), siendo el resto de parámetros del hemograma, bioquímica y coagulación dentro de la normalidad. Se realizan radiografías de tórax y abdomen sin hallazgos de interés, se serian hemocultivos siendo todos negativos, urinocultivos negativos y cultivo de punta de catéter PICC negativo. Ante sospecha de encefalitis se inicia tratamiento antibiótico con ceftriaxona, vancomicina, aciclovir y ganciclovir con escaso beneficio. Se realiza una punción lumbar que muestra un líquido cefaloraquídeo (LCR) claro y transparente y como únicos hallazgos evidencia una pleocitosis linfocitaria de 10 células/ul y una proteinorraquia de 75 mg/dl. Se realiza una serología de sangre periférica que muestra negatividad para Borrelia, CMV, VHS 1 y 2, VEB, VZV y VHH6 negativos. Se solicita una resonancia magnética nuclear (RMN) cerebral que evidencia un extenso cambio de señal que afecta al córtex temporal y perisilviano bilateral, aunque de predominio derecho, que no se modifica tras la administración de contraste paramagnético (14 ml de gadolinio). No se advierten captaciones anómalas que sugieran afectación metastásica. Imágenes compatibles con encefalitis límbica. Se estudió la autoinmunidad de algunos anticuerpos antineuronales (anti-Yo, Ri, Hu, Tr, NMO, NMDA, MAG, VGCC y anti-islotes de Langerhans), siendo todos negativos. Diagnóstico Encefalitis límbica paraneoplásica Tratamiento Ante la sospecha de encefalitis límbica paraneoplásica se decide comenzar el tratamiento específico antes de la confirmación diagnóstica. Se administra metilpredinosolona en bolos de un gramo durante 5 días, descartándose la plasmaféresis por el estado general de la paciente, y ante la escasa mejoría se administran posteriormente inmunoglubulinas 0,4 g/kg de peso durante 3 días. Se planteó el inicio de una nueva línea de tratamiento específica contra su enfermedad de base, sin embargo no fue posible iniciar nuevo tratamiento con quimioterapia debido a un importante deterioro clínico y rápida afectación del estado general. Evolución La paciente presentó una evolución desfavorable a pesar del tratamiento administrado y falleció posteriormente con buen control de síntomas. Ya habiendo fallecido la paciente, se evidenció en el proteinograma del LCR la presencia de bandas oligoclonales que apoyan el diagnóstico de encefalitis límbica paraneoplásica.	[ "Anamnesis", "\n", "Nuestra", "paciente", ",", "una", "mujer", "de", "48", "años", ",", "consulta", "en", "febrero", "del", "2013", "por", "notarse", "nodulación", "en", "mama", "derecha", "con", "eritema", "asociado", ".", "La", "paciente", "no", "presentaba", "antecedentes", "médico", "-", "quirúrgicos", "de", "interés", "y", "no", "tenía", "hábitos", "tóxicos", ".", "\n", "En", "el", "estudio", "diagnóstico", "se", "realizan", ":", "ecografía", "mamaria", "que", "evidencia", "un", "nódulo", "hipoecoico", "de", "2", "", "2", "cm", "en", "el", "cuadrante", "súperoexterno", "(", "CSE", ")", "de", "la", "mama", "derecha", ",", "engrosamiento", "difuso", "de", "piel", "y", "adenopatías", "axilares", ";", "mamografía", "que", "evidencia", "tumoración", "de", "3", "", "2", "cm", "en", "CSE", "de", "mama", "derecha", ".", "Se", "amplía", "el", "estudio", "con", "una", "RMN", "que", "destaca", "engrosamiento", "cutáneo", "de", "la", "piel", "con", "retracción", "asociada", ",", "encontrándose", "el", "volumen", "tumoral", "CSE", "pero", "con", "proyecciones", "espiculadas", "y", "nodulares", "que", "se", "extienden", "por", "todo", "el", "tejido", "mamario", ".", "\n", "Se", "realiza", "una", "biopsia", "por", "aguja", "gruesa", "(", "BAG", ")", "del", "nódulo", "mamario", "que", "evidencia", "un", "carcinoma", "ductal", "infiltrante", "de", "mama", "con", "receptores", "de", "estrógenos", "(", "+", ")", "y", "de", "progesterona", "(", "+", "+", ")", "positivos", ",", "HER", "2", "negativo", ".", "\n", "La", "biopsia", "de", "la", "adenoapatía", "axilar", "revela", "metástasis", "por", "carcinoma", "ductal", ".", "\n", "Tras", "descartarse", "enfermedad", "metastásica", "en", "el", "estudio", "de", "extensión", "se", "decide", "administrar", "quimioterapia", "neoadyuvante", "según", "el", "esquema", "TAC", "(", "docetaxel", ",", "adriamicina", ",", "ciclofosfamida", ")", "por", "4", "ciclos", ".", "Posteriormente", ",", "se", "realiza", "una", "mastectomía", "radical", "modificada", "de", "mama", "derecha", ".", "\n", "El", "estudio", "de", "anatomía", "patológica", "muestra", "un", "foco", "tumoral", "de", "21x23", "mm", ",", "infiltración", "subareolar", "por", "células", "tumorales", "sueltas", "y", "2", "micrometástasis", "en", "14", "adenopatáis", "resecadas", ",", "los", "bordes", "quirúrgicos", "estaban", "libres", "de", "infiltración", "tumoral", ".", "A", "la", "visión", "microscópica", "se", "evidencia", "un", "tejido", "de", "proliferacion", "epitelial", "neoplásica", "constituida", "por", "un", "área", "escasamente", "nodular", "con", "proliferación", "de", "células", "cuboideas", ",", "frecuentes", "mitosis", "con", "abundante", "celularidad", "inflamatoria", ",", "positivas", "para", "CK5/6", "pero", "negativas", "para", "CK14", ",", "débil", "expresión", "del", "receptor", "de", "estrógeno", "(", "Hsocre", "10/300", ",", "Allred", "3/8", "en", "10", "%", "de", "células", ")", ",", "ausencia", "de", "receptores", "de", "progresterona", "(", "Hscore", "0/300", "y", "Allred", "0/8", ")", "y", "una", "alta", "expresión", "de", "Ki67", "(", "50", "%", "en", "áreas", "periféricas", ")", ",", "expresión", "de", "Her2", "negativa", ".", "\n", "Se", "trata", "por", "lo", "tanto", "de", "un", "carcinoma", "infiltrante", "de", "mama", "ypT4d", "ypN1", "mic", "ypM0", "RE+", "RP-", "Her2", "-", "ki67", "50", "%", "fenotipo", "luminal", "B.", "\n", "Se", "completa", "el", "tratamiento", "adyuvante", "con", "TAC", "x", "2", "y", "con", "radioterapia", "externa", "hasta", "una", "dosis", "total", "de", "50", "Gy", ",", "tratamiento", "que", "finaliza", "en", "octubre", "del", "2013", ".", "\n", "La", "paciente", "presenta", "posteriormente", "la", "siguiente", "evolución", "de", "enfermedad", "recibiendo", "los", "siguientes", "tratamientos", "de", "enfermedad", "avanzada", ":", "\n", "Noviembre", "del", "2014", ":", "Progresión", "pulmonar", ",", "hepática", "y", "ósea", ":", "Placlitaxel", "-", "Bevacizumab", "x", "6", "ciclos", "+", "Zolendronato", "terminando", "en", "abril", "del", "2015", "por", "progresión", "de", "enfermedad", ".", "\n", "Mayo", "del", "2015", ":", "Progresión", "de", "enfermedad", "hepática", ":", "Capecitabina", "-", "Zolendronato", "\n", "Noviembre", "del", "2015", ":", "Progresión", "de", "enfermedad", "ganglionar", "y", "hepática", ":", "Exemestano", "-", "everolimus", "+", "Zolendronato", ".", "\n", "Diciembre", "del", "2015", ":", "Progresión", "de", "enfermedad", "cerebral", ":", "Recibe", "radioterapia", "holocraneal", "(", "4", "sesiones", "de", "500cGy", "por", "sesión", ")", "y", "se", "inicia", "tratamiento", "con", "Navelbina", "que", "comienza", "el", "22", "de", "enero", "del", "2016", ".", "La", "paciente", "no", "recibe", "el", "día", "+", "8", "del", "2º", "ciclo", "por", "síndrome", "febril", ".", "\n\n", "EPISODIO", "ACTUAL", ":", "\n", "La", "paciente", "acude", "a", "hospital", "de", "Día", "el", "27", "de", "febrero", "del", "2016", "por", "presentar", "fiebre", "resistente", "a", "antibioterapia", "oral", "con", "levofloxacino", ".", "Asocia", "cefalea", "y", "náuseas", "de", "una", "semana", "de", "evolución", ",", "además", "de", "episodios", "de", "desorientación", "temporo", "-", "espacial", "de", "unos", "dos", "meses", "de", "evolución", "pero", "que", "han", "aumentado", "en", "frecuencia", "en", "los", "últimos", "días", ".", "La", "paciente", "se", "encontraba", "hemodinámicamente", "estable", "y", "a", "la", "exploración", "física", "y", "neurológica", "no", "destacaba", "ningún", "hallazgo", "salvo", "la", "desorientación", "temporo", "-", "espacial", ".", "\n\n", "Exploración", "física", "\n", "La", "paciente", "se", "encontraba", "hemodinámicamente", "estable", "y", "a", "la", "exploración", "física", "y", "neurológica", "no", "destacaba", "ningún", "hallazgo", "salvo", "desorientación", "temporo", "-", "espacial", ".", "No", "existían", "signos", "de", "rigidez", "nucal", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "realiza", "una", "analítica", "al", "ingreso", "donde", "destaca", ":", "GGT", "219", "U", "/", "l", ",", "LDH", "2276", "U", "/", "l", "(", "previo", "1660", ")", ",", "Hb", "11", "g", "/", "dl", ",", "CEA", "2,7", "ng", "/", "ml", ",", "Ca", "15.3", "1088", "U", "/", "ml", "(", "previa", "1038", ")", ",", "siendo", "el", "resto", "de", "parámetros", "del", "hemograma", ",", "bioquímica", "y", "coagulación", "dentro", "de", "la", "normalidad", ".", "Se", "realizan", "radiografías", "de", "tórax", "y", "abdomen", "sin", "hallazgos", "de", "interés", ",", "se", "serian", "hemocultivos", "siendo", "todos", "negativos", ",", "urinocultivos", "negativos", "y", "cultivo", "de", "punta", "de", "catéter", "PICC", "negativo", ".", "\n", "Ante", "sospecha", "de", "encefalitis", "se", "inicia", "tratamiento", "antibiótico", "con", "ceftriaxona", ",", "vancomicina", ",", "aciclovir", "y", "ganciclovir", "con", "escaso", "beneficio", ".", "Se", "realiza", "una", "punción", "lumbar", "que", "muestra", "un", "líquido", "cefaloraquídeo", "(", "LCR", ")", "claro", "y", "transparente", "y", "como", "únicos", "hallazgos", "evidencia", "una", "pleocitosis", "linfocitaria", "de", "10", "células", "/", "ul", "y", "una", "proteinorraquia", "de", "75", "mg", "/", "dl", ".", "Se", "realiza", "una", "serología", "de", "sangre", "periférica", "que", "muestra", "negatividad", "para", "Borrelia", ",", "CMV", ",", "VHS", "1", "y", "2", ",", "VEB", ",", "VZV", "y", "VHH6", "negativos", ".", "\n", "Se", "solicita", "una", "resonancia", "magnética", "nuclear", "(", "RMN", ")", "cerebral", "que", "evidencia", "un", "extenso", "cambio", "de", "señal", "que", "afecta", "al", "córtex", "temporal", "y", "perisilviano", "bilateral", ",", "aunque", "de", "predominio", "derecho", ",", "que", "no", "se", "modifica", "tras", "la", "administración", "de", "contraste", "paramagnético", "(", "14", "ml", "de", "gadolinio", ")", ".", "No", "se", "advierten", "captaciones", "anómalas", "que", "sugieran", "afectación", "metastásica", ".", "Imágenes", "compatibles", "con", "encefalitis", "límbica", ".", "\n", "Se", "estudió", "la", "autoinmunidad", "de", "algunos", "anticuerpos", "antineuronales", "(", "anti", "-", "Yo", ",", "Ri", ",", "Hu", ",", "Tr", ",", "NMO", ",", "NMDA", ",", "MAG", ",", "VGCC", "y", "anti", "-", "islotes", "de", "Langerhans", ")", ",", "siendo", "todos", "negativos", ".", "\n\n", "Diagnóstico", "\n", "Encefalitis", "límbica", "paraneoplásica", "\n\n", "Tratamiento", "\n", "Ante", "la", "sospecha", "de", "encefalitis", "límbica", "paraneoplásica", "se", "decide", "comenzar", "el", "tratamiento", "específico", "antes", "de", "la", "confirmación", "diagnóstica", ".", "Se", "administra", "metilpredinosolona", "en", "bolos", "de", "un", "gramo", "durante", "5", "días", ",", "descartándose", "la", "plasmaféresis", "por", "el", "estado", "general", "de", "la", "paciente", ",", "y", "ante", "la", "escasa", "mejoría", "se", "administran", "posteriormente", "inmunoglubulinas", "0,4", "g", "/", "kg", "de", "peso", "durante", "3", "días", ".", "\n", "Se", "planteó", "el", "inicio", "de", "una", "nueva", "línea", "de", "tratamiento", "específica", "contra", "su", "enfermedad", "de", "base", ",", "sin", "embargo", "no", "fue", "posible", "iniciar", "nuevo", "tratamiento", "con", "quimioterapia", "debido", "a", "un", "importante", "deterioro", "clínico", "y", "rápida", "afectación", "del", "estado", "general", ".", "\n\n", "Evolución", "\n", "La", "paciente", "presentó", "una", "evolución", "desfavorable", "a", "pesar", "del", "tratamiento", "administrado", "y", "falleció", "posteriormente", "con", "buen", "control", "de", "síntomas", ".", "\n", "Ya", "habiendo", "fallecido", "la", "paciente", ",", "se", "evidenció", "en", "el", "proteinograma", "del", "LCR", "la", "presencia", "de", "bandas", "oligoclonales", "que", "apoyan", "el", "diagnóstico", "de", "encefalitis", "límbica", "paraneoplásica", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
tumoración is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, carcinoma ductal infiltrante is a MORFOLOGIA_NEOPLASIA, metástasis por carcinoma ductal is a MORFOLOGIA_NEOPLASIA, metastásica is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, células tumorales is a MORFOLOGIA_NEOPLASIA, micrometástasis is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, proliferacion epitelial neoplásica is a MORFOLOGIA_NEOPLASIA, carcinoma infiltrante is a MORFOLOGIA_NEOPLASIA, ypM0 is a MORFOLOGIA_NEOPLASIA, Progresión pulmonar is a MORFOLOGIA_NEOPLASIA, enfermedad hepática is a MORFOLOGIA_NEOPLASIA, Progresión de enfermedad ganglionar y hepática is a MORFOLOGIA_NEOPLASIA, enfermedad cerebral is a MORFOLOGIA_NEOPLASIA, metastásica is a MORFOLOGIA_NEOPLASIA	299_task1	Sentence: Anamnesis Nuestra paciente, una mujer de 48 años, consulta en febrero del 2013 por notarse nodulación en mama derecha con eritema asociado. La paciente no presentaba antecedentes médico-quirúrgicos de interés y no tenía hábitos tóxicos. En el estudio diagnóstico se realizan: ecografía mamaria que evidencia un nódulo hipoecoico de 22 cm en el cuadrante súperoexterno (CSE) de la mama derecha, engrosamiento difuso de piel y adenopatías axilares; mamografía que evidencia tumoración de 32cm en CSE de mama derecha. Se amplía el estudio con una RMN que destaca engrosamiento cutáneo de la piel con retracción asociada, encontrándose el volumen tumoral CSE pero con proyecciones espiculadas y nodulares que se extienden por todo el tejido mamario. Se realiza una biopsia por aguja gruesa (BAG) del nódulo mamario que evidencia un carcinoma ductal infiltrante de mama con receptores de estrógenos (+) y de progesterona (++) positivos, HER 2 negativo. La biopsia de la adenoapatía axilar revela metástasis por carcinoma ductal. Tras descartarse enfermedad metastásica en el estudio de extensión se decide administrar quimioterapia neoadyuvante según el esquema TAC (docetaxel, adriamicina, ciclofosfamida) por 4 ciclos. Posteriormente, se realiza una mastectomía radical modificada de mama derecha. El estudio de anatomía patológica muestra un foco tumoral de 21x23 mm, infiltración subareolar por células tumorales sueltas y 2 micrometástasis en 14 adenopatáis resecadas, los bordes quirúrgicos estaban libres de infiltración tumoral. A la visión microscópica se evidencia un tejido de proliferacion epitelial neoplásica constituida por un área escasamente nodular con proliferación de células cuboideas, frecuentes mitosis con abundante celularidad inflamatoria, positivas para CK5/6 pero negativas para CK14, débil expresión del receptor de estrógeno (Hsocre 10/300, Allred 3/8 en 10% de células), ausencia de receptores de progresterona (Hscore 0/300 y Allred 0/8) y una alta expresión de Ki67 (50% en áreas periféricas), expresión de Her2 negativa. Se trata por lo tanto de un carcinoma infiltrante de mama ypT4d ypN1 mic ypM0 RE+ RP- Her2 - ki67 50% fenotipo luminal B. Se completa el tratamiento adyuvante con TAC x 2 y con radioterapia externa hasta una dosis total de 50 Gy, tratamiento que finaliza en octubre del 2013. La paciente presenta posteriormente la siguiente evolución de enfermedad recibiendo los siguientes tratamientos de enfermedad avanzada: Noviembre del 2014: Progresión pulmonar, hepática y ósea: Placlitaxel-Bevacizumab x 6 ciclos + Zolendronato terminando en abril del 2015 por progresión de enfermedad. Mayo del 2015: Progresión de enfermedad hepática: Capecitabina - Zolendronato Noviembre del 2015: Progresión de enfermedad ganglionar y hepática: Exemestano-everolimus + Zolendronato. Diciembre del 2015: Progresión de enfermedad cerebral: Recibe radioterapia holocraneal (4 sesiones de 500cGy por sesión) y se inicia tratamiento con Navelbina que comienza el 22 de enero del 2016. La paciente no recibe el día + 8 del 2º ciclo por síndrome febril. EPISODIO ACTUAL: La paciente acude a hospital de Día el 27 de febrero del 2016 por presentar fiebre resistente a antibioterapia oral con levofloxacino. Asocia cefalea y náuseas de una semana de evolución, además de episodios de desorientación temporo-espacial de unos dos meses de evolución pero que han aumentado en frecuencia en los últimos días. La paciente se encontraba hemodinámicamente estable y a la exploración física y neurológica no destacaba ningún hallazgo salvo la desorientación temporo-espacial. Exploración física La paciente se encontraba hemodinámicamente estable y a la exploración física y neurológica no destacaba ningún hallazgo salvo desorientación temporo-espacial. No existían signos de rigidez nucal. Pruebas complementarias Se realiza una analítica al ingreso donde destaca: GGT 219 U/l, LDH 2276 U/l (previo 1660), Hb 11 g/dl, CEA 2,7 ng/ml, Ca 15.3 1088 U/ml (previa 1038), siendo el resto de parámetros del hemograma, bioquímica y coagulación dentro de la normalidad. Se realizan radiografías de tórax y abdomen sin hallazgos de interés, se serian hemocultivos siendo todos negativos, urinocultivos negativos y cultivo de punta de catéter PICC negativo. Ante sospecha de encefalitis se inicia tratamiento antibiótico con ceftriaxona, vancomicina, aciclovir y ganciclovir con escaso beneficio. Se realiza una punción lumbar que muestra un líquido cefaloraquídeo (LCR) claro y transparente y como únicos hallazgos evidencia una pleocitosis linfocitaria de 10 células/ul y una proteinorraquia de 75 mg/dl. Se realiza una serología de sangre periférica que muestra negatividad para Borrelia, CMV, VHS 1 y 2, VEB, VZV y VHH6 negativos. Se solicita una resonancia magnética nuclear (RMN) cerebral que evidencia un extenso cambio de señal que afecta al córtex temporal y perisilviano bilateral, aunque de predominio derecho, que no se modifica tras la administración de contraste paramagnético (14 ml de gadolinio). No se advierten captaciones anómalas que sugieran afectación metastásica. Imágenes compatibles con encefalitis límbica. Se estudió la autoinmunidad de algunos anticuerpos antineuronales (anti-Yo, Ri, Hu, Tr, NMO, NMDA, MAG, VGCC y anti-islotes de Langerhans), siendo todos negativos. Diagnóstico Encefalitis límbica paraneoplásica Tratamiento Ante la sospecha de encefalitis límbica paraneoplásica se decide comenzar el tratamiento específico antes de la confirmación diagnóstica. Se administra metilpredinosolona en bolos de un gramo durante 5 días, descartándose la plasmaféresis por el estado general de la paciente, y ante la escasa mejoría se administran posteriormente inmunoglubulinas 0,4 g/kg de peso durante 3 días. Se planteó el inicio de una nueva línea de tratamiento específica contra su enfermedad de base, sin embargo no fue posible iniciar nuevo tratamiento con quimioterapia debido a un importante deterioro clínico y rápida afectación del estado general. Evolución La paciente presentó una evolución desfavorable a pesar del tratamiento administrado y falleció posteriormente con buen control de síntomas. Ya habiendo fallecido la paciente, se evidenció en el proteinograma del LCR la presencia de bandas oligoclonales que apoyan el diagnóstico de encefalitis límbica paraneoplásica. Instructions: please typing these entity words according to sentence: tumoración, tumoral, carcinoma ductal infiltrante, metástasis por carcinoma ductal, metastásica, tumoral, células tumorales, micrometástasis, tumoral, proliferacion epitelial neoplásica, carcinoma infiltrante, ypM0, Progresión pulmonar, enfermedad hepática, Progresión de enfermedad ganglionar y hepática, enfermedad cerebral, metastásica Options: MORFOLOGIA_NEOPLASIA	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Nuestra paciente, una mujer de 48 años, consulta en febrero del 2013 por notarse nodulación en mama derecha con eritema asociado. La paciente no presentaba antecedentes médico-quirúrgicos de interés y no tenía hábitos tóxicos. En el estudio diagnóstico se realizan: ecografía mamaria que evidencia un nódulo hipoecoico de 22 cm en el cuadrante súperoexterno (CSE) de la mama derecha, engrosamiento difuso de piel y adenopatías axilares; mamografía que evidencia tumoración de 32cm en CSE de mama derecha. Se amplía el estudio con una RMN que destaca engrosamiento cutáneo de la piel con retracción asociada, encontrándose el volumen tumoral CSE pero con proyecciones espiculadas y nodulares que se extienden por todo el tejido mamario. Se realiza una biopsia por aguja gruesa (BAG) del nódulo mamario que evidencia un carcinoma ductal infiltrante de mama con receptores de estrógenos (+) y de progesterona (++) positivos, HER 2 negativo. La biopsia de la adenoapatía axilar revela metástasis por carcinoma ductal. Tras descartarse enfermedad metastásica en el estudio de extensión se decide administrar quimioterapia neoadyuvante según el esquema TAC (docetaxel, adriamicina, ciclofosfamida) por 4 ciclos. Posteriormente, se realiza una mastectomía radical modificada de mama derecha. El estudio de anatomía patológica muestra un foco tumoral de 21x23 mm, infiltración subareolar por células tumorales sueltas y 2 micrometástasis en 14 adenopatáis resecadas, los bordes quirúrgicos estaban libres de infiltración tumoral. A la visión microscópica se evidencia un tejido de proliferacion epitelial neoplásica constituida por un área escasamente nodular con proliferación de células cuboideas, frecuentes mitosis con abundante celularidad inflamatoria, positivas para CK5/6 pero negativas para CK14, débil expresión del receptor de estrógeno (Hsocre 10/300, Allred 3/8 en 10% de células), ausencia de receptores de progresterona (Hscore 0/300 y Allred 0/8) y una alta expresión de Ki67 (50% en áreas periféricas), expresión de Her2 negativa. Se trata por lo tanto de un carcinoma infiltrante de mama ypT4d ypN1 mic ypM0 RE+ RP- Her2 - ki67 50% fenotipo luminal B. Se completa el tratamiento adyuvante con TAC x 2 y con radioterapia externa hasta una dosis total de 50 Gy, tratamiento que finaliza en octubre del 2013. La paciente presenta posteriormente la siguiente evolución de enfermedad recibiendo los siguientes tratamientos de enfermedad avanzada: Noviembre del 2014: Progresión pulmonar, hepática y ósea: Placlitaxel-Bevacizumab x 6 ciclos + Zolendronato terminando en abril del 2015 por progresión de enfermedad. Mayo del 2015: Progresión de enfermedad hepática: Capecitabina - Zolendronato Noviembre del 2015: Progresión de enfermedad ganglionar y hepática: Exemestano-everolimus + Zolendronato. Diciembre del 2015: Progresión de enfermedad cerebral: Recibe radioterapia holocraneal (4 sesiones de 500cGy por sesión) y se inicia tratamiento con Navelbina que comienza el 22 de enero del 2016. La paciente no recibe el día + 8 del 2º ciclo por síndrome febril. EPISODIO ACTUAL: La paciente acude a hospital de Día el 27 de febrero del 2016 por presentar fiebre resistente a antibioterapia oral con levofloxacino. Asocia cefalea y náuseas de una semana de evolución, además de episodios de desorientación temporo-espacial de unos dos meses de evolución pero que han aumentado en frecuencia en los últimos días. La paciente se encontraba hemodinámicamente estable y a la exploración física y neurológica no destacaba ningún hallazgo salvo la desorientación temporo-espacial. Exploración física La paciente se encontraba hemodinámicamente estable y a la exploración física y neurológica no destacaba ningún hallazgo salvo desorientación temporo-espacial. No existían signos de rigidez nucal. Pruebas complementarias Se realiza una analítica al ingreso donde destaca: GGT 219 U/l, LDH 2276 U/l (previo 1660), Hb 11 g/dl, CEA 2,7 ng/ml, Ca 15.3 1088 U/ml (previa 1038), siendo el resto de parámetros del hemograma, bioquímica y coagulación dentro de la normalidad. Se realizan radiografías de tórax y abdomen sin hallazgos de interés, se serian hemocultivos siendo todos negativos, urinocultivos negativos y cultivo de punta de catéter PICC negativo. Ante sospecha de encefalitis se inicia tratamiento antibiótico con ceftriaxona, vancomicina, aciclovir y ganciclovir con escaso beneficio. Se realiza una punción lumbar que muestra un líquido cefaloraquídeo (LCR) claro y transparente y como únicos hallazgos evidencia una pleocitosis linfocitaria de 10 células/ul y una proteinorraquia de 75 mg/dl. Se realiza una serología de sangre periférica que muestra negatividad para Borrelia, CMV, VHS 1 y 2, VEB, VZV y VHH6 negativos. Se solicita una resonancia magnética nuclear (RMN) cerebral que evidencia un extenso cambio de señal que afecta al córtex temporal y perisilviano bilateral, aunque de predominio derecho, que no se modifica tras la administración de contraste paramagnético (14 ml de gadolinio). No se advierten captaciones anómalas que sugieran afectación metastásica. Imágenes compatibles con encefalitis límbica. Se estudió la autoinmunidad de algunos anticuerpos antineuronales (anti-Yo, Ri, Hu, Tr, NMO, NMDA, MAG, VGCC y anti-islotes de Langerhans), siendo todos negativos. Diagnóstico Encefalitis límbica paraneoplásica Tratamiento Ante la sospecha de encefalitis límbica paraneoplásica se decide comenzar el tratamiento específico antes de la confirmación diagnóstica. Se administra metilpredinosolona en bolos de un gramo durante 5 días, descartándose la plasmaféresis por el estado general de la paciente, y ante la escasa mejoría se administran posteriormente inmunoglubulinas 0,4 g/kg de peso durante 3 días. Se planteó el inicio de una nueva línea de tratamiento específica contra su enfermedad de base, sin embargo no fue posible iniciar nuevo tratamiento con quimioterapia debido a un importante deterioro clínico y rápida afectación del estado general. Evolución La paciente presentó una evolución desfavorable a pesar del tratamiento administrado y falleció posteriormente con buen control de síntomas. Ya habiendo fallecido la paciente, se evidenció en el proteinograma del LCR la presencia de bandas oligoclonales que apoyan el diagnóstico de encefalitis límbica paraneoplásica.	[ "Anamnesis", "\n", "Nuestra", "paciente", ",", "una", "mujer", "de", "48", "años", ",", "consulta", "en", "febrero", "del", "2013", "por", "notarse", "nodulación", "en", "mama", "derecha", "con", "eritema", "asociado", ".", "La", "paciente", "no", "presentaba", "antecedentes", "médico", "-", "quirúrgicos", "de", "interés", "y", "no", "tenía", "hábitos", "tóxicos", ".", "\n", "En", "el", "estudio", "diagnóstico", "se", "realizan", ":", "ecografía", "mamaria", "que", "evidencia", "un", "nódulo", "hipoecoico", "de", "2", "", "2", "cm", "en", "el", "cuadrante", "súperoexterno", "(", "CSE", ")", "de", "la", "mama", "derecha", ",", "engrosamiento", "difuso", "de", "piel", "y", "adenopatías", "axilares", ";", "mamografía", "que", "evidencia", "tumoración", "de", "3", "", "2", "cm", "en", "CSE", "de", "mama", "derecha", ".", "Se", "amplía", "el", "estudio", "con", "una", "RMN", "que", "destaca", "engrosamiento", "cutáneo", "de", "la", "piel", "con", "retracción", "asociada", ",", "encontrándose", "el", "volumen", "tumoral", "CSE", "pero", "con", "proyecciones", "espiculadas", "y", "nodulares", "que", "se", "extienden", "por", "todo", "el", "tejido", "mamario", ".", "\n", "Se", "realiza", "una", "biopsia", "por", "aguja", "gruesa", "(", "BAG", ")", "del", "nódulo", "mamario", "que", "evidencia", "un", "carcinoma", "ductal", "infiltrante", "de", "mama", "con", "receptores", "de", "estrógenos", "(", "+", ")", "y", "de", "progesterona", "(", "+", "+", ")", "positivos", ",", "HER", "2", "negativo", ".", "\n", "La", "biopsia", "de", "la", "adenoapatía", "axilar", "revela", "metástasis", "por", "carcinoma", "ductal", ".", "\n", "Tras", "descartarse", "enfermedad", "metastásica", "en", "el", "estudio", "de", "extensión", "se", "decide", "administrar", "quimioterapia", "neoadyuvante", "según", "el", "esquema", "TAC", "(", "docetaxel", ",", "adriamicina", ",", "ciclofosfamida", ")", "por", "4", "ciclos", ".", "Posteriormente", ",", "se", "realiza", "una", "mastectomía", "radical", "modificada", "de", "mama", "derecha", ".", "\n", "El", "estudio", "de", "anatomía", "patológica", "muestra", "un", "foco", "tumoral", "de", "21x23", "mm", ",", "infiltración", "subareolar", "por", "células", "tumorales", "sueltas", "y", "2", "micrometástasis", "en", "14", "adenopatáis", "resecadas", ",", "los", "bordes", "quirúrgicos", "estaban", "libres", "de", "infiltración", "tumoral", ".", "A", "la", "visión", "microscópica", "se", "evidencia", "un", "tejido", "de", "proliferacion", "epitelial", "neoplásica", "constituida", "por", "un", "área", "escasamente", "nodular", "con", "proliferación", "de", "células", "cuboideas", ",", "frecuentes", "mitosis", "con", "abundante", "celularidad", "inflamatoria", ",", "positivas", "para", "CK5/6", "pero", "negativas", "para", "CK14", ",", "débil", "expresión", "del", "receptor", "de", "estrógeno", "(", "Hsocre", "10/300", ",", "Allred", "3/8", "en", "10", "%", "de", "células", ")", ",", "ausencia", "de", "receptores", "de", "progresterona", "(", "Hscore", "0/300", "y", "Allred", "0/8", ")", "y", "una", "alta", "expresión", "de", "Ki67", "(", "50", "%", "en", "áreas", "periféricas", ")", ",", "expresión", "de", "Her2", "negativa", ".", "\n", "Se", "trata", "por", "lo", "tanto", "de", "un", "carcinoma", "infiltrante", "de", "mama", "ypT4d", "ypN1", "mic", "ypM0", "RE+", "RP-", "Her2", "-", "ki67", "50", "%", "fenotipo", "luminal", "B.", "\n", "Se", "completa", "el", "tratamiento", "adyuvante", "con", "TAC", "x", "2", "y", "con", "radioterapia", "externa", "hasta", "una", "dosis", "total", "de", "50", "Gy", ",", "tratamiento", "que", "finaliza", "en", "octubre", "del", "2013", ".", "\n", "La", "paciente", "presenta", "posteriormente", "la", "siguiente", "evolución", "de", "enfermedad", "recibiendo", "los", "siguientes", "tratamientos", "de", "enfermedad", "avanzada", ":", "\n", "Noviembre", "del", "2014", ":", "Progresión", "pulmonar", ",", "hepática", "y", "ósea", ":", "Placlitaxel", "-", "Bevacizumab", "x", "6", "ciclos", "+", "Zolendronato", "terminando", "en", "abril", "del", "2015", "por", "progresión", "de", "enfermedad", ".", "\n", "Mayo", "del", "2015", ":", "Progresión", "de", "enfermedad", "hepática", ":", "Capecitabina", "-", "Zolendronato", "\n", "Noviembre", "del", "2015", ":", "Progresión", "de", "enfermedad", "ganglionar", "y", "hepática", ":", "Exemestano", "-", "everolimus", "+", "Zolendronato", ".", "\n", "Diciembre", "del", "2015", ":", "Progresión", "de", "enfermedad", "cerebral", ":", "Recibe", "radioterapia", "holocraneal", "(", "4", "sesiones", "de", "500cGy", "por", "sesión", ")", "y", "se", "inicia", "tratamiento", "con", "Navelbina", "que", "comienza", "el", "22", "de", "enero", "del", "2016", ".", "La", "paciente", "no", "recibe", "el", "día", "+", "8", "del", "2º", "ciclo", "por", "síndrome", "febril", ".", "\n\n", "EPISODIO", "ACTUAL", ":", "\n", "La", "paciente", "acude", "a", "hospital", "de", "Día", "el", "27", "de", "febrero", "del", "2016", "por", "presentar", "fiebre", "resistente", "a", "antibioterapia", "oral", "con", "levofloxacino", ".", "Asocia", "cefalea", "y", "náuseas", "de", "una", "semana", "de", "evolución", ",", "además", "de", "episodios", "de", "desorientación", "temporo", "-", "espacial", "de", "unos", "dos", "meses", "de", "evolución", "pero", "que", "han", "aumentado", "en", "frecuencia", "en", "los", "últimos", "días", ".", "La", "paciente", "se", "encontraba", "hemodinámicamente", "estable", "y", "a", "la", "exploración", "física", "y", "neurológica", "no", "destacaba", "ningún", "hallazgo", "salvo", "la", "desorientación", "temporo", "-", "espacial", ".", "\n\n", "Exploración", "física", "\n", "La", "paciente", "se", "encontraba", "hemodinámicamente", "estable", "y", "a", "la", "exploración", "física", "y", "neurológica", "no", "destacaba", "ningún", "hallazgo", "salvo", "desorientación", "temporo", "-", "espacial", ".", "No", "existían", "signos", "de", "rigidez", "nucal", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "realiza", "una", "analítica", "al", "ingreso", "donde", "destaca", ":", "GGT", "219", "U", "/", "l", ",", "LDH", "2276", "U", "/", "l", "(", "previo", "1660", ")", ",", "Hb", "11", "g", "/", "dl", ",", "CEA", "2,7", "ng", "/", "ml", ",", "Ca", "15.3", "1088", "U", "/", "ml", "(", "previa", "1038", ")", ",", "siendo", "el", "resto", "de", "parámetros", "del", "hemograma", ",", "bioquímica", "y", "coagulación", "dentro", "de", "la", "normalidad", ".", "Se", "realizan", "radiografías", "de", "tórax", "y", "abdomen", "sin", "hallazgos", "de", "interés", ",", "se", "serian", "hemocultivos", "siendo", "todos", "negativos", ",", "urinocultivos", "negativos", "y", "cultivo", "de", "punta", "de", "catéter", "PICC", "negativo", ".", "\n", "Ante", "sospecha", "de", "encefalitis", "se", "inicia", "tratamiento", "antibiótico", "con", "ceftriaxona", ",", "vancomicina", ",", "aciclovir", "y", "ganciclovir", "con", "escaso", "beneficio", ".", "Se", "realiza", "una", "punción", "lumbar", "que", "muestra", "un", "líquido", "cefaloraquídeo", "(", "LCR", ")", "claro", "y", "transparente", "y", "como", "únicos", "hallazgos", "evidencia", "una", "pleocitosis", "linfocitaria", "de", "10", "células", "/", "ul", "y", "una", "proteinorraquia", "de", "75", "mg", "/", "dl", ".", "Se", "realiza", "una", "serología", "de", "sangre", "periférica", "que", "muestra", "negatividad", "para", "Borrelia", ",", "CMV", ",", "VHS", "1", "y", "2", ",", "VEB", ",", "VZV", "y", "VHH6", "negativos", ".", "\n", "Se", "solicita", "una", "resonancia", "magnética", "nuclear", "(", "RMN", ")", "cerebral", "que", "evidencia", "un", "extenso", "cambio", "de", "señal", "que", "afecta", "al", "córtex", "temporal", "y", "perisilviano", "bilateral", ",", "aunque", "de", "predominio", "derecho", ",", "que", "no", "se", "modifica", "tras", "la", "administración", "de", "contraste", "paramagnético", "(", "14", "ml", "de", "gadolinio", ")", ".", "No", "se", "advierten", "captaciones", "anómalas", "que", "sugieran", "afectación", "metastásica", ".", "Imágenes", "compatibles", "con", "encefalitis", "límbica", ".", "\n", "Se", "estudió", "la", "autoinmunidad", "de", "algunos", "anticuerpos", "antineuronales", "(", "anti", "-", "Yo", ",", "Ri", ",", "Hu", ",", "Tr", ",", "NMO", ",", "NMDA", ",", "MAG", ",", "VGCC", "y", "anti", "-", "islotes", "de", "Langerhans", ")", ",", "siendo", "todos", "negativos", ".", "\n\n", "Diagnóstico", "\n", "Encefalitis", "límbica", "paraneoplásica", "\n\n", "Tratamiento", "\n", "Ante", "la", "sospecha", "de", "encefalitis", "límbica", "paraneoplásica", "se", "decide", "comenzar", "el", "tratamiento", "específico", "antes", "de", "la", "confirmación", "diagnóstica", ".", "Se", "administra", "metilpredinosolona", "en", "bolos", "de", "un", "gramo", "durante", "5", "días", ",", "descartándose", "la", "plasmaféresis", "por", "el", "estado", "general", "de", "la", "paciente", ",", "y", "ante", "la", "escasa", "mejoría", "se", "administran", "posteriormente", "inmunoglubulinas", "0,4", "g", "/", "kg", "de", "peso", "durante", "3", "días", ".", "\n", "Se", "planteó", "el", "inicio", "de", "una", "nueva", "línea", "de", "tratamiento", "específica", "contra", "su", "enfermedad", "de", "base", ",", "sin", "embargo", "no", "fue", "posible", "iniciar", "nuevo", "tratamiento", "con", "quimioterapia", "debido", "a", "un", "importante", "deterioro", "clínico", "y", "rápida", "afectación", "del", "estado", "general", ".", "\n\n", "Evolución", "\n", "La", "paciente", "presentó", "una", "evolución", "desfavorable", "a", "pesar", "del", "tratamiento", "administrado", "y", "falleció", "posteriormente", "con", "buen", "control", "de", "síntomas", ".", "\n", "Ya", "habiendo", "fallecido", "la", "paciente", ",", "se", "evidenció", "en", "el", "proteinograma", "del", "LCR", "la", "presencia", "de", "bandas", "oligoclonales", "que", "apoyan", "el", "diagnóstico", "de", "encefalitis", "límbica", "paraneoplásica", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
tumoración, tumoral, carcinoma ductal infiltrante, metástasis por carcinoma ductal, metastásica, tumoral, células tumorales, micrometástasis, tumoral, proliferacion epitelial neoplásica, carcinoma infiltrante, ypM0, Progresión pulmonar, enfermedad hepática, Progresión de enfermedad ganglionar y hepática, enfermedad cerebral, metastásica	299_task2	Sentence: Anamnesis Nuestra paciente, una mujer de 48 años, consulta en febrero del 2013 por notarse nodulación en mama derecha con eritema asociado. La paciente no presentaba antecedentes médico-quirúrgicos de interés y no tenía hábitos tóxicos. En el estudio diagnóstico se realizan: ecografía mamaria que evidencia un nódulo hipoecoico de 22 cm en el cuadrante súperoexterno (CSE) de la mama derecha, engrosamiento difuso de piel y adenopatías axilares; mamografía que evidencia tumoración de 32cm en CSE de mama derecha. Se amplía el estudio con una RMN que destaca engrosamiento cutáneo de la piel con retracción asociada, encontrándose el volumen tumoral CSE pero con proyecciones espiculadas y nodulares que se extienden por todo el tejido mamario. Se realiza una biopsia por aguja gruesa (BAG) del nódulo mamario que evidencia un carcinoma ductal infiltrante de mama con receptores de estrógenos (+) y de progesterona (++) positivos, HER 2 negativo. La biopsia de la adenoapatía axilar revela metástasis por carcinoma ductal. Tras descartarse enfermedad metastásica en el estudio de extensión se decide administrar quimioterapia neoadyuvante según el esquema TAC (docetaxel, adriamicina, ciclofosfamida) por 4 ciclos. Posteriormente, se realiza una mastectomía radical modificada de mama derecha. El estudio de anatomía patológica muestra un foco tumoral de 21x23 mm, infiltración subareolar por células tumorales sueltas y 2 micrometástasis en 14 adenopatáis resecadas, los bordes quirúrgicos estaban libres de infiltración tumoral. A la visión microscópica se evidencia un tejido de proliferacion epitelial neoplásica constituida por un área escasamente nodular con proliferación de células cuboideas, frecuentes mitosis con abundante celularidad inflamatoria, positivas para CK5/6 pero negativas para CK14, débil expresión del receptor de estrógeno (Hsocre 10/300, Allred 3/8 en 10% de células), ausencia de receptores de progresterona (Hscore 0/300 y Allred 0/8) y una alta expresión de Ki67 (50% en áreas periféricas), expresión de Her2 negativa. Se trata por lo tanto de un carcinoma infiltrante de mama ypT4d ypN1 mic ypM0 RE+ RP- Her2 - ki67 50% fenotipo luminal B. Se completa el tratamiento adyuvante con TAC x 2 y con radioterapia externa hasta una dosis total de 50 Gy, tratamiento que finaliza en octubre del 2013. La paciente presenta posteriormente la siguiente evolución de enfermedad recibiendo los siguientes tratamientos de enfermedad avanzada: Noviembre del 2014: Progresión pulmonar, hepática y ósea: Placlitaxel-Bevacizumab x 6 ciclos + Zolendronato terminando en abril del 2015 por progresión de enfermedad. Mayo del 2015: Progresión de enfermedad hepática: Capecitabina - Zolendronato Noviembre del 2015: Progresión de enfermedad ganglionar y hepática: Exemestano-everolimus + Zolendronato. Diciembre del 2015: Progresión de enfermedad cerebral: Recibe radioterapia holocraneal (4 sesiones de 500cGy por sesión) y se inicia tratamiento con Navelbina que comienza el 22 de enero del 2016. La paciente no recibe el día + 8 del 2º ciclo por síndrome febril. EPISODIO ACTUAL: La paciente acude a hospital de Día el 27 de febrero del 2016 por presentar fiebre resistente a antibioterapia oral con levofloxacino. Asocia cefalea y náuseas de una semana de evolución, además de episodios de desorientación temporo-espacial de unos dos meses de evolución pero que han aumentado en frecuencia en los últimos días. La paciente se encontraba hemodinámicamente estable y a la exploración física y neurológica no destacaba ningún hallazgo salvo la desorientación temporo-espacial. Exploración física La paciente se encontraba hemodinámicamente estable y a la exploración física y neurológica no destacaba ningún hallazgo salvo desorientación temporo-espacial. No existían signos de rigidez nucal. Pruebas complementarias Se realiza una analítica al ingreso donde destaca: GGT 219 U/l, LDH 2276 U/l (previo 1660), Hb 11 g/dl, CEA 2,7 ng/ml, Ca 15.3 1088 U/ml (previa 1038), siendo el resto de parámetros del hemograma, bioquímica y coagulación dentro de la normalidad. Se realizan radiografías de tórax y abdomen sin hallazgos de interés, se serian hemocultivos siendo todos negativos, urinocultivos negativos y cultivo de punta de catéter PICC negativo. Ante sospecha de encefalitis se inicia tratamiento antibiótico con ceftriaxona, vancomicina, aciclovir y ganciclovir con escaso beneficio. Se realiza una punción lumbar que muestra un líquido cefaloraquídeo (LCR) claro y transparente y como únicos hallazgos evidencia una pleocitosis linfocitaria de 10 células/ul y una proteinorraquia de 75 mg/dl. Se realiza una serología de sangre periférica que muestra negatividad para Borrelia, CMV, VHS 1 y 2, VEB, VZV y VHH6 negativos. Se solicita una resonancia magnética nuclear (RMN) cerebral que evidencia un extenso cambio de señal que afecta al córtex temporal y perisilviano bilateral, aunque de predominio derecho, que no se modifica tras la administración de contraste paramagnético (14 ml de gadolinio). No se advierten captaciones anómalas que sugieran afectación metastásica. Imágenes compatibles con encefalitis límbica. Se estudió la autoinmunidad de algunos anticuerpos antineuronales (anti-Yo, Ri, Hu, Tr, NMO, NMDA, MAG, VGCC y anti-islotes de Langerhans), siendo todos negativos. Diagnóstico Encefalitis límbica paraneoplásica Tratamiento Ante la sospecha de encefalitis límbica paraneoplásica se decide comenzar el tratamiento específico antes de la confirmación diagnóstica. Se administra metilpredinosolona en bolos de un gramo durante 5 días, descartándose la plasmaféresis por el estado general de la paciente, y ante la escasa mejoría se administran posteriormente inmunoglubulinas 0,4 g/kg de peso durante 3 días. Se planteó el inicio de una nueva línea de tratamiento específica contra su enfermedad de base, sin embargo no fue posible iniciar nuevo tratamiento con quimioterapia debido a un importante deterioro clínico y rápida afectación del estado general. Evolución La paciente presentó una evolución desfavorable a pesar del tratamiento administrado y falleció posteriormente con buen control de síntomas. Ya habiendo fallecido la paciente, se evidenció en el proteinograma del LCR la presencia de bandas oligoclonales que apoyan el diagnóstico de encefalitis límbica paraneoplásica. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Nuestra paciente, una mujer de 48 años, consulta en febrero del 2013 por notarse nodulación en mama derecha con eritema asociado. La paciente no presentaba antecedentes médico-quirúrgicos de interés y no tenía hábitos tóxicos. En el estudio diagnóstico se realizan: ecografía mamaria que evidencia un nódulo hipoecoico de 22 cm en el cuadrante súperoexterno (CSE) de la mama derecha, engrosamiento difuso de piel y adenopatías axilares; mamografía que evidencia tumoración de 32cm en CSE de mama derecha. Se amplía el estudio con una RMN que destaca engrosamiento cutáneo de la piel con retracción asociada, encontrándose el volumen tumoral CSE pero con proyecciones espiculadas y nodulares que se extienden por todo el tejido mamario. Se realiza una biopsia por aguja gruesa (BAG) del nódulo mamario que evidencia un carcinoma ductal infiltrante de mama con receptores de estrógenos (+) y de progesterona (++) positivos, HER 2 negativo. La biopsia de la adenoapatía axilar revela metástasis por carcinoma ductal. Tras descartarse enfermedad metastásica en el estudio de extensión se decide administrar quimioterapia neoadyuvante según el esquema TAC (docetaxel, adriamicina, ciclofosfamida) por 4 ciclos. Posteriormente, se realiza una mastectomía radical modificada de mama derecha. El estudio de anatomía patológica muestra un foco tumoral de 21x23 mm, infiltración subareolar por células tumorales sueltas y 2 micrometástasis en 14 adenopatáis resecadas, los bordes quirúrgicos estaban libres de infiltración tumoral. A la visión microscópica se evidencia un tejido de proliferacion epitelial neoplásica constituida por un área escasamente nodular con proliferación de células cuboideas, frecuentes mitosis con abundante celularidad inflamatoria, positivas para CK5/6 pero negativas para CK14, débil expresión del receptor de estrógeno (Hsocre 10/300, Allred 3/8 en 10% de células), ausencia de receptores de progresterona (Hscore 0/300 y Allred 0/8) y una alta expresión de Ki67 (50% en áreas periféricas), expresión de Her2 negativa. Se trata por lo tanto de un carcinoma infiltrante de mama ypT4d ypN1 mic ypM0 RE+ RP- Her2 - ki67 50% fenotipo luminal B. Se completa el tratamiento adyuvante con TAC x 2 y con radioterapia externa hasta una dosis total de 50 Gy, tratamiento que finaliza en octubre del 2013. La paciente presenta posteriormente la siguiente evolución de enfermedad recibiendo los siguientes tratamientos de enfermedad avanzada: Noviembre del 2014: Progresión pulmonar, hepática y ósea: Placlitaxel-Bevacizumab x 6 ciclos + Zolendronato terminando en abril del 2015 por progresión de enfermedad. Mayo del 2015: Progresión de enfermedad hepática: Capecitabina - Zolendronato Noviembre del 2015: Progresión de enfermedad ganglionar y hepática: Exemestano-everolimus + Zolendronato. Diciembre del 2015: Progresión de enfermedad cerebral: Recibe radioterapia holocraneal (4 sesiones de 500cGy por sesión) y se inicia tratamiento con Navelbina que comienza el 22 de enero del 2016. La paciente no recibe el día + 8 del 2º ciclo por síndrome febril. EPISODIO ACTUAL: La paciente acude a hospital de Día el 27 de febrero del 2016 por presentar fiebre resistente a antibioterapia oral con levofloxacino. Asocia cefalea y náuseas de una semana de evolución, además de episodios de desorientación temporo-espacial de unos dos meses de evolución pero que han aumentado en frecuencia en los últimos días. La paciente se encontraba hemodinámicamente estable y a la exploración física y neurológica no destacaba ningún hallazgo salvo la desorientación temporo-espacial. Exploración física La paciente se encontraba hemodinámicamente estable y a la exploración física y neurológica no destacaba ningún hallazgo salvo desorientación temporo-espacial. No existían signos de rigidez nucal. Pruebas complementarias Se realiza una analítica al ingreso donde destaca: GGT 219 U/l, LDH 2276 U/l (previo 1660), Hb 11 g/dl, CEA 2,7 ng/ml, Ca 15.3 1088 U/ml (previa 1038), siendo el resto de parámetros del hemograma, bioquímica y coagulación dentro de la normalidad. Se realizan radiografías de tórax y abdomen sin hallazgos de interés, se serian hemocultivos siendo todos negativos, urinocultivos negativos y cultivo de punta de catéter PICC negativo. Ante sospecha de encefalitis se inicia tratamiento antibiótico con ceftriaxona, vancomicina, aciclovir y ganciclovir con escaso beneficio. Se realiza una punción lumbar que muestra un líquido cefaloraquídeo (LCR) claro y transparente y como únicos hallazgos evidencia una pleocitosis linfocitaria de 10 células/ul y una proteinorraquia de 75 mg/dl. Se realiza una serología de sangre periférica que muestra negatividad para Borrelia, CMV, VHS 1 y 2, VEB, VZV y VHH6 negativos. Se solicita una resonancia magnética nuclear (RMN) cerebral que evidencia un extenso cambio de señal que afecta al córtex temporal y perisilviano bilateral, aunque de predominio derecho, que no se modifica tras la administración de contraste paramagnético (14 ml de gadolinio). No se advierten captaciones anómalas que sugieran afectación metastásica. Imágenes compatibles con encefalitis límbica. Se estudió la autoinmunidad de algunos anticuerpos antineuronales (anti-Yo, Ri, Hu, Tr, NMO, NMDA, MAG, VGCC y anti-islotes de Langerhans), siendo todos negativos. Diagnóstico Encefalitis límbica paraneoplásica Tratamiento Ante la sospecha de encefalitis límbica paraneoplásica se decide comenzar el tratamiento específico antes de la confirmación diagnóstica. Se administra metilpredinosolona en bolos de un gramo durante 5 días, descartándose la plasmaféresis por el estado general de la paciente, y ante la escasa mejoría se administran posteriormente inmunoglubulinas 0,4 g/kg de peso durante 3 días. Se planteó el inicio de una nueva línea de tratamiento específica contra su enfermedad de base, sin embargo no fue posible iniciar nuevo tratamiento con quimioterapia debido a un importante deterioro clínico y rápida afectación del estado general. Evolución La paciente presentó una evolución desfavorable a pesar del tratamiento administrado y falleció posteriormente con buen control de síntomas. Ya habiendo fallecido la paciente, se evidenció en el proteinograma del LCR la presencia de bandas oligoclonales que apoyan el diagnóstico de encefalitis límbica paraneoplásica.	[ "Anamnesis", "\n", "Nuestra", "paciente", ",", "una", "mujer", "de", "48", "años", ",", "consulta", "en", "febrero", "del", "2013", "por", "notarse", "nodulación", "en", "mama", "derecha", "con", "eritema", "asociado", ".", "La", "paciente", "no", "presentaba", "antecedentes", "médico", "-", "quirúrgicos", "de", "interés", "y", "no", "tenía", "hábitos", "tóxicos", ".", "\n", "En", "el", "estudio", "diagnóstico", "se", "realizan", ":", "ecografía", "mamaria", "que", "evidencia", "un", "nódulo", "hipoecoico", "de", "2", "", "2", "cm", "en", "el", "cuadrante", "súperoexterno", "(", "CSE", ")", "de", "la", "mama", "derecha", ",", "engrosamiento", "difuso", "de", "piel", "y", "adenopatías", "axilares", ";", "mamografía", "que", "evidencia", "tumoración", "de", "3", "", "2", "cm", "en", "CSE", "de", "mama", "derecha", ".", "Se", "amplía", "el", "estudio", "con", "una", "RMN", "que", "destaca", "engrosamiento", "cutáneo", "de", "la", "piel", "con", "retracción", "asociada", ",", "encontrándose", "el", "volumen", "tumoral", "CSE", "pero", "con", "proyecciones", "espiculadas", "y", "nodulares", "que", "se", "extienden", "por", "todo", "el", "tejido", "mamario", ".", "\n", "Se", "realiza", "una", "biopsia", "por", "aguja", "gruesa", "(", "BAG", ")", "del", "nódulo", "mamario", "que", "evidencia", "un", "carcinoma", "ductal", "infiltrante", "de", "mama", "con", "receptores", "de", "estrógenos", "(", "+", ")", "y", "de", "progesterona", "(", "+", "+", ")", "positivos", ",", "HER", "2", "negativo", ".", "\n", "La", "biopsia", "de", "la", "adenoapatía", "axilar", "revela", "metástasis", "por", "carcinoma", "ductal", ".", "\n", "Tras", "descartarse", "enfermedad", "metastásica", "en", "el", "estudio", "de", "extensión", "se", "decide", "administrar", "quimioterapia", "neoadyuvante", "según", "el", "esquema", "TAC", "(", "docetaxel", ",", "adriamicina", ",", "ciclofosfamida", ")", "por", "4", "ciclos", ".", "Posteriormente", ",", "se", "realiza", "una", "mastectomía", "radical", "modificada", "de", "mama", "derecha", ".", "\n", "El", "estudio", "de", "anatomía", "patológica", "muestra", "un", "foco", "tumoral", "de", "21x23", "mm", ",", "infiltración", "subareolar", "por", "células", "tumorales", "sueltas", "y", "2", "micrometástasis", "en", "14", "adenopatáis", "resecadas", ",", "los", "bordes", "quirúrgicos", "estaban", "libres", "de", "infiltración", "tumoral", ".", "A", "la", "visión", "microscópica", "se", "evidencia", "un", "tejido", "de", "proliferacion", "epitelial", "neoplásica", "constituida", "por", "un", "área", "escasamente", "nodular", "con", "proliferación", "de", "células", "cuboideas", ",", "frecuentes", "mitosis", "con", "abundante", "celularidad", "inflamatoria", ",", "positivas", "para", "CK5/6", "pero", "negativas", "para", "CK14", ",", "débil", "expresión", "del", "receptor", "de", "estrógeno", "(", "Hsocre", "10/300", ",", "Allred", "3/8", "en", "10", "%", "de", "células", ")", ",", "ausencia", "de", "receptores", "de", "progresterona", "(", "Hscore", "0/300", "y", "Allred", "0/8", ")", "y", "una", "alta", "expresión", "de", "Ki67", "(", "50", "%", "en", "áreas", "periféricas", ")", ",", "expresión", "de", "Her2", "negativa", ".", "\n", "Se", "trata", "por", "lo", "tanto", "de", "un", "carcinoma", "infiltrante", "de", "mama", "ypT4d", "ypN1", "mic", "ypM0", "RE+", "RP-", "Her2", "-", "ki67", "50", "%", "fenotipo", "luminal", "B.", "\n", "Se", "completa", "el", "tratamiento", "adyuvante", "con", "TAC", "x", "2", "y", "con", "radioterapia", "externa", "hasta", "una", "dosis", "total", "de", "50", "Gy", ",", "tratamiento", "que", "finaliza", "en", "octubre", "del", "2013", ".", "\n", "La", "paciente", "presenta", "posteriormente", "la", "siguiente", "evolución", "de", "enfermedad", "recibiendo", "los", "siguientes", "tratamientos", "de", "enfermedad", "avanzada", ":", "\n", "Noviembre", "del", "2014", ":", "Progresión", "pulmonar", ",", "hepática", "y", "ósea", ":", "Placlitaxel", "-", "Bevacizumab", "x", "6", "ciclos", "+", "Zolendronato", "terminando", "en", "abril", "del", "2015", "por", "progresión", "de", "enfermedad", ".", "\n", "Mayo", "del", "2015", ":", "Progresión", "de", "enfermedad", "hepática", ":", "Capecitabina", "-", "Zolendronato", "\n", "Noviembre", "del", "2015", ":", "Progresión", "de", "enfermedad", "ganglionar", "y", "hepática", ":", "Exemestano", "-", "everolimus", "+", "Zolendronato", ".", "\n", "Diciembre", "del", "2015", ":", "Progresión", "de", "enfermedad", "cerebral", ":", "Recibe", "radioterapia", "holocraneal", "(", "4", "sesiones", "de", "500cGy", "por", "sesión", ")", "y", "se", "inicia", "tratamiento", "con", "Navelbina", "que", "comienza", "el", "22", "de", "enero", "del", "2016", ".", "La", "paciente", "no", "recibe", "el", "día", "+", "8", "del", "2º", "ciclo", "por", "síndrome", "febril", ".", "\n\n", "EPISODIO", "ACTUAL", ":", "\n", "La", "paciente", "acude", "a", "hospital", "de", "Día", "el", "27", "de", "febrero", "del", "2016", "por", "presentar", "fiebre", "resistente", "a", "antibioterapia", "oral", "con", "levofloxacino", ".", "Asocia", "cefalea", "y", "náuseas", "de", "una", "semana", "de", "evolución", ",", "además", "de", "episodios", "de", "desorientación", "temporo", "-", "espacial", "de", "unos", "dos", "meses", "de", "evolución", "pero", "que", "han", "aumentado", "en", "frecuencia", "en", "los", "últimos", "días", ".", "La", "paciente", "se", "encontraba", "hemodinámicamente", "estable", "y", "a", "la", "exploración", "física", "y", "neurológica", "no", "destacaba", "ningún", "hallazgo", "salvo", "la", "desorientación", "temporo", "-", "espacial", ".", "\n\n", "Exploración", "física", "\n", "La", "paciente", "se", "encontraba", "hemodinámicamente", "estable", "y", "a", "la", "exploración", "física", "y", "neurológica", "no", "destacaba", "ningún", "hallazgo", "salvo", "desorientación", "temporo", "-", "espacial", ".", "No", "existían", "signos", "de", "rigidez", "nucal", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "realiza", "una", "analítica", "al", "ingreso", "donde", "destaca", ":", "GGT", "219", "U", "/", "l", ",", "LDH", "2276", "U", "/", "l", "(", "previo", "1660", ")", ",", "Hb", "11", "g", "/", "dl", ",", "CEA", "2,7", "ng", "/", "ml", ",", "Ca", "15.3", "1088", "U", "/", "ml", "(", "previa", "1038", ")", ",", "siendo", "el", "resto", "de", "parámetros", "del", "hemograma", ",", "bioquímica", "y", "coagulación", "dentro", "de", "la", "normalidad", ".", "Se", "realizan", "radiografías", "de", "tórax", "y", "abdomen", "sin", "hallazgos", "de", "interés", ",", "se", "serian", "hemocultivos", "siendo", "todos", "negativos", ",", "urinocultivos", "negativos", "y", "cultivo", "de", "punta", "de", "catéter", "PICC", "negativo", ".", "\n", "Ante", "sospecha", "de", "encefalitis", "se", "inicia", "tratamiento", "antibiótico", "con", "ceftriaxona", ",", "vancomicina", ",", "aciclovir", "y", "ganciclovir", "con", "escaso", "beneficio", ".", "Se", "realiza", "una", "punción", "lumbar", "que", "muestra", "un", "líquido", "cefaloraquídeo", "(", "LCR", ")", "claro", "y", "transparente", "y", "como", "únicos", "hallazgos", "evidencia", "una", "pleocitosis", "linfocitaria", "de", "10", "células", "/", "ul", "y", "una", "proteinorraquia", "de", "75", "mg", "/", "dl", ".", "Se", "realiza", "una", "serología", "de", "sangre", "periférica", "que", "muestra", "negatividad", "para", "Borrelia", ",", "CMV", ",", "VHS", "1", "y", "2", ",", "VEB", ",", "VZV", "y", "VHH6", "negativos", ".", "\n", "Se", "solicita", "una", "resonancia", "magnética", "nuclear", "(", "RMN", ")", "cerebral", "que", "evidencia", "un", "extenso", "cambio", "de", "señal", "que", "afecta", "al", "córtex", "temporal", "y", "perisilviano", "bilateral", ",", "aunque", "de", "predominio", "derecho", ",", "que", "no", "se", "modifica", "tras", "la", "administración", "de", "contraste", "paramagnético", "(", "14", "ml", "de", "gadolinio", ")", ".", "No", "se", "advierten", "captaciones", "anómalas", "que", "sugieran", "afectación", "metastásica", ".", "Imágenes", "compatibles", "con", "encefalitis", "límbica", ".", "\n", "Se", "estudió", "la", "autoinmunidad", "de", "algunos", "anticuerpos", "antineuronales", "(", "anti", "-", "Yo", ",", "Ri", ",", "Hu", ",", "Tr", ",", "NMO", ",", "NMDA", ",", "MAG", ",", "VGCC", "y", "anti", "-", "islotes", "de", "Langerhans", ")", ",", "siendo", "todos", "negativos", ".", "\n\n", "Diagnóstico", "\n", "Encefalitis", "límbica", "paraneoplásica", "\n\n", "Tratamiento", "\n", "Ante", "la", "sospecha", "de", "encefalitis", "límbica", "paraneoplásica", "se", "decide", "comenzar", "el", "tratamiento", "específico", "antes", "de", "la", "confirmación", "diagnóstica", ".", "Se", "administra", "metilpredinosolona", "en", "bolos", "de", "un", "gramo", "durante", "5", "días", ",", "descartándose", "la", "plasmaféresis", "por", "el", "estado", "general", "de", "la", "paciente", ",", "y", "ante", "la", "escasa", "mejoría", "se", "administran", "posteriormente", "inmunoglubulinas", "0,4", "g", "/", "kg", "de", "peso", "durante", "3", "días", ".", "\n", "Se", "planteó", "el", "inicio", "de", "una", "nueva", "línea", "de", "tratamiento", "específica", "contra", "su", "enfermedad", "de", "base", ",", "sin", "embargo", "no", "fue", "posible", "iniciar", "nuevo", "tratamiento", "con", "quimioterapia", "debido", "a", "un", "importante", "deterioro", "clínico", "y", "rápida", "afectación", "del", "estado", "general", ".", "\n\n", "Evolución", "\n", "La", "paciente", "presentó", "una", "evolución", "desfavorable", "a", "pesar", "del", "tratamiento", "administrado", "y", "falleció", "posteriormente", "con", "buen", "control", "de", "síntomas", ".", "\n", "Ya", "habiendo", "fallecido", "la", "paciente", ",", "se", "evidenció", "en", "el", "proteinograma", "del", "LCR", "la", "presencia", "de", "bandas", "oligoclonales", "que", "apoyan", "el", "diagnóstico", "de", "encefalitis", "límbica", "paraneoplásica", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
Abstract is an umlsterm, caucasian is an umlsterm, woman is an umlsterm, naevus is an umlsterm, eye is an umlsterm, finding is an umlsterm, history is an umlsterm, patient is an umlsterm, naevus is an umlsterm, local anaesthesia is an umlsterm, naevus is an umlsterm	DerHautarzt.40450719.eng.abstr_task0	Sentence: Abstract . We report on the case of a 70-year-old caucasian woman with a large linear sebaceous naevus with multifocal intralesional basaliomas and a lipodermoid of the left eye . This rare finding has been preserved because of the special history of the patient . The naevus spread on the left side from parietal to retroauricular , nuchal and sternal . Because of the patient's cardio-pulmonary insufficiency we excised the basaliomas under local anaesthesia . We also made a partial stripped excision of the left-sided parietal parts of the naevus . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Abstract . We report on the case of a 70-year-old caucasian woman with a large linear sebaceous naevus with multifocal intralesional basaliomas and a lipodermoid of the left eye . This rare finding has been preserved because of the special history of the patient . The naevus spread on the left side from parietal to retroauricular , nuchal and sternal . Because of the patient's cardio-pulmonary insufficiency we excised the basaliomas under local anaesthesia . We also made a partial stripped excision of the left-sided parietal parts of the naevus .	[ "Abstract", ".", "We", "report", "on", "the", "case", "of", "a", "70-year", "-", "old", "caucasian", "woman", "with", "a", "large", "linear", "sebaceous", "naevus", "with", "multifocal", "intralesional", "basaliomas", "and", "a", "lipodermoid", "of", "the", "left", "eye", ".", "This", "rare", "finding", "has", "been", "preserved", "because", "of", "the", "special", "history", "of", "the", "patient", ".", "The", "naevus", "spread", "on", "the", "left", "side", "from", "parietal", "to", "retroauricular", ",", "nuchal", "and", "sternal", ".", "Because", "of", "the", "patient", "'s", "cardio", "-", "pulmonary", "insufficiency", "we", "excised", "the", "basaliomas", "under", "local", "anaesthesia", ".", "We", "also", "made", "a", "partial", "stripped", "excision", "of", "the", "left", "-", "sided", "parietal", "parts", "of", "the", "naevus", "." ]	[ "umlsterm" ]
Abstract is an umlsterm, caucasian is an umlsterm, woman is an umlsterm, naevus is an umlsterm, eye is an umlsterm, finding is an umlsterm, history is an umlsterm, patient is an umlsterm, naevus is an umlsterm, local anaesthesia is an umlsterm, naevus is an umlsterm	DerHautarzt.40450719.eng.abstr_task1	Sentence: Abstract . We report on the case of a 70-year-old caucasian woman with a large linear sebaceous naevus with multifocal intralesional basaliomas and a lipodermoid of the left eye . This rare finding has been preserved because of the special history of the patient . The naevus spread on the left side from parietal to retroauricular , nuchal and sternal . Because of the patient's cardio-pulmonary insufficiency we excised the basaliomas under local anaesthesia . We also made a partial stripped excision of the left-sided parietal parts of the naevus . Instructions: please typing these entity words according to sentence: Abstract, caucasian, woman, naevus, eye, finding, history, patient, naevus, local anaesthesia, naevus Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Abstract . We report on the case of a 70-year-old caucasian woman with a large linear sebaceous naevus with multifocal intralesional basaliomas and a lipodermoid of the left eye . This rare finding has been preserved because of the special history of the patient . The naevus spread on the left side from parietal to retroauricular , nuchal and sternal . Because of the patient's cardio-pulmonary insufficiency we excised the basaliomas under local anaesthesia . We also made a partial stripped excision of the left-sided parietal parts of the naevus .	[ "Abstract", ".", "We", "report", "on", "the", "case", "of", "a", "70-year", "-", "old", "caucasian", "woman", "with", "a", "large", "linear", "sebaceous", "naevus", "with", "multifocal", "intralesional", "basaliomas", "and", "a", "lipodermoid", "of", "the", "left", "eye", ".", "This", "rare", "finding", "has", "been", "preserved", "because", "of", "the", "special", "history", "of", "the", "patient", ".", "The", "naevus", "spread", "on", "the", "left", "side", "from", "parietal", "to", "retroauricular", ",", "nuchal", "and", "sternal", ".", "Because", "of", "the", "patient", "'s", "cardio", "-", "pulmonary", "insufficiency", "we", "excised", "the", "basaliomas", "under", "local", "anaesthesia", ".", "We", "also", "made", "a", "partial", "stripped", "excision", "of", "the", "left", "-", "sided", "parietal", "parts", "of", "the", "naevus", "." ]	[ "umlsterm" ]
Abstract, caucasian, woman, naevus, eye, finding, history, patient, naevus, local anaesthesia, naevus	DerHautarzt.40450719.eng.abstr_task2	Sentence: Abstract . We report on the case of a 70-year-old caucasian woman with a large linear sebaceous naevus with multifocal intralesional basaliomas and a lipodermoid of the left eye . This rare finding has been preserved because of the special history of the patient . The naevus spread on the left side from parietal to retroauricular , nuchal and sternal . Because of the patient's cardio-pulmonary insufficiency we excised the basaliomas under local anaesthesia . We also made a partial stripped excision of the left-sided parietal parts of the naevus . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Abstract . We report on the case of a 70-year-old caucasian woman with a large linear sebaceous naevus with multifocal intralesional basaliomas and a lipodermoid of the left eye . This rare finding has been preserved because of the special history of the patient . The naevus spread on the left side from parietal to retroauricular , nuchal and sternal . Because of the patient's cardio-pulmonary insufficiency we excised the basaliomas under local anaesthesia . We also made a partial stripped excision of the left-sided parietal parts of the naevus .	[ "Abstract", ".", "We", "report", "on", "the", "case", "of", "a", "70-year", "-", "old", "caucasian", "woman", "with", "a", "large", "linear", "sebaceous", "naevus", "with", "multifocal", "intralesional", "basaliomas", "and", "a", "lipodermoid", "of", "the", "left", "eye", ".", "This", "rare", "finding", "has", "been", "preserved", "because", "of", "the", "special", "history", "of", "the", "patient", ".", "The", "naevus", "spread", "on", "the", "left", "side", "from", "parietal", "to", "retroauricular", ",", "nuchal", "and", "sternal", ".", "Because", "of", "the", "patient", "'s", "cardio", "-", "pulmonary", "insufficiency", "we", "excised", "the", "basaliomas", "under", "local", "anaesthesia", ".", "We", "also", "made", "a", "partial", "stripped", "excision", "of", "the", "left", "-", "sided", "parietal", "parts", "of", "the", "naevus", "." ]	[ "umlsterm" ]
disease is an umlsterm, Angiokeratoma corporis diffusum is an umlsterm, disorder is an umlsterm, defect is an umlsterm, gene is an umlsterm, alpha - galactosidase is an umlsterm, enzyme is an umlsterm, glycosphingolipids is an umlsterm, deficiency is an umlsterm, smooth muscle is an umlsterm, cells is an umlsterm, time is an umlsterm, angiokeratomas is an umlsterm, complications is an umlsterm, patient is an umlsterm, findings is an umlsterm, nail is an umlsterm, capillary is an umlsterm, Analysis is an umlsterm, concentration is an umlsterm, alpha - galactosidase is an umlsterm, female is an umlsterm, carriers is an umlsterm, family is an umlsterm	DerHautarzt.60470776.eng.abstr_task0	Sentence: Fabry's disease ( Angiokeratoma corporis diffusum ) is a rare X-chromosome linked recessive disorder belonging to the group of sphingolipoidoses . The basic defect involves the gene encoding alpha-galactosidase . Because this enzyme is responsible for decomposition of glycosphingolipids , its deficiency results in their accumulation in endothelial and smooth muscle cells . With time , generalized angiokeratomas , paresthesias , renal and cardiac insufficiency and cerebrovascular complications develop . We report a patient who in addition to the well-described findings also showed unique nail fold capillary changes not described so far . Analysis of serum concentration of alpha-galactosidase identified three female heterozygous carriers in the patient's family . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	Fabry's disease ( Angiokeratoma corporis diffusum ) is a rare X-chromosome linked recessive disorder belonging to the group of sphingolipoidoses . The basic defect involves the gene encoding alpha-galactosidase . Because this enzyme is responsible for decomposition of glycosphingolipids , its deficiency results in their accumulation in endothelial and smooth muscle cells . With time , generalized angiokeratomas , paresthesias , renal and cardiac insufficiency and cerebrovascular complications develop . We report a patient who in addition to the well-described findings also showed unique nail fold capillary changes not described so far . Analysis of serum concentration of alpha-galactosidase identified three female heterozygous carriers in the patient's family .	[ "Fabry", "'s", "disease", "(", "Angiokeratoma", "corporis", "diffusum", ")", "is", "a", "rare", "X", "-", "chromosome", "linked", "recessive", "disorder", "belonging", "to", "the", "group", "of", "sphingolipoidoses", ".", "The", "basic", "defect", "involves", "the", "gene", "encoding", "alpha", "-", "galactosidase", ".", "Because", "this", "enzyme", "is", "responsible", "for", "decomposition", "of", "glycosphingolipids", ",", "its", "deficiency", "results", "in", "their", "accumulation", "in", "endothelial", "and", "smooth", "muscle", "cells", ".", "With", "time", ",", "generalized", "angiokeratomas", ",", "paresthesias", ",", "renal", "and", "cardiac", "insufficiency", "and", "cerebrovascular", "complications", "develop", ".", "We", "report", "a", "patient", "who", "in", "addition", "to", "the", "well", "-", "described", "findings", "also", "showed", "unique", "nail", "fold", "capillary", "changes", "not", "described", "so", "far", ".", "Analysis", "of", "serum", "concentration", "of", "alpha", "-", "galactosidase", "identified", "three", "female", "heterozygous", "carriers", "in", "the", "patient", "'s", "family", "." ]	[ "umlsterm" ]
disease is an umlsterm, Angiokeratoma corporis diffusum is an umlsterm, disorder is an umlsterm, defect is an umlsterm, gene is an umlsterm, alpha - galactosidase is an umlsterm, enzyme is an umlsterm, glycosphingolipids is an umlsterm, deficiency is an umlsterm, smooth muscle is an umlsterm, cells is an umlsterm, time is an umlsterm, angiokeratomas is an umlsterm, complications is an umlsterm, patient is an umlsterm, findings is an umlsterm, nail is an umlsterm, capillary is an umlsterm, Analysis is an umlsterm, concentration is an umlsterm, alpha - galactosidase is an umlsterm, female is an umlsterm, carriers is an umlsterm, family is an umlsterm	DerHautarzt.60470776.eng.abstr_task1	Sentence: Fabry's disease ( Angiokeratoma corporis diffusum ) is a rare X-chromosome linked recessive disorder belonging to the group of sphingolipoidoses . The basic defect involves the gene encoding alpha-galactosidase . Because this enzyme is responsible for decomposition of glycosphingolipids , its deficiency results in their accumulation in endothelial and smooth muscle cells . With time , generalized angiokeratomas , paresthesias , renal and cardiac insufficiency and cerebrovascular complications develop . We report a patient who in addition to the well-described findings also showed unique nail fold capillary changes not described so far . Analysis of serum concentration of alpha-galactosidase identified three female heterozygous carriers in the patient's family . Instructions: please typing these entity words according to sentence: disease, Angiokeratoma corporis diffusum, disorder, defect, gene, alpha - galactosidase, enzyme, glycosphingolipids, deficiency, smooth muscle, cells, time, angiokeratomas, complications, patient, findings, nail, capillary, Analysis, concentration, alpha - galactosidase, female, carriers, family Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	Fabry's disease ( Angiokeratoma corporis diffusum ) is a rare X-chromosome linked recessive disorder belonging to the group of sphingolipoidoses . The basic defect involves the gene encoding alpha-galactosidase . Because this enzyme is responsible for decomposition of glycosphingolipids , its deficiency results in their accumulation in endothelial and smooth muscle cells . With time , generalized angiokeratomas , paresthesias , renal and cardiac insufficiency and cerebrovascular complications develop . We report a patient who in addition to the well-described findings also showed unique nail fold capillary changes not described so far . Analysis of serum concentration of alpha-galactosidase identified three female heterozygous carriers in the patient's family .	[ "Fabry", "'s", "disease", "(", "Angiokeratoma", "corporis", "diffusum", ")", "is", "a", "rare", "X", "-", "chromosome", "linked", "recessive", "disorder", "belonging", "to", "the", "group", "of", "sphingolipoidoses", ".", "The", "basic", "defect", "involves", "the", "gene", "encoding", "alpha", "-", "galactosidase", ".", "Because", "this", "enzyme", "is", "responsible", "for", "decomposition", "of", "glycosphingolipids", ",", "its", "deficiency", "results", "in", "their", "accumulation", "in", "endothelial", "and", "smooth", "muscle", "cells", ".", "With", "time", ",", "generalized", "angiokeratomas", ",", "paresthesias", ",", "renal", "and", "cardiac", "insufficiency", "and", "cerebrovascular", "complications", "develop", ".", "We", "report", "a", "patient", "who", "in", "addition", "to", "the", "well", "-", "described", "findings", "also", "showed", "unique", "nail", "fold", "capillary", "changes", "not", "described", "so", "far", ".", "Analysis", "of", "serum", "concentration", "of", "alpha", "-", "galactosidase", "identified", "three", "female", "heterozygous", "carriers", "in", "the", "patient", "'s", "family", "." ]	[ "umlsterm" ]
disease, Angiokeratoma corporis diffusum, disorder, defect, gene, alpha - galactosidase, enzyme, glycosphingolipids, deficiency, smooth muscle, cells, time, angiokeratomas, complications, patient, findings, nail, capillary, Analysis, concentration, alpha - galactosidase, female, carriers, family	DerHautarzt.60470776.eng.abstr_task2	Sentence: Fabry's disease ( Angiokeratoma corporis diffusum ) is a rare X-chromosome linked recessive disorder belonging to the group of sphingolipoidoses . The basic defect involves the gene encoding alpha-galactosidase . Because this enzyme is responsible for decomposition of glycosphingolipids , its deficiency results in their accumulation in endothelial and smooth muscle cells . With time , generalized angiokeratomas , paresthesias , renal and cardiac insufficiency and cerebrovascular complications develop . We report a patient who in addition to the well-described findings also showed unique nail fold capillary changes not described so far . Analysis of serum concentration of alpha-galactosidase identified three female heterozygous carriers in the patient's family . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	Fabry's disease ( Angiokeratoma corporis diffusum ) is a rare X-chromosome linked recessive disorder belonging to the group of sphingolipoidoses . The basic defect involves the gene encoding alpha-galactosidase . Because this enzyme is responsible for decomposition of glycosphingolipids , its deficiency results in their accumulation in endothelial and smooth muscle cells . With time , generalized angiokeratomas , paresthesias , renal and cardiac insufficiency and cerebrovascular complications develop . We report a patient who in addition to the well-described findings also showed unique nail fold capillary changes not described so far . Analysis of serum concentration of alpha-galactosidase identified three female heterozygous carriers in the patient's family .	[ "Fabry", "'s", "disease", "(", "Angiokeratoma", "corporis", "diffusum", ")", "is", "a", "rare", "X", "-", "chromosome", "linked", "recessive", "disorder", "belonging", "to", "the", "group", "of", "sphingolipoidoses", ".", "The", "basic", "defect", "involves", "the", "gene", "encoding", "alpha", "-", "galactosidase", ".", "Because", "this", "enzyme", "is", "responsible", "for", "decomposition", "of", "glycosphingolipids", ",", "its", "deficiency", "results", "in", "their", "accumulation", "in", "endothelial", "and", "smooth", "muscle", "cells", ".", "With", "time", ",", "generalized", "angiokeratomas", ",", "paresthesias", ",", "renal", "and", "cardiac", "insufficiency", "and", "cerebrovascular", "complications", "develop", ".", "We", "report", "a", "patient", "who", "in", "addition", "to", "the", "well", "-", "described", "findings", "also", "showed", "unique", "nail", "fold", "capillary", "changes", "not", "described", "so", "far", ".", "Analysis", "of", "serum", "concentration", "of", "alpha", "-", "galactosidase", "identified", "three", "female", "heterozygous", "carriers", "in", "the", "patient", "'s", "family", "." ]	[ "umlsterm" ]
Frakturen is an umlsterm, Mittelhandknochen is an umlsterm, Kopfbereich is an umlsterm, Finger is an umlsterm, Gipsruhigstellung is an umlsterm, Frakturstellung is an umlsterm, Patienten is an umlsterm, Frakturen is an umlsterm, Schaftfrakturen is an umlsterm, Platten- is an umlsterm, Frakturen is an umlsterm, Mittelhandknochen is an umlsterm, Patienten is an umlsterm, Fingergelenke is an umlsterm, Hand is an umlsterm, radiologische is an umlsterm, Frakturfragmente is an umlsterm, Frakturen is an umlsterm, Mittelhandknochen is an umlsterm, Kirschner - Draehte is an umlsterm, radiologisch is an umlsterm	Trauma+Berufskrankheit.0002s386.ger.abstr_task0	Sentence: Frakturen der Mittelhandknochen im Schaft- und Kopfbereich sind haeufig disloziert und mit Rotationsfehlern der entsprechenden Finger verbunden . Die alleinige Reposition und Gipsruhigstellung ist oft langwierig und endet nicht immer mit einer optimalen Frakturstellung . Im Zeitraum von Dezember 1997 bis August 1999 wurden in unserem Haus 144 Patienten mit 166 Frakturen im Bereich des Schafts und der distalen Ossa metacarpalia operativ behandelt . Waehrend Schaftfrakturen mittels Schrauben- , Platten- oder Drahtosteosynthesen sowie Fixateur externe therapiert wurden , kamen bei Frakturen der distalen Mittelhandknochen ausschliesslich intramedullaere Kirschner-Draht-Osteosynthesen zur Anwendung . Bei allen Patienten wurden in definierten Zeitraeumen die Bewegungsausmasse der Fingergelenke , die Kraftentwicklung der Hand , die klinische und radiologische Stellung der Frakturfragmente kontrolliert sowie das Ausheilungsergebnis nach dem DASH-Score ( disability of arm/shoulder/hand ) bewertet . Die Ergebnisse zeigen , dass nach Frakturen des Schafts von Mittelhandknochen meist eine sichere knoecherne Konsolidierung bei guten klinischen Befunden erzielt werden konnte . Mit der intramedullaeren Osteosynthese durch modellierte Kirschner-Draehte konnten in fast allen Faellen von distalen Metakarpalfrakturen klinisch und radiologisch sehr gute Ergebnisse erzielt werden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	Frakturen der Mittelhandknochen im Schaft- und Kopfbereich sind haeufig disloziert und mit Rotationsfehlern der entsprechenden Finger verbunden . Die alleinige Reposition und Gipsruhigstellung ist oft langwierig und endet nicht immer mit einer optimalen Frakturstellung . Im Zeitraum von Dezember 1997 bis August 1999 wurden in unserem Haus 144 Patienten mit 166 Frakturen im Bereich des Schafts und der distalen Ossa metacarpalia operativ behandelt . Waehrend Schaftfrakturen mittels Schrauben- , Platten- oder Drahtosteosynthesen sowie Fixateur externe therapiert wurden , kamen bei Frakturen der distalen Mittelhandknochen ausschliesslich intramedullaere Kirschner-Draht-Osteosynthesen zur Anwendung . Bei allen Patienten wurden in definierten Zeitraeumen die Bewegungsausmasse der Fingergelenke , die Kraftentwicklung der Hand , die klinische und radiologische Stellung der Frakturfragmente kontrolliert sowie das Ausheilungsergebnis nach dem DASH-Score ( disability of arm/shoulder/hand ) bewertet . Die Ergebnisse zeigen , dass nach Frakturen des Schafts von Mittelhandknochen meist eine sichere knoecherne Konsolidierung bei guten klinischen Befunden erzielt werden konnte . Mit der intramedullaeren Osteosynthese durch modellierte Kirschner-Draehte konnten in fast allen Faellen von distalen Metakarpalfrakturen klinisch und radiologisch sehr gute Ergebnisse erzielt werden .	[ "Frakturen", "der", "Mittelhandknochen", "im", "Schaft-", "und", "Kopfbereich", "sind", "haeufig", "disloziert", "und", "mit", "Rotationsfehlern", "der", "entsprechenden", "Finger", "verbunden", ".", "Die", "alleinige", "Reposition", "und", "Gipsruhigstellung", "ist", "oft", "langwierig", "und", "endet", "nicht", "immer", "mit", "einer", "optimalen", "Frakturstellung", ".", "Im", "Zeitraum", "von", "Dezember", "1997", "bis", "August", "1999", "wurden", "in", "unserem", "Haus", "144", "Patienten", "mit", "166", "Frakturen", "im", "Bereich", "des", "Schafts", "und", "der", "distalen", "Ossa", "metacarpalia", "operativ", "behandelt", ".", "Waehrend", "Schaftfrakturen", "mittels", "Schrauben-", ",", "Platten-", "oder", "Drahtosteosynthesen", "sowie", "Fixateur", "externe", "therapiert", "wurden", ",", "kamen", "bei", "Frakturen", "der", "distalen", "Mittelhandknochen", "ausschliesslich", "intramedullaere", "Kirschner", "-", "Draht", "-", "Osteosynthesen", "zur", "Anwendung", ".", "Bei", "allen", "Patienten", "wurden", "in", "definierten", "Zeitraeumen", "die", "Bewegungsausmasse", "der", "Fingergelenke", ",", "die", "Kraftentwicklung", "der", "Hand", ",", "die", "klinische", "und", "radiologische", "Stellung", "der", "Frakturfragmente", "kontrolliert", "sowie", "das", "Ausheilungsergebnis", "nach", "dem", "DASH", "-", "Score", "(", "disability", "of", "arm", "/", "shoulder", "/", "hand", ")", "bewertet", ".", "Die", "Ergebnisse", "zeigen", ",", "dass", "nach", "Frakturen", "des", "Schafts", "von", "Mittelhandknochen", "meist", "eine", "sichere", "knoecherne", "Konsolidierung", "bei", "guten", "klinischen", "Befunden", "erzielt", "werden", "konnte", ".", "Mit", "der", "intramedullaeren", "Osteosynthese", "durch", "modellierte", "Kirschner", "-", "Draehte", "konnten", "in", "fast", "allen", "Faellen", "von", "distalen", "Metakarpalfrakturen", "klinisch", "und", "radiologisch", "sehr", "gute", "Ergebnisse", "erzielt", "werden", "." ]	[ "umlsterm" ]
Frakturen is an umlsterm, Mittelhandknochen is an umlsterm, Kopfbereich is an umlsterm, Finger is an umlsterm, Gipsruhigstellung is an umlsterm, Frakturstellung is an umlsterm, Patienten is an umlsterm, Frakturen is an umlsterm, Schaftfrakturen is an umlsterm, Platten- is an umlsterm, Frakturen is an umlsterm, Mittelhandknochen is an umlsterm, Patienten is an umlsterm, Fingergelenke is an umlsterm, Hand is an umlsterm, radiologische is an umlsterm, Frakturfragmente is an umlsterm, Frakturen is an umlsterm, Mittelhandknochen is an umlsterm, Kirschner - Draehte is an umlsterm, radiologisch is an umlsterm	Trauma+Berufskrankheit.0002s386.ger.abstr_task1	Sentence: Frakturen der Mittelhandknochen im Schaft- und Kopfbereich sind haeufig disloziert und mit Rotationsfehlern der entsprechenden Finger verbunden . Die alleinige Reposition und Gipsruhigstellung ist oft langwierig und endet nicht immer mit einer optimalen Frakturstellung . Im Zeitraum von Dezember 1997 bis August 1999 wurden in unserem Haus 144 Patienten mit 166 Frakturen im Bereich des Schafts und der distalen Ossa metacarpalia operativ behandelt . Waehrend Schaftfrakturen mittels Schrauben- , Platten- oder Drahtosteosynthesen sowie Fixateur externe therapiert wurden , kamen bei Frakturen der distalen Mittelhandknochen ausschliesslich intramedullaere Kirschner-Draht-Osteosynthesen zur Anwendung . Bei allen Patienten wurden in definierten Zeitraeumen die Bewegungsausmasse der Fingergelenke , die Kraftentwicklung der Hand , die klinische und radiologische Stellung der Frakturfragmente kontrolliert sowie das Ausheilungsergebnis nach dem DASH-Score ( disability of arm/shoulder/hand ) bewertet . Die Ergebnisse zeigen , dass nach Frakturen des Schafts von Mittelhandknochen meist eine sichere knoecherne Konsolidierung bei guten klinischen Befunden erzielt werden konnte . Mit der intramedullaeren Osteosynthese durch modellierte Kirschner-Draehte konnten in fast allen Faellen von distalen Metakarpalfrakturen klinisch und radiologisch sehr gute Ergebnisse erzielt werden . Instructions: please typing these entity words according to sentence: Frakturen, Mittelhandknochen, Kopfbereich, Finger, Gipsruhigstellung, Frakturstellung, Patienten, Frakturen, Schaftfrakturen, Platten-, Frakturen, Mittelhandknochen, Patienten, Fingergelenke, Hand, radiologische, Frakturfragmente, Frakturen, Mittelhandknochen, Kirschner - Draehte, radiologisch Options: umlsterm	[ "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	Frakturen der Mittelhandknochen im Schaft- und Kopfbereich sind haeufig disloziert und mit Rotationsfehlern der entsprechenden Finger verbunden . Die alleinige Reposition und Gipsruhigstellung ist oft langwierig und endet nicht immer mit einer optimalen Frakturstellung . Im Zeitraum von Dezember 1997 bis August 1999 wurden in unserem Haus 144 Patienten mit 166 Frakturen im Bereich des Schafts und der distalen Ossa metacarpalia operativ behandelt . Waehrend Schaftfrakturen mittels Schrauben- , Platten- oder Drahtosteosynthesen sowie Fixateur externe therapiert wurden , kamen bei Frakturen der distalen Mittelhandknochen ausschliesslich intramedullaere Kirschner-Draht-Osteosynthesen zur Anwendung . Bei allen Patienten wurden in definierten Zeitraeumen die Bewegungsausmasse der Fingergelenke , die Kraftentwicklung der Hand , die klinische und radiologische Stellung der Frakturfragmente kontrolliert sowie das Ausheilungsergebnis nach dem DASH-Score ( disability of arm/shoulder/hand ) bewertet . Die Ergebnisse zeigen , dass nach Frakturen des Schafts von Mittelhandknochen meist eine sichere knoecherne Konsolidierung bei guten klinischen Befunden erzielt werden konnte . Mit der intramedullaeren Osteosynthese durch modellierte Kirschner-Draehte konnten in fast allen Faellen von distalen Metakarpalfrakturen klinisch und radiologisch sehr gute Ergebnisse erzielt werden .	[ "Frakturen", "der", "Mittelhandknochen", "im", "Schaft-", "und", "Kopfbereich", "sind", "haeufig", "disloziert", "und", "mit", "Rotationsfehlern", "der", "entsprechenden", "Finger", "verbunden", ".", "Die", "alleinige", "Reposition", "und", "Gipsruhigstellung", "ist", "oft", "langwierig", "und", "endet", "nicht", "immer", "mit", "einer", "optimalen", "Frakturstellung", ".", "Im", "Zeitraum", "von", "Dezember", "1997", "bis", "August", "1999", "wurden", "in", "unserem", "Haus", "144", "Patienten", "mit", "166", "Frakturen", "im", "Bereich", "des", "Schafts", "und", "der", "distalen", "Ossa", "metacarpalia", "operativ", "behandelt", ".", "Waehrend", "Schaftfrakturen", "mittels", "Schrauben-", ",", "Platten-", "oder", "Drahtosteosynthesen", "sowie", "Fixateur", "externe", "therapiert", "wurden", ",", "kamen", "bei", "Frakturen", "der", "distalen", "Mittelhandknochen", "ausschliesslich", "intramedullaere", "Kirschner", "-", "Draht", "-", "Osteosynthesen", "zur", "Anwendung", ".", "Bei", "allen", "Patienten", "wurden", "in", "definierten", "Zeitraeumen", "die", "Bewegungsausmasse", "der", "Fingergelenke", ",", "die", "Kraftentwicklung", "der", "Hand", ",", "die", "klinische", "und", "radiologische", "Stellung", "der", "Frakturfragmente", "kontrolliert", "sowie", "das", "Ausheilungsergebnis", "nach", "dem", "DASH", "-", "Score", "(", "disability", "of", "arm", "/", "shoulder", "/", "hand", ")", "bewertet", ".", "Die", "Ergebnisse", "zeigen", ",", "dass", "nach", "Frakturen", "des", "Schafts", "von", "Mittelhandknochen", "meist", "eine", "sichere", "knoecherne", "Konsolidierung", "bei", "guten", "klinischen", "Befunden", "erzielt", "werden", "konnte", ".", "Mit", "der", "intramedullaeren", "Osteosynthese", "durch", "modellierte", "Kirschner", "-", "Draehte", "konnten", "in", "fast", "allen", "Faellen", "von", "distalen", "Metakarpalfrakturen", "klinisch", "und", "radiologisch", "sehr", "gute", "Ergebnisse", "erzielt", "werden", "." ]	[ "umlsterm" ]
Frakturen, Mittelhandknochen, Kopfbereich, Finger, Gipsruhigstellung, Frakturstellung, Patienten, Frakturen, Schaftfrakturen, Platten-, Frakturen, Mittelhandknochen, Patienten, Fingergelenke, Hand, radiologische, Frakturfragmente, Frakturen, Mittelhandknochen, Kirschner - Draehte, radiologisch	Trauma+Berufskrankheit.0002s386.ger.abstr_task2	Sentence: Frakturen der Mittelhandknochen im Schaft- und Kopfbereich sind haeufig disloziert und mit Rotationsfehlern der entsprechenden Finger verbunden . Die alleinige Reposition und Gipsruhigstellung ist oft langwierig und endet nicht immer mit einer optimalen Frakturstellung . Im Zeitraum von Dezember 1997 bis August 1999 wurden in unserem Haus 144 Patienten mit 166 Frakturen im Bereich des Schafts und der distalen Ossa metacarpalia operativ behandelt . Waehrend Schaftfrakturen mittels Schrauben- , Platten- oder Drahtosteosynthesen sowie Fixateur externe therapiert wurden , kamen bei Frakturen der distalen Mittelhandknochen ausschliesslich intramedullaere Kirschner-Draht-Osteosynthesen zur Anwendung . Bei allen Patienten wurden in definierten Zeitraeumen die Bewegungsausmasse der Fingergelenke , die Kraftentwicklung der Hand , die klinische und radiologische Stellung der Frakturfragmente kontrolliert sowie das Ausheilungsergebnis nach dem DASH-Score ( disability of arm/shoulder/hand ) bewertet . Die Ergebnisse zeigen , dass nach Frakturen des Schafts von Mittelhandknochen meist eine sichere knoecherne Konsolidierung bei guten klinischen Befunden erzielt werden konnte . Mit der intramedullaeren Osteosynthese durch modellierte Kirschner-Draehte konnten in fast allen Faellen von distalen Metakarpalfrakturen klinisch und radiologisch sehr gute Ergebnisse erzielt werden . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	Frakturen der Mittelhandknochen im Schaft- und Kopfbereich sind haeufig disloziert und mit Rotationsfehlern der entsprechenden Finger verbunden . Die alleinige Reposition und Gipsruhigstellung ist oft langwierig und endet nicht immer mit einer optimalen Frakturstellung . Im Zeitraum von Dezember 1997 bis August 1999 wurden in unserem Haus 144 Patienten mit 166 Frakturen im Bereich des Schafts und der distalen Ossa metacarpalia operativ behandelt . Waehrend Schaftfrakturen mittels Schrauben- , Platten- oder Drahtosteosynthesen sowie Fixateur externe therapiert wurden , kamen bei Frakturen der distalen Mittelhandknochen ausschliesslich intramedullaere Kirschner-Draht-Osteosynthesen zur Anwendung . Bei allen Patienten wurden in definierten Zeitraeumen die Bewegungsausmasse der Fingergelenke , die Kraftentwicklung der Hand , die klinische und radiologische Stellung der Frakturfragmente kontrolliert sowie das Ausheilungsergebnis nach dem DASH-Score ( disability of arm/shoulder/hand ) bewertet . Die Ergebnisse zeigen , dass nach Frakturen des Schafts von Mittelhandknochen meist eine sichere knoecherne Konsolidierung bei guten klinischen Befunden erzielt werden konnte . Mit der intramedullaeren Osteosynthese durch modellierte Kirschner-Draehte konnten in fast allen Faellen von distalen Metakarpalfrakturen klinisch und radiologisch sehr gute Ergebnisse erzielt werden .	[ "Frakturen", "der", "Mittelhandknochen", "im", "Schaft-", "und", "Kopfbereich", "sind", "haeufig", "disloziert", "und", "mit", "Rotationsfehlern", "der", "entsprechenden", "Finger", "verbunden", ".", "Die", "alleinige", "Reposition", "und", "Gipsruhigstellung", "ist", "oft", "langwierig", "und", "endet", "nicht", "immer", "mit", "einer", "optimalen", "Frakturstellung", ".", "Im", "Zeitraum", "von", "Dezember", "1997", "bis", "August", "1999", "wurden", "in", "unserem", "Haus", "144", "Patienten", "mit", "166", "Frakturen", "im", "Bereich", "des", "Schafts", "und", "der", "distalen", "Ossa", "metacarpalia", "operativ", "behandelt", ".", "Waehrend", "Schaftfrakturen", "mittels", "Schrauben-", ",", "Platten-", "oder", "Drahtosteosynthesen", "sowie", "Fixateur", "externe", "therapiert", "wurden", ",", "kamen", "bei", "Frakturen", "der", "distalen", "Mittelhandknochen", "ausschliesslich", "intramedullaere", "Kirschner", "-", "Draht", "-", "Osteosynthesen", "zur", "Anwendung", ".", "Bei", "allen", "Patienten", "wurden", "in", "definierten", "Zeitraeumen", "die", "Bewegungsausmasse", "der", "Fingergelenke", ",", "die", "Kraftentwicklung", "der", "Hand", ",", "die", "klinische", "und", "radiologische", "Stellung", "der", "Frakturfragmente", "kontrolliert", "sowie", "das", "Ausheilungsergebnis", "nach", "dem", "DASH", "-", "Score", "(", "disability", "of", "arm", "/", "shoulder", "/", "hand", ")", "bewertet", ".", "Die", "Ergebnisse", "zeigen", ",", "dass", "nach", "Frakturen", "des", "Schafts", "von", "Mittelhandknochen", "meist", "eine", "sichere", "knoecherne", "Konsolidierung", "bei", "guten", "klinischen", "Befunden", "erzielt", "werden", "konnte", ".", "Mit", "der", "intramedullaeren", "Osteosynthese", "durch", "modellierte", "Kirschner", "-", "Draehte", "konnten", "in", "fast", "allen", "Faellen", "von", "distalen", "Metakarpalfrakturen", "klinisch", "und", "radiologisch", "sehr", "gute", "Ergebnisse", "erzielt", "werden", "." ]	[ "umlsterm" ]
alpha catenin is a Gene/protein/RNA, beta catenin is a Gene/protein/RNA, gamma catenin is a Gene/protein/RNA	847_task0	Sentence: Treatment of cells with gamma linolenic acid (GLA) increased alpha catenin expression in most cell lines, while beta catenin levels were reduced, and gamma catenin expression was unchanged. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene/protein/RNA	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O" ]	Treatment of cells with gamma linolenic acid (GLA) increased alpha catenin expression in most cell lines, while beta catenin levels were reduced, and gamma catenin expression was unchanged.	[ "Treatment", "of", "cells", "with", "gamma", "linolenic", "acid", "(", "GLA", ")", "increased", "alpha", "catenin", "expression", "in", "most", "cell", "lines", ",", "while", "beta", "catenin", "levels", "were", "reduced", ",", "and", "gamma", "catenin", "expression", "was", "unchanged", "." ]	[ "Gene/protein/RNA" ]
alpha catenin is a Gene/protein/RNA, beta catenin is a Gene/protein/RNA, gamma catenin is a Gene/protein/RNA	847_task1	Sentence: Treatment of cells with gamma linolenic acid (GLA) increased alpha catenin expression in most cell lines, while beta catenin levels were reduced, and gamma catenin expression was unchanged. Instructions: please typing these entity words according to sentence: alpha catenin, beta catenin, gamma catenin Options: Gene/protein/RNA	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O" ]	Treatment of cells with gamma linolenic acid (GLA) increased alpha catenin expression in most cell lines, while beta catenin levels were reduced, and gamma catenin expression was unchanged.	[ "Treatment", "of", "cells", "with", "gamma", "linolenic", "acid", "(", "GLA", ")", "increased", "alpha", "catenin", "expression", "in", "most", "cell", "lines", ",", "while", "beta", "catenin", "levels", "were", "reduced", ",", "and", "gamma", "catenin", "expression", "was", "unchanged", "." ]	[ "Gene/protein/RNA" ]
alpha catenin, beta catenin, gamma catenin	847_task2	Sentence: Treatment of cells with gamma linolenic acid (GLA) increased alpha catenin expression in most cell lines, while beta catenin levels were reduced, and gamma catenin expression was unchanged. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O" ]	Treatment of cells with gamma linolenic acid (GLA) increased alpha catenin expression in most cell lines, while beta catenin levels were reduced, and gamma catenin expression was unchanged.	[ "Treatment", "of", "cells", "with", "gamma", "linolenic", "acid", "(", "GLA", ")", "increased", "alpha", "catenin", "expression", "in", "most", "cell", "lines", ",", "while", "beta", "catenin", "levels", "were", "reduced", ",", "and", "gamma", "catenin", "expression", "was", "unchanged", "." ]	[ "Gene/protein/RNA" ]
X - chromosome inactivation is an other_name, human androgen receptor gene is a DNA_domain_or_region, Humara is a DNA_domain_or_region, chronic myeloproliferative diseases is an other_name, secondary neutrophilia is an other_name, reactive thrombocytosis is an other_name	41696_task0	Sentence: Clonality analysis using X-chromosome inactivation at the human androgen receptor gene (Humara). Evaluation of large cohorts of patients with chronic myeloproliferative diseases, secondary neutrophilia, and reactive thrombocytosis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA_domain_or_region, other_name	[ "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "O", "O", "B-other_name", "I-other_name", "O" ]	Clonality analysis using X-chromosome inactivation at the human androgen receptor gene (Humara). Evaluation of large cohorts of patients with chronic myeloproliferative diseases, secondary neutrophilia, and reactive thrombocytosis.	[ "Clonality", "analysis", "using", "X", "-", "chromosome", "inactivation", "at", "the", "human", "androgen", "receptor", "gene", "(", "Humara", ")", ".", "Evaluation", "of", "large", "cohorts", "of", "patients", "with", "chronic", "myeloproliferative", "diseases", ",", "secondary", "neutrophilia", ",", "and", "reactive", "thrombocytosis", "." ]	[ "other_name", "(OR other_name other_name)", "DNA_domain_or_region", "multi_cell", "", "DNA_molecule" ]
X - chromosome inactivation is an other_name, human androgen receptor gene is a DNA_domain_or_region, Humara is a DNA_domain_or_region, chronic myeloproliferative diseases is an other_name, secondary neutrophilia is an other_name, reactive thrombocytosis is an other_name	41696_task1	Sentence: Clonality analysis using X-chromosome inactivation at the human androgen receptor gene (Humara). Evaluation of large cohorts of patients with chronic myeloproliferative diseases, secondary neutrophilia, and reactive thrombocytosis. Instructions: please typing these entity words according to sentence: X - chromosome inactivation, human androgen receptor gene, Humara, chronic myeloproliferative diseases, secondary neutrophilia, reactive thrombocytosis Options: DNA_domain_or_region, other_name	[ "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "O", "O", "B-other_name", "I-other_name", "O" ]	Clonality analysis using X-chromosome inactivation at the human androgen receptor gene (Humara). Evaluation of large cohorts of patients with chronic myeloproliferative diseases, secondary neutrophilia, and reactive thrombocytosis.	[ "Clonality", "analysis", "using", "X", "-", "chromosome", "inactivation", "at", "the", "human", "androgen", "receptor", "gene", "(", "Humara", ")", ".", "Evaluation", "of", "large", "cohorts", "of", "patients", "with", "chronic", "myeloproliferative", "diseases", ",", "secondary", "neutrophilia", ",", "and", "reactive", "thrombocytosis", "." ]	[ "other_name", "(OR other_name other_name)", "DNA_domain_or_region", "multi_cell", "", "DNA_molecule" ]
X - chromosome inactivation, human androgen receptor gene, Humara, chronic myeloproliferative diseases, secondary neutrophilia, reactive thrombocytosis	41696_task2	Sentence: Clonality analysis using X-chromosome inactivation at the human androgen receptor gene (Humara). Evaluation of large cohorts of patients with chronic myeloproliferative diseases, secondary neutrophilia, and reactive thrombocytosis. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "O", "O", "B-other_name", "I-other_name", "O" ]	Clonality analysis using X-chromosome inactivation at the human androgen receptor gene (Humara). Evaluation of large cohorts of patients with chronic myeloproliferative diseases, secondary neutrophilia, and reactive thrombocytosis.	[ "Clonality", "analysis", "using", "X", "-", "chromosome", "inactivation", "at", "the", "human", "androgen", "receptor", "gene", "(", "Humara", ")", ".", "Evaluation", "of", "large", "cohorts", "of", "patients", "with", "chronic", "myeloproliferative", "diseases", ",", "secondary", "neutrophilia", ",", "and", "reactive", "thrombocytosis", "." ]	[ "other_name", "(OR other_name other_name)", "DNA_domain_or_region", "multi_cell", "", "DNA_molecule" ]
Triebkopf is an umlsterm, Personen is an umlsterm, Unfallereignis is an umlsterm, Unfall is an umlsterm, Unfallgeschehen is an umlsterm, Organisationen is an umlsterm, Personen is an umlsterm, Luftfahrzeuge is an umlsterm, Unfallstelle is an umlsterm, Patienten is an umlsterm, Unfallstelle is an umlsterm, Patienten is an umlsterm, Zielkrankenhaeuser is an umlsterm, Unfallgeschehens is an umlsterm, Luftrettung is an umlsterm, Organisationen is an umlsterm, Polizei is an umlsterm, Katastropheneinsatzleitung is an umlsterm	DerUnfallchirurg.81010813.ger.abstr_task0	Sentence: Am 03.06.1998 , 10.59 Uhr verunfallte ein ICE-Zug bei einer Geschwindigkeit von 200 km/h . Durch eine eingestuerzte Bruecke wurden die Wagen teilweise ziehharmonikaartig durch den hinteren Triebkopf zusammengequetscht . Die Zahl der Toten betrug 101 , 103 Personen wurden verletzt . 4 Minuten nach dem Unfallereignis wurde Alarm gegeben und 16 Minuten nach dem Unfall traf der 1. Notarzt aus dem ca. 20 km entfernten Celle ein . In den ersten 4 Stunden nach dem Unfallgeschehen kamen aus den unterschiedlichsten Organisationen 1.844 Personen zum Einsatz , davon 467 aus dem Rettungs- und Sanitaetsdienst . 39 Luftfahrzeuge standen an der Unfallstelle zur Verfuegung . Die eingeklemmten Schwerverletzten mussten z . T. muehevoll aus zertruemmerten Wagen befreit werden , dennoch befanden sich alle Patienten um 12.55 Uhr mit einer Ausnahme auf dem Weg in die Kliniken . Die Verletzten wurden dezentral auf insgesamt 22 Kliniken verteilt . 95 wurden tot an der Unfallstelle geborgen . 2 Patienten wurden aus medizinischer Indikation verlegt . Dies spricht fuer eine korrekte Auswahl der Zielkrankenhaeuser . Fuer die schnellen Rettungszeiten und den Erfolg in Eschede waren neben den guenstigen aeusseren Umstaenden wie klare Sicht , Zeitpunkt des Unfallgeschehens , Einsatz der Luftrettung , die grosse Zahl von Notaerzten , Rettungs- und Sanitaetspersonal und das hervorragende Zusammenwirken der verschiedenen Organisationen , insbesondere der Feuerwehr , des technischen Hilfswerks , der Bundeswehr , der Polizei , des Bundesgrenzschutzes und der Katastropheneinsatzleitung entscheidend . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Am 03.06.1998 , 10.59 Uhr verunfallte ein ICE-Zug bei einer Geschwindigkeit von 200 km/h . Durch eine eingestuerzte Bruecke wurden die Wagen teilweise ziehharmonikaartig durch den hinteren Triebkopf zusammengequetscht . Die Zahl der Toten betrug 101 , 103 Personen wurden verletzt . 4 Minuten nach dem Unfallereignis wurde Alarm gegeben und 16 Minuten nach dem Unfall traf der 1. Notarzt aus dem ca. 20 km entfernten Celle ein . In den ersten 4 Stunden nach dem Unfallgeschehen kamen aus den unterschiedlichsten Organisationen 1.844 Personen zum Einsatz , davon 467 aus dem Rettungs- und Sanitaetsdienst . 39 Luftfahrzeuge standen an der Unfallstelle zur Verfuegung . Die eingeklemmten Schwerverletzten mussten z . T. muehevoll aus zertruemmerten Wagen befreit werden , dennoch befanden sich alle Patienten um 12.55 Uhr mit einer Ausnahme auf dem Weg in die Kliniken . Die Verletzten wurden dezentral auf insgesamt 22 Kliniken verteilt . 95 wurden tot an der Unfallstelle geborgen . 2 Patienten wurden aus medizinischer Indikation verlegt . Dies spricht fuer eine korrekte Auswahl der Zielkrankenhaeuser . Fuer die schnellen Rettungszeiten und den Erfolg in Eschede waren neben den guenstigen aeusseren Umstaenden wie klare Sicht , Zeitpunkt des Unfallgeschehens , Einsatz der Luftrettung , die grosse Zahl von Notaerzten , Rettungs- und Sanitaetspersonal und das hervorragende Zusammenwirken der verschiedenen Organisationen , insbesondere der Feuerwehr , des technischen Hilfswerks , der Bundeswehr , der Polizei , des Bundesgrenzschutzes und der Katastropheneinsatzleitung entscheidend .	[ "Am", "03.06.1998", ",", "10.59", "Uhr", "verunfallte", "ein", "ICE", "-", "Zug", "bei", "einer", "Geschwindigkeit", "von", "200", "km", "/", "h", ".", "Durch", "eine", "eingestuerzte", "Bruecke", "wurden", "die", "Wagen", "teilweise", "ziehharmonikaartig", "durch", "den", "hinteren", "Triebkopf", "zusammengequetscht", ".", "Die", "Zahl", "der", "Toten", "betrug", "101", ",", "103", "Personen", "wurden", "verletzt", ".", "4", "Minuten", "nach", "dem", "Unfallereignis", "wurde", "Alarm", "gegeben", "und", "16", "Minuten", "nach", "dem", "Unfall", "traf", "der", "1", ".", "Notarzt", "aus", "dem", "ca", ".", "20", "km", "entfernten", "Celle", "ein", ".", "In", "den", "ersten", "4", "Stunden", "nach", "dem", "Unfallgeschehen", "kamen", "aus", "den", "unterschiedlichsten", "Organisationen", "1.844", "Personen", "zum", "Einsatz", ",", "davon", "467", "aus", "dem", "Rettungs-", "und", "Sanitaetsdienst", ".", "39", "Luftfahrzeuge", "standen", "an", "der", "Unfallstelle", "zur", "Verfuegung", ".", "Die", "eingeklemmten", "Schwerverletzten", "mussten", "z", ".", "T.", "muehevoll", "aus", "zertruemmerten", "Wagen", "befreit", "werden", ",", "dennoch", "befanden", "sich", "alle", "Patienten", "um", "12.55", "Uhr", "mit", "einer", "Ausnahme", "auf", "dem", "Weg", "in", "die", "Kliniken", ".", "Die", "Verletzten", "wurden", "dezentral", "auf", "insgesamt", "22", "Kliniken", "verteilt", ".", "95", "wurden", "tot", "an", "der", "Unfallstelle", "geborgen", ".", "2", "Patienten", "wurden", "aus", "medizinischer", "Indikation", "verlegt", ".", "Dies", "spricht", "fuer", "eine", "korrekte", "Auswahl", "der", "Zielkrankenhaeuser", ".", "Fuer", "die", "schnellen", "Rettungszeiten", "und", "den", "Erfolg", "in", "Eschede", "waren", "neben", "den", "guenstigen", "aeusseren", "Umstaenden", "wie", "klare", "Sicht", ",", "Zeitpunkt", "des", "Unfallgeschehens", ",", "Einsatz", "der", "Luftrettung", ",", "die", "grosse", "Zahl", "von", "Notaerzten", ",", "Rettungs-", "und", "Sanitaetspersonal", "und", "das", "hervorragende", "Zusammenwirken", "der", "verschiedenen", "Organisationen", ",", "insbesondere", "der", "Feuerwehr", ",", "des", "technischen", "Hilfswerks", ",", "der", "Bundeswehr", ",", "der", "Polizei", ",", "des", "Bundesgrenzschutzes", "und", "der", "Katastropheneinsatzleitung", "entscheidend", "." ]	[ "umlsterm" ]
Triebkopf is an umlsterm, Personen is an umlsterm, Unfallereignis is an umlsterm, Unfall is an umlsterm, Unfallgeschehen is an umlsterm, Organisationen is an umlsterm, Personen is an umlsterm, Luftfahrzeuge is an umlsterm, Unfallstelle is an umlsterm, Patienten is an umlsterm, Unfallstelle is an umlsterm, Patienten is an umlsterm, Zielkrankenhaeuser is an umlsterm, Unfallgeschehens is an umlsterm, Luftrettung is an umlsterm, Organisationen is an umlsterm, Polizei is an umlsterm, Katastropheneinsatzleitung is an umlsterm	DerUnfallchirurg.81010813.ger.abstr_task1	Sentence: Am 03.06.1998 , 10.59 Uhr verunfallte ein ICE-Zug bei einer Geschwindigkeit von 200 km/h . Durch eine eingestuerzte Bruecke wurden die Wagen teilweise ziehharmonikaartig durch den hinteren Triebkopf zusammengequetscht . Die Zahl der Toten betrug 101 , 103 Personen wurden verletzt . 4 Minuten nach dem Unfallereignis wurde Alarm gegeben und 16 Minuten nach dem Unfall traf der 1. Notarzt aus dem ca. 20 km entfernten Celle ein . In den ersten 4 Stunden nach dem Unfallgeschehen kamen aus den unterschiedlichsten Organisationen 1.844 Personen zum Einsatz , davon 467 aus dem Rettungs- und Sanitaetsdienst . 39 Luftfahrzeuge standen an der Unfallstelle zur Verfuegung . Die eingeklemmten Schwerverletzten mussten z . T. muehevoll aus zertruemmerten Wagen befreit werden , dennoch befanden sich alle Patienten um 12.55 Uhr mit einer Ausnahme auf dem Weg in die Kliniken . Die Verletzten wurden dezentral auf insgesamt 22 Kliniken verteilt . 95 wurden tot an der Unfallstelle geborgen . 2 Patienten wurden aus medizinischer Indikation verlegt . Dies spricht fuer eine korrekte Auswahl der Zielkrankenhaeuser . Fuer die schnellen Rettungszeiten und den Erfolg in Eschede waren neben den guenstigen aeusseren Umstaenden wie klare Sicht , Zeitpunkt des Unfallgeschehens , Einsatz der Luftrettung , die grosse Zahl von Notaerzten , Rettungs- und Sanitaetspersonal und das hervorragende Zusammenwirken der verschiedenen Organisationen , insbesondere der Feuerwehr , des technischen Hilfswerks , der Bundeswehr , der Polizei , des Bundesgrenzschutzes und der Katastropheneinsatzleitung entscheidend . Instructions: please typing these entity words according to sentence: Triebkopf, Personen, Unfallereignis, Unfall, Unfallgeschehen, Organisationen, Personen, Luftfahrzeuge, Unfallstelle, Patienten, Unfallstelle, Patienten, Zielkrankenhaeuser, Unfallgeschehens, Luftrettung, Organisationen, Polizei, Katastropheneinsatzleitung Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Am 03.06.1998 , 10.59 Uhr verunfallte ein ICE-Zug bei einer Geschwindigkeit von 200 km/h . Durch eine eingestuerzte Bruecke wurden die Wagen teilweise ziehharmonikaartig durch den hinteren Triebkopf zusammengequetscht . Die Zahl der Toten betrug 101 , 103 Personen wurden verletzt . 4 Minuten nach dem Unfallereignis wurde Alarm gegeben und 16 Minuten nach dem Unfall traf der 1. Notarzt aus dem ca. 20 km entfernten Celle ein . In den ersten 4 Stunden nach dem Unfallgeschehen kamen aus den unterschiedlichsten Organisationen 1.844 Personen zum Einsatz , davon 467 aus dem Rettungs- und Sanitaetsdienst . 39 Luftfahrzeuge standen an der Unfallstelle zur Verfuegung . Die eingeklemmten Schwerverletzten mussten z . T. muehevoll aus zertruemmerten Wagen befreit werden , dennoch befanden sich alle Patienten um 12.55 Uhr mit einer Ausnahme auf dem Weg in die Kliniken . Die Verletzten wurden dezentral auf insgesamt 22 Kliniken verteilt . 95 wurden tot an der Unfallstelle geborgen . 2 Patienten wurden aus medizinischer Indikation verlegt . Dies spricht fuer eine korrekte Auswahl der Zielkrankenhaeuser . Fuer die schnellen Rettungszeiten und den Erfolg in Eschede waren neben den guenstigen aeusseren Umstaenden wie klare Sicht , Zeitpunkt des Unfallgeschehens , Einsatz der Luftrettung , die grosse Zahl von Notaerzten , Rettungs- und Sanitaetspersonal und das hervorragende Zusammenwirken der verschiedenen Organisationen , insbesondere der Feuerwehr , des technischen Hilfswerks , der Bundeswehr , der Polizei , des Bundesgrenzschutzes und der Katastropheneinsatzleitung entscheidend .	[ "Am", "03.06.1998", ",", "10.59", "Uhr", "verunfallte", "ein", "ICE", "-", "Zug", "bei", "einer", "Geschwindigkeit", "von", "200", "km", "/", "h", ".", "Durch", "eine", "eingestuerzte", "Bruecke", "wurden", "die", "Wagen", "teilweise", "ziehharmonikaartig", "durch", "den", "hinteren", "Triebkopf", "zusammengequetscht", ".", "Die", "Zahl", "der", "Toten", "betrug", "101", ",", "103", "Personen", "wurden", "verletzt", ".", "4", "Minuten", "nach", "dem", "Unfallereignis", "wurde", "Alarm", "gegeben", "und", "16", "Minuten", "nach", "dem", "Unfall", "traf", "der", "1", ".", "Notarzt", "aus", "dem", "ca", ".", "20", "km", "entfernten", "Celle", "ein", ".", "In", "den", "ersten", "4", "Stunden", "nach", "dem", "Unfallgeschehen", "kamen", "aus", "den", "unterschiedlichsten", "Organisationen", "1.844", "Personen", "zum", "Einsatz", ",", "davon", "467", "aus", "dem", "Rettungs-", "und", "Sanitaetsdienst", ".", "39", "Luftfahrzeuge", "standen", "an", "der", "Unfallstelle", "zur", "Verfuegung", ".", "Die", "eingeklemmten", "Schwerverletzten", "mussten", "z", ".", "T.", "muehevoll", "aus", "zertruemmerten", "Wagen", "befreit", "werden", ",", "dennoch", "befanden", "sich", "alle", "Patienten", "um", "12.55", "Uhr", "mit", "einer", "Ausnahme", "auf", "dem", "Weg", "in", "die", "Kliniken", ".", "Die", "Verletzten", "wurden", "dezentral", "auf", "insgesamt", "22", "Kliniken", "verteilt", ".", "95", "wurden", "tot", "an", "der", "Unfallstelle", "geborgen", ".", "2", "Patienten", "wurden", "aus", "medizinischer", "Indikation", "verlegt", ".", "Dies", "spricht", "fuer", "eine", "korrekte", "Auswahl", "der", "Zielkrankenhaeuser", ".", "Fuer", "die", "schnellen", "Rettungszeiten", "und", "den", "Erfolg", "in", "Eschede", "waren", "neben", "den", "guenstigen", "aeusseren", "Umstaenden", "wie", "klare", "Sicht", ",", "Zeitpunkt", "des", "Unfallgeschehens", ",", "Einsatz", "der", "Luftrettung", ",", "die", "grosse", "Zahl", "von", "Notaerzten", ",", "Rettungs-", "und", "Sanitaetspersonal", "und", "das", "hervorragende", "Zusammenwirken", "der", "verschiedenen", "Organisationen", ",", "insbesondere", "der", "Feuerwehr", ",", "des", "technischen", "Hilfswerks", ",", "der", "Bundeswehr", ",", "der", "Polizei", ",", "des", "Bundesgrenzschutzes", "und", "der", "Katastropheneinsatzleitung", "entscheidend", "." ]	[ "umlsterm" ]
Triebkopf, Personen, Unfallereignis, Unfall, Unfallgeschehen, Organisationen, Personen, Luftfahrzeuge, Unfallstelle, Patienten, Unfallstelle, Patienten, Zielkrankenhaeuser, Unfallgeschehens, Luftrettung, Organisationen, Polizei, Katastropheneinsatzleitung	DerUnfallchirurg.81010813.ger.abstr_task2	Sentence: Am 03.06.1998 , 10.59 Uhr verunfallte ein ICE-Zug bei einer Geschwindigkeit von 200 km/h . Durch eine eingestuerzte Bruecke wurden die Wagen teilweise ziehharmonikaartig durch den hinteren Triebkopf zusammengequetscht . Die Zahl der Toten betrug 101 , 103 Personen wurden verletzt . 4 Minuten nach dem Unfallereignis wurde Alarm gegeben und 16 Minuten nach dem Unfall traf der 1. Notarzt aus dem ca. 20 km entfernten Celle ein . In den ersten 4 Stunden nach dem Unfallgeschehen kamen aus den unterschiedlichsten Organisationen 1.844 Personen zum Einsatz , davon 467 aus dem Rettungs- und Sanitaetsdienst . 39 Luftfahrzeuge standen an der Unfallstelle zur Verfuegung . Die eingeklemmten Schwerverletzten mussten z . T. muehevoll aus zertruemmerten Wagen befreit werden , dennoch befanden sich alle Patienten um 12.55 Uhr mit einer Ausnahme auf dem Weg in die Kliniken . Die Verletzten wurden dezentral auf insgesamt 22 Kliniken verteilt . 95 wurden tot an der Unfallstelle geborgen . 2 Patienten wurden aus medizinischer Indikation verlegt . Dies spricht fuer eine korrekte Auswahl der Zielkrankenhaeuser . Fuer die schnellen Rettungszeiten und den Erfolg in Eschede waren neben den guenstigen aeusseren Umstaenden wie klare Sicht , Zeitpunkt des Unfallgeschehens , Einsatz der Luftrettung , die grosse Zahl von Notaerzten , Rettungs- und Sanitaetspersonal und das hervorragende Zusammenwirken der verschiedenen Organisationen , insbesondere der Feuerwehr , des technischen Hilfswerks , der Bundeswehr , der Polizei , des Bundesgrenzschutzes und der Katastropheneinsatzleitung entscheidend . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Am 03.06.1998 , 10.59 Uhr verunfallte ein ICE-Zug bei einer Geschwindigkeit von 200 km/h . Durch eine eingestuerzte Bruecke wurden die Wagen teilweise ziehharmonikaartig durch den hinteren Triebkopf zusammengequetscht . Die Zahl der Toten betrug 101 , 103 Personen wurden verletzt . 4 Minuten nach dem Unfallereignis wurde Alarm gegeben und 16 Minuten nach dem Unfall traf der 1. Notarzt aus dem ca. 20 km entfernten Celle ein . In den ersten 4 Stunden nach dem Unfallgeschehen kamen aus den unterschiedlichsten Organisationen 1.844 Personen zum Einsatz , davon 467 aus dem Rettungs- und Sanitaetsdienst . 39 Luftfahrzeuge standen an der Unfallstelle zur Verfuegung . Die eingeklemmten Schwerverletzten mussten z . T. muehevoll aus zertruemmerten Wagen befreit werden , dennoch befanden sich alle Patienten um 12.55 Uhr mit einer Ausnahme auf dem Weg in die Kliniken . Die Verletzten wurden dezentral auf insgesamt 22 Kliniken verteilt . 95 wurden tot an der Unfallstelle geborgen . 2 Patienten wurden aus medizinischer Indikation verlegt . Dies spricht fuer eine korrekte Auswahl der Zielkrankenhaeuser . Fuer die schnellen Rettungszeiten und den Erfolg in Eschede waren neben den guenstigen aeusseren Umstaenden wie klare Sicht , Zeitpunkt des Unfallgeschehens , Einsatz der Luftrettung , die grosse Zahl von Notaerzten , Rettungs- und Sanitaetspersonal und das hervorragende Zusammenwirken der verschiedenen Organisationen , insbesondere der Feuerwehr , des technischen Hilfswerks , der Bundeswehr , der Polizei , des Bundesgrenzschutzes und der Katastropheneinsatzleitung entscheidend .	[ "Am", "03.06.1998", ",", "10.59", "Uhr", "verunfallte", "ein", "ICE", "-", "Zug", "bei", "einer", "Geschwindigkeit", "von", "200", "km", "/", "h", ".", "Durch", "eine", "eingestuerzte", "Bruecke", "wurden", "die", "Wagen", "teilweise", "ziehharmonikaartig", "durch", "den", "hinteren", "Triebkopf", "zusammengequetscht", ".", "Die", "Zahl", "der", "Toten", "betrug", "101", ",", "103", "Personen", "wurden", "verletzt", ".", "4", "Minuten", "nach", "dem", "Unfallereignis", "wurde", "Alarm", "gegeben", "und", "16", "Minuten", "nach", "dem", "Unfall", "traf", "der", "1", ".", "Notarzt", "aus", "dem", "ca", ".", "20", "km", "entfernten", "Celle", "ein", ".", "In", "den", "ersten", "4", "Stunden", "nach", "dem", "Unfallgeschehen", "kamen", "aus", "den", "unterschiedlichsten", "Organisationen", "1.844", "Personen", "zum", "Einsatz", ",", "davon", "467", "aus", "dem", "Rettungs-", "und", "Sanitaetsdienst", ".", "39", "Luftfahrzeuge", "standen", "an", "der", "Unfallstelle", "zur", "Verfuegung", ".", "Die", "eingeklemmten", "Schwerverletzten", "mussten", "z", ".", "T.", "muehevoll", "aus", "zertruemmerten", "Wagen", "befreit", "werden", ",", "dennoch", "befanden", "sich", "alle", "Patienten", "um", "12.55", "Uhr", "mit", "einer", "Ausnahme", "auf", "dem", "Weg", "in", "die", "Kliniken", ".", "Die", "Verletzten", "wurden", "dezentral", "auf", "insgesamt", "22", "Kliniken", "verteilt", ".", "95", "wurden", "tot", "an", "der", "Unfallstelle", "geborgen", ".", "2", "Patienten", "wurden", "aus", "medizinischer", "Indikation", "verlegt", ".", "Dies", "spricht", "fuer", "eine", "korrekte", "Auswahl", "der", "Zielkrankenhaeuser", ".", "Fuer", "die", "schnellen", "Rettungszeiten", "und", "den", "Erfolg", "in", "Eschede", "waren", "neben", "den", "guenstigen", "aeusseren", "Umstaenden", "wie", "klare", "Sicht", ",", "Zeitpunkt", "des", "Unfallgeschehens", ",", "Einsatz", "der", "Luftrettung", ",", "die", "grosse", "Zahl", "von", "Notaerzten", ",", "Rettungs-", "und", "Sanitaetspersonal", "und", "das", "hervorragende", "Zusammenwirken", "der", "verschiedenen", "Organisationen", ",", "insbesondere", "der", "Feuerwehr", ",", "des", "technischen", "Hilfswerks", ",", "der", "Bundeswehr", ",", "der", "Polizei", ",", "des", "Bundesgrenzschutzes", "und", "der", "Katastropheneinsatzleitung", "entscheidend", "." ]	[ "umlsterm" ]
thrombogenicity is a ADVERSE, thrombogenicity is a ADVERSE	example-102_task0	Sentence: Risk of thrombogenicity among nonionic radiocontrast agents. Several contrast agents have been approved in the United States for radiographic imaging purposes. Most of the older ionic, high-osmolar contrast agents are no longer used because of their side effect profile. Therefore, newer nonionic, low or iso-osmolar contrast agents have been widely accepted as an alternative due to their improved tolerability and safety. We investigated the thrombogenicity of the 6 different nonionic radiocontrast media in terms of their platelet reactivity and noted some minor differences among them. In the 50% contrast concentration group, all of the nonionic contrast agents inhibited aggregation, whereas in the 10% contrast concentration group, all agents showed similar aggregation curves in comparison to the normal control. At 50% contrast concentration, the inhibitory effect of aggregation appeared to be related to the inhibition of calcium mobilization, which may be one of the mechanistic effects. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: ADVERSE	[ "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Risk of thrombogenicity among nonionic radiocontrast agents. Several contrast agents have been approved in the United States for radiographic imaging purposes. Most of the older ionic, high-osmolar contrast agents are no longer used because of their side effect profile. Therefore, newer nonionic, low or iso-osmolar contrast agents have been widely accepted as an alternative due to their improved tolerability and safety. We investigated the thrombogenicity of the 6 different nonionic radiocontrast media in terms of their platelet reactivity and noted some minor differences among them. In the 50% contrast concentration group, all of the nonionic contrast agents inhibited aggregation, whereas in the 10% contrast concentration group, all agents showed similar aggregation curves in comparison to the normal control. At 50% contrast concentration, the inhibitory effect of aggregation appeared to be related to the inhibition of calcium mobilization, which may be one of the mechanistic effects.	[ "Risk", "of", "thrombogenicity", "among", "nonionic", "radiocontrast", "agents", ".", " ", "Several", "contrast", "agents", "have", "been", "approved", "in", "the", "United", "States", "for", "radiographic", "imaging", "purposes", ".", "Most", "of", "the", "older", "ionic", ",", "high", "-", "osmolar", "contrast", "agents", "are", "no", "longer", "used", "because", "of", "their", "side", "effect", "profile", ".", "Therefore", ",", "newer", "nonionic", ",", "low", "or", "iso", "-", "osmolar", "contrast", "agents", "have", "been", "widely", "accepted", "as", "an", "alternative", "due", "to", "their", "improved", "tolerability", "and", "safety", ".", "We", "investigated", "the", "thrombogenicity", "of", "the", "6", "different", "nonionic", "radiocontrast", "media", "in", "terms", "of", "their", "platelet", "reactivity", "and", "noted", "some", "minor", "differences", "among", "them", ".", "In", "the", "50", "%", "contrast", "concentration", "group", ",", "all", "of", "the", "nonionic", "contrast", "agents", "inhibited", "aggregation", ",", "whereas", "in", "the", "10", "%", "contrast", "concentration", "group", ",", "all", "agents", "showed", "similar", "aggregation", "curves", "in", "comparison", "to", "the", "normal", "control", ".", "At", "50", "%", "contrast", "concentration", ",", "the", "inhibitory", "effect", "of", "aggregation", "appeared", "to", "be", "related", "to", "the", "inhibition", "of", "calcium", "mobilization", ",", "which", "may", "be", "one", "of", "the", "mechanistic", "effects", "." ]	[ "ADVERSE" ]
thrombogenicity is a ADVERSE, thrombogenicity is a ADVERSE	example-102_task1	Sentence: Risk of thrombogenicity among nonionic radiocontrast agents. Several contrast agents have been approved in the United States for radiographic imaging purposes. Most of the older ionic, high-osmolar contrast agents are no longer used because of their side effect profile. Therefore, newer nonionic, low or iso-osmolar contrast agents have been widely accepted as an alternative due to their improved tolerability and safety. We investigated the thrombogenicity of the 6 different nonionic radiocontrast media in terms of their platelet reactivity and noted some minor differences among them. In the 50% contrast concentration group, all of the nonionic contrast agents inhibited aggregation, whereas in the 10% contrast concentration group, all agents showed similar aggregation curves in comparison to the normal control. At 50% contrast concentration, the inhibitory effect of aggregation appeared to be related to the inhibition of calcium mobilization, which may be one of the mechanistic effects. Instructions: please typing these entity words according to sentence: thrombogenicity, thrombogenicity Options: ADVERSE	[ "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Risk of thrombogenicity among nonionic radiocontrast agents. Several contrast agents have been approved in the United States for radiographic imaging purposes. Most of the older ionic, high-osmolar contrast agents are no longer used because of their side effect profile. Therefore, newer nonionic, low or iso-osmolar contrast agents have been widely accepted as an alternative due to their improved tolerability and safety. We investigated the thrombogenicity of the 6 different nonionic radiocontrast media in terms of their platelet reactivity and noted some minor differences among them. In the 50% contrast concentration group, all of the nonionic contrast agents inhibited aggregation, whereas in the 10% contrast concentration group, all agents showed similar aggregation curves in comparison to the normal control. At 50% contrast concentration, the inhibitory effect of aggregation appeared to be related to the inhibition of calcium mobilization, which may be one of the mechanistic effects.	[ "Risk", "of", "thrombogenicity", "among", "nonionic", "radiocontrast", "agents", ".", " ", "Several", "contrast", "agents", "have", "been", "approved", "in", "the", "United", "States", "for", "radiographic", "imaging", "purposes", ".", "Most", "of", "the", "older", "ionic", ",", "high", "-", "osmolar", "contrast", "agents", "are", "no", "longer", "used", "because", "of", "their", "side", "effect", "profile", ".", "Therefore", ",", "newer", "nonionic", ",", "low", "or", "iso", "-", "osmolar", "contrast", "agents", "have", "been", "widely", "accepted", "as", "an", "alternative", "due", "to", "their", "improved", "tolerability", "and", "safety", ".", "We", "investigated", "the", "thrombogenicity", "of", "the", "6", "different", "nonionic", "radiocontrast", "media", "in", "terms", "of", "their", "platelet", "reactivity", "and", "noted", "some", "minor", "differences", "among", "them", ".", "In", "the", "50", "%", "contrast", "concentration", "group", ",", "all", "of", "the", "nonionic", "contrast", "agents", "inhibited", "aggregation", ",", "whereas", "in", "the", "10", "%", "contrast", "concentration", "group", ",", "all", "agents", "showed", "similar", "aggregation", "curves", "in", "comparison", "to", "the", "normal", "control", ".", "At", "50", "%", "contrast", "concentration", ",", "the", "inhibitory", "effect", "of", "aggregation", "appeared", "to", "be", "related", "to", "the", "inhibition", "of", "calcium", "mobilization", ",", "which", "may", "be", "one", "of", "the", "mechanistic", "effects", "." ]	[ "ADVERSE" ]
thrombogenicity, thrombogenicity	example-102_task2	Sentence: Risk of thrombogenicity among nonionic radiocontrast agents. Several contrast agents have been approved in the United States for radiographic imaging purposes. Most of the older ionic, high-osmolar contrast agents are no longer used because of their side effect profile. Therefore, newer nonionic, low or iso-osmolar contrast agents have been widely accepted as an alternative due to their improved tolerability and safety. We investigated the thrombogenicity of the 6 different nonionic radiocontrast media in terms of their platelet reactivity and noted some minor differences among them. In the 50% contrast concentration group, all of the nonionic contrast agents inhibited aggregation, whereas in the 10% contrast concentration group, all agents showed similar aggregation curves in comparison to the normal control. At 50% contrast concentration, the inhibitory effect of aggregation appeared to be related to the inhibition of calcium mobilization, which may be one of the mechanistic effects. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Risk of thrombogenicity among nonionic radiocontrast agents. Several contrast agents have been approved in the United States for radiographic imaging purposes. Most of the older ionic, high-osmolar contrast agents are no longer used because of their side effect profile. Therefore, newer nonionic, low or iso-osmolar contrast agents have been widely accepted as an alternative due to their improved tolerability and safety. We investigated the thrombogenicity of the 6 different nonionic radiocontrast media in terms of their platelet reactivity and noted some minor differences among them. In the 50% contrast concentration group, all of the nonionic contrast agents inhibited aggregation, whereas in the 10% contrast concentration group, all agents showed similar aggregation curves in comparison to the normal control. At 50% contrast concentration, the inhibitory effect of aggregation appeared to be related to the inhibition of calcium mobilization, which may be one of the mechanistic effects.	[ "Risk", "of", "thrombogenicity", "among", "nonionic", "radiocontrast", "agents", ".", " ", "Several", "contrast", "agents", "have", "been", "approved", "in", "the", "United", "States", "for", "radiographic", "imaging", "purposes", ".", "Most", "of", "the", "older", "ionic", ",", "high", "-", "osmolar", "contrast", "agents", "are", "no", "longer", "used", "because", "of", "their", "side", "effect", "profile", ".", "Therefore", ",", "newer", "nonionic", ",", "low", "or", "iso", "-", "osmolar", "contrast", "agents", "have", "been", "widely", "accepted", "as", "an", "alternative", "due", "to", "their", "improved", "tolerability", "and", "safety", ".", "We", "investigated", "the", "thrombogenicity", "of", "the", "6", "different", "nonionic", "radiocontrast", "media", "in", "terms", "of", "their", "platelet", "reactivity", "and", "noted", "some", "minor", "differences", "among", "them", ".", "In", "the", "50", "%", "contrast", "concentration", "group", ",", "all", "of", "the", "nonionic", "contrast", "agents", "inhibited", "aggregation", ",", "whereas", "in", "the", "10", "%", "contrast", "concentration", "group", ",", "all", "agents", "showed", "similar", "aggregation", "curves", "in", "comparison", "to", "the", "normal", "control", ".", "At", "50", "%", "contrast", "concentration", ",", "the", "inhibitory", "effect", "of", "aggregation", "appeared", "to", "be", "related", "to", "the", "inhibition", "of", "calcium", "mobilization", ",", "which", "may", "be", "one", "of", "the", "mechanistic", "effects", "." ]	[ "ADVERSE" ]
cyclic adenosine monophosphate signaling is an other_name, platelets is a cell_type, bipolar disorder is an other_name	45000_task0	Sentence: Abnormalities of cyclic adenosine monophosphate signaling in platelets from untreated patients with bipolar disorder. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_type, other_name	[ "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-cell_type", "O", "O", "O", "O", "B-other_name", "I-other_name", "O" ]	Abnormalities of cyclic adenosine monophosphate signaling in platelets from untreated patients with bipolar disorder.	[ "Abnormalities", "of", "cyclic", "adenosine", "monophosphate", "signaling", "in", "platelets", "from", "untreated", "patients", "with", "bipolar", "disorder", "." ]	[ "other_name", "(AND multi_cell multi_cell multi_cell)", "(AND protein_subunit protein_subunit)", "nucleotide", "protein_family_or_group", "multi_cell", "protein_subunit", "protein_molecule", "", "cell_type" ]
cyclic adenosine monophosphate signaling is an other_name, platelets is a cell_type, bipolar disorder is an other_name	45000_task1	Sentence: Abnormalities of cyclic adenosine monophosphate signaling in platelets from untreated patients with bipolar disorder. Instructions: please typing these entity words according to sentence: cyclic adenosine monophosphate signaling, platelets, bipolar disorder Options: cell_type, other_name	[ "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-cell_type", "O", "O", "O", "O", "B-other_name", "I-other_name", "O" ]	Abnormalities of cyclic adenosine monophosphate signaling in platelets from untreated patients with bipolar disorder.	[ "Abnormalities", "of", "cyclic", "adenosine", "monophosphate", "signaling", "in", "platelets", "from", "untreated", "patients", "with", "bipolar", "disorder", "." ]	[ "other_name", "(AND multi_cell multi_cell multi_cell)", "(AND protein_subunit protein_subunit)", "nucleotide", "protein_family_or_group", "multi_cell", "protein_subunit", "protein_molecule", "", "cell_type" ]
cyclic adenosine monophosphate signaling, platelets, bipolar disorder	45000_task2	Sentence: Abnormalities of cyclic adenosine monophosphate signaling in platelets from untreated patients with bipolar disorder. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-cell_type", "O", "O", "O", "O", "B-other_name", "I-other_name", "O" ]	Abnormalities of cyclic adenosine monophosphate signaling in platelets from untreated patients with bipolar disorder.	[ "Abnormalities", "of", "cyclic", "adenosine", "monophosphate", "signaling", "in", "platelets", "from", "untreated", "patients", "with", "bipolar", "disorder", "." ]	[ "other_name", "(AND multi_cell multi_cell multi_cell)", "(AND protein_subunit protein_subunit)", "nucleotide", "protein_family_or_group", "multi_cell", "protein_subunit", "protein_molecule", "", "cell_type" ]
early enteral nutrition with addition of probiotics is a Intervention_Pharmacological, severe acute pancreatitis is a Participant_Condition, early enteral nutrition ( EN ) supplemented with probiotics ( bifidobacterium ) is a Intervention_Pharmacological, severe acute pancreatitis ( ASP ) is a Participant_Condition, Seventy is a Participant_Sample-size, parenteral nutrition ( PN ) is a Intervention_Pharmacological, bifidobacterium added EN ( P+EN ) is a Intervention_Pharmacological, anti - infection and anti - acid agents is a Intervention_Pharmacological, CRP is a Outcome_Physical, LDH is a Outcome_Physical, amylase is a Outcome_Physical, lipase is a Outcome_Physical, plasma levels of IL-8 , TNF - α is a Outcome_Physical, WBC count is a Outcome_Physical, plasma IL-8 , TNF - α , CRP is a Outcome_Physical, incidence is a Outcome_Adverse-effects, upper gastrointestinal bleeding is a Outcome_Adverse-effects	59514_task0	Sentence: [ The effects of early enteral nutrition with addition of probiotics on the prognosis of patients suffering from severe acute pancreatitis ] . OBJECTIVE To investigate the curative effect of early enteral nutrition ( EN ) supplemented with probiotics ( bifidobacterium ) in patients with severe acute pancreatitis ( ASP ) . METHODS Seventy SAP cases admitted from January 2005 to October 2012 were randomly assigned into parenteral nutrition ( PN ) group ( n=22 ) , EN group ( n=25 ) and bifidobacterium added EN ( P+EN ) group ( n=23 ) . In P+EN group , patients were given their nutrition the same as that of EN , and also probiotics ( bifidobacterium , 4 capsules every 12 hours , given through nasal gastric tube , each capsule weighing 210 mg ) . The routine treatment including anti-infection and anti-acid agents , and that of inhibition of pancreatic secretion were given , except for the different nutritional interventions in all groups . The blood samples were collected for e same measurements of interleukin-8 ( IL-8 ) and tumor necrosis factor ( TNF-α ) by enzyme linked immunosorbent assay ( ELISA ) , and for the C-reactive protein ( CRP ) , lactic acid dehydrogenase ( LDH ) , white blood cell ( WBC ) count , amylase and lipase by biochemistry assay 1 day before intervention of nutrition , and 7 days and 14 days after intervention . Changes in organ function and outcome were also recorded at the same time points . RESULTS The plasma levels of IL-8 , TNF-α , CRP , LDH , WBC count , amylase and lipase were significantly reduced after nutritional intervention compared with their levels on day 1 before intervention in all three groups . The plasma IL-8 , TNF-α , CRP , lipase , LDH at 14 days after intervention of nutrition in P+EN group were significantly lower than those in PN group and EN group ( IL-8 : 21.00 ± 7.07 μg/L vs. 48.00 ± 10.32 μg/L , 32.00 ± 9.30 μg/L ; TNF-α : 44.3 ± 10.9 ng/L vs. 132.1 ± 34.1 ng/L , 67.8 ± 22.3 ng/L ; CRP : 35.0 ± 12.4 mg/L vs. 103.2 ± 49.2 mg/L , 63.0 ± 29.2 mg/L ; lipase : 269 ± 79 U/L vs. 670 ± 145 U/L , 310 ± 78 U/L ; LDH : 21.8 ± 10.3 U/L vs. 78.1 ± 37.4 U/L , 37.9 ± 25.1 U/L , P < 0.05 or P < 0.01 ) . The WBC count in P+EN group was significantly lower than that in PN group ( 5.9 ± 3.0 × 10⁹/L , 6.3 ± 3.2 × 10⁹/L vs. 9.6 ± 3.0 ×10⁹/L , both P < 0.05 ) , but there was no significant difference in amylase between P+EN group and PN group ( 211 ± 49 U/L , 236 ± 52 U/L vs. 298 ± 71 U/L , P > 0.05 ) . The gastrointestinal dysfunction score in P+EN , EN , PN groups 14 days after nutritional intervention was 0.28 ± 0.05 , 0.43 ± 0.09 , 0.71 ± 0.11 , respectively , with statistically significant differences ( all P < 0.01 ) . Compared with PN and EN groups , the incidence of upper gastrointestinal bleeding ( 1 vs. 9 , 2 ) , infection and abscess ( 2 vs. 12 , 5 ) was lower ( all P < 0.01 ) , and hospital day was significantly shortened in P+EN group ( 10.4 ± 3.9 days vs. 25.8 ± 6.4 days , 13.4 ± 5.2 days , both P < 0.01 ) . There was no significant statistical difference in mortality rate among three groups . CONCLUSION Our results indicated that early EN with addition of probiotics ( bifidobacterium ) resulted in significant lowering of the level of pro-inflammatory cytokines , earlier restoration of gastrointestinal function , decrease of complications such as infection , and shortening of hospital day in patients with SAP . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Physical, Participant_Sample-size	[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	[ The effects of early enteral nutrition with addition of probiotics on the prognosis of patients suffering from severe acute pancreatitis ] . OBJECTIVE To investigate the curative effect of early enteral nutrition ( EN ) supplemented with probiotics ( bifidobacterium ) in patients with severe acute pancreatitis ( ASP ) . METHODS Seventy SAP cases admitted from January 2005 to October 2012 were randomly assigned into parenteral nutrition ( PN ) group ( n=22 ) , EN group ( n=25 ) and bifidobacterium added EN ( P+EN ) group ( n=23 ) . In P+EN group , patients were given their nutrition the same as that of EN , and also probiotics ( bifidobacterium , 4 capsules every 12 hours , given through nasal gastric tube , each capsule weighing 210 mg ) . The routine treatment including anti-infection and anti-acid agents , and that of inhibition of pancreatic secretion were given , except for the different nutritional interventions in all groups . The blood samples were collected for e same measurements of interleukin-8 ( IL-8 ) and tumor necrosis factor ( TNF-α ) by enzyme linked immunosorbent assay ( ELISA ) , and for the C-reactive protein ( CRP ) , lactic acid dehydrogenase ( LDH ) , white blood cell ( WBC ) count , amylase and lipase by biochemistry assay 1 day before intervention of nutrition , and 7 days and 14 days after intervention . Changes in organ function and outcome were also recorded at the same time points . RESULTS The plasma levels of IL-8 , TNF-α , CRP , LDH , WBC count , amylase and lipase were significantly reduced after nutritional intervention compared with their levels on day 1 before intervention in all three groups . The plasma IL-8 , TNF-α , CRP , lipase , LDH at 14 days after intervention of nutrition in P+EN group were significantly lower than those in PN group and EN group ( IL-8 : 21.00 ± 7.07 μg/L vs. 48.00 ± 10.32 μg/L , 32.00 ± 9.30 μg/L ; TNF-α : 44.3 ± 10.9 ng/L vs. 132.1 ± 34.1 ng/L , 67.8 ± 22.3 ng/L ; CRP : 35.0 ± 12.4 mg/L vs. 103.2 ± 49.2 mg/L , 63.0 ± 29.2 mg/L ; lipase : 269 ± 79 U/L vs. 670 ± 145 U/L , 310 ± 78 U/L ; LDH : 21.8 ± 10.3 U/L vs. 78.1 ± 37.4 U/L , 37.9 ± 25.1 U/L , P < 0.05 or P < 0.01 ) . The WBC count in P+EN group was significantly lower than that in PN group ( 5.9 ± 3.0 × 10⁹/L , 6.3 ± 3.2 × 10⁹/L vs. 9.6 ± 3.0 ×10⁹/L , both P < 0.05 ) , but there was no significant difference in amylase between P+EN group and PN group ( 211 ± 49 U/L , 236 ± 52 U/L vs. 298 ± 71 U/L , P > 0.05 ) . The gastrointestinal dysfunction score in P+EN , EN , PN groups 14 days after nutritional intervention was 0.28 ± 0.05 , 0.43 ± 0.09 , 0.71 ± 0.11 , respectively , with statistically significant differences ( all P < 0.01 ) . Compared with PN and EN groups , the incidence of upper gastrointestinal bleeding ( 1 vs. 9 , 2 ) , infection and abscess ( 2 vs. 12 , 5 ) was lower ( all P < 0.01 ) , and hospital day was significantly shortened in P+EN group ( 10.4 ± 3.9 days vs. 25.8 ± 6.4 days , 13.4 ± 5.2 days , both P < 0.01 ) . There was no significant statistical difference in mortality rate among three groups . CONCLUSION Our results indicated that early EN with addition of probiotics ( bifidobacterium ) resulted in significant lowering of the level of pro-inflammatory cytokines , earlier restoration of gastrointestinal function , decrease of complications such as infection , and shortening of hospital day in patients with SAP .	[ "[", "The", "effects", "of", "early", "enteral", "nutrition", "with", "addition", "of", "probiotics", "on", "the", "prognosis", "of", "patients", "suffering", "from", "severe", "acute", "pancreatitis", "]", ".", "OBJECTIVE", "To", "investigate", "the", "curative", "effect", "of", "early", "enteral", "nutrition", "(", "EN", ")", "supplemented", "with", "probiotics", "(", "bifidobacterium", ")", "in", "patients", "with", "severe", "acute", "pancreatitis", "(", "ASP", ")", ".", "METHODS", "Seventy", "SAP", "cases", "admitted", "from", "January", "2005", "to", "October", "2012", "were", "randomly", "assigned", "into", "parenteral", "nutrition", "(", "PN", ")", "group", "(", "n=22", ")", ",", "EN", "group", "(", "n=25", ")", "and", "bifidobacterium", "added", "EN", "(", "P+EN", ")", "group", "(", "n=23", ")", ".", "In", "P+EN", "group", ",", "patients", "were", "given", "their", "nutrition", "the", "same", "as", "that", "of", "EN", ",", "and", "also", "probiotics", "(", "bifidobacterium", ",", "4", "capsules", "every", "12", "hours", ",", "given", "through", "nasal", "gastric", "tube", ",", "each", "capsule", "weighing", "210", "mg", ")", ".", "The", "routine", "treatment", "including", "anti", "-", "infection", "and", "anti", "-", "acid", "agents", ",", "and", "that", "of", "inhibition", "of", "pancreatic", "secretion", "were", "given", ",", "except", "for", "the", "different", "nutritional", "interventions", "in", "all", "groups", ".", "The", "blood", "samples", "were", "collected", "for", "e", "same", "measurements", "of", "interleukin-8", "(", "IL-8", ")", "and", "tumor", "necrosis", "factor", "(", "TNF", "-", "α", ")", "by", "enzyme", "linked", "immunosorbent", "assay", "(", "ELISA", ")", ",", "and", "for", "the", "C", "-", "reactive", "protein", "(", "CRP", ")", ",", "lactic", "acid", "dehydrogenase", "(", "LDH", ")", ",", "white", "blood", "cell", "(", "WBC", ")", "count", ",", "amylase", "and", "lipase", "by", "biochemistry", "assay", "1", "day", "before", "intervention", "of", "nutrition", ",", "and", "7", "days", "and", "14", "days", "after", "intervention", ".", "Changes", "in", "organ", "function", "and", "outcome", "were", "also", "recorded", "at", "the", "same", "time", "points", ".", "RESULTS", "The", "plasma", "levels", "of", "IL-8", ",", "TNF", "-", "α", ",", "CRP", ",", "LDH", ",", "WBC", "count", ",", "amylase", "and", "lipase", "were", "significantly", "reduced", "after", "nutritional", "intervention", "compared", "with", "their", "levels", "on", "day", "1", "before", "intervention", "in", "all", "three", "groups", ".", "The", "plasma", "IL-8", ",", "TNF", "-", "α", ",", "CRP", ",", "lipase", ",", "LDH", "at", "14", "days", "after", "intervention", "of", "nutrition", "in", "P+EN", "group", "were", "significantly", "lower", "than", "those", "in", "PN", "group", "and", "EN", "group", "(", "IL-8", ":", "21.00", "±", "7.07", "μg", "/", "L", "vs", ".", "48.00", "±", "10.32", "μg", "/", "L", ",", "32.00", "±", "9.30", "μg", "/", "L", ";", "TNF", "-", "α", ":", "44.3", "±", "10.9", "ng", "/", "L", "vs", ".", "132.1", "±", "34.1", "ng", "/", "L", ",", "67.8", "±", "22.3", "ng", "/", "L", ";", "CRP", ":", "35.0", "±", "12.4", "mg", "/", "L", "vs", ".", "103.2", "±", "49.2", "mg", "/", "L", ",", "63.0", "±", "29.2", "mg", "/", "L", ";", "lipase", ":", "269", "±", "79", "U", "/", "L", "vs", ".", "670", "±", "145", "U", "/", "L", ",", "310", "±", "78", "U", "/", "L", ";", "LDH", ":", "21.8", "±", "10.3", "U", "/", "L", "vs", ".", "78.1", "±", "37.4", "U", "/", "L", ",", "37.9", "±", "25.1", "U", "/", "L", ",", "P", "<", "0.05", "or", "P", "<", "0.01", ")", ".", "The", "WBC", "count", "in", "P+EN", "group", "was", "significantly", "lower", "than", "that", "in", "PN", "group", "(", "5.9", "±", "3.0", "×", "10⁹/L", ",", "6.3", "±", "3.2", "×", "10⁹/L", "vs", ".", "9.6", "±", "3.0", "×10⁹/L", ",", "both", "P", "<", "0.05", ")", ",", "but", "there", "was", "no", "significant", "difference", "in", "amylase", "between", "P+EN", "group", "and", "PN", "group", "(", "211", "±", "49", "U", "/", "L", ",", "236", "±", "52", "U", "/", "L", "vs", ".", "298", "±", "71", "U", "/", "L", ",", "P", ">", "0.05", ")", ".", "The", "gastrointestinal", "dysfunction", "score", "in", "P+EN", ",", "EN", ",", "PN", "groups", "14", "days", "after", "nutritional", "intervention", "was", "0.28", "±", "0.05", ",", "0.43", "±", "0.09", ",", "0.71", "±", "0.11", ",", "respectively", ",", "with", "statistically", "significant", "differences", "(", "all", "P", "<", "0.01", ")", ".", "Compared", "with", "PN", "and", "EN", "groups", ",", "the", "incidence", "of", "upper", "gastrointestinal", "bleeding", "(", "1", "vs", ".", "9", ",", "2", ")", ",", "infection", "and", "abscess", "(", "2", "vs", ".", "12", ",", "5", ")", "was", "lower", "(", "all", "P", "<", "0.01", ")", ",", "and", "hospital", "day", "was", "significantly", "shortened", "in", "P+EN", "group", "(", "10.4", "±", "3.9", "days", "vs", ".", "25.8", "±", "6.4", "days", ",", "13.4", "±", "5.2", "days", ",", "both", "P", "<", "0.01", ")", ".", "There", "was", "no", "significant", "statistical", "difference", "in", "mortality", "rate", "among", "three", "groups", ".", "CONCLUSION", "Our", "results", "indicated", "that", "early", "EN", "with", "addition", "of", "probiotics", "(", "bifidobacterium", ")", "resulted", "in", "significant", "lowering", "of", "the", "level", "of", "pro", "-", "inflammatory", "cytokines", ",", "earlier", "restoration", "of", "gastrointestinal", "function", ",", "decrease", "of", "complications", "such", "as", "infection", ",", "and", "shortening", "of", "hospital", "day", "in", "patients", "with", "SAP", "." ]	[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Adverse-effects", "Outcome_Physical", "Participant_Sample-size" ]
early enteral nutrition with addition of probiotics is a Intervention_Pharmacological, severe acute pancreatitis is a Participant_Condition, early enteral nutrition ( EN ) supplemented with probiotics ( bifidobacterium ) is a Intervention_Pharmacological, severe acute pancreatitis ( ASP ) is a Participant_Condition, Seventy is a Participant_Sample-size, parenteral nutrition ( PN ) is a Intervention_Pharmacological, bifidobacterium added EN ( P+EN ) is a Intervention_Pharmacological, anti - infection and anti - acid agents is a Intervention_Pharmacological, CRP is a Outcome_Physical, LDH is a Outcome_Physical, amylase is a Outcome_Physical, lipase is a Outcome_Physical, plasma levels of IL-8 , TNF - α is a Outcome_Physical, WBC count is a Outcome_Physical, plasma IL-8 , TNF - α , CRP is a Outcome_Physical, incidence is a Outcome_Adverse-effects, upper gastrointestinal bleeding is a Outcome_Adverse-effects	59514_task1	Sentence: [ The effects of early enteral nutrition with addition of probiotics on the prognosis of patients suffering from severe acute pancreatitis ] . OBJECTIVE To investigate the curative effect of early enteral nutrition ( EN ) supplemented with probiotics ( bifidobacterium ) in patients with severe acute pancreatitis ( ASP ) . METHODS Seventy SAP cases admitted from January 2005 to October 2012 were randomly assigned into parenteral nutrition ( PN ) group ( n=22 ) , EN group ( n=25 ) and bifidobacterium added EN ( P+EN ) group ( n=23 ) . In P+EN group , patients were given their nutrition the same as that of EN , and also probiotics ( bifidobacterium , 4 capsules every 12 hours , given through nasal gastric tube , each capsule weighing 210 mg ) . The routine treatment including anti-infection and anti-acid agents , and that of inhibition of pancreatic secretion were given , except for the different nutritional interventions in all groups . The blood samples were collected for e same measurements of interleukin-8 ( IL-8 ) and tumor necrosis factor ( TNF-α ) by enzyme linked immunosorbent assay ( ELISA ) , and for the C-reactive protein ( CRP ) , lactic acid dehydrogenase ( LDH ) , white blood cell ( WBC ) count , amylase and lipase by biochemistry assay 1 day before intervention of nutrition , and 7 days and 14 days after intervention . Changes in organ function and outcome were also recorded at the same time points . RESULTS The plasma levels of IL-8 , TNF-α , CRP , LDH , WBC count , amylase and lipase were significantly reduced after nutritional intervention compared with their levels on day 1 before intervention in all three groups . The plasma IL-8 , TNF-α , CRP , lipase , LDH at 14 days after intervention of nutrition in P+EN group were significantly lower than those in PN group and EN group ( IL-8 : 21.00 ± 7.07 μg/L vs. 48.00 ± 10.32 μg/L , 32.00 ± 9.30 μg/L ; TNF-α : 44.3 ± 10.9 ng/L vs. 132.1 ± 34.1 ng/L , 67.8 ± 22.3 ng/L ; CRP : 35.0 ± 12.4 mg/L vs. 103.2 ± 49.2 mg/L , 63.0 ± 29.2 mg/L ; lipase : 269 ± 79 U/L vs. 670 ± 145 U/L , 310 ± 78 U/L ; LDH : 21.8 ± 10.3 U/L vs. 78.1 ± 37.4 U/L , 37.9 ± 25.1 U/L , P < 0.05 or P < 0.01 ) . The WBC count in P+EN group was significantly lower than that in PN group ( 5.9 ± 3.0 × 10⁹/L , 6.3 ± 3.2 × 10⁹/L vs. 9.6 ± 3.0 ×10⁹/L , both P < 0.05 ) , but there was no significant difference in amylase between P+EN group and PN group ( 211 ± 49 U/L , 236 ± 52 U/L vs. 298 ± 71 U/L , P > 0.05 ) . The gastrointestinal dysfunction score in P+EN , EN , PN groups 14 days after nutritional intervention was 0.28 ± 0.05 , 0.43 ± 0.09 , 0.71 ± 0.11 , respectively , with statistically significant differences ( all P < 0.01 ) . Compared with PN and EN groups , the incidence of upper gastrointestinal bleeding ( 1 vs. 9 , 2 ) , infection and abscess ( 2 vs. 12 , 5 ) was lower ( all P < 0.01 ) , and hospital day was significantly shortened in P+EN group ( 10.4 ± 3.9 days vs. 25.8 ± 6.4 days , 13.4 ± 5.2 days , both P < 0.01 ) . There was no significant statistical difference in mortality rate among three groups . CONCLUSION Our results indicated that early EN with addition of probiotics ( bifidobacterium ) resulted in significant lowering of the level of pro-inflammatory cytokines , earlier restoration of gastrointestinal function , decrease of complications such as infection , and shortening of hospital day in patients with SAP . Instructions: please typing these entity words according to sentence: early enteral nutrition with addition of probiotics, severe acute pancreatitis, early enteral nutrition ( EN ) supplemented with probiotics ( bifidobacterium ), severe acute pancreatitis ( ASP ), Seventy, parenteral nutrition ( PN ), bifidobacterium added EN ( P+EN ), anti - infection and anti - acid agents, CRP, LDH, amylase, lipase, plasma levels of IL-8 , TNF - α, WBC count, plasma IL-8 , TNF - α , CRP, incidence, upper gastrointestinal bleeding Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Physical, Participant_Sample-size	[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	[ The effects of early enteral nutrition with addition of probiotics on the prognosis of patients suffering from severe acute pancreatitis ] . OBJECTIVE To investigate the curative effect of early enteral nutrition ( EN ) supplemented with probiotics ( bifidobacterium ) in patients with severe acute pancreatitis ( ASP ) . METHODS Seventy SAP cases admitted from January 2005 to October 2012 were randomly assigned into parenteral nutrition ( PN ) group ( n=22 ) , EN group ( n=25 ) and bifidobacterium added EN ( P+EN ) group ( n=23 ) . In P+EN group , patients were given their nutrition the same as that of EN , and also probiotics ( bifidobacterium , 4 capsules every 12 hours , given through nasal gastric tube , each capsule weighing 210 mg ) . The routine treatment including anti-infection and anti-acid agents , and that of inhibition of pancreatic secretion were given , except for the different nutritional interventions in all groups . The blood samples were collected for e same measurements of interleukin-8 ( IL-8 ) and tumor necrosis factor ( TNF-α ) by enzyme linked immunosorbent assay ( ELISA ) , and for the C-reactive protein ( CRP ) , lactic acid dehydrogenase ( LDH ) , white blood cell ( WBC ) count , amylase and lipase by biochemistry assay 1 day before intervention of nutrition , and 7 days and 14 days after intervention . Changes in organ function and outcome were also recorded at the same time points . RESULTS The plasma levels of IL-8 , TNF-α , CRP , LDH , WBC count , amylase and lipase were significantly reduced after nutritional intervention compared with their levels on day 1 before intervention in all three groups . The plasma IL-8 , TNF-α , CRP , lipase , LDH at 14 days after intervention of nutrition in P+EN group were significantly lower than those in PN group and EN group ( IL-8 : 21.00 ± 7.07 μg/L vs. 48.00 ± 10.32 μg/L , 32.00 ± 9.30 μg/L ; TNF-α : 44.3 ± 10.9 ng/L vs. 132.1 ± 34.1 ng/L , 67.8 ± 22.3 ng/L ; CRP : 35.0 ± 12.4 mg/L vs. 103.2 ± 49.2 mg/L , 63.0 ± 29.2 mg/L ; lipase : 269 ± 79 U/L vs. 670 ± 145 U/L , 310 ± 78 U/L ; LDH : 21.8 ± 10.3 U/L vs. 78.1 ± 37.4 U/L , 37.9 ± 25.1 U/L , P < 0.05 or P < 0.01 ) . The WBC count in P+EN group was significantly lower than that in PN group ( 5.9 ± 3.0 × 10⁹/L , 6.3 ± 3.2 × 10⁹/L vs. 9.6 ± 3.0 ×10⁹/L , both P < 0.05 ) , but there was no significant difference in amylase between P+EN group and PN group ( 211 ± 49 U/L , 236 ± 52 U/L vs. 298 ± 71 U/L , P > 0.05 ) . The gastrointestinal dysfunction score in P+EN , EN , PN groups 14 days after nutritional intervention was 0.28 ± 0.05 , 0.43 ± 0.09 , 0.71 ± 0.11 , respectively , with statistically significant differences ( all P < 0.01 ) . Compared with PN and EN groups , the incidence of upper gastrointestinal bleeding ( 1 vs. 9 , 2 ) , infection and abscess ( 2 vs. 12 , 5 ) was lower ( all P < 0.01 ) , and hospital day was significantly shortened in P+EN group ( 10.4 ± 3.9 days vs. 25.8 ± 6.4 days , 13.4 ± 5.2 days , both P < 0.01 ) . There was no significant statistical difference in mortality rate among three groups . CONCLUSION Our results indicated that early EN with addition of probiotics ( bifidobacterium ) resulted in significant lowering of the level of pro-inflammatory cytokines , earlier restoration of gastrointestinal function , decrease of complications such as infection , and shortening of hospital day in patients with SAP .	[ "[", "The", "effects", "of", "early", "enteral", "nutrition", "with", "addition", "of", "probiotics", "on", "the", "prognosis", "of", "patients", "suffering", "from", "severe", "acute", "pancreatitis", "]", ".", "OBJECTIVE", "To", "investigate", "the", "curative", "effect", "of", "early", "enteral", "nutrition", "(", "EN", ")", "supplemented", "with", "probiotics", "(", "bifidobacterium", ")", "in", "patients", "with", "severe", "acute", "pancreatitis", "(", "ASP", ")", ".", "METHODS", "Seventy", "SAP", "cases", "admitted", "from", "January", "2005", "to", "October", "2012", "were", "randomly", "assigned", "into", "parenteral", "nutrition", "(", "PN", ")", "group", "(", "n=22", ")", ",", "EN", "group", "(", "n=25", ")", "and", "bifidobacterium", "added", "EN", "(", "P+EN", ")", "group", "(", "n=23", ")", ".", "In", "P+EN", "group", ",", "patients", "were", "given", "their", "nutrition", "the", "same", "as", "that", "of", "EN", ",", "and", "also", "probiotics", "(", "bifidobacterium", ",", "4", "capsules", "every", "12", "hours", ",", "given", "through", "nasal", "gastric", "tube", ",", "each", "capsule", "weighing", "210", "mg", ")", ".", "The", "routine", "treatment", "including", "anti", "-", "infection", "and", "anti", "-", "acid", "agents", ",", "and", "that", "of", "inhibition", "of", "pancreatic", "secretion", "were", "given", ",", "except", "for", "the", "different", "nutritional", "interventions", "in", "all", "groups", ".", "The", "blood", "samples", "were", "collected", "for", "e", "same", "measurements", "of", "interleukin-8", "(", "IL-8", ")", "and", "tumor", "necrosis", "factor", "(", "TNF", "-", "α", ")", "by", "enzyme", "linked", "immunosorbent", "assay", "(", "ELISA", ")", ",", "and", "for", "the", "C", "-", "reactive", "protein", "(", "CRP", ")", ",", "lactic", "acid", "dehydrogenase", "(", "LDH", ")", ",", "white", "blood", "cell", "(", "WBC", ")", "count", ",", "amylase", "and", "lipase", "by", "biochemistry", "assay", "1", "day", "before", "intervention", "of", "nutrition", ",", "and", "7", "days", "and", "14", "days", "after", "intervention", ".", "Changes", "in", "organ", "function", "and", "outcome", "were", "also", "recorded", "at", "the", "same", "time", "points", ".", "RESULTS", "The", "plasma", "levels", "of", "IL-8", ",", "TNF", "-", "α", ",", "CRP", ",", "LDH", ",", "WBC", "count", ",", "amylase", "and", "lipase", "were", "significantly", "reduced", "after", "nutritional", "intervention", "compared", "with", "their", "levels", "on", "day", "1", "before", "intervention", "in", "all", "three", "groups", ".", "The", "plasma", "IL-8", ",", "TNF", "-", "α", ",", "CRP", ",", "lipase", ",", "LDH", "at", "14", "days", "after", "intervention", "of", "nutrition", "in", "P+EN", "group", "were", "significantly", "lower", "than", "those", "in", "PN", "group", "and", "EN", "group", "(", "IL-8", ":", "21.00", "±", "7.07", "μg", "/", "L", "vs", ".", "48.00", "±", "10.32", "μg", "/", "L", ",", "32.00", "±", "9.30", "μg", "/", "L", ";", "TNF", "-", "α", ":", "44.3", "±", "10.9", "ng", "/", "L", "vs", ".", "132.1", "±", "34.1", "ng", "/", "L", ",", "67.8", "±", "22.3", "ng", "/", "L", ";", "CRP", ":", "35.0", "±", "12.4", "mg", "/", "L", "vs", ".", "103.2", "±", "49.2", "mg", "/", "L", ",", "63.0", "±", "29.2", "mg", "/", "L", ";", "lipase", ":", "269", "±", "79", "U", "/", "L", "vs", ".", "670", "±", "145", "U", "/", "L", ",", "310", "±", "78", "U", "/", "L", ";", "LDH", ":", "21.8", "±", "10.3", "U", "/", "L", "vs", ".", "78.1", "±", "37.4", "U", "/", "L", ",", "37.9", "±", "25.1", "U", "/", "L", ",", "P", "<", "0.05", "or", "P", "<", "0.01", ")", ".", "The", "WBC", "count", "in", "P+EN", "group", "was", "significantly", "lower", "than", "that", "in", "PN", "group", "(", "5.9", "±", "3.0", "×", "10⁹/L", ",", "6.3", "±", "3.2", "×", "10⁹/L", "vs", ".", "9.6", "±", "3.0", "×10⁹/L", ",", "both", "P", "<", "0.05", ")", ",", "but", "there", "was", "no", "significant", "difference", "in", "amylase", "between", "P+EN", "group", "and", "PN", "group", "(", "211", "±", "49", "U", "/", "L", ",", "236", "±", "52", "U", "/", "L", "vs", ".", "298", "±", "71", "U", "/", "L", ",", "P", ">", "0.05", ")", ".", "The", "gastrointestinal", "dysfunction", "score", "in", "P+EN", ",", "EN", ",", "PN", "groups", "14", "days", "after", "nutritional", "intervention", "was", "0.28", "±", "0.05", ",", "0.43", "±", "0.09", ",", "0.71", "±", "0.11", ",", "respectively", ",", "with", "statistically", "significant", "differences", "(", "all", "P", "<", "0.01", ")", ".", "Compared", "with", "PN", "and", "EN", "groups", ",", "the", "incidence", "of", "upper", "gastrointestinal", "bleeding", "(", "1", "vs", ".", "9", ",", "2", ")", ",", "infection", "and", "abscess", "(", "2", "vs", ".", "12", ",", "5", ")", "was", "lower", "(", "all", "P", "<", "0.01", ")", ",", "and", "hospital", "day", "was", "significantly", "shortened", "in", "P+EN", "group", "(", "10.4", "±", "3.9", "days", "vs", ".", "25.8", "±", "6.4", "days", ",", "13.4", "±", "5.2", "days", ",", "both", "P", "<", "0.01", ")", ".", "There", "was", "no", "significant", "statistical", "difference", "in", "mortality", "rate", "among", "three", "groups", ".", "CONCLUSION", "Our", "results", "indicated", "that", "early", "EN", "with", "addition", "of", "probiotics", "(", "bifidobacterium", ")", "resulted", "in", "significant", "lowering", "of", "the", "level", "of", "pro", "-", "inflammatory", "cytokines", ",", "earlier", "restoration", "of", "gastrointestinal", "function", ",", "decrease", "of", "complications", "such", "as", "infection", ",", "and", "shortening", "of", "hospital", "day", "in", "patients", "with", "SAP", "." ]	[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Adverse-effects", "Outcome_Physical", "Participant_Sample-size" ]
early enteral nutrition with addition of probiotics, severe acute pancreatitis, early enteral nutrition ( EN ) supplemented with probiotics ( bifidobacterium ), severe acute pancreatitis ( ASP ), Seventy, parenteral nutrition ( PN ), bifidobacterium added EN ( P+EN ), anti - infection and anti - acid agents, CRP, LDH, amylase, lipase, plasma levels of IL-8 , TNF - α, WBC count, plasma IL-8 , TNF - α , CRP, incidence, upper gastrointestinal bleeding	59514_task2	Sentence: [ The effects of early enteral nutrition with addition of probiotics on the prognosis of patients suffering from severe acute pancreatitis ] . OBJECTIVE To investigate the curative effect of early enteral nutrition ( EN ) supplemented with probiotics ( bifidobacterium ) in patients with severe acute pancreatitis ( ASP ) . METHODS Seventy SAP cases admitted from January 2005 to October 2012 were randomly assigned into parenteral nutrition ( PN ) group ( n=22 ) , EN group ( n=25 ) and bifidobacterium added EN ( P+EN ) group ( n=23 ) . In P+EN group , patients were given their nutrition the same as that of EN , and also probiotics ( bifidobacterium , 4 capsules every 12 hours , given through nasal gastric tube , each capsule weighing 210 mg ) . The routine treatment including anti-infection and anti-acid agents , and that of inhibition of pancreatic secretion were given , except for the different nutritional interventions in all groups . The blood samples were collected for e same measurements of interleukin-8 ( IL-8 ) and tumor necrosis factor ( TNF-α ) by enzyme linked immunosorbent assay ( ELISA ) , and for the C-reactive protein ( CRP ) , lactic acid dehydrogenase ( LDH ) , white blood cell ( WBC ) count , amylase and lipase by biochemistry assay 1 day before intervention of nutrition , and 7 days and 14 days after intervention . Changes in organ function and outcome were also recorded at the same time points . RESULTS The plasma levels of IL-8 , TNF-α , CRP , LDH , WBC count , amylase and lipase were significantly reduced after nutritional intervention compared with their levels on day 1 before intervention in all three groups . The plasma IL-8 , TNF-α , CRP , lipase , LDH at 14 days after intervention of nutrition in P+EN group were significantly lower than those in PN group and EN group ( IL-8 : 21.00 ± 7.07 μg/L vs. 48.00 ± 10.32 μg/L , 32.00 ± 9.30 μg/L ; TNF-α : 44.3 ± 10.9 ng/L vs. 132.1 ± 34.1 ng/L , 67.8 ± 22.3 ng/L ; CRP : 35.0 ± 12.4 mg/L vs. 103.2 ± 49.2 mg/L , 63.0 ± 29.2 mg/L ; lipase : 269 ± 79 U/L vs. 670 ± 145 U/L , 310 ± 78 U/L ; LDH : 21.8 ± 10.3 U/L vs. 78.1 ± 37.4 U/L , 37.9 ± 25.1 U/L , P < 0.05 or P < 0.01 ) . The WBC count in P+EN group was significantly lower than that in PN group ( 5.9 ± 3.0 × 10⁹/L , 6.3 ± 3.2 × 10⁹/L vs. 9.6 ± 3.0 ×10⁹/L , both P < 0.05 ) , but there was no significant difference in amylase between P+EN group and PN group ( 211 ± 49 U/L , 236 ± 52 U/L vs. 298 ± 71 U/L , P > 0.05 ) . The gastrointestinal dysfunction score in P+EN , EN , PN groups 14 days after nutritional intervention was 0.28 ± 0.05 , 0.43 ± 0.09 , 0.71 ± 0.11 , respectively , with statistically significant differences ( all P < 0.01 ) . Compared with PN and EN groups , the incidence of upper gastrointestinal bleeding ( 1 vs. 9 , 2 ) , infection and abscess ( 2 vs. 12 , 5 ) was lower ( all P < 0.01 ) , and hospital day was significantly shortened in P+EN group ( 10.4 ± 3.9 days vs. 25.8 ± 6.4 days , 13.4 ± 5.2 days , both P < 0.01 ) . There was no significant statistical difference in mortality rate among three groups . CONCLUSION Our results indicated that early EN with addition of probiotics ( bifidobacterium ) resulted in significant lowering of the level of pro-inflammatory cytokines , earlier restoration of gastrointestinal function , decrease of complications such as infection , and shortening of hospital day in patients with SAP . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	[ The effects of early enteral nutrition with addition of probiotics on the prognosis of patients suffering from severe acute pancreatitis ] . OBJECTIVE To investigate the curative effect of early enteral nutrition ( EN ) supplemented with probiotics ( bifidobacterium ) in patients with severe acute pancreatitis ( ASP ) . METHODS Seventy SAP cases admitted from January 2005 to October 2012 were randomly assigned into parenteral nutrition ( PN ) group ( n=22 ) , EN group ( n=25 ) and bifidobacterium added EN ( P+EN ) group ( n=23 ) . In P+EN group , patients were given their nutrition the same as that of EN , and also probiotics ( bifidobacterium , 4 capsules every 12 hours , given through nasal gastric tube , each capsule weighing 210 mg ) . The routine treatment including anti-infection and anti-acid agents , and that of inhibition of pancreatic secretion were given , except for the different nutritional interventions in all groups . The blood samples were collected for e same measurements of interleukin-8 ( IL-8 ) and tumor necrosis factor ( TNF-α ) by enzyme linked immunosorbent assay ( ELISA ) , and for the C-reactive protein ( CRP ) , lactic acid dehydrogenase ( LDH ) , white blood cell ( WBC ) count , amylase and lipase by biochemistry assay 1 day before intervention of nutrition , and 7 days and 14 days after intervention . Changes in organ function and outcome were also recorded at the same time points . RESULTS The plasma levels of IL-8 , TNF-α , CRP , LDH , WBC count , amylase and lipase were significantly reduced after nutritional intervention compared with their levels on day 1 before intervention in all three groups . The plasma IL-8 , TNF-α , CRP , lipase , LDH at 14 days after intervention of nutrition in P+EN group were significantly lower than those in PN group and EN group ( IL-8 : 21.00 ± 7.07 μg/L vs. 48.00 ± 10.32 μg/L , 32.00 ± 9.30 μg/L ; TNF-α : 44.3 ± 10.9 ng/L vs. 132.1 ± 34.1 ng/L , 67.8 ± 22.3 ng/L ; CRP : 35.0 ± 12.4 mg/L vs. 103.2 ± 49.2 mg/L , 63.0 ± 29.2 mg/L ; lipase : 269 ± 79 U/L vs. 670 ± 145 U/L , 310 ± 78 U/L ; LDH : 21.8 ± 10.3 U/L vs. 78.1 ± 37.4 U/L , 37.9 ± 25.1 U/L , P < 0.05 or P < 0.01 ) . The WBC count in P+EN group was significantly lower than that in PN group ( 5.9 ± 3.0 × 10⁹/L , 6.3 ± 3.2 × 10⁹/L vs. 9.6 ± 3.0 ×10⁹/L , both P < 0.05 ) , but there was no significant difference in amylase between P+EN group and PN group ( 211 ± 49 U/L , 236 ± 52 U/L vs. 298 ± 71 U/L , P > 0.05 ) . The gastrointestinal dysfunction score in P+EN , EN , PN groups 14 days after nutritional intervention was 0.28 ± 0.05 , 0.43 ± 0.09 , 0.71 ± 0.11 , respectively , with statistically significant differences ( all P < 0.01 ) . Compared with PN and EN groups , the incidence of upper gastrointestinal bleeding ( 1 vs. 9 , 2 ) , infection and abscess ( 2 vs. 12 , 5 ) was lower ( all P < 0.01 ) , and hospital day was significantly shortened in P+EN group ( 10.4 ± 3.9 days vs. 25.8 ± 6.4 days , 13.4 ± 5.2 days , both P < 0.01 ) . There was no significant statistical difference in mortality rate among three groups . CONCLUSION Our results indicated that early EN with addition of probiotics ( bifidobacterium ) resulted in significant lowering of the level of pro-inflammatory cytokines , earlier restoration of gastrointestinal function , decrease of complications such as infection , and shortening of hospital day in patients with SAP .	[ "[", "The", "effects", "of", "early", "enteral", "nutrition", "with", "addition", "of", "probiotics", "on", "the", "prognosis", "of", "patients", "suffering", "from", "severe", "acute", "pancreatitis", "]", ".", "OBJECTIVE", "To", "investigate", "the", "curative", "effect", "of", "early", "enteral", "nutrition", "(", "EN", ")", "supplemented", "with", "probiotics", "(", "bifidobacterium", ")", "in", "patients", "with", "severe", "acute", "pancreatitis", "(", "ASP", ")", ".", "METHODS", "Seventy", "SAP", "cases", "admitted", "from", "January", "2005", "to", "October", "2012", "were", "randomly", "assigned", "into", "parenteral", "nutrition", "(", "PN", ")", "group", "(", "n=22", ")", ",", "EN", "group", "(", "n=25", ")", "and", "bifidobacterium", "added", "EN", "(", "P+EN", ")", "group", "(", "n=23", ")", ".", "In", "P+EN", "group", ",", "patients", "were", "given", "their", "nutrition", "the", "same", "as", "that", "of", "EN", ",", "and", "also", "probiotics", "(", "bifidobacterium", ",", "4", "capsules", "every", "12", "hours", ",", "given", "through", "nasal", "gastric", "tube", ",", "each", "capsule", "weighing", "210", "mg", ")", ".", "The", "routine", "treatment", "including", "anti", "-", "infection", "and", "anti", "-", "acid", "agents", ",", "and", "that", "of", "inhibition", "of", "pancreatic", "secretion", "were", "given", ",", "except", "for", "the", "different", "nutritional", "interventions", "in", "all", "groups", ".", "The", "blood", "samples", "were", "collected", "for", "e", "same", "measurements", "of", "interleukin-8", "(", "IL-8", ")", "and", "tumor", "necrosis", "factor", "(", "TNF", "-", "α", ")", "by", "enzyme", "linked", "immunosorbent", "assay", "(", "ELISA", ")", ",", "and", "for", "the", "C", "-", "reactive", "protein", "(", "CRP", ")", ",", "lactic", "acid", "dehydrogenase", "(", "LDH", ")", ",", "white", "blood", "cell", "(", "WBC", ")", "count", ",", "amylase", "and", "lipase", "by", "biochemistry", "assay", "1", "day", "before", "intervention", "of", "nutrition", ",", "and", "7", "days", "and", "14", "days", "after", "intervention", ".", "Changes", "in", "organ", "function", "and", "outcome", "were", "also", "recorded", "at", "the", "same", "time", "points", ".", "RESULTS", "The", "plasma", "levels", "of", "IL-8", ",", "TNF", "-", "α", ",", "CRP", ",", "LDH", ",", "WBC", "count", ",", "amylase", "and", "lipase", "were", "significantly", "reduced", "after", "nutritional", "intervention", "compared", "with", "their", "levels", "on", "day", "1", "before", "intervention", "in", "all", "three", "groups", ".", "The", "plasma", "IL-8", ",", "TNF", "-", "α", ",", "CRP", ",", "lipase", ",", "LDH", "at", "14", "days", "after", "intervention", "of", "nutrition", "in", "P+EN", "group", "were", "significantly", "lower", "than", "those", "in", "PN", "group", "and", "EN", "group", "(", "IL-8", ":", "21.00", "±", "7.07", "μg", "/", "L", "vs", ".", "48.00", "±", "10.32", "μg", "/", "L", ",", "32.00", "±", "9.30", "μg", "/", "L", ";", "TNF", "-", "α", ":", "44.3", "±", "10.9", "ng", "/", "L", "vs", ".", "132.1", "±", "34.1", "ng", "/", "L", ",", "67.8", "±", "22.3", "ng", "/", "L", ";", "CRP", ":", "35.0", "±", "12.4", "mg", "/", "L", "vs", ".", "103.2", "±", "49.2", "mg", "/", "L", ",", "63.0", "±", "29.2", "mg", "/", "L", ";", "lipase", ":", "269", "±", "79", "U", "/", "L", "vs", ".", "670", "±", "145", "U", "/", "L", ",", "310", "±", "78", "U", "/", "L", ";", "LDH", ":", "21.8", "±", "10.3", "U", "/", "L", "vs", ".", "78.1", "±", "37.4", "U", "/", "L", ",", "37.9", "±", "25.1", "U", "/", "L", ",", "P", "<", "0.05", "or", "P", "<", "0.01", ")", ".", "The", "WBC", "count", "in", "P+EN", "group", "was", "significantly", "lower", "than", "that", "in", "PN", "group", "(", "5.9", "±", "3.0", "×", "10⁹/L", ",", "6.3", "±", "3.2", "×", "10⁹/L", "vs", ".", "9.6", "±", "3.0", "×10⁹/L", ",", "both", "P", "<", "0.05", ")", ",", "but", "there", "was", "no", "significant", "difference", "in", "amylase", "between", "P+EN", "group", "and", "PN", "group", "(", "211", "±", "49", "U", "/", "L", ",", "236", "±", "52", "U", "/", "L", "vs", ".", "298", "±", "71", "U", "/", "L", ",", "P", ">", "0.05", ")", ".", "The", "gastrointestinal", "dysfunction", "score", "in", "P+EN", ",", "EN", ",", "PN", "groups", "14", "days", "after", "nutritional", "intervention", "was", "0.28", "±", "0.05", ",", "0.43", "±", "0.09", ",", "0.71", "±", "0.11", ",", "respectively", ",", "with", "statistically", "significant", "differences", "(", "all", "P", "<", "0.01", ")", ".", "Compared", "with", "PN", "and", "EN", "groups", ",", "the", "incidence", "of", "upper", "gastrointestinal", "bleeding", "(", "1", "vs", ".", "9", ",", "2", ")", ",", "infection", "and", "abscess", "(", "2", "vs", ".", "12", ",", "5", ")", "was", "lower", "(", "all", "P", "<", "0.01", ")", ",", "and", "hospital", "day", "was", "significantly", "shortened", "in", "P+EN", "group", "(", "10.4", "±", "3.9", "days", "vs", ".", "25.8", "±", "6.4", "days", ",", "13.4", "±", "5.2", "days", ",", "both", "P", "<", "0.01", ")", ".", "There", "was", "no", "significant", "statistical", "difference", "in", "mortality", "rate", "among", "three", "groups", ".", "CONCLUSION", "Our", "results", "indicated", "that", "early", "EN", "with", "addition", "of", "probiotics", "(", "bifidobacterium", ")", "resulted", "in", "significant", "lowering", "of", "the", "level", "of", "pro", "-", "inflammatory", "cytokines", ",", "earlier", "restoration", "of", "gastrointestinal", "function", ",", "decrease", "of", "complications", "such", "as", "infection", ",", "and", "shortening", "of", "hospital", "day", "in", "patients", "with", "SAP", "." ]	[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Adverse-effects", "Outcome_Physical", "Participant_Sample-size" ]
adapalene is a CHEMICAL	9990413_task0	Sentence: Pharmacology of adapalene. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL	[ "O", "O", "B-CHEMICAL", "O" ]	Pharmacology of adapalene.	[ "Pharmacology", "of", "adapalene", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
adapalene is a CHEMICAL	9990413_task1	Sentence: Pharmacology of adapalene. Instructions: please typing these entity words according to sentence: adapalene Options: CHEMICAL	[ "O", "O", "B-CHEMICAL", "O" ]	Pharmacology of adapalene.	[ "Pharmacology", "of", "adapalene", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
adapalene	9990413_task2	Sentence: Pharmacology of adapalene. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-CHEMICAL", "O" ]	Pharmacology of adapalene.	[ "Pharmacology", "of", "adapalene", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
Daniel is a NOMBRE_SUJETO_ASISTENCIA, Perea Dominguez is a NOMBRE_SUJETO_ASISTENCIA, 7842356 is a ID_SUJETO_ASISTENCIA, Madrid is a TERRITORIO, 28001 is a TERRITORIO, 30/03/2017 is a FECHAS, España is a PAIS, 26 dias is a EDAD_SUJETO_ASISTENCIA, 25/04/2017 is a FECHAS, Jose Luis Fernandez Copado is a NOMBRE_PERSONAL_SANITARIO, 28 28 93020 is a ID_TITULACION_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, 26 días is a EDAD_SUJETO_ASISTENCIA, tres semanas is a EDAD_SUJETO_ASISTENCIA, madre is a FAMILIARES_SUJETO_ASISTENCIA, Jose Luis Fernandez Copado is a NOMBRE_PERSONAL_SANITARIO, a00799839@itesm.com is a CORREO_ELECTRONICO	470_task0	Sentence: Datos del paciente. Nombre: Daniel. Apellidos: Perea Dominguez. NHC: 7842356. Domicilio: Calle Conde Duque,19, 3A. Localidad/ Provincia: Madrid. CP: 28001. Datos asistenciales. Fecha de nacimiento: 30/03/2017. País: España. Edad: 26 dias Sexo: H. Fecha de Ingreso: 25/04/2017. Médico: Jose Luis Fernandez Copado. NºCol: 28 28 93020. Informe clínico del paciente:Varón de 26 días de vida sin antecedentes familiares, prenatales o perinatales de relevancia. Hacia las tres semanas de vida comienza a presentar vómitos, que fueron en aumento, y el día previo a su ingreso se presentaron con cada toma, abundantes y en proyectil. El paciente se mostraba ávido por comer y con buen estado general. Al presentarse en el Departamento de Urgencias, se tuvo la sospecha clínica de estenosis hipertrófica de píloro, apoyada por una gasometría que mostraba alcalosis metabólica y un ultrasonido con imagen en diana característica. El paciente fue intervenido de forma abierta mediante la técnica de Ramstedt, sin incidencias. Antes del procedimiento el paciente fue intubado sin complicaciones. A las 14 horas de la cirugía se escucha por primera vez estridor de predominio inspiratorio, que no se modificaba con el sueño, la posición ni con la alimentación. Se reinterrogó a la madre, que negó haberlo escuchado antes. El paciente no presentaba ningún dato de dificultad respiratoria ni desaturación del oxígeno en la pulsioximetría. Dado que se trataba de un paciente previamente sano al que no se le había escuchado estridor antes, se sospechó que la intubación operatoria y el edema postraumático asociado pudieran ser la causa. Se administró nebulización con adrenalina y una dosis de dexametasona intravenosa. Tras dos horas, el estridor no se había modificado, y al continuar el paciente sin signos de dificultad respiratoria, se inició el abordaje de este problema. En una radiografía simple de tórax no se observaron anormalidades en el parénquima pulmonar, estructuras del cuello o columna de aire traqueal. Posteriormente, mediante una nasolaringoendoscopia flexible se comprobaron las estructuras supraglóticas y las cuerdas vocales íntegras, sin alteraciones morfológicas ni movimientos anormales. El siguiente paso fue la realización de una serie fluoroscópica con contraste oral, que demostró una muesca en la pared posterior del tercio superior del esófago. Durante ese tiempo el paciente no mostró cambios en su sintomatología. Tras la cirugía de píloro no había vuelto a presentar vómitos. En ningún momento presentó datos de dificultad respiratoria asociados al estridor. Días después se realizó una broncoscopia, en la que se observó una compresión extrínseca 2 cm por encima de la carina, pulsátil, que obstruía más del 50% de la luz de la tráquea y no se modificaba con presión positiva. Ante la fuerte sospecha de una malformación vascular que fuera responsable de la disminución del calibre traqueal, se realizó una angiografía por tomografía computarizada (angio-TC), en la que se pudo identificar un doble arco aórtico completo, con predominancia del arco derecho como causa de la constricción traqueal. La ecocardiografía fue normal. El paciente fue operado por medio de una cirugía de abordaje torácico lateral izquierdo que se realizó sin contratiempos. En las primeras horas posquirúrgicas se notó una importante disminución en la intensidad del ruido inspiratorio. Fue dado de alta y durante las siguientes semanas el estridor residual continuó disminuyendo. No volvió a presentar síntomas respiratorios ni digestivos, y en una consulta de seguimiento a dos meses de la cirugía el estridor terminó por desaparecer del todo. Remitido por: Dr. Jose Luis Fernandez Copado. Correo electrónico: a00799839@itesm.com Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, FAMILIARES_SUJETO_ASISTENCIA, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Datos del paciente. Nombre: Daniel. Apellidos: Perea Dominguez. NHC: 7842356. Domicilio: Calle Conde Duque,19, 3A. Localidad/ Provincia: Madrid. CP: 28001. Datos asistenciales. Fecha de nacimiento: 30/03/2017. País: España. Edad: 26 dias Sexo: H. Fecha de Ingreso: 25/04/2017. Médico: Jose Luis Fernandez Copado. NºCol: 28 28 93020. Informe clínico del paciente:Varón de 26 días de vida sin antecedentes familiares, prenatales o perinatales de relevancia. Hacia las tres semanas de vida comienza a presentar vómitos, que fueron en aumento, y el día previo a su ingreso se presentaron con cada toma, abundantes y en proyectil. El paciente se mostraba ávido por comer y con buen estado general. Al presentarse en el Departamento de Urgencias, se tuvo la sospecha clínica de estenosis hipertrófica de píloro, apoyada por una gasometría que mostraba alcalosis metabólica y un ultrasonido con imagen en diana característica. El paciente fue intervenido de forma abierta mediante la técnica de Ramstedt, sin incidencias. Antes del procedimiento el paciente fue intubado sin complicaciones. A las 14 horas de la cirugía se escucha por primera vez estridor de predominio inspiratorio, que no se modificaba con el sueño, la posición ni con la alimentación. Se reinterrogó a la madre, que negó haberlo escuchado antes. El paciente no presentaba ningún dato de dificultad respiratoria ni desaturación del oxígeno en la pulsioximetría. Dado que se trataba de un paciente previamente sano al que no se le había escuchado estridor antes, se sospechó que la intubación operatoria y el edema postraumático asociado pudieran ser la causa. Se administró nebulización con adrenalina y una dosis de dexametasona intravenosa. Tras dos horas, el estridor no se había modificado, y al continuar el paciente sin signos de dificultad respiratoria, se inició el abordaje de este problema. En una radiografía simple de tórax no se observaron anormalidades en el parénquima pulmonar, estructuras del cuello o columna de aire traqueal. Posteriormente, mediante una nasolaringoendoscopia flexible se comprobaron las estructuras supraglóticas y las cuerdas vocales íntegras, sin alteraciones morfológicas ni movimientos anormales. El siguiente paso fue la realización de una serie fluoroscópica con contraste oral, que demostró una muesca en la pared posterior del tercio superior del esófago. Durante ese tiempo el paciente no mostró cambios en su sintomatología. Tras la cirugía de píloro no había vuelto a presentar vómitos. En ningún momento presentó datos de dificultad respiratoria asociados al estridor. Días después se realizó una broncoscopia, en la que se observó una compresión extrínseca 2 cm por encima de la carina, pulsátil, que obstruía más del 50% de la luz de la tráquea y no se modificaba con presión positiva. Ante la fuerte sospecha de una malformación vascular que fuera responsable de la disminución del calibre traqueal, se realizó una angiografía por tomografía computarizada (angio-TC), en la que se pudo identificar un doble arco aórtico completo, con predominancia del arco derecho como causa de la constricción traqueal. La ecocardiografía fue normal. El paciente fue operado por medio de una cirugía de abordaje torácico lateral izquierdo que se realizó sin contratiempos. En las primeras horas posquirúrgicas se notó una importante disminución en la intensidad del ruido inspiratorio. Fue dado de alta y durante las siguientes semanas el estridor residual continuó disminuyendo. No volvió a presentar síntomas respiratorios ni digestivos, y en una consulta de seguimiento a dos meses de la cirugía el estridor terminó por desaparecer del todo. Remitido por: Dr. Jose Luis Fernandez Copado. Correo electrónico: a00799839@itesm.com	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", " ", "Daniel", ".", "\n", "Apellidos", ":", "Perea", "Dominguez", ".", "\n", "NHC", ":", "7842356", ".", "\n", "Domicilio", ":", "Calle", "Conde", "Duque,19", ",", "3A.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28001", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "30/03/2017", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "26", "dias", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "25/04/2017", ".", "\n", "Médico", ":", "Jose", "Luis", "Fernandez", "Copado", ".", "NºCol", ":", "28", "28", "93020", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Varón", "de", "26", "días", "de", "vida", "sin", "antecedentes", "familiares", ",", "prenatales", "o", "perinatales", "de", "relevancia", ".", "Hacia", "las", "tres", "semanas", "de", "vida", "comienza", "a", "presentar", "vómitos", ",", "que", "fueron", "en", "aumento", ",", "y", "el", "día", "previo", "a", "su", "ingreso", "se", "presentaron", "con", "cada", "toma", ",", "abundantes", "y", "en", "proyectil", ".", "El", "paciente", "se", "mostraba", "ávido", "por", "comer", "y", "con", "buen", "estado", "general", ".", "\n", "Al", "presentarse", "en", "el", "Departamento", "de", "Urgencias", ",", "se", "tuvo", "la", "sospecha", "clínica", "de", "estenosis", "hipertrófica", "de", "píloro", ",", "apoyada", "por", "una", "gasometría", "que", "mostraba", "alcalosis", "metabólica", "y", "un", "ultrasonido", "con", "imagen", "en", "diana", "característica", ".", "El", "paciente", "fue", "intervenido", "de", "forma", "abierta", "mediante", "la", "técnica", "de", "Ramstedt", ",", "sin", "incidencias", ".", "Antes", "del", "procedimiento", "el", "paciente", "fue", "intubado", "sin", "complicaciones", ".", "\n", "A", "las", "14", "horas", "de", "la", "cirugía", "se", "escucha", "por", "primera", "vez", "estridor", "de", "predominio", "inspiratorio", ",", "que", "no", "se", "modificaba", "con", "el", "sueño", ",", "la", "posición", "ni", "con", "la", "alimentación", ".", "Se", "reinterrogó", "a", "la", "madre", ",", "que", "negó", "haberlo", "escuchado", "antes", ".", "El", "paciente", "no", "presentaba", "ningún", "dato", "de", "dificultad", "respiratoria", "ni", "desaturación", "del", "oxígeno", "en", "la", "pulsioximetría", ".", "\n", "Dado", "que", "se", "trataba", "de", "un", "paciente", "previamente", "sano", "al", "que", "no", "se", "le", "había", "escuchado", "estridor", "antes", ",", "se", "sospechó", "que", "la", "intubación", "operatoria", "y", "el", "edema", "postraumático", "asociado", "pudieran", "ser", "la", "causa", ".", "Se", "administró", "nebulización", "con", "adrenalina", "y", "una", "dosis", "de", "dexametasona", "intravenosa", ".", "Tras", "dos", "horas", ",", "el", "estridor", "no", "se", "había", "modificado", ",", "y", "al", "continuar", "el", "paciente", "sin", "signos", "de", "dificultad", "respiratoria", ",", "se", "inició", "el", "abordaje", "de", "este", "problema", ".", "\n", "En", "una", "radiografía", "simple", "de", "tórax", "no", "se", "observaron", "anormalidades", "en", "el", "parénquima", "pulmonar", ",", "estructuras", "del", "cuello", "o", "columna", "de", "aire", "traqueal", ".", "Posteriormente", ",", "mediante", "una", "nasolaringoendoscopia", "flexible", "se", "comprobaron", "las", "estructuras", "supraglóticas", "y", "las", "cuerdas", "vocales", "íntegras", ",", "sin", "alteraciones", "morfológicas", "ni", "movimientos", "anormales", ".", "El", "siguiente", "paso", "fue", "la", "realización", "de", "una", "serie", "fluoroscópica", "con", "contraste", "oral", ",", "que", "demostró", "una", "muesca", "en", "la", "pared", "posterior", "del", "tercio", "superior", "del", "esófago", ".", "Durante", "ese", "tiempo", "el", "paciente", "no", "mostró", "cambios", "en", "su", "sintomatología", ".", "Tras", "la", "cirugía", "de", "píloro", "no", "había", "vuelto", "a", "presentar", "vómitos", ".", "En", "ningún", "momento", "presentó", "datos", "de", "dificultad", "respiratoria", "asociados", "al", "estridor", ".", "\n", "Días", "después", "se", "realizó", "una", "broncoscopia", ",", "en", "la", "que", "se", "observó", "una", "compresión", "extrínseca", "2", "cm", "por", "encima", "de", "la", "carina", ",", "pulsátil", ",", "que", "obstruía", "más", "del", "50", "%", "de", "la", "luz", "de", "la", "tráquea", "y", "no", "se", "modificaba", "con", "presión", "positiva", ".", "Ante", "la", "fuerte", "sospecha", "de", "una", "malformación", "vascular", "que", "fuera", "responsable", "de", "la", "disminución", "del", "calibre", "traqueal", ",", "se", "realizó", "una", "angiografía", "por", "tomografía", "computarizada", "(", "angio", "-", "TC", ")", ",", "en", "la", "que", "se", "pudo", "identificar", "un", "doble", "arco", "aórtico", "completo", ",", "con", "predominancia", "del", "arco", "derecho", "como", "causa", "de", "la", "constricción", "traqueal", ".", "La", "ecocardiografía", "fue", "normal", ".", "\n", "El", "paciente", "fue", "operado", "por", "medio", "de", "una", "cirugía", "de", "abordaje", "torácico", "lateral", "izquierdo", "que", "se", "realizó", "sin", "contratiempos", ".", "\n", "En", "las", "primeras", "horas", "posquirúrgicas", "se", "notó", "una", "importante", "disminución", "en", "la", "intensidad", "del", "ruido", "inspiratorio", ".", "Fue", "dado", "de", "alta", "y", "durante", "las", "siguientes", "semanas", "el", "estridor", "residual", "continuó", "disminuyendo", ".", "No", "volvió", "a", "presentar", "síntomas", "respiratorios", "ni", "digestivos", ",", "y", "en", "una", "consulta", "de", "seguimiento", "a", "dos", "meses", "de", "la", "cirugía", "el", "estridor", "terminó", "por", "desaparecer", "del", "todo", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Jose", "Luis", "Fernandez", "Copado", ".", "Correo", "electrónico", ":", "a00799839@itesm.com", "\n" ]	[ "NOMBRE_PERSONAL_SANITARIO", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_SUJETO_ASISTENCIA", "EDAD_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "FAMILIARES_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA" ]
Daniel is a NOMBRE_SUJETO_ASISTENCIA, Perea Dominguez is a NOMBRE_SUJETO_ASISTENCIA, 7842356 is a ID_SUJETO_ASISTENCIA, Madrid is a TERRITORIO, 28001 is a TERRITORIO, 30/03/2017 is a FECHAS, España is a PAIS, 26 dias is a EDAD_SUJETO_ASISTENCIA, 25/04/2017 is a FECHAS, Jose Luis Fernandez Copado is a NOMBRE_PERSONAL_SANITARIO, 28 28 93020 is a ID_TITULACION_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, 26 días is a EDAD_SUJETO_ASISTENCIA, tres semanas is a EDAD_SUJETO_ASISTENCIA, madre is a FAMILIARES_SUJETO_ASISTENCIA, Jose Luis Fernandez Copado is a NOMBRE_PERSONAL_SANITARIO, a00799839@itesm.com is a CORREO_ELECTRONICO	470_task1	Sentence: Datos del paciente. Nombre: Daniel. Apellidos: Perea Dominguez. NHC: 7842356. Domicilio: Calle Conde Duque,19, 3A. Localidad/ Provincia: Madrid. CP: 28001. Datos asistenciales. Fecha de nacimiento: 30/03/2017. País: España. Edad: 26 dias Sexo: H. Fecha de Ingreso: 25/04/2017. Médico: Jose Luis Fernandez Copado. NºCol: 28 28 93020. Informe clínico del paciente:Varón de 26 días de vida sin antecedentes familiares, prenatales o perinatales de relevancia. Hacia las tres semanas de vida comienza a presentar vómitos, que fueron en aumento, y el día previo a su ingreso se presentaron con cada toma, abundantes y en proyectil. El paciente se mostraba ávido por comer y con buen estado general. Al presentarse en el Departamento de Urgencias, se tuvo la sospecha clínica de estenosis hipertrófica de píloro, apoyada por una gasometría que mostraba alcalosis metabólica y un ultrasonido con imagen en diana característica. El paciente fue intervenido de forma abierta mediante la técnica de Ramstedt, sin incidencias. Antes del procedimiento el paciente fue intubado sin complicaciones. A las 14 horas de la cirugía se escucha por primera vez estridor de predominio inspiratorio, que no se modificaba con el sueño, la posición ni con la alimentación. Se reinterrogó a la madre, que negó haberlo escuchado antes. El paciente no presentaba ningún dato de dificultad respiratoria ni desaturación del oxígeno en la pulsioximetría. Dado que se trataba de un paciente previamente sano al que no se le había escuchado estridor antes, se sospechó que la intubación operatoria y el edema postraumático asociado pudieran ser la causa. Se administró nebulización con adrenalina y una dosis de dexametasona intravenosa. Tras dos horas, el estridor no se había modificado, y al continuar el paciente sin signos de dificultad respiratoria, se inició el abordaje de este problema. En una radiografía simple de tórax no se observaron anormalidades en el parénquima pulmonar, estructuras del cuello o columna de aire traqueal. Posteriormente, mediante una nasolaringoendoscopia flexible se comprobaron las estructuras supraglóticas y las cuerdas vocales íntegras, sin alteraciones morfológicas ni movimientos anormales. El siguiente paso fue la realización de una serie fluoroscópica con contraste oral, que demostró una muesca en la pared posterior del tercio superior del esófago. Durante ese tiempo el paciente no mostró cambios en su sintomatología. Tras la cirugía de píloro no había vuelto a presentar vómitos. En ningún momento presentó datos de dificultad respiratoria asociados al estridor. Días después se realizó una broncoscopia, en la que se observó una compresión extrínseca 2 cm por encima de la carina, pulsátil, que obstruía más del 50% de la luz de la tráquea y no se modificaba con presión positiva. Ante la fuerte sospecha de una malformación vascular que fuera responsable de la disminución del calibre traqueal, se realizó una angiografía por tomografía computarizada (angio-TC), en la que se pudo identificar un doble arco aórtico completo, con predominancia del arco derecho como causa de la constricción traqueal. La ecocardiografía fue normal. El paciente fue operado por medio de una cirugía de abordaje torácico lateral izquierdo que se realizó sin contratiempos. En las primeras horas posquirúrgicas se notó una importante disminución en la intensidad del ruido inspiratorio. Fue dado de alta y durante las siguientes semanas el estridor residual continuó disminuyendo. No volvió a presentar síntomas respiratorios ni digestivos, y en una consulta de seguimiento a dos meses de la cirugía el estridor terminó por desaparecer del todo. Remitido por: Dr. Jose Luis Fernandez Copado. Correo electrónico: a00799839@itesm.com Instructions: please typing these entity words according to sentence: Daniel, Perea Dominguez, 7842356, Madrid, 28001, 30/03/2017, España, 26 dias, 25/04/2017, Jose Luis Fernandez Copado, 28 28 93020, Varón, 26 días, tres semanas, madre, Jose Luis Fernandez Copado, a00799839@itesm.com Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, FAMILIARES_SUJETO_ASISTENCIA, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Datos del paciente. Nombre: Daniel. Apellidos: Perea Dominguez. NHC: 7842356. Domicilio: Calle Conde Duque,19, 3A. Localidad/ Provincia: Madrid. CP: 28001. Datos asistenciales. Fecha de nacimiento: 30/03/2017. País: España. Edad: 26 dias Sexo: H. Fecha de Ingreso: 25/04/2017. Médico: Jose Luis Fernandez Copado. NºCol: 28 28 93020. Informe clínico del paciente:Varón de 26 días de vida sin antecedentes familiares, prenatales o perinatales de relevancia. Hacia las tres semanas de vida comienza a presentar vómitos, que fueron en aumento, y el día previo a su ingreso se presentaron con cada toma, abundantes y en proyectil. El paciente se mostraba ávido por comer y con buen estado general. Al presentarse en el Departamento de Urgencias, se tuvo la sospecha clínica de estenosis hipertrófica de píloro, apoyada por una gasometría que mostraba alcalosis metabólica y un ultrasonido con imagen en diana característica. El paciente fue intervenido de forma abierta mediante la técnica de Ramstedt, sin incidencias. Antes del procedimiento el paciente fue intubado sin complicaciones. A las 14 horas de la cirugía se escucha por primera vez estridor de predominio inspiratorio, que no se modificaba con el sueño, la posición ni con la alimentación. Se reinterrogó a la madre, que negó haberlo escuchado antes. El paciente no presentaba ningún dato de dificultad respiratoria ni desaturación del oxígeno en la pulsioximetría. Dado que se trataba de un paciente previamente sano al que no se le había escuchado estridor antes, se sospechó que la intubación operatoria y el edema postraumático asociado pudieran ser la causa. Se administró nebulización con adrenalina y una dosis de dexametasona intravenosa. Tras dos horas, el estridor no se había modificado, y al continuar el paciente sin signos de dificultad respiratoria, se inició el abordaje de este problema. En una radiografía simple de tórax no se observaron anormalidades en el parénquima pulmonar, estructuras del cuello o columna de aire traqueal. Posteriormente, mediante una nasolaringoendoscopia flexible se comprobaron las estructuras supraglóticas y las cuerdas vocales íntegras, sin alteraciones morfológicas ni movimientos anormales. El siguiente paso fue la realización de una serie fluoroscópica con contraste oral, que demostró una muesca en la pared posterior del tercio superior del esófago. Durante ese tiempo el paciente no mostró cambios en su sintomatología. Tras la cirugía de píloro no había vuelto a presentar vómitos. En ningún momento presentó datos de dificultad respiratoria asociados al estridor. Días después se realizó una broncoscopia, en la que se observó una compresión extrínseca 2 cm por encima de la carina, pulsátil, que obstruía más del 50% de la luz de la tráquea y no se modificaba con presión positiva. Ante la fuerte sospecha de una malformación vascular que fuera responsable de la disminución del calibre traqueal, se realizó una angiografía por tomografía computarizada (angio-TC), en la que se pudo identificar un doble arco aórtico completo, con predominancia del arco derecho como causa de la constricción traqueal. La ecocardiografía fue normal. El paciente fue operado por medio de una cirugía de abordaje torácico lateral izquierdo que se realizó sin contratiempos. En las primeras horas posquirúrgicas se notó una importante disminución en la intensidad del ruido inspiratorio. Fue dado de alta y durante las siguientes semanas el estridor residual continuó disminuyendo. No volvió a presentar síntomas respiratorios ni digestivos, y en una consulta de seguimiento a dos meses de la cirugía el estridor terminó por desaparecer del todo. Remitido por: Dr. Jose Luis Fernandez Copado. Correo electrónico: a00799839@itesm.com	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", " ", "Daniel", ".", "\n", "Apellidos", ":", "Perea", "Dominguez", ".", "\n", "NHC", ":", "7842356", ".", "\n", "Domicilio", ":", "Calle", "Conde", "Duque,19", ",", "3A.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28001", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "30/03/2017", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "26", "dias", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "25/04/2017", ".", "\n", "Médico", ":", "Jose", "Luis", "Fernandez", "Copado", ".", "NºCol", ":", "28", "28", "93020", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Varón", "de", "26", "días", "de", "vida", "sin", "antecedentes", "familiares", ",", "prenatales", "o", "perinatales", "de", "relevancia", ".", "Hacia", "las", "tres", "semanas", "de", "vida", "comienza", "a", "presentar", "vómitos", ",", "que", "fueron", "en", "aumento", ",", "y", "el", "día", "previo", "a", "su", "ingreso", "se", "presentaron", "con", "cada", "toma", ",", "abundantes", "y", "en", "proyectil", ".", "El", "paciente", "se", "mostraba", "ávido", "por", "comer", "y", "con", "buen", "estado", "general", ".", "\n", "Al", "presentarse", "en", "el", "Departamento", "de", "Urgencias", ",", "se", "tuvo", "la", "sospecha", "clínica", "de", "estenosis", "hipertrófica", "de", "píloro", ",", "apoyada", "por", "una", "gasometría", "que", "mostraba", "alcalosis", "metabólica", "y", "un", "ultrasonido", "con", "imagen", "en", "diana", "característica", ".", "El", "paciente", "fue", "intervenido", "de", "forma", "abierta", "mediante", "la", "técnica", "de", "Ramstedt", ",", "sin", "incidencias", ".", "Antes", "del", "procedimiento", "el", "paciente", "fue", "intubado", "sin", "complicaciones", ".", "\n", "A", "las", "14", "horas", "de", "la", "cirugía", "se", "escucha", "por", "primera", "vez", "estridor", "de", "predominio", "inspiratorio", ",", "que", "no", "se", "modificaba", "con", "el", "sueño", ",", "la", "posición", "ni", "con", "la", "alimentación", ".", "Se", "reinterrogó", "a", "la", "madre", ",", "que", "negó", "haberlo", "escuchado", "antes", ".", "El", "paciente", "no", "presentaba", "ningún", "dato", "de", "dificultad", "respiratoria", "ni", "desaturación", "del", "oxígeno", "en", "la", "pulsioximetría", ".", "\n", "Dado", "que", "se", "trataba", "de", "un", "paciente", "previamente", "sano", "al", "que", "no", "se", "le", "había", "escuchado", "estridor", "antes", ",", "se", "sospechó", "que", "la", "intubación", "operatoria", "y", "el", "edema", "postraumático", "asociado", "pudieran", "ser", "la", "causa", ".", "Se", "administró", "nebulización", "con", "adrenalina", "y", "una", "dosis", "de", "dexametasona", "intravenosa", ".", "Tras", "dos", "horas", ",", "el", "estridor", "no", "se", "había", "modificado", ",", "y", "al", "continuar", "el", "paciente", "sin", "signos", "de", "dificultad", "respiratoria", ",", "se", "inició", "el", "abordaje", "de", "este", "problema", ".", "\n", "En", "una", "radiografía", "simple", "de", "tórax", "no", "se", "observaron", "anormalidades", "en", "el", "parénquima", "pulmonar", ",", "estructuras", "del", "cuello", "o", "columna", "de", "aire", "traqueal", ".", "Posteriormente", ",", "mediante", "una", "nasolaringoendoscopia", "flexible", "se", "comprobaron", "las", "estructuras", "supraglóticas", "y", "las", "cuerdas", "vocales", "íntegras", ",", "sin", "alteraciones", "morfológicas", "ni", "movimientos", "anormales", ".", "El", "siguiente", "paso", "fue", "la", "realización", "de", "una", "serie", "fluoroscópica", "con", "contraste", "oral", ",", "que", "demostró", "una", "muesca", "en", "la", "pared", "posterior", "del", "tercio", "superior", "del", "esófago", ".", "Durante", "ese", "tiempo", "el", "paciente", "no", "mostró", "cambios", "en", "su", "sintomatología", ".", "Tras", "la", "cirugía", "de", "píloro", "no", "había", "vuelto", "a", "presentar", "vómitos", ".", "En", "ningún", "momento", "presentó", "datos", "de", "dificultad", "respiratoria", "asociados", "al", "estridor", ".", "\n", "Días", "después", "se", "realizó", "una", "broncoscopia", ",", "en", "la", "que", "se", "observó", "una", "compresión", "extrínseca", "2", "cm", "por", "encima", "de", "la", "carina", ",", "pulsátil", ",", "que", "obstruía", "más", "del", "50", "%", "de", "la", "luz", "de", "la", "tráquea", "y", "no", "se", "modificaba", "con", "presión", "positiva", ".", "Ante", "la", "fuerte", "sospecha", "de", "una", "malformación", "vascular", "que", "fuera", "responsable", "de", "la", "disminución", "del", "calibre", "traqueal", ",", "se", "realizó", "una", "angiografía", "por", "tomografía", "computarizada", "(", "angio", "-", "TC", ")", ",", "en", "la", "que", "se", "pudo", "identificar", "un", "doble", "arco", "aórtico", "completo", ",", "con", "predominancia", "del", "arco", "derecho", "como", "causa", "de", "la", "constricción", "traqueal", ".", "La", "ecocardiografía", "fue", "normal", ".", "\n", "El", "paciente", "fue", "operado", "por", "medio", "de", "una", "cirugía", "de", "abordaje", "torácico", "lateral", "izquierdo", "que", "se", "realizó", "sin", "contratiempos", ".", "\n", "En", "las", "primeras", "horas", "posquirúrgicas", "se", "notó", "una", "importante", "disminución", "en", "la", "intensidad", "del", "ruido", "inspiratorio", ".", "Fue", "dado", "de", "alta", "y", "durante", "las", "siguientes", "semanas", "el", "estridor", "residual", "continuó", "disminuyendo", ".", "No", "volvió", "a", "presentar", "síntomas", "respiratorios", "ni", "digestivos", ",", "y", "en", "una", "consulta", "de", "seguimiento", "a", "dos", "meses", "de", "la", "cirugía", "el", "estridor", "terminó", "por", "desaparecer", "del", "todo", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Jose", "Luis", "Fernandez", "Copado", ".", "Correo", "electrónico", ":", "a00799839@itesm.com", "\n" ]	[ "NOMBRE_PERSONAL_SANITARIO", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_SUJETO_ASISTENCIA", "EDAD_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "FAMILIARES_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA" ]
Daniel, Perea Dominguez, 7842356, Madrid, 28001, 30/03/2017, España, 26 dias, 25/04/2017, Jose Luis Fernandez Copado, 28 28 93020, Varón, 26 días, tres semanas, madre, Jose Luis Fernandez Copado, a00799839@itesm.com	470_task2	Sentence: Datos del paciente. Nombre: Daniel. Apellidos: Perea Dominguez. NHC: 7842356. Domicilio: Calle Conde Duque,19, 3A. Localidad/ Provincia: Madrid. CP: 28001. Datos asistenciales. Fecha de nacimiento: 30/03/2017. País: España. Edad: 26 dias Sexo: H. Fecha de Ingreso: 25/04/2017. Médico: Jose Luis Fernandez Copado. NºCol: 28 28 93020. Informe clínico del paciente:Varón de 26 días de vida sin antecedentes familiares, prenatales o perinatales de relevancia. Hacia las tres semanas de vida comienza a presentar vómitos, que fueron en aumento, y el día previo a su ingreso se presentaron con cada toma, abundantes y en proyectil. El paciente se mostraba ávido por comer y con buen estado general. Al presentarse en el Departamento de Urgencias, se tuvo la sospecha clínica de estenosis hipertrófica de píloro, apoyada por una gasometría que mostraba alcalosis metabólica y un ultrasonido con imagen en diana característica. El paciente fue intervenido de forma abierta mediante la técnica de Ramstedt, sin incidencias. Antes del procedimiento el paciente fue intubado sin complicaciones. A las 14 horas de la cirugía se escucha por primera vez estridor de predominio inspiratorio, que no se modificaba con el sueño, la posición ni con la alimentación. Se reinterrogó a la madre, que negó haberlo escuchado antes. El paciente no presentaba ningún dato de dificultad respiratoria ni desaturación del oxígeno en la pulsioximetría. Dado que se trataba de un paciente previamente sano al que no se le había escuchado estridor antes, se sospechó que la intubación operatoria y el edema postraumático asociado pudieran ser la causa. Se administró nebulización con adrenalina y una dosis de dexametasona intravenosa. Tras dos horas, el estridor no se había modificado, y al continuar el paciente sin signos de dificultad respiratoria, se inició el abordaje de este problema. En una radiografía simple de tórax no se observaron anormalidades en el parénquima pulmonar, estructuras del cuello o columna de aire traqueal. Posteriormente, mediante una nasolaringoendoscopia flexible se comprobaron las estructuras supraglóticas y las cuerdas vocales íntegras, sin alteraciones morfológicas ni movimientos anormales. El siguiente paso fue la realización de una serie fluoroscópica con contraste oral, que demostró una muesca en la pared posterior del tercio superior del esófago. Durante ese tiempo el paciente no mostró cambios en su sintomatología. Tras la cirugía de píloro no había vuelto a presentar vómitos. En ningún momento presentó datos de dificultad respiratoria asociados al estridor. Días después se realizó una broncoscopia, en la que se observó una compresión extrínseca 2 cm por encima de la carina, pulsátil, que obstruía más del 50% de la luz de la tráquea y no se modificaba con presión positiva. Ante la fuerte sospecha de una malformación vascular que fuera responsable de la disminución del calibre traqueal, se realizó una angiografía por tomografía computarizada (angio-TC), en la que se pudo identificar un doble arco aórtico completo, con predominancia del arco derecho como causa de la constricción traqueal. La ecocardiografía fue normal. El paciente fue operado por medio de una cirugía de abordaje torácico lateral izquierdo que se realizó sin contratiempos. En las primeras horas posquirúrgicas se notó una importante disminución en la intensidad del ruido inspiratorio. Fue dado de alta y durante las siguientes semanas el estridor residual continuó disminuyendo. No volvió a presentar síntomas respiratorios ni digestivos, y en una consulta de seguimiento a dos meses de la cirugía el estridor terminó por desaparecer del todo. Remitido por: Dr. Jose Luis Fernandez Copado. Correo electrónico: a00799839@itesm.com Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Datos del paciente. Nombre: Daniel. Apellidos: Perea Dominguez. NHC: 7842356. Domicilio: Calle Conde Duque,19, 3A. Localidad/ Provincia: Madrid. CP: 28001. Datos asistenciales. Fecha de nacimiento: 30/03/2017. País: España. Edad: 26 dias Sexo: H. Fecha de Ingreso: 25/04/2017. Médico: Jose Luis Fernandez Copado. NºCol: 28 28 93020. Informe clínico del paciente:Varón de 26 días de vida sin antecedentes familiares, prenatales o perinatales de relevancia. Hacia las tres semanas de vida comienza a presentar vómitos, que fueron en aumento, y el día previo a su ingreso se presentaron con cada toma, abundantes y en proyectil. El paciente se mostraba ávido por comer y con buen estado general. Al presentarse en el Departamento de Urgencias, se tuvo la sospecha clínica de estenosis hipertrófica de píloro, apoyada por una gasometría que mostraba alcalosis metabólica y un ultrasonido con imagen en diana característica. El paciente fue intervenido de forma abierta mediante la técnica de Ramstedt, sin incidencias. Antes del procedimiento el paciente fue intubado sin complicaciones. A las 14 horas de la cirugía se escucha por primera vez estridor de predominio inspiratorio, que no se modificaba con el sueño, la posición ni con la alimentación. Se reinterrogó a la madre, que negó haberlo escuchado antes. El paciente no presentaba ningún dato de dificultad respiratoria ni desaturación del oxígeno en la pulsioximetría. Dado que se trataba de un paciente previamente sano al que no se le había escuchado estridor antes, se sospechó que la intubación operatoria y el edema postraumático asociado pudieran ser la causa. Se administró nebulización con adrenalina y una dosis de dexametasona intravenosa. Tras dos horas, el estridor no se había modificado, y al continuar el paciente sin signos de dificultad respiratoria, se inició el abordaje de este problema. En una radiografía simple de tórax no se observaron anormalidades en el parénquima pulmonar, estructuras del cuello o columna de aire traqueal. Posteriormente, mediante una nasolaringoendoscopia flexible se comprobaron las estructuras supraglóticas y las cuerdas vocales íntegras, sin alteraciones morfológicas ni movimientos anormales. El siguiente paso fue la realización de una serie fluoroscópica con contraste oral, que demostró una muesca en la pared posterior del tercio superior del esófago. Durante ese tiempo el paciente no mostró cambios en su sintomatología. Tras la cirugía de píloro no había vuelto a presentar vómitos. En ningún momento presentó datos de dificultad respiratoria asociados al estridor. Días después se realizó una broncoscopia, en la que se observó una compresión extrínseca 2 cm por encima de la carina, pulsátil, que obstruía más del 50% de la luz de la tráquea y no se modificaba con presión positiva. Ante la fuerte sospecha de una malformación vascular que fuera responsable de la disminución del calibre traqueal, se realizó una angiografía por tomografía computarizada (angio-TC), en la que se pudo identificar un doble arco aórtico completo, con predominancia del arco derecho como causa de la constricción traqueal. La ecocardiografía fue normal. El paciente fue operado por medio de una cirugía de abordaje torácico lateral izquierdo que se realizó sin contratiempos. En las primeras horas posquirúrgicas se notó una importante disminución en la intensidad del ruido inspiratorio. Fue dado de alta y durante las siguientes semanas el estridor residual continuó disminuyendo. No volvió a presentar síntomas respiratorios ni digestivos, y en una consulta de seguimiento a dos meses de la cirugía el estridor terminó por desaparecer del todo. Remitido por: Dr. Jose Luis Fernandez Copado. Correo electrónico: a00799839@itesm.com	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", " ", "Daniel", ".", "\n", "Apellidos", ":", "Perea", "Dominguez", ".", "\n", "NHC", ":", "7842356", ".", "\n", "Domicilio", ":", "Calle", "Conde", "Duque,19", ",", "3A.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28001", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "30/03/2017", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "26", "dias", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "25/04/2017", ".", "\n", "Médico", ":", "Jose", "Luis", "Fernandez", "Copado", ".", "NºCol", ":", "28", "28", "93020", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Varón", "de", "26", "días", "de", "vida", "sin", "antecedentes", "familiares", ",", "prenatales", "o", "perinatales", "de", "relevancia", ".", "Hacia", "las", "tres", "semanas", "de", "vida", "comienza", "a", "presentar", "vómitos", ",", "que", "fueron", "en", "aumento", ",", "y", "el", "día", "previo", "a", "su", "ingreso", "se", "presentaron", "con", "cada", "toma", ",", "abundantes", "y", "en", "proyectil", ".", "El", "paciente", "se", "mostraba", "ávido", "por", "comer", "y", "con", "buen", "estado", "general", ".", "\n", "Al", "presentarse", "en", "el", "Departamento", "de", "Urgencias", ",", "se", "tuvo", "la", "sospecha", "clínica", "de", "estenosis", "hipertrófica", "de", "píloro", ",", "apoyada", "por", "una", "gasometría", "que", "mostraba", "alcalosis", "metabólica", "y", "un", "ultrasonido", "con", "imagen", "en", "diana", "característica", ".", "El", "paciente", "fue", "intervenido", "de", "forma", "abierta", "mediante", "la", "técnica", "de", "Ramstedt", ",", "sin", "incidencias", ".", "Antes", "del", "procedimiento", "el", "paciente", "fue", "intubado", "sin", "complicaciones", ".", "\n", "A", "las", "14", "horas", "de", "la", "cirugía", "se", "escucha", "por", "primera", "vez", "estridor", "de", "predominio", "inspiratorio", ",", "que", "no", "se", "modificaba", "con", "el", "sueño", ",", "la", "posición", "ni", "con", "la", "alimentación", ".", "Se", "reinterrogó", "a", "la", "madre", ",", "que", "negó", "haberlo", "escuchado", "antes", ".", "El", "paciente", "no", "presentaba", "ningún", "dato", "de", "dificultad", "respiratoria", "ni", "desaturación", "del", "oxígeno", "en", "la", "pulsioximetría", ".", "\n", "Dado", "que", "se", "trataba", "de", "un", "paciente", "previamente", "sano", "al", "que", "no", "se", "le", "había", "escuchado", "estridor", "antes", ",", "se", "sospechó", "que", "la", "intubación", "operatoria", "y", "el", "edema", "postraumático", "asociado", "pudieran", "ser", "la", "causa", ".", "Se", "administró", "nebulización", "con", "adrenalina", "y", "una", "dosis", "de", "dexametasona", "intravenosa", ".", "Tras", "dos", "horas", ",", "el", "estridor", "no", "se", "había", "modificado", ",", "y", "al", "continuar", "el", "paciente", "sin", "signos", "de", "dificultad", "respiratoria", ",", "se", "inició", "el", "abordaje", "de", "este", "problema", ".", "\n", "En", "una", "radiografía", "simple", "de", "tórax", "no", "se", "observaron", "anormalidades", "en", "el", "parénquima", "pulmonar", ",", "estructuras", "del", "cuello", "o", "columna", "de", "aire", "traqueal", ".", "Posteriormente", ",", "mediante", "una", "nasolaringoendoscopia", "flexible", "se", "comprobaron", "las", "estructuras", "supraglóticas", "y", "las", "cuerdas", "vocales", "íntegras", ",", "sin", "alteraciones", "morfológicas", "ni", "movimientos", "anormales", ".", "El", "siguiente", "paso", "fue", "la", "realización", "de", "una", "serie", "fluoroscópica", "con", "contraste", "oral", ",", "que", "demostró", "una", "muesca", "en", "la", "pared", "posterior", "del", "tercio", "superior", "del", "esófago", ".", "Durante", "ese", "tiempo", "el", "paciente", "no", "mostró", "cambios", "en", "su", "sintomatología", ".", "Tras", "la", "cirugía", "de", "píloro", "no", "había", "vuelto", "a", "presentar", "vómitos", ".", "En", "ningún", "momento", "presentó", "datos", "de", "dificultad", "respiratoria", "asociados", "al", "estridor", ".", "\n", "Días", "después", "se", "realizó", "una", "broncoscopia", ",", "en", "la", "que", "se", "observó", "una", "compresión", "extrínseca", "2", "cm", "por", "encima", "de", "la", "carina", ",", "pulsátil", ",", "que", "obstruía", "más", "del", "50", "%", "de", "la", "luz", "de", "la", "tráquea", "y", "no", "se", "modificaba", "con", "presión", "positiva", ".", "Ante", "la", "fuerte", "sospecha", "de", "una", "malformación", "vascular", "que", "fuera", "responsable", "de", "la", "disminución", "del", "calibre", "traqueal", ",", "se", "realizó", "una", "angiografía", "por", "tomografía", "computarizada", "(", "angio", "-", "TC", ")", ",", "en", "la", "que", "se", "pudo", "identificar", "un", "doble", "arco", "aórtico", "completo", ",", "con", "predominancia", "del", "arco", "derecho", "como", "causa", "de", "la", "constricción", "traqueal", ".", "La", "ecocardiografía", "fue", "normal", ".", "\n", "El", "paciente", "fue", "operado", "por", "medio", "de", "una", "cirugía", "de", "abordaje", "torácico", "lateral", "izquierdo", "que", "se", "realizó", "sin", "contratiempos", ".", "\n", "En", "las", "primeras", "horas", "posquirúrgicas", "se", "notó", "una", "importante", "disminución", "en", "la", "intensidad", "del", "ruido", "inspiratorio", ".", "Fue", "dado", "de", "alta", "y", "durante", "las", "siguientes", "semanas", "el", "estridor", "residual", "continuó", "disminuyendo", ".", "No", "volvió", "a", "presentar", "síntomas", "respiratorios", "ni", "digestivos", ",", "y", "en", "una", "consulta", "de", "seguimiento", "a", "dos", "meses", "de", "la", "cirugía", "el", "estridor", "terminó", "por", "desaparecer", "del", "todo", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Jose", "Luis", "Fernandez", "Copado", ".", "Correo", "electrónico", ":", "a00799839@itesm.com", "\n" ]	[ "NOMBRE_PERSONAL_SANITARIO", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_SUJETO_ASISTENCIA", "EDAD_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "FAMILIARES_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA" ]
noninvasive haemoglobin measurement is a Outcome_Other, pulse oximetry is a Intervention_Physical, oximetry haemoglobin is a Outcome_Physical, infusion experiments is a Intervention_Physical	57863_task0	Sentence: Accuracy of noninvasive haemoglobin measurement by pulse oximetry depends on the type of infusion fluid . CONTEXT Measurement of blood haemoglobin concentration by pulse oximetry could be of value in determining when erythrocytes should be transfused during surgery , but the effect of infusion fluids on the results is unclear . OBJECTIVE To study the effect of crystalloid and colloid fluid on the accuracy ( bias ) and precision of pulse oximetry haemoglobin estimation to indicate the venous haemoglobin concentration in volunteers . DESIGN Open interventional crossover study . SETTING Single university hospital . PARTICIPANTS Ten male volunteers aged 18-28 ( mean 22 ) years . INTERVENTIONS Each volunteer underwent three infusion experiments on separate days and in random order . The infusions were Ringer 's acetate ( 20 ml kg ) , hydroxyethyl starch 130/0.4 ( 10 ml kg ) and a combination of both . RESULTS At the end of the infusions of Ringer 's acetate , pulse oximetry haemoglobin concentration had decreased more than the true haemoglobin concentration ( 15 vs. 8 % ; P < 0.005 ; n = 10 ) whereas starch solution decreased pulse oximetry haemoglobin concentration less than true haemoglobin concentration ( 7 vs. 11 % ; P < 0.02 ; n = 20 ) . The same differences were seen when the fluids were infused separately and when they were combined . The overall difference between all 956 pairs of pulse oximetry haemoglobin concentration and true haemoglobin concentrations ( the bias ) averaged only -0.7 g l whereas the 95 % prediction interval was wide , ranging from -24.9 to 23.7 g l. In addition to the choice of infusion fluid , the bias was strongly dependent on the volunteer ( each factor , P < 0.001 ) . CONCLUSION The bias of measuring haemoglobin concentration by pulse oximetry is dependent on whether a crystalloid or a colloid fluid is infused . TRIAL REGISTRATION ClinicalTrials identifier : NCT01195025 . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Outcome_Other, Outcome_Physical	[ "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Accuracy of noninvasive haemoglobin measurement by pulse oximetry depends on the type of infusion fluid . CONTEXT Measurement of blood haemoglobin concentration by pulse oximetry could be of value in determining when erythrocytes should be transfused during surgery , but the effect of infusion fluids on the results is unclear . OBJECTIVE To study the effect of crystalloid and colloid fluid on the accuracy ( bias ) and precision of pulse oximetry haemoglobin estimation to indicate the venous haemoglobin concentration in volunteers . DESIGN Open interventional crossover study . SETTING Single university hospital . PARTICIPANTS Ten male volunteers aged 18-28 ( mean 22 ) years . INTERVENTIONS Each volunteer underwent three infusion experiments on separate days and in random order . The infusions were Ringer 's acetate ( 20 ml kg ) , hydroxyethyl starch 130/0.4 ( 10 ml kg ) and a combination of both . RESULTS At the end of the infusions of Ringer 's acetate , pulse oximetry haemoglobin concentration had decreased more than the true haemoglobin concentration ( 15 vs. 8 % ; P < 0.005 ; n = 10 ) whereas starch solution decreased pulse oximetry haemoglobin concentration less than true haemoglobin concentration ( 7 vs. 11 % ; P < 0.02 ; n = 20 ) . The same differences were seen when the fluids were infused separately and when they were combined . The overall difference between all 956 pairs of pulse oximetry haemoglobin concentration and true haemoglobin concentrations ( the bias ) averaged only -0.7 g l whereas the 95 % prediction interval was wide , ranging from -24.9 to 23.7 g l. In addition to the choice of infusion fluid , the bias was strongly dependent on the volunteer ( each factor , P < 0.001 ) . CONCLUSION The bias of measuring haemoglobin concentration by pulse oximetry is dependent on whether a crystalloid or a colloid fluid is infused . TRIAL REGISTRATION ClinicalTrials identifier : NCT01195025 .	[ "Accuracy", "of", "noninvasive", "haemoglobin", "measurement", "by", "pulse", "oximetry", "depends", "on", "the", "type", "of", "infusion", "fluid", ".", "CONTEXT", "Measurement", "of", "blood", "haemoglobin", "concentration", "by", "pulse", "oximetry", "could", "be", "of", "value", "in", "determining", "when", "erythrocytes", "should", "be", "transfused", "during", "surgery", ",", "but", "the", "effect", "of", "infusion", "fluids", "on", "the", "results", "is", "unclear", ".", "OBJECTIVE", "To", "study", "the", "effect", "of", "crystalloid", "and", "colloid", "fluid", "on", "the", "accuracy", "(", "bias", ")", "and", "precision", "of", "pulse", "oximetry", "haemoglobin", "estimation", "to", "indicate", "the", "venous", "haemoglobin", "concentration", "in", "volunteers", ".", "DESIGN", "Open", "interventional", "crossover", "study", ".", "SETTING", "Single", "university", "hospital", ".", "PARTICIPANTS", "Ten", "male", "volunteers", "aged", "18", "-", "28", "(", "mean", "22", ")", "years", ".", "INTERVENTIONS", "Each", "volunteer", "underwent", "three", "infusion", "experiments", "on", "separate", "days", "and", "in", "random", "order", ".", "The", "infusions", "were", "Ringer", "'", "s", "acetate", "(", "20", "ml", "kg", ")", ",", "hydroxyethyl", "starch", "130/0.4", "(", "10", "ml", "kg", ")", "and", "a", "combination", "of", "both", ".", "RESULTS", "At", "the", "end", "of", "the", "infusions", "of", "Ringer", "'", "s", "acetate", ",", "pulse", "oximetry", "haemoglobin", "concentration", "had", "decreased", "more", "than", "the", "true", "haemoglobin", "concentration", "(", "15", "vs", ".", "8", "%", ";", "P", "<", "0.005", ";", "n", "=", "10", ")", "whereas", "starch", "solution", "decreased", "pulse", "oximetry", "haemoglobin", "concentration", "less", "than", "true", "haemoglobin", "concentration", "(", "7", "vs", ".", "11", "%", ";", "P", "<", "0.02", ";", "n", "=", "20", ")", ".", "The", "same", "differences", "were", "seen", "when", "the", "fluids", "were", "infused", "separately", "and", "when", "they", "were", "combined", ".", "The", "overall", "difference", "between", "all", "956", "pairs", "of", "pulse", "oximetry", "haemoglobin", "concentration", "and", "true", "haemoglobin", "concentrations", "(", "the", "bias", ")", "averaged", "only", "-0.7", "g", "l", "whereas", "the", "95", "%", "prediction", "interval", "was", "wide", ",", "ranging", "from", "-24.9", "to", "23.7", "g", "l.", "In", "addition", "to", "the", "choice", "of", "infusion", "fluid", ",", "the", "bias", "was", "strongly", "dependent", "on", "the", "volunteer", "(", "each", "factor", ",", "P", "<", "0.001", ")", ".", "CONCLUSION", "The", "bias", "of", "measuring", "haemoglobin", "concentration", "by", "pulse", "oximetry", "is", "dependent", "on", "whether", "a", "crystalloid", "or", "a", "colloid", "fluid", "is", "infused", ".", "TRIAL", "REGISTRATION", "ClinicalTrials", "identifier", ":", "NCT01195025", "." ]	[ "Outcome_Other", "Intervention_Physical", "Outcome_Physical" ]
noninvasive haemoglobin measurement is a Outcome_Other, pulse oximetry is a Intervention_Physical, oximetry haemoglobin is a Outcome_Physical, infusion experiments is a Intervention_Physical	57863_task1	Sentence: Accuracy of noninvasive haemoglobin measurement by pulse oximetry depends on the type of infusion fluid . CONTEXT Measurement of blood haemoglobin concentration by pulse oximetry could be of value in determining when erythrocytes should be transfused during surgery , but the effect of infusion fluids on the results is unclear . OBJECTIVE To study the effect of crystalloid and colloid fluid on the accuracy ( bias ) and precision of pulse oximetry haemoglobin estimation to indicate the venous haemoglobin concentration in volunteers . DESIGN Open interventional crossover study . SETTING Single university hospital . PARTICIPANTS Ten male volunteers aged 18-28 ( mean 22 ) years . INTERVENTIONS Each volunteer underwent three infusion experiments on separate days and in random order . The infusions were Ringer 's acetate ( 20 ml kg ) , hydroxyethyl starch 130/0.4 ( 10 ml kg ) and a combination of both . RESULTS At the end of the infusions of Ringer 's acetate , pulse oximetry haemoglobin concentration had decreased more than the true haemoglobin concentration ( 15 vs. 8 % ; P < 0.005 ; n = 10 ) whereas starch solution decreased pulse oximetry haemoglobin concentration less than true haemoglobin concentration ( 7 vs. 11 % ; P < 0.02 ; n = 20 ) . The same differences were seen when the fluids were infused separately and when they were combined . The overall difference between all 956 pairs of pulse oximetry haemoglobin concentration and true haemoglobin concentrations ( the bias ) averaged only -0.7 g l whereas the 95 % prediction interval was wide , ranging from -24.9 to 23.7 g l. In addition to the choice of infusion fluid , the bias was strongly dependent on the volunteer ( each factor , P < 0.001 ) . CONCLUSION The bias of measuring haemoglobin concentration by pulse oximetry is dependent on whether a crystalloid or a colloid fluid is infused . TRIAL REGISTRATION ClinicalTrials identifier : NCT01195025 . Instructions: please typing these entity words according to sentence: noninvasive haemoglobin measurement, pulse oximetry, oximetry haemoglobin, infusion experiments Options: Intervention_Physical, Outcome_Other, Outcome_Physical	[ "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Accuracy of noninvasive haemoglobin measurement by pulse oximetry depends on the type of infusion fluid . CONTEXT Measurement of blood haemoglobin concentration by pulse oximetry could be of value in determining when erythrocytes should be transfused during surgery , but the effect of infusion fluids on the results is unclear . OBJECTIVE To study the effect of crystalloid and colloid fluid on the accuracy ( bias ) and precision of pulse oximetry haemoglobin estimation to indicate the venous haemoglobin concentration in volunteers . DESIGN Open interventional crossover study . SETTING Single university hospital . PARTICIPANTS Ten male volunteers aged 18-28 ( mean 22 ) years . INTERVENTIONS Each volunteer underwent three infusion experiments on separate days and in random order . The infusions were Ringer 's acetate ( 20 ml kg ) , hydroxyethyl starch 130/0.4 ( 10 ml kg ) and a combination of both . RESULTS At the end of the infusions of Ringer 's acetate , pulse oximetry haemoglobin concentration had decreased more than the true haemoglobin concentration ( 15 vs. 8 % ; P < 0.005 ; n = 10 ) whereas starch solution decreased pulse oximetry haemoglobin concentration less than true haemoglobin concentration ( 7 vs. 11 % ; P < 0.02 ; n = 20 ) . The same differences were seen when the fluids were infused separately and when they were combined . The overall difference between all 956 pairs of pulse oximetry haemoglobin concentration and true haemoglobin concentrations ( the bias ) averaged only -0.7 g l whereas the 95 % prediction interval was wide , ranging from -24.9 to 23.7 g l. In addition to the choice of infusion fluid , the bias was strongly dependent on the volunteer ( each factor , P < 0.001 ) . CONCLUSION The bias of measuring haemoglobin concentration by pulse oximetry is dependent on whether a crystalloid or a colloid fluid is infused . TRIAL REGISTRATION ClinicalTrials identifier : NCT01195025 .	[ "Accuracy", "of", "noninvasive", "haemoglobin", "measurement", "by", "pulse", "oximetry", "depends", "on", "the", "type", "of", "infusion", "fluid", ".", "CONTEXT", "Measurement", "of", "blood", "haemoglobin", "concentration", "by", "pulse", "oximetry", "could", "be", "of", "value", "in", "determining", "when", "erythrocytes", "should", "be", "transfused", "during", "surgery", ",", "but", "the", "effect", "of", "infusion", "fluids", "on", "the", "results", "is", "unclear", ".", "OBJECTIVE", "To", "study", "the", "effect", "of", "crystalloid", "and", "colloid", "fluid", "on", "the", "accuracy", "(", "bias", ")", "and", "precision", "of", "pulse", "oximetry", "haemoglobin", "estimation", "to", "indicate", "the", "venous", "haemoglobin", "concentration", "in", "volunteers", ".", "DESIGN", "Open", "interventional", "crossover", "study", ".", "SETTING", "Single", "university", "hospital", ".", "PARTICIPANTS", "Ten", "male", "volunteers", "aged", "18", "-", "28", "(", "mean", "22", ")", "years", ".", "INTERVENTIONS", "Each", "volunteer", "underwent", "three", "infusion", "experiments", "on", "separate", "days", "and", "in", "random", "order", ".", "The", "infusions", "were", "Ringer", "'", "s", "acetate", "(", "20", "ml", "kg", ")", ",", "hydroxyethyl", "starch", "130/0.4", "(", "10", "ml", "kg", ")", "and", "a", "combination", "of", "both", ".", "RESULTS", "At", "the", "end", "of", "the", "infusions", "of", "Ringer", "'", "s", "acetate", ",", "pulse", "oximetry", "haemoglobin", "concentration", "had", "decreased", "more", "than", "the", "true", "haemoglobin", "concentration", "(", "15", "vs", ".", "8", "%", ";", "P", "<", "0.005", ";", "n", "=", "10", ")", "whereas", "starch", "solution", "decreased", "pulse", "oximetry", "haemoglobin", "concentration", "less", "than", "true", "haemoglobin", "concentration", "(", "7", "vs", ".", "11", "%", ";", "P", "<", "0.02", ";", "n", "=", "20", ")", ".", "The", "same", "differences", "were", "seen", "when", "the", "fluids", "were", "infused", "separately", "and", "when", "they", "were", "combined", ".", "The", "overall", "difference", "between", "all", "956", "pairs", "of", "pulse", "oximetry", "haemoglobin", "concentration", "and", "true", "haemoglobin", "concentrations", "(", "the", "bias", ")", "averaged", "only", "-0.7", "g", "l", "whereas", "the", "95", "%", "prediction", "interval", "was", "wide", ",", "ranging", "from", "-24.9", "to", "23.7", "g", "l.", "In", "addition", "to", "the", "choice", "of", "infusion", "fluid", ",", "the", "bias", "was", "strongly", "dependent", "on", "the", "volunteer", "(", "each", "factor", ",", "P", "<", "0.001", ")", ".", "CONCLUSION", "The", "bias", "of", "measuring", "haemoglobin", "concentration", "by", "pulse", "oximetry", "is", "dependent", "on", "whether", "a", "crystalloid", "or", "a", "colloid", "fluid", "is", "infused", ".", "TRIAL", "REGISTRATION", "ClinicalTrials", "identifier", ":", "NCT01195025", "." ]	[ "Outcome_Other", "Intervention_Physical", "Outcome_Physical" ]

Prior is a Temporal, chemotherapy or radiotherapy is a Scope, within 2 weeks prior is a Temporal, entering the study is a Reference_point, not is a Negation, recovered is a Condition, adverse events is a Condition, agents is a Drug, more than 2 weeks earlier is a Temporal, Systemic steroids is a Drug, not is a Negation, stabilized is a Qualifier, ≥ 5 days is a Temporal, ≤10 mg / day is a Multiplier, prednisone is a Drug, prior to is a Temporal, start of the study drugs is a Reference_point, other investigational agents is a Drug, History is a Observation, allergic reactions is a Condition, TGR-1202 or carfilzomib is a Scope, Uncontrolled is a Qualifier, inter - current illness is a Condition, Pregnant is a Condition, women is a Person, Nursing is a Condition, women is a Person, Current is a Temporal, malignancy is a Condition, history of a prior is a Observation, malignancy is a Condition, Hepatitis A is a Condition, Hepatitis B is a Condition, Hepatitis C is a Condition

NCT02867618_exc_task1

Sentence: 1. Prior Therapy Exposure to chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier. Systemic steroids that have not been stabilized (≥ 5 days) to the equivalent of ≤10 mg/day prednisone prior to the start of the study drugs. No other investigational agents are allowed. 2. History of allergic reactions to TGR-1202 or carfilzomib 3. Uncontrolled inter-current illness 4. Pregnant women 5. Nursing women 6. Current malignancy or history of a prior malignancy 7. Patient known to be Human Immunodeficiency Virus (HIV)-positive 8. Active Hepatitis A, Hepatitis B, or Hepatitis C infection Instructions: please typing these entity words according to sentence: Prior, chemotherapy or radiotherapy, within 2 weeks prior, entering the study, not, recovered, adverse events, agents, more than 2 weeks earlier, Systemic steroids, not, stabilized, ≥ 5 days, ≤10 mg / day, prednisone, prior to, start of the study drugs, other investigational agents, History, allergic reactions, TGR-1202 or carfilzomib, Uncontrolled, inter - current illness, Pregnant, women, Nursing, women, Current, malignancy, history of a prior, malignancy, Hepatitis A, Hepatitis B, Hepatitis C Options: Temporal, Condition, Qualifier, Person, Observation, Multiplier, Reference_point, Negation, Scope, Drug

[ "O", "O", "B-Temporal", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Reference_point", "I-Reference_point", "I-Reference_point", "O", "O", "O", "O", "B-Negation", "B-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Drug", "I-Drug", "O", "O", "B-Negation", "O", "B-Qualifier", "O", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "B-Drug", "B-Temporal", "I-Temporal", "O", "B-Reference_point", "I-Reference_point", "I-Reference_point", "I-Reference_point", "I-Reference_point", "O", "O", "B-Drug", "I-Drug", "I-Drug", "O", "O", "O", "O", "O", "O", "B-Observation", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Condition", "B-Person", "O", "O", "O", "B-Condition", "B-Person", "O", "O", "O", "B-Temporal", "B-Condition", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "B-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Condition", "I-Condition", "O", "O" ]

1. Prior Therapy Exposure to chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier. Systemic steroids that have not been stabilized (≥ 5 days) to the equivalent of ≤10 mg/day prednisone prior to the start of the study drugs. No other investigational agents are allowed. 2. History of allergic reactions to TGR-1202 or carfilzomib 3. Uncontrolled inter-current illness 4. Pregnant women 5. Nursing women 6. Current malignancy or history of a prior malignancy 7. Patient known to be Human Immunodeficiency Virus (HIV)-positive 8. Active Hepatitis A, Hepatitis B, or Hepatitis C infection

[ "1", ".", "Prior", "Therapy", "Exposure", "to", "chemotherapy", "or", "radiotherapy", "within", "2", "weeks", "prior", "to", "entering", "the", "study", "or", "those", "who", "have", "not", "recovered", "from", "adverse", "events", "due", "to", "agents", "administered", "more", "than", "2", "weeks", "earlier", ".", "Systemic", "steroids", "that", "have", "not", "been", "stabilized", "(", "≥", "5", "days", ")", "to", "the", "equivalent", "of", "≤10", "mg", "/", "day", "prednisone", "prior", "to", "the", "start", "of", "the", "study", "drugs", ".", "No", "other", "investigational", "agents", "are", "allowed", ".", "\n", "2", ".", "History", "of", "allergic", "reactions", "to", "TGR-1202", "or", "carfilzomib", "\n", "3", ".", "Uncontrolled", "inter", "-", "current", "illness", "\n", "4", ".", "Pregnant", "women", "\n", "5", ".", "Nursing", "women", "\n", "6", ".", "Current", "malignancy", "or", "history", "of", "a", "prior", "malignancy", "\n", "7", ".", "Patient", "known", "to", "be", "Human", "Immunodeficiency", "Virus", "(", "HIV)-positive", "\n", "8", ".", "Active", "Hepatitis", "A", ",", "Hepatitis", "B", ",", "or", "Hepatitis", "C", "infection", " \n \n" ]

[ "Measurement", "Scope", "Drug", "Temporal", "Reference_point", "Condition", "Observation", "Procedure", "Qualifier", "Multiplier", "Value", "Person", "Negation" ]

Prior, chemotherapy or radiotherapy, within 2 weeks prior, entering the study, not, recovered, adverse events, agents, more than 2 weeks earlier, Systemic steroids, not, stabilized, ≥ 5 days, ≤10 mg / day, prednisone, prior to, start of the study drugs, other investigational agents, History, allergic reactions, TGR-1202 or carfilzomib, Uncontrolled, inter - current illness, Pregnant, women, Nursing, women, Current, malignancy, history of a prior, malignancy, Hepatitis A, Hepatitis B, Hepatitis C

NCT02867618_exc_task2

Sentence: 1. Prior Therapy Exposure to chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier. Systemic steroids that have not been stabilized (≥ 5 days) to the equivalent of ≤10 mg/day prednisone prior to the start of the study drugs. No other investigational agents are allowed. 2. History of allergic reactions to TGR-1202 or carfilzomib 3. Uncontrolled inter-current illness 4. Pregnant women 5. Nursing women 6. Current malignancy or history of a prior malignancy 7. Patient known to be Human Immunodeficiency Virus (HIV)-positive 8. Active Hepatitis A, Hepatitis B, or Hepatitis C infection Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Temporal", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Reference_point", "I-Reference_point", "I-Reference_point", "O", "O", "O", "O", "B-Negation", "B-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Drug", "I-Drug", "O", "O", "B-Negation", "O", "B-Qualifier", "O", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "B-Drug", "B-Temporal", "I-Temporal", "O", "B-Reference_point", "I-Reference_point", "I-Reference_point", "I-Reference_point", "I-Reference_point", "O", "O", "B-Drug", "I-Drug", "I-Drug", "O", "O", "O", "O", "O", "O", "B-Observation", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Condition", "B-Person", "O", "O", "O", "B-Condition", "B-Person", "O", "O", "O", "B-Temporal", "B-Condition", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "B-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Condition", "I-Condition", "O", "O" ]

1. Prior Therapy Exposure to chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier. Systemic steroids that have not been stabilized (≥ 5 days) to the equivalent of ≤10 mg/day prednisone prior to the start of the study drugs. No other investigational agents are allowed. 2. History of allergic reactions to TGR-1202 or carfilzomib 3. Uncontrolled inter-current illness 4. Pregnant women 5. Nursing women 6. Current malignancy or history of a prior malignancy 7. Patient known to be Human Immunodeficiency Virus (HIV)-positive 8. Active Hepatitis A, Hepatitis B, or Hepatitis C infection

[ "1", ".", "Prior", "Therapy", "Exposure", "to", "chemotherapy", "or", "radiotherapy", "within", "2", "weeks", "prior", "to", "entering", "the", "study", "or", "those", "who", "have", "not", "recovered", "from", "adverse", "events", "due", "to", "agents", "administered", "more", "than", "2", "weeks", "earlier", ".", "Systemic", "steroids", "that", "have", "not", "been", "stabilized", "(", "≥", "5", "days", ")", "to", "the", "equivalent", "of", "≤10", "mg", "/", "day", "prednisone", "prior", "to", "the", "start", "of", "the", "study", "drugs", ".", "No", "other", "investigational", "agents", "are", "allowed", ".", "\n", "2", ".", "History", "of", "allergic", "reactions", "to", "TGR-1202", "or", "carfilzomib", "\n", "3", ".", "Uncontrolled", "inter", "-", "current", "illness", "\n", "4", ".", "Pregnant", "women", "\n", "5", ".", "Nursing", "women", "\n", "6", ".", "Current", "malignancy", "or", "history", "of", "a", "prior", "malignancy", "\n", "7", ".", "Patient", "known", "to", "be", "Human", "Immunodeficiency", "Virus", "(", "HIV)-positive", "\n", "8", ".", "Active", "Hepatitis", "A", ",", "Hepatitis", "B", ",", "or", "Hepatitis", "C", "infection", " \n \n" ]

[ "Measurement", "Scope", "Drug", "Temporal", "Reference_point", "Condition", "Observation", "Procedure", "Qualifier", "Multiplier", "Value", "Person", "Negation" ]

patients is an umlsterm, hemodynamics is an umlsterm, rest is an umlsterm, exercise is an umlsterm, myocardial infarction is an umlsterm, left - heart is an umlsterm, catheterizations is an umlsterm, catheterization is an umlsterm, ventricular function is an umlsterm, patient is an umlsterm, PTCA is an umlsterm, surgery is an umlsterm, hemodynamics is an umlsterm, rest is an umlsterm, exercise is an umlsterm, exercise tolerance is an umlsterm, ventricular function is an umlsterm, hemodynamics is an umlsterm, patients is an umlsterm, pressures is an umlsterm, exercise is an umlsterm, control is an umlsterm, exercise tolerance is an umlsterm, Ventricular function is an umlsterm, Measurement is an umlsterm, hemodynamics is an umlsterm, rest is an umlsterm, exercise is an umlsterm, future is an umlsterm, patient is an umlsterm

ZfuerKardiologie.70860485.eng.abstr_task0

Sentence: In 123 consecutive patients pulmonary hemodynamics at rest and during exercise were measured 7-10 days after acute myocardial infarction and systemic thrombolysis . Right- and left-heart catheterizations were performed at the same session and repeated after 6 months . We investigated if right-heart catheterization could predict the number of stenotic or occluded coronaries , the angiographic ventricular function andor , most important , if the patient would profit from revascularization by PTCA or coronary surgery . Results : 1 ) Pulmonary hemodynamics at rest and during exercise did not correlate to the number of stenotic or occluded coronaries , but exercise tolerance did . 2 ) Correlation between ventricular function and pulmonary hemodynamics was weak . 3 ) Only patients with pathologically elevated pulmonary pressures at exercise showed profit from revascularization ( increase of ejection fraction > 5% at control ) . This profit was closely correlated to the angiographic extent of ventricular damage . Consequences from our results : Individual exercise tolerance can easily be measured non-invasively . Ventricular function can be measured non-invasively as well as by echocardiography . Measurement of pulmonary hemodynamics at rest and during exercise does not contribute to planning the future management of the postinfarction patient and does not replace coronarography when indicated by clinical or non-invasive parameters . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In 123 consecutive patients pulmonary hemodynamics at rest and during exercise were measured 7-10 days after acute myocardial infarction and systemic thrombolysis . Right- and left-heart catheterizations were performed at the same session and repeated after 6 months . We investigated if right-heart catheterization could predict the number of stenotic or occluded coronaries , the angiographic ventricular function andor , most important , if the patient would profit from revascularization by PTCA or coronary surgery . Results : 1 ) Pulmonary hemodynamics at rest and during exercise did not correlate to the number of stenotic or occluded coronaries , but exercise tolerance did . 2 ) Correlation between ventricular function and pulmonary hemodynamics was weak . 3 ) Only patients with pathologically elevated pulmonary pressures at exercise showed profit from revascularization ( increase of ejection fraction > 5% at control ) . This profit was closely correlated to the angiographic extent of ventricular damage . Consequences from our results : Individual exercise tolerance can easily be measured non-invasively . Ventricular function can be measured non-invasively as well as by echocardiography . Measurement of pulmonary hemodynamics at rest and during exercise does not contribute to planning the future management of the postinfarction patient and does not replace coronarography when indicated by clinical or non-invasive parameters .

[ "In", "123", "consecutive", "patients", "pulmonary", "hemodynamics", "at", "rest", "and", "during", "exercise", "were", "measured", "7", "-", "10", "days", "after", "acute", "myocardial", "infarction", "and", "systemic", "thrombolysis", ".", "Right-", "and", "left", "-", "heart", "catheterizations", "were", "performed", "at", "the", "same", "session", "and", "repeated", "after", "6", "months", ".", "We", "investigated", "if", "right", "-", "heart", "catheterization", "could", "predict", "the", "number", "of", "stenotic", "or", "occluded", "coronaries", ",", "the", "angiographic", "ventricular", "function", "andor", ",", "most", "important", ",", "if", "the", "patient", "would", "profit", "from", "revascularization", "by", "PTCA", "or", "coronary", "surgery", ".", "Results", ":", "1", ")", "Pulmonary", "hemodynamics", "at", "rest", "and", "during", "exercise", "did", "not", "correlate", "to", "the", "number", "of", "stenotic", "or", "occluded", "coronaries", ",", "but", "exercise", "tolerance", "did", ".", "2", ")", "Correlation", "between", "ventricular", "function", "and", "pulmonary", "hemodynamics", "was", "weak", ".", "3", ")", "Only", "patients", "with", "pathologically", "elevated", "pulmonary", "pressures", "at", "exercise", "showed", "profit", "from", "revascularization", "(", "increase", "of", "ejection", "fraction", ">", "5", "%", "at", "control", ")", ".", "This", "profit", "was", "closely", "correlated", "to", "the", "angiographic", "extent", "of", "ventricular", "damage", ".", "Consequences", "from", "our", "results", ":", "Individual", "exercise", "tolerance", "can", "easily", "be", "measured", "non", "-", "invasively", ".", "Ventricular", "function", "can", "be", "measured", "non", "-", "invasively", "as", "well", "as", "by", "echocardiography", ".", "Measurement", "of", "pulmonary", "hemodynamics", "at", "rest", "and", "during", "exercise", "does", "not", "contribute", "to", "planning", "the", "future", "management", "of", "the", "postinfarction", "patient", "and", "does", "not", "replace", "coronarography", "when", "indicated", "by", "clinical", "or", "non", "-", "invasive", "parameters", "." ]

[ "umlsterm" ]

patients is an umlsterm, hemodynamics is an umlsterm, rest is an umlsterm, exercise is an umlsterm, myocardial infarction is an umlsterm, left - heart is an umlsterm, catheterizations is an umlsterm, catheterization is an umlsterm, ventricular function is an umlsterm, patient is an umlsterm, PTCA is an umlsterm, surgery is an umlsterm, hemodynamics is an umlsterm, rest is an umlsterm, exercise is an umlsterm, exercise tolerance is an umlsterm, ventricular function is an umlsterm, hemodynamics is an umlsterm, patients is an umlsterm, pressures is an umlsterm, exercise is an umlsterm, control is an umlsterm, exercise tolerance is an umlsterm, Ventricular function is an umlsterm, Measurement is an umlsterm, hemodynamics is an umlsterm, rest is an umlsterm, exercise is an umlsterm, future is an umlsterm, patient is an umlsterm

ZfuerKardiologie.70860485.eng.abstr_task1

Sentence: In 123 consecutive patients pulmonary hemodynamics at rest and during exercise were measured 7-10 days after acute myocardial infarction and systemic thrombolysis . Right- and left-heart catheterizations were performed at the same session and repeated after 6 months . We investigated if right-heart catheterization could predict the number of stenotic or occluded coronaries , the angiographic ventricular function andor , most important , if the patient would profit from revascularization by PTCA or coronary surgery . Results : 1 ) Pulmonary hemodynamics at rest and during exercise did not correlate to the number of stenotic or occluded coronaries , but exercise tolerance did . 2 ) Correlation between ventricular function and pulmonary hemodynamics was weak . 3 ) Only patients with pathologically elevated pulmonary pressures at exercise showed profit from revascularization ( increase of ejection fraction > 5% at control ) . This profit was closely correlated to the angiographic extent of ventricular damage . Consequences from our results : Individual exercise tolerance can easily be measured non-invasively . Ventricular function can be measured non-invasively as well as by echocardiography . Measurement of pulmonary hemodynamics at rest and during exercise does not contribute to planning the future management of the postinfarction patient and does not replace coronarography when indicated by clinical or non-invasive parameters . Instructions: please typing these entity words according to sentence: patients, hemodynamics, rest, exercise, myocardial infarction, left - heart, catheterizations, catheterization, ventricular function, patient, PTCA, surgery, hemodynamics, rest, exercise, exercise tolerance, ventricular function, hemodynamics, patients, pressures, exercise, control, exercise tolerance, Ventricular function, Measurement, hemodynamics, rest, exercise, future, patient Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In 123 consecutive patients pulmonary hemodynamics at rest and during exercise were measured 7-10 days after acute myocardial infarction and systemic thrombolysis . Right- and left-heart catheterizations were performed at the same session and repeated after 6 months . We investigated if right-heart catheterization could predict the number of stenotic or occluded coronaries , the angiographic ventricular function andor , most important , if the patient would profit from revascularization by PTCA or coronary surgery . Results : 1 ) Pulmonary hemodynamics at rest and during exercise did not correlate to the number of stenotic or occluded coronaries , but exercise tolerance did . 2 ) Correlation between ventricular function and pulmonary hemodynamics was weak . 3 ) Only patients with pathologically elevated pulmonary pressures at exercise showed profit from revascularization ( increase of ejection fraction > 5% at control ) . This profit was closely correlated to the angiographic extent of ventricular damage . Consequences from our results : Individual exercise tolerance can easily be measured non-invasively . Ventricular function can be measured non-invasively as well as by echocardiography . Measurement of pulmonary hemodynamics at rest and during exercise does not contribute to planning the future management of the postinfarction patient and does not replace coronarography when indicated by clinical or non-invasive parameters .

[ "In", "123", "consecutive", "patients", "pulmonary", "hemodynamics", "at", "rest", "and", "during", "exercise", "were", "measured", "7", "-", "10", "days", "after", "acute", "myocardial", "infarction", "and", "systemic", "thrombolysis", ".", "Right-", "and", "left", "-", "heart", "catheterizations", "were", "performed", "at", "the", "same", "session", "and", "repeated", "after", "6", "months", ".", "We", "investigated", "if", "right", "-", "heart", "catheterization", "could", "predict", "the", "number", "of", "stenotic", "or", "occluded", "coronaries", ",", "the", "angiographic", "ventricular", "function", "andor", ",", "most", "important", ",", "if", "the", "patient", "would", "profit", "from", "revascularization", "by", "PTCA", "or", "coronary", "surgery", ".", "Results", ":", "1", ")", "Pulmonary", "hemodynamics", "at", "rest", "and", "during", "exercise", "did", "not", "correlate", "to", "the", "number", "of", "stenotic", "or", "occluded", "coronaries", ",", "but", "exercise", "tolerance", "did", ".", "2", ")", "Correlation", "between", "ventricular", "function", "and", "pulmonary", "hemodynamics", "was", "weak", ".", "3", ")", "Only", "patients", "with", "pathologically", "elevated", "pulmonary", "pressures", "at", "exercise", "showed", "profit", "from", "revascularization", "(", "increase", "of", "ejection", "fraction", ">", "5", "%", "at", "control", ")", ".", "This", "profit", "was", "closely", "correlated", "to", "the", "angiographic", "extent", "of", "ventricular", "damage", ".", "Consequences", "from", "our", "results", ":", "Individual", "exercise", "tolerance", "can", "easily", "be", "measured", "non", "-", "invasively", ".", "Ventricular", "function", "can", "be", "measured", "non", "-", "invasively", "as", "well", "as", "by", "echocardiography", ".", "Measurement", "of", "pulmonary", "hemodynamics", "at", "rest", "and", "during", "exercise", "does", "not", "contribute", "to", "planning", "the", "future", "management", "of", "the", "postinfarction", "patient", "and", "does", "not", "replace", "coronarography", "when", "indicated", "by", "clinical", "or", "non", "-", "invasive", "parameters", "." ]

[ "umlsterm" ]

patients, hemodynamics, rest, exercise, myocardial infarction, left - heart, catheterizations, catheterization, ventricular function, patient, PTCA, surgery, hemodynamics, rest, exercise, exercise tolerance, ventricular function, hemodynamics, patients, pressures, exercise, control, exercise tolerance, Ventricular function, Measurement, hemodynamics, rest, exercise, future, patient

ZfuerKardiologie.70860485.eng.abstr_task2

Sentence: In 123 consecutive patients pulmonary hemodynamics at rest and during exercise were measured 7-10 days after acute myocardial infarction and systemic thrombolysis . Right- and left-heart catheterizations were performed at the same session and repeated after 6 months . We investigated if right-heart catheterization could predict the number of stenotic or occluded coronaries , the angiographic ventricular function andor , most important , if the patient would profit from revascularization by PTCA or coronary surgery . Results : 1 ) Pulmonary hemodynamics at rest and during exercise did not correlate to the number of stenotic or occluded coronaries , but exercise tolerance did . 2 ) Correlation between ventricular function and pulmonary hemodynamics was weak . 3 ) Only patients with pathologically elevated pulmonary pressures at exercise showed profit from revascularization ( increase of ejection fraction > 5% at control ) . This profit was closely correlated to the angiographic extent of ventricular damage . Consequences from our results : Individual exercise tolerance can easily be measured non-invasively . Ventricular function can be measured non-invasively as well as by echocardiography . Measurement of pulmonary hemodynamics at rest and during exercise does not contribute to planning the future management of the postinfarction patient and does not replace coronarography when indicated by clinical or non-invasive parameters . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In 123 consecutive patients pulmonary hemodynamics at rest and during exercise were measured 7-10 days after acute myocardial infarction and systemic thrombolysis . Right- and left-heart catheterizations were performed at the same session and repeated after 6 months . We investigated if right-heart catheterization could predict the number of stenotic or occluded coronaries , the angiographic ventricular function andor , most important , if the patient would profit from revascularization by PTCA or coronary surgery . Results : 1 ) Pulmonary hemodynamics at rest and during exercise did not correlate to the number of stenotic or occluded coronaries , but exercise tolerance did . 2 ) Correlation between ventricular function and pulmonary hemodynamics was weak . 3 ) Only patients with pathologically elevated pulmonary pressures at exercise showed profit from revascularization ( increase of ejection fraction > 5% at control ) . This profit was closely correlated to the angiographic extent of ventricular damage . Consequences from our results : Individual exercise tolerance can easily be measured non-invasively . Ventricular function can be measured non-invasively as well as by echocardiography . Measurement of pulmonary hemodynamics at rest and during exercise does not contribute to planning the future management of the postinfarction patient and does not replace coronarography when indicated by clinical or non-invasive parameters .

[ "In", "123", "consecutive", "patients", "pulmonary", "hemodynamics", "at", "rest", "and", "during", "exercise", "were", "measured", "7", "-", "10", "days", "after", "acute", "myocardial", "infarction", "and", "systemic", "thrombolysis", ".", "Right-", "and", "left", "-", "heart", "catheterizations", "were", "performed", "at", "the", "same", "session", "and", "repeated", "after", "6", "months", ".", "We", "investigated", "if", "right", "-", "heart", "catheterization", "could", "predict", "the", "number", "of", "stenotic", "or", "occluded", "coronaries", ",", "the", "angiographic", "ventricular", "function", "andor", ",", "most", "important", ",", "if", "the", "patient", "would", "profit", "from", "revascularization", "by", "PTCA", "or", "coronary", "surgery", ".", "Results", ":", "1", ")", "Pulmonary", "hemodynamics", "at", "rest", "and", "during", "exercise", "did", "not", "correlate", "to", "the", "number", "of", "stenotic", "or", "occluded", "coronaries", ",", "but", "exercise", "tolerance", "did", ".", "2", ")", "Correlation", "between", "ventricular", "function", "and", "pulmonary", "hemodynamics", "was", "weak", ".", "3", ")", "Only", "patients", "with", "pathologically", "elevated", "pulmonary", "pressures", "at", "exercise", "showed", "profit", "from", "revascularization", "(", "increase", "of", "ejection", "fraction", ">", "5", "%", "at", "control", ")", ".", "This", "profit", "was", "closely", "correlated", "to", "the", "angiographic", "extent", "of", "ventricular", "damage", ".", "Consequences", "from", "our", "results", ":", "Individual", "exercise", "tolerance", "can", "easily", "be", "measured", "non", "-", "invasively", ".", "Ventricular", "function", "can", "be", "measured", "non", "-", "invasively", "as", "well", "as", "by", "echocardiography", ".", "Measurement", "of", "pulmonary", "hemodynamics", "at", "rest", "and", "during", "exercise", "does", "not", "contribute", "to", "planning", "the", "future", "management", "of", "the", "postinfarction", "patient", "and", "does", "not", "replace", "coronarography", "when", "indicated", "by", "clinical", "or", "non", "-", "invasive", "parameters", "." ]

[ "umlsterm" ]

Patienten is an umlsterm, Arterien is an umlsterm, Patienten is an umlsterm, wachsende is an umlsterm, Patienten is an umlsterm, Erwachsenenalter is an umlsterm, Schwangerschaft is an umlsterm, Patienten is an umlsterm, Literatursuche is an umlsterm, MEDLINE is an umlsterm, Schwangerschaften is an umlsterm, Schwangerschaften is an umlsterm, Komplikationen is an umlsterm, Fruehaborten is an umlsterm, Fehlgeburt is an umlsterm, Abort is an umlsterm, Kinder is an umlsterm, Komplikationen is an umlsterm, Muettern is an umlsterm, therapiebeduerftige is an umlsterm, koerperlichen Leistungsfaehigkeit is an umlsterm, Komplikationen is an umlsterm, Patienten is an umlsterm, Tachykardien is an umlsterm, Prognose is an umlsterm, Muetter is an umlsterm, Kinder is an umlsterm

ZfuerKardiologie.70860945.ger.abstr_task0

Sentence: Hintergrund : Patienten nach atrialen Umkehroperationen ( Mustard- oder Senning-Operation ) zur Korrektur einer Transposition der grossen Arterien ( TGA ) unterscheiden sich in einem wesentlichen Punkt von anderen Patienten mit kongenitalen Vitien : Der anatomisch rechte ( vorne gelegene ) Ventrikel fungiert bei ihnen als Systemventrikel . Da eine wachsende Zahl derart operierter Patienten das Erwachsenenalter erreicht , gewinnt die Frage , ob eine Schwangerschaft fuer die so operierten Patientinnen wegen der dabei auftretenden , ausgepraegten haemodynamischen Veraenderungen eine Gefaehrdung darstellt , zunehmende Bedeutung . Patienten : Initiiert durch die Vorstellung einer schwangeren Patientin in unserer Klinik konnten durch Literatursuche in MEDLINE weitere 26 Kasuistiken ueber Schwangerschaften nach Mustard-Operation identifiziert werden . Bei den somit insgesamt 27 Patientinnen wurde ueber 39 Schwangerschaften berichtet . Fetale Komplikationen : Es kam zu drei Fruehaborten im 1. Trimenon und einer Fehlgeburt in der 23. Schwangerschaftswoche . Weiterhin wurde ein elektiver Abort im 1. Trimenon durchgefuehrt . 35 Kinder ( ein Zwillingspaar ) wurden lebend geboren ohne kardiovaskulaere Fehlbildungen . Muetterliche Komplikationen : Von den Muettern verstarb keine . Acht Patientinnen entwickelten eine therapiebeduerftige Herzinsuffizienz , wobei alle drei Patientinnen mit vormals komplexer TGA ( zusaetzliche andere kardiale Fehlbildungen ) betroffen waren . Von diesen erholten sich vier Patientinnen innerhalb der Nachbeobachtungszeit , die anderen vier Patientinnen zeigten eine anhaltende Verschlechterung ihrer koerperlichen Leistungsfaehigkeit oder klinische Zeichen einer Herzinsuffizienz . Als weitere Komplikationen kam es bei fuenf Patienten zu supraventrikulaeren Tachykardien und bei 22% der Patientinnen zu einer Hypertonie/Prae-Eklampsie . Schlussfolgerung : Zusammenfassend zeigt sich eine gute Prognose fuer Muetter nach Mustard-Operation und ihre Kinder , ein intensives und spezielles Monitoring vorausgesetzt . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

Hintergrund : Patienten nach atrialen Umkehroperationen ( Mustard- oder Senning-Operation ) zur Korrektur einer Transposition der grossen Arterien ( TGA ) unterscheiden sich in einem wesentlichen Punkt von anderen Patienten mit kongenitalen Vitien : Der anatomisch rechte ( vorne gelegene ) Ventrikel fungiert bei ihnen als Systemventrikel . Da eine wachsende Zahl derart operierter Patienten das Erwachsenenalter erreicht , gewinnt die Frage , ob eine Schwangerschaft fuer die so operierten Patientinnen wegen der dabei auftretenden , ausgepraegten haemodynamischen Veraenderungen eine Gefaehrdung darstellt , zunehmende Bedeutung . Patienten : Initiiert durch die Vorstellung einer schwangeren Patientin in unserer Klinik konnten durch Literatursuche in MEDLINE weitere 26 Kasuistiken ueber Schwangerschaften nach Mustard-Operation identifiziert werden . Bei den somit insgesamt 27 Patientinnen wurde ueber 39 Schwangerschaften berichtet . Fetale Komplikationen : Es kam zu drei Fruehaborten im 1. Trimenon und einer Fehlgeburt in der 23. Schwangerschaftswoche . Weiterhin wurde ein elektiver Abort im 1. Trimenon durchgefuehrt . 35 Kinder ( ein Zwillingspaar ) wurden lebend geboren ohne kardiovaskulaere Fehlbildungen . Muetterliche Komplikationen : Von den Muettern verstarb keine . Acht Patientinnen entwickelten eine therapiebeduerftige Herzinsuffizienz , wobei alle drei Patientinnen mit vormals komplexer TGA ( zusaetzliche andere kardiale Fehlbildungen ) betroffen waren . Von diesen erholten sich vier Patientinnen innerhalb der Nachbeobachtungszeit , die anderen vier Patientinnen zeigten eine anhaltende Verschlechterung ihrer koerperlichen Leistungsfaehigkeit oder klinische Zeichen einer Herzinsuffizienz . Als weitere Komplikationen kam es bei fuenf Patienten zu supraventrikulaeren Tachykardien und bei 22% der Patientinnen zu einer Hypertonie/Prae-Eklampsie . Schlussfolgerung : Zusammenfassend zeigt sich eine gute Prognose fuer Muetter nach Mustard-Operation und ihre Kinder , ein intensives und spezielles Monitoring vorausgesetzt .

[ "Hintergrund", ":", "Patienten", "nach", "atrialen", "Umkehroperationen", "(", "Mustard-", "oder", "Senning", "-", "Operation", ")", "zur", "Korrektur", "einer", "Transposition", "der", "grossen", "Arterien", "(", "TGA", ")", "unterscheiden", "sich", "in", "einem", "wesentlichen", "Punkt", "von", "anderen", "Patienten", "mit", "kongenitalen", "Vitien", ":", "Der", "anatomisch", "rechte", "(", "vorne", "gelegene", ")", "Ventrikel", "fungiert", "bei", "ihnen", "als", "Systemventrikel", ".", "Da", "eine", "wachsende", "Zahl", "derart", "operierter", "Patienten", "das", "Erwachsenenalter", "erreicht", ",", "gewinnt", "die", "Frage", ",", "ob", "eine", "Schwangerschaft", "fuer", "die", "so", "operierten", "Patientinnen", "wegen", "der", "dabei", "auftretenden", ",", "ausgepraegten", "haemodynamischen", "Veraenderungen", "eine", "Gefaehrdung", "darstellt", ",", "zunehmende", "Bedeutung", ".", "Patienten", ":", "Initiiert", "durch", "die", "Vorstellung", "einer", "schwangeren", "Patientin", "in", "unserer", "Klinik", "konnten", "durch", "Literatursuche", "in", "MEDLINE", "weitere", "26", "Kasuistiken", "ueber", "Schwangerschaften", "nach", "Mustard", "-", "Operation", "identifiziert", "werden", ".", "Bei", "den", "somit", "insgesamt", "27", "Patientinnen", "wurde", "ueber", "39", "Schwangerschaften", "berichtet", ".", "Fetale", "Komplikationen", ":", "Es", "kam", "zu", "drei", "Fruehaborten", "im", "1", ".", "Trimenon", "und", "einer", "Fehlgeburt", "in", "der", "23", ".", "Schwangerschaftswoche", ".", "Weiterhin", "wurde", "ein", "elektiver", "Abort", "im", "1", ".", "Trimenon", "durchgefuehrt", ".", "35", "Kinder", "(", "ein", "Zwillingspaar", ")", "wurden", "lebend", "geboren", "ohne", "kardiovaskulaere", "Fehlbildungen", ".", "Muetterliche", "Komplikationen", ":", "Von", "den", "Muettern", "verstarb", "keine", ".", "Acht", "Patientinnen", "entwickelten", "eine", "therapiebeduerftige", "Herzinsuffizienz", ",", "wobei", "alle", "drei", "Patientinnen", "mit", "vormals", "komplexer", "TGA", "(", "zusaetzliche", "andere", "kardiale", "Fehlbildungen", ")", "betroffen", "waren", ".", "Von", "diesen", "erholten", "sich", "vier", "Patientinnen", "innerhalb", "der", "Nachbeobachtungszeit", ",", "die", "anderen", "vier", "Patientinnen", "zeigten", "eine", "anhaltende", "Verschlechterung", "ihrer", "koerperlichen", "Leistungsfaehigkeit", "oder", "klinische", "Zeichen", "einer", "Herzinsuffizienz", ".", "Als", "weitere", "Komplikationen", "kam", "es", "bei", "fuenf", "Patienten", "zu", "supraventrikulaeren", "Tachykardien", "und", "bei", "22", "%", "der", "Patientinnen", "zu", "einer", "Hypertonie", "/", "Prae", "-", "Eklampsie", ".", "Schlussfolgerung", ":", "Zusammenfassend", "zeigt", "sich", "eine", "gute", "Prognose", "fuer", "Muetter", "nach", "Mustard", "-", "Operation", "und", "ihre", "Kinder", ",", "ein", "intensives", "und", "spezielles", "Monitoring", "vorausgesetzt", "." ]

[ "umlsterm" ]

Patienten is an umlsterm, Arterien is an umlsterm, Patienten is an umlsterm, wachsende is an umlsterm, Patienten is an umlsterm, Erwachsenenalter is an umlsterm, Schwangerschaft is an umlsterm, Patienten is an umlsterm, Literatursuche is an umlsterm, MEDLINE is an umlsterm, Schwangerschaften is an umlsterm, Schwangerschaften is an umlsterm, Komplikationen is an umlsterm, Fruehaborten is an umlsterm, Fehlgeburt is an umlsterm, Abort is an umlsterm, Kinder is an umlsterm, Komplikationen is an umlsterm, Muettern is an umlsterm, therapiebeduerftige is an umlsterm, koerperlichen Leistungsfaehigkeit is an umlsterm, Komplikationen is an umlsterm, Patienten is an umlsterm, Tachykardien is an umlsterm, Prognose is an umlsterm, Muetter is an umlsterm, Kinder is an umlsterm

ZfuerKardiologie.70860945.ger.abstr_task1

Sentence: Hintergrund : Patienten nach atrialen Umkehroperationen ( Mustard- oder Senning-Operation ) zur Korrektur einer Transposition der grossen Arterien ( TGA ) unterscheiden sich in einem wesentlichen Punkt von anderen Patienten mit kongenitalen Vitien : Der anatomisch rechte ( vorne gelegene ) Ventrikel fungiert bei ihnen als Systemventrikel . Da eine wachsende Zahl derart operierter Patienten das Erwachsenenalter erreicht , gewinnt die Frage , ob eine Schwangerschaft fuer die so operierten Patientinnen wegen der dabei auftretenden , ausgepraegten haemodynamischen Veraenderungen eine Gefaehrdung darstellt , zunehmende Bedeutung . Patienten : Initiiert durch die Vorstellung einer schwangeren Patientin in unserer Klinik konnten durch Literatursuche in MEDLINE weitere 26 Kasuistiken ueber Schwangerschaften nach Mustard-Operation identifiziert werden . Bei den somit insgesamt 27 Patientinnen wurde ueber 39 Schwangerschaften berichtet . Fetale Komplikationen : Es kam zu drei Fruehaborten im 1. Trimenon und einer Fehlgeburt in der 23. Schwangerschaftswoche . Weiterhin wurde ein elektiver Abort im 1. Trimenon durchgefuehrt . 35 Kinder ( ein Zwillingspaar ) wurden lebend geboren ohne kardiovaskulaere Fehlbildungen . Muetterliche Komplikationen : Von den Muettern verstarb keine . Acht Patientinnen entwickelten eine therapiebeduerftige Herzinsuffizienz , wobei alle drei Patientinnen mit vormals komplexer TGA ( zusaetzliche andere kardiale Fehlbildungen ) betroffen waren . Von diesen erholten sich vier Patientinnen innerhalb der Nachbeobachtungszeit , die anderen vier Patientinnen zeigten eine anhaltende Verschlechterung ihrer koerperlichen Leistungsfaehigkeit oder klinische Zeichen einer Herzinsuffizienz . Als weitere Komplikationen kam es bei fuenf Patienten zu supraventrikulaeren Tachykardien und bei 22% der Patientinnen zu einer Hypertonie/Prae-Eklampsie . Schlussfolgerung : Zusammenfassend zeigt sich eine gute Prognose fuer Muetter nach Mustard-Operation und ihre Kinder , ein intensives und spezielles Monitoring vorausgesetzt . Instructions: please typing these entity words according to sentence: Patienten, Arterien, Patienten, wachsende, Patienten, Erwachsenenalter, Schwangerschaft, Patienten, Literatursuche, MEDLINE, Schwangerschaften, Schwangerschaften, Komplikationen, Fruehaborten, Fehlgeburt, Abort, Kinder, Komplikationen, Muettern, therapiebeduerftige, koerperlichen Leistungsfaehigkeit, Komplikationen, Patienten, Tachykardien, Prognose, Muetter, Kinder Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

Hintergrund : Patienten nach atrialen Umkehroperationen ( Mustard- oder Senning-Operation ) zur Korrektur einer Transposition der grossen Arterien ( TGA ) unterscheiden sich in einem wesentlichen Punkt von anderen Patienten mit kongenitalen Vitien : Der anatomisch rechte ( vorne gelegene ) Ventrikel fungiert bei ihnen als Systemventrikel . Da eine wachsende Zahl derart operierter Patienten das Erwachsenenalter erreicht , gewinnt die Frage , ob eine Schwangerschaft fuer die so operierten Patientinnen wegen der dabei auftretenden , ausgepraegten haemodynamischen Veraenderungen eine Gefaehrdung darstellt , zunehmende Bedeutung . Patienten : Initiiert durch die Vorstellung einer schwangeren Patientin in unserer Klinik konnten durch Literatursuche in MEDLINE weitere 26 Kasuistiken ueber Schwangerschaften nach Mustard-Operation identifiziert werden . Bei den somit insgesamt 27 Patientinnen wurde ueber 39 Schwangerschaften berichtet . Fetale Komplikationen : Es kam zu drei Fruehaborten im 1. Trimenon und einer Fehlgeburt in der 23. Schwangerschaftswoche . Weiterhin wurde ein elektiver Abort im 1. Trimenon durchgefuehrt . 35 Kinder ( ein Zwillingspaar ) wurden lebend geboren ohne kardiovaskulaere Fehlbildungen . Muetterliche Komplikationen : Von den Muettern verstarb keine . Acht Patientinnen entwickelten eine therapiebeduerftige Herzinsuffizienz , wobei alle drei Patientinnen mit vormals komplexer TGA ( zusaetzliche andere kardiale Fehlbildungen ) betroffen waren . Von diesen erholten sich vier Patientinnen innerhalb der Nachbeobachtungszeit , die anderen vier Patientinnen zeigten eine anhaltende Verschlechterung ihrer koerperlichen Leistungsfaehigkeit oder klinische Zeichen einer Herzinsuffizienz . Als weitere Komplikationen kam es bei fuenf Patienten zu supraventrikulaeren Tachykardien und bei 22% der Patientinnen zu einer Hypertonie/Prae-Eklampsie . Schlussfolgerung : Zusammenfassend zeigt sich eine gute Prognose fuer Muetter nach Mustard-Operation und ihre Kinder , ein intensives und spezielles Monitoring vorausgesetzt .

[ "Hintergrund", ":", "Patienten", "nach", "atrialen", "Umkehroperationen", "(", "Mustard-", "oder", "Senning", "-", "Operation", ")", "zur", "Korrektur", "einer", "Transposition", "der", "grossen", "Arterien", "(", "TGA", ")", "unterscheiden", "sich", "in", "einem", "wesentlichen", "Punkt", "von", "anderen", "Patienten", "mit", "kongenitalen", "Vitien", ":", "Der", "anatomisch", "rechte", "(", "vorne", "gelegene", ")", "Ventrikel", "fungiert", "bei", "ihnen", "als", "Systemventrikel", ".", "Da", "eine", "wachsende", "Zahl", "derart", "operierter", "Patienten", "das", "Erwachsenenalter", "erreicht", ",", "gewinnt", "die", "Frage", ",", "ob", "eine", "Schwangerschaft", "fuer", "die", "so", "operierten", "Patientinnen", "wegen", "der", "dabei", "auftretenden", ",", "ausgepraegten", "haemodynamischen", "Veraenderungen", "eine", "Gefaehrdung", "darstellt", ",", "zunehmende", "Bedeutung", ".", "Patienten", ":", "Initiiert", "durch", "die", "Vorstellung", "einer", "schwangeren", "Patientin", "in", "unserer", "Klinik", "konnten", "durch", "Literatursuche", "in", "MEDLINE", "weitere", "26", "Kasuistiken", "ueber", "Schwangerschaften", "nach", "Mustard", "-", "Operation", "identifiziert", "werden", ".", "Bei", "den", "somit", "insgesamt", "27", "Patientinnen", "wurde", "ueber", "39", "Schwangerschaften", "berichtet", ".", "Fetale", "Komplikationen", ":", "Es", "kam", "zu", "drei", "Fruehaborten", "im", "1", ".", "Trimenon", "und", "einer", "Fehlgeburt", "in", "der", "23", ".", "Schwangerschaftswoche", ".", "Weiterhin", "wurde", "ein", "elektiver", "Abort", "im", "1", ".", "Trimenon", "durchgefuehrt", ".", "35", "Kinder", "(", "ein", "Zwillingspaar", ")", "wurden", "lebend", "geboren", "ohne", "kardiovaskulaere", "Fehlbildungen", ".", "Muetterliche", "Komplikationen", ":", "Von", "den", "Muettern", "verstarb", "keine", ".", "Acht", "Patientinnen", "entwickelten", "eine", "therapiebeduerftige", "Herzinsuffizienz", ",", "wobei", "alle", "drei", "Patientinnen", "mit", "vormals", "komplexer", "TGA", "(", "zusaetzliche", "andere", "kardiale", "Fehlbildungen", ")", "betroffen", "waren", ".", "Von", "diesen", "erholten", "sich", "vier", "Patientinnen", "innerhalb", "der", "Nachbeobachtungszeit", ",", "die", "anderen", "vier", "Patientinnen", "zeigten", "eine", "anhaltende", "Verschlechterung", "ihrer", "koerperlichen", "Leistungsfaehigkeit", "oder", "klinische", "Zeichen", "einer", "Herzinsuffizienz", ".", "Als", "weitere", "Komplikationen", "kam", "es", "bei", "fuenf", "Patienten", "zu", "supraventrikulaeren", "Tachykardien", "und", "bei", "22", "%", "der", "Patientinnen", "zu", "einer", "Hypertonie", "/", "Prae", "-", "Eklampsie", ".", "Schlussfolgerung", ":", "Zusammenfassend", "zeigt", "sich", "eine", "gute", "Prognose", "fuer", "Muetter", "nach", "Mustard", "-", "Operation", "und", "ihre", "Kinder", ",", "ein", "intensives", "und", "spezielles", "Monitoring", "vorausgesetzt", "." ]

[ "umlsterm" ]

Patienten, Arterien, Patienten, wachsende, Patienten, Erwachsenenalter, Schwangerschaft, Patienten, Literatursuche, MEDLINE, Schwangerschaften, Schwangerschaften, Komplikationen, Fruehaborten, Fehlgeburt, Abort, Kinder, Komplikationen, Muettern, therapiebeduerftige, koerperlichen Leistungsfaehigkeit, Komplikationen, Patienten, Tachykardien, Prognose, Muetter, Kinder

ZfuerKardiologie.70860945.ger.abstr_task2

Sentence: Hintergrund : Patienten nach atrialen Umkehroperationen ( Mustard- oder Senning-Operation ) zur Korrektur einer Transposition der grossen Arterien ( TGA ) unterscheiden sich in einem wesentlichen Punkt von anderen Patienten mit kongenitalen Vitien : Der anatomisch rechte ( vorne gelegene ) Ventrikel fungiert bei ihnen als Systemventrikel . Da eine wachsende Zahl derart operierter Patienten das Erwachsenenalter erreicht , gewinnt die Frage , ob eine Schwangerschaft fuer die so operierten Patientinnen wegen der dabei auftretenden , ausgepraegten haemodynamischen Veraenderungen eine Gefaehrdung darstellt , zunehmende Bedeutung . Patienten : Initiiert durch die Vorstellung einer schwangeren Patientin in unserer Klinik konnten durch Literatursuche in MEDLINE weitere 26 Kasuistiken ueber Schwangerschaften nach Mustard-Operation identifiziert werden . Bei den somit insgesamt 27 Patientinnen wurde ueber 39 Schwangerschaften berichtet . Fetale Komplikationen : Es kam zu drei Fruehaborten im 1. Trimenon und einer Fehlgeburt in der 23. Schwangerschaftswoche . Weiterhin wurde ein elektiver Abort im 1. Trimenon durchgefuehrt . 35 Kinder ( ein Zwillingspaar ) wurden lebend geboren ohne kardiovaskulaere Fehlbildungen . Muetterliche Komplikationen : Von den Muettern verstarb keine . Acht Patientinnen entwickelten eine therapiebeduerftige Herzinsuffizienz , wobei alle drei Patientinnen mit vormals komplexer TGA ( zusaetzliche andere kardiale Fehlbildungen ) betroffen waren . Von diesen erholten sich vier Patientinnen innerhalb der Nachbeobachtungszeit , die anderen vier Patientinnen zeigten eine anhaltende Verschlechterung ihrer koerperlichen Leistungsfaehigkeit oder klinische Zeichen einer Herzinsuffizienz . Als weitere Komplikationen kam es bei fuenf Patienten zu supraventrikulaeren Tachykardien und bei 22% der Patientinnen zu einer Hypertonie/Prae-Eklampsie . Schlussfolgerung : Zusammenfassend zeigt sich eine gute Prognose fuer Muetter nach Mustard-Operation und ihre Kinder , ein intensives und spezielles Monitoring vorausgesetzt . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

Hintergrund : Patienten nach atrialen Umkehroperationen ( Mustard- oder Senning-Operation ) zur Korrektur einer Transposition der grossen Arterien ( TGA ) unterscheiden sich in einem wesentlichen Punkt von anderen Patienten mit kongenitalen Vitien : Der anatomisch rechte ( vorne gelegene ) Ventrikel fungiert bei ihnen als Systemventrikel . Da eine wachsende Zahl derart operierter Patienten das Erwachsenenalter erreicht , gewinnt die Frage , ob eine Schwangerschaft fuer die so operierten Patientinnen wegen der dabei auftretenden , ausgepraegten haemodynamischen Veraenderungen eine Gefaehrdung darstellt , zunehmende Bedeutung . Patienten : Initiiert durch die Vorstellung einer schwangeren Patientin in unserer Klinik konnten durch Literatursuche in MEDLINE weitere 26 Kasuistiken ueber Schwangerschaften nach Mustard-Operation identifiziert werden . Bei den somit insgesamt 27 Patientinnen wurde ueber 39 Schwangerschaften berichtet . Fetale Komplikationen : Es kam zu drei Fruehaborten im 1. Trimenon und einer Fehlgeburt in der 23. Schwangerschaftswoche . Weiterhin wurde ein elektiver Abort im 1. Trimenon durchgefuehrt . 35 Kinder ( ein Zwillingspaar ) wurden lebend geboren ohne kardiovaskulaere Fehlbildungen . Muetterliche Komplikationen : Von den Muettern verstarb keine . Acht Patientinnen entwickelten eine therapiebeduerftige Herzinsuffizienz , wobei alle drei Patientinnen mit vormals komplexer TGA ( zusaetzliche andere kardiale Fehlbildungen ) betroffen waren . Von diesen erholten sich vier Patientinnen innerhalb der Nachbeobachtungszeit , die anderen vier Patientinnen zeigten eine anhaltende Verschlechterung ihrer koerperlichen Leistungsfaehigkeit oder klinische Zeichen einer Herzinsuffizienz . Als weitere Komplikationen kam es bei fuenf Patienten zu supraventrikulaeren Tachykardien und bei 22% der Patientinnen zu einer Hypertonie/Prae-Eklampsie . Schlussfolgerung : Zusammenfassend zeigt sich eine gute Prognose fuer Muetter nach Mustard-Operation und ihre Kinder , ein intensives und spezielles Monitoring vorausgesetzt .

[ "Hintergrund", ":", "Patienten", "nach", "atrialen", "Umkehroperationen", "(", "Mustard-", "oder", "Senning", "-", "Operation", ")", "zur", "Korrektur", "einer", "Transposition", "der", "grossen", "Arterien", "(", "TGA", ")", "unterscheiden", "sich", "in", "einem", "wesentlichen", "Punkt", "von", "anderen", "Patienten", "mit", "kongenitalen", "Vitien", ":", "Der", "anatomisch", "rechte", "(", "vorne", "gelegene", ")", "Ventrikel", "fungiert", "bei", "ihnen", "als", "Systemventrikel", ".", "Da", "eine", "wachsende", "Zahl", "derart", "operierter", "Patienten", "das", "Erwachsenenalter", "erreicht", ",", "gewinnt", "die", "Frage", ",", "ob", "eine", "Schwangerschaft", "fuer", "die", "so", "operierten", "Patientinnen", "wegen", "der", "dabei", "auftretenden", ",", "ausgepraegten", "haemodynamischen", "Veraenderungen", "eine", "Gefaehrdung", "darstellt", ",", "zunehmende", "Bedeutung", ".", "Patienten", ":", "Initiiert", "durch", "die", "Vorstellung", "einer", "schwangeren", "Patientin", "in", "unserer", "Klinik", "konnten", "durch", "Literatursuche", "in", "MEDLINE", "weitere", "26", "Kasuistiken", "ueber", "Schwangerschaften", "nach", "Mustard", "-", "Operation", "identifiziert", "werden", ".", "Bei", "den", "somit", "insgesamt", "27", "Patientinnen", "wurde", "ueber", "39", "Schwangerschaften", "berichtet", ".", "Fetale", "Komplikationen", ":", "Es", "kam", "zu", "drei", "Fruehaborten", "im", "1", ".", "Trimenon", "und", "einer", "Fehlgeburt", "in", "der", "23", ".", "Schwangerschaftswoche", ".", "Weiterhin", "wurde", "ein", "elektiver", "Abort", "im", "1", ".", "Trimenon", "durchgefuehrt", ".", "35", "Kinder", "(", "ein", "Zwillingspaar", ")", "wurden", "lebend", "geboren", "ohne", "kardiovaskulaere", "Fehlbildungen", ".", "Muetterliche", "Komplikationen", ":", "Von", "den", "Muettern", "verstarb", "keine", ".", "Acht", "Patientinnen", "entwickelten", "eine", "therapiebeduerftige", "Herzinsuffizienz", ",", "wobei", "alle", "drei", "Patientinnen", "mit", "vormals", "komplexer", "TGA", "(", "zusaetzliche", "andere", "kardiale", "Fehlbildungen", ")", "betroffen", "waren", ".", "Von", "diesen", "erholten", "sich", "vier", "Patientinnen", "innerhalb", "der", "Nachbeobachtungszeit", ",", "die", "anderen", "vier", "Patientinnen", "zeigten", "eine", "anhaltende", "Verschlechterung", "ihrer", "koerperlichen", "Leistungsfaehigkeit", "oder", "klinische", "Zeichen", "einer", "Herzinsuffizienz", ".", "Als", "weitere", "Komplikationen", "kam", "es", "bei", "fuenf", "Patienten", "zu", "supraventrikulaeren", "Tachykardien", "und", "bei", "22", "%", "der", "Patientinnen", "zu", "einer", "Hypertonie", "/", "Prae", "-", "Eklampsie", ".", "Schlussfolgerung", ":", "Zusammenfassend", "zeigt", "sich", "eine", "gute", "Prognose", "fuer", "Muetter", "nach", "Mustard", "-", "Operation", "und", "ihre", "Kinder", ",", "ein", "intensives", "und", "spezielles", "Monitoring", "vorausgesetzt", "." ]

[ "umlsterm" ]

Natural products is an umlsterm, derivatives is an umlsterm, clinical research is an umlsterm, drugs is an umlsterm, plants is an umlsterm, developments is an umlsterm, screening is an umlsterm, techniques is an umlsterm, marine is an umlsterm, origin is an umlsterm, methods is an umlsterm, natural products is an umlsterm, use is an umlsterm, research is an umlsterm, natural products is an umlsterm

DerGynaekologe.00330006.eng.abstr_task0

Sentence: Natural products and their derivatives are well established in clinical research and for medical applications . There are excellent drugs available from various plants and microorganisms . Recent developments in the different screening techniques have accelerated the discovery of new compounds . Furthermore , the investigation of compounds of marine origin , which have been more difficult to obtain , has become possible . With the help of combinatorial methods , natural products can be modified to optimize their use for medical applications . Due to the enormous medical potential , modern research on natural products will also be important in the next century . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Natural products and their derivatives are well established in clinical research and for medical applications . There are excellent drugs available from various plants and microorganisms . Recent developments in the different screening techniques have accelerated the discovery of new compounds . Furthermore , the investigation of compounds of marine origin , which have been more difficult to obtain , has become possible . With the help of combinatorial methods , natural products can be modified to optimize their use for medical applications . Due to the enormous medical potential , modern research on natural products will also be important in the next century .

[ "Natural", "products", "and", "their", "derivatives", "are", "well", "established", "in", "clinical", "research", "and", "for", "medical", "applications", ".", "There", "are", "excellent", "drugs", "available", "from", "various", "plants", "and", "microorganisms", ".", "Recent", "developments", "in", "the", "different", "screening", "techniques", "have", "accelerated", "the", "discovery", "of", "new", "compounds", ".", "Furthermore", ",", "the", "investigation", "of", "compounds", "of", "marine", "origin", ",", "which", "have", "been", "more", "difficult", "to", "obtain", ",", "has", "become", "possible", ".", "With", "the", "help", "of", "combinatorial", "methods", ",", "natural", "products", "can", "be", "modified", "to", "optimize", "their", "use", "for", "medical", "applications", ".", "Due", "to", "the", "enormous", "medical", "potential", ",", "modern", "research", "on", "natural", "products", "will", "also", "be", "important", "in", "the", "next", "century", "." ]

[ "umlsterm" ]

Natural products is an umlsterm, derivatives is an umlsterm, clinical research is an umlsterm, drugs is an umlsterm, plants is an umlsterm, developments is an umlsterm, screening is an umlsterm, techniques is an umlsterm, marine is an umlsterm, origin is an umlsterm, methods is an umlsterm, natural products is an umlsterm, use is an umlsterm, research is an umlsterm, natural products is an umlsterm

DerGynaekologe.00330006.eng.abstr_task1

Sentence: Natural products and their derivatives are well established in clinical research and for medical applications . There are excellent drugs available from various plants and microorganisms . Recent developments in the different screening techniques have accelerated the discovery of new compounds . Furthermore , the investigation of compounds of marine origin , which have been more difficult to obtain , has become possible . With the help of combinatorial methods , natural products can be modified to optimize their use for medical applications . Due to the enormous medical potential , modern research on natural products will also be important in the next century . Instructions: please typing these entity words according to sentence: Natural products, derivatives, clinical research, drugs, plants, developments, screening, techniques, marine, origin, methods, natural products, use, research, natural products Options: umlsterm

[ "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Natural products and their derivatives are well established in clinical research and for medical applications . There are excellent drugs available from various plants and microorganisms . Recent developments in the different screening techniques have accelerated the discovery of new compounds . Furthermore , the investigation of compounds of marine origin , which have been more difficult to obtain , has become possible . With the help of combinatorial methods , natural products can be modified to optimize their use for medical applications . Due to the enormous medical potential , modern research on natural products will also be important in the next century .

[ "Natural", "products", "and", "their", "derivatives", "are", "well", "established", "in", "clinical", "research", "and", "for", "medical", "applications", ".", "There", "are", "excellent", "drugs", "available", "from", "various", "plants", "and", "microorganisms", ".", "Recent", "developments", "in", "the", "different", "screening", "techniques", "have", "accelerated", "the", "discovery", "of", "new", "compounds", ".", "Furthermore", ",", "the", "investigation", "of", "compounds", "of", "marine", "origin", ",", "which", "have", "been", "more", "difficult", "to", "obtain", ",", "has", "become", "possible", ".", "With", "the", "help", "of", "combinatorial", "methods", ",", "natural", "products", "can", "be", "modified", "to", "optimize", "their", "use", "for", "medical", "applications", ".", "Due", "to", "the", "enormous", "medical", "potential", ",", "modern", "research", "on", "natural", "products", "will", "also", "be", "important", "in", "the", "next", "century", "." ]

[ "umlsterm" ]

Natural products, derivatives, clinical research, drugs, plants, developments, screening, techniques, marine, origin, methods, natural products, use, research, natural products

DerGynaekologe.00330006.eng.abstr_task2

Sentence: Natural products and their derivatives are well established in clinical research and for medical applications . There are excellent drugs available from various plants and microorganisms . Recent developments in the different screening techniques have accelerated the discovery of new compounds . Furthermore , the investigation of compounds of marine origin , which have been more difficult to obtain , has become possible . With the help of combinatorial methods , natural products can be modified to optimize their use for medical applications . Due to the enormous medical potential , modern research on natural products will also be important in the next century . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Natural products and their derivatives are well established in clinical research and for medical applications . There are excellent drugs available from various plants and microorganisms . Recent developments in the different screening techniques have accelerated the discovery of new compounds . Furthermore , the investigation of compounds of marine origin , which have been more difficult to obtain , has become possible . With the help of combinatorial methods , natural products can be modified to optimize their use for medical applications . Due to the enormous medical potential , modern research on natural products will also be important in the next century .

[ "Natural", "products", "and", "their", "derivatives", "are", "well", "established", "in", "clinical", "research", "and", "for", "medical", "applications", ".", "There", "are", "excellent", "drugs", "available", "from", "various", "plants", "and", "microorganisms", ".", "Recent", "developments", "in", "the", "different", "screening", "techniques", "have", "accelerated", "the", "discovery", "of", "new", "compounds", ".", "Furthermore", ",", "the", "investigation", "of", "compounds", "of", "marine", "origin", ",", "which", "have", "been", "more", "difficult", "to", "obtain", ",", "has", "become", "possible", ".", "With", "the", "help", "of", "combinatorial", "methods", ",", "natural", "products", "can", "be", "modified", "to", "optimize", "their", "use", "for", "medical", "applications", ".", "Due", "to", "the", "enormous", "medical", "potential", ",", "modern", "research", "on", "natural", "products", "will", "also", "be", "important", "in", "the", "next", "century", "." ]

[ "umlsterm" ]

bladder is an umlsterm, drainage is an umlsterm, technique is an umlsterm, pancreas transplants is an umlsterm, transplants is an umlsterm, United States is an umlsterm, contrast is an umlsterm, pancreas transplants is an umlsterm, Eurotransplant is an umlsterm, community is an umlsterm, grafts is an umlsterm, June is an umlsterm, October is an umlsterm, graft is an umlsterm, function is an umlsterm, pancreas is an umlsterm, kidney is an umlsterm, grafts is an umlsterm, standard is an umlsterm, procedure is an umlsterm, patients is an umlsterm, insulin - dependent diabetes mellitus is an umlsterm, end - stage renal disease is an umlsterm, Germany is an umlsterm

DerChirurg.60671002.eng.abstr_task0

Sentence: Sinde the introduction of the bladder drainage technique , the number of pancreas transplants performed has now reached 1000/year worldwide . Most of these transplants have been performed in the United States . In contrast , the number of pancreas transplants performed in the Eurotransplant community has remained at a low level for several years . The results of a consecutive series of 20 simultaneous pancreas/kidney grafts ( SPK ) performed between June 1994 and October 1995 demonstrate that high graft function rates of 83.5 % for pancreas and kidney grafts can be achieved . Therefore SPK can be recommended as a standard procedure for patients with insulin-dependent diabetes mellitus and end-stage renal disease in Germany , too . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]

Sinde the introduction of the bladder drainage technique , the number of pancreas transplants performed has now reached 1000/year worldwide . Most of these transplants have been performed in the United States . In contrast , the number of pancreas transplants performed in the Eurotransplant community has remained at a low level for several years . The results of a consecutive series of 20 simultaneous pancreas/kidney grafts ( SPK ) performed between June 1994 and October 1995 demonstrate that high graft function rates of 83.5 % for pancreas and kidney grafts can be achieved . Therefore SPK can be recommended as a standard procedure for patients with insulin-dependent diabetes mellitus and end-stage renal disease in Germany , too .

[ "Sinde", "the", "introduction", "of", "the", "bladder", "drainage", "technique", ",", "the", "number", "of", "pancreas", "transplants", "performed", "has", "now", "reached", "1000", "/", "year", "worldwide", ".", "Most", "of", "these", "transplants", "have", "been", "performed", "in", "the", "United", "States", ".", "In", "contrast", ",", "the", "number", "of", "pancreas", "transplants", "performed", "in", "the", "Eurotransplant", "community", "has", "remained", "at", "a", "low", "level", "for", "several", "years", ".", "The", "results", "of", "a", "consecutive", "series", "of", "20", "simultaneous", "pancreas", "/", "kidney", "grafts", "(", "SPK", ")", "performed", "between", "June", "1994", "and", "October", "1995", "demonstrate", "that", "high", "graft", "function", "rates", "of", "83.5", "%", "for", "pancreas", "and", "kidney", "grafts", "can", "be", "achieved", ".", "Therefore", "SPK", "can", "be", "recommended", "as", "a", "standard", "procedure", "for", "patients", "with", "insulin", "-", "dependent", "diabetes", "mellitus", "and", "end", "-", "stage", "renal", "disease", "in", "Germany", ",", "too", "." ]

[ "umlsterm" ]

bladder is an umlsterm, drainage is an umlsterm, technique is an umlsterm, pancreas transplants is an umlsterm, transplants is an umlsterm, United States is an umlsterm, contrast is an umlsterm, pancreas transplants is an umlsterm, Eurotransplant is an umlsterm, community is an umlsterm, grafts is an umlsterm, June is an umlsterm, October is an umlsterm, graft is an umlsterm, function is an umlsterm, pancreas is an umlsterm, kidney is an umlsterm, grafts is an umlsterm, standard is an umlsterm, procedure is an umlsterm, patients is an umlsterm, insulin - dependent diabetes mellitus is an umlsterm, end - stage renal disease is an umlsterm, Germany is an umlsterm

DerChirurg.60671002.eng.abstr_task1

Sentence: Sinde the introduction of the bladder drainage technique , the number of pancreas transplants performed has now reached 1000/year worldwide . Most of these transplants have been performed in the United States . In contrast , the number of pancreas transplants performed in the Eurotransplant community has remained at a low level for several years . The results of a consecutive series of 20 simultaneous pancreas/kidney grafts ( SPK ) performed between June 1994 and October 1995 demonstrate that high graft function rates of 83.5 % for pancreas and kidney grafts can be achieved . Therefore SPK can be recommended as a standard procedure for patients with insulin-dependent diabetes mellitus and end-stage renal disease in Germany , too . Instructions: please typing these entity words according to sentence: bladder, drainage, technique, pancreas transplants, transplants, United States, contrast, pancreas transplants, Eurotransplant, community, grafts, June, October, graft, function, pancreas, kidney, grafts, standard, procedure, patients, insulin - dependent diabetes mellitus, end - stage renal disease, Germany Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]

Sinde the introduction of the bladder drainage technique , the number of pancreas transplants performed has now reached 1000/year worldwide . Most of these transplants have been performed in the United States . In contrast , the number of pancreas transplants performed in the Eurotransplant community has remained at a low level for several years . The results of a consecutive series of 20 simultaneous pancreas/kidney grafts ( SPK ) performed between June 1994 and October 1995 demonstrate that high graft function rates of 83.5 % for pancreas and kidney grafts can be achieved . Therefore SPK can be recommended as a standard procedure for patients with insulin-dependent diabetes mellitus and end-stage renal disease in Germany , too .

[ "Sinde", "the", "introduction", "of", "the", "bladder", "drainage", "technique", ",", "the", "number", "of", "pancreas", "transplants", "performed", "has", "now", "reached", "1000", "/", "year", "worldwide", ".", "Most", "of", "these", "transplants", "have", "been", "performed", "in", "the", "United", "States", ".", "In", "contrast", ",", "the", "number", "of", "pancreas", "transplants", "performed", "in", "the", "Eurotransplant", "community", "has", "remained", "at", "a", "low", "level", "for", "several", "years", ".", "The", "results", "of", "a", "consecutive", "series", "of", "20", "simultaneous", "pancreas", "/", "kidney", "grafts", "(", "SPK", ")", "performed", "between", "June", "1994", "and", "October", "1995", "demonstrate", "that", "high", "graft", "function", "rates", "of", "83.5", "%", "for", "pancreas", "and", "kidney", "grafts", "can", "be", "achieved", ".", "Therefore", "SPK", "can", "be", "recommended", "as", "a", "standard", "procedure", "for", "patients", "with", "insulin", "-", "dependent", "diabetes", "mellitus", "and", "end", "-", "stage", "renal", "disease", "in", "Germany", ",", "too", "." ]

[ "umlsterm" ]

bladder, drainage, technique, pancreas transplants, transplants, United States, contrast, pancreas transplants, Eurotransplant, community, grafts, June, October, graft, function, pancreas, kidney, grafts, standard, procedure, patients, insulin - dependent diabetes mellitus, end - stage renal disease, Germany

DerChirurg.60671002.eng.abstr_task2

Sentence: Sinde the introduction of the bladder drainage technique , the number of pancreas transplants performed has now reached 1000/year worldwide . Most of these transplants have been performed in the United States . In contrast , the number of pancreas transplants performed in the Eurotransplant community has remained at a low level for several years . The results of a consecutive series of 20 simultaneous pancreas/kidney grafts ( SPK ) performed between June 1994 and October 1995 demonstrate that high graft function rates of 83.5 % for pancreas and kidney grafts can be achieved . Therefore SPK can be recommended as a standard procedure for patients with insulin-dependent diabetes mellitus and end-stage renal disease in Germany , too . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]

Sinde the introduction of the bladder drainage technique , the number of pancreas transplants performed has now reached 1000/year worldwide . Most of these transplants have been performed in the United States . In contrast , the number of pancreas transplants performed in the Eurotransplant community has remained at a low level for several years . The results of a consecutive series of 20 simultaneous pancreas/kidney grafts ( SPK ) performed between June 1994 and October 1995 demonstrate that high graft function rates of 83.5 % for pancreas and kidney grafts can be achieved . Therefore SPK can be recommended as a standard procedure for patients with insulin-dependent diabetes mellitus and end-stage renal disease in Germany , too .

[ "Sinde", "the", "introduction", "of", "the", "bladder", "drainage", "technique", ",", "the", "number", "of", "pancreas", "transplants", "performed", "has", "now", "reached", "1000", "/", "year", "worldwide", ".", "Most", "of", "these", "transplants", "have", "been", "performed", "in", "the", "United", "States", ".", "In", "contrast", ",", "the", "number", "of", "pancreas", "transplants", "performed", "in", "the", "Eurotransplant", "community", "has", "remained", "at", "a", "low", "level", "for", "several", "years", ".", "The", "results", "of", "a", "consecutive", "series", "of", "20", "simultaneous", "pancreas", "/", "kidney", "grafts", "(", "SPK", ")", "performed", "between", "June", "1994", "and", "October", "1995", "demonstrate", "that", "high", "graft", "function", "rates", "of", "83.5", "%", "for", "pancreas", "and", "kidney", "grafts", "can", "be", "achieved", ".", "Therefore", "SPK", "can", "be", "recommended", "as", "a", "standard", "procedure", "for", "patients", "with", "insulin", "-", "dependent", "diabetes", "mellitus", "and", "end", "-", "stage", "renal", "disease", "in", "Germany", ",", "too", "." ]

[ "umlsterm" ]

RNF-5 is a Protein, PAT-3 is a Protein, beta - integrin is a Protein, UNC-95 is a Protein, RNF-5 is a Protein, RNF-5 is a Protein, UNC-95 is a Protein, RNF-5 is a Protein, unc-95 is a Protein, RNF-5 is a Protein

483_task0

Sentence: Molting-specific downregulation of C. elegans body-wall muscle attachment sites: the role of RNF-5 E3 ligase. Repeated molting of the cuticula is an integral part of arthropod and nematode development. Shedding of the old cuticle takes place on the surface of hypodermal cells, which are also responsible for secretion and synthesis of a new cuticle. Here, we use the model nematode Caenorhabditis elegans to show that muscle cells, laying beneath and mechanically linked to the hypodermis, play an important role during molting. We followed the molecular composition and distribution of integrin mediated adhesion structures called dense bodies (DB), which indirectly connect muscles to the hypodermis. We found the concentration of two DB proteins (PAT-3/beta-integrin and UNC-95) to decrease during the quiescent phase of molting, concomitant with an apparent increase in lateral movement of the DB. We show that levels of the E3-ligase RNF-5 increase specifically during molting, and that RNF-5 acts to ubiquitinate the DB protein UNC-95. Persistent high levels of RNF-5 driven by a heatshock or unc-95 promoter lead to failure of ecdysis, and in non-molting worms to a progressive detachment of the cuticle from the hypodermis. These observations indicate that increased DB dynamics characterizes the lethargus phase of molting in parallel to decreased levels of DB components and that temporal expression of RNF-5 contributes to an efficient molting process. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]

Molting-specific downregulation of C. elegans body-wall muscle attachment sites: the role of RNF-5 E3 ligase. Repeated molting of the cuticula is an integral part of arthropod and nematode development. Shedding of the old cuticle takes place on the surface of hypodermal cells, which are also responsible for secretion and synthesis of a new cuticle. Here, we use the model nematode Caenorhabditis elegans to show that muscle cells, laying beneath and mechanically linked to the hypodermis, play an important role during molting. We followed the molecular composition and distribution of integrin mediated adhesion structures called dense bodies (DB), which indirectly connect muscles to the hypodermis. We found the concentration of two DB proteins (PAT-3/beta-integrin and UNC-95) to decrease during the quiescent phase of molting, concomitant with an apparent increase in lateral movement of the DB. We show that levels of the E3-ligase RNF-5 increase specifically during molting, and that RNF-5 acts to ubiquitinate the DB protein UNC-95. Persistent high levels of RNF-5 driven by a heatshock or unc-95 promoter lead to failure of ecdysis, and in non-molting worms to a progressive detachment of the cuticle from the hypodermis. These observations indicate that increased DB dynamics characterizes the lethargus phase of molting in parallel to decreased levels of DB components and that temporal expression of RNF-5 contributes to an efficient molting process.

[ "Molting", "-", "specific", "downregulation", "of", "C.", "elegans", "body", "-", "wall", "muscle", "attachment", "sites", ":", "the", "role", "of", "RNF-5", "E3", "ligase", ".", "\n", "Repeated", "molting", "of", "the", "cuticula", "is", "an", "integral", "part", "of", "arthropod", "and", "nematode", "development", ".", "Shedding", "of", "the", "old", "cuticle", "takes", "place", "on", "the", "surface", "of", "hypodermal", "cells", ",", "which", "are", "also", "responsible", "for", "secretion", "and", "synthesis", "of", "a", "new", "cuticle", ".", "Here", ",", "we", "use", "the", "model", "nematode", "Caenorhabditis", "elegans", "to", "show", "that", "muscle", "cells", ",", "laying", "beneath", "and", "mechanically", "linked", "to", "the", "hypodermis", ",", "play", "an", "important", "role", "during", "molting", ".", "We", "followed", "the", "molecular", "composition", "and", "distribution", "of", "integrin", "mediated", "adhesion", "structures", "called", "dense", "bodies", "(", "DB", ")", ",", "which", "indirectly", "connect", "muscles", "to", "the", "hypodermis", ".", "We", "found", "the", "concentration", "of", "two", "DB", "proteins", "(", "PAT-3", "/", "beta", "-", "integrin", "and", "UNC-95", ")", "to", "decrease", "during", "the", "quiescent", "phase", "of", "molting", ",", "concomitant", "with", "an", "apparent", "increase", "in", "lateral", "movement", "of", "the", "DB", ".", "We", "show", "that", "levels", "of", "the", "E3-ligase", "RNF-5", "increase", "specifically", "during", "molting", ",", "and", "that", "RNF-5", "acts", "to", "ubiquitinate", "the", "DB", "protein", "UNC-95", ".", "Persistent", "high", "levels", "of", "RNF-5", "driven", "by", "a", "heatshock", "or", "unc-95", "promoter", "lead", "to", "failure", "of", "ecdysis", ",", "and", "in", "non", "-", "molting", "worms", "to", "a", "progressive", "detachment", "of", "the", "cuticle", "from", "the", "hypodermis", ".", "These", "observations", "indicate", "that", "increased", "DB", "dynamics", "characterizes", "the", "lethargus", "phase", "of", "molting", "in", "parallel", "to", "decreased", "levels", "of", "DB", "components", "and", "that", "temporal", "expression", "of", "RNF-5", "contributes", "to", "an", "efficient", "molting", "process", ".", "\n" ]

[ "Protein" ]

RNF-5 is a Protein, PAT-3 is a Protein, beta - integrin is a Protein, UNC-95 is a Protein, RNF-5 is a Protein, RNF-5 is a Protein, UNC-95 is a Protein, RNF-5 is a Protein, unc-95 is a Protein, RNF-5 is a Protein

483_task1

Sentence: Molting-specific downregulation of C. elegans body-wall muscle attachment sites: the role of RNF-5 E3 ligase. Repeated molting of the cuticula is an integral part of arthropod and nematode development. Shedding of the old cuticle takes place on the surface of hypodermal cells, which are also responsible for secretion and synthesis of a new cuticle. Here, we use the model nematode Caenorhabditis elegans to show that muscle cells, laying beneath and mechanically linked to the hypodermis, play an important role during molting. We followed the molecular composition and distribution of integrin mediated adhesion structures called dense bodies (DB), which indirectly connect muscles to the hypodermis. We found the concentration of two DB proteins (PAT-3/beta-integrin and UNC-95) to decrease during the quiescent phase of molting, concomitant with an apparent increase in lateral movement of the DB. We show that levels of the E3-ligase RNF-5 increase specifically during molting, and that RNF-5 acts to ubiquitinate the DB protein UNC-95. Persistent high levels of RNF-5 driven by a heatshock or unc-95 promoter lead to failure of ecdysis, and in non-molting worms to a progressive detachment of the cuticle from the hypodermis. These observations indicate that increased DB dynamics characterizes the lethargus phase of molting in parallel to decreased levels of DB components and that temporal expression of RNF-5 contributes to an efficient molting process. Instructions: please typing these entity words according to sentence: RNF-5, PAT-3, beta - integrin, UNC-95, RNF-5, RNF-5, UNC-95, RNF-5, unc-95, RNF-5 Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]

Molting-specific downregulation of C. elegans body-wall muscle attachment sites: the role of RNF-5 E3 ligase. Repeated molting of the cuticula is an integral part of arthropod and nematode development. Shedding of the old cuticle takes place on the surface of hypodermal cells, which are also responsible for secretion and synthesis of a new cuticle. Here, we use the model nematode Caenorhabditis elegans to show that muscle cells, laying beneath and mechanically linked to the hypodermis, play an important role during molting. We followed the molecular composition and distribution of integrin mediated adhesion structures called dense bodies (DB), which indirectly connect muscles to the hypodermis. We found the concentration of two DB proteins (PAT-3/beta-integrin and UNC-95) to decrease during the quiescent phase of molting, concomitant with an apparent increase in lateral movement of the DB. We show that levels of the E3-ligase RNF-5 increase specifically during molting, and that RNF-5 acts to ubiquitinate the DB protein UNC-95. Persistent high levels of RNF-5 driven by a heatshock or unc-95 promoter lead to failure of ecdysis, and in non-molting worms to a progressive detachment of the cuticle from the hypodermis. These observations indicate that increased DB dynamics characterizes the lethargus phase of molting in parallel to decreased levels of DB components and that temporal expression of RNF-5 contributes to an efficient molting process.

[ "Molting", "-", "specific", "downregulation", "of", "C.", "elegans", "body", "-", "wall", "muscle", "attachment", "sites", ":", "the", "role", "of", "RNF-5", "E3", "ligase", ".", "\n", "Repeated", "molting", "of", "the", "cuticula", "is", "an", "integral", "part", "of", "arthropod", "and", "nematode", "development", ".", "Shedding", "of", "the", "old", "cuticle", "takes", "place", "on", "the", "surface", "of", "hypodermal", "cells", ",", "which", "are", "also", "responsible", "for", "secretion", "and", "synthesis", "of", "a", "new", "cuticle", ".", "Here", ",", "we", "use", "the", "model", "nematode", "Caenorhabditis", "elegans", "to", "show", "that", "muscle", "cells", ",", "laying", "beneath", "and", "mechanically", "linked", "to", "the", "hypodermis", ",", "play", "an", "important", "role", "during", "molting", ".", "We", "followed", "the", "molecular", "composition", "and", "distribution", "of", "integrin", "mediated", "adhesion", "structures", "called", "dense", "bodies", "(", "DB", ")", ",", "which", "indirectly", "connect", "muscles", "to", "the", "hypodermis", ".", "We", "found", "the", "concentration", "of", "two", "DB", "proteins", "(", "PAT-3", "/", "beta", "-", "integrin", "and", "UNC-95", ")", "to", "decrease", "during", "the", "quiescent", "phase", "of", "molting", ",", "concomitant", "with", "an", "apparent", "increase", "in", "lateral", "movement", "of", "the", "DB", ".", "We", "show", "that", "levels", "of", "the", "E3-ligase", "RNF-5", "increase", "specifically", "during", "molting", ",", "and", "that", "RNF-5", "acts", "to", "ubiquitinate", "the", "DB", "protein", "UNC-95", ".", "Persistent", "high", "levels", "of", "RNF-5", "driven", "by", "a", "heatshock", "or", "unc-95", "promoter", "lead", "to", "failure", "of", "ecdysis", ",", "and", "in", "non", "-", "molting", "worms", "to", "a", "progressive", "detachment", "of", "the", "cuticle", "from", "the", "hypodermis", ".", "These", "observations", "indicate", "that", "increased", "DB", "dynamics", "characterizes", "the", "lethargus", "phase", "of", "molting", "in", "parallel", "to", "decreased", "levels", "of", "DB", "components", "and", "that", "temporal", "expression", "of", "RNF-5", "contributes", "to", "an", "efficient", "molting", "process", ".", "\n" ]

[ "Protein" ]

RNF-5, PAT-3, beta - integrin, UNC-95, RNF-5, RNF-5, UNC-95, RNF-5, unc-95, RNF-5

483_task2

Sentence: Molting-specific downregulation of C. elegans body-wall muscle attachment sites: the role of RNF-5 E3 ligase. Repeated molting of the cuticula is an integral part of arthropod and nematode development. Shedding of the old cuticle takes place on the surface of hypodermal cells, which are also responsible for secretion and synthesis of a new cuticle. Here, we use the model nematode Caenorhabditis elegans to show that muscle cells, laying beneath and mechanically linked to the hypodermis, play an important role during molting. We followed the molecular composition and distribution of integrin mediated adhesion structures called dense bodies (DB), which indirectly connect muscles to the hypodermis. We found the concentration of two DB proteins (PAT-3/beta-integrin and UNC-95) to decrease during the quiescent phase of molting, concomitant with an apparent increase in lateral movement of the DB. We show that levels of the E3-ligase RNF-5 increase specifically during molting, and that RNF-5 acts to ubiquitinate the DB protein UNC-95. Persistent high levels of RNF-5 driven by a heatshock or unc-95 promoter lead to failure of ecdysis, and in non-molting worms to a progressive detachment of the cuticle from the hypodermis. These observations indicate that increased DB dynamics characterizes the lethargus phase of molting in parallel to decreased levels of DB components and that temporal expression of RNF-5 contributes to an efficient molting process. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]

Molting-specific downregulation of C. elegans body-wall muscle attachment sites: the role of RNF-5 E3 ligase. Repeated molting of the cuticula is an integral part of arthropod and nematode development. Shedding of the old cuticle takes place on the surface of hypodermal cells, which are also responsible for secretion and synthesis of a new cuticle. Here, we use the model nematode Caenorhabditis elegans to show that muscle cells, laying beneath and mechanically linked to the hypodermis, play an important role during molting. We followed the molecular composition and distribution of integrin mediated adhesion structures called dense bodies (DB), which indirectly connect muscles to the hypodermis. We found the concentration of two DB proteins (PAT-3/beta-integrin and UNC-95) to decrease during the quiescent phase of molting, concomitant with an apparent increase in lateral movement of the DB. We show that levels of the E3-ligase RNF-5 increase specifically during molting, and that RNF-5 acts to ubiquitinate the DB protein UNC-95. Persistent high levels of RNF-5 driven by a heatshock or unc-95 promoter lead to failure of ecdysis, and in non-molting worms to a progressive detachment of the cuticle from the hypodermis. These observations indicate that increased DB dynamics characterizes the lethargus phase of molting in parallel to decreased levels of DB components and that temporal expression of RNF-5 contributes to an efficient molting process.

[ "Molting", "-", "specific", "downregulation", "of", "C.", "elegans", "body", "-", "wall", "muscle", "attachment", "sites", ":", "the", "role", "of", "RNF-5", "E3", "ligase", ".", "\n", "Repeated", "molting", "of", "the", "cuticula", "is", "an", "integral", "part", "of", "arthropod", "and", "nematode", "development", ".", "Shedding", "of", "the", "old", "cuticle", "takes", "place", "on", "the", "surface", "of", "hypodermal", "cells", ",", "which", "are", "also", "responsible", "for", "secretion", "and", "synthesis", "of", "a", "new", "cuticle", ".", "Here", ",", "we", "use", "the", "model", "nematode", "Caenorhabditis", "elegans", "to", "show", "that", "muscle", "cells", ",", "laying", "beneath", "and", "mechanically", "linked", "to", "the", "hypodermis", ",", "play", "an", "important", "role", "during", "molting", ".", "We", "followed", "the", "molecular", "composition", "and", "distribution", "of", "integrin", "mediated", "adhesion", "structures", "called", "dense", "bodies", "(", "DB", ")", ",", "which", "indirectly", "connect", "muscles", "to", "the", "hypodermis", ".", "We", "found", "the", "concentration", "of", "two", "DB", "proteins", "(", "PAT-3", "/", "beta", "-", "integrin", "and", "UNC-95", ")", "to", "decrease", "during", "the", "quiescent", "phase", "of", "molting", ",", "concomitant", "with", "an", "apparent", "increase", "in", "lateral", "movement", "of", "the", "DB", ".", "We", "show", "that", "levels", "of", "the", "E3-ligase", "RNF-5", "increase", "specifically", "during", "molting", ",", "and", "that", "RNF-5", "acts", "to", "ubiquitinate", "the", "DB", "protein", "UNC-95", ".", "Persistent", "high", "levels", "of", "RNF-5", "driven", "by", "a", "heatshock", "or", "unc-95", "promoter", "lead", "to", "failure", "of", "ecdysis", ",", "and", "in", "non", "-", "molting", "worms", "to", "a", "progressive", "detachment", "of", "the", "cuticle", "from", "the", "hypodermis", ".", "These", "observations", "indicate", "that", "increased", "DB", "dynamics", "characterizes", "the", "lethargus", "phase", "of", "molting", "in", "parallel", "to", "decreased", "levels", "of", "DB", "components", "and", "that", "temporal", "expression", "of", "RNF-5", "contributes", "to", "an", "efficient", "molting", "process", ".", "\n" ]

[ "Protein" ]

octamer - DNA is a Entity, Oct-1 is a Protein, Oct-2 is a Protein, ' octamer ' sequence is a Entity, ATGCAAAT is a Entity, ATTTGCAT is a Entity, immunoglobulin genes is a Entity, housekeeping genes is a Entity, Oct-2A is a Protein, Oct-1 is a Protein, octamer site is a Entity, interleukin-1 is a Entity, MHC class II genes is a Entity, octamer sequence is a Entity, promoter is a Entity, octamer is a Entity, octamer is a Entity, octamer DNA sequence is a Entity, Oct-1 is a Protein, Oct-2A is a Protein, Oct-1 is a Protein, Oct-2A is a Protein, Oct-1 is a Protein, Oct-2A is a Protein, Oct-1 is a Protein, Oct-2A is a Protein, N - Oct-3 is a Protein, lymphocyte - specific promoter is a Entity, Oct-2A is a Protein, N - Oct-3 is a Protein

266_task0

Sentence: Astrocytes and glioblastoma cells express novel octamer-DNA binding proteins distinct from the ubiquitous Oct-1 and B cell type Oct-2 proteins. The 'octamer' sequence, ATGCAAAT or its complement ATTTGCAT, is a key element for the transcriptional regulation of immunoglobulin genes in B-lymphocytes as well as a number of housekeeping genes in all cell types. In lymphocytes, the octamer-binding protein Oct-2A and variants thereof are thought to contribute to the B-cell specific gene expression, while the ubiquitous protein Oct-1 seems to control general octamer site-dependent transcription. Various other genes, for example interleukin-1 and MHC class II genes, contain an octamer sequence in the promoter and are expressed in cells of both the immune and nervous systems. This prompted us to analyze the octamer-binding proteins in the latter cells. Using the electrophoretic mobility shift assay, at least six novel octamer binding proteins were detected in nuclear extracts of cultured mouse astrocytes. These proteins are differentially expressed in human glioblastoma and neuroblastoma cell lines. The nervous system-derived (N-Oct) proteins bound to the octamer DNA sequence in a manner which is indistinguishable from the Oct-1 and Oct-2A proteins. The relationship of the N-Oct proteins to Oct-1 and Oct-2A was analyzed by proteolytic clipping bandshift assays and by their reactivity towards antisera raised against recombinant Oct-1 and Oct-2A proteins. On the basis of these assays, all N-Oct-factors were found to be distinct from the ubiquitous Oct-1 and the lymphoid-specific Oct-2A proteins. In melanoma cells that contain the N-Oct-3 factor, a transfected lymphocyte-specific promoter was neither activated nor was it repressed upon contransfection with an Oct-2A expression vector. We therefore speculate that N-Oct-3 and other N-Oct factors have a specific role in gene expression in cells of the nervous system. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Astrocytes and glioblastoma cells express novel octamer-DNA binding proteins distinct from the ubiquitous Oct-1 and B cell type Oct-2 proteins. The 'octamer' sequence, ATGCAAAT or its complement ATTTGCAT, is a key element for the transcriptional regulation of immunoglobulin genes in B-lymphocytes as well as a number of housekeeping genes in all cell types. In lymphocytes, the octamer-binding protein Oct-2A and variants thereof are thought to contribute to the B-cell specific gene expression, while the ubiquitous protein Oct-1 seems to control general octamer site-dependent transcription. Various other genes, for example interleukin-1 and MHC class II genes, contain an octamer sequence in the promoter and are expressed in cells of both the immune and nervous systems. This prompted us to analyze the octamer-binding proteins in the latter cells. Using the electrophoretic mobility shift assay, at least six novel octamer binding proteins were detected in nuclear extracts of cultured mouse astrocytes. These proteins are differentially expressed in human glioblastoma and neuroblastoma cell lines. The nervous system-derived (N-Oct) proteins bound to the octamer DNA sequence in a manner which is indistinguishable from the Oct-1 and Oct-2A proteins. The relationship of the N-Oct proteins to Oct-1 and Oct-2A was analyzed by proteolytic clipping bandshift assays and by their reactivity towards antisera raised against recombinant Oct-1 and Oct-2A proteins. On the basis of these assays, all N-Oct-factors were found to be distinct from the ubiquitous Oct-1 and the lymphoid-specific Oct-2A proteins. In melanoma cells that contain the N-Oct-3 factor, a transfected lymphocyte-specific promoter was neither activated nor was it repressed upon contransfection with an Oct-2A expression vector. We therefore speculate that N-Oct-3 and other N-Oct factors have a specific role in gene expression in cells of the nervous system.

[ "Astrocytes", "and", "glioblastoma", "cells", "express", "novel", "octamer", "-", "DNA", "binding", "proteins", "distinct", "from", "the", "ubiquitous", "Oct-1", "and", "B", "cell", "type", "Oct-2", "proteins", ".", "\n", "The", "'", "octamer", "'", "sequence", ",", "ATGCAAAT", "or", "its", "complement", "ATTTGCAT", ",", "is", "a", "key", "element", "for", "the", "transcriptional", "regulation", "of", "immunoglobulin", "genes", "in", "B", "-", "lymphocytes", "as", "well", "as", "a", "number", "of", "housekeeping", "genes", "in", "all", "cell", "types", ".", "In", "lymphocytes", ",", "the", "octamer", "-", "binding", "protein", "Oct-2A", "and", "variants", "thereof", "are", "thought", "to", "contribute", "to", "the", "B", "-", "cell", "specific", "gene", "expression", ",", "while", "the", "ubiquitous", "protein", "Oct-1", "seems", "to", "control", "general", "octamer", "site", "-", "dependent", "transcription", ".", "Various", "other", "genes", ",", "for", "example", "interleukin-1", "and", "MHC", "class", "II", "genes", ",", "contain", "an", "octamer", "sequence", "in", "the", "promoter", "and", "are", "expressed", "in", "cells", "of", "both", "the", "immune", "and", "nervous", "systems", ".", "This", "prompted", "us", "to", "analyze", "the", "octamer", "-", "binding", "proteins", "in", "the", "latter", "cells", ".", "Using", "the", "electrophoretic", "mobility", "shift", "assay", ",", "at", "least", "six", "novel", "octamer", "binding", "proteins", "were", "detected", "in", "nuclear", "extracts", "of", "cultured", "mouse", "astrocytes", ".", "These", "proteins", "are", "differentially", "expressed", "in", "human", "glioblastoma", "and", "neuroblastoma", "cell", "lines", ".", "The", "nervous", "system", "-", "derived", "(", "N", "-", "Oct", ")", "proteins", "bound", "to", "the", "octamer", "DNA", "sequence", "in", "a", "manner", "which", "is", "indistinguishable", "from", "the", "Oct-1", "and", "Oct-2A", "proteins", ".", "The", "relationship", "of", "the", "N", "-", "Oct", "proteins", "to", "Oct-1", "and", "Oct-2A", "was", "analyzed", "by", "proteolytic", "clipping", "bandshift", "assays", "and", "by", "their", "reactivity", "towards", "antisera", "raised", "against", "recombinant", "Oct-1", "and", "Oct-2A", "proteins", ".", "On", "the", "basis", "of", "these", "assays", ",", "all", "N", "-", "Oct", "-", "factors", "were", "found", "to", "be", "distinct", "from", "the", "ubiquitous", "Oct-1", "and", "the", "lymphoid", "-", "specific", "Oct-2A", "proteins", ".", "In", "melanoma", "cells", "that", "contain", "the", "N", "-", "Oct-3", "factor", ",", "a", "transfected", "lymphocyte", "-", "specific", "promoter", "was", "neither", "activated", "nor", "was", "it", "repressed", "upon", "contransfection", "with", "an", "Oct-2A", "expression", "vector", ".", "We", "therefore", "speculate", "that", "N", "-", "Oct-3", "and", "other", "N", "-", "Oct", "factors", "have", "a", "specific", "role", "in", "gene", "expression", "in", "cells", "of", "the", "nervous", "system", ".", "\n" ]

[ "Entity", "Protein" ]

octamer - DNA is a Entity, Oct-1 is a Protein, Oct-2 is a Protein, ' octamer ' sequence is a Entity, ATGCAAAT is a Entity, ATTTGCAT is a Entity, immunoglobulin genes is a Entity, housekeeping genes is a Entity, Oct-2A is a Protein, Oct-1 is a Protein, octamer site is a Entity, interleukin-1 is a Entity, MHC class II genes is a Entity, octamer sequence is a Entity, promoter is a Entity, octamer is a Entity, octamer is a Entity, octamer DNA sequence is a Entity, Oct-1 is a Protein, Oct-2A is a Protein, Oct-1 is a Protein, Oct-2A is a Protein, Oct-1 is a Protein, Oct-2A is a Protein, Oct-1 is a Protein, Oct-2A is a Protein, N - Oct-3 is a Protein, lymphocyte - specific promoter is a Entity, Oct-2A is a Protein, N - Oct-3 is a Protein

266_task1

Sentence: Astrocytes and glioblastoma cells express novel octamer-DNA binding proteins distinct from the ubiquitous Oct-1 and B cell type Oct-2 proteins. The 'octamer' sequence, ATGCAAAT or its complement ATTTGCAT, is a key element for the transcriptional regulation of immunoglobulin genes in B-lymphocytes as well as a number of housekeeping genes in all cell types. In lymphocytes, the octamer-binding protein Oct-2A and variants thereof are thought to contribute to the B-cell specific gene expression, while the ubiquitous protein Oct-1 seems to control general octamer site-dependent transcription. Various other genes, for example interleukin-1 and MHC class II genes, contain an octamer sequence in the promoter and are expressed in cells of both the immune and nervous systems. This prompted us to analyze the octamer-binding proteins in the latter cells. Using the electrophoretic mobility shift assay, at least six novel octamer binding proteins were detected in nuclear extracts of cultured mouse astrocytes. These proteins are differentially expressed in human glioblastoma and neuroblastoma cell lines. The nervous system-derived (N-Oct) proteins bound to the octamer DNA sequence in a manner which is indistinguishable from the Oct-1 and Oct-2A proteins. The relationship of the N-Oct proteins to Oct-1 and Oct-2A was analyzed by proteolytic clipping bandshift assays and by their reactivity towards antisera raised against recombinant Oct-1 and Oct-2A proteins. On the basis of these assays, all N-Oct-factors were found to be distinct from the ubiquitous Oct-1 and the lymphoid-specific Oct-2A proteins. In melanoma cells that contain the N-Oct-3 factor, a transfected lymphocyte-specific promoter was neither activated nor was it repressed upon contransfection with an Oct-2A expression vector. We therefore speculate that N-Oct-3 and other N-Oct factors have a specific role in gene expression in cells of the nervous system. Instructions: please typing these entity words according to sentence: octamer - DNA, Oct-1, Oct-2, ' octamer ' sequence, ATGCAAAT, ATTTGCAT, immunoglobulin genes, housekeeping genes, Oct-2A, Oct-1, octamer site, interleukin-1, MHC class II genes, octamer sequence, promoter, octamer, octamer, octamer DNA sequence, Oct-1, Oct-2A, Oct-1, Oct-2A, Oct-1, Oct-2A, Oct-1, Oct-2A, N - Oct-3, lymphocyte - specific promoter, Oct-2A, N - Oct-3 Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Astrocytes and glioblastoma cells express novel octamer-DNA binding proteins distinct from the ubiquitous Oct-1 and B cell type Oct-2 proteins. The 'octamer' sequence, ATGCAAAT or its complement ATTTGCAT, is a key element for the transcriptional regulation of immunoglobulin genes in B-lymphocytes as well as a number of housekeeping genes in all cell types. In lymphocytes, the octamer-binding protein Oct-2A and variants thereof are thought to contribute to the B-cell specific gene expression, while the ubiquitous protein Oct-1 seems to control general octamer site-dependent transcription. Various other genes, for example interleukin-1 and MHC class II genes, contain an octamer sequence in the promoter and are expressed in cells of both the immune and nervous systems. This prompted us to analyze the octamer-binding proteins in the latter cells. Using the electrophoretic mobility shift assay, at least six novel octamer binding proteins were detected in nuclear extracts of cultured mouse astrocytes. These proteins are differentially expressed in human glioblastoma and neuroblastoma cell lines. The nervous system-derived (N-Oct) proteins bound to the octamer DNA sequence in a manner which is indistinguishable from the Oct-1 and Oct-2A proteins. The relationship of the N-Oct proteins to Oct-1 and Oct-2A was analyzed by proteolytic clipping bandshift assays and by their reactivity towards antisera raised against recombinant Oct-1 and Oct-2A proteins. On the basis of these assays, all N-Oct-factors were found to be distinct from the ubiquitous Oct-1 and the lymphoid-specific Oct-2A proteins. In melanoma cells that contain the N-Oct-3 factor, a transfected lymphocyte-specific promoter was neither activated nor was it repressed upon contransfection with an Oct-2A expression vector. We therefore speculate that N-Oct-3 and other N-Oct factors have a specific role in gene expression in cells of the nervous system.

[ "Astrocytes", "and", "glioblastoma", "cells", "express", "novel", "octamer", "-", "DNA", "binding", "proteins", "distinct", "from", "the", "ubiquitous", "Oct-1", "and", "B", "cell", "type", "Oct-2", "proteins", ".", "\n", "The", "'", "octamer", "'", "sequence", ",", "ATGCAAAT", "or", "its", "complement", "ATTTGCAT", ",", "is", "a", "key", "element", "for", "the", "transcriptional", "regulation", "of", "immunoglobulin", "genes", "in", "B", "-", "lymphocytes", "as", "well", "as", "a", "number", "of", "housekeeping", "genes", "in", "all", "cell", "types", ".", "In", "lymphocytes", ",", "the", "octamer", "-", "binding", "protein", "Oct-2A", "and", "variants", "thereof", "are", "thought", "to", "contribute", "to", "the", "B", "-", "cell", "specific", "gene", "expression", ",", "while", "the", "ubiquitous", "protein", "Oct-1", "seems", "to", "control", "general", "octamer", "site", "-", "dependent", "transcription", ".", "Various", "other", "genes", ",", "for", "example", "interleukin-1", "and", "MHC", "class", "II", "genes", ",", "contain", "an", "octamer", "sequence", "in", "the", "promoter", "and", "are", "expressed", "in", "cells", "of", "both", "the", "immune", "and", "nervous", "systems", ".", "This", "prompted", "us", "to", "analyze", "the", "octamer", "-", "binding", "proteins", "in", "the", "latter", "cells", ".", "Using", "the", "electrophoretic", "mobility", "shift", "assay", ",", "at", "least", "six", "novel", "octamer", "binding", "proteins", "were", "detected", "in", "nuclear", "extracts", "of", "cultured", "mouse", "astrocytes", ".", "These", "proteins", "are", "differentially", "expressed", "in", "human", "glioblastoma", "and", "neuroblastoma", "cell", "lines", ".", "The", "nervous", "system", "-", "derived", "(", "N", "-", "Oct", ")", "proteins", "bound", "to", "the", "octamer", "DNA", "sequence", "in", "a", "manner", "which", "is", "indistinguishable", "from", "the", "Oct-1", "and", "Oct-2A", "proteins", ".", "The", "relationship", "of", "the", "N", "-", "Oct", "proteins", "to", "Oct-1", "and", "Oct-2A", "was", "analyzed", "by", "proteolytic", "clipping", "bandshift", "assays", "and", "by", "their", "reactivity", "towards", "antisera", "raised", "against", "recombinant", "Oct-1", "and", "Oct-2A", "proteins", ".", "On", "the", "basis", "of", "these", "assays", ",", "all", "N", "-", "Oct", "-", "factors", "were", "found", "to", "be", "distinct", "from", "the", "ubiquitous", "Oct-1", "and", "the", "lymphoid", "-", "specific", "Oct-2A", "proteins", ".", "In", "melanoma", "cells", "that", "contain", "the", "N", "-", "Oct-3", "factor", ",", "a", "transfected", "lymphocyte", "-", "specific", "promoter", "was", "neither", "activated", "nor", "was", "it", "repressed", "upon", "contransfection", "with", "an", "Oct-2A", "expression", "vector", ".", "We", "therefore", "speculate", "that", "N", "-", "Oct-3", "and", "other", "N", "-", "Oct", "factors", "have", "a", "specific", "role", "in", "gene", "expression", "in", "cells", "of", "the", "nervous", "system", ".", "\n" ]

[ "Entity", "Protein" ]

octamer - DNA, Oct-1, Oct-2, ' octamer ' sequence, ATGCAAAT, ATTTGCAT, immunoglobulin genes, housekeeping genes, Oct-2A, Oct-1, octamer site, interleukin-1, MHC class II genes, octamer sequence, promoter, octamer, octamer, octamer DNA sequence, Oct-1, Oct-2A, Oct-1, Oct-2A, Oct-1, Oct-2A, Oct-1, Oct-2A, N - Oct-3, lymphocyte - specific promoter, Oct-2A, N - Oct-3

266_task2

Sentence: Astrocytes and glioblastoma cells express novel octamer-DNA binding proteins distinct from the ubiquitous Oct-1 and B cell type Oct-2 proteins. The 'octamer' sequence, ATGCAAAT or its complement ATTTGCAT, is a key element for the transcriptional regulation of immunoglobulin genes in B-lymphocytes as well as a number of housekeeping genes in all cell types. In lymphocytes, the octamer-binding protein Oct-2A and variants thereof are thought to contribute to the B-cell specific gene expression, while the ubiquitous protein Oct-1 seems to control general octamer site-dependent transcription. Various other genes, for example interleukin-1 and MHC class II genes, contain an octamer sequence in the promoter and are expressed in cells of both the immune and nervous systems. This prompted us to analyze the octamer-binding proteins in the latter cells. Using the electrophoretic mobility shift assay, at least six novel octamer binding proteins were detected in nuclear extracts of cultured mouse astrocytes. These proteins are differentially expressed in human glioblastoma and neuroblastoma cell lines. The nervous system-derived (N-Oct) proteins bound to the octamer DNA sequence in a manner which is indistinguishable from the Oct-1 and Oct-2A proteins. The relationship of the N-Oct proteins to Oct-1 and Oct-2A was analyzed by proteolytic clipping bandshift assays and by their reactivity towards antisera raised against recombinant Oct-1 and Oct-2A proteins. On the basis of these assays, all N-Oct-factors were found to be distinct from the ubiquitous Oct-1 and the lymphoid-specific Oct-2A proteins. In melanoma cells that contain the N-Oct-3 factor, a transfected lymphocyte-specific promoter was neither activated nor was it repressed upon contransfection with an Oct-2A expression vector. We therefore speculate that N-Oct-3 and other N-Oct factors have a specific role in gene expression in cells of the nervous system. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Astrocytes and glioblastoma cells express novel octamer-DNA binding proteins distinct from the ubiquitous Oct-1 and B cell type Oct-2 proteins. The 'octamer' sequence, ATGCAAAT or its complement ATTTGCAT, is a key element for the transcriptional regulation of immunoglobulin genes in B-lymphocytes as well as a number of housekeeping genes in all cell types. In lymphocytes, the octamer-binding protein Oct-2A and variants thereof are thought to contribute to the B-cell specific gene expression, while the ubiquitous protein Oct-1 seems to control general octamer site-dependent transcription. Various other genes, for example interleukin-1 and MHC class II genes, contain an octamer sequence in the promoter and are expressed in cells of both the immune and nervous systems. This prompted us to analyze the octamer-binding proteins in the latter cells. Using the electrophoretic mobility shift assay, at least six novel octamer binding proteins were detected in nuclear extracts of cultured mouse astrocytes. These proteins are differentially expressed in human glioblastoma and neuroblastoma cell lines. The nervous system-derived (N-Oct) proteins bound to the octamer DNA sequence in a manner which is indistinguishable from the Oct-1 and Oct-2A proteins. The relationship of the N-Oct proteins to Oct-1 and Oct-2A was analyzed by proteolytic clipping bandshift assays and by their reactivity towards antisera raised against recombinant Oct-1 and Oct-2A proteins. On the basis of these assays, all N-Oct-factors were found to be distinct from the ubiquitous Oct-1 and the lymphoid-specific Oct-2A proteins. In melanoma cells that contain the N-Oct-3 factor, a transfected lymphocyte-specific promoter was neither activated nor was it repressed upon contransfection with an Oct-2A expression vector. We therefore speculate that N-Oct-3 and other N-Oct factors have a specific role in gene expression in cells of the nervous system.

[ "Astrocytes", "and", "glioblastoma", "cells", "express", "novel", "octamer", "-", "DNA", "binding", "proteins", "distinct", "from", "the", "ubiquitous", "Oct-1", "and", "B", "cell", "type", "Oct-2", "proteins", ".", "\n", "The", "'", "octamer", "'", "sequence", ",", "ATGCAAAT", "or", "its", "complement", "ATTTGCAT", ",", "is", "a", "key", "element", "for", "the", "transcriptional", "regulation", "of", "immunoglobulin", "genes", "in", "B", "-", "lymphocytes", "as", "well", "as", "a", "number", "of", "housekeeping", "genes", "in", "all", "cell", "types", ".", "In", "lymphocytes", ",", "the", "octamer", "-", "binding", "protein", "Oct-2A", "and", "variants", "thereof", "are", "thought", "to", "contribute", "to", "the", "B", "-", "cell", "specific", "gene", "expression", ",", "while", "the", "ubiquitous", "protein", "Oct-1", "seems", "to", "control", "general", "octamer", "site", "-", "dependent", "transcription", ".", "Various", "other", "genes", ",", "for", "example", "interleukin-1", "and", "MHC", "class", "II", "genes", ",", "contain", "an", "octamer", "sequence", "in", "the", "promoter", "and", "are", "expressed", "in", "cells", "of", "both", "the", "immune", "and", "nervous", "systems", ".", "This", "prompted", "us", "to", "analyze", "the", "octamer", "-", "binding", "proteins", "in", "the", "latter", "cells", ".", "Using", "the", "electrophoretic", "mobility", "shift", "assay", ",", "at", "least", "six", "novel", "octamer", "binding", "proteins", "were", "detected", "in", "nuclear", "extracts", "of", "cultured", "mouse", "astrocytes", ".", "These", "proteins", "are", "differentially", "expressed", "in", "human", "glioblastoma", "and", "neuroblastoma", "cell", "lines", ".", "The", "nervous", "system", "-", "derived", "(", "N", "-", "Oct", ")", "proteins", "bound", "to", "the", "octamer", "DNA", "sequence", "in", "a", "manner", "which", "is", "indistinguishable", "from", "the", "Oct-1", "and", "Oct-2A", "proteins", ".", "The", "relationship", "of", "the", "N", "-", "Oct", "proteins", "to", "Oct-1", "and", "Oct-2A", "was", "analyzed", "by", "proteolytic", "clipping", "bandshift", "assays", "and", "by", "their", "reactivity", "towards", "antisera", "raised", "against", "recombinant", "Oct-1", "and", "Oct-2A", "proteins", ".", "On", "the", "basis", "of", "these", "assays", ",", "all", "N", "-", "Oct", "-", "factors", "were", "found", "to", "be", "distinct", "from", "the", "ubiquitous", "Oct-1", "and", "the", "lymphoid", "-", "specific", "Oct-2A", "proteins", ".", "In", "melanoma", "cells", "that", "contain", "the", "N", "-", "Oct-3", "factor", ",", "a", "transfected", "lymphocyte", "-", "specific", "promoter", "was", "neither", "activated", "nor", "was", "it", "repressed", "upon", "contransfection", "with", "an", "Oct-2A", "expression", "vector", ".", "We", "therefore", "speculate", "that", "N", "-", "Oct-3", "and", "other", "N", "-", "Oct", "factors", "have", "a", "specific", "role", "in", "gene", "expression", "in", "cells", "of", "the", "nervous", "system", ".", "\n" ]

[ "Entity", "Protein" ]

Wound healing is an umlsterm, growth factors is an umlsterm, Economic aspects is an umlsterm, wound healing is an umlsterm, Germany is an umlsterm, patients is an umlsterm, chronic venous insufficiency is an umlsterm, ulcers is an umlsterm, bacterial infection is an umlsterm, ulcers is an umlsterm, bacteria is an umlsterm, antibiotic is an umlsterm, treatment is an umlsterm, wound healing is an umlsterm, in vitro is an umlsterm, antiseptic is an umlsterm, function is an umlsterm, cultures is an umlsterm, fibroblasts is an umlsterm, antiseptic is an umlsterm, growth is an umlsterm, fibroblasts is an umlsterm, solution is an umlsterm, antiseptic is an umlsterm, growth is an umlsterm, fibroblasts is an umlsterm, treatment is an umlsterm, radiation is an umlsterm, antiseptic is an umlsterm

DerHautarzt.50460319.eng.abstr_task0

Sentence: Wound healing represents a dynamic process of increasing scientific interest , especially with the detection of the different growth factors . Economic aspects are also of importance in the investigation of substances used for wound healing . In Germany 25% of all patients ( ca. 1 million ) with severe chronic venous insufficiency have crural ulcers . The influence of bacterial infection of crural ulcers is controversial . There is no doubt that the quantity of bacteria is of importance . Local antibiotic treatment is difficult , as most of the substances used are known to inhibit wound healing . In vivo and in vitro investigations showed , that chiniofon-containing antiseptic has a bacteriostatic function . Additionally it was shown , using cultures of fibroblasts , that chiniofon-containing antiseptic does not inhibit the growth of fibroblasts , whereas PVP-iodine solution , a widely used antiseptic , clearly reduces the growth of fibroblasts . The good clinical results in the treatment of acute and chronic radiation damage indicate that chiniofon-containing antiseptic may have antiflammatory activity . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]

Wound healing represents a dynamic process of increasing scientific interest , especially with the detection of the different growth factors . Economic aspects are also of importance in the investigation of substances used for wound healing . In Germany 25% of all patients ( ca. 1 million ) with severe chronic venous insufficiency have crural ulcers . The influence of bacterial infection of crural ulcers is controversial . There is no doubt that the quantity of bacteria is of importance . Local antibiotic treatment is difficult , as most of the substances used are known to inhibit wound healing . In vivo and in vitro investigations showed , that chiniofon-containing antiseptic has a bacteriostatic function . Additionally it was shown , using cultures of fibroblasts , that chiniofon-containing antiseptic does not inhibit the growth of fibroblasts , whereas PVP-iodine solution , a widely used antiseptic , clearly reduces the growth of fibroblasts . The good clinical results in the treatment of acute and chronic radiation damage indicate that chiniofon-containing antiseptic may have antiflammatory activity .

[ "Wound", "healing", "represents", "a", "dynamic", "process", "of", "increasing", "scientific", "interest", ",", "especially", "with", "the", "detection", "of", "the", "different", "growth", "factors", ".", "Economic", "aspects", "are", "also", "of", "importance", "in", "the", "investigation", "of", "substances", "used", "for", "wound", "healing", ".", "In", "Germany", "25", "%", "of", "all", "patients", "(", "ca", ".", "1", "million", ")", "with", "severe", "chronic", "venous", "insufficiency", "have", "crural", "ulcers", ".", "The", "influence", "of", "bacterial", "infection", "of", "crural", "ulcers", "is", "controversial", ".", "There", "is", "no", "doubt", "that", "the", "quantity", "of", "bacteria", "is", "of", "importance", ".", "Local", "antibiotic", "treatment", "is", "difficult", ",", "as", "most", "of", "the", "substances", "used", "are", "known", "to", "inhibit", "wound", "healing", ".", "In", "vivo", "and", "in", "vitro", "investigations", "showed", ",", "that", "chiniofon", "-", "containing", "antiseptic", "has", "a", "bacteriostatic", "function", ".", "Additionally", "it", "was", "shown", ",", "using", "cultures", "of", "fibroblasts", ",", "that", "chiniofon", "-", "containing", "antiseptic", "does", "not", "inhibit", "the", "growth", "of", "fibroblasts", ",", "whereas", "PVP", "-", "iodine", "solution", ",", "a", "widely", "used", "antiseptic", ",", "clearly", "reduces", "the", "growth", "of", "fibroblasts", ".", "The", "good", "clinical", "results", "in", "the", "treatment", "of", "acute", "and", "chronic", "radiation", "damage", "indicate", "that", "chiniofon", "-", "containing", "antiseptic", "may", "have", "antiflammatory", "activity", "." ]

[ "umlsterm" ]

Wound healing is an umlsterm, growth factors is an umlsterm, Economic aspects is an umlsterm, wound healing is an umlsterm, Germany is an umlsterm, patients is an umlsterm, chronic venous insufficiency is an umlsterm, ulcers is an umlsterm, bacterial infection is an umlsterm, ulcers is an umlsterm, bacteria is an umlsterm, antibiotic is an umlsterm, treatment is an umlsterm, wound healing is an umlsterm, in vitro is an umlsterm, antiseptic is an umlsterm, function is an umlsterm, cultures is an umlsterm, fibroblasts is an umlsterm, antiseptic is an umlsterm, growth is an umlsterm, fibroblasts is an umlsterm, solution is an umlsterm, antiseptic is an umlsterm, growth is an umlsterm, fibroblasts is an umlsterm, treatment is an umlsterm, radiation is an umlsterm, antiseptic is an umlsterm

DerHautarzt.50460319.eng.abstr_task1

Sentence: Wound healing represents a dynamic process of increasing scientific interest , especially with the detection of the different growth factors . Economic aspects are also of importance in the investigation of substances used for wound healing . In Germany 25% of all patients ( ca. 1 million ) with severe chronic venous insufficiency have crural ulcers . The influence of bacterial infection of crural ulcers is controversial . There is no doubt that the quantity of bacteria is of importance . Local antibiotic treatment is difficult , as most of the substances used are known to inhibit wound healing . In vivo and in vitro investigations showed , that chiniofon-containing antiseptic has a bacteriostatic function . Additionally it was shown , using cultures of fibroblasts , that chiniofon-containing antiseptic does not inhibit the growth of fibroblasts , whereas PVP-iodine solution , a widely used antiseptic , clearly reduces the growth of fibroblasts . The good clinical results in the treatment of acute and chronic radiation damage indicate that chiniofon-containing antiseptic may have antiflammatory activity . Instructions: please typing these entity words according to sentence: Wound healing, growth factors, Economic aspects, wound healing, Germany, patients, chronic venous insufficiency, ulcers, bacterial infection, ulcers, bacteria, antibiotic, treatment, wound healing, in vitro, antiseptic, function, cultures, fibroblasts, antiseptic, growth, fibroblasts, solution, antiseptic, growth, fibroblasts, treatment, radiation, antiseptic Options: umlsterm

[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]

Wound healing represents a dynamic process of increasing scientific interest , especially with the detection of the different growth factors . Economic aspects are also of importance in the investigation of substances used for wound healing . In Germany 25% of all patients ( ca. 1 million ) with severe chronic venous insufficiency have crural ulcers . The influence of bacterial infection of crural ulcers is controversial . There is no doubt that the quantity of bacteria is of importance . Local antibiotic treatment is difficult , as most of the substances used are known to inhibit wound healing . In vivo and in vitro investigations showed , that chiniofon-containing antiseptic has a bacteriostatic function . Additionally it was shown , using cultures of fibroblasts , that chiniofon-containing antiseptic does not inhibit the growth of fibroblasts , whereas PVP-iodine solution , a widely used antiseptic , clearly reduces the growth of fibroblasts . The good clinical results in the treatment of acute and chronic radiation damage indicate that chiniofon-containing antiseptic may have antiflammatory activity .

[ "Wound", "healing", "represents", "a", "dynamic", "process", "of", "increasing", "scientific", "interest", ",", "especially", "with", "the", "detection", "of", "the", "different", "growth", "factors", ".", "Economic", "aspects", "are", "also", "of", "importance", "in", "the", "investigation", "of", "substances", "used", "for", "wound", "healing", ".", "In", "Germany", "25", "%", "of", "all", "patients", "(", "ca", ".", "1", "million", ")", "with", "severe", "chronic", "venous", "insufficiency", "have", "crural", "ulcers", ".", "The", "influence", "of", "bacterial", "infection", "of", "crural", "ulcers", "is", "controversial", ".", "There", "is", "no", "doubt", "that", "the", "quantity", "of", "bacteria", "is", "of", "importance", ".", "Local", "antibiotic", "treatment", "is", "difficult", ",", "as", "most", "of", "the", "substances", "used", "are", "known", "to", "inhibit", "wound", "healing", ".", "In", "vivo", "and", "in", "vitro", "investigations", "showed", ",", "that", "chiniofon", "-", "containing", "antiseptic", "has", "a", "bacteriostatic", "function", ".", "Additionally", "it", "was", "shown", ",", "using", "cultures", "of", "fibroblasts", ",", "that", "chiniofon", "-", "containing", "antiseptic", "does", "not", "inhibit", "the", "growth", "of", "fibroblasts", ",", "whereas", "PVP", "-", "iodine", "solution", ",", "a", "widely", "used", "antiseptic", ",", "clearly", "reduces", "the", "growth", "of", "fibroblasts", ".", "The", "good", "clinical", "results", "in", "the", "treatment", "of", "acute", "and", "chronic", "radiation", "damage", "indicate", "that", "chiniofon", "-", "containing", "antiseptic", "may", "have", "antiflammatory", "activity", "." ]

[ "umlsterm" ]

Wound healing, growth factors, Economic aspects, wound healing, Germany, patients, chronic venous insufficiency, ulcers, bacterial infection, ulcers, bacteria, antibiotic, treatment, wound healing, in vitro, antiseptic, function, cultures, fibroblasts, antiseptic, growth, fibroblasts, solution, antiseptic, growth, fibroblasts, treatment, radiation, antiseptic

DerHautarzt.50460319.eng.abstr_task2

Sentence: Wound healing represents a dynamic process of increasing scientific interest , especially with the detection of the different growth factors . Economic aspects are also of importance in the investigation of substances used for wound healing . In Germany 25% of all patients ( ca. 1 million ) with severe chronic venous insufficiency have crural ulcers . The influence of bacterial infection of crural ulcers is controversial . There is no doubt that the quantity of bacteria is of importance . Local antibiotic treatment is difficult , as most of the substances used are known to inhibit wound healing . In vivo and in vitro investigations showed , that chiniofon-containing antiseptic has a bacteriostatic function . Additionally it was shown , using cultures of fibroblasts , that chiniofon-containing antiseptic does not inhibit the growth of fibroblasts , whereas PVP-iodine solution , a widely used antiseptic , clearly reduces the growth of fibroblasts . The good clinical results in the treatment of acute and chronic radiation damage indicate that chiniofon-containing antiseptic may have antiflammatory activity . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]

Wound healing represents a dynamic process of increasing scientific interest , especially with the detection of the different growth factors . Economic aspects are also of importance in the investigation of substances used for wound healing . In Germany 25% of all patients ( ca. 1 million ) with severe chronic venous insufficiency have crural ulcers . The influence of bacterial infection of crural ulcers is controversial . There is no doubt that the quantity of bacteria is of importance . Local antibiotic treatment is difficult , as most of the substances used are known to inhibit wound healing . In vivo and in vitro investigations showed , that chiniofon-containing antiseptic has a bacteriostatic function . Additionally it was shown , using cultures of fibroblasts , that chiniofon-containing antiseptic does not inhibit the growth of fibroblasts , whereas PVP-iodine solution , a widely used antiseptic , clearly reduces the growth of fibroblasts . The good clinical results in the treatment of acute and chronic radiation damage indicate that chiniofon-containing antiseptic may have antiflammatory activity .

[ "Wound", "healing", "represents", "a", "dynamic", "process", "of", "increasing", "scientific", "interest", ",", "especially", "with", "the", "detection", "of", "the", "different", "growth", "factors", ".", "Economic", "aspects", "are", "also", "of", "importance", "in", "the", "investigation", "of", "substances", "used", "for", "wound", "healing", ".", "In", "Germany", "25", "%", "of", "all", "patients", "(", "ca", ".", "1", "million", ")", "with", "severe", "chronic", "venous", "insufficiency", "have", "crural", "ulcers", ".", "The", "influence", "of", "bacterial", "infection", "of", "crural", "ulcers", "is", "controversial", ".", "There", "is", "no", "doubt", "that", "the", "quantity", "of", "bacteria", "is", "of", "importance", ".", "Local", "antibiotic", "treatment", "is", "difficult", ",", "as", "most", "of", "the", "substances", "used", "are", "known", "to", "inhibit", "wound", "healing", ".", "In", "vivo", "and", "in", "vitro", "investigations", "showed", ",", "that", "chiniofon", "-", "containing", "antiseptic", "has", "a", "bacteriostatic", "function", ".", "Additionally", "it", "was", "shown", ",", "using", "cultures", "of", "fibroblasts", ",", "that", "chiniofon", "-", "containing", "antiseptic", "does", "not", "inhibit", "the", "growth", "of", "fibroblasts", ",", "whereas", "PVP", "-", "iodine", "solution", ",", "a", "widely", "used", "antiseptic", ",", "clearly", "reduces", "the", "growth", "of", "fibroblasts", ".", "The", "good", "clinical", "results", "in", "the", "treatment", "of", "acute", "and", "chronic", "radiation", "damage", "indicate", "that", "chiniofon", "-", "containing", "antiseptic", "may", "have", "antiflammatory", "activity", "." ]

[ "umlsterm" ]

Insulin - like growth factor-1 is a Genes & Molecular Sequences, Fas is a Genes & Molecular Sequences, phosphatidylinositol-3 kinase is a Genes & Molecular Sequences

11504_task0

Sentence: Insulin-like growth factor-1 delays Fas-mediated apoptosis in human neutrophils through the phosphatidylinositol-3 kinase pathway. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Genes & Molecular Sequences

[ "B-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "O", "B-Genes & Molecular Sequences", "O", "O", "O", "O", "O", "O", "O", "O", "B-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "O", "O" ]

Insulin-like growth factor-1 delays Fas-mediated apoptosis in human neutrophils through the phosphatidylinositol-3 kinase pathway.

[ "Insulin", "-", "like", "growth", "factor-1", "delays", "Fas", "-", "mediated", "apoptosis", "in", "human", "neutrophils", "through", "the", "phosphatidylinositol-3", "kinase", "pathway", "." ]

[ "Genes & Molecular Sequences", "Chemicals & Drugs", "" ]

Insulin - like growth factor-1 is a Genes & Molecular Sequences, Fas is a Genes & Molecular Sequences, phosphatidylinositol-3 kinase is a Genes & Molecular Sequences

11504_task1

Sentence: Insulin-like growth factor-1 delays Fas-mediated apoptosis in human neutrophils through the phosphatidylinositol-3 kinase pathway. Instructions: please typing these entity words according to sentence: Insulin - like growth factor-1, Fas, phosphatidylinositol-3 kinase Options: Genes & Molecular Sequences

[ "B-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "O", "B-Genes & Molecular Sequences", "O", "O", "O", "O", "O", "O", "O", "O", "B-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "O", "O" ]

Insulin-like growth factor-1 delays Fas-mediated apoptosis in human neutrophils through the phosphatidylinositol-3 kinase pathway.

[ "Insulin", "-", "like", "growth", "factor-1", "delays", "Fas", "-", "mediated", "apoptosis", "in", "human", "neutrophils", "through", "the", "phosphatidylinositol-3", "kinase", "pathway", "." ]

[ "Genes & Molecular Sequences", "Chemicals & Drugs", "" ]

Insulin - like growth factor-1, Fas, phosphatidylinositol-3 kinase

11504_task2

Sentence: Insulin-like growth factor-1 delays Fas-mediated apoptosis in human neutrophils through the phosphatidylinositol-3 kinase pathway. Instructions: please extract entity words from the input sentence

[ "B-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "O", "B-Genes & Molecular Sequences", "O", "O", "O", "O", "O", "O", "O", "O", "B-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "O", "O" ]

Insulin-like growth factor-1 delays Fas-mediated apoptosis in human neutrophils through the phosphatidylinositol-3 kinase pathway.

[ "Insulin", "-", "like", "growth", "factor-1", "delays", "Fas", "-", "mediated", "apoptosis", "in", "human", "neutrophils", "through", "the", "phosphatidylinositol-3", "kinase", "pathway", "." ]

[ "Genes & Molecular Sequences", "Chemicals & Drugs", "" ]

Arterien is an umlsterm, Kalksalzen is an umlsterm, Arterien is an umlsterm, unteren Extremitaet is an umlsterm, Beckenarterien is an umlsterm, Bauchaorta is an umlsterm, Herzkranzarterien is an umlsterm

ZfuerKardiologie.80870928.ger.abstr_task0

Sentence: Mediakalzinose MK ) ( ist eine Erkrankung der Arterien vom muskulaeren Typ , die durch eine zunehmende Ablagerung von Kalksalzen in der mittleren Gefaesswandschicht , der Media , charakterisiert ist . Am haeufigsten erkranken die Arterien der unteren Extremitaet , wobei ein ausgedehnter Befall mit Einbeziehung der Beckenarterien und der Bauchaorta nicht ungewoehnlich ist . Eine systemische Ausbreitung der MK mit Beteiligung der Herzkranzarterien wurde ebenfalls beschrieben , ist jedoch nach heutiger Auffassung selten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Mediakalzinose MK ) ( ist eine Erkrankung der Arterien vom muskulaeren Typ , die durch eine zunehmende Ablagerung von Kalksalzen in der mittleren Gefaesswandschicht , der Media , charakterisiert ist . Am haeufigsten erkranken die Arterien der unteren Extremitaet , wobei ein ausgedehnter Befall mit Einbeziehung der Beckenarterien und der Bauchaorta nicht ungewoehnlich ist . Eine systemische Ausbreitung der MK mit Beteiligung der Herzkranzarterien wurde ebenfalls beschrieben , ist jedoch nach heutiger Auffassung selten .

[ "Mediakalzinose", "MK", ")", "(", "ist", "eine", "Erkrankung", "der", "Arterien", "vom", "muskulaeren", "Typ", ",", "die", "durch", "eine", "zunehmende", "Ablagerung", "von", "Kalksalzen", "in", "der", "mittleren", "Gefaesswandschicht", ",", "der", "Media", ",", "charakterisiert", "ist", ".", "Am", "haeufigsten", "erkranken", "die", "Arterien", "der", "unteren", "Extremitaet", ",", "wobei", "ein", "ausgedehnter", "Befall", "mit", "Einbeziehung", "der", "Beckenarterien", "und", "der", "Bauchaorta", "nicht", "ungewoehnlich", "ist", ".", "Eine", "systemische", "Ausbreitung", "der", "MK", "mit", "Beteiligung", "der", "Herzkranzarterien", "wurde", "ebenfalls", "beschrieben", ",", "ist", "jedoch", "nach", "heutiger", "Auffassung", "selten", "." ]

[ "umlsterm" ]

Arterien is an umlsterm, Kalksalzen is an umlsterm, Arterien is an umlsterm, unteren Extremitaet is an umlsterm, Beckenarterien is an umlsterm, Bauchaorta is an umlsterm, Herzkranzarterien is an umlsterm

ZfuerKardiologie.80870928.ger.abstr_task1

Sentence: Mediakalzinose MK ) ( ist eine Erkrankung der Arterien vom muskulaeren Typ , die durch eine zunehmende Ablagerung von Kalksalzen in der mittleren Gefaesswandschicht , der Media , charakterisiert ist . Am haeufigsten erkranken die Arterien der unteren Extremitaet , wobei ein ausgedehnter Befall mit Einbeziehung der Beckenarterien und der Bauchaorta nicht ungewoehnlich ist . Eine systemische Ausbreitung der MK mit Beteiligung der Herzkranzarterien wurde ebenfalls beschrieben , ist jedoch nach heutiger Auffassung selten . Instructions: please typing these entity words according to sentence: Arterien, Kalksalzen, Arterien, unteren Extremitaet, Beckenarterien, Bauchaorta, Herzkranzarterien Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Mediakalzinose MK ) ( ist eine Erkrankung der Arterien vom muskulaeren Typ , die durch eine zunehmende Ablagerung von Kalksalzen in der mittleren Gefaesswandschicht , der Media , charakterisiert ist . Am haeufigsten erkranken die Arterien der unteren Extremitaet , wobei ein ausgedehnter Befall mit Einbeziehung der Beckenarterien und der Bauchaorta nicht ungewoehnlich ist . Eine systemische Ausbreitung der MK mit Beteiligung der Herzkranzarterien wurde ebenfalls beschrieben , ist jedoch nach heutiger Auffassung selten .

[ "Mediakalzinose", "MK", ")", "(", "ist", "eine", "Erkrankung", "der", "Arterien", "vom", "muskulaeren", "Typ", ",", "die", "durch", "eine", "zunehmende", "Ablagerung", "von", "Kalksalzen", "in", "der", "mittleren", "Gefaesswandschicht", ",", "der", "Media", ",", "charakterisiert", "ist", ".", "Am", "haeufigsten", "erkranken", "die", "Arterien", "der", "unteren", "Extremitaet", ",", "wobei", "ein", "ausgedehnter", "Befall", "mit", "Einbeziehung", "der", "Beckenarterien", "und", "der", "Bauchaorta", "nicht", "ungewoehnlich", "ist", ".", "Eine", "systemische", "Ausbreitung", "der", "MK", "mit", "Beteiligung", "der", "Herzkranzarterien", "wurde", "ebenfalls", "beschrieben", ",", "ist", "jedoch", "nach", "heutiger", "Auffassung", "selten", "." ]

[ "umlsterm" ]

Arterien, Kalksalzen, Arterien, unteren Extremitaet, Beckenarterien, Bauchaorta, Herzkranzarterien

ZfuerKardiologie.80870928.ger.abstr_task2

Sentence: Mediakalzinose MK ) ( ist eine Erkrankung der Arterien vom muskulaeren Typ , die durch eine zunehmende Ablagerung von Kalksalzen in der mittleren Gefaesswandschicht , der Media , charakterisiert ist . Am haeufigsten erkranken die Arterien der unteren Extremitaet , wobei ein ausgedehnter Befall mit Einbeziehung der Beckenarterien und der Bauchaorta nicht ungewoehnlich ist . Eine systemische Ausbreitung der MK mit Beteiligung der Herzkranzarterien wurde ebenfalls beschrieben , ist jedoch nach heutiger Auffassung selten . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Mediakalzinose MK ) ( ist eine Erkrankung der Arterien vom muskulaeren Typ , die durch eine zunehmende Ablagerung von Kalksalzen in der mittleren Gefaesswandschicht , der Media , charakterisiert ist . Am haeufigsten erkranken die Arterien der unteren Extremitaet , wobei ein ausgedehnter Befall mit Einbeziehung der Beckenarterien und der Bauchaorta nicht ungewoehnlich ist . Eine systemische Ausbreitung der MK mit Beteiligung der Herzkranzarterien wurde ebenfalls beschrieben , ist jedoch nach heutiger Auffassung selten .

[ "Mediakalzinose", "MK", ")", "(", "ist", "eine", "Erkrankung", "der", "Arterien", "vom", "muskulaeren", "Typ", ",", "die", "durch", "eine", "zunehmende", "Ablagerung", "von", "Kalksalzen", "in", "der", "mittleren", "Gefaesswandschicht", ",", "der", "Media", ",", "charakterisiert", "ist", ".", "Am", "haeufigsten", "erkranken", "die", "Arterien", "der", "unteren", "Extremitaet", ",", "wobei", "ein", "ausgedehnter", "Befall", "mit", "Einbeziehung", "der", "Beckenarterien", "und", "der", "Bauchaorta", "nicht", "ungewoehnlich", "ist", ".", "Eine", "systemische", "Ausbreitung", "der", "MK", "mit", "Beteiligung", "der", "Herzkranzarterien", "wurde", "ebenfalls", "beschrieben", ",", "ist", "jedoch", "nach", "heutiger", "Auffassung", "selten", "." ]

[ "umlsterm" ]

Mepyramine is a CHEMICAL, histamine H1 receptor is a GENE-N, rat and human P450 2D is a GENE-N

7853212_task0

Sentence: Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, CHEMICAL

[ "B-CHEMICAL", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O" ]

Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms.

[ "Mepyramine", ",", "a", "histamine", "H1", "receptor", "antagonist", ",", "inhibits", "the", "metabolic", "activity", "of", "rat", "and", "human", "P450", "2D", "forms", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

Mepyramine is a CHEMICAL, histamine H1 receptor is a GENE-N, rat and human P450 2D is a GENE-N

7853212_task1

Sentence: Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms. Instructions: please typing these entity words according to sentence: Mepyramine, histamine H1 receptor, rat and human P450 2D Options: GENE-N, CHEMICAL

[ "B-CHEMICAL", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O" ]

Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms.

[ "Mepyramine", ",", "a", "histamine", "H1", "receptor", "antagonist", ",", "inhibits", "the", "metabolic", "activity", "of", "rat", "and", "human", "P450", "2D", "forms", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

Mepyramine, histamine H1 receptor, rat and human P450 2D

7853212_task2

Sentence: Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms. Instructions: please extract entity words from the input sentence

[ "B-CHEMICAL", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O" ]

Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms.

[ "Mepyramine", ",", "a", "histamine", "H1", "receptor", "antagonist", ",", "inhibits", "the", "metabolic", "activity", "of", "rat", "and", "human", "P450", "2D", "forms", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

Monoamine Oxidase A is a GENE-Y, Harmaline is a CHEMICAL, 5-Methoxy - N , N - Dimethyltryptamine is a CHEMICAL, CYP2D6 is a GENE-Y, 5-Methoxy - N , N - dimethyltryptamine is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, 5-MEO is a CHEMICAL, indolealkylamines is a CHEMICAL, monoamine oxidase A is a GENE-Y, MAO - A is a GENE-Y, harmaline is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, harmaline is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, CYP2D6 is a GENE-Y, harmaline is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, O is a CHEMICAL, bufotenine is a CHEMICAL, MAO - A is a GENE-Y, harmaline is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, harmaline is a CHEMICAL, CYP2D6 is a GENE-Y, Harmaline is a CHEMICAL, bufotenine is a CHEMICAL, CYP2D6 is a GENE-Y, harmaline is a CHEMICAL, bufotenine is a CHEMICAL, harmaline is a CHEMICAL, bufotenine is a CHEMICAL, CYP2D6 is a GENE-Y, 5-MeO - DMT is a CHEMICAL, harmaline is a CHEMICAL, harmaline is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, bufotenine is a CHEMICAL, CYP2D6 is a GENE-Y, harmaline is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, CYP2D6 is a GENE-Y

6196_task0

Sentence: Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name "5-MEO") is a newer designer drug belonging to a group of naturally occurring indolealkylamines. Our recent study has demonstrated that coadministration of monoamine oxidase A (MAO-A) inhibitor harmaline (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine. This study is aimed at delineating harmaline and 5-MeO-DMT pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of CYP2D6 that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine. Our data revealed that inhibition of MAO-A-mediated metabolic elimination by harmaline (2, 5, and 15 mg/kg) led to a sharp increase in systemic and cerebral exposure to 5-MeO-DMT (2 and 10 mg/kg) at all dose combinations. A more pronounced effect on 5-MeO-DMT PK was associated with greater exposure to harmaline in wild-type mice than CYP2D6-humanized (Tg-CYP2D6) mice. Harmaline (5 mg/kg) also increased blood and brain bufotenine concentrations that were generally higher in Tg-CYP2D6 mice. Surprisingly, greater harmaline dose (15 mg/kg) reduced bufotenine levels. The in vivo inhibitory effect of harmaline on CYP2D6-catalyzed bufotenine formation was confirmed by in vitro study using purified CYP2D6. Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models. This PK model may be further employed to predict harmaline and 5-MeO-DMT PK interactions at various doses, define the impact of CYP2D6 status, and drive harmaline-5-MeO-DMT pharmacodynamics. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL

[ "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name "5-MEO") is a newer designer drug belonging to a group of naturally occurring indolealkylamines. Our recent study has demonstrated that coadministration of monoamine oxidase A (MAO-A) inhibitor harmaline (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine. This study is aimed at delineating harmaline and 5-MeO-DMT pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of CYP2D6 that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine. Our data revealed that inhibition of MAO-A-mediated metabolic elimination by harmaline (2, 5, and 15 mg/kg) led to a sharp increase in systemic and cerebral exposure to 5-MeO-DMT (2 and 10 mg/kg) at all dose combinations. A more pronounced effect on 5-MeO-DMT PK was associated with greater exposure to harmaline in wild-type mice than CYP2D6-humanized (Tg-CYP2D6) mice. Harmaline (5 mg/kg) also increased blood and brain bufotenine concentrations that were generally higher in Tg-CYP2D6 mice. Surprisingly, greater harmaline dose (15 mg/kg) reduced bufotenine levels. The in vivo inhibitory effect of harmaline on CYP2D6-catalyzed bufotenine formation was confirmed by in vitro study using purified CYP2D6. Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models. This PK model may be further employed to predict harmaline and 5-MeO-DMT PK interactions at various doses, define the impact of CYP2D6 status, and drive harmaline-5-MeO-DMT pharmacodynamics.

[ "Pharmacokinetic", "Interactions", "between", "Monoamine", "Oxidase", "A", "Inhibitor", "Harmaline", "and", "5-Methoxy", "-", "N", ",", "N", "-", "Dimethyltryptamine", ",", "and", "the", "Impact", "of", "CYP2D6", "Status", ".", "\n", "5-Methoxy", "-", "N", ",", "N", "-", "dimethyltryptamine", "(", "5-MeO", "-", "DMT", "or", "street", "name", "\"", "5-MEO", "\"", ")", "is", "a", "newer", "designer", "drug", "belonging", "to", "a", "group", "of", "naturally", "occurring", "indolealkylamines", ".", "Our", "recent", "study", "has", "demonstrated", "that", "coadministration", "of", "monoamine", "oxidase", "A", "(", "MAO", "-", "A", ")", "inhibitor", "harmaline", "(", "5", "mg", "/", "kg", ")", "increases", "systemic", "exposure", "to", "5-MeO", "-", "DMT", "(", "2", "mg", "/", "kg", ")", "and", "active", "metabolite", "bufotenine", ".", "This", "study", "is", "aimed", "at", "delineating", "harmaline", "and", "5-MeO", "-", "DMT", "pharmacokinetic", "(", "PK", ")", "interactions", "at", "multiple", "dose", "levels", ",", "as", "well", "as", "the", "impact", "of", "CYP2D6", "that", "affects", "harmaline", "PK", "and", "determines", "5-MeO", "-", "DMT", "O", "-", "demethylation", "to", "produce", "bufotenine", ".", "Our", "data", "revealed", "that", "inhibition", "of", "MAO", "-", "A", "-", "mediated", "metabolic", "elimination", "by", "harmaline", "(", "2", ",", "5", ",", "and", "15", "mg", "/", "kg", ")", "led", "to", "a", "sharp", "increase", "in", "systemic", "and", "cerebral", "exposure", "to", "5-MeO", "-", "DMT", "(", "2", "and", "10", "mg", "/", "kg", ")", "at", "all", "dose", "combinations", ".", "A", "more", "pronounced", "effect", "on", "5-MeO", "-", "DMT", "PK", "was", "associated", "with", "greater", "exposure", "to", "harmaline", "in", "wild", "-", "type", "mice", "than", "CYP2D6-humanized", "(", "Tg", "-", "CYP2D6", ")", "mice", ".", "Harmaline", "(", "5", "mg", "/", "kg", ")", "also", "increased", "blood", "and", "brain", "bufotenine", "concentrations", "that", "were", "generally", "higher", "in", "Tg", "-", "CYP2D6", "mice", ".", "Surprisingly", ",", "greater", "harmaline", "dose", "(", "15", "mg", "/", "kg", ")", "reduced", "bufotenine", "levels", ".", "The", "in", "vivo", "inhibitory", "effect", "of", "harmaline", "on", "CYP2D6-catalyzed", "bufotenine", "formation", "was", "confirmed", "by", "in", "vitro", "study", "using", "purified", "CYP2D6", ".", "Given", "these", "findings", ",", "a", "unified", "PK", "model", "including", "the", "inhibition", "of", "MAO", "-", "A-", "and", "CYP2D6-catalyzed", "5-MeO", "-", "DMT", "metabolism", "by", "harmaline", "was", "developed", "to", "describe", "blood", "harmaline", ",", "5-MeO", "-", "DMT", ",", "and", "bufotenine", "PK", "profiles", "in", "both", "wild", "-", "type", "and", "Tg", "-", "CYP2D6", "mouse", "models", ".", "This", "PK", "model", "may", "be", "further", "employed", "to", "predict", "harmaline", "and", "5-MeO", "-", "DMT", "PK", "interactions", "at", "various", "doses", ",", "define", "the", "impact", "of", "CYP2D6", "status", ",", "and", "drive", "harmaline-5-MeO", "-", "DMT", "pharmacodynamics", "." ]

[ "CHEMICAL", "GENE-Y" ]

Monoamine Oxidase A is a GENE-Y, Harmaline is a CHEMICAL, 5-Methoxy - N , N - Dimethyltryptamine is a CHEMICAL, CYP2D6 is a GENE-Y, 5-Methoxy - N , N - dimethyltryptamine is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, 5-MEO is a CHEMICAL, indolealkylamines is a CHEMICAL, monoamine oxidase A is a GENE-Y, MAO - A is a GENE-Y, harmaline is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, harmaline is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, CYP2D6 is a GENE-Y, harmaline is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, O is a CHEMICAL, bufotenine is a CHEMICAL, MAO - A is a GENE-Y, harmaline is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, harmaline is a CHEMICAL, CYP2D6 is a GENE-Y, Harmaline is a CHEMICAL, bufotenine is a CHEMICAL, CYP2D6 is a GENE-Y, harmaline is a CHEMICAL, bufotenine is a CHEMICAL, harmaline is a CHEMICAL, bufotenine is a CHEMICAL, CYP2D6 is a GENE-Y, 5-MeO - DMT is a CHEMICAL, harmaline is a CHEMICAL, harmaline is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, bufotenine is a CHEMICAL, CYP2D6 is a GENE-Y, harmaline is a CHEMICAL, 5-MeO - DMT is a CHEMICAL, CYP2D6 is a GENE-Y

6196_task1

Sentence: Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name "5-MEO") is a newer designer drug belonging to a group of naturally occurring indolealkylamines. Our recent study has demonstrated that coadministration of monoamine oxidase A (MAO-A) inhibitor harmaline (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine. This study is aimed at delineating harmaline and 5-MeO-DMT pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of CYP2D6 that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine. Our data revealed that inhibition of MAO-A-mediated metabolic elimination by harmaline (2, 5, and 15 mg/kg) led to a sharp increase in systemic and cerebral exposure to 5-MeO-DMT (2 and 10 mg/kg) at all dose combinations. A more pronounced effect on 5-MeO-DMT PK was associated with greater exposure to harmaline in wild-type mice than CYP2D6-humanized (Tg-CYP2D6) mice. Harmaline (5 mg/kg) also increased blood and brain bufotenine concentrations that were generally higher in Tg-CYP2D6 mice. Surprisingly, greater harmaline dose (15 mg/kg) reduced bufotenine levels. The in vivo inhibitory effect of harmaline on CYP2D6-catalyzed bufotenine formation was confirmed by in vitro study using purified CYP2D6. Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models. This PK model may be further employed to predict harmaline and 5-MeO-DMT PK interactions at various doses, define the impact of CYP2D6 status, and drive harmaline-5-MeO-DMT pharmacodynamics. Instructions: please typing these entity words according to sentence: Monoamine Oxidase A, Harmaline, 5-Methoxy - N , N - Dimethyltryptamine, CYP2D6, 5-Methoxy - N , N - dimethyltryptamine, 5-MeO - DMT, 5-MEO, indolealkylamines, monoamine oxidase A, MAO - A, harmaline, 5-MeO - DMT, harmaline, 5-MeO - DMT, CYP2D6, harmaline, 5-MeO - DMT, O, bufotenine, MAO - A, harmaline, 5-MeO - DMT, 5-MeO - DMT, harmaline, CYP2D6, Harmaline, bufotenine, CYP2D6, harmaline, bufotenine, harmaline, bufotenine, CYP2D6, 5-MeO - DMT, harmaline, harmaline, 5-MeO - DMT, bufotenine, CYP2D6, harmaline, 5-MeO - DMT, CYP2D6 Options: GENE-Y, CHEMICAL

[ "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name "5-MEO") is a newer designer drug belonging to a group of naturally occurring indolealkylamines. Our recent study has demonstrated that coadministration of monoamine oxidase A (MAO-A) inhibitor harmaline (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine. This study is aimed at delineating harmaline and 5-MeO-DMT pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of CYP2D6 that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine. Our data revealed that inhibition of MAO-A-mediated metabolic elimination by harmaline (2, 5, and 15 mg/kg) led to a sharp increase in systemic and cerebral exposure to 5-MeO-DMT (2 and 10 mg/kg) at all dose combinations. A more pronounced effect on 5-MeO-DMT PK was associated with greater exposure to harmaline in wild-type mice than CYP2D6-humanized (Tg-CYP2D6) mice. Harmaline (5 mg/kg) also increased blood and brain bufotenine concentrations that were generally higher in Tg-CYP2D6 mice. Surprisingly, greater harmaline dose (15 mg/kg) reduced bufotenine levels. The in vivo inhibitory effect of harmaline on CYP2D6-catalyzed bufotenine formation was confirmed by in vitro study using purified CYP2D6. Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models. This PK model may be further employed to predict harmaline and 5-MeO-DMT PK interactions at various doses, define the impact of CYP2D6 status, and drive harmaline-5-MeO-DMT pharmacodynamics.

[ "Pharmacokinetic", "Interactions", "between", "Monoamine", "Oxidase", "A", "Inhibitor", "Harmaline", "and", "5-Methoxy", "-", "N", ",", "N", "-", "Dimethyltryptamine", ",", "and", "the", "Impact", "of", "CYP2D6", "Status", ".", "\n", "5-Methoxy", "-", "N", ",", "N", "-", "dimethyltryptamine", "(", "5-MeO", "-", "DMT", "or", "street", "name", "\"", "5-MEO", "\"", ")", "is", "a", "newer", "designer", "drug", "belonging", "to", "a", "group", "of", "naturally", "occurring", "indolealkylamines", ".", "Our", "recent", "study", "has", "demonstrated", "that", "coadministration", "of", "monoamine", "oxidase", "A", "(", "MAO", "-", "A", ")", "inhibitor", "harmaline", "(", "5", "mg", "/", "kg", ")", "increases", "systemic", "exposure", "to", "5-MeO", "-", "DMT", "(", "2", "mg", "/", "kg", ")", "and", "active", "metabolite", "bufotenine", ".", "This", "study", "is", "aimed", "at", "delineating", "harmaline", "and", "5-MeO", "-", "DMT", "pharmacokinetic", "(", "PK", ")", "interactions", "at", "multiple", "dose", "levels", ",", "as", "well", "as", "the", "impact", "of", "CYP2D6", "that", "affects", "harmaline", "PK", "and", "determines", "5-MeO", "-", "DMT", "O", "-", "demethylation", "to", "produce", "bufotenine", ".", "Our", "data", "revealed", "that", "inhibition", "of", "MAO", "-", "A", "-", "mediated", "metabolic", "elimination", "by", "harmaline", "(", "2", ",", "5", ",", "and", "15", "mg", "/", "kg", ")", "led", "to", "a", "sharp", "increase", "in", "systemic", "and", "cerebral", "exposure", "to", "5-MeO", "-", "DMT", "(", "2", "and", "10", "mg", "/", "kg", ")", "at", "all", "dose", "combinations", ".", "A", "more", "pronounced", "effect", "on", "5-MeO", "-", "DMT", "PK", "was", "associated", "with", "greater", "exposure", "to", "harmaline", "in", "wild", "-", "type", "mice", "than", "CYP2D6-humanized", "(", "Tg", "-", "CYP2D6", ")", "mice", ".", "Harmaline", "(", "5", "mg", "/", "kg", ")", "also", "increased", "blood", "and", "brain", "bufotenine", "concentrations", "that", "were", "generally", "higher", "in", "Tg", "-", "CYP2D6", "mice", ".", "Surprisingly", ",", "greater", "harmaline", "dose", "(", "15", "mg", "/", "kg", ")", "reduced", "bufotenine", "levels", ".", "The", "in", "vivo", "inhibitory", "effect", "of", "harmaline", "on", "CYP2D6-catalyzed", "bufotenine", "formation", "was", "confirmed", "by", "in", "vitro", "study", "using", "purified", "CYP2D6", ".", "Given", "these", "findings", ",", "a", "unified", "PK", "model", "including", "the", "inhibition", "of", "MAO", "-", "A-", "and", "CYP2D6-catalyzed", "5-MeO", "-", "DMT", "metabolism", "by", "harmaline", "was", "developed", "to", "describe", "blood", "harmaline", ",", "5-MeO", "-", "DMT", ",", "and", "bufotenine", "PK", "profiles", "in", "both", "wild", "-", "type", "and", "Tg", "-", "CYP2D6", "mouse", "models", ".", "This", "PK", "model", "may", "be", "further", "employed", "to", "predict", "harmaline", "and", "5-MeO", "-", "DMT", "PK", "interactions", "at", "various", "doses", ",", "define", "the", "impact", "of", "CYP2D6", "status", ",", "and", "drive", "harmaline-5-MeO", "-", "DMT", "pharmacodynamics", "." ]

[ "CHEMICAL", "GENE-Y" ]

Monoamine Oxidase A, Harmaline, 5-Methoxy - N , N - Dimethyltryptamine, CYP2D6, 5-Methoxy - N , N - dimethyltryptamine, 5-MeO - DMT, 5-MEO, indolealkylamines, monoamine oxidase A, MAO - A, harmaline, 5-MeO - DMT, harmaline, 5-MeO - DMT, CYP2D6, harmaline, 5-MeO - DMT, O, bufotenine, MAO - A, harmaline, 5-MeO - DMT, 5-MeO - DMT, harmaline, CYP2D6, Harmaline, bufotenine, CYP2D6, harmaline, bufotenine, harmaline, bufotenine, CYP2D6, 5-MeO - DMT, harmaline, harmaline, 5-MeO - DMT, bufotenine, CYP2D6, harmaline, 5-MeO - DMT, CYP2D6

6196_task2

Sentence: Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name "5-MEO") is a newer designer drug belonging to a group of naturally occurring indolealkylamines. Our recent study has demonstrated that coadministration of monoamine oxidase A (MAO-A) inhibitor harmaline (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine. This study is aimed at delineating harmaline and 5-MeO-DMT pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of CYP2D6 that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine. Our data revealed that inhibition of MAO-A-mediated metabolic elimination by harmaline (2, 5, and 15 mg/kg) led to a sharp increase in systemic and cerebral exposure to 5-MeO-DMT (2 and 10 mg/kg) at all dose combinations. A more pronounced effect on 5-MeO-DMT PK was associated with greater exposure to harmaline in wild-type mice than CYP2D6-humanized (Tg-CYP2D6) mice. Harmaline (5 mg/kg) also increased blood and brain bufotenine concentrations that were generally higher in Tg-CYP2D6 mice. Surprisingly, greater harmaline dose (15 mg/kg) reduced bufotenine levels. The in vivo inhibitory effect of harmaline on CYP2D6-catalyzed bufotenine formation was confirmed by in vitro study using purified CYP2D6. Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models. This PK model may be further employed to predict harmaline and 5-MeO-DMT PK interactions at various doses, define the impact of CYP2D6 status, and drive harmaline-5-MeO-DMT pharmacodynamics. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name "5-MEO") is a newer designer drug belonging to a group of naturally occurring indolealkylamines. Our recent study has demonstrated that coadministration of monoamine oxidase A (MAO-A) inhibitor harmaline (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine. This study is aimed at delineating harmaline and 5-MeO-DMT pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of CYP2D6 that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine. Our data revealed that inhibition of MAO-A-mediated metabolic elimination by harmaline (2, 5, and 15 mg/kg) led to a sharp increase in systemic and cerebral exposure to 5-MeO-DMT (2 and 10 mg/kg) at all dose combinations. A more pronounced effect on 5-MeO-DMT PK was associated with greater exposure to harmaline in wild-type mice than CYP2D6-humanized (Tg-CYP2D6) mice. Harmaline (5 mg/kg) also increased blood and brain bufotenine concentrations that were generally higher in Tg-CYP2D6 mice. Surprisingly, greater harmaline dose (15 mg/kg) reduced bufotenine levels. The in vivo inhibitory effect of harmaline on CYP2D6-catalyzed bufotenine formation was confirmed by in vitro study using purified CYP2D6. Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models. This PK model may be further employed to predict harmaline and 5-MeO-DMT PK interactions at various doses, define the impact of CYP2D6 status, and drive harmaline-5-MeO-DMT pharmacodynamics.

[ "Pharmacokinetic", "Interactions", "between", "Monoamine", "Oxidase", "A", "Inhibitor", "Harmaline", "and", "5-Methoxy", "-", "N", ",", "N", "-", "Dimethyltryptamine", ",", "and", "the", "Impact", "of", "CYP2D6", "Status", ".", "\n", "5-Methoxy", "-", "N", ",", "N", "-", "dimethyltryptamine", "(", "5-MeO", "-", "DMT", "or", "street", "name", "\"", "5-MEO", "\"", ")", "is", "a", "newer", "designer", "drug", "belonging", "to", "a", "group", "of", "naturally", "occurring", "indolealkylamines", ".", "Our", "recent", "study", "has", "demonstrated", "that", "coadministration", "of", "monoamine", "oxidase", "A", "(", "MAO", "-", "A", ")", "inhibitor", "harmaline", "(", "5", "mg", "/", "kg", ")", "increases", "systemic", "exposure", "to", "5-MeO", "-", "DMT", "(", "2", "mg", "/", "kg", ")", "and", "active", "metabolite", "bufotenine", ".", "This", "study", "is", "aimed", "at", "delineating", "harmaline", "and", "5-MeO", "-", "DMT", "pharmacokinetic", "(", "PK", ")", "interactions", "at", "multiple", "dose", "levels", ",", "as", "well", "as", "the", "impact", "of", "CYP2D6", "that", "affects", "harmaline", "PK", "and", "determines", "5-MeO", "-", "DMT", "O", "-", "demethylation", "to", "produce", "bufotenine", ".", "Our", "data", "revealed", "that", "inhibition", "of", "MAO", "-", "A", "-", "mediated", "metabolic", "elimination", "by", "harmaline", "(", "2", ",", "5", ",", "and", "15", "mg", "/", "kg", ")", "led", "to", "a", "sharp", "increase", "in", "systemic", "and", "cerebral", "exposure", "to", "5-MeO", "-", "DMT", "(", "2", "and", "10", "mg", "/", "kg", ")", "at", "all", "dose", "combinations", ".", "A", "more", "pronounced", "effect", "on", "5-MeO", "-", "DMT", "PK", "was", "associated", "with", "greater", "exposure", "to", "harmaline", "in", "wild", "-", "type", "mice", "than", "CYP2D6-humanized", "(", "Tg", "-", "CYP2D6", ")", "mice", ".", "Harmaline", "(", "5", "mg", "/", "kg", ")", "also", "increased", "blood", "and", "brain", "bufotenine", "concentrations", "that", "were", "generally", "higher", "in", "Tg", "-", "CYP2D6", "mice", ".", "Surprisingly", ",", "greater", "harmaline", "dose", "(", "15", "mg", "/", "kg", ")", "reduced", "bufotenine", "levels", ".", "The", "in", "vivo", "inhibitory", "effect", "of", "harmaline", "on", "CYP2D6-catalyzed", "bufotenine", "formation", "was", "confirmed", "by", "in", "vitro", "study", "using", "purified", "CYP2D6", ".", "Given", "these", "findings", ",", "a", "unified", "PK", "model", "including", "the", "inhibition", "of", "MAO", "-", "A-", "and", "CYP2D6-catalyzed", "5-MeO", "-", "DMT", "metabolism", "by", "harmaline", "was", "developed", "to", "describe", "blood", "harmaline", ",", "5-MeO", "-", "DMT", ",", "and", "bufotenine", "PK", "profiles", "in", "both", "wild", "-", "type", "and", "Tg", "-", "CYP2D6", "mouse", "models", ".", "This", "PK", "model", "may", "be", "further", "employed", "to", "predict", "harmaline", "and", "5-MeO", "-", "DMT", "PK", "interactions", "at", "various", "doses", ",", "define", "the", "impact", "of", "CYP2D6", "status", ",", "and", "drive", "harmaline-5-MeO", "-", "DMT", "pharmacodynamics", "." ]

[ "CHEMICAL", "GENE-Y" ]

perfluoroalkyl acid is a CHEMICAL

23567314_task0

Sentence: Evaluation of perfluoroalkyl acid activity using primary mouse and human hepatocytes. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL

[ "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]

Evaluation of perfluoroalkyl acid activity using primary mouse and human hepatocytes.

[ "Evaluation", "of", "perfluoroalkyl", "acid", "activity", "using", "primary", "mouse", "and", "human", "hepatocytes", "." ]

[ "GENE-Y", "CHEMICAL" ]

perfluoroalkyl acid is a CHEMICAL

23567314_task1

Sentence: Evaluation of perfluoroalkyl acid activity using primary mouse and human hepatocytes. Instructions: please typing these entity words according to sentence: perfluoroalkyl acid Options: CHEMICAL

[ "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]

Evaluation of perfluoroalkyl acid activity using primary mouse and human hepatocytes.

[ "Evaluation", "of", "perfluoroalkyl", "acid", "activity", "using", "primary", "mouse", "and", "human", "hepatocytes", "." ]

[ "GENE-Y", "CHEMICAL" ]

perfluoroalkyl acid

23567314_task2

Sentence: Evaluation of perfluoroalkyl acid activity using primary mouse and human hepatocytes. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]

Evaluation of perfluoroalkyl acid activity using primary mouse and human hepatocytes.

[ "Evaluation", "of", "perfluoroalkyl", "acid", "activity", "using", "primary", "mouse", "and", "human", "hepatocytes", "." ]

[ "GENE-Y", "CHEMICAL" ]

Irene is a NOMBRE_SUJETO_ASISTENCIA, Martinez Alejandre is a NOMBRE_SUJETO_ASISTENCIA, 4356456 is a ID_SUJETO_ASISTENCIA, 06 52839679 56 is a ID_ASEGURAMIENTO, Pamplona is a TERRITORIO, 31256 is a TERRITORIO, 21/04/1992 is a FECHAS, España is a PAIS, 26 años is a EDAD_SUJETO_ASISTENCIA, 08/06/2018 is a FECHAS, Francisco Javier Repáraz Padrós is a NOMBRE_PERSONAL_SANITARIO, 31 31 25402 is a ID_TITULACION_PERSONAL_SANITARIO, 26 años is a EDAD_SUJETO_ASISTENCIA, Francisco Javier Repáraz Padrós is a NOMBRE_PERSONAL_SANITARIO, Hospital de Navarra is a HOSPITAL, Irunlarrea , 3 is a CALLE, 31008 is a TERRITORIO, Pamplona is a TERRITORIO, 848422206 is a NUMERO_TELEFONO, repamapr@hotmail.com is a CORREO_ELECTRONICO

407_task0

Sentence: Datos del paciente. Nombre: Irene. Apellidos: Martinez Alejandre. NHC: 4356456. NASS: 06 52839679 56. Domicilio: Calle Las Lomas, 13, 7C. Localidad/ Provincia: Pamplona. CP: 31256. Datos asistenciales. Fecha de nacimiento: 21/04/1992. País de nacimiento: España. Edad: 26 años Sexo: M. Fecha de Ingreso: 08/06/2018. Médico:Francisco Javier Repáraz Padrós NºCol: 31 31 25402. Informe clínico del paciente: paciente de 26 años que acude a consulta por dolor en la muñeca derecha de 7 años de evolución sin antecedente traumático. El dolor en reposo era de carácter leve, pero aumentaba con la actividad manual y especialmente con la extensión forzada de la muñeca. No mejoraba con tratamiento médico sintomático. La interlínea articular radiocarpiana dorsal y el polo proximal del escafoides eran dolorosos a la palpación. No se apreciaba tumoración palpable. La movilidad de la muñeca presentaba una ligera limitación en los últimos grados de flexión y extensión. La imagen radiológica mostraba una lesión radiolucente, bien definida, ovalada, localizada en el tercio medio-dorsal del escafoides. En la TAC se apreciaba la localización excéntrica dorsal de la lesión y un punteado compatible con calcificaciones. En la RM destacaban signos de marcado edema óseo en el escafoides, excepto en su tercio distal y sinovitis adyacente. Con el diagnóstico de sospecha de una lesión benigna (encondroma, ganglión intraóseo) se decidió el tratamiento quirúrgico de la lesión. Éste se realizó mediante una vía de abordaje dorsal del escafoides. Tras la apertura de la cápsula articular se expuso la cara dorsal de la epífisis distal del radio y del escafoides, apreciándose en el tercio medio de este último una tumoración de aspecto nacarado y coloración rojo vinosa que ocupaba la cresta dorsal del hueso navicular. Se realizó un legrado exhaustivo de la lesión y relleno del defecto con injerto óseo esponjoso de cresta iliaca. El material remitido estaba formado por islotes de matriz cartilaginosa rodeados por un tejido celular abundante constituido por células pseudo-condroblásticas. Dichas células eran redondeadas u ovoides con núcleos hipercromáticos, un citoplasma claro o moderadamente eosinófilo y una membrana plasmática nítida. El pleomorfismo celular era mínimo y el índice mitótico muy bajo. Algunas células contenían hierro. Entre las células pseudocondroblásticas se encontraban abundantes células gigantes de tipo osteoclástico. En algunas áreas había zonas de calcificación irregular. Se observaban además algunas áreas de transformación quística que asemejaban quistes aneurismáticos. El diagnóstico anatomopatológico fue condroblastoma de escafoides carpiano. Tras el tratamiento quirúrgico se inmovilizó la muñeca con una férula antebraquial durante 3 semanas y posteriormente la paciente fue remitida al Servicio de Rehabilitación. En la revisión efectuada a los 3 meses se apreció una recuperación completa de la movilidad de la muñeca e imagen radiológica de consolidación ósea del autoinjerto de cresta iliaca. Dos años después del tratamiento quirúrgico no hay evidencia de recidiva y persiste una desaparición completa del dolor con movilidad de la muñeca similar a la contralateral, así como una imagen radiológica del escafoides totalmente normalizada. Responsable clínico: Francisco Javier Repáraz Padrós Servicio de Cirugía Ortopédica y Traumatología Hospital de Navarra Irunlarrea, 3 31008 Pamplona Tfno. 848422206 E-mail: repamapr@hotmail.com Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, ID_SUJETO_ASISTENCIA, FECHAS, NUMERO_TELEFONO, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "O", "B-NUMERO_TELEFONO", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Datos del paciente. Nombre: Irene. Apellidos: Martinez Alejandre. NHC: 4356456. NASS: 06 52839679 56. Domicilio: Calle Las Lomas, 13, 7C. Localidad/ Provincia: Pamplona. CP: 31256. Datos asistenciales. Fecha de nacimiento: 21/04/1992. País de nacimiento: España. Edad: 26 años Sexo: M. Fecha de Ingreso: 08/06/2018. Médico:Francisco Javier Repáraz Padrós NºCol: 31 31 25402. Informe clínico del paciente: paciente de 26 años que acude a consulta por dolor en la muñeca derecha de 7 años de evolución sin antecedente traumático. El dolor en reposo era de carácter leve, pero aumentaba con la actividad manual y especialmente con la extensión forzada de la muñeca. No mejoraba con tratamiento médico sintomático. La interlínea articular radiocarpiana dorsal y el polo proximal del escafoides eran dolorosos a la palpación. No se apreciaba tumoración palpable. La movilidad de la muñeca presentaba una ligera limitación en los últimos grados de flexión y extensión. La imagen radiológica mostraba una lesión radiolucente, bien definida, ovalada, localizada en el tercio medio-dorsal del escafoides. En la TAC se apreciaba la localización excéntrica dorsal de la lesión y un punteado compatible con calcificaciones. En la RM destacaban signos de marcado edema óseo en el escafoides, excepto en su tercio distal y sinovitis adyacente. Con el diagnóstico de sospecha de una lesión benigna (encondroma, ganglión intraóseo) se decidió el tratamiento quirúrgico de la lesión. Éste se realizó mediante una vía de abordaje dorsal del escafoides. Tras la apertura de la cápsula articular se expuso la cara dorsal de la epífisis distal del radio y del escafoides, apreciándose en el tercio medio de este último una tumoración de aspecto nacarado y coloración rojo vinosa que ocupaba la cresta dorsal del hueso navicular. Se realizó un legrado exhaustivo de la lesión y relleno del defecto con injerto óseo esponjoso de cresta iliaca. El material remitido estaba formado por islotes de matriz cartilaginosa rodeados por un tejido celular abundante constituido por células pseudo-condroblásticas. Dichas células eran redondeadas u ovoides con núcleos hipercromáticos, un citoplasma claro o moderadamente eosinófilo y una membrana plasmática nítida. El pleomorfismo celular era mínimo y el índice mitótico muy bajo. Algunas células contenían hierro. Entre las células pseudocondroblásticas se encontraban abundantes células gigantes de tipo osteoclástico. En algunas áreas había zonas de calcificación irregular. Se observaban además algunas áreas de transformación quística que asemejaban quistes aneurismáticos. El diagnóstico anatomopatológico fue condroblastoma de escafoides carpiano. Tras el tratamiento quirúrgico se inmovilizó la muñeca con una férula antebraquial durante 3 semanas y posteriormente la paciente fue remitida al Servicio de Rehabilitación. En la revisión efectuada a los 3 meses se apreció una recuperación completa de la movilidad de la muñeca e imagen radiológica de consolidación ósea del autoinjerto de cresta iliaca. Dos años después del tratamiento quirúrgico no hay evidencia de recidiva y persiste una desaparición completa del dolor con movilidad de la muñeca similar a la contralateral, así como una imagen radiológica del escafoides totalmente normalizada. Responsable clínico: Francisco Javier Repáraz Padrós Servicio de Cirugía Ortopédica y Traumatología Hospital de Navarra Irunlarrea, 3 31008 Pamplona Tfno. 848422206 E-mail: repamapr@hotmail.com

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", " ", "Irene", ".", "\n", "Apellidos", ":", "Martinez", "Alejandre", ".", "\n", "NHC", ":", "4356456", ".", "\n", "NASS", ":", "06", "52839679", "56", ".", "\n", "Domicilio", ":", "Calle", "Las", "Lomas", ",", "13", ",", "7C.", "\n", "Localidad/", "Provincia", ":", "Pamplona", ".", "\n", "CP", ":", "31256", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "21/04/1992", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "26", "años", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "08/06/2018", ".", "\n", "Médico", ":", "Francisco", "Javier", "Repáraz", "Padrós", " ", "NºCol", ":", "31", "31", "25402", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "paciente", "de", "26", "años", "que", "acude", "a", "consulta", "por", "dolor", "en", "la", "muñeca", "derecha", "de", "7", "años", "de", "evolución", "sin", "antecedente", "traumático", ".", "El", "dolor", "en", "reposo", "era", "de", "carácter", "leve", ",", "pero", "aumentaba", "con", "la", "actividad", "manual", "y", "especialmente", "con", "la", "extensión", "forzada", "de", "la", "muñeca", ".", "No", "mejoraba", "con", "tratamiento", "médico", "sintomático", ".", "\n", "La", "interlínea", "articular", "radiocarpiana", "dorsal", "y", "el", "polo", "proximal", "del", "escafoides", "eran", "dolorosos", "a", "la", "palpación", ".", "No", "se", "apreciaba", "tumoración", "palpable", ".", "La", "movilidad", "de", "la", "muñeca", "presentaba", "una", "ligera", "limitación", "en", "los", "últimos", "grados", "de", "flexión", "y", "extensión", ".", "\n", "La", "imagen", "radiológica", "mostraba", "una", "lesión", "radiolucente", ",", "bien", "definida", ",", "ovalada", ",", "localizada", "en", "el", "tercio", "medio", "-", "dorsal", "del", "escafoides", ".", "En", "la", "TAC", "se", "apreciaba", "la", "localización", "excéntrica", "dorsal", "de", "la", "lesión", "y", "un", "punteado", "compatible", "con", "calcificaciones", ".", "En", "la", "RM", "destacaban", "signos", "de", "marcado", "edema", "óseo", "en", "el", "escafoides", ",", "excepto", "en", "su", "tercio", "distal", "y", "sinovitis", "adyacente", ".", "Con", "el", "diagnóstico", "de", "sospecha", "de", "una", "lesión", "benigna", "(", "encondroma", ",", "ganglión", "intraóseo", ")", "se", "decidió", "el", "tratamiento", "quirúrgico", "de", "la", "lesión", ".", "Éste", "se", "realizó", "mediante", "una", "vía", "de", "abordaje", "dorsal", "del", "escafoides", ".", "Tras", "la", "apertura", "de", "la", "cápsula", "articular", "se", "expuso", "la", "cara", "dorsal", "de", "la", "epífisis", "distal", "del", "radio", "y", "del", "escafoides", ",", "apreciándose", "en", "el", "tercio", "medio", "de", "este", "último", "una", "tumoración", "de", "aspecto", "nacarado", "y", "coloración", "rojo", "vinosa", "que", "ocupaba", "la", "cresta", "dorsal", "del", "hueso", "navicular", ".", "Se", "realizó", "un", "legrado", "exhaustivo", "de", "la", "lesión", "y", "relleno", "del", "defecto", "con", "injerto", "óseo", "esponjoso", "de", "cresta", "iliaca", ".", "\n", "El", "material", "remitido", "estaba", "formado", "por", "islotes", "de", "matriz", "cartilaginosa", "rodeados", "por", "un", "tejido", "celular", "abundante", "constituido", "por", "células", "pseudo", "-", "condroblásticas", ".", "Dichas", "células", "eran", "redondeadas", "u", "ovoides", "con", "núcleos", "hipercromáticos", ",", "un", "citoplasma", "claro", "o", "moderadamente", "eosinófilo", "y", "una", "membrana", "plasmática", "nítida", ".", "El", "pleomorfismo", "celular", "era", "mínimo", "y", "el", "índice", "mitótico", "muy", "bajo", ".", "Algunas", "células", "contenían", "hierro", ".", "Entre", "las", "células", "pseudocondroblásticas", "se", "encontraban", "abundantes", "células", "gigantes", "de", "tipo", "osteoclástico", ".", "En", "algunas", "áreas", "había", "zonas", "de", "calcificación", "irregular", ".", "Se", "observaban", "además", "algunas", "áreas", "de", "transformación", "quística", "que", "asemejaban", "quistes", "aneurismáticos", ".", "El", "diagnóstico", "anatomopatológico", "fue", "condroblastoma", "de", "escafoides", "carpiano", ".", "\n", "Tras", "el", "tratamiento", "quirúrgico", "se", "inmovilizó", "la", "muñeca", "con", "una", "férula", "antebraquial", "durante", "3", "semanas", "y", "posteriormente", "la", "paciente", "fue", "remitida", "al", "Servicio", "de", "Rehabilitación", ".", "En", "la", "revisión", "efectuada", "a", "los", "3", "meses", "se", "apreció", "una", "recuperación", "completa", "de", "la", "movilidad", "de", "la", "muñeca", "e", "imagen", "radiológica", "de", "consolidación", "ósea", "del", "autoinjerto", "de", "cresta", "iliaca", ".", "\n", "Dos", "años", "después", "del", "tratamiento", "quirúrgico", "no", "hay", "evidencia", "de", "recidiva", "y", "persiste", "una", "desaparición", "completa", "del", "dolor", "con", "movilidad", "de", "la", "muñeca", "similar", "a", "la", "contralateral", ",", "así", "como", "una", "imagen", "radiológica", "del", "escafoides", "totalmente", "normalizada", ".", "\n", "Responsable", "clínico", ":", "Francisco", "Javier", "Repáraz", "Padrós", "Servicio", "de", "Cirugía", "Ortopédica", "y", "Traumatología", "Hospital", "de", "Navarra", "Irunlarrea", ",", "3", "31008", "Pamplona", "Tfno", ".", "848422206", "E", "-", "mail", ":", "repamapr@hotmail.com", "\n" ]

[ "NOMBRE_PERSONAL_SANITARIO", "CALLE", "CORREO_ELECTRONICO", "HOSPITAL", "NOMBRE_SUJETO_ASISTENCIA", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "NUMERO_TELEFONO", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]

Irene is a NOMBRE_SUJETO_ASISTENCIA, Martinez Alejandre is a NOMBRE_SUJETO_ASISTENCIA, 4356456 is a ID_SUJETO_ASISTENCIA, 06 52839679 56 is a ID_ASEGURAMIENTO, Pamplona is a TERRITORIO, 31256 is a TERRITORIO, 21/04/1992 is a FECHAS, España is a PAIS, 26 años is a EDAD_SUJETO_ASISTENCIA, 08/06/2018 is a FECHAS, Francisco Javier Repáraz Padrós is a NOMBRE_PERSONAL_SANITARIO, 31 31 25402 is a ID_TITULACION_PERSONAL_SANITARIO, 26 años is a EDAD_SUJETO_ASISTENCIA, Francisco Javier Repáraz Padrós is a NOMBRE_PERSONAL_SANITARIO, Hospital de Navarra is a HOSPITAL, Irunlarrea , 3 is a CALLE, 31008 is a TERRITORIO, Pamplona is a TERRITORIO, 848422206 is a NUMERO_TELEFONO, repamapr@hotmail.com is a CORREO_ELECTRONICO

407_task1

Sentence: Datos del paciente. Nombre: Irene. Apellidos: Martinez Alejandre. NHC: 4356456. NASS: 06 52839679 56. Domicilio: Calle Las Lomas, 13, 7C. Localidad/ Provincia: Pamplona. CP: 31256. Datos asistenciales. Fecha de nacimiento: 21/04/1992. País de nacimiento: España. Edad: 26 años Sexo: M. Fecha de Ingreso: 08/06/2018. Médico:Francisco Javier Repáraz Padrós NºCol: 31 31 25402. Informe clínico del paciente: paciente de 26 años que acude a consulta por dolor en la muñeca derecha de 7 años de evolución sin antecedente traumático. El dolor en reposo era de carácter leve, pero aumentaba con la actividad manual y especialmente con la extensión forzada de la muñeca. No mejoraba con tratamiento médico sintomático. La interlínea articular radiocarpiana dorsal y el polo proximal del escafoides eran dolorosos a la palpación. No se apreciaba tumoración palpable. La movilidad de la muñeca presentaba una ligera limitación en los últimos grados de flexión y extensión. La imagen radiológica mostraba una lesión radiolucente, bien definida, ovalada, localizada en el tercio medio-dorsal del escafoides. En la TAC se apreciaba la localización excéntrica dorsal de la lesión y un punteado compatible con calcificaciones. En la RM destacaban signos de marcado edema óseo en el escafoides, excepto en su tercio distal y sinovitis adyacente. Con el diagnóstico de sospecha de una lesión benigna (encondroma, ganglión intraóseo) se decidió el tratamiento quirúrgico de la lesión. Éste se realizó mediante una vía de abordaje dorsal del escafoides. Tras la apertura de la cápsula articular se expuso la cara dorsal de la epífisis distal del radio y del escafoides, apreciándose en el tercio medio de este último una tumoración de aspecto nacarado y coloración rojo vinosa que ocupaba la cresta dorsal del hueso navicular. Se realizó un legrado exhaustivo de la lesión y relleno del defecto con injerto óseo esponjoso de cresta iliaca. El material remitido estaba formado por islotes de matriz cartilaginosa rodeados por un tejido celular abundante constituido por células pseudo-condroblásticas. Dichas células eran redondeadas u ovoides con núcleos hipercromáticos, un citoplasma claro o moderadamente eosinófilo y una membrana plasmática nítida. El pleomorfismo celular era mínimo y el índice mitótico muy bajo. Algunas células contenían hierro. Entre las células pseudocondroblásticas se encontraban abundantes células gigantes de tipo osteoclástico. En algunas áreas había zonas de calcificación irregular. Se observaban además algunas áreas de transformación quística que asemejaban quistes aneurismáticos. El diagnóstico anatomopatológico fue condroblastoma de escafoides carpiano. Tras el tratamiento quirúrgico se inmovilizó la muñeca con una férula antebraquial durante 3 semanas y posteriormente la paciente fue remitida al Servicio de Rehabilitación. En la revisión efectuada a los 3 meses se apreció una recuperación completa de la movilidad de la muñeca e imagen radiológica de consolidación ósea del autoinjerto de cresta iliaca. Dos años después del tratamiento quirúrgico no hay evidencia de recidiva y persiste una desaparición completa del dolor con movilidad de la muñeca similar a la contralateral, así como una imagen radiológica del escafoides totalmente normalizada. Responsable clínico: Francisco Javier Repáraz Padrós Servicio de Cirugía Ortopédica y Traumatología Hospital de Navarra Irunlarrea, 3 31008 Pamplona Tfno. 848422206 E-mail: repamapr@hotmail.com Instructions: please typing these entity words according to sentence: Irene, Martinez Alejandre, 4356456, 06 52839679 56, Pamplona, 31256, 21/04/1992, España, 26 años, 08/06/2018, Francisco Javier Repáraz Padrós, 31 31 25402, 26 años, Francisco Javier Repáraz Padrós, Hospital de Navarra, Irunlarrea , 3, 31008, Pamplona, 848422206, repamapr@hotmail.com Options: TERRITORIO, ID_SUJETO_ASISTENCIA, FECHAS, NUMERO_TELEFONO, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "O", "B-NUMERO_TELEFONO", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Datos del paciente. Nombre: Irene. Apellidos: Martinez Alejandre. NHC: 4356456. NASS: 06 52839679 56. Domicilio: Calle Las Lomas, 13, 7C. Localidad/ Provincia: Pamplona. CP: 31256. Datos asistenciales. Fecha de nacimiento: 21/04/1992. País de nacimiento: España. Edad: 26 años Sexo: M. Fecha de Ingreso: 08/06/2018. Médico:Francisco Javier Repáraz Padrós NºCol: 31 31 25402. Informe clínico del paciente: paciente de 26 años que acude a consulta por dolor en la muñeca derecha de 7 años de evolución sin antecedente traumático. El dolor en reposo era de carácter leve, pero aumentaba con la actividad manual y especialmente con la extensión forzada de la muñeca. No mejoraba con tratamiento médico sintomático. La interlínea articular radiocarpiana dorsal y el polo proximal del escafoides eran dolorosos a la palpación. No se apreciaba tumoración palpable. La movilidad de la muñeca presentaba una ligera limitación en los últimos grados de flexión y extensión. La imagen radiológica mostraba una lesión radiolucente, bien definida, ovalada, localizada en el tercio medio-dorsal del escafoides. En la TAC se apreciaba la localización excéntrica dorsal de la lesión y un punteado compatible con calcificaciones. En la RM destacaban signos de marcado edema óseo en el escafoides, excepto en su tercio distal y sinovitis adyacente. Con el diagnóstico de sospecha de una lesión benigna (encondroma, ganglión intraóseo) se decidió el tratamiento quirúrgico de la lesión. Éste se realizó mediante una vía de abordaje dorsal del escafoides. Tras la apertura de la cápsula articular se expuso la cara dorsal de la epífisis distal del radio y del escafoides, apreciándose en el tercio medio de este último una tumoración de aspecto nacarado y coloración rojo vinosa que ocupaba la cresta dorsal del hueso navicular. Se realizó un legrado exhaustivo de la lesión y relleno del defecto con injerto óseo esponjoso de cresta iliaca. El material remitido estaba formado por islotes de matriz cartilaginosa rodeados por un tejido celular abundante constituido por células pseudo-condroblásticas. Dichas células eran redondeadas u ovoides con núcleos hipercromáticos, un citoplasma claro o moderadamente eosinófilo y una membrana plasmática nítida. El pleomorfismo celular era mínimo y el índice mitótico muy bajo. Algunas células contenían hierro. Entre las células pseudocondroblásticas se encontraban abundantes células gigantes de tipo osteoclástico. En algunas áreas había zonas de calcificación irregular. Se observaban además algunas áreas de transformación quística que asemejaban quistes aneurismáticos. El diagnóstico anatomopatológico fue condroblastoma de escafoides carpiano. Tras el tratamiento quirúrgico se inmovilizó la muñeca con una férula antebraquial durante 3 semanas y posteriormente la paciente fue remitida al Servicio de Rehabilitación. En la revisión efectuada a los 3 meses se apreció una recuperación completa de la movilidad de la muñeca e imagen radiológica de consolidación ósea del autoinjerto de cresta iliaca. Dos años después del tratamiento quirúrgico no hay evidencia de recidiva y persiste una desaparición completa del dolor con movilidad de la muñeca similar a la contralateral, así como una imagen radiológica del escafoides totalmente normalizada. Responsable clínico: Francisco Javier Repáraz Padrós Servicio de Cirugía Ortopédica y Traumatología Hospital de Navarra Irunlarrea, 3 31008 Pamplona Tfno. 848422206 E-mail: repamapr@hotmail.com

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", " ", "Irene", ".", "\n", "Apellidos", ":", "Martinez", "Alejandre", ".", "\n", "NHC", ":", "4356456", ".", "\n", "NASS", ":", "06", "52839679", "56", ".", "\n", "Domicilio", ":", "Calle", "Las", "Lomas", ",", "13", ",", "7C.", "\n", "Localidad/", "Provincia", ":", "Pamplona", ".", "\n", "CP", ":", "31256", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "21/04/1992", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "26", "años", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "08/06/2018", ".", "\n", "Médico", ":", "Francisco", "Javier", "Repáraz", "Padrós", " ", "NºCol", ":", "31", "31", "25402", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "paciente", "de", "26", "años", "que", "acude", "a", "consulta", "por", "dolor", "en", "la", "muñeca", "derecha", "de", "7", "años", "de", "evolución", "sin", "antecedente", "traumático", ".", "El", "dolor", "en", "reposo", "era", "de", "carácter", "leve", ",", "pero", "aumentaba", "con", "la", "actividad", "manual", "y", "especialmente", "con", "la", "extensión", "forzada", "de", "la", "muñeca", ".", "No", "mejoraba", "con", "tratamiento", "médico", "sintomático", ".", "\n", "La", "interlínea", "articular", "radiocarpiana", "dorsal", "y", "el", "polo", "proximal", "del", "escafoides", "eran", "dolorosos", "a", "la", "palpación", ".", "No", "se", "apreciaba", "tumoración", "palpable", ".", "La", "movilidad", "de", "la", "muñeca", "presentaba", "una", "ligera", "limitación", "en", "los", "últimos", "grados", "de", "flexión", "y", "extensión", ".", "\n", "La", "imagen", "radiológica", "mostraba", "una", "lesión", "radiolucente", ",", "bien", "definida", ",", "ovalada", ",", "localizada", "en", "el", "tercio", "medio", "-", "dorsal", "del", "escafoides", ".", "En", "la", "TAC", "se", "apreciaba", "la", "localización", "excéntrica", "dorsal", "de", "la", "lesión", "y", "un", "punteado", "compatible", "con", "calcificaciones", ".", "En", "la", "RM", "destacaban", "signos", "de", "marcado", "edema", "óseo", "en", "el", "escafoides", ",", "excepto", "en", "su", "tercio", "distal", "y", "sinovitis", "adyacente", ".", "Con", "el", "diagnóstico", "de", "sospecha", "de", "una", "lesión", "benigna", "(", "encondroma", ",", "ganglión", "intraóseo", ")", "se", "decidió", "el", "tratamiento", "quirúrgico", "de", "la", "lesión", ".", "Éste", "se", "realizó", "mediante", "una", "vía", "de", "abordaje", "dorsal", "del", "escafoides", ".", "Tras", "la", "apertura", "de", "la", "cápsula", "articular", "se", "expuso", "la", "cara", "dorsal", "de", "la", "epífisis", "distal", "del", "radio", "y", "del", "escafoides", ",", "apreciándose", "en", "el", "tercio", "medio", "de", "este", "último", "una", "tumoración", "de", "aspecto", "nacarado", "y", "coloración", "rojo", "vinosa", "que", "ocupaba", "la", "cresta", "dorsal", "del", "hueso", "navicular", ".", "Se", "realizó", "un", "legrado", "exhaustivo", "de", "la", "lesión", "y", "relleno", "del", "defecto", "con", "injerto", "óseo", "esponjoso", "de", "cresta", "iliaca", ".", "\n", "El", "material", "remitido", "estaba", "formado", "por", "islotes", "de", "matriz", "cartilaginosa", "rodeados", "por", "un", "tejido", "celular", "abundante", "constituido", "por", "células", "pseudo", "-", "condroblásticas", ".", "Dichas", "células", "eran", "redondeadas", "u", "ovoides", "con", "núcleos", "hipercromáticos", ",", "un", "citoplasma", "claro", "o", "moderadamente", "eosinófilo", "y", "una", "membrana", "plasmática", "nítida", ".", "El", "pleomorfismo", "celular", "era", "mínimo", "y", "el", "índice", "mitótico", "muy", "bajo", ".", "Algunas", "células", "contenían", "hierro", ".", "Entre", "las", "células", "pseudocondroblásticas", "se", "encontraban", "abundantes", "células", "gigantes", "de", "tipo", "osteoclástico", ".", "En", "algunas", "áreas", "había", "zonas", "de", "calcificación", "irregular", ".", "Se", "observaban", "además", "algunas", "áreas", "de", "transformación", "quística", "que", "asemejaban", "quistes", "aneurismáticos", ".", "El", "diagnóstico", "anatomopatológico", "fue", "condroblastoma", "de", "escafoides", "carpiano", ".", "\n", "Tras", "el", "tratamiento", "quirúrgico", "se", "inmovilizó", "la", "muñeca", "con", "una", "férula", "antebraquial", "durante", "3", "semanas", "y", "posteriormente", "la", "paciente", "fue", "remitida", "al", "Servicio", "de", "Rehabilitación", ".", "En", "la", "revisión", "efectuada", "a", "los", "3", "meses", "se", "apreció", "una", "recuperación", "completa", "de", "la", "movilidad", "de", "la", "muñeca", "e", "imagen", "radiológica", "de", "consolidación", "ósea", "del", "autoinjerto", "de", "cresta", "iliaca", ".", "\n", "Dos", "años", "después", "del", "tratamiento", "quirúrgico", "no", "hay", "evidencia", "de", "recidiva", "y", "persiste", "una", "desaparición", "completa", "del", "dolor", "con", "movilidad", "de", "la", "muñeca", "similar", "a", "la", "contralateral", ",", "así", "como", "una", "imagen", "radiológica", "del", "escafoides", "totalmente", "normalizada", ".", "\n", "Responsable", "clínico", ":", "Francisco", "Javier", "Repáraz", "Padrós", "Servicio", "de", "Cirugía", "Ortopédica", "y", "Traumatología", "Hospital", "de", "Navarra", "Irunlarrea", ",", "3", "31008", "Pamplona", "Tfno", ".", "848422206", "E", "-", "mail", ":", "repamapr@hotmail.com", "\n" ]

[ "NOMBRE_PERSONAL_SANITARIO", "CALLE", "CORREO_ELECTRONICO", "HOSPITAL", "NOMBRE_SUJETO_ASISTENCIA", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "NUMERO_TELEFONO", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]

Irene, Martinez Alejandre, 4356456, 06 52839679 56, Pamplona, 31256, 21/04/1992, España, 26 años, 08/06/2018, Francisco Javier Repáraz Padrós, 31 31 25402, 26 años, Francisco Javier Repáraz Padrós, Hospital de Navarra, Irunlarrea , 3, 31008, Pamplona, 848422206, repamapr@hotmail.com

407_task2

Sentence: Datos del paciente. Nombre: Irene. Apellidos: Martinez Alejandre. NHC: 4356456. NASS: 06 52839679 56. Domicilio: Calle Las Lomas, 13, 7C. Localidad/ Provincia: Pamplona. CP: 31256. Datos asistenciales. Fecha de nacimiento: 21/04/1992. País de nacimiento: España. Edad: 26 años Sexo: M. Fecha de Ingreso: 08/06/2018. Médico:Francisco Javier Repáraz Padrós NºCol: 31 31 25402. Informe clínico del paciente: paciente de 26 años que acude a consulta por dolor en la muñeca derecha de 7 años de evolución sin antecedente traumático. El dolor en reposo era de carácter leve, pero aumentaba con la actividad manual y especialmente con la extensión forzada de la muñeca. No mejoraba con tratamiento médico sintomático. La interlínea articular radiocarpiana dorsal y el polo proximal del escafoides eran dolorosos a la palpación. No se apreciaba tumoración palpable. La movilidad de la muñeca presentaba una ligera limitación en los últimos grados de flexión y extensión. La imagen radiológica mostraba una lesión radiolucente, bien definida, ovalada, localizada en el tercio medio-dorsal del escafoides. En la TAC se apreciaba la localización excéntrica dorsal de la lesión y un punteado compatible con calcificaciones. En la RM destacaban signos de marcado edema óseo en el escafoides, excepto en su tercio distal y sinovitis adyacente. Con el diagnóstico de sospecha de una lesión benigna (encondroma, ganglión intraóseo) se decidió el tratamiento quirúrgico de la lesión. Éste se realizó mediante una vía de abordaje dorsal del escafoides. Tras la apertura de la cápsula articular se expuso la cara dorsal de la epífisis distal del radio y del escafoides, apreciándose en el tercio medio de este último una tumoración de aspecto nacarado y coloración rojo vinosa que ocupaba la cresta dorsal del hueso navicular. Se realizó un legrado exhaustivo de la lesión y relleno del defecto con injerto óseo esponjoso de cresta iliaca. El material remitido estaba formado por islotes de matriz cartilaginosa rodeados por un tejido celular abundante constituido por células pseudo-condroblásticas. Dichas células eran redondeadas u ovoides con núcleos hipercromáticos, un citoplasma claro o moderadamente eosinófilo y una membrana plasmática nítida. El pleomorfismo celular era mínimo y el índice mitótico muy bajo. Algunas células contenían hierro. Entre las células pseudocondroblásticas se encontraban abundantes células gigantes de tipo osteoclástico. En algunas áreas había zonas de calcificación irregular. Se observaban además algunas áreas de transformación quística que asemejaban quistes aneurismáticos. El diagnóstico anatomopatológico fue condroblastoma de escafoides carpiano. Tras el tratamiento quirúrgico se inmovilizó la muñeca con una férula antebraquial durante 3 semanas y posteriormente la paciente fue remitida al Servicio de Rehabilitación. En la revisión efectuada a los 3 meses se apreció una recuperación completa de la movilidad de la muñeca e imagen radiológica de consolidación ósea del autoinjerto de cresta iliaca. Dos años después del tratamiento quirúrgico no hay evidencia de recidiva y persiste una desaparición completa del dolor con movilidad de la muñeca similar a la contralateral, así como una imagen radiológica del escafoides totalmente normalizada. Responsable clínico: Francisco Javier Repáraz Padrós Servicio de Cirugía Ortopédica y Traumatología Hospital de Navarra Irunlarrea, 3 31008 Pamplona Tfno. 848422206 E-mail: repamapr@hotmail.com Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "O", "B-NUMERO_TELEFONO", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Datos del paciente. Nombre: Irene. Apellidos: Martinez Alejandre. NHC: 4356456. NASS: 06 52839679 56. Domicilio: Calle Las Lomas, 13, 7C. Localidad/ Provincia: Pamplona. CP: 31256. Datos asistenciales. Fecha de nacimiento: 21/04/1992. País de nacimiento: España. Edad: 26 años Sexo: M. Fecha de Ingreso: 08/06/2018. Médico:Francisco Javier Repáraz Padrós NºCol: 31 31 25402. Informe clínico del paciente: paciente de 26 años que acude a consulta por dolor en la muñeca derecha de 7 años de evolución sin antecedente traumático. El dolor en reposo era de carácter leve, pero aumentaba con la actividad manual y especialmente con la extensión forzada de la muñeca. No mejoraba con tratamiento médico sintomático. La interlínea articular radiocarpiana dorsal y el polo proximal del escafoides eran dolorosos a la palpación. No se apreciaba tumoración palpable. La movilidad de la muñeca presentaba una ligera limitación en los últimos grados de flexión y extensión. La imagen radiológica mostraba una lesión radiolucente, bien definida, ovalada, localizada en el tercio medio-dorsal del escafoides. En la TAC se apreciaba la localización excéntrica dorsal de la lesión y un punteado compatible con calcificaciones. En la RM destacaban signos de marcado edema óseo en el escafoides, excepto en su tercio distal y sinovitis adyacente. Con el diagnóstico de sospecha de una lesión benigna (encondroma, ganglión intraóseo) se decidió el tratamiento quirúrgico de la lesión. Éste se realizó mediante una vía de abordaje dorsal del escafoides. Tras la apertura de la cápsula articular se expuso la cara dorsal de la epífisis distal del radio y del escafoides, apreciándose en el tercio medio de este último una tumoración de aspecto nacarado y coloración rojo vinosa que ocupaba la cresta dorsal del hueso navicular. Se realizó un legrado exhaustivo de la lesión y relleno del defecto con injerto óseo esponjoso de cresta iliaca. El material remitido estaba formado por islotes de matriz cartilaginosa rodeados por un tejido celular abundante constituido por células pseudo-condroblásticas. Dichas células eran redondeadas u ovoides con núcleos hipercromáticos, un citoplasma claro o moderadamente eosinófilo y una membrana plasmática nítida. El pleomorfismo celular era mínimo y el índice mitótico muy bajo. Algunas células contenían hierro. Entre las células pseudocondroblásticas se encontraban abundantes células gigantes de tipo osteoclástico. En algunas áreas había zonas de calcificación irregular. Se observaban además algunas áreas de transformación quística que asemejaban quistes aneurismáticos. El diagnóstico anatomopatológico fue condroblastoma de escafoides carpiano. Tras el tratamiento quirúrgico se inmovilizó la muñeca con una férula antebraquial durante 3 semanas y posteriormente la paciente fue remitida al Servicio de Rehabilitación. En la revisión efectuada a los 3 meses se apreció una recuperación completa de la movilidad de la muñeca e imagen radiológica de consolidación ósea del autoinjerto de cresta iliaca. Dos años después del tratamiento quirúrgico no hay evidencia de recidiva y persiste una desaparición completa del dolor con movilidad de la muñeca similar a la contralateral, así como una imagen radiológica del escafoides totalmente normalizada. Responsable clínico: Francisco Javier Repáraz Padrós Servicio de Cirugía Ortopédica y Traumatología Hospital de Navarra Irunlarrea, 3 31008 Pamplona Tfno. 848422206 E-mail: repamapr@hotmail.com

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", " ", "Irene", ".", "\n", "Apellidos", ":", "Martinez", "Alejandre", ".", "\n", "NHC", ":", "4356456", ".", "\n", "NASS", ":", "06", "52839679", "56", ".", "\n", "Domicilio", ":", "Calle", "Las", "Lomas", ",", "13", ",", "7C.", "\n", "Localidad/", "Provincia", ":", "Pamplona", ".", "\n", "CP", ":", "31256", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "21/04/1992", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "26", "años", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "08/06/2018", ".", "\n", "Médico", ":", "Francisco", "Javier", "Repáraz", "Padrós", " ", "NºCol", ":", "31", "31", "25402", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "paciente", "de", "26", "años", "que", "acude", "a", "consulta", "por", "dolor", "en", "la", "muñeca", "derecha", "de", "7", "años", "de", "evolución", "sin", "antecedente", "traumático", ".", "El", "dolor", "en", "reposo", "era", "de", "carácter", "leve", ",", "pero", "aumentaba", "con", "la", "actividad", "manual", "y", "especialmente", "con", "la", "extensión", "forzada", "de", "la", "muñeca", ".", "No", "mejoraba", "con", "tratamiento", "médico", "sintomático", ".", "\n", "La", "interlínea", "articular", "radiocarpiana", "dorsal", "y", "el", "polo", "proximal", "del", "escafoides", "eran", "dolorosos", "a", "la", "palpación", ".", "No", "se", "apreciaba", "tumoración", "palpable", ".", "La", "movilidad", "de", "la", "muñeca", "presentaba", "una", "ligera", "limitación", "en", "los", "últimos", "grados", "de", "flexión", "y", "extensión", ".", "\n", "La", "imagen", "radiológica", "mostraba", "una", "lesión", "radiolucente", ",", "bien", "definida", ",", "ovalada", ",", "localizada", "en", "el", "tercio", "medio", "-", "dorsal", "del", "escafoides", ".", "En", "la", "TAC", "se", "apreciaba", "la", "localización", "excéntrica", "dorsal", "de", "la", "lesión", "y", "un", "punteado", "compatible", "con", "calcificaciones", ".", "En", "la", "RM", "destacaban", "signos", "de", "marcado", "edema", "óseo", "en", "el", "escafoides", ",", "excepto", "en", "su", "tercio", "distal", "y", "sinovitis", "adyacente", ".", "Con", "el", "diagnóstico", "de", "sospecha", "de", "una", "lesión", "benigna", "(", "encondroma", ",", "ganglión", "intraóseo", ")", "se", "decidió", "el", "tratamiento", "quirúrgico", "de", "la", "lesión", ".", "Éste", "se", "realizó", "mediante", "una", "vía", "de", "abordaje", "dorsal", "del", "escafoides", ".", "Tras", "la", "apertura", "de", "la", "cápsula", "articular", "se", "expuso", "la", "cara", "dorsal", "de", "la", "epífisis", "distal", "del", "radio", "y", "del", "escafoides", ",", "apreciándose", "en", "el", "tercio", "medio", "de", "este", "último", "una", "tumoración", "de", "aspecto", "nacarado", "y", "coloración", "rojo", "vinosa", "que", "ocupaba", "la", "cresta", "dorsal", "del", "hueso", "navicular", ".", "Se", "realizó", "un", "legrado", "exhaustivo", "de", "la", "lesión", "y", "relleno", "del", "defecto", "con", "injerto", "óseo", "esponjoso", "de", "cresta", "iliaca", ".", "\n", "El", "material", "remitido", "estaba", "formado", "por", "islotes", "de", "matriz", "cartilaginosa", "rodeados", "por", "un", "tejido", "celular", "abundante", "constituido", "por", "células", "pseudo", "-", "condroblásticas", ".", "Dichas", "células", "eran", "redondeadas", "u", "ovoides", "con", "núcleos", "hipercromáticos", ",", "un", "citoplasma", "claro", "o", "moderadamente", "eosinófilo", "y", "una", "membrana", "plasmática", "nítida", ".", "El", "pleomorfismo", "celular", "era", "mínimo", "y", "el", "índice", "mitótico", "muy", "bajo", ".", "Algunas", "células", "contenían", "hierro", ".", "Entre", "las", "células", "pseudocondroblásticas", "se", "encontraban", "abundantes", "células", "gigantes", "de", "tipo", "osteoclástico", ".", "En", "algunas", "áreas", "había", "zonas", "de", "calcificación", "irregular", ".", "Se", "observaban", "además", "algunas", "áreas", "de", "transformación", "quística", "que", "asemejaban", "quistes", "aneurismáticos", ".", "El", "diagnóstico", "anatomopatológico", "fue", "condroblastoma", "de", "escafoides", "carpiano", ".", "\n", "Tras", "el", "tratamiento", "quirúrgico", "se", "inmovilizó", "la", "muñeca", "con", "una", "férula", "antebraquial", "durante", "3", "semanas", "y", "posteriormente", "la", "paciente", "fue", "remitida", "al", "Servicio", "de", "Rehabilitación", ".", "En", "la", "revisión", "efectuada", "a", "los", "3", "meses", "se", "apreció", "una", "recuperación", "completa", "de", "la", "movilidad", "de", "la", "muñeca", "e", "imagen", "radiológica", "de", "consolidación", "ósea", "del", "autoinjerto", "de", "cresta", "iliaca", ".", "\n", "Dos", "años", "después", "del", "tratamiento", "quirúrgico", "no", "hay", "evidencia", "de", "recidiva", "y", "persiste", "una", "desaparición", "completa", "del", "dolor", "con", "movilidad", "de", "la", "muñeca", "similar", "a", "la", "contralateral", ",", "así", "como", "una", "imagen", "radiológica", "del", "escafoides", "totalmente", "normalizada", ".", "\n", "Responsable", "clínico", ":", "Francisco", "Javier", "Repáraz", "Padrós", "Servicio", "de", "Cirugía", "Ortopédica", "y", "Traumatología", "Hospital", "de", "Navarra", "Irunlarrea", ",", "3", "31008", "Pamplona", "Tfno", ".", "848422206", "E", "-", "mail", ":", "repamapr@hotmail.com", "\n" ]

[ "NOMBRE_PERSONAL_SANITARIO", "CALLE", "CORREO_ELECTRONICO", "HOSPITAL", "NOMBRE_SUJETO_ASISTENCIA", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "NUMERO_TELEFONO", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]

PEBP2 alpha A is a Protein, PEBP2 alpha B is a Protein, PEBP2 alpha B is a Protein, AML1 is a Protein, PEBP2 alpha A is a Protein, AML1 / PEBP2 alpha B is a Protein, CD4 is a Protein, CD4 is a Protein, AML1 / PEBP2 alpha B is a Protein, AML1 / PEBP2 alpha B is a Protein

7862157_task0

Sentence: Expression of the Runt domain-encoding PEBP2 alpha genes in T cells during thymic development. The PEBP2 alpha A and PEBP2 alpha B genes encode the DNA-binding subunit of a murine transcription factor, PEBP2, which is implicated as a T-cell-specific transcriptional regulator. These two related genes share the evolutionarily conserved region encoding the Runt domain. PEBP2 alpha B is the murine counterpart of human AML1, which is located at the breakpoints of the 8;21 and 3;21 chromosome translocations associated with acute myeloid leukemia. Northern (RNA) blots of various adult mouse tissues revealed that the levels of expression of both genes were most prominent in the thymus. Furthermore, transcripts of PEBP2 alpha A and mouse AML1/PEBP2 alpha B were detected in T lymphocytes in the thymuses from day 16 embryos and newborns, as well as 4-week-old adult mice, by in situ hybridization. The expression of the genes persisted in peripheral lymph nodes of adult mice. The transcripts were detected in all the CD4- CD8-, CD4+ CD8+, CD4+ CD8-, and CD4- CD8+ cell populations. The results indicated that both genes are expressed in T cells throughout their development, supporting the notion that PEBP2 is a T-cell-specific transcription factor. Transcripts of mouse AML1/PEBP2 alpha B were also detected in day 12 fetal hematopoietic liver and in the bone marrow cells of newborn mice. The implication of mouse AML1/PEBP2 alpha B expression in hematopoietic cells other than those of T-cell lineage is discussed in relation to myeloid leukemogenesis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Expression of the Runt domain-encoding PEBP2 alpha genes in T cells during thymic development. The PEBP2 alpha A and PEBP2 alpha B genes encode the DNA-binding subunit of a murine transcription factor, PEBP2, which is implicated as a T-cell-specific transcriptional regulator. These two related genes share the evolutionarily conserved region encoding the Runt domain. PEBP2 alpha B is the murine counterpart of human AML1, which is located at the breakpoints of the 8;21 and 3;21 chromosome translocations associated with acute myeloid leukemia. Northern (RNA) blots of various adult mouse tissues revealed that the levels of expression of both genes were most prominent in the thymus. Furthermore, transcripts of PEBP2 alpha A and mouse AML1/PEBP2 alpha B were detected in T lymphocytes in the thymuses from day 16 embryos and newborns, as well as 4-week-old adult mice, by in situ hybridization. The expression of the genes persisted in peripheral lymph nodes of adult mice. The transcripts were detected in all the CD4- CD8-, CD4+ CD8+, CD4+ CD8-, and CD4- CD8+ cell populations. The results indicated that both genes are expressed in T cells throughout their development, supporting the notion that PEBP2 is a T-cell-specific transcription factor. Transcripts of mouse AML1/PEBP2 alpha B were also detected in day 12 fetal hematopoietic liver and in the bone marrow cells of newborn mice. The implication of mouse AML1/PEBP2 alpha B expression in hematopoietic cells other than those of T-cell lineage is discussed in relation to myeloid leukemogenesis.

[ "Expression", "of", "the", "Runt", "domain", "-", "encoding", "PEBP2", "alpha", "genes", "in", "T", "cells", "during", "thymic", "development", ".", "\n", "The", "PEBP2", "alpha", "A", "and", "PEBP2", "alpha", "B", "genes", "encode", "the", "DNA", "-", "binding", "subunit", "of", "a", "murine", "transcription", "factor", ",", "PEBP2", ",", "which", "is", "implicated", "as", "a", "T", "-", "cell", "-", "specific", "transcriptional", "regulator", ".", "These", "two", "related", "genes", "share", "the", "evolutionarily", "conserved", "region", "encoding", "the", "Runt", "domain", ".", "PEBP2", "alpha", "B", "is", "the", "murine", "counterpart", "of", "human", "AML1", ",", "which", "is", "located", "at", "the", "breakpoints", "of", "the", "8;21", "and", "3;21", "chromosome", "translocations", "associated", "with", "acute", "myeloid", "leukemia", ".", "Northern", "(", "RNA", ")", "blots", "of", "various", "adult", "mouse", "tissues", "revealed", "that", "the", "levels", "of", "expression", "of", "both", "genes", "were", "most", "prominent", "in", "the", "thymus", ".", "Furthermore", ",", "transcripts", "of", "PEBP2", "alpha", "A", "and", "mouse", "AML1", "/", "PEBP2", "alpha", "B", "were", "detected", "in", "T", "lymphocytes", "in", "the", "thymuses", "from", "day", "16", "embryos", "and", "newborns", ",", "as", "well", "as", "4-week", "-", "old", "adult", "mice", ",", "by", "in", "situ", "hybridization", ".", "The", "expression", "of", "the", "genes", "persisted", "in", "peripheral", "lymph", "nodes", "of", "adult", "mice", ".", "The", "transcripts", "were", "detected", "in", "all", "the", "CD4-", "CD8-", ",", "CD4", "+", "CD8", "+", ",", "CD4", "+", "CD8-", ",", "and", "CD4-", "CD8", "+", "cell", "populations", ".", "The", "results", "indicated", "that", "both", "genes", "are", "expressed", "in", "T", "cells", "throughout", "their", "development", ",", "supporting", "the", "notion", "that", "PEBP2", "is", "a", "T", "-", "cell", "-", "specific", "transcription", "factor", ".", "Transcripts", "of", "mouse", "AML1", "/", "PEBP2", "alpha", "B", "were", "also", "detected", "in", "day", "12", "fetal", "hematopoietic", "liver", "and", "in", "the", "bone", "marrow", "cells", "of", "newborn", "mice", ".", "The", "implication", "of", "mouse", "AML1", "/", "PEBP2", "alpha", "B", "expression", "in", "hematopoietic", "cells", "other", "than", "those", "of", "T", "-", "cell", "lineage", "is", "discussed", "in", "relation", "to", "myeloid", "leukemogenesis", "." ]

[ "Protein" ]

PEBP2 alpha A is a Protein, PEBP2 alpha B is a Protein, PEBP2 alpha B is a Protein, AML1 is a Protein, PEBP2 alpha A is a Protein, AML1 / PEBP2 alpha B is a Protein, CD4 is a Protein, CD4 is a Protein, AML1 / PEBP2 alpha B is a Protein, AML1 / PEBP2 alpha B is a Protein

7862157_task1

Sentence: Expression of the Runt domain-encoding PEBP2 alpha genes in T cells during thymic development. The PEBP2 alpha A and PEBP2 alpha B genes encode the DNA-binding subunit of a murine transcription factor, PEBP2, which is implicated as a T-cell-specific transcriptional regulator. These two related genes share the evolutionarily conserved region encoding the Runt domain. PEBP2 alpha B is the murine counterpart of human AML1, which is located at the breakpoints of the 8;21 and 3;21 chromosome translocations associated with acute myeloid leukemia. Northern (RNA) blots of various adult mouse tissues revealed that the levels of expression of both genes were most prominent in the thymus. Furthermore, transcripts of PEBP2 alpha A and mouse AML1/PEBP2 alpha B were detected in T lymphocytes in the thymuses from day 16 embryos and newborns, as well as 4-week-old adult mice, by in situ hybridization. The expression of the genes persisted in peripheral lymph nodes of adult mice. The transcripts were detected in all the CD4- CD8-, CD4+ CD8+, CD4+ CD8-, and CD4- CD8+ cell populations. The results indicated that both genes are expressed in T cells throughout their development, supporting the notion that PEBP2 is a T-cell-specific transcription factor. Transcripts of mouse AML1/PEBP2 alpha B were also detected in day 12 fetal hematopoietic liver and in the bone marrow cells of newborn mice. The implication of mouse AML1/PEBP2 alpha B expression in hematopoietic cells other than those of T-cell lineage is discussed in relation to myeloid leukemogenesis. Instructions: please typing these entity words according to sentence: PEBP2 alpha A, PEBP2 alpha B, PEBP2 alpha B, AML1, PEBP2 alpha A, AML1 / PEBP2 alpha B, CD4, CD4, AML1 / PEBP2 alpha B, AML1 / PEBP2 alpha B Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Expression of the Runt domain-encoding PEBP2 alpha genes in T cells during thymic development. The PEBP2 alpha A and PEBP2 alpha B genes encode the DNA-binding subunit of a murine transcription factor, PEBP2, which is implicated as a T-cell-specific transcriptional regulator. These two related genes share the evolutionarily conserved region encoding the Runt domain. PEBP2 alpha B is the murine counterpart of human AML1, which is located at the breakpoints of the 8;21 and 3;21 chromosome translocations associated with acute myeloid leukemia. Northern (RNA) blots of various adult mouse tissues revealed that the levels of expression of both genes were most prominent in the thymus. Furthermore, transcripts of PEBP2 alpha A and mouse AML1/PEBP2 alpha B were detected in T lymphocytes in the thymuses from day 16 embryos and newborns, as well as 4-week-old adult mice, by in situ hybridization. The expression of the genes persisted in peripheral lymph nodes of adult mice. The transcripts were detected in all the CD4- CD8-, CD4+ CD8+, CD4+ CD8-, and CD4- CD8+ cell populations. The results indicated that both genes are expressed in T cells throughout their development, supporting the notion that PEBP2 is a T-cell-specific transcription factor. Transcripts of mouse AML1/PEBP2 alpha B were also detected in day 12 fetal hematopoietic liver and in the bone marrow cells of newborn mice. The implication of mouse AML1/PEBP2 alpha B expression in hematopoietic cells other than those of T-cell lineage is discussed in relation to myeloid leukemogenesis.

[ "Expression", "of", "the", "Runt", "domain", "-", "encoding", "PEBP2", "alpha", "genes", "in", "T", "cells", "during", "thymic", "development", ".", "\n", "The", "PEBP2", "alpha", "A", "and", "PEBP2", "alpha", "B", "genes", "encode", "the", "DNA", "-", "binding", "subunit", "of", "a", "murine", "transcription", "factor", ",", "PEBP2", ",", "which", "is", "implicated", "as", "a", "T", "-", "cell", "-", "specific", "transcriptional", "regulator", ".", "These", "two", "related", "genes", "share", "the", "evolutionarily", "conserved", "region", "encoding", "the", "Runt", "domain", ".", "PEBP2", "alpha", "B", "is", "the", "murine", "counterpart", "of", "human", "AML1", ",", "which", "is", "located", "at", "the", "breakpoints", "of", "the", "8;21", "and", "3;21", "chromosome", "translocations", "associated", "with", "acute", "myeloid", "leukemia", ".", "Northern", "(", "RNA", ")", "blots", "of", "various", "adult", "mouse", "tissues", "revealed", "that", "the", "levels", "of", "expression", "of", "both", "genes", "were", "most", "prominent", "in", "the", "thymus", ".", "Furthermore", ",", "transcripts", "of", "PEBP2", "alpha", "A", "and", "mouse", "AML1", "/", "PEBP2", "alpha", "B", "were", "detected", "in", "T", "lymphocytes", "in", "the", "thymuses", "from", "day", "16", "embryos", "and", "newborns", ",", "as", "well", "as", "4-week", "-", "old", "adult", "mice", ",", "by", "in", "situ", "hybridization", ".", "The", "expression", "of", "the", "genes", "persisted", "in", "peripheral", "lymph", "nodes", "of", "adult", "mice", ".", "The", "transcripts", "were", "detected", "in", "all", "the", "CD4-", "CD8-", ",", "CD4", "+", "CD8", "+", ",", "CD4", "+", "CD8-", ",", "and", "CD4-", "CD8", "+", "cell", "populations", ".", "The", "results", "indicated", "that", "both", "genes", "are", "expressed", "in", "T", "cells", "throughout", "their", "development", ",", "supporting", "the", "notion", "that", "PEBP2", "is", "a", "T", "-", "cell", "-", "specific", "transcription", "factor", ".", "Transcripts", "of", "mouse", "AML1", "/", "PEBP2", "alpha", "B", "were", "also", "detected", "in", "day", "12", "fetal", "hematopoietic", "liver", "and", "in", "the", "bone", "marrow", "cells", "of", "newborn", "mice", ".", "The", "implication", "of", "mouse", "AML1", "/", "PEBP2", "alpha", "B", "expression", "in", "hematopoietic", "cells", "other", "than", "those", "of", "T", "-", "cell", "lineage", "is", "discussed", "in", "relation", "to", "myeloid", "leukemogenesis", "." ]

[ "Protein" ]

PEBP2 alpha A, PEBP2 alpha B, PEBP2 alpha B, AML1, PEBP2 alpha A, AML1 / PEBP2 alpha B, CD4, CD4, AML1 / PEBP2 alpha B, AML1 / PEBP2 alpha B

7862157_task2

Sentence: Expression of the Runt domain-encoding PEBP2 alpha genes in T cells during thymic development. The PEBP2 alpha A and PEBP2 alpha B genes encode the DNA-binding subunit of a murine transcription factor, PEBP2, which is implicated as a T-cell-specific transcriptional regulator. These two related genes share the evolutionarily conserved region encoding the Runt domain. PEBP2 alpha B is the murine counterpart of human AML1, which is located at the breakpoints of the 8;21 and 3;21 chromosome translocations associated with acute myeloid leukemia. Northern (RNA) blots of various adult mouse tissues revealed that the levels of expression of both genes were most prominent in the thymus. Furthermore, transcripts of PEBP2 alpha A and mouse AML1/PEBP2 alpha B were detected in T lymphocytes in the thymuses from day 16 embryos and newborns, as well as 4-week-old adult mice, by in situ hybridization. The expression of the genes persisted in peripheral lymph nodes of adult mice. The transcripts were detected in all the CD4- CD8-, CD4+ CD8+, CD4+ CD8-, and CD4- CD8+ cell populations. The results indicated that both genes are expressed in T cells throughout their development, supporting the notion that PEBP2 is a T-cell-specific transcription factor. Transcripts of mouse AML1/PEBP2 alpha B were also detected in day 12 fetal hematopoietic liver and in the bone marrow cells of newborn mice. The implication of mouse AML1/PEBP2 alpha B expression in hematopoietic cells other than those of T-cell lineage is discussed in relation to myeloid leukemogenesis. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Expression of the Runt domain-encoding PEBP2 alpha genes in T cells during thymic development. The PEBP2 alpha A and PEBP2 alpha B genes encode the DNA-binding subunit of a murine transcription factor, PEBP2, which is implicated as a T-cell-specific transcriptional regulator. These two related genes share the evolutionarily conserved region encoding the Runt domain. PEBP2 alpha B is the murine counterpart of human AML1, which is located at the breakpoints of the 8;21 and 3;21 chromosome translocations associated with acute myeloid leukemia. Northern (RNA) blots of various adult mouse tissues revealed that the levels of expression of both genes were most prominent in the thymus. Furthermore, transcripts of PEBP2 alpha A and mouse AML1/PEBP2 alpha B were detected in T lymphocytes in the thymuses from day 16 embryos and newborns, as well as 4-week-old adult mice, by in situ hybridization. The expression of the genes persisted in peripheral lymph nodes of adult mice. The transcripts were detected in all the CD4- CD8-, CD4+ CD8+, CD4+ CD8-, and CD4- CD8+ cell populations. The results indicated that both genes are expressed in T cells throughout their development, supporting the notion that PEBP2 is a T-cell-specific transcription factor. Transcripts of mouse AML1/PEBP2 alpha B were also detected in day 12 fetal hematopoietic liver and in the bone marrow cells of newborn mice. The implication of mouse AML1/PEBP2 alpha B expression in hematopoietic cells other than those of T-cell lineage is discussed in relation to myeloid leukemogenesis.

[ "Expression", "of", "the", "Runt", "domain", "-", "encoding", "PEBP2", "alpha", "genes", "in", "T", "cells", "during", "thymic", "development", ".", "\n", "The", "PEBP2", "alpha", "A", "and", "PEBP2", "alpha", "B", "genes", "encode", "the", "DNA", "-", "binding", "subunit", "of", "a", "murine", "transcription", "factor", ",", "PEBP2", ",", "which", "is", "implicated", "as", "a", "T", "-", "cell", "-", "specific", "transcriptional", "regulator", ".", "These", "two", "related", "genes", "share", "the", "evolutionarily", "conserved", "region", "encoding", "the", "Runt", "domain", ".", "PEBP2", "alpha", "B", "is", "the", "murine", "counterpart", "of", "human", "AML1", ",", "which", "is", "located", "at", "the", "breakpoints", "of", "the", "8;21", "and", "3;21", "chromosome", "translocations", "associated", "with", "acute", "myeloid", "leukemia", ".", "Northern", "(", "RNA", ")", "blots", "of", "various", "adult", "mouse", "tissues", "revealed", "that", "the", "levels", "of", "expression", "of", "both", "genes", "were", "most", "prominent", "in", "the", "thymus", ".", "Furthermore", ",", "transcripts", "of", "PEBP2", "alpha", "A", "and", "mouse", "AML1", "/", "PEBP2", "alpha", "B", "were", "detected", "in", "T", "lymphocytes", "in", "the", "thymuses", "from", "day", "16", "embryos", "and", "newborns", ",", "as", "well", "as", "4-week", "-", "old", "adult", "mice", ",", "by", "in", "situ", "hybridization", ".", "The", "expression", "of", "the", "genes", "persisted", "in", "peripheral", "lymph", "nodes", "of", "adult", "mice", ".", "The", "transcripts", "were", "detected", "in", "all", "the", "CD4-", "CD8-", ",", "CD4", "+", "CD8", "+", ",", "CD4", "+", "CD8-", ",", "and", "CD4-", "CD8", "+", "cell", "populations", ".", "The", "results", "indicated", "that", "both", "genes", "are", "expressed", "in", "T", "cells", "throughout", "their", "development", ",", "supporting", "the", "notion", "that", "PEBP2", "is", "a", "T", "-", "cell", "-", "specific", "transcription", "factor", ".", "Transcripts", "of", "mouse", "AML1", "/", "PEBP2", "alpha", "B", "were", "also", "detected", "in", "day", "12", "fetal", "hematopoietic", "liver", "and", "in", "the", "bone", "marrow", "cells", "of", "newborn", "mice", ".", "The", "implication", "of", "mouse", "AML1", "/", "PEBP2", "alpha", "B", "expression", "in", "hematopoietic", "cells", "other", "than", "those", "of", "T", "-", "cell", "lineage", "is", "discussed", "in", "relation", "to", "myeloid", "leukemogenesis", "." ]

[ "Protein" ]

Amphotericin B is a Intervention_Pharmacological, children is a Participant_Age, malignant disease : is a Participant_Condition, amphotericin B administered in dextrose is a Intervention_Pharmacological, lipid emulsion is a Intervention_Pharmacological, amphotericin B ( AmB ) is a Intervention_Pharmacological, AmB infused in lipid emulsion is a Intervention_Pharmacological, 82 is a Participant_Sample-size, pharmacokinetics of AmB is a Outcome_Physical, AmB in dextrose is a Intervention_Pharmacological, AmB in lipid emulsion is a Intervention_Pharmacological, concentration of AmB in plasma is a Outcome_Physical, clearance ( CL ) of AmB in dextrose is a Outcome_Physical, steady - state volume of distribution for AmB is a Outcome_Physical, safety and tolerance is a Outcome_Other

1014_task0

Sentence: Amphotericin B in children with malignant disease : a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion . In a prospective , randomized clinical trial , the toxicity of 1 mg of amphotericin B ( AmB ) per kg of body weight per day infused in 5 % dextrose was compared with that of AmB infused in lipid emulsion in children with malignant disease . In an analysis of 82 children who received a full course of 6 days or more of AmB ( 117 courses ) , it was shown that there were significant increases in plasma urea and creatinine concentrations and in potassium requirement after 6 days of therapy with both AmB infused in dextrose and AmB infused in lipid emulsion , with there being no difference between the two methods of AmB administration . An intent-to-treat comparison of the numbers of courses affected by acute toxicity ( fever , rigors ) and chronic toxicity ( nephrotoxicity ) also indicated that there was no significant difference between AmB infused in dextrose ( 78 courses ) and AmB infused in lipid emulsion ( 84 courses ) . The pharmacokinetics of AmB were investigated in 20 children who received AmB in dextrose and 15 children who received AmB in lipid emulsion . Blood samples were collected up to 24 h after administration of the first dose , and the concentration of AmB in plasma was analyzed by a high-performance liquid chromatography assay . The clearance ( CL ) of AmB in dextrose ( 0.039 +/- 0.016 liter . h-1 . kg-1 ) was significantly lower ( P < 0.005 ) than the CL of AmB in lipid emulsion ( 0.062 +/- 0 . 024 liter . h-1 . kg-1 ) . The steady-state volume of distribution for AmB in dextrose ( 0.83 +/- 0.33 liter . kg-1 ) was also significantly lower ( P < 0.005 ) than that for AmB in lipid emulsion ( 1.47 +/- 0.77 liter . kg-1 ) . Although AmB in lipid emulsion is apparently cleared faster and distributes more widely than AmB in dextrose , this study did not reveal any significant advantage with respect to safety and tolerance in the administration of AmB in lipid emulsion compared to its administration in dextrose in children with malignant disease . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Other

[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Amphotericin B in children with malignant disease : a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion . In a prospective , randomized clinical trial , the toxicity of 1 mg of amphotericin B ( AmB ) per kg of body weight per day infused in 5 % dextrose was compared with that of AmB infused in lipid emulsion in children with malignant disease . In an analysis of 82 children who received a full course of 6 days or more of AmB ( 117 courses ) , it was shown that there were significant increases in plasma urea and creatinine concentrations and in potassium requirement after 6 days of therapy with both AmB infused in dextrose and AmB infused in lipid emulsion , with there being no difference between the two methods of AmB administration . An intent-to-treat comparison of the numbers of courses affected by acute toxicity ( fever , rigors ) and chronic toxicity ( nephrotoxicity ) also indicated that there was no significant difference between AmB infused in dextrose ( 78 courses ) and AmB infused in lipid emulsion ( 84 courses ) . The pharmacokinetics of AmB were investigated in 20 children who received AmB in dextrose and 15 children who received AmB in lipid emulsion . Blood samples were collected up to 24 h after administration of the first dose , and the concentration of AmB in plasma was analyzed by a high-performance liquid chromatography assay . The clearance ( CL ) of AmB in dextrose ( 0.039 +/- 0.016 liter . h-1 . kg-1 ) was significantly lower ( P < 0.005 ) than the CL of AmB in lipid emulsion ( 0.062 +/- 0 . 024 liter . h-1 . kg-1 ) . The steady-state volume of distribution for AmB in dextrose ( 0.83 +/- 0.33 liter . kg-1 ) was also significantly lower ( P < 0.005 ) than that for AmB in lipid emulsion ( 1.47 +/- 0.77 liter . kg-1 ) . Although AmB in lipid emulsion is apparently cleared faster and distributes more widely than AmB in dextrose , this study did not reveal any significant advantage with respect to safety and tolerance in the administration of AmB in lipid emulsion compared to its administration in dextrose in children with malignant disease .

[ "Amphotericin", "B", "in", "children", "with", "malignant", "disease", ":", "a", "comparison", "of", "the", "toxicities", "and", "pharmacokinetics", "of", "amphotericin", "B", "administered", "in", "dextrose", "versus", "lipid", "emulsion", ".", "In", "a", "prospective", ",", "randomized", "clinical", "trial", ",", "the", "toxicity", "of", "1", "mg", "of", "amphotericin", "B", "(", "AmB", ")", "per", "kg", "of", "body", "weight", "per", "day", "infused", "in", "5", "%", "dextrose", "was", "compared", "with", "that", "of", "AmB", "infused", "in", "lipid", "emulsion", "in", "children", "with", "malignant", "disease", ".", "In", "an", "analysis", "of", "82", "children", "who", "received", "a", "full", "course", "of", "6", "days", "or", "more", "of", "AmB", "(", "117", "courses", ")", ",", "it", "was", "shown", "that", "there", "were", "significant", "increases", "in", "plasma", "urea", "and", "creatinine", "concentrations", "and", "in", "potassium", "requirement", "after", "6", "days", "of", "therapy", "with", "both", "AmB", "infused", "in", "dextrose", "and", "AmB", "infused", "in", "lipid", "emulsion", ",", "with", "there", "being", "no", "difference", "between", "the", "two", "methods", "of", "AmB", "administration", ".", "An", "intent", "-", "to", "-", "treat", "comparison", "of", "the", "numbers", "of", "courses", "affected", "by", "acute", "toxicity", "(", "fever", ",", "rigors", ")", "and", "chronic", "toxicity", "(", "nephrotoxicity", ")", "also", "indicated", "that", "there", "was", "no", "significant", "difference", "between", "AmB", "infused", "in", "dextrose", "(", "78", "courses", ")", "and", "AmB", "infused", "in", "lipid", "emulsion", "(", "84", "courses", ")", ".", "The", "pharmacokinetics", "of", "AmB", "were", "investigated", "in", "20", "children", "who", "received", "AmB", "in", "dextrose", "and", "15", "children", "who", "received", "AmB", "in", "lipid", "emulsion", ".", "Blood", "samples", "were", "collected", "up", "to", "24", "h", "after", "administration", "of", "the", "first", "dose", ",", "and", "the", "concentration", "of", "AmB", "in", "plasma", "was", "analyzed", "by", "a", "high", "-", "performance", "liquid", "chromatography", "assay", ".", "The", "clearance", "(", "CL", ")", "of", "AmB", "in", "dextrose", "(", "0.039", "+", "/-", "0.016", "liter", ".", "h-1", ".", "kg-1", ")", "was", "significantly", "lower", "(", "P", "<", "0.005", ")", "than", "the", "CL", "of", "AmB", "in", "lipid", "emulsion", "(", "0.062", "+", "/-", "0", ".", "024", "liter", ".", "h-1", ".", "kg-1", ")", ".", "The", "steady", "-", "state", "volume", "of", "distribution", "for", "AmB", "in", "dextrose", "(", "0.83", "+", "/-", "0.33", "liter", ".", "kg-1", ")", "was", "also", "significantly", "lower", "(", "P", "<", "0.005", ")", "than", "that", "for", "AmB", "in", "lipid", "emulsion", "(", "1.47", "+", "/-", "0.77", "liter", ".", "kg-1", ")", ".", "Although", "AmB", "in", "lipid", "emulsion", "is", "apparently", "cleared", "faster", "and", "distributes", "more", "widely", "than", "AmB", "in", "dextrose", ",", "this", "study", "did", "not", "reveal", "any", "significant", "advantage", "with", "respect", "to", "safety", "and", "tolerance", "in", "the", "administration", "of", "AmB", "in", "lipid", "emulsion", "compared", "to", "its", "administration", "in", "dextrose", "in", "children", "with", "malignant", "disease", "." ]

[ "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Other", "Participant_Condition", "Participant_Age", "Participant_Sample-size" ]

Amphotericin B is a Intervention_Pharmacological, children is a Participant_Age, malignant disease : is a Participant_Condition, amphotericin B administered in dextrose is a Intervention_Pharmacological, lipid emulsion is a Intervention_Pharmacological, amphotericin B ( AmB ) is a Intervention_Pharmacological, AmB infused in lipid emulsion is a Intervention_Pharmacological, 82 is a Participant_Sample-size, pharmacokinetics of AmB is a Outcome_Physical, AmB in dextrose is a Intervention_Pharmacological, AmB in lipid emulsion is a Intervention_Pharmacological, concentration of AmB in plasma is a Outcome_Physical, clearance ( CL ) of AmB in dextrose is a Outcome_Physical, steady - state volume of distribution for AmB is a Outcome_Physical, safety and tolerance is a Outcome_Other

1014_task1

Sentence: Amphotericin B in children with malignant disease : a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion . In a prospective , randomized clinical trial , the toxicity of 1 mg of amphotericin B ( AmB ) per kg of body weight per day infused in 5 % dextrose was compared with that of AmB infused in lipid emulsion in children with malignant disease . In an analysis of 82 children who received a full course of 6 days or more of AmB ( 117 courses ) , it was shown that there were significant increases in plasma urea and creatinine concentrations and in potassium requirement after 6 days of therapy with both AmB infused in dextrose and AmB infused in lipid emulsion , with there being no difference between the two methods of AmB administration . An intent-to-treat comparison of the numbers of courses affected by acute toxicity ( fever , rigors ) and chronic toxicity ( nephrotoxicity ) also indicated that there was no significant difference between AmB infused in dextrose ( 78 courses ) and AmB infused in lipid emulsion ( 84 courses ) . The pharmacokinetics of AmB were investigated in 20 children who received AmB in dextrose and 15 children who received AmB in lipid emulsion . Blood samples were collected up to 24 h after administration of the first dose , and the concentration of AmB in plasma was analyzed by a high-performance liquid chromatography assay . The clearance ( CL ) of AmB in dextrose ( 0.039 +/- 0.016 liter . h-1 . kg-1 ) was significantly lower ( P < 0.005 ) than the CL of AmB in lipid emulsion ( 0.062 +/- 0 . 024 liter . h-1 . kg-1 ) . The steady-state volume of distribution for AmB in dextrose ( 0.83 +/- 0.33 liter . kg-1 ) was also significantly lower ( P < 0.005 ) than that for AmB in lipid emulsion ( 1.47 +/- 0.77 liter . kg-1 ) . Although AmB in lipid emulsion is apparently cleared faster and distributes more widely than AmB in dextrose , this study did not reveal any significant advantage with respect to safety and tolerance in the administration of AmB in lipid emulsion compared to its administration in dextrose in children with malignant disease . Instructions: please typing these entity words according to sentence: Amphotericin B, children, malignant disease :, amphotericin B administered in dextrose, lipid emulsion, amphotericin B ( AmB ), AmB infused in lipid emulsion, 82, pharmacokinetics of AmB, AmB in dextrose, AmB in lipid emulsion, concentration of AmB in plasma, clearance ( CL ) of AmB in dextrose, steady - state volume of distribution for AmB, safety and tolerance Options: Intervention_Pharmacological, Participant_Condition, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Other

[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Amphotericin B in children with malignant disease : a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion . In a prospective , randomized clinical trial , the toxicity of 1 mg of amphotericin B ( AmB ) per kg of body weight per day infused in 5 % dextrose was compared with that of AmB infused in lipid emulsion in children with malignant disease . In an analysis of 82 children who received a full course of 6 days or more of AmB ( 117 courses ) , it was shown that there were significant increases in plasma urea and creatinine concentrations and in potassium requirement after 6 days of therapy with both AmB infused in dextrose and AmB infused in lipid emulsion , with there being no difference between the two methods of AmB administration . An intent-to-treat comparison of the numbers of courses affected by acute toxicity ( fever , rigors ) and chronic toxicity ( nephrotoxicity ) also indicated that there was no significant difference between AmB infused in dextrose ( 78 courses ) and AmB infused in lipid emulsion ( 84 courses ) . The pharmacokinetics of AmB were investigated in 20 children who received AmB in dextrose and 15 children who received AmB in lipid emulsion . Blood samples were collected up to 24 h after administration of the first dose , and the concentration of AmB in plasma was analyzed by a high-performance liquid chromatography assay . The clearance ( CL ) of AmB in dextrose ( 0.039 +/- 0.016 liter . h-1 . kg-1 ) was significantly lower ( P < 0.005 ) than the CL of AmB in lipid emulsion ( 0.062 +/- 0 . 024 liter . h-1 . kg-1 ) . The steady-state volume of distribution for AmB in dextrose ( 0.83 +/- 0.33 liter . kg-1 ) was also significantly lower ( P < 0.005 ) than that for AmB in lipid emulsion ( 1.47 +/- 0.77 liter . kg-1 ) . Although AmB in lipid emulsion is apparently cleared faster and distributes more widely than AmB in dextrose , this study did not reveal any significant advantage with respect to safety and tolerance in the administration of AmB in lipid emulsion compared to its administration in dextrose in children with malignant disease .

[ "Amphotericin", "B", "in", "children", "with", "malignant", "disease", ":", "a", "comparison", "of", "the", "toxicities", "and", "pharmacokinetics", "of", "amphotericin", "B", "administered", "in", "dextrose", "versus", "lipid", "emulsion", ".", "In", "a", "prospective", ",", "randomized", "clinical", "trial", ",", "the", "toxicity", "of", "1", "mg", "of", "amphotericin", "B", "(", "AmB", ")", "per", "kg", "of", "body", "weight", "per", "day", "infused", "in", "5", "%", "dextrose", "was", "compared", "with", "that", "of", "AmB", "infused", "in", "lipid", "emulsion", "in", "children", "with", "malignant", "disease", ".", "In", "an", "analysis", "of", "82", "children", "who", "received", "a", "full", "course", "of", "6", "days", "or", "more", "of", "AmB", "(", "117", "courses", ")", ",", "it", "was", "shown", "that", "there", "were", "significant", "increases", "in", "plasma", "urea", "and", "creatinine", "concentrations", "and", "in", "potassium", "requirement", "after", "6", "days", "of", "therapy", "with", "both", "AmB", "infused", "in", "dextrose", "and", "AmB", "infused", "in", "lipid", "emulsion", ",", "with", "there", "being", "no", "difference", "between", "the", "two", "methods", "of", "AmB", "administration", ".", "An", "intent", "-", "to", "-", "treat", "comparison", "of", "the", "numbers", "of", "courses", "affected", "by", "acute", "toxicity", "(", "fever", ",", "rigors", ")", "and", "chronic", "toxicity", "(", "nephrotoxicity", ")", "also", "indicated", "that", "there", "was", "no", "significant", "difference", "between", "AmB", "infused", "in", "dextrose", "(", "78", "courses", ")", "and", "AmB", "infused", "in", "lipid", "emulsion", "(", "84", "courses", ")", ".", "The", "pharmacokinetics", "of", "AmB", "were", "investigated", "in", "20", "children", "who", "received", "AmB", "in", "dextrose", "and", "15", "children", "who", "received", "AmB", "in", "lipid", "emulsion", ".", "Blood", "samples", "were", "collected", "up", "to", "24", "h", "after", "administration", "of", "the", "first", "dose", ",", "and", "the", "concentration", "of", "AmB", "in", "plasma", "was", "analyzed", "by", "a", "high", "-", "performance", "liquid", "chromatography", "assay", ".", "The", "clearance", "(", "CL", ")", "of", "AmB", "in", "dextrose", "(", "0.039", "+", "/-", "0.016", "liter", ".", "h-1", ".", "kg-1", ")", "was", "significantly", "lower", "(", "P", "<", "0.005", ")", "than", "the", "CL", "of", "AmB", "in", "lipid", "emulsion", "(", "0.062", "+", "/-", "0", ".", "024", "liter", ".", "h-1", ".", "kg-1", ")", ".", "The", "steady", "-", "state", "volume", "of", "distribution", "for", "AmB", "in", "dextrose", "(", "0.83", "+", "/-", "0.33", "liter", ".", "kg-1", ")", "was", "also", "significantly", "lower", "(", "P", "<", "0.005", ")", "than", "that", "for", "AmB", "in", "lipid", "emulsion", "(", "1.47", "+", "/-", "0.77", "liter", ".", "kg-1", ")", ".", "Although", "AmB", "in", "lipid", "emulsion", "is", "apparently", "cleared", "faster", "and", "distributes", "more", "widely", "than", "AmB", "in", "dextrose", ",", "this", "study", "did", "not", "reveal", "any", "significant", "advantage", "with", "respect", "to", "safety", "and", "tolerance", "in", "the", "administration", "of", "AmB", "in", "lipid", "emulsion", "compared", "to", "its", "administration", "in", "dextrose", "in", "children", "with", "malignant", "disease", "." ]

[ "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Other", "Participant_Condition", "Participant_Age", "Participant_Sample-size" ]

Amphotericin B, children, malignant disease :, amphotericin B administered in dextrose, lipid emulsion, amphotericin B ( AmB ), AmB infused in lipid emulsion, 82, pharmacokinetics of AmB, AmB in dextrose, AmB in lipid emulsion, concentration of AmB in plasma, clearance ( CL ) of AmB in dextrose, steady - state volume of distribution for AmB, safety and tolerance

1014_task2

Sentence: Amphotericin B in children with malignant disease : a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion . In a prospective , randomized clinical trial , the toxicity of 1 mg of amphotericin B ( AmB ) per kg of body weight per day infused in 5 % dextrose was compared with that of AmB infused in lipid emulsion in children with malignant disease . In an analysis of 82 children who received a full course of 6 days or more of AmB ( 117 courses ) , it was shown that there were significant increases in plasma urea and creatinine concentrations and in potassium requirement after 6 days of therapy with both AmB infused in dextrose and AmB infused in lipid emulsion , with there being no difference between the two methods of AmB administration . An intent-to-treat comparison of the numbers of courses affected by acute toxicity ( fever , rigors ) and chronic toxicity ( nephrotoxicity ) also indicated that there was no significant difference between AmB infused in dextrose ( 78 courses ) and AmB infused in lipid emulsion ( 84 courses ) . The pharmacokinetics of AmB were investigated in 20 children who received AmB in dextrose and 15 children who received AmB in lipid emulsion . Blood samples were collected up to 24 h after administration of the first dose , and the concentration of AmB in plasma was analyzed by a high-performance liquid chromatography assay . The clearance ( CL ) of AmB in dextrose ( 0.039 +/- 0.016 liter . h-1 . kg-1 ) was significantly lower ( P < 0.005 ) than the CL of AmB in lipid emulsion ( 0.062 +/- 0 . 024 liter . h-1 . kg-1 ) . The steady-state volume of distribution for AmB in dextrose ( 0.83 +/- 0.33 liter . kg-1 ) was also significantly lower ( P < 0.005 ) than that for AmB in lipid emulsion ( 1.47 +/- 0.77 liter . kg-1 ) . Although AmB in lipid emulsion is apparently cleared faster and distributes more widely than AmB in dextrose , this study did not reveal any significant advantage with respect to safety and tolerance in the administration of AmB in lipid emulsion compared to its administration in dextrose in children with malignant disease . Instructions: please extract entity words from the input sentence

[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Amphotericin B in children with malignant disease : a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion . In a prospective , randomized clinical trial , the toxicity of 1 mg of amphotericin B ( AmB ) per kg of body weight per day infused in 5 % dextrose was compared with that of AmB infused in lipid emulsion in children with malignant disease . In an analysis of 82 children who received a full course of 6 days or more of AmB ( 117 courses ) , it was shown that there were significant increases in plasma urea and creatinine concentrations and in potassium requirement after 6 days of therapy with both AmB infused in dextrose and AmB infused in lipid emulsion , with there being no difference between the two methods of AmB administration . An intent-to-treat comparison of the numbers of courses affected by acute toxicity ( fever , rigors ) and chronic toxicity ( nephrotoxicity ) also indicated that there was no significant difference between AmB infused in dextrose ( 78 courses ) and AmB infused in lipid emulsion ( 84 courses ) . The pharmacokinetics of AmB were investigated in 20 children who received AmB in dextrose and 15 children who received AmB in lipid emulsion . Blood samples were collected up to 24 h after administration of the first dose , and the concentration of AmB in plasma was analyzed by a high-performance liquid chromatography assay . The clearance ( CL ) of AmB in dextrose ( 0.039 +/- 0.016 liter . h-1 . kg-1 ) was significantly lower ( P < 0.005 ) than the CL of AmB in lipid emulsion ( 0.062 +/- 0 . 024 liter . h-1 . kg-1 ) . The steady-state volume of distribution for AmB in dextrose ( 0.83 +/- 0.33 liter . kg-1 ) was also significantly lower ( P < 0.005 ) than that for AmB in lipid emulsion ( 1.47 +/- 0.77 liter . kg-1 ) . Although AmB in lipid emulsion is apparently cleared faster and distributes more widely than AmB in dextrose , this study did not reveal any significant advantage with respect to safety and tolerance in the administration of AmB in lipid emulsion compared to its administration in dextrose in children with malignant disease .

[ "Amphotericin", "B", "in", "children", "with", "malignant", "disease", ":", "a", "comparison", "of", "the", "toxicities", "and", "pharmacokinetics", "of", "amphotericin", "B", "administered", "in", "dextrose", "versus", "lipid", "emulsion", ".", "In", "a", "prospective", ",", "randomized", "clinical", "trial", ",", "the", "toxicity", "of", "1", "mg", "of", "amphotericin", "B", "(", "AmB", ")", "per", "kg", "of", "body", "weight", "per", "day", "infused", "in", "5", "%", "dextrose", "was", "compared", "with", "that", "of", "AmB", "infused", "in", "lipid", "emulsion", "in", "children", "with", "malignant", "disease", ".", "In", "an", "analysis", "of", "82", "children", "who", "received", "a", "full", "course", "of", "6", "days", "or", "more", "of", "AmB", "(", "117", "courses", ")", ",", "it", "was", "shown", "that", "there", "were", "significant", "increases", "in", "plasma", "urea", "and", "creatinine", "concentrations", "and", "in", "potassium", "requirement", "after", "6", "days", "of", "therapy", "with", "both", "AmB", "infused", "in", "dextrose", "and", "AmB", "infused", "in", "lipid", "emulsion", ",", "with", "there", "being", "no", "difference", "between", "the", "two", "methods", "of", "AmB", "administration", ".", "An", "intent", "-", "to", "-", "treat", "comparison", "of", "the", "numbers", "of", "courses", "affected", "by", "acute", "toxicity", "(", "fever", ",", "rigors", ")", "and", "chronic", "toxicity", "(", "nephrotoxicity", ")", "also", "indicated", "that", "there", "was", "no", "significant", "difference", "between", "AmB", "infused", "in", "dextrose", "(", "78", "courses", ")", "and", "AmB", "infused", "in", "lipid", "emulsion", "(", "84", "courses", ")", ".", "The", "pharmacokinetics", "of", "AmB", "were", "investigated", "in", "20", "children", "who", "received", "AmB", "in", "dextrose", "and", "15", "children", "who", "received", "AmB", "in", "lipid", "emulsion", ".", "Blood", "samples", "were", "collected", "up", "to", "24", "h", "after", "administration", "of", "the", "first", "dose", ",", "and", "the", "concentration", "of", "AmB", "in", "plasma", "was", "analyzed", "by", "a", "high", "-", "performance", "liquid", "chromatography", "assay", ".", "The", "clearance", "(", "CL", ")", "of", "AmB", "in", "dextrose", "(", "0.039", "+", "/-", "0.016", "liter", ".", "h-1", ".", "kg-1", ")", "was", "significantly", "lower", "(", "P", "<", "0.005", ")", "than", "the", "CL", "of", "AmB", "in", "lipid", "emulsion", "(", "0.062", "+", "/-", "0", ".", "024", "liter", ".", "h-1", ".", "kg-1", ")", ".", "The", "steady", "-", "state", "volume", "of", "distribution", "for", "AmB", "in", "dextrose", "(", "0.83", "+", "/-", "0.33", "liter", ".", "kg-1", ")", "was", "also", "significantly", "lower", "(", "P", "<", "0.005", ")", "than", "that", "for", "AmB", "in", "lipid", "emulsion", "(", "1.47", "+", "/-", "0.77", "liter", ".", "kg-1", ")", ".", "Although", "AmB", "in", "lipid", "emulsion", "is", "apparently", "cleared", "faster", "and", "distributes", "more", "widely", "than", "AmB", "in", "dextrose", ",", "this", "study", "did", "not", "reveal", "any", "significant", "advantage", "with", "respect", "to", "safety", "and", "tolerance", "in", "the", "administration", "of", "AmB", "in", "lipid", "emulsion", "compared", "to", "its", "administration", "in", "dextrose", "in", "children", "with", "malignant", "disease", "." ]

[ "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Other", "Participant_Condition", "Participant_Age", "Participant_Sample-size" ]

homocysteine is a compound, MTHFR is a protein, folate is a compound, cobalamin is a compound

DS.d1330_task0

Sentence: Total plasma homocysteine level, MTHFR C677T polymorphism, inherited abnormalities of the natural anticoagulant system as well as plasma folate and cobalamin levels were determined. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "O", "O", "B-compound", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "B-compound", "O", "O", "O", "O" ]

Total plasma homocysteine level, MTHFR C677T polymorphism, inherited abnormalities of the natural anticoagulant system as well as plasma folate and cobalamin levels were determined.

[ "Total", "plasma", "homocysteine", "level", ",", "MTHFR", "C677", "T", "polymorphism", ",", "inherited", "abnormalities", "of", "the", "natural", "anticoagulant", "system", "as", "well", "as", "plasma", "folate", "and", "cobalamin", "levels", "were", "determined", "." ]

[ "compound", "protein" ]

homocysteine is a compound, MTHFR is a protein, folate is a compound, cobalamin is a compound

DS.d1330_task1

Sentence: Total plasma homocysteine level, MTHFR C677T polymorphism, inherited abnormalities of the natural anticoagulant system as well as plasma folate and cobalamin levels were determined. Instructions: please typing these entity words according to sentence: homocysteine, MTHFR, folate, cobalamin Options: compound, protein

[ "O", "O", "B-compound", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "B-compound", "O", "O", "O", "O" ]

Total plasma homocysteine level, MTHFR C677T polymorphism, inherited abnormalities of the natural anticoagulant system as well as plasma folate and cobalamin levels were determined.

[ "Total", "plasma", "homocysteine", "level", ",", "MTHFR", "C677", "T", "polymorphism", ",", "inherited", "abnormalities", "of", "the", "natural", "anticoagulant", "system", "as", "well", "as", "plasma", "folate", "and", "cobalamin", "levels", "were", "determined", "." ]

[ "compound", "protein" ]

homocysteine, MTHFR, folate, cobalamin

DS.d1330_task2

Sentence: Total plasma homocysteine level, MTHFR C677T polymorphism, inherited abnormalities of the natural anticoagulant system as well as plasma folate and cobalamin levels were determined. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-compound", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "B-compound", "O", "O", "O", "O" ]

Total plasma homocysteine level, MTHFR C677T polymorphism, inherited abnormalities of the natural anticoagulant system as well as plasma folate and cobalamin levels were determined.

[ "Total", "plasma", "homocysteine", "level", ",", "MTHFR", "C677", "T", "polymorphism", ",", "inherited", "abnormalities", "of", "the", "natural", "anticoagulant", "system", "as", "well", "as", "plasma", "folate", "and", "cobalamin", "levels", "were", "determined", "." ]

[ "compound", "protein" ]

Vitamin C is a CHEMICAL, diethylmaleate is a CHEMICAL, L - cystine is a CHEMICAL

12498985_task0

Sentence: Vitamin C inhibits diethylmaleate-induced L-cystine transport in human vascular smooth muscle cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL

[ "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]

Vitamin C inhibits diethylmaleate-induced L-cystine transport in human vascular smooth muscle cells.

[ "Vitamin", "C", "inhibits", "diethylmaleate", "-", "induced", "L", "-", "cystine", "transport", "in", "human", "vascular", "smooth", "muscle", "cells", "." ]

[ "GENE-Y", "CHEMICAL", "GENE-N" ]

Vitamin C is a CHEMICAL, diethylmaleate is a CHEMICAL, L - cystine is a CHEMICAL

12498985_task1

Sentence: Vitamin C inhibits diethylmaleate-induced L-cystine transport in human vascular smooth muscle cells. Instructions: please typing these entity words according to sentence: Vitamin C, diethylmaleate, L - cystine Options: CHEMICAL

[ "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]

Vitamin C inhibits diethylmaleate-induced L-cystine transport in human vascular smooth muscle cells.

[ "Vitamin", "C", "inhibits", "diethylmaleate", "-", "induced", "L", "-", "cystine", "transport", "in", "human", "vascular", "smooth", "muscle", "cells", "." ]

[ "GENE-Y", "CHEMICAL", "GENE-N" ]

Vitamin C, diethylmaleate, L - cystine

12498985_task2

Sentence: Vitamin C inhibits diethylmaleate-induced L-cystine transport in human vascular smooth muscle cells. Instructions: please extract entity words from the input sentence

[ "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]

Vitamin C inhibits diethylmaleate-induced L-cystine transport in human vascular smooth muscle cells.

[ "Vitamin", "C", "inhibits", "diethylmaleate", "-", "induced", "L", "-", "cystine", "transport", "in", "human", "vascular", "smooth", "muscle", "cells", "." ]

[ "GENE-Y", "CHEMICAL", "GENE-N" ]

Jun oncogene family members is a DNA_family_or_group, glucocorticoid receptor - dependent transcription is an other_name

83922_task0

Sentence: Cell-specific bifunctional role of Jun oncogene family members on glucocorticoid receptor-dependent transcription. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA_family_or_group, other_name

[ "O", "O", "O", "O", "O", "O", "B-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O" ]

Cell-specific bifunctional role of Jun oncogene family members on glucocorticoid receptor-dependent transcription.

[ "Cell", "-", "specific", "bifunctional", "role", "of", "Jun", "oncogene", "family", "members", "on", "glucocorticoid", "receptor", "-", "dependent", "transcription", "." ]

[ "other_name", "DNA_molecule", "(OR DNA_molecule DNA_molecule DNA_molecule)", "other_organic_compound", "(OR protein_domain_or_region protein_domain_or_region)", "protein_molecule", "DNA_family_or_group", "DNA_domain_or_region", "virus", "protein_family_or_group", "protein_domain_or_region", "cell_line", "", "cell_type" ]

Jun oncogene family members is a DNA_family_or_group, glucocorticoid receptor - dependent transcription is an other_name

83922_task1

Sentence: Cell-specific bifunctional role of Jun oncogene family members on glucocorticoid receptor-dependent transcription. Instructions: please typing these entity words according to sentence: Jun oncogene family members, glucocorticoid receptor - dependent transcription Options: DNA_family_or_group, other_name

[ "O", "O", "O", "O", "O", "O", "B-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O" ]

Cell-specific bifunctional role of Jun oncogene family members on glucocorticoid receptor-dependent transcription.

[ "Cell", "-", "specific", "bifunctional", "role", "of", "Jun", "oncogene", "family", "members", "on", "glucocorticoid", "receptor", "-", "dependent", "transcription", "." ]

[ "other_name", "DNA_molecule", "(OR DNA_molecule DNA_molecule DNA_molecule)", "other_organic_compound", "(OR protein_domain_or_region protein_domain_or_region)", "protein_molecule", "DNA_family_or_group", "DNA_domain_or_region", "virus", "protein_family_or_group", "protein_domain_or_region", "cell_line", "", "cell_type" ]

Jun oncogene family members, glucocorticoid receptor - dependent transcription

83922_task2

Sentence: Cell-specific bifunctional role of Jun oncogene family members on glucocorticoid receptor-dependent transcription. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O" ]

Cell-specific bifunctional role of Jun oncogene family members on glucocorticoid receptor-dependent transcription.

[ "Cell", "-", "specific", "bifunctional", "role", "of", "Jun", "oncogene", "family", "members", "on", "glucocorticoid", "receptor", "-", "dependent", "transcription", "." ]

[ "other_name", "DNA_molecule", "(OR DNA_molecule DNA_molecule DNA_molecule)", "other_organic_compound", "(OR protein_domain_or_region protein_domain_or_region)", "protein_molecule", "DNA_family_or_group", "DNA_domain_or_region", "virus", "protein_family_or_group", "protein_domain_or_region", "cell_line", "", "cell_type" ]

aldo - keto reductases is a GENE-N, NF - E2-related factor 2 is a GENE-Y, NRF2 is a GENE-Y, Nrf2 is a GENE-Y, human NRF2 promoter is a GENE-N, NRF2 is a GENE-Y, NRF2 is a GENE-Y, NRF2 is a GENE-Y, NRF2 is a GENE-Y, NRF2 is a GENE-Y, NRF2 is a GENE-Y, sulforaphane is a CHEMICAL, tert - butylhydroquinone is a CHEMICAL, cinnamic aldehyde is a CHEMICAL, hydrogen peroxide is a CHEMICAL, aldo - keto reductase ( AKR ) 1C1 is a GENE-Y, AKRs is a GENE-N, KEAP1 is a GENE-Y, NRF2 is a GENE-Y, AKR1A1 , 1B1 , 1B10 , 1C1 , 1C2 , and 1C3 is a GENE-N, NRF2 is a GENE-Y, AKRs is a GENE-N, NRF2 is a GENE-Y, sulforaphane is a CHEMICAL, AKR1B1 , 1B10 , 1C1 , 1C2 , and 1C3 is a GENE-N, sulforaphane is a CHEMICAL, AKR1C1 is a GENE-Y, AKR1C1 is a GENE-Y, NRF2 is a GENE-Y, AKRs is a GENE-N, NRF2 is a GENE-Y

8099_task0

Sentence: Identification of aldo-keto reductases as NRF2-target marker genes in human cells. Transcription factor NF-E2-related factor 2 (NRF2) plays a crucial role in the cellular defense against oxidative/electrophilic stress by up-regulating multiple antioxidant genes. Numerous studies with genetically modified animals have demonstrated that Nrf2 is a sensitivity determining factor upon the exposure to environmental chemicals including carcinogens. Moreover, recent studies have demonstrated that polymorphism in the human NRF2 promoter is associated with higher risks for developing acute lung injury, gastric mucosal inflammation, and nephritis. Therefore, the identification of reliable and effective human target genes of NRF2 may allow the monitoring of NRF2 activity and to predict individual sensitivity to environmental stress-induced damage. For this purpose, we investigated genes that are tightly controlled by NRF2 to establish markers for NRF2 activity in human cells. Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments. Accordantly, the basal and inducible expressions of AKRs were significantly attenuated in NRF2-silenced HK-2 cells. Whereas, cells with stable KEAP1 knockdown, which causes a modest NRF2 activation, demonstrated substantially increased levels of AKR1A1, 1B1, 1B10, 1C1, 1C2, and 1C3. Secondly, the linkage between NRF2 and the AKRs was confirmed in human monocytic leukemia cell line U937, which can be a model of peripherally available blood cells. The treatment of U937 cells with NRF2 inducers including sulforaphane effectively elevated the expression of AKR1B1, 1B10, 1C1, 1C2, and 1C3. Whereas, the levels of both the basal and sulforaphane-inducible expression of AKR1C1 were significantly reduced in NRF2-silenced stable U937 cells compared to the control cells. Similarly, the inducible expression of AKR1C1 was observed in another human monocytic leukemia cell line THP-1 as well as in human primary blood CD14(+) monocytes. In conclusion, together with the high inducibility and NRF2 dependency shown in renal epithelial cells as well as in peripherally available blood cells, current findings suggest that AKRs can be utilized as a marker of NRF2 activity in human cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N, CHEMICAL

[ "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O" ]

Identification of aldo-keto reductases as NRF2-target marker genes in human cells. Transcription factor NF-E2-related factor 2 (NRF2) plays a crucial role in the cellular defense against oxidative/electrophilic stress by up-regulating multiple antioxidant genes. Numerous studies with genetically modified animals have demonstrated that Nrf2 is a sensitivity determining factor upon the exposure to environmental chemicals including carcinogens. Moreover, recent studies have demonstrated that polymorphism in the human NRF2 promoter is associated with higher risks for developing acute lung injury, gastric mucosal inflammation, and nephritis. Therefore, the identification of reliable and effective human target genes of NRF2 may allow the monitoring of NRF2 activity and to predict individual sensitivity to environmental stress-induced damage. For this purpose, we investigated genes that are tightly controlled by NRF2 to establish markers for NRF2 activity in human cells. Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments. Accordantly, the basal and inducible expressions of AKRs were significantly attenuated in NRF2-silenced HK-2 cells. Whereas, cells with stable KEAP1 knockdown, which causes a modest NRF2 activation, demonstrated substantially increased levels of AKR1A1, 1B1, 1B10, 1C1, 1C2, and 1C3. Secondly, the linkage between NRF2 and the AKRs was confirmed in human monocytic leukemia cell line U937, which can be a model of peripherally available blood cells. The treatment of U937 cells with NRF2 inducers including sulforaphane effectively elevated the expression of AKR1B1, 1B10, 1C1, 1C2, and 1C3. Whereas, the levels of both the basal and sulforaphane-inducible expression of AKR1C1 were significantly reduced in NRF2-silenced stable U937 cells compared to the control cells. Similarly, the inducible expression of AKR1C1 was observed in another human monocytic leukemia cell line THP-1 as well as in human primary blood CD14(+) monocytes. In conclusion, together with the high inducibility and NRF2 dependency shown in renal epithelial cells as well as in peripherally available blood cells, current findings suggest that AKRs can be utilized as a marker of NRF2 activity in human cells.

[ "Identification", "of", "aldo", "-", "keto", "reductases", "as", "NRF2-target", "marker", "genes", "in", "human", "cells", ".", "\n", "Transcription", "factor", "NF", "-", "E2-related", "factor", "2", "(", "NRF2", ")", "plays", "a", "crucial", "role", "in", "the", "cellular", "defense", "against", "oxidative", "/", "electrophilic", "stress", "by", "up", "-", "regulating", "multiple", "antioxidant", "genes", ".", "Numerous", "studies", "with", "genetically", "modified", "animals", "have", "demonstrated", "that", "Nrf2", "is", "a", "sensitivity", "determining", "factor", "upon", "the", "exposure", "to", "environmental", "chemicals", "including", "carcinogens", ".", "Moreover", ",", "recent", "studies", "have", "demonstrated", "that", "polymorphism", "in", "the", "human", "NRF2", "promoter", "is", "associated", "with", "higher", "risks", "for", "developing", "acute", "lung", "injury", ",", "gastric", "mucosal", "inflammation", ",", "and", "nephritis", ".", "Therefore", ",", "the", "identification", "of", "reliable", "and", "effective", "human", "target", "genes", "of", "NRF2", "may", "allow", "the", "monitoring", "of", "NRF2", "activity", "and", "to", "predict", "individual", "sensitivity", "to", "environmental", "stress", "-", "induced", "damage", ".", "For", "this", "purpose", ",", "we", "investigated", "genes", "that", "are", "tightly", "controlled", "by", "NRF2", "to", "establish", "markers", "for", "NRF2", "activity", "in", "human", "cells", ".", "Firstly", ",", "in", "the", "normal", "human", "renal", "epithelial", "HK-2", "cells", ",", "the", "measurement", "of", "the", "expression", "of", "30", "previously", "reported", "NRF2", "target", "genes", "in", "response", "to", "NRF2", "inducers", "(", "sulforaphane", ",", "tert", "-", "butylhydroquinone", ",", "cinnamic", "aldehyde", ",", "and", "hydrogen", "peroxide", ")", "showed", "that", "the", "aldo", "-", "keto", "reductase", "(", "AKR", ")", "1C1", "is", "highly", "inducible", "by", "all", "treatments", ".", "Accordantly", ",", "the", "basal", "and", "inducible", "expressions", "of", "AKRs", "were", "significantly", "attenuated", "in", "NRF2-silenced", "HK-2", "cells", ".", "Whereas", ",", "cells", "with", "stable", "KEAP1", "knockdown", ",", "which", "causes", "a", "modest", "NRF2", "activation", ",", "demonstrated", "substantially", "increased", "levels", "of", "AKR1A1", ",", "1B1", ",", "1B10", ",", "1C1", ",", "1C2", ",", "and", "1C3", ".", "Secondly", ",", "the", "linkage", "between", "NRF2", "and", "the", "AKRs", "was", "confirmed", "in", "human", "monocytic", "leukemia", "cell", "line", "U937", ",", "which", "can", "be", "a", "model", "of", "peripherally", "available", "blood", "cells", ".", "The", "treatment", "of", "U937", "cells", "with", "NRF2", "inducers", "including", "sulforaphane", "effectively", "elevated", "the", "expression", "of", "AKR1B1", ",", "1B10", ",", "1C1", ",", "1C2", ",", "and", "1C3", ".", "Whereas", ",", "the", "levels", "of", "both", "the", "basal", "and", "sulforaphane", "-", "inducible", "expression", "of", "AKR1C1", "were", "significantly", "reduced", "in", "NRF2-silenced", "stable", "U937", "cells", "compared", "to", "the", "control", "cells", ".", "Similarly", ",", "the", "inducible", "expression", "of", "AKR1C1", "was", "observed", "in", "another", "human", "monocytic", "leukemia", "cell", "line", "THP-1", "as", "well", "as", "in", "human", "primary", "blood", "CD14(+", ")", "monocytes", ".", "In", "conclusion", ",", "together", "with", "the", "high", "inducibility", "and", "NRF2", "dependency", "shown", "in", "renal", "epithelial", "cells", "as", "well", "as", "in", "peripherally", "available", "blood", "cells", ",", "current", "findings", "suggest", "that", "AKRs", "can", "be", "utilized", "as", "a", "marker", "of", "NRF2", "activity", "in", "human", "cells", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

aldo - keto reductases is a GENE-N, NF - E2-related factor 2 is a GENE-Y, NRF2 is a GENE-Y, Nrf2 is a GENE-Y, human NRF2 promoter is a GENE-N, NRF2 is a GENE-Y, NRF2 is a GENE-Y, NRF2 is a GENE-Y, NRF2 is a GENE-Y, NRF2 is a GENE-Y, NRF2 is a GENE-Y, sulforaphane is a CHEMICAL, tert - butylhydroquinone is a CHEMICAL, cinnamic aldehyde is a CHEMICAL, hydrogen peroxide is a CHEMICAL, aldo - keto reductase ( AKR ) 1C1 is a GENE-Y, AKRs is a GENE-N, KEAP1 is a GENE-Y, NRF2 is a GENE-Y, AKR1A1 , 1B1 , 1B10 , 1C1 , 1C2 , and 1C3 is a GENE-N, NRF2 is a GENE-Y, AKRs is a GENE-N, NRF2 is a GENE-Y, sulforaphane is a CHEMICAL, AKR1B1 , 1B10 , 1C1 , 1C2 , and 1C3 is a GENE-N, sulforaphane is a CHEMICAL, AKR1C1 is a GENE-Y, AKR1C1 is a GENE-Y, NRF2 is a GENE-Y, AKRs is a GENE-N, NRF2 is a GENE-Y

8099_task1

Sentence: Identification of aldo-keto reductases as NRF2-target marker genes in human cells. Transcription factor NF-E2-related factor 2 (NRF2) plays a crucial role in the cellular defense against oxidative/electrophilic stress by up-regulating multiple antioxidant genes. Numerous studies with genetically modified animals have demonstrated that Nrf2 is a sensitivity determining factor upon the exposure to environmental chemicals including carcinogens. Moreover, recent studies have demonstrated that polymorphism in the human NRF2 promoter is associated with higher risks for developing acute lung injury, gastric mucosal inflammation, and nephritis. Therefore, the identification of reliable and effective human target genes of NRF2 may allow the monitoring of NRF2 activity and to predict individual sensitivity to environmental stress-induced damage. For this purpose, we investigated genes that are tightly controlled by NRF2 to establish markers for NRF2 activity in human cells. Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments. Accordantly, the basal and inducible expressions of AKRs were significantly attenuated in NRF2-silenced HK-2 cells. Whereas, cells with stable KEAP1 knockdown, which causes a modest NRF2 activation, demonstrated substantially increased levels of AKR1A1, 1B1, 1B10, 1C1, 1C2, and 1C3. Secondly, the linkage between NRF2 and the AKRs was confirmed in human monocytic leukemia cell line U937, which can be a model of peripherally available blood cells. The treatment of U937 cells with NRF2 inducers including sulforaphane effectively elevated the expression of AKR1B1, 1B10, 1C1, 1C2, and 1C3. Whereas, the levels of both the basal and sulforaphane-inducible expression of AKR1C1 were significantly reduced in NRF2-silenced stable U937 cells compared to the control cells. Similarly, the inducible expression of AKR1C1 was observed in another human monocytic leukemia cell line THP-1 as well as in human primary blood CD14(+) monocytes. In conclusion, together with the high inducibility and NRF2 dependency shown in renal epithelial cells as well as in peripherally available blood cells, current findings suggest that AKRs can be utilized as a marker of NRF2 activity in human cells. Instructions: please typing these entity words according to sentence: aldo - keto reductases, NF - E2-related factor 2, NRF2, Nrf2, human NRF2 promoter, NRF2, NRF2, NRF2, NRF2, NRF2, NRF2, sulforaphane, tert - butylhydroquinone, cinnamic aldehyde, hydrogen peroxide, aldo - keto reductase ( AKR ) 1C1, AKRs, KEAP1, NRF2, AKR1A1 , 1B1 , 1B10 , 1C1 , 1C2 , and 1C3, NRF2, AKRs, NRF2, sulforaphane, AKR1B1 , 1B10 , 1C1 , 1C2 , and 1C3, sulforaphane, AKR1C1, AKR1C1, NRF2, AKRs, NRF2 Options: GENE-Y, GENE-N, CHEMICAL

[ "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O" ]

Identification of aldo-keto reductases as NRF2-target marker genes in human cells. Transcription factor NF-E2-related factor 2 (NRF2) plays a crucial role in the cellular defense against oxidative/electrophilic stress by up-regulating multiple antioxidant genes. Numerous studies with genetically modified animals have demonstrated that Nrf2 is a sensitivity determining factor upon the exposure to environmental chemicals including carcinogens. Moreover, recent studies have demonstrated that polymorphism in the human NRF2 promoter is associated with higher risks for developing acute lung injury, gastric mucosal inflammation, and nephritis. Therefore, the identification of reliable and effective human target genes of NRF2 may allow the monitoring of NRF2 activity and to predict individual sensitivity to environmental stress-induced damage. For this purpose, we investigated genes that are tightly controlled by NRF2 to establish markers for NRF2 activity in human cells. Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments. Accordantly, the basal and inducible expressions of AKRs were significantly attenuated in NRF2-silenced HK-2 cells. Whereas, cells with stable KEAP1 knockdown, which causes a modest NRF2 activation, demonstrated substantially increased levels of AKR1A1, 1B1, 1B10, 1C1, 1C2, and 1C3. Secondly, the linkage between NRF2 and the AKRs was confirmed in human monocytic leukemia cell line U937, which can be a model of peripherally available blood cells. The treatment of U937 cells with NRF2 inducers including sulforaphane effectively elevated the expression of AKR1B1, 1B10, 1C1, 1C2, and 1C3. Whereas, the levels of both the basal and sulforaphane-inducible expression of AKR1C1 were significantly reduced in NRF2-silenced stable U937 cells compared to the control cells. Similarly, the inducible expression of AKR1C1 was observed in another human monocytic leukemia cell line THP-1 as well as in human primary blood CD14(+) monocytes. In conclusion, together with the high inducibility and NRF2 dependency shown in renal epithelial cells as well as in peripherally available blood cells, current findings suggest that AKRs can be utilized as a marker of NRF2 activity in human cells.

[ "Identification", "of", "aldo", "-", "keto", "reductases", "as", "NRF2-target", "marker", "genes", "in", "human", "cells", ".", "\n", "Transcription", "factor", "NF", "-", "E2-related", "factor", "2", "(", "NRF2", ")", "plays", "a", "crucial", "role", "in", "the", "cellular", "defense", "against", "oxidative", "/", "electrophilic", "stress", "by", "up", "-", "regulating", "multiple", "antioxidant", "genes", ".", "Numerous", "studies", "with", "genetically", "modified", "animals", "have", "demonstrated", "that", "Nrf2", "is", "a", "sensitivity", "determining", "factor", "upon", "the", "exposure", "to", "environmental", "chemicals", "including", "carcinogens", ".", "Moreover", ",", "recent", "studies", "have", "demonstrated", "that", "polymorphism", "in", "the", "human", "NRF2", "promoter", "is", "associated", "with", "higher", "risks", "for", "developing", "acute", "lung", "injury", ",", "gastric", "mucosal", "inflammation", ",", "and", "nephritis", ".", "Therefore", ",", "the", "identification", "of", "reliable", "and", "effective", "human", "target", "genes", "of", "NRF2", "may", "allow", "the", "monitoring", "of", "NRF2", "activity", "and", "to", "predict", "individual", "sensitivity", "to", "environmental", "stress", "-", "induced", "damage", ".", "For", "this", "purpose", ",", "we", "investigated", "genes", "that", "are", "tightly", "controlled", "by", "NRF2", "to", "establish", "markers", "for", "NRF2", "activity", "in", "human", "cells", ".", "Firstly", ",", "in", "the", "normal", "human", "renal", "epithelial", "HK-2", "cells", ",", "the", "measurement", "of", "the", "expression", "of", "30", "previously", "reported", "NRF2", "target", "genes", "in", "response", "to", "NRF2", "inducers", "(", "sulforaphane", ",", "tert", "-", "butylhydroquinone", ",", "cinnamic", "aldehyde", ",", "and", "hydrogen", "peroxide", ")", "showed", "that", "the", "aldo", "-", "keto", "reductase", "(", "AKR", ")", "1C1", "is", "highly", "inducible", "by", "all", "treatments", ".", "Accordantly", ",", "the", "basal", "and", "inducible", "expressions", "of", "AKRs", "were", "significantly", "attenuated", "in", "NRF2-silenced", "HK-2", "cells", ".", "Whereas", ",", "cells", "with", "stable", "KEAP1", "knockdown", ",", "which", "causes", "a", "modest", "NRF2", "activation", ",", "demonstrated", "substantially", "increased", "levels", "of", "AKR1A1", ",", "1B1", ",", "1B10", ",", "1C1", ",", "1C2", ",", "and", "1C3", ".", "Secondly", ",", "the", "linkage", "between", "NRF2", "and", "the", "AKRs", "was", "confirmed", "in", "human", "monocytic", "leukemia", "cell", "line", "U937", ",", "which", "can", "be", "a", "model", "of", "peripherally", "available", "blood", "cells", ".", "The", "treatment", "of", "U937", "cells", "with", "NRF2", "inducers", "including", "sulforaphane", "effectively", "elevated", "the", "expression", "of", "AKR1B1", ",", "1B10", ",", "1C1", ",", "1C2", ",", "and", "1C3", ".", "Whereas", ",", "the", "levels", "of", "both", "the", "basal", "and", "sulforaphane", "-", "inducible", "expression", "of", "AKR1C1", "were", "significantly", "reduced", "in", "NRF2-silenced", "stable", "U937", "cells", "compared", "to", "the", "control", "cells", ".", "Similarly", ",", "the", "inducible", "expression", "of", "AKR1C1", "was", "observed", "in", "another", "human", "monocytic", "leukemia", "cell", "line", "THP-1", "as", "well", "as", "in", "human", "primary", "blood", "CD14(+", ")", "monocytes", ".", "In", "conclusion", ",", "together", "with", "the", "high", "inducibility", "and", "NRF2", "dependency", "shown", "in", "renal", "epithelial", "cells", "as", "well", "as", "in", "peripherally", "available", "blood", "cells", ",", "current", "findings", "suggest", "that", "AKRs", "can", "be", "utilized", "as", "a", "marker", "of", "NRF2", "activity", "in", "human", "cells", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

aldo - keto reductases, NF - E2-related factor 2, NRF2, Nrf2, human NRF2 promoter, NRF2, NRF2, NRF2, NRF2, NRF2, NRF2, sulforaphane, tert - butylhydroquinone, cinnamic aldehyde, hydrogen peroxide, aldo - keto reductase ( AKR ) 1C1, AKRs, KEAP1, NRF2, AKR1A1 , 1B1 , 1B10 , 1C1 , 1C2 , and 1C3, NRF2, AKRs, NRF2, sulforaphane, AKR1B1 , 1B10 , 1C1 , 1C2 , and 1C3, sulforaphane, AKR1C1, AKR1C1, NRF2, AKRs, NRF2

8099_task2

Sentence: Identification of aldo-keto reductases as NRF2-target marker genes in human cells. Transcription factor NF-E2-related factor 2 (NRF2) plays a crucial role in the cellular defense against oxidative/electrophilic stress by up-regulating multiple antioxidant genes. Numerous studies with genetically modified animals have demonstrated that Nrf2 is a sensitivity determining factor upon the exposure to environmental chemicals including carcinogens. Moreover, recent studies have demonstrated that polymorphism in the human NRF2 promoter is associated with higher risks for developing acute lung injury, gastric mucosal inflammation, and nephritis. Therefore, the identification of reliable and effective human target genes of NRF2 may allow the monitoring of NRF2 activity and to predict individual sensitivity to environmental stress-induced damage. For this purpose, we investigated genes that are tightly controlled by NRF2 to establish markers for NRF2 activity in human cells. Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments. Accordantly, the basal and inducible expressions of AKRs were significantly attenuated in NRF2-silenced HK-2 cells. Whereas, cells with stable KEAP1 knockdown, which causes a modest NRF2 activation, demonstrated substantially increased levels of AKR1A1, 1B1, 1B10, 1C1, 1C2, and 1C3. Secondly, the linkage between NRF2 and the AKRs was confirmed in human monocytic leukemia cell line U937, which can be a model of peripherally available blood cells. The treatment of U937 cells with NRF2 inducers including sulforaphane effectively elevated the expression of AKR1B1, 1B10, 1C1, 1C2, and 1C3. Whereas, the levels of both the basal and sulforaphane-inducible expression of AKR1C1 were significantly reduced in NRF2-silenced stable U937 cells compared to the control cells. Similarly, the inducible expression of AKR1C1 was observed in another human monocytic leukemia cell line THP-1 as well as in human primary blood CD14(+) monocytes. In conclusion, together with the high inducibility and NRF2 dependency shown in renal epithelial cells as well as in peripherally available blood cells, current findings suggest that AKRs can be utilized as a marker of NRF2 activity in human cells. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O" ]

Identification of aldo-keto reductases as NRF2-target marker genes in human cells. Transcription factor NF-E2-related factor 2 (NRF2) plays a crucial role in the cellular defense against oxidative/electrophilic stress by up-regulating multiple antioxidant genes. Numerous studies with genetically modified animals have demonstrated that Nrf2 is a sensitivity determining factor upon the exposure to environmental chemicals including carcinogens. Moreover, recent studies have demonstrated that polymorphism in the human NRF2 promoter is associated with higher risks for developing acute lung injury, gastric mucosal inflammation, and nephritis. Therefore, the identification of reliable and effective human target genes of NRF2 may allow the monitoring of NRF2 activity and to predict individual sensitivity to environmental stress-induced damage. For this purpose, we investigated genes that are tightly controlled by NRF2 to establish markers for NRF2 activity in human cells. Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments. Accordantly, the basal and inducible expressions of AKRs were significantly attenuated in NRF2-silenced HK-2 cells. Whereas, cells with stable KEAP1 knockdown, which causes a modest NRF2 activation, demonstrated substantially increased levels of AKR1A1, 1B1, 1B10, 1C1, 1C2, and 1C3. Secondly, the linkage between NRF2 and the AKRs was confirmed in human monocytic leukemia cell line U937, which can be a model of peripherally available blood cells. The treatment of U937 cells with NRF2 inducers including sulforaphane effectively elevated the expression of AKR1B1, 1B10, 1C1, 1C2, and 1C3. Whereas, the levels of both the basal and sulforaphane-inducible expression of AKR1C1 were significantly reduced in NRF2-silenced stable U937 cells compared to the control cells. Similarly, the inducible expression of AKR1C1 was observed in another human monocytic leukemia cell line THP-1 as well as in human primary blood CD14(+) monocytes. In conclusion, together with the high inducibility and NRF2 dependency shown in renal epithelial cells as well as in peripherally available blood cells, current findings suggest that AKRs can be utilized as a marker of NRF2 activity in human cells.

[ "Identification", "of", "aldo", "-", "keto", "reductases", "as", "NRF2-target", "marker", "genes", "in", "human", "cells", ".", "\n", "Transcription", "factor", "NF", "-", "E2-related", "factor", "2", "(", "NRF2", ")", "plays", "a", "crucial", "role", "in", "the", "cellular", "defense", "against", "oxidative", "/", "electrophilic", "stress", "by", "up", "-", "regulating", "multiple", "antioxidant", "genes", ".", "Numerous", "studies", "with", "genetically", "modified", "animals", "have", "demonstrated", "that", "Nrf2", "is", "a", "sensitivity", "determining", "factor", "upon", "the", "exposure", "to", "environmental", "chemicals", "including", "carcinogens", ".", "Moreover", ",", "recent", "studies", "have", "demonstrated", "that", "polymorphism", "in", "the", "human", "NRF2", "promoter", "is", "associated", "with", "higher", "risks", "for", "developing", "acute", "lung", "injury", ",", "gastric", "mucosal", "inflammation", ",", "and", "nephritis", ".", "Therefore", ",", "the", "identification", "of", "reliable", "and", "effective", "human", "target", "genes", "of", "NRF2", "may", "allow", "the", "monitoring", "of", "NRF2", "activity", "and", "to", "predict", "individual", "sensitivity", "to", "environmental", "stress", "-", "induced", "damage", ".", "For", "this", "purpose", ",", "we", "investigated", "genes", "that", "are", "tightly", "controlled", "by", "NRF2", "to", "establish", "markers", "for", "NRF2", "activity", "in", "human", "cells", ".", "Firstly", ",", "in", "the", "normal", "human", "renal", "epithelial", "HK-2", "cells", ",", "the", "measurement", "of", "the", "expression", "of", "30", "previously", "reported", "NRF2", "target", "genes", "in", "response", "to", "NRF2", "inducers", "(", "sulforaphane", ",", "tert", "-", "butylhydroquinone", ",", "cinnamic", "aldehyde", ",", "and", "hydrogen", "peroxide", ")", "showed", "that", "the", "aldo", "-", "keto", "reductase", "(", "AKR", ")", "1C1", "is", "highly", "inducible", "by", "all", "treatments", ".", "Accordantly", ",", "the", "basal", "and", "inducible", "expressions", "of", "AKRs", "were", "significantly", "attenuated", "in", "NRF2-silenced", "HK-2", "cells", ".", "Whereas", ",", "cells", "with", "stable", "KEAP1", "knockdown", ",", "which", "causes", "a", "modest", "NRF2", "activation", ",", "demonstrated", "substantially", "increased", "levels", "of", "AKR1A1", ",", "1B1", ",", "1B10", ",", "1C1", ",", "1C2", ",", "and", "1C3", ".", "Secondly", ",", "the", "linkage", "between", "NRF2", "and", "the", "AKRs", "was", "confirmed", "in", "human", "monocytic", "leukemia", "cell", "line", "U937", ",", "which", "can", "be", "a", "model", "of", "peripherally", "available", "blood", "cells", ".", "The", "treatment", "of", "U937", "cells", "with", "NRF2", "inducers", "including", "sulforaphane", "effectively", "elevated", "the", "expression", "of", "AKR1B1", ",", "1B10", ",", "1C1", ",", "1C2", ",", "and", "1C3", ".", "Whereas", ",", "the", "levels", "of", "both", "the", "basal", "and", "sulforaphane", "-", "inducible", "expression", "of", "AKR1C1", "were", "significantly", "reduced", "in", "NRF2-silenced", "stable", "U937", "cells", "compared", "to", "the", "control", "cells", ".", "Similarly", ",", "the", "inducible", "expression", "of", "AKR1C1", "was", "observed", "in", "another", "human", "monocytic", "leukemia", "cell", "line", "THP-1", "as", "well", "as", "in", "human", "primary", "blood", "CD14(+", ")", "monocytes", ".", "In", "conclusion", ",", "together", "with", "the", "high", "inducibility", "and", "NRF2", "dependency", "shown", "in", "renal", "epithelial", "cells", "as", "well", "as", "in", "peripherally", "available", "blood", "cells", ",", "current", "findings", "suggest", "that", "AKRs", "can", "be", "utilized", "as", "a", "marker", "of", "NRF2", "activity", "in", "human", "cells", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

proliferating cell nuclear antigen is a Protein, HLTF is a Protein, SHPRH is a Protein, proliferating cell nuclear antigen is a Protein, PCNA is a Protein, SHPRH is a Protein, Rad5 is a Protein, HLTF is a Protein, RAD5 is a Protein, HLTF is a Protein, SHPRH is a Protein, Rad5 is a Protein, PCNA is a Protein, Rad5 is a Protein, HLTF is a Protein, UBC13 is a Protein, PCNA is a Protein, SHPRH is a Protein, SHPRH is a Protein, HLTF is a Protein, Hltf is a Protein, HLTF is a Protein, SHPRH is a Protein, Rad5 is a Protein, PCNA is a Protein

333_task0

Sentence: Polyubiquitination of proliferating cell nuclear antigen by HLTF and SHPRH prevents genomic instability from stalled replication forks. Chronic stalling of DNA replication forks caused by DNA damage can lead to genomic instability. Cells have evolved lesion bypass pathways such as postreplication repair (PRR) to resolve these arrested forks. In yeast, one branch of PRR involves proliferating cell nuclear antigen (PCNA) polyubiquitination mediated by the Rad5-Ubc13-Mms2 complex that allows bypass of DNA lesion by a template-switching mechanism. Previously, we identified human SHPRH as a functional homologue of yeast Rad5 and revealed the existence of RAD5-like pathway in human cells. Here we report the identification of HLTF as a second RAD5 homologue in human cells. HLTF, like SHPRH, shares a unique domain architecture with Rad5 and promotes lysine 63-linked polyubiquitination of PCNA. Similar to yeast Rad5, HLTF is able to interact with UBC13 and PCNA, as well as SHPRH; and the reduction of either SHPRH or HLTF expression enhances spontaneous mutagenesis. Moreover, Hltf-deficient mouse embryonic fibroblasts show elevated chromosome breaks and fusions after methyl methane sulfonate treatment. Our results suggest that HLTF and SHPRH are functional homologues of yeast Rad5 that cooperatively mediate PCNA polyubiquitination and maintain genomic stability. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O" ]

Polyubiquitination of proliferating cell nuclear antigen by HLTF and SHPRH prevents genomic instability from stalled replication forks. Chronic stalling of DNA replication forks caused by DNA damage can lead to genomic instability. Cells have evolved lesion bypass pathways such as postreplication repair (PRR) to resolve these arrested forks. In yeast, one branch of PRR involves proliferating cell nuclear antigen (PCNA) polyubiquitination mediated by the Rad5-Ubc13-Mms2 complex that allows bypass of DNA lesion by a template-switching mechanism. Previously, we identified human SHPRH as a functional homologue of yeast Rad5 and revealed the existence of RAD5-like pathway in human cells. Here we report the identification of HLTF as a second RAD5 homologue in human cells. HLTF, like SHPRH, shares a unique domain architecture with Rad5 and promotes lysine 63-linked polyubiquitination of PCNA. Similar to yeast Rad5, HLTF is able to interact with UBC13 and PCNA, as well as SHPRH; and the reduction of either SHPRH or HLTF expression enhances spontaneous mutagenesis. Moreover, Hltf-deficient mouse embryonic fibroblasts show elevated chromosome breaks and fusions after methyl methane sulfonate treatment. Our results suggest that HLTF and SHPRH are functional homologues of yeast Rad5 that cooperatively mediate PCNA polyubiquitination and maintain genomic stability.

[ "Polyubiquitination", "of", "proliferating", "cell", "nuclear", "antigen", "by", "HLTF", "and", "SHPRH", "prevents", "genomic", "instability", "from", "stalled", "replication", "forks", ".", "\n", "Chronic", "stalling", "of", "DNA", "replication", "forks", "caused", "by", "DNA", "damage", "can", "lead", "to", "genomic", "instability", ".", "Cells", "have", "evolved", "lesion", "bypass", "pathways", "such", "as", "postreplication", "repair", "(", "PRR", ")", "to", "resolve", "these", "arrested", "forks", ".", "In", "yeast", ",", "one", "branch", "of", "PRR", "involves", "proliferating", "cell", "nuclear", "antigen", "(", "PCNA", ")", "polyubiquitination", "mediated", "by", "the", "Rad5-Ubc13-Mms2", "complex", "that", "allows", "bypass", "of", "DNA", "lesion", "by", "a", "template", "-", "switching", "mechanism", ".", "Previously", ",", "we", "identified", "human", "SHPRH", "as", "a", "functional", "homologue", "of", "yeast", "Rad5", "and", "revealed", "the", "existence", "of", "RAD5-like", "pathway", "in", "human", "cells", ".", "Here", "we", "report", "the", "identification", "of", "HLTF", "as", "a", "second", "RAD5", "homologue", "in", "human", "cells", ".", "HLTF", ",", "like", "SHPRH", ",", "shares", "a", "unique", "domain", "architecture", "with", "Rad5", "and", "promotes", "lysine", "63-linked", "polyubiquitination", "of", "PCNA", ".", "Similar", "to", "yeast", "Rad5", ",", "HLTF", "is", "able", "to", "interact", "with", "UBC13", "and", "PCNA", ",", "as", "well", "as", "SHPRH", ";", "and", "the", "reduction", "of", "either", "SHPRH", "or", "HLTF", "expression", "enhances", "spontaneous", "mutagenesis", ".", "Moreover", ",", "Hltf", "-", "deficient", "mouse", "embryonic", "fibroblasts", "show", "elevated", "chromosome", "breaks", "and", "fusions", "after", "methyl", "methane", "sulfonate", "treatment", ".", "Our", "results", "suggest", "that", "HLTF", "and", "SHPRH", "are", "functional", "homologues", "of", "yeast", "Rad5", "that", "cooperatively", "mediate", "PCNA", "polyubiquitination", "and", "maintain", "genomic", "stability", ".", "\n" ]

[ "Protein" ]

proliferating cell nuclear antigen is a Protein, HLTF is a Protein, SHPRH is a Protein, proliferating cell nuclear antigen is a Protein, PCNA is a Protein, SHPRH is a Protein, Rad5 is a Protein, HLTF is a Protein, RAD5 is a Protein, HLTF is a Protein, SHPRH is a Protein, Rad5 is a Protein, PCNA is a Protein, Rad5 is a Protein, HLTF is a Protein, UBC13 is a Protein, PCNA is a Protein, SHPRH is a Protein, SHPRH is a Protein, HLTF is a Protein, Hltf is a Protein, HLTF is a Protein, SHPRH is a Protein, Rad5 is a Protein, PCNA is a Protein

333_task1

Sentence: Polyubiquitination of proliferating cell nuclear antigen by HLTF and SHPRH prevents genomic instability from stalled replication forks. Chronic stalling of DNA replication forks caused by DNA damage can lead to genomic instability. Cells have evolved lesion bypass pathways such as postreplication repair (PRR) to resolve these arrested forks. In yeast, one branch of PRR involves proliferating cell nuclear antigen (PCNA) polyubiquitination mediated by the Rad5-Ubc13-Mms2 complex that allows bypass of DNA lesion by a template-switching mechanism. Previously, we identified human SHPRH as a functional homologue of yeast Rad5 and revealed the existence of RAD5-like pathway in human cells. Here we report the identification of HLTF as a second RAD5 homologue in human cells. HLTF, like SHPRH, shares a unique domain architecture with Rad5 and promotes lysine 63-linked polyubiquitination of PCNA. Similar to yeast Rad5, HLTF is able to interact with UBC13 and PCNA, as well as SHPRH; and the reduction of either SHPRH or HLTF expression enhances spontaneous mutagenesis. Moreover, Hltf-deficient mouse embryonic fibroblasts show elevated chromosome breaks and fusions after methyl methane sulfonate treatment. Our results suggest that HLTF and SHPRH are functional homologues of yeast Rad5 that cooperatively mediate PCNA polyubiquitination and maintain genomic stability. Instructions: please typing these entity words according to sentence: proliferating cell nuclear antigen, HLTF, SHPRH, proliferating cell nuclear antigen, PCNA, SHPRH, Rad5, HLTF, RAD5, HLTF, SHPRH, Rad5, PCNA, Rad5, HLTF, UBC13, PCNA, SHPRH, SHPRH, HLTF, Hltf, HLTF, SHPRH, Rad5, PCNA Options: Protein

[ "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O" ]

Polyubiquitination of proliferating cell nuclear antigen by HLTF and SHPRH prevents genomic instability from stalled replication forks. Chronic stalling of DNA replication forks caused by DNA damage can lead to genomic instability. Cells have evolved lesion bypass pathways such as postreplication repair (PRR) to resolve these arrested forks. In yeast, one branch of PRR involves proliferating cell nuclear antigen (PCNA) polyubiquitination mediated by the Rad5-Ubc13-Mms2 complex that allows bypass of DNA lesion by a template-switching mechanism. Previously, we identified human SHPRH as a functional homologue of yeast Rad5 and revealed the existence of RAD5-like pathway in human cells. Here we report the identification of HLTF as a second RAD5 homologue in human cells. HLTF, like SHPRH, shares a unique domain architecture with Rad5 and promotes lysine 63-linked polyubiquitination of PCNA. Similar to yeast Rad5, HLTF is able to interact with UBC13 and PCNA, as well as SHPRH; and the reduction of either SHPRH or HLTF expression enhances spontaneous mutagenesis. Moreover, Hltf-deficient mouse embryonic fibroblasts show elevated chromosome breaks and fusions after methyl methane sulfonate treatment. Our results suggest that HLTF and SHPRH are functional homologues of yeast Rad5 that cooperatively mediate PCNA polyubiquitination and maintain genomic stability.

[ "Polyubiquitination", "of", "proliferating", "cell", "nuclear", "antigen", "by", "HLTF", "and", "SHPRH", "prevents", "genomic", "instability", "from", "stalled", "replication", "forks", ".", "\n", "Chronic", "stalling", "of", "DNA", "replication", "forks", "caused", "by", "DNA", "damage", "can", "lead", "to", "genomic", "instability", ".", "Cells", "have", "evolved", "lesion", "bypass", "pathways", "such", "as", "postreplication", "repair", "(", "PRR", ")", "to", "resolve", "these", "arrested", "forks", ".", "In", "yeast", ",", "one", "branch", "of", "PRR", "involves", "proliferating", "cell", "nuclear", "antigen", "(", "PCNA", ")", "polyubiquitination", "mediated", "by", "the", "Rad5-Ubc13-Mms2", "complex", "that", "allows", "bypass", "of", "DNA", "lesion", "by", "a", "template", "-", "switching", "mechanism", ".", "Previously", ",", "we", "identified", "human", "SHPRH", "as", "a", "functional", "homologue", "of", "yeast", "Rad5", "and", "revealed", "the", "existence", "of", "RAD5-like", "pathway", "in", "human", "cells", ".", "Here", "we", "report", "the", "identification", "of", "HLTF", "as", "a", "second", "RAD5", "homologue", "in", "human", "cells", ".", "HLTF", ",", "like", "SHPRH", ",", "shares", "a", "unique", "domain", "architecture", "with", "Rad5", "and", "promotes", "lysine", "63-linked", "polyubiquitination", "of", "PCNA", ".", "Similar", "to", "yeast", "Rad5", ",", "HLTF", "is", "able", "to", "interact", "with", "UBC13", "and", "PCNA", ",", "as", "well", "as", "SHPRH", ";", "and", "the", "reduction", "of", "either", "SHPRH", "or", "HLTF", "expression", "enhances", "spontaneous", "mutagenesis", ".", "Moreover", ",", "Hltf", "-", "deficient", "mouse", "embryonic", "fibroblasts", "show", "elevated", "chromosome", "breaks", "and", "fusions", "after", "methyl", "methane", "sulfonate", "treatment", ".", "Our", "results", "suggest", "that", "HLTF", "and", "SHPRH", "are", "functional", "homologues", "of", "yeast", "Rad5", "that", "cooperatively", "mediate", "PCNA", "polyubiquitination", "and", "maintain", "genomic", "stability", ".", "\n" ]

[ "Protein" ]

proliferating cell nuclear antigen, HLTF, SHPRH, proliferating cell nuclear antigen, PCNA, SHPRH, Rad5, HLTF, RAD5, HLTF, SHPRH, Rad5, PCNA, Rad5, HLTF, UBC13, PCNA, SHPRH, SHPRH, HLTF, Hltf, HLTF, SHPRH, Rad5, PCNA

333_task2

Sentence: Polyubiquitination of proliferating cell nuclear antigen by HLTF and SHPRH prevents genomic instability from stalled replication forks. Chronic stalling of DNA replication forks caused by DNA damage can lead to genomic instability. Cells have evolved lesion bypass pathways such as postreplication repair (PRR) to resolve these arrested forks. In yeast, one branch of PRR involves proliferating cell nuclear antigen (PCNA) polyubiquitination mediated by the Rad5-Ubc13-Mms2 complex that allows bypass of DNA lesion by a template-switching mechanism. Previously, we identified human SHPRH as a functional homologue of yeast Rad5 and revealed the existence of RAD5-like pathway in human cells. Here we report the identification of HLTF as a second RAD5 homologue in human cells. HLTF, like SHPRH, shares a unique domain architecture with Rad5 and promotes lysine 63-linked polyubiquitination of PCNA. Similar to yeast Rad5, HLTF is able to interact with UBC13 and PCNA, as well as SHPRH; and the reduction of either SHPRH or HLTF expression enhances spontaneous mutagenesis. Moreover, Hltf-deficient mouse embryonic fibroblasts show elevated chromosome breaks and fusions after methyl methane sulfonate treatment. Our results suggest that HLTF and SHPRH are functional homologues of yeast Rad5 that cooperatively mediate PCNA polyubiquitination and maintain genomic stability. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O" ]

Polyubiquitination of proliferating cell nuclear antigen by HLTF and SHPRH prevents genomic instability from stalled replication forks. Chronic stalling of DNA replication forks caused by DNA damage can lead to genomic instability. Cells have evolved lesion bypass pathways such as postreplication repair (PRR) to resolve these arrested forks. In yeast, one branch of PRR involves proliferating cell nuclear antigen (PCNA) polyubiquitination mediated by the Rad5-Ubc13-Mms2 complex that allows bypass of DNA lesion by a template-switching mechanism. Previously, we identified human SHPRH as a functional homologue of yeast Rad5 and revealed the existence of RAD5-like pathway in human cells. Here we report the identification of HLTF as a second RAD5 homologue in human cells. HLTF, like SHPRH, shares a unique domain architecture with Rad5 and promotes lysine 63-linked polyubiquitination of PCNA. Similar to yeast Rad5, HLTF is able to interact with UBC13 and PCNA, as well as SHPRH; and the reduction of either SHPRH or HLTF expression enhances spontaneous mutagenesis. Moreover, Hltf-deficient mouse embryonic fibroblasts show elevated chromosome breaks and fusions after methyl methane sulfonate treatment. Our results suggest that HLTF and SHPRH are functional homologues of yeast Rad5 that cooperatively mediate PCNA polyubiquitination and maintain genomic stability.

[ "Polyubiquitination", "of", "proliferating", "cell", "nuclear", "antigen", "by", "HLTF", "and", "SHPRH", "prevents", "genomic", "instability", "from", "stalled", "replication", "forks", ".", "\n", "Chronic", "stalling", "of", "DNA", "replication", "forks", "caused", "by", "DNA", "damage", "can", "lead", "to", "genomic", "instability", ".", "Cells", "have", "evolved", "lesion", "bypass", "pathways", "such", "as", "postreplication", "repair", "(", "PRR", ")", "to", "resolve", "these", "arrested", "forks", ".", "In", "yeast", ",", "one", "branch", "of", "PRR", "involves", "proliferating", "cell", "nuclear", "antigen", "(", "PCNA", ")", "polyubiquitination", "mediated", "by", "the", "Rad5-Ubc13-Mms2", "complex", "that", "allows", "bypass", "of", "DNA", "lesion", "by", "a", "template", "-", "switching", "mechanism", ".", "Previously", ",", "we", "identified", "human", "SHPRH", "as", "a", "functional", "homologue", "of", "yeast", "Rad5", "and", "revealed", "the", "existence", "of", "RAD5-like", "pathway", "in", "human", "cells", ".", "Here", "we", "report", "the", "identification", "of", "HLTF", "as", "a", "second", "RAD5", "homologue", "in", "human", "cells", ".", "HLTF", ",", "like", "SHPRH", ",", "shares", "a", "unique", "domain", "architecture", "with", "Rad5", "and", "promotes", "lysine", "63-linked", "polyubiquitination", "of", "PCNA", ".", "Similar", "to", "yeast", "Rad5", ",", "HLTF", "is", "able", "to", "interact", "with", "UBC13", "and", "PCNA", ",", "as", "well", "as", "SHPRH", ";", "and", "the", "reduction", "of", "either", "SHPRH", "or", "HLTF", "expression", "enhances", "spontaneous", "mutagenesis", ".", "Moreover", ",", "Hltf", "-", "deficient", "mouse", "embryonic", "fibroblasts", "show", "elevated", "chromosome", "breaks", "and", "fusions", "after", "methyl", "methane", "sulfonate", "treatment", ".", "Our", "results", "suggest", "that", "HLTF", "and", "SHPRH", "are", "functional", "homologues", "of", "yeast", "Rad5", "that", "cooperatively", "mediate", "PCNA", "polyubiquitination", "and", "maintain", "genomic", "stability", ".", "\n" ]

[ "Protein" ]

tumoración is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, carcinoma ductal infiltrante is a MORFOLOGIA_NEOPLASIA, metástasis por carcinoma ductal is a MORFOLOGIA_NEOPLASIA, metastásica is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, células tumorales is a MORFOLOGIA_NEOPLASIA, micrometástasis is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, proliferacion epitelial neoplásica is a MORFOLOGIA_NEOPLASIA, carcinoma infiltrante is a MORFOLOGIA_NEOPLASIA, ypM0 is a MORFOLOGIA_NEOPLASIA, Progresión pulmonar is a MORFOLOGIA_NEOPLASIA, enfermedad hepática is a MORFOLOGIA_NEOPLASIA, Progresión de enfermedad ganglionar y hepática is a MORFOLOGIA_NEOPLASIA, enfermedad cerebral is a MORFOLOGIA_NEOPLASIA, metastásica is a MORFOLOGIA_NEOPLASIA

299_task0

Sentence: Anamnesis Nuestra paciente, una mujer de 48 años, consulta en febrero del 2013 por notarse nodulación en mama derecha con eritema asociado. La paciente no presentaba antecedentes médico-quirúrgicos de interés y no tenía hábitos tóxicos. En el estudio diagnóstico se realizan: ecografía mamaria que evidencia un nódulo hipoecoico de 2*2 cm en el cuadrante súperoexterno (CSE) de la mama derecha, engrosamiento difuso de piel y adenopatías axilares; mamografía que evidencia tumoración de 3*2cm en CSE de mama derecha. Se amplía el estudio con una RMN que destaca engrosamiento cutáneo de la piel con retracción asociada, encontrándose el volumen tumoral CSE pero con proyecciones espiculadas y nodulares que se extienden por todo el tejido mamario. Se realiza una biopsia por aguja gruesa (BAG) del nódulo mamario que evidencia un carcinoma ductal infiltrante de mama con receptores de estrógenos (+) y de progesterona (++) positivos, HER 2 negativo. La biopsia de la adenoapatía axilar revela metástasis por carcinoma ductal. Tras descartarse enfermedad metastásica en el estudio de extensión se decide administrar quimioterapia neoadyuvante según el esquema TAC (docetaxel, adriamicina, ciclofosfamida) por 4 ciclos. Posteriormente, se realiza una mastectomía radical modificada de mama derecha. El estudio de anatomía patológica muestra un foco tumoral de 21x23 mm, infiltración subareolar por células tumorales sueltas y 2 micrometástasis en 14 adenopatáis resecadas, los bordes quirúrgicos estaban libres de infiltración tumoral. A la visión microscópica se evidencia un tejido de proliferacion epitelial neoplásica constituida por un área escasamente nodular con proliferación de células cuboideas, frecuentes mitosis con abundante celularidad inflamatoria, positivas para CK5/6 pero negativas para CK14, débil expresión del receptor de estrógeno (Hsocre 10/300, Allred 3/8 en 10% de células), ausencia de receptores de progresterona (Hscore 0/300 y Allred 0/8) y una alta expresión de Ki67 (50% en áreas periféricas), expresión de Her2 negativa. Se trata por lo tanto de un carcinoma infiltrante de mama ypT4d ypN1 mic ypM0 RE+ RP- Her2 - ki67 50% fenotipo luminal B. Se completa el tratamiento adyuvante con TAC x 2 y con radioterapia externa hasta una dosis total de 50 Gy, tratamiento que finaliza en octubre del 2013. La paciente presenta posteriormente la siguiente evolución de enfermedad recibiendo los siguientes tratamientos de enfermedad avanzada: Noviembre del 2014: Progresión pulmonar, hepática y ósea: Placlitaxel-Bevacizumab x 6 ciclos + Zolendronato terminando en abril del 2015 por progresión de enfermedad. Mayo del 2015: Progresión de enfermedad hepática: Capecitabina - Zolendronato Noviembre del 2015: Progresión de enfermedad ganglionar y hepática: Exemestano-everolimus + Zolendronato. Diciembre del 2015: Progresión de enfermedad cerebral: Recibe radioterapia holocraneal (4 sesiones de 500cGy por sesión) y se inicia tratamiento con Navelbina que comienza el 22 de enero del 2016. La paciente no recibe el día + 8 del 2º ciclo por síndrome febril. EPISODIO ACTUAL: La paciente acude a hospital de Día el 27 de febrero del 2016 por presentar fiebre resistente a antibioterapia oral con levofloxacino. Asocia cefalea y náuseas de una semana de evolución, además de episodios de desorientación temporo-espacial de unos dos meses de evolución pero que han aumentado en frecuencia en los últimos días. La paciente se encontraba hemodinámicamente estable y a la exploración física y neurológica no destacaba ningún hallazgo salvo la desorientación temporo-espacial. Exploración física La paciente se encontraba hemodinámicamente estable y a la exploración física y neurológica no destacaba ningún hallazgo salvo desorientación temporo-espacial. No existían signos de rigidez nucal. Pruebas complementarias Se realiza una analítica al ingreso donde destaca: GGT 219 U/l, LDH 2276 U/l (previo 1660), Hb 11 g/dl, CEA 2,7 ng/ml, Ca 15.3 1088 U/ml (previa 1038), siendo el resto de parámetros del hemograma, bioquímica y coagulación dentro de la normalidad. Se realizan radiografías de tórax y abdomen sin hallazgos de interés, se serian hemocultivos siendo todos negativos, urinocultivos negativos y cultivo de punta de catéter PICC negativo. Ante sospecha de encefalitis se inicia tratamiento antibiótico con ceftriaxona, vancomicina, aciclovir y ganciclovir con escaso beneficio. Se realiza una punción lumbar que muestra un líquido cefaloraquídeo (LCR) claro y transparente y como únicos hallazgos evidencia una pleocitosis linfocitaria de 10 células/ul y una proteinorraquia de 75 mg/dl. Se realiza una serología de sangre periférica que muestra negatividad para Borrelia, CMV, VHS 1 y 2, VEB, VZV y VHH6 negativos. Se solicita una resonancia magnética nuclear (RMN) cerebral que evidencia un extenso cambio de señal que afecta al córtex temporal y perisilviano bilateral, aunque de predominio derecho, que no se modifica tras la administración de contraste paramagnético (14 ml de gadolinio). No se advierten captaciones anómalas que sugieran afectación metastásica. Imágenes compatibles con encefalitis límbica. Se estudió la autoinmunidad de algunos anticuerpos antineuronales (anti-Yo, Ri, Hu, Tr, NMO, NMDA, MAG, VGCC y anti-islotes de Langerhans), siendo todos negativos. Diagnóstico Encefalitis límbica paraneoplásica Tratamiento Ante la sospecha de encefalitis límbica paraneoplásica se decide comenzar el tratamiento específico antes de la confirmación diagnóstica. Se administra metilpredinosolona en bolos de un gramo durante 5 días, descartándose la plasmaféresis por el estado general de la paciente, y ante la escasa mejoría se administran posteriormente inmunoglubulinas 0,4 g/kg de peso durante 3 días. Se planteó el inicio de una nueva línea de tratamiento específica contra su enfermedad de base, sin embargo no fue posible iniciar nuevo tratamiento con quimioterapia debido a un importante deterioro clínico y rápida afectación del estado general. Evolución La paciente presentó una evolución desfavorable a pesar del tratamiento administrado y falleció posteriormente con buen control de síntomas. Ya habiendo fallecido la paciente, se evidenció en el proteinograma del LCR la presencia de bandas oligoclonales que apoyan el diagnóstico de encefalitis límbica paraneoplásica. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Nuestra paciente, una mujer de 48 años, consulta en febrero del 2013 por notarse nodulación en mama derecha con eritema asociado. La paciente no presentaba antecedentes médico-quirúrgicos de interés y no tenía hábitos tóxicos. En el estudio diagnóstico se realizan: ecografía mamaria que evidencia un nódulo hipoecoico de 2*2 cm en el cuadrante súperoexterno (CSE) de la mama derecha, engrosamiento difuso de piel y adenopatías axilares; mamografía que evidencia tumoración de 3*2cm en CSE de mama derecha. Se amplía el estudio con una RMN que destaca engrosamiento cutáneo de la piel con retracción asociada, encontrándose el volumen tumoral CSE pero con proyecciones espiculadas y nodulares que se extienden por todo el tejido mamario. Se realiza una biopsia por aguja gruesa (BAG) del nódulo mamario que evidencia un carcinoma ductal infiltrante de mama con receptores de estrógenos (+) y de progesterona (++) positivos, HER 2 negativo. La biopsia de la adenoapatía axilar revela metástasis por carcinoma ductal. Tras descartarse enfermedad metastásica en el estudio de extensión se decide administrar quimioterapia neoadyuvante según el esquema TAC (docetaxel, adriamicina, ciclofosfamida) por 4 ciclos. Posteriormente, se realiza una mastectomía radical modificada de mama derecha. El estudio de anatomía patológica muestra un foco tumoral de 21x23 mm, infiltración subareolar por células tumorales sueltas y 2 micrometástasis en 14 adenopatáis resecadas, los bordes quirúrgicos estaban libres de infiltración tumoral. A la visión microscópica se evidencia un tejido de proliferacion epitelial neoplásica constituida por un área escasamente nodular con proliferación de células cuboideas, frecuentes mitosis con abundante celularidad inflamatoria, positivas para CK5/6 pero negativas para CK14, débil expresión del receptor de estrógeno (Hsocre 10/300, Allred 3/8 en 10% de células), ausencia de receptores de progresterona (Hscore 0/300 y Allred 0/8) y una alta expresión de Ki67 (50% en áreas periféricas), expresión de Her2 negativa. Se trata por lo tanto de un carcinoma infiltrante de mama ypT4d ypN1 mic ypM0 RE+ RP- Her2 - ki67 50% fenotipo luminal B. Se completa el tratamiento adyuvante con TAC x 2 y con radioterapia externa hasta una dosis total de 50 Gy, tratamiento que finaliza en octubre del 2013. La paciente presenta posteriormente la siguiente evolución de enfermedad recibiendo los siguientes tratamientos de enfermedad avanzada: Noviembre del 2014: Progresión pulmonar, hepática y ósea: Placlitaxel-Bevacizumab x 6 ciclos + Zolendronato terminando en abril del 2015 por progresión de enfermedad. Mayo del 2015: Progresión de enfermedad hepática: Capecitabina - Zolendronato Noviembre del 2015: Progresión de enfermedad ganglionar y hepática: Exemestano-everolimus + Zolendronato. Diciembre del 2015: Progresión de enfermedad cerebral: Recibe radioterapia holocraneal (4 sesiones de 500cGy por sesión) y se inicia tratamiento con Navelbina que comienza el 22 de enero del 2016. La paciente no recibe el día + 8 del 2º ciclo por síndrome febril. EPISODIO ACTUAL: La paciente acude a hospital de Día el 27 de febrero del 2016 por presentar fiebre resistente a antibioterapia oral con levofloxacino. Asocia cefalea y náuseas de una semana de evolución, además de episodios de desorientación temporo-espacial de unos dos meses de evolución pero que han aumentado en frecuencia en los últimos días. La paciente se encontraba hemodinámicamente estable y a la exploración física y neurológica no destacaba ningún hallazgo salvo la desorientación temporo-espacial. Exploración física La paciente se encontraba hemodinámicamente estable y a la exploración física y neurológica no destacaba ningún hallazgo salvo desorientación temporo-espacial. No existían signos de rigidez nucal. Pruebas complementarias Se realiza una analítica al ingreso donde destaca: GGT 219 U/l, LDH 2276 U/l (previo 1660), Hb 11 g/dl, CEA 2,7 ng/ml, Ca 15.3 1088 U/ml (previa 1038), siendo el resto de parámetros del hemograma, bioquímica y coagulación dentro de la normalidad. Se realizan radiografías de tórax y abdomen sin hallazgos de interés, se serian hemocultivos siendo todos negativos, urinocultivos negativos y cultivo de punta de catéter PICC negativo. Ante sospecha de encefalitis se inicia tratamiento antibiótico con ceftriaxona, vancomicina, aciclovir y ganciclovir con escaso beneficio. Se realiza una punción lumbar que muestra un líquido cefaloraquídeo (LCR) claro y transparente y como únicos hallazgos evidencia una pleocitosis linfocitaria de 10 células/ul y una proteinorraquia de 75 mg/dl. Se realiza una serología de sangre periférica que muestra negatividad para Borrelia, CMV, VHS 1 y 2, VEB, VZV y VHH6 negativos. Se solicita una resonancia magnética nuclear (RMN) cerebral que evidencia un extenso cambio de señal que afecta al córtex temporal y perisilviano bilateral, aunque de predominio derecho, que no se modifica tras la administración de contraste paramagnético (14 ml de gadolinio). No se advierten captaciones anómalas que sugieran afectación metastásica. Imágenes compatibles con encefalitis límbica. Se estudió la autoinmunidad de algunos anticuerpos antineuronales (anti-Yo, Ri, Hu, Tr, NMO, NMDA, MAG, VGCC y anti-islotes de Langerhans), siendo todos negativos. Diagnóstico Encefalitis límbica paraneoplásica Tratamiento Ante la sospecha de encefalitis límbica paraneoplásica se decide comenzar el tratamiento específico antes de la confirmación diagnóstica. Se administra metilpredinosolona en bolos de un gramo durante 5 días, descartándose la plasmaféresis por el estado general de la paciente, y ante la escasa mejoría se administran posteriormente inmunoglubulinas 0,4 g/kg de peso durante 3 días. Se planteó el inicio de una nueva línea de tratamiento específica contra su enfermedad de base, sin embargo no fue posible iniciar nuevo tratamiento con quimioterapia debido a un importante deterioro clínico y rápida afectación del estado general. Evolución La paciente presentó una evolución desfavorable a pesar del tratamiento administrado y falleció posteriormente con buen control de síntomas. Ya habiendo fallecido la paciente, se evidenció en el proteinograma del LCR la presencia de bandas oligoclonales que apoyan el diagnóstico de encefalitis límbica paraneoplásica.

[ "Anamnesis", "\n", "Nuestra", "paciente", ",", "una", "mujer", "de", "48", "años", ",", "consulta", "en", "febrero", "del", "2013", "por", "notarse", "nodulación", "en", "mama", "derecha", "con", "eritema", "asociado", ".", "La", "paciente", "no", "presentaba", "antecedentes", "médico", "-", "quirúrgicos", "de", "interés", "y", "no", "tenía", "hábitos", "tóxicos", ".", "\n", "En", "el", "estudio", "diagnóstico", "se", "realizan", ":", "ecografía", "mamaria", "que", "evidencia", "un", "nódulo", "hipoecoico", "de", "2", "*", "2", "cm", "en", "el", "cuadrante", "súperoexterno", "(", "CSE", ")", "de", "la", "mama", "derecha", ",", "engrosamiento", "difuso", "de", "piel", "y", "adenopatías", "axilares", ";", "mamografía", "que", "evidencia", "tumoración", "de", "3", "*", "2", "cm", "en", "CSE", "de", "mama", "derecha", ".", "Se", "amplía", "el", "estudio", "con", "una", "RMN", "que", "destaca", "engrosamiento", "cutáneo", "de", "la", "piel", "con", "retracción", "asociada", ",", "encontrándose", "el", "volumen", "tumoral", "CSE", "pero", "con", "proyecciones", "espiculadas", "y", "nodulares", "que", "se", "extienden", "por", "todo", "el", "tejido", "mamario", ".", "\n", "Se", "realiza", "una", "biopsia", "por", "aguja", "gruesa", "(", "BAG", ")", "del", "nódulo", "mamario", "que", "evidencia", "un", "carcinoma", "ductal", "infiltrante", "de", "mama", "con", "receptores", "de", "estrógenos", "(", "+", ")", "y", "de", "progesterona", "(", "+", "+", ")", "positivos", ",", "HER", "2", "negativo", ".", "\n", "La", "biopsia", "de", "la", "adenoapatía", "axilar", "revela", "metástasis", "por", "carcinoma", "ductal", ".", "\n", "Tras", "descartarse", "enfermedad", "metastásica", "en", "el", "estudio", "de", "extensión", "se", "decide", "administrar", "quimioterapia", "neoadyuvante", "según", "el", "esquema", "TAC", "(", "docetaxel", ",", "adriamicina", ",", "ciclofosfamida", ")", "por", "4", "ciclos", ".", "Posteriormente", ",", "se", "realiza", "una", "mastectomía", "radical", "modificada", "de", "mama", "derecha", ".", "\n", "El", "estudio", "de", "anatomía", "patológica", "muestra", "un", "foco", "tumoral", "de", "21x23", "mm", ",", "infiltración", "subareolar", "por", "células", "tumorales", "sueltas", "y", "2", "micrometástasis", "en", "14", "adenopatáis", "resecadas", ",", "los", "bordes", "quirúrgicos", "estaban", "libres", "de", "infiltración", "tumoral", ".", "A", "la", "visión", "microscópica", "se", "evidencia", "un", "tejido", "de", "proliferacion", "epitelial", "neoplásica", "constituida", "por", "un", "área", "escasamente", "nodular", "con", "proliferación", "de", "células", "cuboideas", ",", "frecuentes", "mitosis", "con", "abundante", "celularidad", "inflamatoria", ",", "positivas", "para", "CK5/6", "pero", "negativas", "para", "CK14", ",", "débil", "expresión", "del", "receptor", "de", "estrógeno", "(", "Hsocre", "10/300", ",", "Allred", "3/8", "en", "10", "%", "de", "células", ")", ",", "ausencia", "de", "receptores", "de", "progresterona", "(", "Hscore", "0/300", "y", "Allred", "0/8", ")", "y", "una", "alta", "expresión", "de", "Ki67", "(", "50", "%", "en", "áreas", "periféricas", ")", ",", "expresión", "de", "Her2", "negativa", ".", "\n", "Se", "trata", "por", "lo", "tanto", "de", "un", "carcinoma", "infiltrante", "de", "mama", "ypT4d", "ypN1", "mic", "ypM0", "RE+", "RP-", "Her2", "-", "ki67", "50", "%", "fenotipo", "luminal", "B.", "\n", "Se", "completa", "el", "tratamiento", "adyuvante", "con", "TAC", "x", "2", "y", "con", "radioterapia", "externa", "hasta", "una", "dosis", "total", "de", "50", "Gy", ",", "tratamiento", "que", "finaliza", "en", "octubre", "del", "2013", ".", "\n", "La", "paciente", "presenta", "posteriormente", "la", "siguiente", "evolución", "de", "enfermedad", "recibiendo", "los", "siguientes", "tratamientos", "de", "enfermedad", "avanzada", ":", "\n", "Noviembre", "del", "2014", ":", "Progresión", "pulmonar", ",", "hepática", "y", "ósea", ":", "Placlitaxel", "-", "Bevacizumab", "x", "6", "ciclos", "+", "Zolendronato", "terminando", "en", "abril", "del", "2015", "por", "progresión", "de", "enfermedad", ".", "\n", "Mayo", "del", "2015", ":", "Progresión", "de", "enfermedad", "hepática", ":", "Capecitabina", "-", "Zolendronato", "\n", "Noviembre", "del", "2015", ":", "Progresión", "de", "enfermedad", "ganglionar", "y", "hepática", ":", "Exemestano", "-", "everolimus", "+", "Zolendronato", ".", "\n", "Diciembre", "del", "2015", ":", "Progresión", "de", "enfermedad", "cerebral", ":", "Recibe", "radioterapia", "holocraneal", "(", "4", "sesiones", "de", "500cGy", "por", "sesión", ")", "y", "se", "inicia", "tratamiento", "con", "Navelbina", "que", "comienza", "el", "22", "de", "enero", "del", "2016", ".", "La", "paciente", "no", "recibe", "el", "día", "+", "8", "del", "2º", "ciclo", "por", "síndrome", "febril", ".", "\n\n", "EPISODIO", "ACTUAL", ":", "\n", "La", "paciente", "acude", "a", "hospital", "de", "Día", "el", "27", "de", "febrero", "del", "2016", "por", "presentar", "fiebre", "resistente", "a", "antibioterapia", "oral", "con", "levofloxacino", ".", "Asocia", "cefalea", "y", "náuseas", "de", "una", "semana", "de", "evolución", ",", "además", "de", "episodios", "de", "desorientación", "temporo", "-", "espacial", "de", "unos", "dos", "meses", "de", "evolución", "pero", "que", "han", "aumentado", "en", "frecuencia", "en", "los", "últimos", "días", ".", "La", "paciente", "se", "encontraba", "hemodinámicamente", "estable", "y", "a", "la", "exploración", "física", "y", "neurológica", "no", "destacaba", "ningún", "hallazgo", "salvo", "la", "desorientación", "temporo", "-", "espacial", ".", "\n\n", "Exploración", "física", "\n", "La", "paciente", "se", "encontraba", "hemodinámicamente", "estable", "y", "a", "la", "exploración", "física", "y", "neurológica", "no", "destacaba", "ningún", "hallazgo", "salvo", "desorientación", "temporo", "-", "espacial", ".", "No", "existían", "signos", "de", "rigidez", "nucal", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "realiza", "una", "analítica", "al", "ingreso", "donde", "destaca", ":", "GGT", "219", "U", "/", "l", ",", "LDH", "2276", "U", "/", "l", "(", "previo", "1660", ")", ",", "Hb", "11", "g", "/", "dl", ",", "CEA", "2,7", "ng", "/", "ml", ",", "Ca", "15.3", "1088", "U", "/", "ml", "(", "previa", "1038", ")", ",", "siendo", "el", "resto", "de", "parámetros", "del", "hemograma", ",", "bioquímica", "y", "coagulación", "dentro", "de", "la", "normalidad", ".", "Se", "realizan", "radiografías", "de", "tórax", "y", "abdomen", "sin", "hallazgos", "de", "interés", ",", "se", "serian", "hemocultivos", "siendo", "todos", "negativos", ",", "urinocultivos", "negativos", "y", "cultivo", "de", "punta", "de", "catéter", "PICC", "negativo", ".", "\n", "Ante", "sospecha", "de", "encefalitis", "se", "inicia", "tratamiento", "antibiótico", "con", "ceftriaxona", ",", "vancomicina", ",", "aciclovir", "y", "ganciclovir", "con", "escaso", "beneficio", ".", "Se", "realiza", "una", "punción", "lumbar", "que", "muestra", "un", "líquido", "cefaloraquídeo", "(", "LCR", ")", "claro", "y", "transparente", "y", "como", "únicos", "hallazgos", "evidencia", "una", "pleocitosis", "linfocitaria", "de", "10", "células", "/", "ul", "y", "una", "proteinorraquia", "de", "75", "mg", "/", "dl", ".", "Se", "realiza", "una", "serología", "de", "sangre", "periférica", "que", "muestra", "negatividad", "para", "Borrelia", ",", "CMV", ",", "VHS", "1", "y", "2", ",", "VEB", ",", "VZV", "y", "VHH6", "negativos", ".", "\n", "Se", "solicita", "una", "resonancia", "magnética", "nuclear", "(", "RMN", ")", "cerebral", "que", "evidencia", "un", "extenso", "cambio", "de", "señal", "que", "afecta", "al", "córtex", "temporal", "y", "perisilviano", "bilateral", ",", "aunque", "de", "predominio", "derecho", ",", "que", "no", "se", "modifica", "tras", "la", "administración", "de", "contraste", "paramagnético", "(", "14", "ml", "de", "gadolinio", ")", ".", "No", "se", "advierten", "captaciones", "anómalas", "que", "sugieran", "afectación", "metastásica", ".", "Imágenes", "compatibles", "con", "encefalitis", "límbica", ".", "\n", "Se", "estudió", "la", "autoinmunidad", "de", "algunos", "anticuerpos", "antineuronales", "(", "anti", "-", "Yo", ",", "Ri", ",", "Hu", ",", "Tr", ",", "NMO", ",", "NMDA", ",", "MAG", ",", "VGCC", "y", "anti", "-", "islotes", "de", "Langerhans", ")", ",", "siendo", "todos", "negativos", ".", "\n\n", "Diagnóstico", "\n", "Encefalitis", "límbica", "paraneoplásica", "\n\n", "Tratamiento", "\n", "Ante", "la", "sospecha", "de", "encefalitis", "límbica", "paraneoplásica", "se", "decide", "comenzar", "el", "tratamiento", "específico", "antes", "de", "la", "confirmación", "diagnóstica", ".", "Se", "administra", "metilpredinosolona", "en", "bolos", "de", "un", "gramo", "durante", "5", "días", ",", "descartándose", "la", "plasmaféresis", "por", "el", "estado", "general", "de", "la", "paciente", ",", "y", "ante", "la", "escasa", "mejoría", "se", "administran", "posteriormente", "inmunoglubulinas", "0,4", "g", "/", "kg", "de", "peso", "durante", "3", "días", ".", "\n", "Se", "planteó", "el", "inicio", "de", "una", "nueva", "línea", "de", "tratamiento", "específica", "contra", "su", "enfermedad", "de", "base", ",", "sin", "embargo", "no", "fue", "posible", "iniciar", "nuevo", "tratamiento", "con", "quimioterapia", "debido", "a", "un", "importante", "deterioro", "clínico", "y", "rápida", "afectación", "del", "estado", "general", ".", "\n\n", "Evolución", "\n", "La", "paciente", "presentó", "una", "evolución", "desfavorable", "a", "pesar", "del", "tratamiento", "administrado", "y", "falleció", "posteriormente", "con", "buen", "control", "de", "síntomas", ".", "\n", "Ya", "habiendo", "fallecido", "la", "paciente", ",", "se", "evidenció", "en", "el", "proteinograma", "del", "LCR", "la", "presencia", "de", "bandas", "oligoclonales", "que", "apoyan", "el", "diagnóstico", "de", "encefalitis", "límbica", "paraneoplásica", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

tumoración is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, carcinoma ductal infiltrante is a MORFOLOGIA_NEOPLASIA, metástasis por carcinoma ductal is a MORFOLOGIA_NEOPLASIA, metastásica is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, células tumorales is a MORFOLOGIA_NEOPLASIA, micrometástasis is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, proliferacion epitelial neoplásica is a MORFOLOGIA_NEOPLASIA, carcinoma infiltrante is a MORFOLOGIA_NEOPLASIA, ypM0 is a MORFOLOGIA_NEOPLASIA, Progresión pulmonar is a MORFOLOGIA_NEOPLASIA, enfermedad hepática is a MORFOLOGIA_NEOPLASIA, Progresión de enfermedad ganglionar y hepática is a MORFOLOGIA_NEOPLASIA, enfermedad cerebral is a MORFOLOGIA_NEOPLASIA, metastásica is a MORFOLOGIA_NEOPLASIA

299_task1

Sentence: Anamnesis Nuestra paciente, una mujer de 48 años, consulta en febrero del 2013 por notarse nodulación en mama derecha con eritema asociado. La paciente no presentaba antecedentes médico-quirúrgicos de interés y no tenía hábitos tóxicos. En el estudio diagnóstico se realizan: ecografía mamaria que evidencia un nódulo hipoecoico de 2*2 cm en el cuadrante súperoexterno (CSE) de la mama derecha, engrosamiento difuso de piel y adenopatías axilares; mamografía que evidencia tumoración de 3*2cm en CSE de mama derecha. Se amplía el estudio con una RMN que destaca engrosamiento cutáneo de la piel con retracción asociada, encontrándose el volumen tumoral CSE pero con proyecciones espiculadas y nodulares que se extienden por todo el tejido mamario. Se realiza una biopsia por aguja gruesa (BAG) del nódulo mamario que evidencia un carcinoma ductal infiltrante de mama con receptores de estrógenos (+) y de progesterona (++) positivos, HER 2 negativo. La biopsia de la adenoapatía axilar revela metástasis por carcinoma ductal. Tras descartarse enfermedad metastásica en el estudio de extensión se decide administrar quimioterapia neoadyuvante según el esquema TAC (docetaxel, adriamicina, ciclofosfamida) por 4 ciclos. Posteriormente, se realiza una mastectomía radical modificada de mama derecha. El estudio de anatomía patológica muestra un foco tumoral de 21x23 mm, infiltración subareolar por células tumorales sueltas y 2 micrometástasis en 14 adenopatáis resecadas, los bordes quirúrgicos estaban libres de infiltración tumoral. A la visión microscópica se evidencia un tejido de proliferacion epitelial neoplásica constituida por un área escasamente nodular con proliferación de células cuboideas, frecuentes mitosis con abundante celularidad inflamatoria, positivas para CK5/6 pero negativas para CK14, débil expresión del receptor de estrógeno (Hsocre 10/300, Allred 3/8 en 10% de células), ausencia de receptores de progresterona (Hscore 0/300 y Allred 0/8) y una alta expresión de Ki67 (50% en áreas periféricas), expresión de Her2 negativa. Se trata por lo tanto de un carcinoma infiltrante de mama ypT4d ypN1 mic ypM0 RE+ RP- Her2 - ki67 50% fenotipo luminal B. Se completa el tratamiento adyuvante con TAC x 2 y con radioterapia externa hasta una dosis total de 50 Gy, tratamiento que finaliza en octubre del 2013. La paciente presenta posteriormente la siguiente evolución de enfermedad recibiendo los siguientes tratamientos de enfermedad avanzada: Noviembre del 2014: Progresión pulmonar, hepática y ósea: Placlitaxel-Bevacizumab x 6 ciclos + Zolendronato terminando en abril del 2015 por progresión de enfermedad. Mayo del 2015: Progresión de enfermedad hepática: Capecitabina - Zolendronato Noviembre del 2015: Progresión de enfermedad ganglionar y hepática: Exemestano-everolimus + Zolendronato. Diciembre del 2015: Progresión de enfermedad cerebral: Recibe radioterapia holocraneal (4 sesiones de 500cGy por sesión) y se inicia tratamiento con Navelbina que comienza el 22 de enero del 2016. La paciente no recibe el día + 8 del 2º ciclo por síndrome febril. EPISODIO ACTUAL: La paciente acude a hospital de Día el 27 de febrero del 2016 por presentar fiebre resistente a antibioterapia oral con levofloxacino. Asocia cefalea y náuseas de una semana de evolución, además de episodios de desorientación temporo-espacial de unos dos meses de evolución pero que han aumentado en frecuencia en los últimos días. La paciente se encontraba hemodinámicamente estable y a la exploración física y neurológica no destacaba ningún hallazgo salvo la desorientación temporo-espacial. Exploración física La paciente se encontraba hemodinámicamente estable y a la exploración física y neurológica no destacaba ningún hallazgo salvo desorientación temporo-espacial. No existían signos de rigidez nucal. Pruebas complementarias Se realiza una analítica al ingreso donde destaca: GGT 219 U/l, LDH 2276 U/l (previo 1660), Hb 11 g/dl, CEA 2,7 ng/ml, Ca 15.3 1088 U/ml (previa 1038), siendo el resto de parámetros del hemograma, bioquímica y coagulación dentro de la normalidad. Se realizan radiografías de tórax y abdomen sin hallazgos de interés, se serian hemocultivos siendo todos negativos, urinocultivos negativos y cultivo de punta de catéter PICC negativo. Ante sospecha de encefalitis se inicia tratamiento antibiótico con ceftriaxona, vancomicina, aciclovir y ganciclovir con escaso beneficio. Se realiza una punción lumbar que muestra un líquido cefaloraquídeo (LCR) claro y transparente y como únicos hallazgos evidencia una pleocitosis linfocitaria de 10 células/ul y una proteinorraquia de 75 mg/dl. Se realiza una serología de sangre periférica que muestra negatividad para Borrelia, CMV, VHS 1 y 2, VEB, VZV y VHH6 negativos. Se solicita una resonancia magnética nuclear (RMN) cerebral que evidencia un extenso cambio de señal que afecta al córtex temporal y perisilviano bilateral, aunque de predominio derecho, que no se modifica tras la administración de contraste paramagnético (14 ml de gadolinio). No se advierten captaciones anómalas que sugieran afectación metastásica. Imágenes compatibles con encefalitis límbica. Se estudió la autoinmunidad de algunos anticuerpos antineuronales (anti-Yo, Ri, Hu, Tr, NMO, NMDA, MAG, VGCC y anti-islotes de Langerhans), siendo todos negativos. Diagnóstico Encefalitis límbica paraneoplásica Tratamiento Ante la sospecha de encefalitis límbica paraneoplásica se decide comenzar el tratamiento específico antes de la confirmación diagnóstica. Se administra metilpredinosolona en bolos de un gramo durante 5 días, descartándose la plasmaféresis por el estado general de la paciente, y ante la escasa mejoría se administran posteriormente inmunoglubulinas 0,4 g/kg de peso durante 3 días. Se planteó el inicio de una nueva línea de tratamiento específica contra su enfermedad de base, sin embargo no fue posible iniciar nuevo tratamiento con quimioterapia debido a un importante deterioro clínico y rápida afectación del estado general. Evolución La paciente presentó una evolución desfavorable a pesar del tratamiento administrado y falleció posteriormente con buen control de síntomas. Ya habiendo fallecido la paciente, se evidenció en el proteinograma del LCR la presencia de bandas oligoclonales que apoyan el diagnóstico de encefalitis límbica paraneoplásica. Instructions: please typing these entity words according to sentence: tumoración, tumoral, carcinoma ductal infiltrante, metástasis por carcinoma ductal, metastásica, tumoral, células tumorales, micrometástasis, tumoral, proliferacion epitelial neoplásica, carcinoma infiltrante, ypM0, Progresión pulmonar, enfermedad hepática, Progresión de enfermedad ganglionar y hepática, enfermedad cerebral, metastásica Options: MORFOLOGIA_NEOPLASIA

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Nuestra paciente, una mujer de 48 años, consulta en febrero del 2013 por notarse nodulación en mama derecha con eritema asociado. La paciente no presentaba antecedentes médico-quirúrgicos de interés y no tenía hábitos tóxicos. En el estudio diagnóstico se realizan: ecografía mamaria que evidencia un nódulo hipoecoico de 2*2 cm en el cuadrante súperoexterno (CSE) de la mama derecha, engrosamiento difuso de piel y adenopatías axilares; mamografía que evidencia tumoración de 3*2cm en CSE de mama derecha. Se amplía el estudio con una RMN que destaca engrosamiento cutáneo de la piel con retracción asociada, encontrándose el volumen tumoral CSE pero con proyecciones espiculadas y nodulares que se extienden por todo el tejido mamario. Se realiza una biopsia por aguja gruesa (BAG) del nódulo mamario que evidencia un carcinoma ductal infiltrante de mama con receptores de estrógenos (+) y de progesterona (++) positivos, HER 2 negativo. La biopsia de la adenoapatía axilar revela metástasis por carcinoma ductal. Tras descartarse enfermedad metastásica en el estudio de extensión se decide administrar quimioterapia neoadyuvante según el esquema TAC (docetaxel, adriamicina, ciclofosfamida) por 4 ciclos. Posteriormente, se realiza una mastectomía radical modificada de mama derecha. El estudio de anatomía patológica muestra un foco tumoral de 21x23 mm, infiltración subareolar por células tumorales sueltas y 2 micrometástasis en 14 adenopatáis resecadas, los bordes quirúrgicos estaban libres de infiltración tumoral. A la visión microscópica se evidencia un tejido de proliferacion epitelial neoplásica constituida por un área escasamente nodular con proliferación de células cuboideas, frecuentes mitosis con abundante celularidad inflamatoria, positivas para CK5/6 pero negativas para CK14, débil expresión del receptor de estrógeno (Hsocre 10/300, Allred 3/8 en 10% de células), ausencia de receptores de progresterona (Hscore 0/300 y Allred 0/8) y una alta expresión de Ki67 (50% en áreas periféricas), expresión de Her2 negativa. Se trata por lo tanto de un carcinoma infiltrante de mama ypT4d ypN1 mic ypM0 RE+ RP- Her2 - ki67 50% fenotipo luminal B. Se completa el tratamiento adyuvante con TAC x 2 y con radioterapia externa hasta una dosis total de 50 Gy, tratamiento que finaliza en octubre del 2013. La paciente presenta posteriormente la siguiente evolución de enfermedad recibiendo los siguientes tratamientos de enfermedad avanzada: Noviembre del 2014: Progresión pulmonar, hepática y ósea: Placlitaxel-Bevacizumab x 6 ciclos + Zolendronato terminando en abril del 2015 por progresión de enfermedad. Mayo del 2015: Progresión de enfermedad hepática: Capecitabina - Zolendronato Noviembre del 2015: Progresión de enfermedad ganglionar y hepática: Exemestano-everolimus + Zolendronato. Diciembre del 2015: Progresión de enfermedad cerebral: Recibe radioterapia holocraneal (4 sesiones de 500cGy por sesión) y se inicia tratamiento con Navelbina que comienza el 22 de enero del 2016. La paciente no recibe el día + 8 del 2º ciclo por síndrome febril. EPISODIO ACTUAL: La paciente acude a hospital de Día el 27 de febrero del 2016 por presentar fiebre resistente a antibioterapia oral con levofloxacino. Asocia cefalea y náuseas de una semana de evolución, además de episodios de desorientación temporo-espacial de unos dos meses de evolución pero que han aumentado en frecuencia en los últimos días. La paciente se encontraba hemodinámicamente estable y a la exploración física y neurológica no destacaba ningún hallazgo salvo la desorientación temporo-espacial. Exploración física La paciente se encontraba hemodinámicamente estable y a la exploración física y neurológica no destacaba ningún hallazgo salvo desorientación temporo-espacial. No existían signos de rigidez nucal. Pruebas complementarias Se realiza una analítica al ingreso donde destaca: GGT 219 U/l, LDH 2276 U/l (previo 1660), Hb 11 g/dl, CEA 2,7 ng/ml, Ca 15.3 1088 U/ml (previa 1038), siendo el resto de parámetros del hemograma, bioquímica y coagulación dentro de la normalidad. Se realizan radiografías de tórax y abdomen sin hallazgos de interés, se serian hemocultivos siendo todos negativos, urinocultivos negativos y cultivo de punta de catéter PICC negativo. Ante sospecha de encefalitis se inicia tratamiento antibiótico con ceftriaxona, vancomicina, aciclovir y ganciclovir con escaso beneficio. Se realiza una punción lumbar que muestra un líquido cefaloraquídeo (LCR) claro y transparente y como únicos hallazgos evidencia una pleocitosis linfocitaria de 10 células/ul y una proteinorraquia de 75 mg/dl. Se realiza una serología de sangre periférica que muestra negatividad para Borrelia, CMV, VHS 1 y 2, VEB, VZV y VHH6 negativos. Se solicita una resonancia magnética nuclear (RMN) cerebral que evidencia un extenso cambio de señal que afecta al córtex temporal y perisilviano bilateral, aunque de predominio derecho, que no se modifica tras la administración de contraste paramagnético (14 ml de gadolinio). No se advierten captaciones anómalas que sugieran afectación metastásica. Imágenes compatibles con encefalitis límbica. Se estudió la autoinmunidad de algunos anticuerpos antineuronales (anti-Yo, Ri, Hu, Tr, NMO, NMDA, MAG, VGCC y anti-islotes de Langerhans), siendo todos negativos. Diagnóstico Encefalitis límbica paraneoplásica Tratamiento Ante la sospecha de encefalitis límbica paraneoplásica se decide comenzar el tratamiento específico antes de la confirmación diagnóstica. Se administra metilpredinosolona en bolos de un gramo durante 5 días, descartándose la plasmaféresis por el estado general de la paciente, y ante la escasa mejoría se administran posteriormente inmunoglubulinas 0,4 g/kg de peso durante 3 días. Se planteó el inicio de una nueva línea de tratamiento específica contra su enfermedad de base, sin embargo no fue posible iniciar nuevo tratamiento con quimioterapia debido a un importante deterioro clínico y rápida afectación del estado general. Evolución La paciente presentó una evolución desfavorable a pesar del tratamiento administrado y falleció posteriormente con buen control de síntomas. Ya habiendo fallecido la paciente, se evidenció en el proteinograma del LCR la presencia de bandas oligoclonales que apoyan el diagnóstico de encefalitis límbica paraneoplásica.

[ "Anamnesis", "\n", "Nuestra", "paciente", ",", "una", "mujer", "de", "48", "años", ",", "consulta", "en", "febrero", "del", "2013", "por", "notarse", "nodulación", "en", "mama", "derecha", "con", "eritema", "asociado", ".", "La", "paciente", "no", "presentaba", "antecedentes", "médico", "-", "quirúrgicos", "de", "interés", "y", "no", "tenía", "hábitos", "tóxicos", ".", "\n", "En", "el", "estudio", "diagnóstico", "se", "realizan", ":", "ecografía", "mamaria", "que", "evidencia", "un", "nódulo", "hipoecoico", "de", "2", "*", "2", "cm", "en", "el", "cuadrante", "súperoexterno", "(", "CSE", ")", "de", "la", "mama", "derecha", ",", "engrosamiento", "difuso", "de", "piel", "y", "adenopatías", "axilares", ";", "mamografía", "que", "evidencia", "tumoración", "de", "3", "*", "2", "cm", "en", "CSE", "de", "mama", "derecha", ".", "Se", "amplía", "el", "estudio", "con", "una", "RMN", "que", "destaca", "engrosamiento", "cutáneo", "de", "la", "piel", "con", "retracción", "asociada", ",", "encontrándose", "el", "volumen", "tumoral", "CSE", "pero", "con", "proyecciones", "espiculadas", "y", "nodulares", "que", "se", "extienden", "por", "todo", "el", "tejido", "mamario", ".", "\n", "Se", "realiza", "una", "biopsia", "por", "aguja", "gruesa", "(", "BAG", ")", "del", "nódulo", "mamario", "que", "evidencia", "un", "carcinoma", "ductal", "infiltrante", "de", "mama", "con", "receptores", "de", "estrógenos", "(", "+", ")", "y", "de", "progesterona", "(", "+", "+", ")", "positivos", ",", "HER", "2", "negativo", ".", "\n", "La", "biopsia", "de", "la", "adenoapatía", "axilar", "revela", "metástasis", "por", "carcinoma", "ductal", ".", "\n", "Tras", "descartarse", "enfermedad", "metastásica", "en", "el", "estudio", "de", "extensión", "se", "decide", "administrar", "quimioterapia", "neoadyuvante", "según", "el", "esquema", "TAC", "(", "docetaxel", ",", "adriamicina", ",", "ciclofosfamida", ")", "por", "4", "ciclos", ".", "Posteriormente", ",", "se", "realiza", "una", "mastectomía", "radical", "modificada", "de", "mama", "derecha", ".", "\n", "El", "estudio", "de", "anatomía", "patológica", "muestra", "un", "foco", "tumoral", "de", "21x23", "mm", ",", "infiltración", "subareolar", "por", "células", "tumorales", "sueltas", "y", "2", "micrometástasis", "en", "14", "adenopatáis", "resecadas", ",", "los", "bordes", "quirúrgicos", "estaban", "libres", "de", "infiltración", "tumoral", ".", "A", "la", "visión", "microscópica", "se", "evidencia", "un", "tejido", "de", "proliferacion", "epitelial", "neoplásica", "constituida", "por", "un", "área", "escasamente", "nodular", "con", "proliferación", "de", "células", "cuboideas", ",", "frecuentes", "mitosis", "con", "abundante", "celularidad", "inflamatoria", ",", "positivas", "para", "CK5/6", "pero", "negativas", "para", "CK14", ",", "débil", "expresión", "del", "receptor", "de", "estrógeno", "(", "Hsocre", "10/300", ",", "Allred", "3/8", "en", "10", "%", "de", "células", ")", ",", "ausencia", "de", "receptores", "de", "progresterona", "(", "Hscore", "0/300", "y", "Allred", "0/8", ")", "y", "una", "alta", "expresión", "de", "Ki67", "(", "50", "%", "en", "áreas", "periféricas", ")", ",", "expresión", "de", "Her2", "negativa", ".", "\n", "Se", "trata", "por", "lo", "tanto", "de", "un", "carcinoma", "infiltrante", "de", "mama", "ypT4d", "ypN1", "mic", "ypM0", "RE+", "RP-", "Her2", "-", "ki67", "50", "%", "fenotipo", "luminal", "B.", "\n", "Se", "completa", "el", "tratamiento", "adyuvante", "con", "TAC", "x", "2", "y", "con", "radioterapia", "externa", "hasta", "una", "dosis", "total", "de", "50", "Gy", ",", "tratamiento", "que", "finaliza", "en", "octubre", "del", "2013", ".", "\n", "La", "paciente", "presenta", "posteriormente", "la", "siguiente", "evolución", "de", "enfermedad", "recibiendo", "los", "siguientes", "tratamientos", "de", "enfermedad", "avanzada", ":", "\n", "Noviembre", "del", "2014", ":", "Progresión", "pulmonar", ",", "hepática", "y", "ósea", ":", "Placlitaxel", "-", "Bevacizumab", "x", "6", "ciclos", "+", "Zolendronato", "terminando", "en", "abril", "del", "2015", "por", "progresión", "de", "enfermedad", ".", "\n", "Mayo", "del", "2015", ":", "Progresión", "de", "enfermedad", "hepática", ":", "Capecitabina", "-", "Zolendronato", "\n", "Noviembre", "del", "2015", ":", "Progresión", "de", "enfermedad", "ganglionar", "y", "hepática", ":", "Exemestano", "-", "everolimus", "+", "Zolendronato", ".", "\n", "Diciembre", "del", "2015", ":", "Progresión", "de", "enfermedad", "cerebral", ":", "Recibe", "radioterapia", "holocraneal", "(", "4", "sesiones", "de", "500cGy", "por", "sesión", ")", "y", "se", "inicia", "tratamiento", "con", "Navelbina", "que", "comienza", "el", "22", "de", "enero", "del", "2016", ".", "La", "paciente", "no", "recibe", "el", "día", "+", "8", "del", "2º", "ciclo", "por", "síndrome", "febril", ".", "\n\n", "EPISODIO", "ACTUAL", ":", "\n", "La", "paciente", "acude", "a", "hospital", "de", "Día", "el", "27", "de", "febrero", "del", "2016", "por", "presentar", "fiebre", "resistente", "a", "antibioterapia", "oral", "con", "levofloxacino", ".", "Asocia", "cefalea", "y", "náuseas", "de", "una", "semana", "de", "evolución", ",", "además", "de", "episodios", "de", "desorientación", "temporo", "-", "espacial", "de", "unos", "dos", "meses", "de", "evolución", "pero", "que", "han", "aumentado", "en", "frecuencia", "en", "los", "últimos", "días", ".", "La", "paciente", "se", "encontraba", "hemodinámicamente", "estable", "y", "a", "la", "exploración", "física", "y", "neurológica", "no", "destacaba", "ningún", "hallazgo", "salvo", "la", "desorientación", "temporo", "-", "espacial", ".", "\n\n", "Exploración", "física", "\n", "La", "paciente", "se", "encontraba", "hemodinámicamente", "estable", "y", "a", "la", "exploración", "física", "y", "neurológica", "no", "destacaba", "ningún", "hallazgo", "salvo", "desorientación", "temporo", "-", "espacial", ".", "No", "existían", "signos", "de", "rigidez", "nucal", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "realiza", "una", "analítica", "al", "ingreso", "donde", "destaca", ":", "GGT", "219", "U", "/", "l", ",", "LDH", "2276", "U", "/", "l", "(", "previo", "1660", ")", ",", "Hb", "11", "g", "/", "dl", ",", "CEA", "2,7", "ng", "/", "ml", ",", "Ca", "15.3", "1088", "U", "/", "ml", "(", "previa", "1038", ")", ",", "siendo", "el", "resto", "de", "parámetros", "del", "hemograma", ",", "bioquímica", "y", "coagulación", "dentro", "de", "la", "normalidad", ".", "Se", "realizan", "radiografías", "de", "tórax", "y", "abdomen", "sin", "hallazgos", "de", "interés", ",", "se", "serian", "hemocultivos", "siendo", "todos", "negativos", ",", "urinocultivos", "negativos", "y", "cultivo", "de", "punta", "de", "catéter", "PICC", "negativo", ".", "\n", "Ante", "sospecha", "de", "encefalitis", "se", "inicia", "tratamiento", "antibiótico", "con", "ceftriaxona", ",", "vancomicina", ",", "aciclovir", "y", "ganciclovir", "con", "escaso", "beneficio", ".", "Se", "realiza", "una", "punción", "lumbar", "que", "muestra", "un", "líquido", "cefaloraquídeo", "(", "LCR", ")", "claro", "y", "transparente", "y", "como", "únicos", "hallazgos", "evidencia", "una", "pleocitosis", "linfocitaria", "de", "10", "células", "/", "ul", "y", "una", "proteinorraquia", "de", "75", "mg", "/", "dl", ".", "Se", "realiza", "una", "serología", "de", "sangre", "periférica", "que", "muestra", "negatividad", "para", "Borrelia", ",", "CMV", ",", "VHS", "1", "y", "2", ",", "VEB", ",", "VZV", "y", "VHH6", "negativos", ".", "\n", "Se", "solicita", "una", "resonancia", "magnética", "nuclear", "(", "RMN", ")", "cerebral", "que", "evidencia", "un", "extenso", "cambio", "de", "señal", "que", "afecta", "al", "córtex", "temporal", "y", "perisilviano", "bilateral", ",", "aunque", "de", "predominio", "derecho", ",", "que", "no", "se", "modifica", "tras", "la", "administración", "de", "contraste", "paramagnético", "(", "14", "ml", "de", "gadolinio", ")", ".", "No", "se", "advierten", "captaciones", "anómalas", "que", "sugieran", "afectación", "metastásica", ".", "Imágenes", "compatibles", "con", "encefalitis", "límbica", ".", "\n", "Se", "estudió", "la", "autoinmunidad", "de", "algunos", "anticuerpos", "antineuronales", "(", "anti", "-", "Yo", ",", "Ri", ",", "Hu", ",", "Tr", ",", "NMO", ",", "NMDA", ",", "MAG", ",", "VGCC", "y", "anti", "-", "islotes", "de", "Langerhans", ")", ",", "siendo", "todos", "negativos", ".", "\n\n", "Diagnóstico", "\n", "Encefalitis", "límbica", "paraneoplásica", "\n\n", "Tratamiento", "\n", "Ante", "la", "sospecha", "de", "encefalitis", "límbica", "paraneoplásica", "se", "decide", "comenzar", "el", "tratamiento", "específico", "antes", "de", "la", "confirmación", "diagnóstica", ".", "Se", "administra", "metilpredinosolona", "en", "bolos", "de", "un", "gramo", "durante", "5", "días", ",", "descartándose", "la", "plasmaféresis", "por", "el", "estado", "general", "de", "la", "paciente", ",", "y", "ante", "la", "escasa", "mejoría", "se", "administran", "posteriormente", "inmunoglubulinas", "0,4", "g", "/", "kg", "de", "peso", "durante", "3", "días", ".", "\n", "Se", "planteó", "el", "inicio", "de", "una", "nueva", "línea", "de", "tratamiento", "específica", "contra", "su", "enfermedad", "de", "base", ",", "sin", "embargo", "no", "fue", "posible", "iniciar", "nuevo", "tratamiento", "con", "quimioterapia", "debido", "a", "un", "importante", "deterioro", "clínico", "y", "rápida", "afectación", "del", "estado", "general", ".", "\n\n", "Evolución", "\n", "La", "paciente", "presentó", "una", "evolución", "desfavorable", "a", "pesar", "del", "tratamiento", "administrado", "y", "falleció", "posteriormente", "con", "buen", "control", "de", "síntomas", ".", "\n", "Ya", "habiendo", "fallecido", "la", "paciente", ",", "se", "evidenció", "en", "el", "proteinograma", "del", "LCR", "la", "presencia", "de", "bandas", "oligoclonales", "que", "apoyan", "el", "diagnóstico", "de", "encefalitis", "límbica", "paraneoplásica", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

tumoración, tumoral, carcinoma ductal infiltrante, metástasis por carcinoma ductal, metastásica, tumoral, células tumorales, micrometástasis, tumoral, proliferacion epitelial neoplásica, carcinoma infiltrante, ypM0, Progresión pulmonar, enfermedad hepática, Progresión de enfermedad ganglionar y hepática, enfermedad cerebral, metastásica

299_task2

Sentence: Anamnesis Nuestra paciente, una mujer de 48 años, consulta en febrero del 2013 por notarse nodulación en mama derecha con eritema asociado. La paciente no presentaba antecedentes médico-quirúrgicos de interés y no tenía hábitos tóxicos. En el estudio diagnóstico se realizan: ecografía mamaria que evidencia un nódulo hipoecoico de 2*2 cm en el cuadrante súperoexterno (CSE) de la mama derecha, engrosamiento difuso de piel y adenopatías axilares; mamografía que evidencia tumoración de 3*2cm en CSE de mama derecha. Se amplía el estudio con una RMN que destaca engrosamiento cutáneo de la piel con retracción asociada, encontrándose el volumen tumoral CSE pero con proyecciones espiculadas y nodulares que se extienden por todo el tejido mamario. Se realiza una biopsia por aguja gruesa (BAG) del nódulo mamario que evidencia un carcinoma ductal infiltrante de mama con receptores de estrógenos (+) y de progesterona (++) positivos, HER 2 negativo. La biopsia de la adenoapatía axilar revela metástasis por carcinoma ductal. Tras descartarse enfermedad metastásica en el estudio de extensión se decide administrar quimioterapia neoadyuvante según el esquema TAC (docetaxel, adriamicina, ciclofosfamida) por 4 ciclos. Posteriormente, se realiza una mastectomía radical modificada de mama derecha. El estudio de anatomía patológica muestra un foco tumoral de 21x23 mm, infiltración subareolar por células tumorales sueltas y 2 micrometástasis en 14 adenopatáis resecadas, los bordes quirúrgicos estaban libres de infiltración tumoral. A la visión microscópica se evidencia un tejido de proliferacion epitelial neoplásica constituida por un área escasamente nodular con proliferación de células cuboideas, frecuentes mitosis con abundante celularidad inflamatoria, positivas para CK5/6 pero negativas para CK14, débil expresión del receptor de estrógeno (Hsocre 10/300, Allred 3/8 en 10% de células), ausencia de receptores de progresterona (Hscore 0/300 y Allred 0/8) y una alta expresión de Ki67 (50% en áreas periféricas), expresión de Her2 negativa. Se trata por lo tanto de un carcinoma infiltrante de mama ypT4d ypN1 mic ypM0 RE+ RP- Her2 - ki67 50% fenotipo luminal B. Se completa el tratamiento adyuvante con TAC x 2 y con radioterapia externa hasta una dosis total de 50 Gy, tratamiento que finaliza en octubre del 2013. La paciente presenta posteriormente la siguiente evolución de enfermedad recibiendo los siguientes tratamientos de enfermedad avanzada: Noviembre del 2014: Progresión pulmonar, hepática y ósea: Placlitaxel-Bevacizumab x 6 ciclos + Zolendronato terminando en abril del 2015 por progresión de enfermedad. Mayo del 2015: Progresión de enfermedad hepática: Capecitabina - Zolendronato Noviembre del 2015: Progresión de enfermedad ganglionar y hepática: Exemestano-everolimus + Zolendronato. Diciembre del 2015: Progresión de enfermedad cerebral: Recibe radioterapia holocraneal (4 sesiones de 500cGy por sesión) y se inicia tratamiento con Navelbina que comienza el 22 de enero del 2016. La paciente no recibe el día + 8 del 2º ciclo por síndrome febril. EPISODIO ACTUAL: La paciente acude a hospital de Día el 27 de febrero del 2016 por presentar fiebre resistente a antibioterapia oral con levofloxacino. Asocia cefalea y náuseas de una semana de evolución, además de episodios de desorientación temporo-espacial de unos dos meses de evolución pero que han aumentado en frecuencia en los últimos días. La paciente se encontraba hemodinámicamente estable y a la exploración física y neurológica no destacaba ningún hallazgo salvo la desorientación temporo-espacial. Exploración física La paciente se encontraba hemodinámicamente estable y a la exploración física y neurológica no destacaba ningún hallazgo salvo desorientación temporo-espacial. No existían signos de rigidez nucal. Pruebas complementarias Se realiza una analítica al ingreso donde destaca: GGT 219 U/l, LDH 2276 U/l (previo 1660), Hb 11 g/dl, CEA 2,7 ng/ml, Ca 15.3 1088 U/ml (previa 1038), siendo el resto de parámetros del hemograma, bioquímica y coagulación dentro de la normalidad. Se realizan radiografías de tórax y abdomen sin hallazgos de interés, se serian hemocultivos siendo todos negativos, urinocultivos negativos y cultivo de punta de catéter PICC negativo. Ante sospecha de encefalitis se inicia tratamiento antibiótico con ceftriaxona, vancomicina, aciclovir y ganciclovir con escaso beneficio. Se realiza una punción lumbar que muestra un líquido cefaloraquídeo (LCR) claro y transparente y como únicos hallazgos evidencia una pleocitosis linfocitaria de 10 células/ul y una proteinorraquia de 75 mg/dl. Se realiza una serología de sangre periférica que muestra negatividad para Borrelia, CMV, VHS 1 y 2, VEB, VZV y VHH6 negativos. Se solicita una resonancia magnética nuclear (RMN) cerebral que evidencia un extenso cambio de señal que afecta al córtex temporal y perisilviano bilateral, aunque de predominio derecho, que no se modifica tras la administración de contraste paramagnético (14 ml de gadolinio). No se advierten captaciones anómalas que sugieran afectación metastásica. Imágenes compatibles con encefalitis límbica. Se estudió la autoinmunidad de algunos anticuerpos antineuronales (anti-Yo, Ri, Hu, Tr, NMO, NMDA, MAG, VGCC y anti-islotes de Langerhans), siendo todos negativos. Diagnóstico Encefalitis límbica paraneoplásica Tratamiento Ante la sospecha de encefalitis límbica paraneoplásica se decide comenzar el tratamiento específico antes de la confirmación diagnóstica. Se administra metilpredinosolona en bolos de un gramo durante 5 días, descartándose la plasmaféresis por el estado general de la paciente, y ante la escasa mejoría se administran posteriormente inmunoglubulinas 0,4 g/kg de peso durante 3 días. Se planteó el inicio de una nueva línea de tratamiento específica contra su enfermedad de base, sin embargo no fue posible iniciar nuevo tratamiento con quimioterapia debido a un importante deterioro clínico y rápida afectación del estado general. Evolución La paciente presentó una evolución desfavorable a pesar del tratamiento administrado y falleció posteriormente con buen control de síntomas. Ya habiendo fallecido la paciente, se evidenció en el proteinograma del LCR la presencia de bandas oligoclonales que apoyan el diagnóstico de encefalitis límbica paraneoplásica. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Nuestra paciente, una mujer de 48 años, consulta en febrero del 2013 por notarse nodulación en mama derecha con eritema asociado. La paciente no presentaba antecedentes médico-quirúrgicos de interés y no tenía hábitos tóxicos. En el estudio diagnóstico se realizan: ecografía mamaria que evidencia un nódulo hipoecoico de 2*2 cm en el cuadrante súperoexterno (CSE) de la mama derecha, engrosamiento difuso de piel y adenopatías axilares; mamografía que evidencia tumoración de 3*2cm en CSE de mama derecha. Se amplía el estudio con una RMN que destaca engrosamiento cutáneo de la piel con retracción asociada, encontrándose el volumen tumoral CSE pero con proyecciones espiculadas y nodulares que se extienden por todo el tejido mamario. Se realiza una biopsia por aguja gruesa (BAG) del nódulo mamario que evidencia un carcinoma ductal infiltrante de mama con receptores de estrógenos (+) y de progesterona (++) positivos, HER 2 negativo. La biopsia de la adenoapatía axilar revela metástasis por carcinoma ductal. Tras descartarse enfermedad metastásica en el estudio de extensión se decide administrar quimioterapia neoadyuvante según el esquema TAC (docetaxel, adriamicina, ciclofosfamida) por 4 ciclos. Posteriormente, se realiza una mastectomía radical modificada de mama derecha. El estudio de anatomía patológica muestra un foco tumoral de 21x23 mm, infiltración subareolar por células tumorales sueltas y 2 micrometástasis en 14 adenopatáis resecadas, los bordes quirúrgicos estaban libres de infiltración tumoral. A la visión microscópica se evidencia un tejido de proliferacion epitelial neoplásica constituida por un área escasamente nodular con proliferación de células cuboideas, frecuentes mitosis con abundante celularidad inflamatoria, positivas para CK5/6 pero negativas para CK14, débil expresión del receptor de estrógeno (Hsocre 10/300, Allred 3/8 en 10% de células), ausencia de receptores de progresterona (Hscore 0/300 y Allred 0/8) y una alta expresión de Ki67 (50% en áreas periféricas), expresión de Her2 negativa. Se trata por lo tanto de un carcinoma infiltrante de mama ypT4d ypN1 mic ypM0 RE+ RP- Her2 - ki67 50% fenotipo luminal B. Se completa el tratamiento adyuvante con TAC x 2 y con radioterapia externa hasta una dosis total de 50 Gy, tratamiento que finaliza en octubre del 2013. La paciente presenta posteriormente la siguiente evolución de enfermedad recibiendo los siguientes tratamientos de enfermedad avanzada: Noviembre del 2014: Progresión pulmonar, hepática y ósea: Placlitaxel-Bevacizumab x 6 ciclos + Zolendronato terminando en abril del 2015 por progresión de enfermedad. Mayo del 2015: Progresión de enfermedad hepática: Capecitabina - Zolendronato Noviembre del 2015: Progresión de enfermedad ganglionar y hepática: Exemestano-everolimus + Zolendronato. Diciembre del 2015: Progresión de enfermedad cerebral: Recibe radioterapia holocraneal (4 sesiones de 500cGy por sesión) y se inicia tratamiento con Navelbina que comienza el 22 de enero del 2016. La paciente no recibe el día + 8 del 2º ciclo por síndrome febril. EPISODIO ACTUAL: La paciente acude a hospital de Día el 27 de febrero del 2016 por presentar fiebre resistente a antibioterapia oral con levofloxacino. Asocia cefalea y náuseas de una semana de evolución, además de episodios de desorientación temporo-espacial de unos dos meses de evolución pero que han aumentado en frecuencia en los últimos días. La paciente se encontraba hemodinámicamente estable y a la exploración física y neurológica no destacaba ningún hallazgo salvo la desorientación temporo-espacial. Exploración física La paciente se encontraba hemodinámicamente estable y a la exploración física y neurológica no destacaba ningún hallazgo salvo desorientación temporo-espacial. No existían signos de rigidez nucal. Pruebas complementarias Se realiza una analítica al ingreso donde destaca: GGT 219 U/l, LDH 2276 U/l (previo 1660), Hb 11 g/dl, CEA 2,7 ng/ml, Ca 15.3 1088 U/ml (previa 1038), siendo el resto de parámetros del hemograma, bioquímica y coagulación dentro de la normalidad. Se realizan radiografías de tórax y abdomen sin hallazgos de interés, se serian hemocultivos siendo todos negativos, urinocultivos negativos y cultivo de punta de catéter PICC negativo. Ante sospecha de encefalitis se inicia tratamiento antibiótico con ceftriaxona, vancomicina, aciclovir y ganciclovir con escaso beneficio. Se realiza una punción lumbar que muestra un líquido cefaloraquídeo (LCR) claro y transparente y como únicos hallazgos evidencia una pleocitosis linfocitaria de 10 células/ul y una proteinorraquia de 75 mg/dl. Se realiza una serología de sangre periférica que muestra negatividad para Borrelia, CMV, VHS 1 y 2, VEB, VZV y VHH6 negativos. Se solicita una resonancia magnética nuclear (RMN) cerebral que evidencia un extenso cambio de señal que afecta al córtex temporal y perisilviano bilateral, aunque de predominio derecho, que no se modifica tras la administración de contraste paramagnético (14 ml de gadolinio). No se advierten captaciones anómalas que sugieran afectación metastásica. Imágenes compatibles con encefalitis límbica. Se estudió la autoinmunidad de algunos anticuerpos antineuronales (anti-Yo, Ri, Hu, Tr, NMO, NMDA, MAG, VGCC y anti-islotes de Langerhans), siendo todos negativos. Diagnóstico Encefalitis límbica paraneoplásica Tratamiento Ante la sospecha de encefalitis límbica paraneoplásica se decide comenzar el tratamiento específico antes de la confirmación diagnóstica. Se administra metilpredinosolona en bolos de un gramo durante 5 días, descartándose la plasmaféresis por el estado general de la paciente, y ante la escasa mejoría se administran posteriormente inmunoglubulinas 0,4 g/kg de peso durante 3 días. Se planteó el inicio de una nueva línea de tratamiento específica contra su enfermedad de base, sin embargo no fue posible iniciar nuevo tratamiento con quimioterapia debido a un importante deterioro clínico y rápida afectación del estado general. Evolución La paciente presentó una evolución desfavorable a pesar del tratamiento administrado y falleció posteriormente con buen control de síntomas. Ya habiendo fallecido la paciente, se evidenció en el proteinograma del LCR la presencia de bandas oligoclonales que apoyan el diagnóstico de encefalitis límbica paraneoplásica.

[ "Anamnesis", "\n", "Nuestra", "paciente", ",", "una", "mujer", "de", "48", "años", ",", "consulta", "en", "febrero", "del", "2013", "por", "notarse", "nodulación", "en", "mama", "derecha", "con", "eritema", "asociado", ".", "La", "paciente", "no", "presentaba", "antecedentes", "médico", "-", "quirúrgicos", "de", "interés", "y", "no", "tenía", "hábitos", "tóxicos", ".", "\n", "En", "el", "estudio", "diagnóstico", "se", "realizan", ":", "ecografía", "mamaria", "que", "evidencia", "un", "nódulo", "hipoecoico", "de", "2", "*", "2", "cm", "en", "el", "cuadrante", "súperoexterno", "(", "CSE", ")", "de", "la", "mama", "derecha", ",", "engrosamiento", "difuso", "de", "piel", "y", "adenopatías", "axilares", ";", "mamografía", "que", "evidencia", "tumoración", "de", "3", "*", "2", "cm", "en", "CSE", "de", "mama", "derecha", ".", "Se", "amplía", "el", "estudio", "con", "una", "RMN", "que", "destaca", "engrosamiento", "cutáneo", "de", "la", "piel", "con", "retracción", "asociada", ",", "encontrándose", "el", "volumen", "tumoral", "CSE", "pero", "con", "proyecciones", "espiculadas", "y", "nodulares", "que", "se", "extienden", "por", "todo", "el", "tejido", "mamario", ".", "\n", "Se", "realiza", "una", "biopsia", "por", "aguja", "gruesa", "(", "BAG", ")", "del", "nódulo", "mamario", "que", "evidencia", "un", "carcinoma", "ductal", "infiltrante", "de", "mama", "con", "receptores", "de", "estrógenos", "(", "+", ")", "y", "de", "progesterona", "(", "+", "+", ")", "positivos", ",", "HER", "2", "negativo", ".", "\n", "La", "biopsia", "de", "la", "adenoapatía", "axilar", "revela", "metástasis", "por", "carcinoma", "ductal", ".", "\n", "Tras", "descartarse", "enfermedad", "metastásica", "en", "el", "estudio", "de", "extensión", "se", "decide", "administrar", "quimioterapia", "neoadyuvante", "según", "el", "esquema", "TAC", "(", "docetaxel", ",", "adriamicina", ",", "ciclofosfamida", ")", "por", "4", "ciclos", ".", "Posteriormente", ",", "se", "realiza", "una", "mastectomía", "radical", "modificada", "de", "mama", "derecha", ".", "\n", "El", "estudio", "de", "anatomía", "patológica", "muestra", "un", "foco", "tumoral", "de", "21x23", "mm", ",", "infiltración", "subareolar", "por", "células", "tumorales", "sueltas", "y", "2", "micrometástasis", "en", "14", "adenopatáis", "resecadas", ",", "los", "bordes", "quirúrgicos", "estaban", "libres", "de", "infiltración", "tumoral", ".", "A", "la", "visión", "microscópica", "se", "evidencia", "un", "tejido", "de", "proliferacion", "epitelial", "neoplásica", "constituida", "por", "un", "área", "escasamente", "nodular", "con", "proliferación", "de", "células", "cuboideas", ",", "frecuentes", "mitosis", "con", "abundante", "celularidad", "inflamatoria", ",", "positivas", "para", "CK5/6", "pero", "negativas", "para", "CK14", ",", "débil", "expresión", "del", "receptor", "de", "estrógeno", "(", "Hsocre", "10/300", ",", "Allred", "3/8", "en", "10", "%", "de", "células", ")", ",", "ausencia", "de", "receptores", "de", "progresterona", "(", "Hscore", "0/300", "y", "Allred", "0/8", ")", "y", "una", "alta", "expresión", "de", "Ki67", "(", "50", "%", "en", "áreas", "periféricas", ")", ",", "expresión", "de", "Her2", "negativa", ".", "\n", "Se", "trata", "por", "lo", "tanto", "de", "un", "carcinoma", "infiltrante", "de", "mama", "ypT4d", "ypN1", "mic", "ypM0", "RE+", "RP-", "Her2", "-", "ki67", "50", "%", "fenotipo", "luminal", "B.", "\n", "Se", "completa", "el", "tratamiento", "adyuvante", "con", "TAC", "x", "2", "y", "con", "radioterapia", "externa", "hasta", "una", "dosis", "total", "de", "50", "Gy", ",", "tratamiento", "que", "finaliza", "en", "octubre", "del", "2013", ".", "\n", "La", "paciente", "presenta", "posteriormente", "la", "siguiente", "evolución", "de", "enfermedad", "recibiendo", "los", "siguientes", "tratamientos", "de", "enfermedad", "avanzada", ":", "\n", "Noviembre", "del", "2014", ":", "Progresión", "pulmonar", ",", "hepática", "y", "ósea", ":", "Placlitaxel", "-", "Bevacizumab", "x", "6", "ciclos", "+", "Zolendronato", "terminando", "en", "abril", "del", "2015", "por", "progresión", "de", "enfermedad", ".", "\n", "Mayo", "del", "2015", ":", "Progresión", "de", "enfermedad", "hepática", ":", "Capecitabina", "-", "Zolendronato", "\n", "Noviembre", "del", "2015", ":", "Progresión", "de", "enfermedad", "ganglionar", "y", "hepática", ":", "Exemestano", "-", "everolimus", "+", "Zolendronato", ".", "\n", "Diciembre", "del", "2015", ":", "Progresión", "de", "enfermedad", "cerebral", ":", "Recibe", "radioterapia", "holocraneal", "(", "4", "sesiones", "de", "500cGy", "por", "sesión", ")", "y", "se", "inicia", "tratamiento", "con", "Navelbina", "que", "comienza", "el", "22", "de", "enero", "del", "2016", ".", "La", "paciente", "no", "recibe", "el", "día", "+", "8", "del", "2º", "ciclo", "por", "síndrome", "febril", ".", "\n\n", "EPISODIO", "ACTUAL", ":", "\n", "La", "paciente", "acude", "a", "hospital", "de", "Día", "el", "27", "de", "febrero", "del", "2016", "por", "presentar", "fiebre", "resistente", "a", "antibioterapia", "oral", "con", "levofloxacino", ".", "Asocia", "cefalea", "y", "náuseas", "de", "una", "semana", "de", "evolución", ",", "además", "de", "episodios", "de", "desorientación", "temporo", "-", "espacial", "de", "unos", "dos", "meses", "de", "evolución", "pero", "que", "han", "aumentado", "en", "frecuencia", "en", "los", "últimos", "días", ".", "La", "paciente", "se", "encontraba", "hemodinámicamente", "estable", "y", "a", "la", "exploración", "física", "y", "neurológica", "no", "destacaba", "ningún", "hallazgo", "salvo", "la", "desorientación", "temporo", "-", "espacial", ".", "\n\n", "Exploración", "física", "\n", "La", "paciente", "se", "encontraba", "hemodinámicamente", "estable", "y", "a", "la", "exploración", "física", "y", "neurológica", "no", "destacaba", "ningún", "hallazgo", "salvo", "desorientación", "temporo", "-", "espacial", ".", "No", "existían", "signos", "de", "rigidez", "nucal", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "realiza", "una", "analítica", "al", "ingreso", "donde", "destaca", ":", "GGT", "219", "U", "/", "l", ",", "LDH", "2276", "U", "/", "l", "(", "previo", "1660", ")", ",", "Hb", "11", "g", "/", "dl", ",", "CEA", "2,7", "ng", "/", "ml", ",", "Ca", "15.3", "1088", "U", "/", "ml", "(", "previa", "1038", ")", ",", "siendo", "el", "resto", "de", "parámetros", "del", "hemograma", ",", "bioquímica", "y", "coagulación", "dentro", "de", "la", "normalidad", ".", "Se", "realizan", "radiografías", "de", "tórax", "y", "abdomen", "sin", "hallazgos", "de", "interés", ",", "se", "serian", "hemocultivos", "siendo", "todos", "negativos", ",", "urinocultivos", "negativos", "y", "cultivo", "de", "punta", "de", "catéter", "PICC", "negativo", ".", "\n", "Ante", "sospecha", "de", "encefalitis", "se", "inicia", "tratamiento", "antibiótico", "con", "ceftriaxona", ",", "vancomicina", ",", "aciclovir", "y", "ganciclovir", "con", "escaso", "beneficio", ".", "Se", "realiza", "una", "punción", "lumbar", "que", "muestra", "un", "líquido", "cefaloraquídeo", "(", "LCR", ")", "claro", "y", "transparente", "y", "como", "únicos", "hallazgos", "evidencia", "una", "pleocitosis", "linfocitaria", "de", "10", "células", "/", "ul", "y", "una", "proteinorraquia", "de", "75", "mg", "/", "dl", ".", "Se", "realiza", "una", "serología", "de", "sangre", "periférica", "que", "muestra", "negatividad", "para", "Borrelia", ",", "CMV", ",", "VHS", "1", "y", "2", ",", "VEB", ",", "VZV", "y", "VHH6", "negativos", ".", "\n", "Se", "solicita", "una", "resonancia", "magnética", "nuclear", "(", "RMN", ")", "cerebral", "que", "evidencia", "un", "extenso", "cambio", "de", "señal", "que", "afecta", "al", "córtex", "temporal", "y", "perisilviano", "bilateral", ",", "aunque", "de", "predominio", "derecho", ",", "que", "no", "se", "modifica", "tras", "la", "administración", "de", "contraste", "paramagnético", "(", "14", "ml", "de", "gadolinio", ")", ".", "No", "se", "advierten", "captaciones", "anómalas", "que", "sugieran", "afectación", "metastásica", ".", "Imágenes", "compatibles", "con", "encefalitis", "límbica", ".", "\n", "Se", "estudió", "la", "autoinmunidad", "de", "algunos", "anticuerpos", "antineuronales", "(", "anti", "-", "Yo", ",", "Ri", ",", "Hu", ",", "Tr", ",", "NMO", ",", "NMDA", ",", "MAG", ",", "VGCC", "y", "anti", "-", "islotes", "de", "Langerhans", ")", ",", "siendo", "todos", "negativos", ".", "\n\n", "Diagnóstico", "\n", "Encefalitis", "límbica", "paraneoplásica", "\n\n", "Tratamiento", "\n", "Ante", "la", "sospecha", "de", "encefalitis", "límbica", "paraneoplásica", "se", "decide", "comenzar", "el", "tratamiento", "específico", "antes", "de", "la", "confirmación", "diagnóstica", ".", "Se", "administra", "metilpredinosolona", "en", "bolos", "de", "un", "gramo", "durante", "5", "días", ",", "descartándose", "la", "plasmaféresis", "por", "el", "estado", "general", "de", "la", "paciente", ",", "y", "ante", "la", "escasa", "mejoría", "se", "administran", "posteriormente", "inmunoglubulinas", "0,4", "g", "/", "kg", "de", "peso", "durante", "3", "días", ".", "\n", "Se", "planteó", "el", "inicio", "de", "una", "nueva", "línea", "de", "tratamiento", "específica", "contra", "su", "enfermedad", "de", "base", ",", "sin", "embargo", "no", "fue", "posible", "iniciar", "nuevo", "tratamiento", "con", "quimioterapia", "debido", "a", "un", "importante", "deterioro", "clínico", "y", "rápida", "afectación", "del", "estado", "general", ".", "\n\n", "Evolución", "\n", "La", "paciente", "presentó", "una", "evolución", "desfavorable", "a", "pesar", "del", "tratamiento", "administrado", "y", "falleció", "posteriormente", "con", "buen", "control", "de", "síntomas", ".", "\n", "Ya", "habiendo", "fallecido", "la", "paciente", ",", "se", "evidenció", "en", "el", "proteinograma", "del", "LCR", "la", "presencia", "de", "bandas", "oligoclonales", "que", "apoyan", "el", "diagnóstico", "de", "encefalitis", "límbica", "paraneoplásica", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

Abstract is an umlsterm, caucasian is an umlsterm, woman is an umlsterm, naevus is an umlsterm, eye is an umlsterm, finding is an umlsterm, history is an umlsterm, patient is an umlsterm, naevus is an umlsterm, local anaesthesia is an umlsterm, naevus is an umlsterm

DerHautarzt.40450719.eng.abstr_task0

Sentence: Abstract . We report on the case of a 70-year-old caucasian woman with a large linear sebaceous naevus with multifocal intralesional basaliomas and a lipodermoid of the left eye . This rare finding has been preserved because of the special history of the patient . The naevus spread on the left side from parietal to retroauricular , nuchal and sternal . Because of the patient's cardio-pulmonary insufficiency we excised the basaliomas under local anaesthesia . We also made a partial stripped excision of the left-sided parietal parts of the naevus . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Abstract . We report on the case of a 70-year-old caucasian woman with a large linear sebaceous naevus with multifocal intralesional basaliomas and a lipodermoid of the left eye . This rare finding has been preserved because of the special history of the patient . The naevus spread on the left side from parietal to retroauricular , nuchal and sternal . Because of the patient's cardio-pulmonary insufficiency we excised the basaliomas under local anaesthesia . We also made a partial stripped excision of the left-sided parietal parts of the naevus .

[ "Abstract", ".", "We", "report", "on", "the", "case", "of", "a", "70-year", "-", "old", "caucasian", "woman", "with", "a", "large", "linear", "sebaceous", "naevus", "with", "multifocal", "intralesional", "basaliomas", "and", "a", "lipodermoid", "of", "the", "left", "eye", ".", "This", "rare", "finding", "has", "been", "preserved", "because", "of", "the", "special", "history", "of", "the", "patient", ".", "The", "naevus", "spread", "on", "the", "left", "side", "from", "parietal", "to", "retroauricular", ",", "nuchal", "and", "sternal", ".", "Because", "of", "the", "patient", "'s", "cardio", "-", "pulmonary", "insufficiency", "we", "excised", "the", "basaliomas", "under", "local", "anaesthesia", ".", "We", "also", "made", "a", "partial", "stripped", "excision", "of", "the", "left", "-", "sided", "parietal", "parts", "of", "the", "naevus", "." ]

[ "umlsterm" ]

Abstract is an umlsterm, caucasian is an umlsterm, woman is an umlsterm, naevus is an umlsterm, eye is an umlsterm, finding is an umlsterm, history is an umlsterm, patient is an umlsterm, naevus is an umlsterm, local anaesthesia is an umlsterm, naevus is an umlsterm

DerHautarzt.40450719.eng.abstr_task1

Sentence: Abstract . We report on the case of a 70-year-old caucasian woman with a large linear sebaceous naevus with multifocal intralesional basaliomas and a lipodermoid of the left eye . This rare finding has been preserved because of the special history of the patient . The naevus spread on the left side from parietal to retroauricular , nuchal and sternal . Because of the patient's cardio-pulmonary insufficiency we excised the basaliomas under local anaesthesia . We also made a partial stripped excision of the left-sided parietal parts of the naevus . Instructions: please typing these entity words according to sentence: Abstract, caucasian, woman, naevus, eye, finding, history, patient, naevus, local anaesthesia, naevus Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Abstract . We report on the case of a 70-year-old caucasian woman with a large linear sebaceous naevus with multifocal intralesional basaliomas and a lipodermoid of the left eye . This rare finding has been preserved because of the special history of the patient . The naevus spread on the left side from parietal to retroauricular , nuchal and sternal . Because of the patient's cardio-pulmonary insufficiency we excised the basaliomas under local anaesthesia . We also made a partial stripped excision of the left-sided parietal parts of the naevus .

[ "Abstract", ".", "We", "report", "on", "the", "case", "of", "a", "70-year", "-", "old", "caucasian", "woman", "with", "a", "large", "linear", "sebaceous", "naevus", "with", "multifocal", "intralesional", "basaliomas", "and", "a", "lipodermoid", "of", "the", "left", "eye", ".", "This", "rare", "finding", "has", "been", "preserved", "because", "of", "the", "special", "history", "of", "the", "patient", ".", "The", "naevus", "spread", "on", "the", "left", "side", "from", "parietal", "to", "retroauricular", ",", "nuchal", "and", "sternal", ".", "Because", "of", "the", "patient", "'s", "cardio", "-", "pulmonary", "insufficiency", "we", "excised", "the", "basaliomas", "under", "local", "anaesthesia", ".", "We", "also", "made", "a", "partial", "stripped", "excision", "of", "the", "left", "-", "sided", "parietal", "parts", "of", "the", "naevus", "." ]

[ "umlsterm" ]

Abstract, caucasian, woman, naevus, eye, finding, history, patient, naevus, local anaesthesia, naevus

DerHautarzt.40450719.eng.abstr_task2

Sentence: Abstract . We report on the case of a 70-year-old caucasian woman with a large linear sebaceous naevus with multifocal intralesional basaliomas and a lipodermoid of the left eye . This rare finding has been preserved because of the special history of the patient . The naevus spread on the left side from parietal to retroauricular , nuchal and sternal . Because of the patient's cardio-pulmonary insufficiency we excised the basaliomas under local anaesthesia . We also made a partial stripped excision of the left-sided parietal parts of the naevus . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Abstract . We report on the case of a 70-year-old caucasian woman with a large linear sebaceous naevus with multifocal intralesional basaliomas and a lipodermoid of the left eye . This rare finding has been preserved because of the special history of the patient . The naevus spread on the left side from parietal to retroauricular , nuchal and sternal . Because of the patient's cardio-pulmonary insufficiency we excised the basaliomas under local anaesthesia . We also made a partial stripped excision of the left-sided parietal parts of the naevus .

[ "Abstract", ".", "We", "report", "on", "the", "case", "of", "a", "70-year", "-", "old", "caucasian", "woman", "with", "a", "large", "linear", "sebaceous", "naevus", "with", "multifocal", "intralesional", "basaliomas", "and", "a", "lipodermoid", "of", "the", "left", "eye", ".", "This", "rare", "finding", "has", "been", "preserved", "because", "of", "the", "special", "history", "of", "the", "patient", ".", "The", "naevus", "spread", "on", "the", "left", "side", "from", "parietal", "to", "retroauricular", ",", "nuchal", "and", "sternal", ".", "Because", "of", "the", "patient", "'s", "cardio", "-", "pulmonary", "insufficiency", "we", "excised", "the", "basaliomas", "under", "local", "anaesthesia", ".", "We", "also", "made", "a", "partial", "stripped", "excision", "of", "the", "left", "-", "sided", "parietal", "parts", "of", "the", "naevus", "." ]

[ "umlsterm" ]

disease is an umlsterm, Angiokeratoma corporis diffusum is an umlsterm, disorder is an umlsterm, defect is an umlsterm, gene is an umlsterm, alpha - galactosidase is an umlsterm, enzyme is an umlsterm, glycosphingolipids is an umlsterm, deficiency is an umlsterm, smooth muscle is an umlsterm, cells is an umlsterm, time is an umlsterm, angiokeratomas is an umlsterm, complications is an umlsterm, patient is an umlsterm, findings is an umlsterm, nail is an umlsterm, capillary is an umlsterm, Analysis is an umlsterm, concentration is an umlsterm, alpha - galactosidase is an umlsterm, female is an umlsterm, carriers is an umlsterm, family is an umlsterm

DerHautarzt.60470776.eng.abstr_task0

Sentence: Fabry's disease ( Angiokeratoma corporis diffusum ) is a rare X-chromosome linked recessive disorder belonging to the group of sphingolipoidoses . The basic defect involves the gene encoding alpha-galactosidase . Because this enzyme is responsible for decomposition of glycosphingolipids , its deficiency results in their accumulation in endothelial and smooth muscle cells . With time , generalized angiokeratomas , paresthesias , renal and cardiac insufficiency and cerebrovascular complications develop . We report a patient who in addition to the well-described findings also showed unique nail fold capillary changes not described so far . Analysis of serum concentration of alpha-galactosidase identified three female heterozygous carriers in the patient's family . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

Fabry's disease ( Angiokeratoma corporis diffusum ) is a rare X-chromosome linked recessive disorder belonging to the group of sphingolipoidoses . The basic defect involves the gene encoding alpha-galactosidase . Because this enzyme is responsible for decomposition of glycosphingolipids , its deficiency results in their accumulation in endothelial and smooth muscle cells . With time , generalized angiokeratomas , paresthesias , renal and cardiac insufficiency and cerebrovascular complications develop . We report a patient who in addition to the well-described findings also showed unique nail fold capillary changes not described so far . Analysis of serum concentration of alpha-galactosidase identified three female heterozygous carriers in the patient's family .

[ "Fabry", "'s", "disease", "(", "Angiokeratoma", "corporis", "diffusum", ")", "is", "a", "rare", "X", "-", "chromosome", "linked", "recessive", "disorder", "belonging", "to", "the", "group", "of", "sphingolipoidoses", ".", "The", "basic", "defect", "involves", "the", "gene", "encoding", "alpha", "-", "galactosidase", ".", "Because", "this", "enzyme", "is", "responsible", "for", "decomposition", "of", "glycosphingolipids", ",", "its", "deficiency", "results", "in", "their", "accumulation", "in", "endothelial", "and", "smooth", "muscle", "cells", ".", "With", "time", ",", "generalized", "angiokeratomas", ",", "paresthesias", ",", "renal", "and", "cardiac", "insufficiency", "and", "cerebrovascular", "complications", "develop", ".", "We", "report", "a", "patient", "who", "in", "addition", "to", "the", "well", "-", "described", "findings", "also", "showed", "unique", "nail", "fold", "capillary", "changes", "not", "described", "so", "far", ".", "Analysis", "of", "serum", "concentration", "of", "alpha", "-", "galactosidase", "identified", "three", "female", "heterozygous", "carriers", "in", "the", "patient", "'s", "family", "." ]

[ "umlsterm" ]

disease is an umlsterm, Angiokeratoma corporis diffusum is an umlsterm, disorder is an umlsterm, defect is an umlsterm, gene is an umlsterm, alpha - galactosidase is an umlsterm, enzyme is an umlsterm, glycosphingolipids is an umlsterm, deficiency is an umlsterm, smooth muscle is an umlsterm, cells is an umlsterm, time is an umlsterm, angiokeratomas is an umlsterm, complications is an umlsterm, patient is an umlsterm, findings is an umlsterm, nail is an umlsterm, capillary is an umlsterm, Analysis is an umlsterm, concentration is an umlsterm, alpha - galactosidase is an umlsterm, female is an umlsterm, carriers is an umlsterm, family is an umlsterm

DerHautarzt.60470776.eng.abstr_task1

Sentence: Fabry's disease ( Angiokeratoma corporis diffusum ) is a rare X-chromosome linked recessive disorder belonging to the group of sphingolipoidoses . The basic defect involves the gene encoding alpha-galactosidase . Because this enzyme is responsible for decomposition of glycosphingolipids , its deficiency results in their accumulation in endothelial and smooth muscle cells . With time , generalized angiokeratomas , paresthesias , renal and cardiac insufficiency and cerebrovascular complications develop . We report a patient who in addition to the well-described findings also showed unique nail fold capillary changes not described so far . Analysis of serum concentration of alpha-galactosidase identified three female heterozygous carriers in the patient's family . Instructions: please typing these entity words according to sentence: disease, Angiokeratoma corporis diffusum, disorder, defect, gene, alpha - galactosidase, enzyme, glycosphingolipids, deficiency, smooth muscle, cells, time, angiokeratomas, complications, patient, findings, nail, capillary, Analysis, concentration, alpha - galactosidase, female, carriers, family Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

Fabry's disease ( Angiokeratoma corporis diffusum ) is a rare X-chromosome linked recessive disorder belonging to the group of sphingolipoidoses . The basic defect involves the gene encoding alpha-galactosidase . Because this enzyme is responsible for decomposition of glycosphingolipids , its deficiency results in their accumulation in endothelial and smooth muscle cells . With time , generalized angiokeratomas , paresthesias , renal and cardiac insufficiency and cerebrovascular complications develop . We report a patient who in addition to the well-described findings also showed unique nail fold capillary changes not described so far . Analysis of serum concentration of alpha-galactosidase identified three female heterozygous carriers in the patient's family .

[ "Fabry", "'s", "disease", "(", "Angiokeratoma", "corporis", "diffusum", ")", "is", "a", "rare", "X", "-", "chromosome", "linked", "recessive", "disorder", "belonging", "to", "the", "group", "of", "sphingolipoidoses", ".", "The", "basic", "defect", "involves", "the", "gene", "encoding", "alpha", "-", "galactosidase", ".", "Because", "this", "enzyme", "is", "responsible", "for", "decomposition", "of", "glycosphingolipids", ",", "its", "deficiency", "results", "in", "their", "accumulation", "in", "endothelial", "and", "smooth", "muscle", "cells", ".", "With", "time", ",", "generalized", "angiokeratomas", ",", "paresthesias", ",", "renal", "and", "cardiac", "insufficiency", "and", "cerebrovascular", "complications", "develop", ".", "We", "report", "a", "patient", "who", "in", "addition", "to", "the", "well", "-", "described", "findings", "also", "showed", "unique", "nail", "fold", "capillary", "changes", "not", "described", "so", "far", ".", "Analysis", "of", "serum", "concentration", "of", "alpha", "-", "galactosidase", "identified", "three", "female", "heterozygous", "carriers", "in", "the", "patient", "'s", "family", "." ]

[ "umlsterm" ]

disease, Angiokeratoma corporis diffusum, disorder, defect, gene, alpha - galactosidase, enzyme, glycosphingolipids, deficiency, smooth muscle, cells, time, angiokeratomas, complications, patient, findings, nail, capillary, Analysis, concentration, alpha - galactosidase, female, carriers, family

DerHautarzt.60470776.eng.abstr_task2

Sentence: Fabry's disease ( Angiokeratoma corporis diffusum ) is a rare X-chromosome linked recessive disorder belonging to the group of sphingolipoidoses . The basic defect involves the gene encoding alpha-galactosidase . Because this enzyme is responsible for decomposition of glycosphingolipids , its deficiency results in their accumulation in endothelial and smooth muscle cells . With time , generalized angiokeratomas , paresthesias , renal and cardiac insufficiency and cerebrovascular complications develop . We report a patient who in addition to the well-described findings also showed unique nail fold capillary changes not described so far . Analysis of serum concentration of alpha-galactosidase identified three female heterozygous carriers in the patient's family . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

Fabry's disease ( Angiokeratoma corporis diffusum ) is a rare X-chromosome linked recessive disorder belonging to the group of sphingolipoidoses . The basic defect involves the gene encoding alpha-galactosidase . Because this enzyme is responsible for decomposition of glycosphingolipids , its deficiency results in their accumulation in endothelial and smooth muscle cells . With time , generalized angiokeratomas , paresthesias , renal and cardiac insufficiency and cerebrovascular complications develop . We report a patient who in addition to the well-described findings also showed unique nail fold capillary changes not described so far . Analysis of serum concentration of alpha-galactosidase identified three female heterozygous carriers in the patient's family .

[ "Fabry", "'s", "disease", "(", "Angiokeratoma", "corporis", "diffusum", ")", "is", "a", "rare", "X", "-", "chromosome", "linked", "recessive", "disorder", "belonging", "to", "the", "group", "of", "sphingolipoidoses", ".", "The", "basic", "defect", "involves", "the", "gene", "encoding", "alpha", "-", "galactosidase", ".", "Because", "this", "enzyme", "is", "responsible", "for", "decomposition", "of", "glycosphingolipids", ",", "its", "deficiency", "results", "in", "their", "accumulation", "in", "endothelial", "and", "smooth", "muscle", "cells", ".", "With", "time", ",", "generalized", "angiokeratomas", ",", "paresthesias", ",", "renal", "and", "cardiac", "insufficiency", "and", "cerebrovascular", "complications", "develop", ".", "We", "report", "a", "patient", "who", "in", "addition", "to", "the", "well", "-", "described", "findings", "also", "showed", "unique", "nail", "fold", "capillary", "changes", "not", "described", "so", "far", ".", "Analysis", "of", "serum", "concentration", "of", "alpha", "-", "galactosidase", "identified", "three", "female", "heterozygous", "carriers", "in", "the", "patient", "'s", "family", "." ]

[ "umlsterm" ]

Frakturen is an umlsterm, Mittelhandknochen is an umlsterm, Kopfbereich is an umlsterm, Finger is an umlsterm, Gipsruhigstellung is an umlsterm, Frakturstellung is an umlsterm, Patienten is an umlsterm, Frakturen is an umlsterm, Schaftfrakturen is an umlsterm, Platten- is an umlsterm, Frakturen is an umlsterm, Mittelhandknochen is an umlsterm, Patienten is an umlsterm, Fingergelenke is an umlsterm, Hand is an umlsterm, radiologische is an umlsterm, Frakturfragmente is an umlsterm, Frakturen is an umlsterm, Mittelhandknochen is an umlsterm, Kirschner - Draehte is an umlsterm, radiologisch is an umlsterm

Trauma+Berufskrankheit.0002s386.ger.abstr_task0

Sentence: Frakturen der Mittelhandknochen im Schaft- und Kopfbereich sind haeufig disloziert und mit Rotationsfehlern der entsprechenden Finger verbunden . Die alleinige Reposition und Gipsruhigstellung ist oft langwierig und endet nicht immer mit einer optimalen Frakturstellung . Im Zeitraum von Dezember 1997 bis August 1999 wurden in unserem Haus 144 Patienten mit 166 Frakturen im Bereich des Schafts und der distalen Ossa metacarpalia operativ behandelt . Waehrend Schaftfrakturen mittels Schrauben- , Platten- oder Drahtosteosynthesen sowie Fixateur externe therapiert wurden , kamen bei Frakturen der distalen Mittelhandknochen ausschliesslich intramedullaere Kirschner-Draht-Osteosynthesen zur Anwendung . Bei allen Patienten wurden in definierten Zeitraeumen die Bewegungsausmasse der Fingergelenke , die Kraftentwicklung der Hand , die klinische und radiologische Stellung der Frakturfragmente kontrolliert sowie das Ausheilungsergebnis nach dem DASH-Score ( disability of arm/shoulder/hand ) bewertet . Die Ergebnisse zeigen , dass nach Frakturen des Schafts von Mittelhandknochen meist eine sichere knoecherne Konsolidierung bei guten klinischen Befunden erzielt werden konnte . Mit der intramedullaeren Osteosynthese durch modellierte Kirschner-Draehte konnten in fast allen Faellen von distalen Metakarpalfrakturen klinisch und radiologisch sehr gute Ergebnisse erzielt werden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

Frakturen der Mittelhandknochen im Schaft- und Kopfbereich sind haeufig disloziert und mit Rotationsfehlern der entsprechenden Finger verbunden . Die alleinige Reposition und Gipsruhigstellung ist oft langwierig und endet nicht immer mit einer optimalen Frakturstellung . Im Zeitraum von Dezember 1997 bis August 1999 wurden in unserem Haus 144 Patienten mit 166 Frakturen im Bereich des Schafts und der distalen Ossa metacarpalia operativ behandelt . Waehrend Schaftfrakturen mittels Schrauben- , Platten- oder Drahtosteosynthesen sowie Fixateur externe therapiert wurden , kamen bei Frakturen der distalen Mittelhandknochen ausschliesslich intramedullaere Kirschner-Draht-Osteosynthesen zur Anwendung . Bei allen Patienten wurden in definierten Zeitraeumen die Bewegungsausmasse der Fingergelenke , die Kraftentwicklung der Hand , die klinische und radiologische Stellung der Frakturfragmente kontrolliert sowie das Ausheilungsergebnis nach dem DASH-Score ( disability of arm/shoulder/hand ) bewertet . Die Ergebnisse zeigen , dass nach Frakturen des Schafts von Mittelhandknochen meist eine sichere knoecherne Konsolidierung bei guten klinischen Befunden erzielt werden konnte . Mit der intramedullaeren Osteosynthese durch modellierte Kirschner-Draehte konnten in fast allen Faellen von distalen Metakarpalfrakturen klinisch und radiologisch sehr gute Ergebnisse erzielt werden .

[ "Frakturen", "der", "Mittelhandknochen", "im", "Schaft-", "und", "Kopfbereich", "sind", "haeufig", "disloziert", "und", "mit", "Rotationsfehlern", "der", "entsprechenden", "Finger", "verbunden", ".", "Die", "alleinige", "Reposition", "und", "Gipsruhigstellung", "ist", "oft", "langwierig", "und", "endet", "nicht", "immer", "mit", "einer", "optimalen", "Frakturstellung", ".", "Im", "Zeitraum", "von", "Dezember", "1997", "bis", "August", "1999", "wurden", "in", "unserem", "Haus", "144", "Patienten", "mit", "166", "Frakturen", "im", "Bereich", "des", "Schafts", "und", "der", "distalen", "Ossa", "metacarpalia", "operativ", "behandelt", ".", "Waehrend", "Schaftfrakturen", "mittels", "Schrauben-", ",", "Platten-", "oder", "Drahtosteosynthesen", "sowie", "Fixateur", "externe", "therapiert", "wurden", ",", "kamen", "bei", "Frakturen", "der", "distalen", "Mittelhandknochen", "ausschliesslich", "intramedullaere", "Kirschner", "-", "Draht", "-", "Osteosynthesen", "zur", "Anwendung", ".", "Bei", "allen", "Patienten", "wurden", "in", "definierten", "Zeitraeumen", "die", "Bewegungsausmasse", "der", "Fingergelenke", ",", "die", "Kraftentwicklung", "der", "Hand", ",", "die", "klinische", "und", "radiologische", "Stellung", "der", "Frakturfragmente", "kontrolliert", "sowie", "das", "Ausheilungsergebnis", "nach", "dem", "DASH", "-", "Score", "(", "disability", "of", "arm", "/", "shoulder", "/", "hand", ")", "bewertet", ".", "Die", "Ergebnisse", "zeigen", ",", "dass", "nach", "Frakturen", "des", "Schafts", "von", "Mittelhandknochen", "meist", "eine", "sichere", "knoecherne", "Konsolidierung", "bei", "guten", "klinischen", "Befunden", "erzielt", "werden", "konnte", ".", "Mit", "der", "intramedullaeren", "Osteosynthese", "durch", "modellierte", "Kirschner", "-", "Draehte", "konnten", "in", "fast", "allen", "Faellen", "von", "distalen", "Metakarpalfrakturen", "klinisch", "und", "radiologisch", "sehr", "gute", "Ergebnisse", "erzielt", "werden", "." ]

[ "umlsterm" ]

Frakturen is an umlsterm, Mittelhandknochen is an umlsterm, Kopfbereich is an umlsterm, Finger is an umlsterm, Gipsruhigstellung is an umlsterm, Frakturstellung is an umlsterm, Patienten is an umlsterm, Frakturen is an umlsterm, Schaftfrakturen is an umlsterm, Platten- is an umlsterm, Frakturen is an umlsterm, Mittelhandknochen is an umlsterm, Patienten is an umlsterm, Fingergelenke is an umlsterm, Hand is an umlsterm, radiologische is an umlsterm, Frakturfragmente is an umlsterm, Frakturen is an umlsterm, Mittelhandknochen is an umlsterm, Kirschner - Draehte is an umlsterm, radiologisch is an umlsterm

Trauma+Berufskrankheit.0002s386.ger.abstr_task1

Sentence: Frakturen der Mittelhandknochen im Schaft- und Kopfbereich sind haeufig disloziert und mit Rotationsfehlern der entsprechenden Finger verbunden . Die alleinige Reposition und Gipsruhigstellung ist oft langwierig und endet nicht immer mit einer optimalen Frakturstellung . Im Zeitraum von Dezember 1997 bis August 1999 wurden in unserem Haus 144 Patienten mit 166 Frakturen im Bereich des Schafts und der distalen Ossa metacarpalia operativ behandelt . Waehrend Schaftfrakturen mittels Schrauben- , Platten- oder Drahtosteosynthesen sowie Fixateur externe therapiert wurden , kamen bei Frakturen der distalen Mittelhandknochen ausschliesslich intramedullaere Kirschner-Draht-Osteosynthesen zur Anwendung . Bei allen Patienten wurden in definierten Zeitraeumen die Bewegungsausmasse der Fingergelenke , die Kraftentwicklung der Hand , die klinische und radiologische Stellung der Frakturfragmente kontrolliert sowie das Ausheilungsergebnis nach dem DASH-Score ( disability of arm/shoulder/hand ) bewertet . Die Ergebnisse zeigen , dass nach Frakturen des Schafts von Mittelhandknochen meist eine sichere knoecherne Konsolidierung bei guten klinischen Befunden erzielt werden konnte . Mit der intramedullaeren Osteosynthese durch modellierte Kirschner-Draehte konnten in fast allen Faellen von distalen Metakarpalfrakturen klinisch und radiologisch sehr gute Ergebnisse erzielt werden . Instructions: please typing these entity words according to sentence: Frakturen, Mittelhandknochen, Kopfbereich, Finger, Gipsruhigstellung, Frakturstellung, Patienten, Frakturen, Schaftfrakturen, Platten-, Frakturen, Mittelhandknochen, Patienten, Fingergelenke, Hand, radiologische, Frakturfragmente, Frakturen, Mittelhandknochen, Kirschner - Draehte, radiologisch Options: umlsterm

[ "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

Frakturen der Mittelhandknochen im Schaft- und Kopfbereich sind haeufig disloziert und mit Rotationsfehlern der entsprechenden Finger verbunden . Die alleinige Reposition und Gipsruhigstellung ist oft langwierig und endet nicht immer mit einer optimalen Frakturstellung . Im Zeitraum von Dezember 1997 bis August 1999 wurden in unserem Haus 144 Patienten mit 166 Frakturen im Bereich des Schafts und der distalen Ossa metacarpalia operativ behandelt . Waehrend Schaftfrakturen mittels Schrauben- , Platten- oder Drahtosteosynthesen sowie Fixateur externe therapiert wurden , kamen bei Frakturen der distalen Mittelhandknochen ausschliesslich intramedullaere Kirschner-Draht-Osteosynthesen zur Anwendung . Bei allen Patienten wurden in definierten Zeitraeumen die Bewegungsausmasse der Fingergelenke , die Kraftentwicklung der Hand , die klinische und radiologische Stellung der Frakturfragmente kontrolliert sowie das Ausheilungsergebnis nach dem DASH-Score ( disability of arm/shoulder/hand ) bewertet . Die Ergebnisse zeigen , dass nach Frakturen des Schafts von Mittelhandknochen meist eine sichere knoecherne Konsolidierung bei guten klinischen Befunden erzielt werden konnte . Mit der intramedullaeren Osteosynthese durch modellierte Kirschner-Draehte konnten in fast allen Faellen von distalen Metakarpalfrakturen klinisch und radiologisch sehr gute Ergebnisse erzielt werden .

[ "Frakturen", "der", "Mittelhandknochen", "im", "Schaft-", "und", "Kopfbereich", "sind", "haeufig", "disloziert", "und", "mit", "Rotationsfehlern", "der", "entsprechenden", "Finger", "verbunden", ".", "Die", "alleinige", "Reposition", "und", "Gipsruhigstellung", "ist", "oft", "langwierig", "und", "endet", "nicht", "immer", "mit", "einer", "optimalen", "Frakturstellung", ".", "Im", "Zeitraum", "von", "Dezember", "1997", "bis", "August", "1999", "wurden", "in", "unserem", "Haus", "144", "Patienten", "mit", "166", "Frakturen", "im", "Bereich", "des", "Schafts", "und", "der", "distalen", "Ossa", "metacarpalia", "operativ", "behandelt", ".", "Waehrend", "Schaftfrakturen", "mittels", "Schrauben-", ",", "Platten-", "oder", "Drahtosteosynthesen", "sowie", "Fixateur", "externe", "therapiert", "wurden", ",", "kamen", "bei", "Frakturen", "der", "distalen", "Mittelhandknochen", "ausschliesslich", "intramedullaere", "Kirschner", "-", "Draht", "-", "Osteosynthesen", "zur", "Anwendung", ".", "Bei", "allen", "Patienten", "wurden", "in", "definierten", "Zeitraeumen", "die", "Bewegungsausmasse", "der", "Fingergelenke", ",", "die", "Kraftentwicklung", "der", "Hand", ",", "die", "klinische", "und", "radiologische", "Stellung", "der", "Frakturfragmente", "kontrolliert", "sowie", "das", "Ausheilungsergebnis", "nach", "dem", "DASH", "-", "Score", "(", "disability", "of", "arm", "/", "shoulder", "/", "hand", ")", "bewertet", ".", "Die", "Ergebnisse", "zeigen", ",", "dass", "nach", "Frakturen", "des", "Schafts", "von", "Mittelhandknochen", "meist", "eine", "sichere", "knoecherne", "Konsolidierung", "bei", "guten", "klinischen", "Befunden", "erzielt", "werden", "konnte", ".", "Mit", "der", "intramedullaeren", "Osteosynthese", "durch", "modellierte", "Kirschner", "-", "Draehte", "konnten", "in", "fast", "allen", "Faellen", "von", "distalen", "Metakarpalfrakturen", "klinisch", "und", "radiologisch", "sehr", "gute", "Ergebnisse", "erzielt", "werden", "." ]

[ "umlsterm" ]

Frakturen, Mittelhandknochen, Kopfbereich, Finger, Gipsruhigstellung, Frakturstellung, Patienten, Frakturen, Schaftfrakturen, Platten-, Frakturen, Mittelhandknochen, Patienten, Fingergelenke, Hand, radiologische, Frakturfragmente, Frakturen, Mittelhandknochen, Kirschner - Draehte, radiologisch

Trauma+Berufskrankheit.0002s386.ger.abstr_task2

Sentence: Frakturen der Mittelhandknochen im Schaft- und Kopfbereich sind haeufig disloziert und mit Rotationsfehlern der entsprechenden Finger verbunden . Die alleinige Reposition und Gipsruhigstellung ist oft langwierig und endet nicht immer mit einer optimalen Frakturstellung . Im Zeitraum von Dezember 1997 bis August 1999 wurden in unserem Haus 144 Patienten mit 166 Frakturen im Bereich des Schafts und der distalen Ossa metacarpalia operativ behandelt . Waehrend Schaftfrakturen mittels Schrauben- , Platten- oder Drahtosteosynthesen sowie Fixateur externe therapiert wurden , kamen bei Frakturen der distalen Mittelhandknochen ausschliesslich intramedullaere Kirschner-Draht-Osteosynthesen zur Anwendung . Bei allen Patienten wurden in definierten Zeitraeumen die Bewegungsausmasse der Fingergelenke , die Kraftentwicklung der Hand , die klinische und radiologische Stellung der Frakturfragmente kontrolliert sowie das Ausheilungsergebnis nach dem DASH-Score ( disability of arm/shoulder/hand ) bewertet . Die Ergebnisse zeigen , dass nach Frakturen des Schafts von Mittelhandknochen meist eine sichere knoecherne Konsolidierung bei guten klinischen Befunden erzielt werden konnte . Mit der intramedullaeren Osteosynthese durch modellierte Kirschner-Draehte konnten in fast allen Faellen von distalen Metakarpalfrakturen klinisch und radiologisch sehr gute Ergebnisse erzielt werden . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

Frakturen der Mittelhandknochen im Schaft- und Kopfbereich sind haeufig disloziert und mit Rotationsfehlern der entsprechenden Finger verbunden . Die alleinige Reposition und Gipsruhigstellung ist oft langwierig und endet nicht immer mit einer optimalen Frakturstellung . Im Zeitraum von Dezember 1997 bis August 1999 wurden in unserem Haus 144 Patienten mit 166 Frakturen im Bereich des Schafts und der distalen Ossa metacarpalia operativ behandelt . Waehrend Schaftfrakturen mittels Schrauben- , Platten- oder Drahtosteosynthesen sowie Fixateur externe therapiert wurden , kamen bei Frakturen der distalen Mittelhandknochen ausschliesslich intramedullaere Kirschner-Draht-Osteosynthesen zur Anwendung . Bei allen Patienten wurden in definierten Zeitraeumen die Bewegungsausmasse der Fingergelenke , die Kraftentwicklung der Hand , die klinische und radiologische Stellung der Frakturfragmente kontrolliert sowie das Ausheilungsergebnis nach dem DASH-Score ( disability of arm/shoulder/hand ) bewertet . Die Ergebnisse zeigen , dass nach Frakturen des Schafts von Mittelhandknochen meist eine sichere knoecherne Konsolidierung bei guten klinischen Befunden erzielt werden konnte . Mit der intramedullaeren Osteosynthese durch modellierte Kirschner-Draehte konnten in fast allen Faellen von distalen Metakarpalfrakturen klinisch und radiologisch sehr gute Ergebnisse erzielt werden .

[ "Frakturen", "der", "Mittelhandknochen", "im", "Schaft-", "und", "Kopfbereich", "sind", "haeufig", "disloziert", "und", "mit", "Rotationsfehlern", "der", "entsprechenden", "Finger", "verbunden", ".", "Die", "alleinige", "Reposition", "und", "Gipsruhigstellung", "ist", "oft", "langwierig", "und", "endet", "nicht", "immer", "mit", "einer", "optimalen", "Frakturstellung", ".", "Im", "Zeitraum", "von", "Dezember", "1997", "bis", "August", "1999", "wurden", "in", "unserem", "Haus", "144", "Patienten", "mit", "166", "Frakturen", "im", "Bereich", "des", "Schafts", "und", "der", "distalen", "Ossa", "metacarpalia", "operativ", "behandelt", ".", "Waehrend", "Schaftfrakturen", "mittels", "Schrauben-", ",", "Platten-", "oder", "Drahtosteosynthesen", "sowie", "Fixateur", "externe", "therapiert", "wurden", ",", "kamen", "bei", "Frakturen", "der", "distalen", "Mittelhandknochen", "ausschliesslich", "intramedullaere", "Kirschner", "-", "Draht", "-", "Osteosynthesen", "zur", "Anwendung", ".", "Bei", "allen", "Patienten", "wurden", "in", "definierten", "Zeitraeumen", "die", "Bewegungsausmasse", "der", "Fingergelenke", ",", "die", "Kraftentwicklung", "der", "Hand", ",", "die", "klinische", "und", "radiologische", "Stellung", "der", "Frakturfragmente", "kontrolliert", "sowie", "das", "Ausheilungsergebnis", "nach", "dem", "DASH", "-", "Score", "(", "disability", "of", "arm", "/", "shoulder", "/", "hand", ")", "bewertet", ".", "Die", "Ergebnisse", "zeigen", ",", "dass", "nach", "Frakturen", "des", "Schafts", "von", "Mittelhandknochen", "meist", "eine", "sichere", "knoecherne", "Konsolidierung", "bei", "guten", "klinischen", "Befunden", "erzielt", "werden", "konnte", ".", "Mit", "der", "intramedullaeren", "Osteosynthese", "durch", "modellierte", "Kirschner", "-", "Draehte", "konnten", "in", "fast", "allen", "Faellen", "von", "distalen", "Metakarpalfrakturen", "klinisch", "und", "radiologisch", "sehr", "gute", "Ergebnisse", "erzielt", "werden", "." ]

[ "umlsterm" ]

alpha catenin is a Gene/protein/RNA, beta catenin is a Gene/protein/RNA, gamma catenin is a Gene/protein/RNA

847_task0

Sentence: Treatment of cells with gamma linolenic acid (GLA) increased alpha catenin expression in most cell lines, while beta catenin levels were reduced, and gamma catenin expression was unchanged. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene/protein/RNA

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O" ]

Treatment of cells with gamma linolenic acid (GLA) increased alpha catenin expression in most cell lines, while beta catenin levels were reduced, and gamma catenin expression was unchanged.

[ "Treatment", "of", "cells", "with", "gamma", "linolenic", "acid", "(", "GLA", ")", "increased", "alpha", "catenin", "expression", "in", "most", "cell", "lines", ",", "while", "beta", "catenin", "levels", "were", "reduced", ",", "and", "gamma", "catenin", "expression", "was", "unchanged", "." ]

[ "Gene/protein/RNA" ]

alpha catenin is a Gene/protein/RNA, beta catenin is a Gene/protein/RNA, gamma catenin is a Gene/protein/RNA

847_task1

Sentence: Treatment of cells with gamma linolenic acid (GLA) increased alpha catenin expression in most cell lines, while beta catenin levels were reduced, and gamma catenin expression was unchanged. Instructions: please typing these entity words according to sentence: alpha catenin, beta catenin, gamma catenin Options: Gene/protein/RNA

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O" ]

Treatment of cells with gamma linolenic acid (GLA) increased alpha catenin expression in most cell lines, while beta catenin levels were reduced, and gamma catenin expression was unchanged.

[ "Treatment", "of", "cells", "with", "gamma", "linolenic", "acid", "(", "GLA", ")", "increased", "alpha", "catenin", "expression", "in", "most", "cell", "lines", ",", "while", "beta", "catenin", "levels", "were", "reduced", ",", "and", "gamma", "catenin", "expression", "was", "unchanged", "." ]

[ "Gene/protein/RNA" ]

alpha catenin, beta catenin, gamma catenin

847_task2

Sentence: Treatment of cells with gamma linolenic acid (GLA) increased alpha catenin expression in most cell lines, while beta catenin levels were reduced, and gamma catenin expression was unchanged. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O" ]

Treatment of cells with gamma linolenic acid (GLA) increased alpha catenin expression in most cell lines, while beta catenin levels were reduced, and gamma catenin expression was unchanged.

[ "Treatment", "of", "cells", "with", "gamma", "linolenic", "acid", "(", "GLA", ")", "increased", "alpha", "catenin", "expression", "in", "most", "cell", "lines", ",", "while", "beta", "catenin", "levels", "were", "reduced", ",", "and", "gamma", "catenin", "expression", "was", "unchanged", "." ]

[ "Gene/protein/RNA" ]

X - chromosome inactivation is an other_name, human androgen receptor gene is a DNA_domain_or_region, Humara is a DNA_domain_or_region, chronic myeloproliferative diseases is an other_name, secondary neutrophilia is an other_name, reactive thrombocytosis is an other_name

41696_task0

Sentence: Clonality analysis using X-chromosome inactivation at the human androgen receptor gene (Humara). Evaluation of large cohorts of patients with chronic myeloproliferative diseases, secondary neutrophilia, and reactive thrombocytosis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA_domain_or_region, other_name

[ "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "O", "O", "B-other_name", "I-other_name", "O" ]

Clonality analysis using X-chromosome inactivation at the human androgen receptor gene (Humara). Evaluation of large cohorts of patients with chronic myeloproliferative diseases, secondary neutrophilia, and reactive thrombocytosis.

[ "Clonality", "analysis", "using", "X", "-", "chromosome", "inactivation", "at", "the", "human", "androgen", "receptor", "gene", "(", "Humara", ")", ".", "Evaluation", "of", "large", "cohorts", "of", "patients", "with", "chronic", "myeloproliferative", "diseases", ",", "secondary", "neutrophilia", ",", "and", "reactive", "thrombocytosis", "." ]

[ "other_name", "(OR other_name other_name)", "DNA_domain_or_region", "multi_cell", "", "DNA_molecule" ]

X - chromosome inactivation is an other_name, human androgen receptor gene is a DNA_domain_or_region, Humara is a DNA_domain_or_region, chronic myeloproliferative diseases is an other_name, secondary neutrophilia is an other_name, reactive thrombocytosis is an other_name

41696_task1

Sentence: Clonality analysis using X-chromosome inactivation at the human androgen receptor gene (Humara). Evaluation of large cohorts of patients with chronic myeloproliferative diseases, secondary neutrophilia, and reactive thrombocytosis. Instructions: please typing these entity words according to sentence: X - chromosome inactivation, human androgen receptor gene, Humara, chronic myeloproliferative diseases, secondary neutrophilia, reactive thrombocytosis Options: DNA_domain_or_region, other_name

[ "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "O", "O", "B-other_name", "I-other_name", "O" ]

Clonality analysis using X-chromosome inactivation at the human androgen receptor gene (Humara). Evaluation of large cohorts of patients with chronic myeloproliferative diseases, secondary neutrophilia, and reactive thrombocytosis.

[ "Clonality", "analysis", "using", "X", "-", "chromosome", "inactivation", "at", "the", "human", "androgen", "receptor", "gene", "(", "Humara", ")", ".", "Evaluation", "of", "large", "cohorts", "of", "patients", "with", "chronic", "myeloproliferative", "diseases", ",", "secondary", "neutrophilia", ",", "and", "reactive", "thrombocytosis", "." ]

[ "other_name", "(OR other_name other_name)", "DNA_domain_or_region", "multi_cell", "", "DNA_molecule" ]

X - chromosome inactivation, human androgen receptor gene, Humara, chronic myeloproliferative diseases, secondary neutrophilia, reactive thrombocytosis

41696_task2

Sentence: Clonality analysis using X-chromosome inactivation at the human androgen receptor gene (Humara). Evaluation of large cohorts of patients with chronic myeloproliferative diseases, secondary neutrophilia, and reactive thrombocytosis. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "O", "O", "B-other_name", "I-other_name", "O" ]

Clonality analysis using X-chromosome inactivation at the human androgen receptor gene (Humara). Evaluation of large cohorts of patients with chronic myeloproliferative diseases, secondary neutrophilia, and reactive thrombocytosis.

[ "Clonality", "analysis", "using", "X", "-", "chromosome", "inactivation", "at", "the", "human", "androgen", "receptor", "gene", "(", "Humara", ")", ".", "Evaluation", "of", "large", "cohorts", "of", "patients", "with", "chronic", "myeloproliferative", "diseases", ",", "secondary", "neutrophilia", ",", "and", "reactive", "thrombocytosis", "." ]

[ "other_name", "(OR other_name other_name)", "DNA_domain_or_region", "multi_cell", "", "DNA_molecule" ]

Triebkopf is an umlsterm, Personen is an umlsterm, Unfallereignis is an umlsterm, Unfall is an umlsterm, Unfallgeschehen is an umlsterm, Organisationen is an umlsterm, Personen is an umlsterm, Luftfahrzeuge is an umlsterm, Unfallstelle is an umlsterm, Patienten is an umlsterm, Unfallstelle is an umlsterm, Patienten is an umlsterm, Zielkrankenhaeuser is an umlsterm, Unfallgeschehens is an umlsterm, Luftrettung is an umlsterm, Organisationen is an umlsterm, Polizei is an umlsterm, Katastropheneinsatzleitung is an umlsterm

DerUnfallchirurg.81010813.ger.abstr_task0

Sentence: Am 03.06.1998 , 10.59 Uhr verunfallte ein ICE-Zug bei einer Geschwindigkeit von 200 km/h . Durch eine eingestuerzte Bruecke wurden die Wagen teilweise ziehharmonikaartig durch den hinteren Triebkopf zusammengequetscht . Die Zahl der Toten betrug 101 , 103 Personen wurden verletzt . 4 Minuten nach dem Unfallereignis wurde Alarm gegeben und 16 Minuten nach dem Unfall traf der 1. Notarzt aus dem ca. 20 km entfernten Celle ein . In den ersten 4 Stunden nach dem Unfallgeschehen kamen aus den unterschiedlichsten Organisationen 1.844 Personen zum Einsatz , davon 467 aus dem Rettungs- und Sanitaetsdienst . 39 Luftfahrzeuge standen an der Unfallstelle zur Verfuegung . Die eingeklemmten Schwerverletzten mussten z . T. muehevoll aus zertruemmerten Wagen befreit werden , dennoch befanden sich alle Patienten um 12.55 Uhr mit einer Ausnahme auf dem Weg in die Kliniken . Die Verletzten wurden dezentral auf insgesamt 22 Kliniken verteilt . 95 wurden tot an der Unfallstelle geborgen . 2 Patienten wurden aus medizinischer Indikation verlegt . Dies spricht fuer eine korrekte Auswahl der Zielkrankenhaeuser . Fuer die schnellen Rettungszeiten und den Erfolg in Eschede waren neben den guenstigen aeusseren Umstaenden wie klare Sicht , Zeitpunkt des Unfallgeschehens , Einsatz der Luftrettung , die grosse Zahl von Notaerzten , Rettungs- und Sanitaetspersonal und das hervorragende Zusammenwirken der verschiedenen Organisationen , insbesondere der Feuerwehr , des technischen Hilfswerks , der Bundeswehr , der Polizei , des Bundesgrenzschutzes und der Katastropheneinsatzleitung entscheidend . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Am 03.06.1998 , 10.59 Uhr verunfallte ein ICE-Zug bei einer Geschwindigkeit von 200 km/h . Durch eine eingestuerzte Bruecke wurden die Wagen teilweise ziehharmonikaartig durch den hinteren Triebkopf zusammengequetscht . Die Zahl der Toten betrug 101 , 103 Personen wurden verletzt . 4 Minuten nach dem Unfallereignis wurde Alarm gegeben und 16 Minuten nach dem Unfall traf der 1. Notarzt aus dem ca. 20 km entfernten Celle ein . In den ersten 4 Stunden nach dem Unfallgeschehen kamen aus den unterschiedlichsten Organisationen 1.844 Personen zum Einsatz , davon 467 aus dem Rettungs- und Sanitaetsdienst . 39 Luftfahrzeuge standen an der Unfallstelle zur Verfuegung . Die eingeklemmten Schwerverletzten mussten z . T. muehevoll aus zertruemmerten Wagen befreit werden , dennoch befanden sich alle Patienten um 12.55 Uhr mit einer Ausnahme auf dem Weg in die Kliniken . Die Verletzten wurden dezentral auf insgesamt 22 Kliniken verteilt . 95 wurden tot an der Unfallstelle geborgen . 2 Patienten wurden aus medizinischer Indikation verlegt . Dies spricht fuer eine korrekte Auswahl der Zielkrankenhaeuser . Fuer die schnellen Rettungszeiten und den Erfolg in Eschede waren neben den guenstigen aeusseren Umstaenden wie klare Sicht , Zeitpunkt des Unfallgeschehens , Einsatz der Luftrettung , die grosse Zahl von Notaerzten , Rettungs- und Sanitaetspersonal und das hervorragende Zusammenwirken der verschiedenen Organisationen , insbesondere der Feuerwehr , des technischen Hilfswerks , der Bundeswehr , der Polizei , des Bundesgrenzschutzes und der Katastropheneinsatzleitung entscheidend .

[ "Am", "03.06.1998", ",", "10.59", "Uhr", "verunfallte", "ein", "ICE", "-", "Zug", "bei", "einer", "Geschwindigkeit", "von", "200", "km", "/", "h", ".", "Durch", "eine", "eingestuerzte", "Bruecke", "wurden", "die", "Wagen", "teilweise", "ziehharmonikaartig", "durch", "den", "hinteren", "Triebkopf", "zusammengequetscht", ".", "Die", "Zahl", "der", "Toten", "betrug", "101", ",", "103", "Personen", "wurden", "verletzt", ".", "4", "Minuten", "nach", "dem", "Unfallereignis", "wurde", "Alarm", "gegeben", "und", "16", "Minuten", "nach", "dem", "Unfall", "traf", "der", "1", ".", "Notarzt", "aus", "dem", "ca", ".", "20", "km", "entfernten", "Celle", "ein", ".", "In", "den", "ersten", "4", "Stunden", "nach", "dem", "Unfallgeschehen", "kamen", "aus", "den", "unterschiedlichsten", "Organisationen", "1.844", "Personen", "zum", "Einsatz", ",", "davon", "467", "aus", "dem", "Rettungs-", "und", "Sanitaetsdienst", ".", "39", "Luftfahrzeuge", "standen", "an", "der", "Unfallstelle", "zur", "Verfuegung", ".", "Die", "eingeklemmten", "Schwerverletzten", "mussten", "z", ".", "T.", "muehevoll", "aus", "zertruemmerten", "Wagen", "befreit", "werden", ",", "dennoch", "befanden", "sich", "alle", "Patienten", "um", "12.55", "Uhr", "mit", "einer", "Ausnahme", "auf", "dem", "Weg", "in", "die", "Kliniken", ".", "Die", "Verletzten", "wurden", "dezentral", "auf", "insgesamt", "22", "Kliniken", "verteilt", ".", "95", "wurden", "tot", "an", "der", "Unfallstelle", "geborgen", ".", "2", "Patienten", "wurden", "aus", "medizinischer", "Indikation", "verlegt", ".", "Dies", "spricht", "fuer", "eine", "korrekte", "Auswahl", "der", "Zielkrankenhaeuser", ".", "Fuer", "die", "schnellen", "Rettungszeiten", "und", "den", "Erfolg", "in", "Eschede", "waren", "neben", "den", "guenstigen", "aeusseren", "Umstaenden", "wie", "klare", "Sicht", ",", "Zeitpunkt", "des", "Unfallgeschehens", ",", "Einsatz", "der", "Luftrettung", ",", "die", "grosse", "Zahl", "von", "Notaerzten", ",", "Rettungs-", "und", "Sanitaetspersonal", "und", "das", "hervorragende", "Zusammenwirken", "der", "verschiedenen", "Organisationen", ",", "insbesondere", "der", "Feuerwehr", ",", "des", "technischen", "Hilfswerks", ",", "der", "Bundeswehr", ",", "der", "Polizei", ",", "des", "Bundesgrenzschutzes", "und", "der", "Katastropheneinsatzleitung", "entscheidend", "." ]

[ "umlsterm" ]

Triebkopf is an umlsterm, Personen is an umlsterm, Unfallereignis is an umlsterm, Unfall is an umlsterm, Unfallgeschehen is an umlsterm, Organisationen is an umlsterm, Personen is an umlsterm, Luftfahrzeuge is an umlsterm, Unfallstelle is an umlsterm, Patienten is an umlsterm, Unfallstelle is an umlsterm, Patienten is an umlsterm, Zielkrankenhaeuser is an umlsterm, Unfallgeschehens is an umlsterm, Luftrettung is an umlsterm, Organisationen is an umlsterm, Polizei is an umlsterm, Katastropheneinsatzleitung is an umlsterm

DerUnfallchirurg.81010813.ger.abstr_task1

Sentence: Am 03.06.1998 , 10.59 Uhr verunfallte ein ICE-Zug bei einer Geschwindigkeit von 200 km/h . Durch eine eingestuerzte Bruecke wurden die Wagen teilweise ziehharmonikaartig durch den hinteren Triebkopf zusammengequetscht . Die Zahl der Toten betrug 101 , 103 Personen wurden verletzt . 4 Minuten nach dem Unfallereignis wurde Alarm gegeben und 16 Minuten nach dem Unfall traf der 1. Notarzt aus dem ca. 20 km entfernten Celle ein . In den ersten 4 Stunden nach dem Unfallgeschehen kamen aus den unterschiedlichsten Organisationen 1.844 Personen zum Einsatz , davon 467 aus dem Rettungs- und Sanitaetsdienst . 39 Luftfahrzeuge standen an der Unfallstelle zur Verfuegung . Die eingeklemmten Schwerverletzten mussten z . T. muehevoll aus zertruemmerten Wagen befreit werden , dennoch befanden sich alle Patienten um 12.55 Uhr mit einer Ausnahme auf dem Weg in die Kliniken . Die Verletzten wurden dezentral auf insgesamt 22 Kliniken verteilt . 95 wurden tot an der Unfallstelle geborgen . 2 Patienten wurden aus medizinischer Indikation verlegt . Dies spricht fuer eine korrekte Auswahl der Zielkrankenhaeuser . Fuer die schnellen Rettungszeiten und den Erfolg in Eschede waren neben den guenstigen aeusseren Umstaenden wie klare Sicht , Zeitpunkt des Unfallgeschehens , Einsatz der Luftrettung , die grosse Zahl von Notaerzten , Rettungs- und Sanitaetspersonal und das hervorragende Zusammenwirken der verschiedenen Organisationen , insbesondere der Feuerwehr , des technischen Hilfswerks , der Bundeswehr , der Polizei , des Bundesgrenzschutzes und der Katastropheneinsatzleitung entscheidend . Instructions: please typing these entity words according to sentence: Triebkopf, Personen, Unfallereignis, Unfall, Unfallgeschehen, Organisationen, Personen, Luftfahrzeuge, Unfallstelle, Patienten, Unfallstelle, Patienten, Zielkrankenhaeuser, Unfallgeschehens, Luftrettung, Organisationen, Polizei, Katastropheneinsatzleitung Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Am 03.06.1998 , 10.59 Uhr verunfallte ein ICE-Zug bei einer Geschwindigkeit von 200 km/h . Durch eine eingestuerzte Bruecke wurden die Wagen teilweise ziehharmonikaartig durch den hinteren Triebkopf zusammengequetscht . Die Zahl der Toten betrug 101 , 103 Personen wurden verletzt . 4 Minuten nach dem Unfallereignis wurde Alarm gegeben und 16 Minuten nach dem Unfall traf der 1. Notarzt aus dem ca. 20 km entfernten Celle ein . In den ersten 4 Stunden nach dem Unfallgeschehen kamen aus den unterschiedlichsten Organisationen 1.844 Personen zum Einsatz , davon 467 aus dem Rettungs- und Sanitaetsdienst . 39 Luftfahrzeuge standen an der Unfallstelle zur Verfuegung . Die eingeklemmten Schwerverletzten mussten z . T. muehevoll aus zertruemmerten Wagen befreit werden , dennoch befanden sich alle Patienten um 12.55 Uhr mit einer Ausnahme auf dem Weg in die Kliniken . Die Verletzten wurden dezentral auf insgesamt 22 Kliniken verteilt . 95 wurden tot an der Unfallstelle geborgen . 2 Patienten wurden aus medizinischer Indikation verlegt . Dies spricht fuer eine korrekte Auswahl der Zielkrankenhaeuser . Fuer die schnellen Rettungszeiten und den Erfolg in Eschede waren neben den guenstigen aeusseren Umstaenden wie klare Sicht , Zeitpunkt des Unfallgeschehens , Einsatz der Luftrettung , die grosse Zahl von Notaerzten , Rettungs- und Sanitaetspersonal und das hervorragende Zusammenwirken der verschiedenen Organisationen , insbesondere der Feuerwehr , des technischen Hilfswerks , der Bundeswehr , der Polizei , des Bundesgrenzschutzes und der Katastropheneinsatzleitung entscheidend .

[ "Am", "03.06.1998", ",", "10.59", "Uhr", "verunfallte", "ein", "ICE", "-", "Zug", "bei", "einer", "Geschwindigkeit", "von", "200", "km", "/", "h", ".", "Durch", "eine", "eingestuerzte", "Bruecke", "wurden", "die", "Wagen", "teilweise", "ziehharmonikaartig", "durch", "den", "hinteren", "Triebkopf", "zusammengequetscht", ".", "Die", "Zahl", "der", "Toten", "betrug", "101", ",", "103", "Personen", "wurden", "verletzt", ".", "4", "Minuten", "nach", "dem", "Unfallereignis", "wurde", "Alarm", "gegeben", "und", "16", "Minuten", "nach", "dem", "Unfall", "traf", "der", "1", ".", "Notarzt", "aus", "dem", "ca", ".", "20", "km", "entfernten", "Celle", "ein", ".", "In", "den", "ersten", "4", "Stunden", "nach", "dem", "Unfallgeschehen", "kamen", "aus", "den", "unterschiedlichsten", "Organisationen", "1.844", "Personen", "zum", "Einsatz", ",", "davon", "467", "aus", "dem", "Rettungs-", "und", "Sanitaetsdienst", ".", "39", "Luftfahrzeuge", "standen", "an", "der", "Unfallstelle", "zur", "Verfuegung", ".", "Die", "eingeklemmten", "Schwerverletzten", "mussten", "z", ".", "T.", "muehevoll", "aus", "zertruemmerten", "Wagen", "befreit", "werden", ",", "dennoch", "befanden", "sich", "alle", "Patienten", "um", "12.55", "Uhr", "mit", "einer", "Ausnahme", "auf", "dem", "Weg", "in", "die", "Kliniken", ".", "Die", "Verletzten", "wurden", "dezentral", "auf", "insgesamt", "22", "Kliniken", "verteilt", ".", "95", "wurden", "tot", "an", "der", "Unfallstelle", "geborgen", ".", "2", "Patienten", "wurden", "aus", "medizinischer", "Indikation", "verlegt", ".", "Dies", "spricht", "fuer", "eine", "korrekte", "Auswahl", "der", "Zielkrankenhaeuser", ".", "Fuer", "die", "schnellen", "Rettungszeiten", "und", "den", "Erfolg", "in", "Eschede", "waren", "neben", "den", "guenstigen", "aeusseren", "Umstaenden", "wie", "klare", "Sicht", ",", "Zeitpunkt", "des", "Unfallgeschehens", ",", "Einsatz", "der", "Luftrettung", ",", "die", "grosse", "Zahl", "von", "Notaerzten", ",", "Rettungs-", "und", "Sanitaetspersonal", "und", "das", "hervorragende", "Zusammenwirken", "der", "verschiedenen", "Organisationen", ",", "insbesondere", "der", "Feuerwehr", ",", "des", "technischen", "Hilfswerks", ",", "der", "Bundeswehr", ",", "der", "Polizei", ",", "des", "Bundesgrenzschutzes", "und", "der", "Katastropheneinsatzleitung", "entscheidend", "." ]

[ "umlsterm" ]

Triebkopf, Personen, Unfallereignis, Unfall, Unfallgeschehen, Organisationen, Personen, Luftfahrzeuge, Unfallstelle, Patienten, Unfallstelle, Patienten, Zielkrankenhaeuser, Unfallgeschehens, Luftrettung, Organisationen, Polizei, Katastropheneinsatzleitung

DerUnfallchirurg.81010813.ger.abstr_task2

Sentence: Am 03.06.1998 , 10.59 Uhr verunfallte ein ICE-Zug bei einer Geschwindigkeit von 200 km/h . Durch eine eingestuerzte Bruecke wurden die Wagen teilweise ziehharmonikaartig durch den hinteren Triebkopf zusammengequetscht . Die Zahl der Toten betrug 101 , 103 Personen wurden verletzt . 4 Minuten nach dem Unfallereignis wurde Alarm gegeben und 16 Minuten nach dem Unfall traf der 1. Notarzt aus dem ca. 20 km entfernten Celle ein . In den ersten 4 Stunden nach dem Unfallgeschehen kamen aus den unterschiedlichsten Organisationen 1.844 Personen zum Einsatz , davon 467 aus dem Rettungs- und Sanitaetsdienst . 39 Luftfahrzeuge standen an der Unfallstelle zur Verfuegung . Die eingeklemmten Schwerverletzten mussten z . T. muehevoll aus zertruemmerten Wagen befreit werden , dennoch befanden sich alle Patienten um 12.55 Uhr mit einer Ausnahme auf dem Weg in die Kliniken . Die Verletzten wurden dezentral auf insgesamt 22 Kliniken verteilt . 95 wurden tot an der Unfallstelle geborgen . 2 Patienten wurden aus medizinischer Indikation verlegt . Dies spricht fuer eine korrekte Auswahl der Zielkrankenhaeuser . Fuer die schnellen Rettungszeiten und den Erfolg in Eschede waren neben den guenstigen aeusseren Umstaenden wie klare Sicht , Zeitpunkt des Unfallgeschehens , Einsatz der Luftrettung , die grosse Zahl von Notaerzten , Rettungs- und Sanitaetspersonal und das hervorragende Zusammenwirken der verschiedenen Organisationen , insbesondere der Feuerwehr , des technischen Hilfswerks , der Bundeswehr , der Polizei , des Bundesgrenzschutzes und der Katastropheneinsatzleitung entscheidend . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Am 03.06.1998 , 10.59 Uhr verunfallte ein ICE-Zug bei einer Geschwindigkeit von 200 km/h . Durch eine eingestuerzte Bruecke wurden die Wagen teilweise ziehharmonikaartig durch den hinteren Triebkopf zusammengequetscht . Die Zahl der Toten betrug 101 , 103 Personen wurden verletzt . 4 Minuten nach dem Unfallereignis wurde Alarm gegeben und 16 Minuten nach dem Unfall traf der 1. Notarzt aus dem ca. 20 km entfernten Celle ein . In den ersten 4 Stunden nach dem Unfallgeschehen kamen aus den unterschiedlichsten Organisationen 1.844 Personen zum Einsatz , davon 467 aus dem Rettungs- und Sanitaetsdienst . 39 Luftfahrzeuge standen an der Unfallstelle zur Verfuegung . Die eingeklemmten Schwerverletzten mussten z . T. muehevoll aus zertruemmerten Wagen befreit werden , dennoch befanden sich alle Patienten um 12.55 Uhr mit einer Ausnahme auf dem Weg in die Kliniken . Die Verletzten wurden dezentral auf insgesamt 22 Kliniken verteilt . 95 wurden tot an der Unfallstelle geborgen . 2 Patienten wurden aus medizinischer Indikation verlegt . Dies spricht fuer eine korrekte Auswahl der Zielkrankenhaeuser . Fuer die schnellen Rettungszeiten und den Erfolg in Eschede waren neben den guenstigen aeusseren Umstaenden wie klare Sicht , Zeitpunkt des Unfallgeschehens , Einsatz der Luftrettung , die grosse Zahl von Notaerzten , Rettungs- und Sanitaetspersonal und das hervorragende Zusammenwirken der verschiedenen Organisationen , insbesondere der Feuerwehr , des technischen Hilfswerks , der Bundeswehr , der Polizei , des Bundesgrenzschutzes und der Katastropheneinsatzleitung entscheidend .

[ "Am", "03.06.1998", ",", "10.59", "Uhr", "verunfallte", "ein", "ICE", "-", "Zug", "bei", "einer", "Geschwindigkeit", "von", "200", "km", "/", "h", ".", "Durch", "eine", "eingestuerzte", "Bruecke", "wurden", "die", "Wagen", "teilweise", "ziehharmonikaartig", "durch", "den", "hinteren", "Triebkopf", "zusammengequetscht", ".", "Die", "Zahl", "der", "Toten", "betrug", "101", ",", "103", "Personen", "wurden", "verletzt", ".", "4", "Minuten", "nach", "dem", "Unfallereignis", "wurde", "Alarm", "gegeben", "und", "16", "Minuten", "nach", "dem", "Unfall", "traf", "der", "1", ".", "Notarzt", "aus", "dem", "ca", ".", "20", "km", "entfernten", "Celle", "ein", ".", "In", "den", "ersten", "4", "Stunden", "nach", "dem", "Unfallgeschehen", "kamen", "aus", "den", "unterschiedlichsten", "Organisationen", "1.844", "Personen", "zum", "Einsatz", ",", "davon", "467", "aus", "dem", "Rettungs-", "und", "Sanitaetsdienst", ".", "39", "Luftfahrzeuge", "standen", "an", "der", "Unfallstelle", "zur", "Verfuegung", ".", "Die", "eingeklemmten", "Schwerverletzten", "mussten", "z", ".", "T.", "muehevoll", "aus", "zertruemmerten", "Wagen", "befreit", "werden", ",", "dennoch", "befanden", "sich", "alle", "Patienten", "um", "12.55", "Uhr", "mit", "einer", "Ausnahme", "auf", "dem", "Weg", "in", "die", "Kliniken", ".", "Die", "Verletzten", "wurden", "dezentral", "auf", "insgesamt", "22", "Kliniken", "verteilt", ".", "95", "wurden", "tot", "an", "der", "Unfallstelle", "geborgen", ".", "2", "Patienten", "wurden", "aus", "medizinischer", "Indikation", "verlegt", ".", "Dies", "spricht", "fuer", "eine", "korrekte", "Auswahl", "der", "Zielkrankenhaeuser", ".", "Fuer", "die", "schnellen", "Rettungszeiten", "und", "den", "Erfolg", "in", "Eschede", "waren", "neben", "den", "guenstigen", "aeusseren", "Umstaenden", "wie", "klare", "Sicht", ",", "Zeitpunkt", "des", "Unfallgeschehens", ",", "Einsatz", "der", "Luftrettung", ",", "die", "grosse", "Zahl", "von", "Notaerzten", ",", "Rettungs-", "und", "Sanitaetspersonal", "und", "das", "hervorragende", "Zusammenwirken", "der", "verschiedenen", "Organisationen", ",", "insbesondere", "der", "Feuerwehr", ",", "des", "technischen", "Hilfswerks", ",", "der", "Bundeswehr", ",", "der", "Polizei", ",", "des", "Bundesgrenzschutzes", "und", "der", "Katastropheneinsatzleitung", "entscheidend", "." ]

[ "umlsterm" ]

thrombogenicity is a ADVERSE, thrombogenicity is a ADVERSE

example-102_task0

Sentence: Risk of thrombogenicity among nonionic radiocontrast agents. Several contrast agents have been approved in the United States for radiographic imaging purposes. Most of the older ionic, high-osmolar contrast agents are no longer used because of their side effect profile. Therefore, newer nonionic, low or iso-osmolar contrast agents have been widely accepted as an alternative due to their improved tolerability and safety. We investigated the thrombogenicity of the 6 different nonionic radiocontrast media in terms of their platelet reactivity and noted some minor differences among them. In the 50% contrast concentration group, all of the nonionic contrast agents inhibited aggregation, whereas in the 10% contrast concentration group, all agents showed similar aggregation curves in comparison to the normal control. At 50% contrast concentration, the inhibitory effect of aggregation appeared to be related to the inhibition of calcium mobilization, which may be one of the mechanistic effects. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: ADVERSE

[ "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Risk of thrombogenicity among nonionic radiocontrast agents. Several contrast agents have been approved in the United States for radiographic imaging purposes. Most of the older ionic, high-osmolar contrast agents are no longer used because of their side effect profile. Therefore, newer nonionic, low or iso-osmolar contrast agents have been widely accepted as an alternative due to their improved tolerability and safety. We investigated the thrombogenicity of the 6 different nonionic radiocontrast media in terms of their platelet reactivity and noted some minor differences among them. In the 50% contrast concentration group, all of the nonionic contrast agents inhibited aggregation, whereas in the 10% contrast concentration group, all agents showed similar aggregation curves in comparison to the normal control. At 50% contrast concentration, the inhibitory effect of aggregation appeared to be related to the inhibition of calcium mobilization, which may be one of the mechanistic effects.

[ "Risk", "of", "thrombogenicity", "among", "nonionic", "radiocontrast", "agents", ".", " ", "Several", "contrast", "agents", "have", "been", "approved", "in", "the", "United", "States", "for", "radiographic", "imaging", "purposes", ".", "Most", "of", "the", "older", "ionic", ",", "high", "-", "osmolar", "contrast", "agents", "are", "no", "longer", "used", "because", "of", "their", "side", "effect", "profile", ".", "Therefore", ",", "newer", "nonionic", ",", "low", "or", "iso", "-", "osmolar", "contrast", "agents", "have", "been", "widely", "accepted", "as", "an", "alternative", "due", "to", "their", "improved", "tolerability", "and", "safety", ".", "We", "investigated", "the", "thrombogenicity", "of", "the", "6", "different", "nonionic", "radiocontrast", "media", "in", "terms", "of", "their", "platelet", "reactivity", "and", "noted", "some", "minor", "differences", "among", "them", ".", "In", "the", "50", "%", "contrast", "concentration", "group", ",", "all", "of", "the", "nonionic", "contrast", "agents", "inhibited", "aggregation", ",", "whereas", "in", "the", "10", "%", "contrast", "concentration", "group", ",", "all", "agents", "showed", "similar", "aggregation", "curves", "in", "comparison", "to", "the", "normal", "control", ".", "At", "50", "%", "contrast", "concentration", ",", "the", "inhibitory", "effect", "of", "aggregation", "appeared", "to", "be", "related", "to", "the", "inhibition", "of", "calcium", "mobilization", ",", "which", "may", "be", "one", "of", "the", "mechanistic", "effects", "." ]

[ "ADVERSE" ]

thrombogenicity is a ADVERSE, thrombogenicity is a ADVERSE

example-102_task1

Sentence: Risk of thrombogenicity among nonionic radiocontrast agents. Several contrast agents have been approved in the United States for radiographic imaging purposes. Most of the older ionic, high-osmolar contrast agents are no longer used because of their side effect profile. Therefore, newer nonionic, low or iso-osmolar contrast agents have been widely accepted as an alternative due to their improved tolerability and safety. We investigated the thrombogenicity of the 6 different nonionic radiocontrast media in terms of their platelet reactivity and noted some minor differences among them. In the 50% contrast concentration group, all of the nonionic contrast agents inhibited aggregation, whereas in the 10% contrast concentration group, all agents showed similar aggregation curves in comparison to the normal control. At 50% contrast concentration, the inhibitory effect of aggregation appeared to be related to the inhibition of calcium mobilization, which may be one of the mechanistic effects. Instructions: please typing these entity words according to sentence: thrombogenicity, thrombogenicity Options: ADVERSE

[ "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Risk of thrombogenicity among nonionic radiocontrast agents. Several contrast agents have been approved in the United States for radiographic imaging purposes. Most of the older ionic, high-osmolar contrast agents are no longer used because of their side effect profile. Therefore, newer nonionic, low or iso-osmolar contrast agents have been widely accepted as an alternative due to their improved tolerability and safety. We investigated the thrombogenicity of the 6 different nonionic radiocontrast media in terms of their platelet reactivity and noted some minor differences among them. In the 50% contrast concentration group, all of the nonionic contrast agents inhibited aggregation, whereas in the 10% contrast concentration group, all agents showed similar aggregation curves in comparison to the normal control. At 50% contrast concentration, the inhibitory effect of aggregation appeared to be related to the inhibition of calcium mobilization, which may be one of the mechanistic effects.

[ "Risk", "of", "thrombogenicity", "among", "nonionic", "radiocontrast", "agents", ".", " ", "Several", "contrast", "agents", "have", "been", "approved", "in", "the", "United", "States", "for", "radiographic", "imaging", "purposes", ".", "Most", "of", "the", "older", "ionic", ",", "high", "-", "osmolar", "contrast", "agents", "are", "no", "longer", "used", "because", "of", "their", "side", "effect", "profile", ".", "Therefore", ",", "newer", "nonionic", ",", "low", "or", "iso", "-", "osmolar", "contrast", "agents", "have", "been", "widely", "accepted", "as", "an", "alternative", "due", "to", "their", "improved", "tolerability", "and", "safety", ".", "We", "investigated", "the", "thrombogenicity", "of", "the", "6", "different", "nonionic", "radiocontrast", "media", "in", "terms", "of", "their", "platelet", "reactivity", "and", "noted", "some", "minor", "differences", "among", "them", ".", "In", "the", "50", "%", "contrast", "concentration", "group", ",", "all", "of", "the", "nonionic", "contrast", "agents", "inhibited", "aggregation", ",", "whereas", "in", "the", "10", "%", "contrast", "concentration", "group", ",", "all", "agents", "showed", "similar", "aggregation", "curves", "in", "comparison", "to", "the", "normal", "control", ".", "At", "50", "%", "contrast", "concentration", ",", "the", "inhibitory", "effect", "of", "aggregation", "appeared", "to", "be", "related", "to", "the", "inhibition", "of", "calcium", "mobilization", ",", "which", "may", "be", "one", "of", "the", "mechanistic", "effects", "." ]

[ "ADVERSE" ]

thrombogenicity, thrombogenicity

example-102_task2

Sentence: Risk of thrombogenicity among nonionic radiocontrast agents. Several contrast agents have been approved in the United States for radiographic imaging purposes. Most of the older ionic, high-osmolar contrast agents are no longer used because of their side effect profile. Therefore, newer nonionic, low or iso-osmolar contrast agents have been widely accepted as an alternative due to their improved tolerability and safety. We investigated the thrombogenicity of the 6 different nonionic radiocontrast media in terms of their platelet reactivity and noted some minor differences among them. In the 50% contrast concentration group, all of the nonionic contrast agents inhibited aggregation, whereas in the 10% contrast concentration group, all agents showed similar aggregation curves in comparison to the normal control. At 50% contrast concentration, the inhibitory effect of aggregation appeared to be related to the inhibition of calcium mobilization, which may be one of the mechanistic effects. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Risk of thrombogenicity among nonionic radiocontrast agents. Several contrast agents have been approved in the United States for radiographic imaging purposes. Most of the older ionic, high-osmolar contrast agents are no longer used because of their side effect profile. Therefore, newer nonionic, low or iso-osmolar contrast agents have been widely accepted as an alternative due to their improved tolerability and safety. We investigated the thrombogenicity of the 6 different nonionic radiocontrast media in terms of their platelet reactivity and noted some minor differences among them. In the 50% contrast concentration group, all of the nonionic contrast agents inhibited aggregation, whereas in the 10% contrast concentration group, all agents showed similar aggregation curves in comparison to the normal control. At 50% contrast concentration, the inhibitory effect of aggregation appeared to be related to the inhibition of calcium mobilization, which may be one of the mechanistic effects.

[ "Risk", "of", "thrombogenicity", "among", "nonionic", "radiocontrast", "agents", ".", " ", "Several", "contrast", "agents", "have", "been", "approved", "in", "the", "United", "States", "for", "radiographic", "imaging", "purposes", ".", "Most", "of", "the", "older", "ionic", ",", "high", "-", "osmolar", "contrast", "agents", "are", "no", "longer", "used", "because", "of", "their", "side", "effect", "profile", ".", "Therefore", ",", "newer", "nonionic", ",", "low", "or", "iso", "-", "osmolar", "contrast", "agents", "have", "been", "widely", "accepted", "as", "an", "alternative", "due", "to", "their", "improved", "tolerability", "and", "safety", ".", "We", "investigated", "the", "thrombogenicity", "of", "the", "6", "different", "nonionic", "radiocontrast", "media", "in", "terms", "of", "their", "platelet", "reactivity", "and", "noted", "some", "minor", "differences", "among", "them", ".", "In", "the", "50", "%", "contrast", "concentration", "group", ",", "all", "of", "the", "nonionic", "contrast", "agents", "inhibited", "aggregation", ",", "whereas", "in", "the", "10", "%", "contrast", "concentration", "group", ",", "all", "agents", "showed", "similar", "aggregation", "curves", "in", "comparison", "to", "the", "normal", "control", ".", "At", "50", "%", "contrast", "concentration", ",", "the", "inhibitory", "effect", "of", "aggregation", "appeared", "to", "be", "related", "to", "the", "inhibition", "of", "calcium", "mobilization", ",", "which", "may", "be", "one", "of", "the", "mechanistic", "effects", "." ]

[ "ADVERSE" ]

cyclic adenosine monophosphate signaling is an other_name, platelets is a cell_type, bipolar disorder is an other_name

45000_task0

Sentence: Abnormalities of cyclic adenosine monophosphate signaling in platelets from untreated patients with bipolar disorder. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_type, other_name

[ "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-cell_type", "O", "O", "O", "O", "B-other_name", "I-other_name", "O" ]

Abnormalities of cyclic adenosine monophosphate signaling in platelets from untreated patients with bipolar disorder.

[ "Abnormalities", "of", "cyclic", "adenosine", "monophosphate", "signaling", "in", "platelets", "from", "untreated", "patients", "with", "bipolar", "disorder", "." ]

[ "other_name", "(AND multi_cell multi_cell multi_cell)", "(AND protein_subunit protein_subunit)", "nucleotide", "protein_family_or_group", "multi_cell", "protein_subunit", "protein_molecule", "", "cell_type" ]

cyclic adenosine monophosphate signaling is an other_name, platelets is a cell_type, bipolar disorder is an other_name

45000_task1

Sentence: Abnormalities of cyclic adenosine monophosphate signaling in platelets from untreated patients with bipolar disorder. Instructions: please typing these entity words according to sentence: cyclic adenosine monophosphate signaling, platelets, bipolar disorder Options: cell_type, other_name

[ "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-cell_type", "O", "O", "O", "O", "B-other_name", "I-other_name", "O" ]

Abnormalities of cyclic adenosine monophosphate signaling in platelets from untreated patients with bipolar disorder.

[ "Abnormalities", "of", "cyclic", "adenosine", "monophosphate", "signaling", "in", "platelets", "from", "untreated", "patients", "with", "bipolar", "disorder", "." ]

[ "other_name", "(AND multi_cell multi_cell multi_cell)", "(AND protein_subunit protein_subunit)", "nucleotide", "protein_family_or_group", "multi_cell", "protein_subunit", "protein_molecule", "", "cell_type" ]

cyclic adenosine monophosphate signaling, platelets, bipolar disorder

45000_task2

Sentence: Abnormalities of cyclic adenosine monophosphate signaling in platelets from untreated patients with bipolar disorder. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-cell_type", "O", "O", "O", "O", "B-other_name", "I-other_name", "O" ]

Abnormalities of cyclic adenosine monophosphate signaling in platelets from untreated patients with bipolar disorder.

[ "Abnormalities", "of", "cyclic", "adenosine", "monophosphate", "signaling", "in", "platelets", "from", "untreated", "patients", "with", "bipolar", "disorder", "." ]

[ "other_name", "(AND multi_cell multi_cell multi_cell)", "(AND protein_subunit protein_subunit)", "nucleotide", "protein_family_or_group", "multi_cell", "protein_subunit", "protein_molecule", "", "cell_type" ]

early enteral nutrition with addition of probiotics is a Intervention_Pharmacological, severe acute pancreatitis is a Participant_Condition, early enteral nutrition ( EN ) supplemented with probiotics ( bifidobacterium ) is a Intervention_Pharmacological, severe acute pancreatitis ( ASP ) is a Participant_Condition, Seventy is a Participant_Sample-size, parenteral nutrition ( PN ) is a Intervention_Pharmacological, bifidobacterium added EN ( P+EN ) is a Intervention_Pharmacological, anti - infection and anti - acid agents is a Intervention_Pharmacological, CRP is a Outcome_Physical, LDH is a Outcome_Physical, amylase is a Outcome_Physical, lipase is a Outcome_Physical, plasma levels of IL-8 , TNF - α is a Outcome_Physical, WBC count is a Outcome_Physical, plasma IL-8 , TNF - α , CRP is a Outcome_Physical, incidence is a Outcome_Adverse-effects, upper gastrointestinal bleeding is a Outcome_Adverse-effects

59514_task0

Sentence: [ The effects of early enteral nutrition with addition of probiotics on the prognosis of patients suffering from severe acute pancreatitis ] . OBJECTIVE To investigate the curative effect of early enteral nutrition ( EN ) supplemented with probiotics ( bifidobacterium ) in patients with severe acute pancreatitis ( ASP ) . METHODS Seventy SAP cases admitted from January 2005 to October 2012 were randomly assigned into parenteral nutrition ( PN ) group ( n=22 ) , EN group ( n=25 ) and bifidobacterium added EN ( P+EN ) group ( n=23 ) . In P+EN group , patients were given their nutrition the same as that of EN , and also probiotics ( bifidobacterium , 4 capsules every 12 hours , given through nasal gastric tube , each capsule weighing 210 mg ) . The routine treatment including anti-infection and anti-acid agents , and that of inhibition of pancreatic secretion were given , except for the different nutritional interventions in all groups . The blood samples were collected for e same measurements of interleukin-8 ( IL-8 ) and tumor necrosis factor ( TNF-α ) by enzyme linked immunosorbent assay ( ELISA ) , and for the C-reactive protein ( CRP ) , lactic acid dehydrogenase ( LDH ) , white blood cell ( WBC ) count , amylase and lipase by biochemistry assay 1 day before intervention of nutrition , and 7 days and 14 days after intervention . Changes in organ function and outcome were also recorded at the same time points . RESULTS The plasma levels of IL-8 , TNF-α , CRP , LDH , WBC count , amylase and lipase were significantly reduced after nutritional intervention compared with their levels on day 1 before intervention in all three groups . The plasma IL-8 , TNF-α , CRP , lipase , LDH at 14 days after intervention of nutrition in P+EN group were significantly lower than those in PN group and EN group ( IL-8 : 21.00 ± 7.07 μg/L vs. 48.00 ± 10.32 μg/L , 32.00 ± 9.30 μg/L ; TNF-α : 44.3 ± 10.9 ng/L vs. 132.1 ± 34.1 ng/L , 67.8 ± 22.3 ng/L ; CRP : 35.0 ± 12.4 mg/L vs. 103.2 ± 49.2 mg/L , 63.0 ± 29.2 mg/L ; lipase : 269 ± 79 U/L vs. 670 ± 145 U/L , 310 ± 78 U/L ; LDH : 21.8 ± 10.3 U/L vs. 78.1 ± 37.4 U/L , 37.9 ± 25.1 U/L , P < 0.05 or P < 0.01 ) . The WBC count in P+EN group was significantly lower than that in PN group ( 5.9 ± 3.0 × 10⁹/L , 6.3 ± 3.2 × 10⁹/L vs. 9.6 ± 3.0 ×10⁹/L , both P < 0.05 ) , but there was no significant difference in amylase between P+EN group and PN group ( 211 ± 49 U/L , 236 ± 52 U/L vs. 298 ± 71 U/L , P > 0.05 ) . The gastrointestinal dysfunction score in P+EN , EN , PN groups 14 days after nutritional intervention was 0.28 ± 0.05 , 0.43 ± 0.09 , 0.71 ± 0.11 , respectively , with statistically significant differences ( all P < 0.01 ) . Compared with PN and EN groups , the incidence of upper gastrointestinal bleeding ( 1 vs. 9 , 2 ) , infection and abscess ( 2 vs. 12 , 5 ) was lower ( all P < 0.01 ) , and hospital day was significantly shortened in P+EN group ( 10.4 ± 3.9 days vs. 25.8 ± 6.4 days , 13.4 ± 5.2 days , both P < 0.01 ) . There was no significant statistical difference in mortality rate among three groups . CONCLUSION Our results indicated that early EN with addition of probiotics ( bifidobacterium ) resulted in significant lowering of the level of pro-inflammatory cytokines , earlier restoration of gastrointestinal function , decrease of complications such as infection , and shortening of hospital day in patients with SAP . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Physical, Participant_Sample-size

[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

[ The effects of early enteral nutrition with addition of probiotics on the prognosis of patients suffering from severe acute pancreatitis ] . OBJECTIVE To investigate the curative effect of early enteral nutrition ( EN ) supplemented with probiotics ( bifidobacterium ) in patients with severe acute pancreatitis ( ASP ) . METHODS Seventy SAP cases admitted from January 2005 to October 2012 were randomly assigned into parenteral nutrition ( PN ) group ( n=22 ) , EN group ( n=25 ) and bifidobacterium added EN ( P+EN ) group ( n=23 ) . In P+EN group , patients were given their nutrition the same as that of EN , and also probiotics ( bifidobacterium , 4 capsules every 12 hours , given through nasal gastric tube , each capsule weighing 210 mg ) . The routine treatment including anti-infection and anti-acid agents , and that of inhibition of pancreatic secretion were given , except for the different nutritional interventions in all groups . The blood samples were collected for e same measurements of interleukin-8 ( IL-8 ) and tumor necrosis factor ( TNF-α ) by enzyme linked immunosorbent assay ( ELISA ) , and for the C-reactive protein ( CRP ) , lactic acid dehydrogenase ( LDH ) , white blood cell ( WBC ) count , amylase and lipase by biochemistry assay 1 day before intervention of nutrition , and 7 days and 14 days after intervention . Changes in organ function and outcome were also recorded at the same time points . RESULTS The plasma levels of IL-8 , TNF-α , CRP , LDH , WBC count , amylase and lipase were significantly reduced after nutritional intervention compared with their levels on day 1 before intervention in all three groups . The plasma IL-8 , TNF-α , CRP , lipase , LDH at 14 days after intervention of nutrition in P+EN group were significantly lower than those in PN group and EN group ( IL-8 : 21.00 ± 7.07 μg/L vs. 48.00 ± 10.32 μg/L , 32.00 ± 9.30 μg/L ; TNF-α : 44.3 ± 10.9 ng/L vs. 132.1 ± 34.1 ng/L , 67.8 ± 22.3 ng/L ; CRP : 35.0 ± 12.4 mg/L vs. 103.2 ± 49.2 mg/L , 63.0 ± 29.2 mg/L ; lipase : 269 ± 79 U/L vs. 670 ± 145 U/L , 310 ± 78 U/L ; LDH : 21.8 ± 10.3 U/L vs. 78.1 ± 37.4 U/L , 37.9 ± 25.1 U/L , P < 0.05 or P < 0.01 ) . The WBC count in P+EN group was significantly lower than that in PN group ( 5.9 ± 3.0 × 10⁹/L , 6.3 ± 3.2 × 10⁹/L vs. 9.6 ± 3.0 ×10⁹/L , both P < 0.05 ) , but there was no significant difference in amylase between P+EN group and PN group ( 211 ± 49 U/L , 236 ± 52 U/L vs. 298 ± 71 U/L , P > 0.05 ) . The gastrointestinal dysfunction score in P+EN , EN , PN groups 14 days after nutritional intervention was 0.28 ± 0.05 , 0.43 ± 0.09 , 0.71 ± 0.11 , respectively , with statistically significant differences ( all P < 0.01 ) . Compared with PN and EN groups , the incidence of upper gastrointestinal bleeding ( 1 vs. 9 , 2 ) , infection and abscess ( 2 vs. 12 , 5 ) was lower ( all P < 0.01 ) , and hospital day was significantly shortened in P+EN group ( 10.4 ± 3.9 days vs. 25.8 ± 6.4 days , 13.4 ± 5.2 days , both P < 0.01 ) . There was no significant statistical difference in mortality rate among three groups . CONCLUSION Our results indicated that early EN with addition of probiotics ( bifidobacterium ) resulted in significant lowering of the level of pro-inflammatory cytokines , earlier restoration of gastrointestinal function , decrease of complications such as infection , and shortening of hospital day in patients with SAP .

[ "[", "The", "effects", "of", "early", "enteral", "nutrition", "with", "addition", "of", "probiotics", "on", "the", "prognosis", "of", "patients", "suffering", "from", "severe", "acute", "pancreatitis", "]", ".", "OBJECTIVE", "To", "investigate", "the", "curative", "effect", "of", "early", "enteral", "nutrition", "(", "EN", ")", "supplemented", "with", "probiotics", "(", "bifidobacterium", ")", "in", "patients", "with", "severe", "acute", "pancreatitis", "(", "ASP", ")", ".", "METHODS", "Seventy", "SAP", "cases", "admitted", "from", "January", "2005", "to", "October", "2012", "were", "randomly", "assigned", "into", "parenteral", "nutrition", "(", "PN", ")", "group", "(", "n=22", ")", ",", "EN", "group", "(", "n=25", ")", "and", "bifidobacterium", "added", "EN", "(", "P+EN", ")", "group", "(", "n=23", ")", ".", "In", "P+EN", "group", ",", "patients", "were", "given", "their", "nutrition", "the", "same", "as", "that", "of", "EN", ",", "and", "also", "probiotics", "(", "bifidobacterium", ",", "4", "capsules", "every", "12", "hours", ",", "given", "through", "nasal", "gastric", "tube", ",", "each", "capsule", "weighing", "210", "mg", ")", ".", "The", "routine", "treatment", "including", "anti", "-", "infection", "and", "anti", "-", "acid", "agents", ",", "and", "that", "of", "inhibition", "of", "pancreatic", "secretion", "were", "given", ",", "except", "for", "the", "different", "nutritional", "interventions", "in", "all", "groups", ".", "The", "blood", "samples", "were", "collected", "for", "e", "same", "measurements", "of", "interleukin-8", "(", "IL-8", ")", "and", "tumor", "necrosis", "factor", "(", "TNF", "-", "α", ")", "by", "enzyme", "linked", "immunosorbent", "assay", "(", "ELISA", ")", ",", "and", "for", "the", "C", "-", "reactive", "protein", "(", "CRP", ")", ",", "lactic", "acid", "dehydrogenase", "(", "LDH", ")", ",", "white", "blood", "cell", "(", "WBC", ")", "count", ",", "amylase", "and", "lipase", "by", "biochemistry", "assay", "1", "day", "before", "intervention", "of", "nutrition", ",", "and", "7", "days", "and", "14", "days", "after", "intervention", ".", "Changes", "in", "organ", "function", "and", "outcome", "were", "also", "recorded", "at", "the", "same", "time", "points", ".", "RESULTS", "The", "plasma", "levels", "of", "IL-8", ",", "TNF", "-", "α", ",", "CRP", ",", "LDH", ",", "WBC", "count", ",", "amylase", "and", "lipase", "were", "significantly", "reduced", "after", "nutritional", "intervention", "compared", "with", "their", "levels", "on", "day", "1", "before", "intervention", "in", "all", "three", "groups", ".", "The", "plasma", "IL-8", ",", "TNF", "-", "α", ",", "CRP", ",", "lipase", ",", "LDH", "at", "14", "days", "after", "intervention", "of", "nutrition", "in", "P+EN", "group", "were", "significantly", "lower", "than", "those", "in", "PN", "group", "and", "EN", "group", "(", "IL-8", ":", "21.00", "±", "7.07", "μg", "/", "L", "vs", ".", "48.00", "±", "10.32", "μg", "/", "L", ",", "32.00", "±", "9.30", "μg", "/", "L", ";", "TNF", "-", "α", ":", "44.3", "±", "10.9", "ng", "/", "L", "vs", ".", "132.1", "±", "34.1", "ng", "/", "L", ",", "67.8", "±", "22.3", "ng", "/", "L", ";", "CRP", ":", "35.0", "±", "12.4", "mg", "/", "L", "vs", ".", "103.2", "±", "49.2", "mg", "/", "L", ",", "63.0", "±", "29.2", "mg", "/", "L", ";", "lipase", ":", "269", "±", "79", "U", "/", "L", "vs", ".", "670", "±", "145", "U", "/", "L", ",", "310", "±", "78", "U", "/", "L", ";", "LDH", ":", "21.8", "±", "10.3", "U", "/", "L", "vs", ".", "78.1", "±", "37.4", "U", "/", "L", ",", "37.9", "±", "25.1", "U", "/", "L", ",", "P", "<", "0.05", "or", "P", "<", "0.01", ")", ".", "The", "WBC", "count", "in", "P+EN", "group", "was", "significantly", "lower", "than", "that", "in", "PN", "group", "(", "5.9", "±", "3.0", "×", "10⁹/L", ",", "6.3", "±", "3.2", "×", "10⁹/L", "vs", ".", "9.6", "±", "3.0", "×10⁹/L", ",", "both", "P", "<", "0.05", ")", ",", "but", "there", "was", "no", "significant", "difference", "in", "amylase", "between", "P+EN", "group", "and", "PN", "group", "(", "211", "±", "49", "U", "/", "L", ",", "236", "±", "52", "U", "/", "L", "vs", ".", "298", "±", "71", "U", "/", "L", ",", "P", ">", "0.05", ")", ".", "The", "gastrointestinal", "dysfunction", "score", "in", "P+EN", ",", "EN", ",", "PN", "groups", "14", "days", "after", "nutritional", "intervention", "was", "0.28", "±", "0.05", ",", "0.43", "±", "0.09", ",", "0.71", "±", "0.11", ",", "respectively", ",", "with", "statistically", "significant", "differences", "(", "all", "P", "<", "0.01", ")", ".", "Compared", "with", "PN", "and", "EN", "groups", ",", "the", "incidence", "of", "upper", "gastrointestinal", "bleeding", "(", "1", "vs", ".", "9", ",", "2", ")", ",", "infection", "and", "abscess", "(", "2", "vs", ".", "12", ",", "5", ")", "was", "lower", "(", "all", "P", "<", "0.01", ")", ",", "and", "hospital", "day", "was", "significantly", "shortened", "in", "P+EN", "group", "(", "10.4", "±", "3.9", "days", "vs", ".", "25.8", "±", "6.4", "days", ",", "13.4", "±", "5.2", "days", ",", "both", "P", "<", "0.01", ")", ".", "There", "was", "no", "significant", "statistical", "difference", "in", "mortality", "rate", "among", "three", "groups", ".", "CONCLUSION", "Our", "results", "indicated", "that", "early", "EN", "with", "addition", "of", "probiotics", "(", "bifidobacterium", ")", "resulted", "in", "significant", "lowering", "of", "the", "level", "of", "pro", "-", "inflammatory", "cytokines", ",", "earlier", "restoration", "of", "gastrointestinal", "function", ",", "decrease", "of", "complications", "such", "as", "infection", ",", "and", "shortening", "of", "hospital", "day", "in", "patients", "with", "SAP", "." ]

[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Adverse-effects", "Outcome_Physical", "Participant_Sample-size" ]

early enteral nutrition with addition of probiotics is a Intervention_Pharmacological, severe acute pancreatitis is a Participant_Condition, early enteral nutrition ( EN ) supplemented with probiotics ( bifidobacterium ) is a Intervention_Pharmacological, severe acute pancreatitis ( ASP ) is a Participant_Condition, Seventy is a Participant_Sample-size, parenteral nutrition ( PN ) is a Intervention_Pharmacological, bifidobacterium added EN ( P+EN ) is a Intervention_Pharmacological, anti - infection and anti - acid agents is a Intervention_Pharmacological, CRP is a Outcome_Physical, LDH is a Outcome_Physical, amylase is a Outcome_Physical, lipase is a Outcome_Physical, plasma levels of IL-8 , TNF - α is a Outcome_Physical, WBC count is a Outcome_Physical, plasma IL-8 , TNF - α , CRP is a Outcome_Physical, incidence is a Outcome_Adverse-effects, upper gastrointestinal bleeding is a Outcome_Adverse-effects

59514_task1

Sentence: [ The effects of early enteral nutrition with addition of probiotics on the prognosis of patients suffering from severe acute pancreatitis ] . OBJECTIVE To investigate the curative effect of early enteral nutrition ( EN ) supplemented with probiotics ( bifidobacterium ) in patients with severe acute pancreatitis ( ASP ) . METHODS Seventy SAP cases admitted from January 2005 to October 2012 were randomly assigned into parenteral nutrition ( PN ) group ( n=22 ) , EN group ( n=25 ) and bifidobacterium added EN ( P+EN ) group ( n=23 ) . In P+EN group , patients were given their nutrition the same as that of EN , and also probiotics ( bifidobacterium , 4 capsules every 12 hours , given through nasal gastric tube , each capsule weighing 210 mg ) . The routine treatment including anti-infection and anti-acid agents , and that of inhibition of pancreatic secretion were given , except for the different nutritional interventions in all groups . The blood samples were collected for e same measurements of interleukin-8 ( IL-8 ) and tumor necrosis factor ( TNF-α ) by enzyme linked immunosorbent assay ( ELISA ) , and for the C-reactive protein ( CRP ) , lactic acid dehydrogenase ( LDH ) , white blood cell ( WBC ) count , amylase and lipase by biochemistry assay 1 day before intervention of nutrition , and 7 days and 14 days after intervention . Changes in organ function and outcome were also recorded at the same time points . RESULTS The plasma levels of IL-8 , TNF-α , CRP , LDH , WBC count , amylase and lipase were significantly reduced after nutritional intervention compared with their levels on day 1 before intervention in all three groups . The plasma IL-8 , TNF-α , CRP , lipase , LDH at 14 days after intervention of nutrition in P+EN group were significantly lower than those in PN group and EN group ( IL-8 : 21.00 ± 7.07 μg/L vs. 48.00 ± 10.32 μg/L , 32.00 ± 9.30 μg/L ; TNF-α : 44.3 ± 10.9 ng/L vs. 132.1 ± 34.1 ng/L , 67.8 ± 22.3 ng/L ; CRP : 35.0 ± 12.4 mg/L vs. 103.2 ± 49.2 mg/L , 63.0 ± 29.2 mg/L ; lipase : 269 ± 79 U/L vs. 670 ± 145 U/L , 310 ± 78 U/L ; LDH : 21.8 ± 10.3 U/L vs. 78.1 ± 37.4 U/L , 37.9 ± 25.1 U/L , P < 0.05 or P < 0.01 ) . The WBC count in P+EN group was significantly lower than that in PN group ( 5.9 ± 3.0 × 10⁹/L , 6.3 ± 3.2 × 10⁹/L vs. 9.6 ± 3.0 ×10⁹/L , both P < 0.05 ) , but there was no significant difference in amylase between P+EN group and PN group ( 211 ± 49 U/L , 236 ± 52 U/L vs. 298 ± 71 U/L , P > 0.05 ) . The gastrointestinal dysfunction score in P+EN , EN , PN groups 14 days after nutritional intervention was 0.28 ± 0.05 , 0.43 ± 0.09 , 0.71 ± 0.11 , respectively , with statistically significant differences ( all P < 0.01 ) . Compared with PN and EN groups , the incidence of upper gastrointestinal bleeding ( 1 vs. 9 , 2 ) , infection and abscess ( 2 vs. 12 , 5 ) was lower ( all P < 0.01 ) , and hospital day was significantly shortened in P+EN group ( 10.4 ± 3.9 days vs. 25.8 ± 6.4 days , 13.4 ± 5.2 days , both P < 0.01 ) . There was no significant statistical difference in mortality rate among three groups . CONCLUSION Our results indicated that early EN with addition of probiotics ( bifidobacterium ) resulted in significant lowering of the level of pro-inflammatory cytokines , earlier restoration of gastrointestinal function , decrease of complications such as infection , and shortening of hospital day in patients with SAP . Instructions: please typing these entity words according to sentence: early enteral nutrition with addition of probiotics, severe acute pancreatitis, early enteral nutrition ( EN ) supplemented with probiotics ( bifidobacterium ), severe acute pancreatitis ( ASP ), Seventy, parenteral nutrition ( PN ), bifidobacterium added EN ( P+EN ), anti - infection and anti - acid agents, CRP, LDH, amylase, lipase, plasma levels of IL-8 , TNF - α, WBC count, plasma IL-8 , TNF - α , CRP, incidence, upper gastrointestinal bleeding Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Physical, Participant_Sample-size

[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

[ The effects of early enteral nutrition with addition of probiotics on the prognosis of patients suffering from severe acute pancreatitis ] . OBJECTIVE To investigate the curative effect of early enteral nutrition ( EN ) supplemented with probiotics ( bifidobacterium ) in patients with severe acute pancreatitis ( ASP ) . METHODS Seventy SAP cases admitted from January 2005 to October 2012 were randomly assigned into parenteral nutrition ( PN ) group ( n=22 ) , EN group ( n=25 ) and bifidobacterium added EN ( P+EN ) group ( n=23 ) . In P+EN group , patients were given their nutrition the same as that of EN , and also probiotics ( bifidobacterium , 4 capsules every 12 hours , given through nasal gastric tube , each capsule weighing 210 mg ) . The routine treatment including anti-infection and anti-acid agents , and that of inhibition of pancreatic secretion were given , except for the different nutritional interventions in all groups . The blood samples were collected for e same measurements of interleukin-8 ( IL-8 ) and tumor necrosis factor ( TNF-α ) by enzyme linked immunosorbent assay ( ELISA ) , and for the C-reactive protein ( CRP ) , lactic acid dehydrogenase ( LDH ) , white blood cell ( WBC ) count , amylase and lipase by biochemistry assay 1 day before intervention of nutrition , and 7 days and 14 days after intervention . Changes in organ function and outcome were also recorded at the same time points . RESULTS The plasma levels of IL-8 , TNF-α , CRP , LDH , WBC count , amylase and lipase were significantly reduced after nutritional intervention compared with their levels on day 1 before intervention in all three groups . The plasma IL-8 , TNF-α , CRP , lipase , LDH at 14 days after intervention of nutrition in P+EN group were significantly lower than those in PN group and EN group ( IL-8 : 21.00 ± 7.07 μg/L vs. 48.00 ± 10.32 μg/L , 32.00 ± 9.30 μg/L ; TNF-α : 44.3 ± 10.9 ng/L vs. 132.1 ± 34.1 ng/L , 67.8 ± 22.3 ng/L ; CRP : 35.0 ± 12.4 mg/L vs. 103.2 ± 49.2 mg/L , 63.0 ± 29.2 mg/L ; lipase : 269 ± 79 U/L vs. 670 ± 145 U/L , 310 ± 78 U/L ; LDH : 21.8 ± 10.3 U/L vs. 78.1 ± 37.4 U/L , 37.9 ± 25.1 U/L , P < 0.05 or P < 0.01 ) . The WBC count in P+EN group was significantly lower than that in PN group ( 5.9 ± 3.0 × 10⁹/L , 6.3 ± 3.2 × 10⁹/L vs. 9.6 ± 3.0 ×10⁹/L , both P < 0.05 ) , but there was no significant difference in amylase between P+EN group and PN group ( 211 ± 49 U/L , 236 ± 52 U/L vs. 298 ± 71 U/L , P > 0.05 ) . The gastrointestinal dysfunction score in P+EN , EN , PN groups 14 days after nutritional intervention was 0.28 ± 0.05 , 0.43 ± 0.09 , 0.71 ± 0.11 , respectively , with statistically significant differences ( all P < 0.01 ) . Compared with PN and EN groups , the incidence of upper gastrointestinal bleeding ( 1 vs. 9 , 2 ) , infection and abscess ( 2 vs. 12 , 5 ) was lower ( all P < 0.01 ) , and hospital day was significantly shortened in P+EN group ( 10.4 ± 3.9 days vs. 25.8 ± 6.4 days , 13.4 ± 5.2 days , both P < 0.01 ) . There was no significant statistical difference in mortality rate among three groups . CONCLUSION Our results indicated that early EN with addition of probiotics ( bifidobacterium ) resulted in significant lowering of the level of pro-inflammatory cytokines , earlier restoration of gastrointestinal function , decrease of complications such as infection , and shortening of hospital day in patients with SAP .

[ "[", "The", "effects", "of", "early", "enteral", "nutrition", "with", "addition", "of", "probiotics", "on", "the", "prognosis", "of", "patients", "suffering", "from", "severe", "acute", "pancreatitis", "]", ".", "OBJECTIVE", "To", "investigate", "the", "curative", "effect", "of", "early", "enteral", "nutrition", "(", "EN", ")", "supplemented", "with", "probiotics", "(", "bifidobacterium", ")", "in", "patients", "with", "severe", "acute", "pancreatitis", "(", "ASP", ")", ".", "METHODS", "Seventy", "SAP", "cases", "admitted", "from", "January", "2005", "to", "October", "2012", "were", "randomly", "assigned", "into", "parenteral", "nutrition", "(", "PN", ")", "group", "(", "n=22", ")", ",", "EN", "group", "(", "n=25", ")", "and", "bifidobacterium", "added", "EN", "(", "P+EN", ")", "group", "(", "n=23", ")", ".", "In", "P+EN", "group", ",", "patients", "were", "given", "their", "nutrition", "the", "same", "as", "that", "of", "EN", ",", "and", "also", "probiotics", "(", "bifidobacterium", ",", "4", "capsules", "every", "12", "hours", ",", "given", "through", "nasal", "gastric", "tube", ",", "each", "capsule", "weighing", "210", "mg", ")", ".", "The", "routine", "treatment", "including", "anti", "-", "infection", "and", "anti", "-", "acid", "agents", ",", "and", "that", "of", "inhibition", "of", "pancreatic", "secretion", "were", "given", ",", "except", "for", "the", "different", "nutritional", "interventions", "in", "all", "groups", ".", "The", "blood", "samples", "were", "collected", "for", "e", "same", "measurements", "of", "interleukin-8", "(", "IL-8", ")", "and", "tumor", "necrosis", "factor", "(", "TNF", "-", "α", ")", "by", "enzyme", "linked", "immunosorbent", "assay", "(", "ELISA", ")", ",", "and", "for", "the", "C", "-", "reactive", "protein", "(", "CRP", ")", ",", "lactic", "acid", "dehydrogenase", "(", "LDH", ")", ",", "white", "blood", "cell", "(", "WBC", ")", "count", ",", "amylase", "and", "lipase", "by", "biochemistry", "assay", "1", "day", "before", "intervention", "of", "nutrition", ",", "and", "7", "days", "and", "14", "days", "after", "intervention", ".", "Changes", "in", "organ", "function", "and", "outcome", "were", "also", "recorded", "at", "the", "same", "time", "points", ".", "RESULTS", "The", "plasma", "levels", "of", "IL-8", ",", "TNF", "-", "α", ",", "CRP", ",", "LDH", ",", "WBC", "count", ",", "amylase", "and", "lipase", "were", "significantly", "reduced", "after", "nutritional", "intervention", "compared", "with", "their", "levels", "on", "day", "1", "before", "intervention", "in", "all", "three", "groups", ".", "The", "plasma", "IL-8", ",", "TNF", "-", "α", ",", "CRP", ",", "lipase", ",", "LDH", "at", "14", "days", "after", "intervention", "of", "nutrition", "in", "P+EN", "group", "were", "significantly", "lower", "than", "those", "in", "PN", "group", "and", "EN", "group", "(", "IL-8", ":", "21.00", "±", "7.07", "μg", "/", "L", "vs", ".", "48.00", "±", "10.32", "μg", "/", "L", ",", "32.00", "±", "9.30", "μg", "/", "L", ";", "TNF", "-", "α", ":", "44.3", "±", "10.9", "ng", "/", "L", "vs", ".", "132.1", "±", "34.1", "ng", "/", "L", ",", "67.8", "±", "22.3", "ng", "/", "L", ";", "CRP", ":", "35.0", "±", "12.4", "mg", "/", "L", "vs", ".", "103.2", "±", "49.2", "mg", "/", "L", ",", "63.0", "±", "29.2", "mg", "/", "L", ";", "lipase", ":", "269", "±", "79", "U", "/", "L", "vs", ".", "670", "±", "145", "U", "/", "L", ",", "310", "±", "78", "U", "/", "L", ";", "LDH", ":", "21.8", "±", "10.3", "U", "/", "L", "vs", ".", "78.1", "±", "37.4", "U", "/", "L", ",", "37.9", "±", "25.1", "U", "/", "L", ",", "P", "<", "0.05", "or", "P", "<", "0.01", ")", ".", "The", "WBC", "count", "in", "P+EN", "group", "was", "significantly", "lower", "than", "that", "in", "PN", "group", "(", "5.9", "±", "3.0", "×", "10⁹/L", ",", "6.3", "±", "3.2", "×", "10⁹/L", "vs", ".", "9.6", "±", "3.0", "×10⁹/L", ",", "both", "P", "<", "0.05", ")", ",", "but", "there", "was", "no", "significant", "difference", "in", "amylase", "between", "P+EN", "group", "and", "PN", "group", "(", "211", "±", "49", "U", "/", "L", ",", "236", "±", "52", "U", "/", "L", "vs", ".", "298", "±", "71", "U", "/", "L", ",", "P", ">", "0.05", ")", ".", "The", "gastrointestinal", "dysfunction", "score", "in", "P+EN", ",", "EN", ",", "PN", "groups", "14", "days", "after", "nutritional", "intervention", "was", "0.28", "±", "0.05", ",", "0.43", "±", "0.09", ",", "0.71", "±", "0.11", ",", "respectively", ",", "with", "statistically", "significant", "differences", "(", "all", "P", "<", "0.01", ")", ".", "Compared", "with", "PN", "and", "EN", "groups", ",", "the", "incidence", "of", "upper", "gastrointestinal", "bleeding", "(", "1", "vs", ".", "9", ",", "2", ")", ",", "infection", "and", "abscess", "(", "2", "vs", ".", "12", ",", "5", ")", "was", "lower", "(", "all", "P", "<", "0.01", ")", ",", "and", "hospital", "day", "was", "significantly", "shortened", "in", "P+EN", "group", "(", "10.4", "±", "3.9", "days", "vs", ".", "25.8", "±", "6.4", "days", ",", "13.4", "±", "5.2", "days", ",", "both", "P", "<", "0.01", ")", ".", "There", "was", "no", "significant", "statistical", "difference", "in", "mortality", "rate", "among", "three", "groups", ".", "CONCLUSION", "Our", "results", "indicated", "that", "early", "EN", "with", "addition", "of", "probiotics", "(", "bifidobacterium", ")", "resulted", "in", "significant", "lowering", "of", "the", "level", "of", "pro", "-", "inflammatory", "cytokines", ",", "earlier", "restoration", "of", "gastrointestinal", "function", ",", "decrease", "of", "complications", "such", "as", "infection", ",", "and", "shortening", "of", "hospital", "day", "in", "patients", "with", "SAP", "." ]

[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Adverse-effects", "Outcome_Physical", "Participant_Sample-size" ]

early enteral nutrition with addition of probiotics, severe acute pancreatitis, early enteral nutrition ( EN ) supplemented with probiotics ( bifidobacterium ), severe acute pancreatitis ( ASP ), Seventy, parenteral nutrition ( PN ), bifidobacterium added EN ( P+EN ), anti - infection and anti - acid agents, CRP, LDH, amylase, lipase, plasma levels of IL-8 , TNF - α, WBC count, plasma IL-8 , TNF - α , CRP, incidence, upper gastrointestinal bleeding

59514_task2

Sentence: [ The effects of early enteral nutrition with addition of probiotics on the prognosis of patients suffering from severe acute pancreatitis ] . OBJECTIVE To investigate the curative effect of early enteral nutrition ( EN ) supplemented with probiotics ( bifidobacterium ) in patients with severe acute pancreatitis ( ASP ) . METHODS Seventy SAP cases admitted from January 2005 to October 2012 were randomly assigned into parenteral nutrition ( PN ) group ( n=22 ) , EN group ( n=25 ) and bifidobacterium added EN ( P+EN ) group ( n=23 ) . In P+EN group , patients were given their nutrition the same as that of EN , and also probiotics ( bifidobacterium , 4 capsules every 12 hours , given through nasal gastric tube , each capsule weighing 210 mg ) . The routine treatment including anti-infection and anti-acid agents , and that of inhibition of pancreatic secretion were given , except for the different nutritional interventions in all groups . The blood samples were collected for e same measurements of interleukin-8 ( IL-8 ) and tumor necrosis factor ( TNF-α ) by enzyme linked immunosorbent assay ( ELISA ) , and for the C-reactive protein ( CRP ) , lactic acid dehydrogenase ( LDH ) , white blood cell ( WBC ) count , amylase and lipase by biochemistry assay 1 day before intervention of nutrition , and 7 days and 14 days after intervention . Changes in organ function and outcome were also recorded at the same time points . RESULTS The plasma levels of IL-8 , TNF-α , CRP , LDH , WBC count , amylase and lipase were significantly reduced after nutritional intervention compared with their levels on day 1 before intervention in all three groups . The plasma IL-8 , TNF-α , CRP , lipase , LDH at 14 days after intervention of nutrition in P+EN group were significantly lower than those in PN group and EN group ( IL-8 : 21.00 ± 7.07 μg/L vs. 48.00 ± 10.32 μg/L , 32.00 ± 9.30 μg/L ; TNF-α : 44.3 ± 10.9 ng/L vs. 132.1 ± 34.1 ng/L , 67.8 ± 22.3 ng/L ; CRP : 35.0 ± 12.4 mg/L vs. 103.2 ± 49.2 mg/L , 63.0 ± 29.2 mg/L ; lipase : 269 ± 79 U/L vs. 670 ± 145 U/L , 310 ± 78 U/L ; LDH : 21.8 ± 10.3 U/L vs. 78.1 ± 37.4 U/L , 37.9 ± 25.1 U/L , P < 0.05 or P < 0.01 ) . The WBC count in P+EN group was significantly lower than that in PN group ( 5.9 ± 3.0 × 10⁹/L , 6.3 ± 3.2 × 10⁹/L vs. 9.6 ± 3.0 ×10⁹/L , both P < 0.05 ) , but there was no significant difference in amylase between P+EN group and PN group ( 211 ± 49 U/L , 236 ± 52 U/L vs. 298 ± 71 U/L , P > 0.05 ) . The gastrointestinal dysfunction score in P+EN , EN , PN groups 14 days after nutritional intervention was 0.28 ± 0.05 , 0.43 ± 0.09 , 0.71 ± 0.11 , respectively , with statistically significant differences ( all P < 0.01 ) . Compared with PN and EN groups , the incidence of upper gastrointestinal bleeding ( 1 vs. 9 , 2 ) , infection and abscess ( 2 vs. 12 , 5 ) was lower ( all P < 0.01 ) , and hospital day was significantly shortened in P+EN group ( 10.4 ± 3.9 days vs. 25.8 ± 6.4 days , 13.4 ± 5.2 days , both P < 0.01 ) . There was no significant statistical difference in mortality rate among three groups . CONCLUSION Our results indicated that early EN with addition of probiotics ( bifidobacterium ) resulted in significant lowering of the level of pro-inflammatory cytokines , earlier restoration of gastrointestinal function , decrease of complications such as infection , and shortening of hospital day in patients with SAP . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

[ The effects of early enteral nutrition with addition of probiotics on the prognosis of patients suffering from severe acute pancreatitis ] . OBJECTIVE To investigate the curative effect of early enteral nutrition ( EN ) supplemented with probiotics ( bifidobacterium ) in patients with severe acute pancreatitis ( ASP ) . METHODS Seventy SAP cases admitted from January 2005 to October 2012 were randomly assigned into parenteral nutrition ( PN ) group ( n=22 ) , EN group ( n=25 ) and bifidobacterium added EN ( P+EN ) group ( n=23 ) . In P+EN group , patients were given their nutrition the same as that of EN , and also probiotics ( bifidobacterium , 4 capsules every 12 hours , given through nasal gastric tube , each capsule weighing 210 mg ) . The routine treatment including anti-infection and anti-acid agents , and that of inhibition of pancreatic secretion were given , except for the different nutritional interventions in all groups . The blood samples were collected for e same measurements of interleukin-8 ( IL-8 ) and tumor necrosis factor ( TNF-α ) by enzyme linked immunosorbent assay ( ELISA ) , and for the C-reactive protein ( CRP ) , lactic acid dehydrogenase ( LDH ) , white blood cell ( WBC ) count , amylase and lipase by biochemistry assay 1 day before intervention of nutrition , and 7 days and 14 days after intervention . Changes in organ function and outcome were also recorded at the same time points . RESULTS The plasma levels of IL-8 , TNF-α , CRP , LDH , WBC count , amylase and lipase were significantly reduced after nutritional intervention compared with their levels on day 1 before intervention in all three groups . The plasma IL-8 , TNF-α , CRP , lipase , LDH at 14 days after intervention of nutrition in P+EN group were significantly lower than those in PN group and EN group ( IL-8 : 21.00 ± 7.07 μg/L vs. 48.00 ± 10.32 μg/L , 32.00 ± 9.30 μg/L ; TNF-α : 44.3 ± 10.9 ng/L vs. 132.1 ± 34.1 ng/L , 67.8 ± 22.3 ng/L ; CRP : 35.0 ± 12.4 mg/L vs. 103.2 ± 49.2 mg/L , 63.0 ± 29.2 mg/L ; lipase : 269 ± 79 U/L vs. 670 ± 145 U/L , 310 ± 78 U/L ; LDH : 21.8 ± 10.3 U/L vs. 78.1 ± 37.4 U/L , 37.9 ± 25.1 U/L , P < 0.05 or P < 0.01 ) . The WBC count in P+EN group was significantly lower than that in PN group ( 5.9 ± 3.0 × 10⁹/L , 6.3 ± 3.2 × 10⁹/L vs. 9.6 ± 3.0 ×10⁹/L , both P < 0.05 ) , but there was no significant difference in amylase between P+EN group and PN group ( 211 ± 49 U/L , 236 ± 52 U/L vs. 298 ± 71 U/L , P > 0.05 ) . The gastrointestinal dysfunction score in P+EN , EN , PN groups 14 days after nutritional intervention was 0.28 ± 0.05 , 0.43 ± 0.09 , 0.71 ± 0.11 , respectively , with statistically significant differences ( all P < 0.01 ) . Compared with PN and EN groups , the incidence of upper gastrointestinal bleeding ( 1 vs. 9 , 2 ) , infection and abscess ( 2 vs. 12 , 5 ) was lower ( all P < 0.01 ) , and hospital day was significantly shortened in P+EN group ( 10.4 ± 3.9 days vs. 25.8 ± 6.4 days , 13.4 ± 5.2 days , both P < 0.01 ) . There was no significant statistical difference in mortality rate among three groups . CONCLUSION Our results indicated that early EN with addition of probiotics ( bifidobacterium ) resulted in significant lowering of the level of pro-inflammatory cytokines , earlier restoration of gastrointestinal function , decrease of complications such as infection , and shortening of hospital day in patients with SAP .

[ "[", "The", "effects", "of", "early", "enteral", "nutrition", "with", "addition", "of", "probiotics", "on", "the", "prognosis", "of", "patients", "suffering", "from", "severe", "acute", "pancreatitis", "]", ".", "OBJECTIVE", "To", "investigate", "the", "curative", "effect", "of", "early", "enteral", "nutrition", "(", "EN", ")", "supplemented", "with", "probiotics", "(", "bifidobacterium", ")", "in", "patients", "with", "severe", "acute", "pancreatitis", "(", "ASP", ")", ".", "METHODS", "Seventy", "SAP", "cases", "admitted", "from", "January", "2005", "to", "October", "2012", "were", "randomly", "assigned", "into", "parenteral", "nutrition", "(", "PN", ")", "group", "(", "n=22", ")", ",", "EN", "group", "(", "n=25", ")", "and", "bifidobacterium", "added", "EN", "(", "P+EN", ")", "group", "(", "n=23", ")", ".", "In", "P+EN", "group", ",", "patients", "were", "given", "their", "nutrition", "the", "same", "as", "that", "of", "EN", ",", "and", "also", "probiotics", "(", "bifidobacterium", ",", "4", "capsules", "every", "12", "hours", ",", "given", "through", "nasal", "gastric", "tube", ",", "each", "capsule", "weighing", "210", "mg", ")", ".", "The", "routine", "treatment", "including", "anti", "-", "infection", "and", "anti", "-", "acid", "agents", ",", "and", "that", "of", "inhibition", "of", "pancreatic", "secretion", "were", "given", ",", "except", "for", "the", "different", "nutritional", "interventions", "in", "all", "groups", ".", "The", "blood", "samples", "were", "collected", "for", "e", "same", "measurements", "of", "interleukin-8", "(", "IL-8", ")", "and", "tumor", "necrosis", "factor", "(", "TNF", "-", "α", ")", "by", "enzyme", "linked", "immunosorbent", "assay", "(", "ELISA", ")", ",", "and", "for", "the", "C", "-", "reactive", "protein", "(", "CRP", ")", ",", "lactic", "acid", "dehydrogenase", "(", "LDH", ")", ",", "white", "blood", "cell", "(", "WBC", ")", "count", ",", "amylase", "and", "lipase", "by", "biochemistry", "assay", "1", "day", "before", "intervention", "of", "nutrition", ",", "and", "7", "days", "and", "14", "days", "after", "intervention", ".", "Changes", "in", "organ", "function", "and", "outcome", "were", "also", "recorded", "at", "the", "same", "time", "points", ".", "RESULTS", "The", "plasma", "levels", "of", "IL-8", ",", "TNF", "-", "α", ",", "CRP", ",", "LDH", ",", "WBC", "count", ",", "amylase", "and", "lipase", "were", "significantly", "reduced", "after", "nutritional", "intervention", "compared", "with", "their", "levels", "on", "day", "1", "before", "intervention", "in", "all", "three", "groups", ".", "The", "plasma", "IL-8", ",", "TNF", "-", "α", ",", "CRP", ",", "lipase", ",", "LDH", "at", "14", "days", "after", "intervention", "of", "nutrition", "in", "P+EN", "group", "were", "significantly", "lower", "than", "those", "in", "PN", "group", "and", "EN", "group", "(", "IL-8", ":", "21.00", "±", "7.07", "μg", "/", "L", "vs", ".", "48.00", "±", "10.32", "μg", "/", "L", ",", "32.00", "±", "9.30", "μg", "/", "L", ";", "TNF", "-", "α", ":", "44.3", "±", "10.9", "ng", "/", "L", "vs", ".", "132.1", "±", "34.1", "ng", "/", "L", ",", "67.8", "±", "22.3", "ng", "/", "L", ";", "CRP", ":", "35.0", "±", "12.4", "mg", "/", "L", "vs", ".", "103.2", "±", "49.2", "mg", "/", "L", ",", "63.0", "±", "29.2", "mg", "/", "L", ";", "lipase", ":", "269", "±", "79", "U", "/", "L", "vs", ".", "670", "±", "145", "U", "/", "L", ",", "310", "±", "78", "U", "/", "L", ";", "LDH", ":", "21.8", "±", "10.3", "U", "/", "L", "vs", ".", "78.1", "±", "37.4", "U", "/", "L", ",", "37.9", "±", "25.1", "U", "/", "L", ",", "P", "<", "0.05", "or", "P", "<", "0.01", ")", ".", "The", "WBC", "count", "in", "P+EN", "group", "was", "significantly", "lower", "than", "that", "in", "PN", "group", "(", "5.9", "±", "3.0", "×", "10⁹/L", ",", "6.3", "±", "3.2", "×", "10⁹/L", "vs", ".", "9.6", "±", "3.0", "×10⁹/L", ",", "both", "P", "<", "0.05", ")", ",", "but", "there", "was", "no", "significant", "difference", "in", "amylase", "between", "P+EN", "group", "and", "PN", "group", "(", "211", "±", "49", "U", "/", "L", ",", "236", "±", "52", "U", "/", "L", "vs", ".", "298", "±", "71", "U", "/", "L", ",", "P", ">", "0.05", ")", ".", "The", "gastrointestinal", "dysfunction", "score", "in", "P+EN", ",", "EN", ",", "PN", "groups", "14", "days", "after", "nutritional", "intervention", "was", "0.28", "±", "0.05", ",", "0.43", "±", "0.09", ",", "0.71", "±", "0.11", ",", "respectively", ",", "with", "statistically", "significant", "differences", "(", "all", "P", "<", "0.01", ")", ".", "Compared", "with", "PN", "and", "EN", "groups", ",", "the", "incidence", "of", "upper", "gastrointestinal", "bleeding", "(", "1", "vs", ".", "9", ",", "2", ")", ",", "infection", "and", "abscess", "(", "2", "vs", ".", "12", ",", "5", ")", "was", "lower", "(", "all", "P", "<", "0.01", ")", ",", "and", "hospital", "day", "was", "significantly", "shortened", "in", "P+EN", "group", "(", "10.4", "±", "3.9", "days", "vs", ".", "25.8", "±", "6.4", "days", ",", "13.4", "±", "5.2", "days", ",", "both", "P", "<", "0.01", ")", ".", "There", "was", "no", "significant", "statistical", "difference", "in", "mortality", "rate", "among", "three", "groups", ".", "CONCLUSION", "Our", "results", "indicated", "that", "early", "EN", "with", "addition", "of", "probiotics", "(", "bifidobacterium", ")", "resulted", "in", "significant", "lowering", "of", "the", "level", "of", "pro", "-", "inflammatory", "cytokines", ",", "earlier", "restoration", "of", "gastrointestinal", "function", ",", "decrease", "of", "complications", "such", "as", "infection", ",", "and", "shortening", "of", "hospital", "day", "in", "patients", "with", "SAP", "." ]

[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Adverse-effects", "Outcome_Physical", "Participant_Sample-size" ]

adapalene is a CHEMICAL

9990413_task0

Sentence: Pharmacology of adapalene. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL

[ "O", "O", "B-CHEMICAL", "O" ]

Pharmacology of adapalene.

[ "Pharmacology", "of", "adapalene", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

adapalene is a CHEMICAL

9990413_task1

Sentence: Pharmacology of adapalene. Instructions: please typing these entity words according to sentence: adapalene Options: CHEMICAL

[ "O", "O", "B-CHEMICAL", "O" ]

Pharmacology of adapalene.

[ "Pharmacology", "of", "adapalene", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

adapalene

9990413_task2

Sentence: Pharmacology of adapalene. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-CHEMICAL", "O" ]

Pharmacology of adapalene.

[ "Pharmacology", "of", "adapalene", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

Daniel is a NOMBRE_SUJETO_ASISTENCIA, Perea Dominguez is a NOMBRE_SUJETO_ASISTENCIA, 7842356 is a ID_SUJETO_ASISTENCIA, Madrid is a TERRITORIO, 28001 is a TERRITORIO, 30/03/2017 is a FECHAS, España is a PAIS, 26 dias is a EDAD_SUJETO_ASISTENCIA, 25/04/2017 is a FECHAS, Jose Luis Fernandez Copado is a NOMBRE_PERSONAL_SANITARIO, 28 28 93020 is a ID_TITULACION_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, 26 días is a EDAD_SUJETO_ASISTENCIA, tres semanas is a EDAD_SUJETO_ASISTENCIA, madre is a FAMILIARES_SUJETO_ASISTENCIA, Jose Luis Fernandez Copado is a NOMBRE_PERSONAL_SANITARIO, a00799839@itesm.com is a CORREO_ELECTRONICO

470_task0

Sentence: Datos del paciente. Nombre: Daniel. Apellidos: Perea Dominguez. NHC: 7842356. Domicilio: Calle Conde Duque,19, 3A. Localidad/ Provincia: Madrid. CP: 28001. Datos asistenciales. Fecha de nacimiento: 30/03/2017. País: España. Edad: 26 dias Sexo: H. Fecha de Ingreso: 25/04/2017. Médico: Jose Luis Fernandez Copado. NºCol: 28 28 93020. Informe clínico del paciente:Varón de 26 días de vida sin antecedentes familiares, prenatales o perinatales de relevancia. Hacia las tres semanas de vida comienza a presentar vómitos, que fueron en aumento, y el día previo a su ingreso se presentaron con cada toma, abundantes y en proyectil. El paciente se mostraba ávido por comer y con buen estado general. Al presentarse en el Departamento de Urgencias, se tuvo la sospecha clínica de estenosis hipertrófica de píloro, apoyada por una gasometría que mostraba alcalosis metabólica y un ultrasonido con imagen en diana característica. El paciente fue intervenido de forma abierta mediante la técnica de Ramstedt, sin incidencias. Antes del procedimiento el paciente fue intubado sin complicaciones. A las 14 horas de la cirugía se escucha por primera vez estridor de predominio inspiratorio, que no se modificaba con el sueño, la posición ni con la alimentación. Se reinterrogó a la madre, que negó haberlo escuchado antes. El paciente no presentaba ningún dato de dificultad respiratoria ni desaturación del oxígeno en la pulsioximetría. Dado que se trataba de un paciente previamente sano al que no se le había escuchado estridor antes, se sospechó que la intubación operatoria y el edema postraumático asociado pudieran ser la causa. Se administró nebulización con adrenalina y una dosis de dexametasona intravenosa. Tras dos horas, el estridor no se había modificado, y al continuar el paciente sin signos de dificultad respiratoria, se inició el abordaje de este problema. En una radiografía simple de tórax no se observaron anormalidades en el parénquima pulmonar, estructuras del cuello o columna de aire traqueal. Posteriormente, mediante una nasolaringoendoscopia flexible se comprobaron las estructuras supraglóticas y las cuerdas vocales íntegras, sin alteraciones morfológicas ni movimientos anormales. El siguiente paso fue la realización de una serie fluoroscópica con contraste oral, que demostró una muesca en la pared posterior del tercio superior del esófago. Durante ese tiempo el paciente no mostró cambios en su sintomatología. Tras la cirugía de píloro no había vuelto a presentar vómitos. En ningún momento presentó datos de dificultad respiratoria asociados al estridor. Días después se realizó una broncoscopia, en la que se observó una compresión extrínseca 2 cm por encima de la carina, pulsátil, que obstruía más del 50% de la luz de la tráquea y no se modificaba con presión positiva. Ante la fuerte sospecha de una malformación vascular que fuera responsable de la disminución del calibre traqueal, se realizó una angiografía por tomografía computarizada (angio-TC), en la que se pudo identificar un doble arco aórtico completo, con predominancia del arco derecho como causa de la constricción traqueal. La ecocardiografía fue normal. El paciente fue operado por medio de una cirugía de abordaje torácico lateral izquierdo que se realizó sin contratiempos. En las primeras horas posquirúrgicas se notó una importante disminución en la intensidad del ruido inspiratorio. Fue dado de alta y durante las siguientes semanas el estridor residual continuó disminuyendo. No volvió a presentar síntomas respiratorios ni digestivos, y en una consulta de seguimiento a dos meses de la cirugía el estridor terminó por desaparecer del todo. Remitido por: Dr. Jose Luis Fernandez Copado. Correo electrónico: a00799839@itesm.com Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, FAMILIARES_SUJETO_ASISTENCIA, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Datos del paciente. Nombre: Daniel. Apellidos: Perea Dominguez. NHC: 7842356. Domicilio: Calle Conde Duque,19, 3A. Localidad/ Provincia: Madrid. CP: 28001. Datos asistenciales. Fecha de nacimiento: 30/03/2017. País: España. Edad: 26 dias Sexo: H. Fecha de Ingreso: 25/04/2017. Médico: Jose Luis Fernandez Copado. NºCol: 28 28 93020. Informe clínico del paciente:Varón de 26 días de vida sin antecedentes familiares, prenatales o perinatales de relevancia. Hacia las tres semanas de vida comienza a presentar vómitos, que fueron en aumento, y el día previo a su ingreso se presentaron con cada toma, abundantes y en proyectil. El paciente se mostraba ávido por comer y con buen estado general. Al presentarse en el Departamento de Urgencias, se tuvo la sospecha clínica de estenosis hipertrófica de píloro, apoyada por una gasometría que mostraba alcalosis metabólica y un ultrasonido con imagen en diana característica. El paciente fue intervenido de forma abierta mediante la técnica de Ramstedt, sin incidencias. Antes del procedimiento el paciente fue intubado sin complicaciones. A las 14 horas de la cirugía se escucha por primera vez estridor de predominio inspiratorio, que no se modificaba con el sueño, la posición ni con la alimentación. Se reinterrogó a la madre, que negó haberlo escuchado antes. El paciente no presentaba ningún dato de dificultad respiratoria ni desaturación del oxígeno en la pulsioximetría. Dado que se trataba de un paciente previamente sano al que no se le había escuchado estridor antes, se sospechó que la intubación operatoria y el edema postraumático asociado pudieran ser la causa. Se administró nebulización con adrenalina y una dosis de dexametasona intravenosa. Tras dos horas, el estridor no se había modificado, y al continuar el paciente sin signos de dificultad respiratoria, se inició el abordaje de este problema. En una radiografía simple de tórax no se observaron anormalidades en el parénquima pulmonar, estructuras del cuello o columna de aire traqueal. Posteriormente, mediante una nasolaringoendoscopia flexible se comprobaron las estructuras supraglóticas y las cuerdas vocales íntegras, sin alteraciones morfológicas ni movimientos anormales. El siguiente paso fue la realización de una serie fluoroscópica con contraste oral, que demostró una muesca en la pared posterior del tercio superior del esófago. Durante ese tiempo el paciente no mostró cambios en su sintomatología. Tras la cirugía de píloro no había vuelto a presentar vómitos. En ningún momento presentó datos de dificultad respiratoria asociados al estridor. Días después se realizó una broncoscopia, en la que se observó una compresión extrínseca 2 cm por encima de la carina, pulsátil, que obstruía más del 50% de la luz de la tráquea y no se modificaba con presión positiva. Ante la fuerte sospecha de una malformación vascular que fuera responsable de la disminución del calibre traqueal, se realizó una angiografía por tomografía computarizada (angio-TC), en la que se pudo identificar un doble arco aórtico completo, con predominancia del arco derecho como causa de la constricción traqueal. La ecocardiografía fue normal. El paciente fue operado por medio de una cirugía de abordaje torácico lateral izquierdo que se realizó sin contratiempos. En las primeras horas posquirúrgicas se notó una importante disminución en la intensidad del ruido inspiratorio. Fue dado de alta y durante las siguientes semanas el estridor residual continuó disminuyendo. No volvió a presentar síntomas respiratorios ni digestivos, y en una consulta de seguimiento a dos meses de la cirugía el estridor terminó por desaparecer del todo. Remitido por: Dr. Jose Luis Fernandez Copado. Correo electrónico: a00799839@itesm.com

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", " ", "Daniel", ".", "\n", "Apellidos", ":", "Perea", "Dominguez", ".", "\n", "NHC", ":", "7842356", ".", "\n", "Domicilio", ":", "Calle", "Conde", "Duque,19", ",", "3A.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28001", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "30/03/2017", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "26", "dias", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "25/04/2017", ".", "\n", "Médico", ":", "Jose", "Luis", "Fernandez", "Copado", ".", "NºCol", ":", "28", "28", "93020", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Varón", "de", "26", "días", "de", "vida", "sin", "antecedentes", "familiares", ",", "prenatales", "o", "perinatales", "de", "relevancia", ".", "Hacia", "las", "tres", "semanas", "de", "vida", "comienza", "a", "presentar", "vómitos", ",", "que", "fueron", "en", "aumento", ",", "y", "el", "día", "previo", "a", "su", "ingreso", "se", "presentaron", "con", "cada", "toma", ",", "abundantes", "y", "en", "proyectil", ".", "El", "paciente", "se", "mostraba", "ávido", "por", "comer", "y", "con", "buen", "estado", "general", ".", "\n", "Al", "presentarse", "en", "el", "Departamento", "de", "Urgencias", ",", "se", "tuvo", "la", "sospecha", "clínica", "de", "estenosis", "hipertrófica", "de", "píloro", ",", "apoyada", "por", "una", "gasometría", "que", "mostraba", "alcalosis", "metabólica", "y", "un", "ultrasonido", "con", "imagen", "en", "diana", "característica", ".", "El", "paciente", "fue", "intervenido", "de", "forma", "abierta", "mediante", "la", "técnica", "de", "Ramstedt", ",", "sin", "incidencias", ".", "Antes", "del", "procedimiento", "el", "paciente", "fue", "intubado", "sin", "complicaciones", ".", "\n", "A", "las", "14", "horas", "de", "la", "cirugía", "se", "escucha", "por", "primera", "vez", "estridor", "de", "predominio", "inspiratorio", ",", "que", "no", "se", "modificaba", "con", "el", "sueño", ",", "la", "posición", "ni", "con", "la", "alimentación", ".", "Se", "reinterrogó", "a", "la", "madre", ",", "que", "negó", "haberlo", "escuchado", "antes", ".", "El", "paciente", "no", "presentaba", "ningún", "dato", "de", "dificultad", "respiratoria", "ni", "desaturación", "del", "oxígeno", "en", "la", "pulsioximetría", ".", "\n", "Dado", "que", "se", "trataba", "de", "un", "paciente", "previamente", "sano", "al", "que", "no", "se", "le", "había", "escuchado", "estridor", "antes", ",", "se", "sospechó", "que", "la", "intubación", "operatoria", "y", "el", "edema", "postraumático", "asociado", "pudieran", "ser", "la", "causa", ".", "Se", "administró", "nebulización", "con", "adrenalina", "y", "una", "dosis", "de", "dexametasona", "intravenosa", ".", "Tras", "dos", "horas", ",", "el", "estridor", "no", "se", "había", "modificado", ",", "y", "al", "continuar", "el", "paciente", "sin", "signos", "de", "dificultad", "respiratoria", ",", "se", "inició", "el", "abordaje", "de", "este", "problema", ".", "\n", "En", "una", "radiografía", "simple", "de", "tórax", "no", "se", "observaron", "anormalidades", "en", "el", "parénquima", "pulmonar", ",", "estructuras", "del", "cuello", "o", "columna", "de", "aire", "traqueal", ".", "Posteriormente", ",", "mediante", "una", "nasolaringoendoscopia", "flexible", "se", "comprobaron", "las", "estructuras", "supraglóticas", "y", "las", "cuerdas", "vocales", "íntegras", ",", "sin", "alteraciones", "morfológicas", "ni", "movimientos", "anormales", ".", "El", "siguiente", "paso", "fue", "la", "realización", "de", "una", "serie", "fluoroscópica", "con", "contraste", "oral", ",", "que", "demostró", "una", "muesca", "en", "la", "pared", "posterior", "del", "tercio", "superior", "del", "esófago", ".", "Durante", "ese", "tiempo", "el", "paciente", "no", "mostró", "cambios", "en", "su", "sintomatología", ".", "Tras", "la", "cirugía", "de", "píloro", "no", "había", "vuelto", "a", "presentar", "vómitos", ".", "En", "ningún", "momento", "presentó", "datos", "de", "dificultad", "respiratoria", "asociados", "al", "estridor", ".", "\n", "Días", "después", "se", "realizó", "una", "broncoscopia", ",", "en", "la", "que", "se", "observó", "una", "compresión", "extrínseca", "2", "cm", "por", "encima", "de", "la", "carina", ",", "pulsátil", ",", "que", "obstruía", "más", "del", "50", "%", "de", "la", "luz", "de", "la", "tráquea", "y", "no", "se", "modificaba", "con", "presión", "positiva", ".", "Ante", "la", "fuerte", "sospecha", "de", "una", "malformación", "vascular", "que", "fuera", "responsable", "de", "la", "disminución", "del", "calibre", "traqueal", ",", "se", "realizó", "una", "angiografía", "por", "tomografía", "computarizada", "(", "angio", "-", "TC", ")", ",", "en", "la", "que", "se", "pudo", "identificar", "un", "doble", "arco", "aórtico", "completo", ",", "con", "predominancia", "del", "arco", "derecho", "como", "causa", "de", "la", "constricción", "traqueal", ".", "La", "ecocardiografía", "fue", "normal", ".", "\n", "El", "paciente", "fue", "operado", "por", "medio", "de", "una", "cirugía", "de", "abordaje", "torácico", "lateral", "izquierdo", "que", "se", "realizó", "sin", "contratiempos", ".", "\n", "En", "las", "primeras", "horas", "posquirúrgicas", "se", "notó", "una", "importante", "disminución", "en", "la", "intensidad", "del", "ruido", "inspiratorio", ".", "Fue", "dado", "de", "alta", "y", "durante", "las", "siguientes", "semanas", "el", "estridor", "residual", "continuó", "disminuyendo", ".", "No", "volvió", "a", "presentar", "síntomas", "respiratorios", "ni", "digestivos", ",", "y", "en", "una", "consulta", "de", "seguimiento", "a", "dos", "meses", "de", "la", "cirugía", "el", "estridor", "terminó", "por", "desaparecer", "del", "todo", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Jose", "Luis", "Fernandez", "Copado", ".", "Correo", "electrónico", ":", "a00799839@itesm.com", "\n" ]

[ "NOMBRE_PERSONAL_SANITARIO", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_SUJETO_ASISTENCIA", "EDAD_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "FAMILIARES_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA" ]

Daniel is a NOMBRE_SUJETO_ASISTENCIA, Perea Dominguez is a NOMBRE_SUJETO_ASISTENCIA, 7842356 is a ID_SUJETO_ASISTENCIA, Madrid is a TERRITORIO, 28001 is a TERRITORIO, 30/03/2017 is a FECHAS, España is a PAIS, 26 dias is a EDAD_SUJETO_ASISTENCIA, 25/04/2017 is a FECHAS, Jose Luis Fernandez Copado is a NOMBRE_PERSONAL_SANITARIO, 28 28 93020 is a ID_TITULACION_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, 26 días is a EDAD_SUJETO_ASISTENCIA, tres semanas is a EDAD_SUJETO_ASISTENCIA, madre is a FAMILIARES_SUJETO_ASISTENCIA, Jose Luis Fernandez Copado is a NOMBRE_PERSONAL_SANITARIO, a00799839@itesm.com is a CORREO_ELECTRONICO

470_task1

Sentence: Datos del paciente. Nombre: Daniel. Apellidos: Perea Dominguez. NHC: 7842356. Domicilio: Calle Conde Duque,19, 3A. Localidad/ Provincia: Madrid. CP: 28001. Datos asistenciales. Fecha de nacimiento: 30/03/2017. País: España. Edad: 26 dias Sexo: H. Fecha de Ingreso: 25/04/2017. Médico: Jose Luis Fernandez Copado. NºCol: 28 28 93020. Informe clínico del paciente:Varón de 26 días de vida sin antecedentes familiares, prenatales o perinatales de relevancia. Hacia las tres semanas de vida comienza a presentar vómitos, que fueron en aumento, y el día previo a su ingreso se presentaron con cada toma, abundantes y en proyectil. El paciente se mostraba ávido por comer y con buen estado general. Al presentarse en el Departamento de Urgencias, se tuvo la sospecha clínica de estenosis hipertrófica de píloro, apoyada por una gasometría que mostraba alcalosis metabólica y un ultrasonido con imagen en diana característica. El paciente fue intervenido de forma abierta mediante la técnica de Ramstedt, sin incidencias. Antes del procedimiento el paciente fue intubado sin complicaciones. A las 14 horas de la cirugía se escucha por primera vez estridor de predominio inspiratorio, que no se modificaba con el sueño, la posición ni con la alimentación. Se reinterrogó a la madre, que negó haberlo escuchado antes. El paciente no presentaba ningún dato de dificultad respiratoria ni desaturación del oxígeno en la pulsioximetría. Dado que se trataba de un paciente previamente sano al que no se le había escuchado estridor antes, se sospechó que la intubación operatoria y el edema postraumático asociado pudieran ser la causa. Se administró nebulización con adrenalina y una dosis de dexametasona intravenosa. Tras dos horas, el estridor no se había modificado, y al continuar el paciente sin signos de dificultad respiratoria, se inició el abordaje de este problema. En una radiografía simple de tórax no se observaron anormalidades en el parénquima pulmonar, estructuras del cuello o columna de aire traqueal. Posteriormente, mediante una nasolaringoendoscopia flexible se comprobaron las estructuras supraglóticas y las cuerdas vocales íntegras, sin alteraciones morfológicas ni movimientos anormales. El siguiente paso fue la realización de una serie fluoroscópica con contraste oral, que demostró una muesca en la pared posterior del tercio superior del esófago. Durante ese tiempo el paciente no mostró cambios en su sintomatología. Tras la cirugía de píloro no había vuelto a presentar vómitos. En ningún momento presentó datos de dificultad respiratoria asociados al estridor. Días después se realizó una broncoscopia, en la que se observó una compresión extrínseca 2 cm por encima de la carina, pulsátil, que obstruía más del 50% de la luz de la tráquea y no se modificaba con presión positiva. Ante la fuerte sospecha de una malformación vascular que fuera responsable de la disminución del calibre traqueal, se realizó una angiografía por tomografía computarizada (angio-TC), en la que se pudo identificar un doble arco aórtico completo, con predominancia del arco derecho como causa de la constricción traqueal. La ecocardiografía fue normal. El paciente fue operado por medio de una cirugía de abordaje torácico lateral izquierdo que se realizó sin contratiempos. En las primeras horas posquirúrgicas se notó una importante disminución en la intensidad del ruido inspiratorio. Fue dado de alta y durante las siguientes semanas el estridor residual continuó disminuyendo. No volvió a presentar síntomas respiratorios ni digestivos, y en una consulta de seguimiento a dos meses de la cirugía el estridor terminó por desaparecer del todo. Remitido por: Dr. Jose Luis Fernandez Copado. Correo electrónico: a00799839@itesm.com Instructions: please typing these entity words according to sentence: Daniel, Perea Dominguez, 7842356, Madrid, 28001, 30/03/2017, España, 26 dias, 25/04/2017, Jose Luis Fernandez Copado, 28 28 93020, Varón, 26 días, tres semanas, madre, Jose Luis Fernandez Copado, a00799839@itesm.com Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, FAMILIARES_SUJETO_ASISTENCIA, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Datos del paciente. Nombre: Daniel. Apellidos: Perea Dominguez. NHC: 7842356. Domicilio: Calle Conde Duque,19, 3A. Localidad/ Provincia: Madrid. CP: 28001. Datos asistenciales. Fecha de nacimiento: 30/03/2017. País: España. Edad: 26 dias Sexo: H. Fecha de Ingreso: 25/04/2017. Médico: Jose Luis Fernandez Copado. NºCol: 28 28 93020. Informe clínico del paciente:Varón de 26 días de vida sin antecedentes familiares, prenatales o perinatales de relevancia. Hacia las tres semanas de vida comienza a presentar vómitos, que fueron en aumento, y el día previo a su ingreso se presentaron con cada toma, abundantes y en proyectil. El paciente se mostraba ávido por comer y con buen estado general. Al presentarse en el Departamento de Urgencias, se tuvo la sospecha clínica de estenosis hipertrófica de píloro, apoyada por una gasometría que mostraba alcalosis metabólica y un ultrasonido con imagen en diana característica. El paciente fue intervenido de forma abierta mediante la técnica de Ramstedt, sin incidencias. Antes del procedimiento el paciente fue intubado sin complicaciones. A las 14 horas de la cirugía se escucha por primera vez estridor de predominio inspiratorio, que no se modificaba con el sueño, la posición ni con la alimentación. Se reinterrogó a la madre, que negó haberlo escuchado antes. El paciente no presentaba ningún dato de dificultad respiratoria ni desaturación del oxígeno en la pulsioximetría. Dado que se trataba de un paciente previamente sano al que no se le había escuchado estridor antes, se sospechó que la intubación operatoria y el edema postraumático asociado pudieran ser la causa. Se administró nebulización con adrenalina y una dosis de dexametasona intravenosa. Tras dos horas, el estridor no se había modificado, y al continuar el paciente sin signos de dificultad respiratoria, se inició el abordaje de este problema. En una radiografía simple de tórax no se observaron anormalidades en el parénquima pulmonar, estructuras del cuello o columna de aire traqueal. Posteriormente, mediante una nasolaringoendoscopia flexible se comprobaron las estructuras supraglóticas y las cuerdas vocales íntegras, sin alteraciones morfológicas ni movimientos anormales. El siguiente paso fue la realización de una serie fluoroscópica con contraste oral, que demostró una muesca en la pared posterior del tercio superior del esófago. Durante ese tiempo el paciente no mostró cambios en su sintomatología. Tras la cirugía de píloro no había vuelto a presentar vómitos. En ningún momento presentó datos de dificultad respiratoria asociados al estridor. Días después se realizó una broncoscopia, en la que se observó una compresión extrínseca 2 cm por encima de la carina, pulsátil, que obstruía más del 50% de la luz de la tráquea y no se modificaba con presión positiva. Ante la fuerte sospecha de una malformación vascular que fuera responsable de la disminución del calibre traqueal, se realizó una angiografía por tomografía computarizada (angio-TC), en la que se pudo identificar un doble arco aórtico completo, con predominancia del arco derecho como causa de la constricción traqueal. La ecocardiografía fue normal. El paciente fue operado por medio de una cirugía de abordaje torácico lateral izquierdo que se realizó sin contratiempos. En las primeras horas posquirúrgicas se notó una importante disminución en la intensidad del ruido inspiratorio. Fue dado de alta y durante las siguientes semanas el estridor residual continuó disminuyendo. No volvió a presentar síntomas respiratorios ni digestivos, y en una consulta de seguimiento a dos meses de la cirugía el estridor terminó por desaparecer del todo. Remitido por: Dr. Jose Luis Fernandez Copado. Correo electrónico: a00799839@itesm.com

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", " ", "Daniel", ".", "\n", "Apellidos", ":", "Perea", "Dominguez", ".", "\n", "NHC", ":", "7842356", ".", "\n", "Domicilio", ":", "Calle", "Conde", "Duque,19", ",", "3A.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28001", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "30/03/2017", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "26", "dias", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "25/04/2017", ".", "\n", "Médico", ":", "Jose", "Luis", "Fernandez", "Copado", ".", "NºCol", ":", "28", "28", "93020", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Varón", "de", "26", "días", "de", "vida", "sin", "antecedentes", "familiares", ",", "prenatales", "o", "perinatales", "de", "relevancia", ".", "Hacia", "las", "tres", "semanas", "de", "vida", "comienza", "a", "presentar", "vómitos", ",", "que", "fueron", "en", "aumento", ",", "y", "el", "día", "previo", "a", "su", "ingreso", "se", "presentaron", "con", "cada", "toma", ",", "abundantes", "y", "en", "proyectil", ".", "El", "paciente", "se", "mostraba", "ávido", "por", "comer", "y", "con", "buen", "estado", "general", ".", "\n", "Al", "presentarse", "en", "el", "Departamento", "de", "Urgencias", ",", "se", "tuvo", "la", "sospecha", "clínica", "de", "estenosis", "hipertrófica", "de", "píloro", ",", "apoyada", "por", "una", "gasometría", "que", "mostraba", "alcalosis", "metabólica", "y", "un", "ultrasonido", "con", "imagen", "en", "diana", "característica", ".", "El", "paciente", "fue", "intervenido", "de", "forma", "abierta", "mediante", "la", "técnica", "de", "Ramstedt", ",", "sin", "incidencias", ".", "Antes", "del", "procedimiento", "el", "paciente", "fue", "intubado", "sin", "complicaciones", ".", "\n", "A", "las", "14", "horas", "de", "la", "cirugía", "se", "escucha", "por", "primera", "vez", "estridor", "de", "predominio", "inspiratorio", ",", "que", "no", "se", "modificaba", "con", "el", "sueño", ",", "la", "posición", "ni", "con", "la", "alimentación", ".", "Se", "reinterrogó", "a", "la", "madre", ",", "que", "negó", "haberlo", "escuchado", "antes", ".", "El", "paciente", "no", "presentaba", "ningún", "dato", "de", "dificultad", "respiratoria", "ni", "desaturación", "del", "oxígeno", "en", "la", "pulsioximetría", ".", "\n", "Dado", "que", "se", "trataba", "de", "un", "paciente", "previamente", "sano", "al", "que", "no", "se", "le", "había", "escuchado", "estridor", "antes", ",", "se", "sospechó", "que", "la", "intubación", "operatoria", "y", "el", "edema", "postraumático", "asociado", "pudieran", "ser", "la", "causa", ".", "Se", "administró", "nebulización", "con", "adrenalina", "y", "una", "dosis", "de", "dexametasona", "intravenosa", ".", "Tras", "dos", "horas", ",", "el", "estridor", "no", "se", "había", "modificado", ",", "y", "al", "continuar", "el", "paciente", "sin", "signos", "de", "dificultad", "respiratoria", ",", "se", "inició", "el", "abordaje", "de", "este", "problema", ".", "\n", "En", "una", "radiografía", "simple", "de", "tórax", "no", "se", "observaron", "anormalidades", "en", "el", "parénquima", "pulmonar", ",", "estructuras", "del", "cuello", "o", "columna", "de", "aire", "traqueal", ".", "Posteriormente", ",", "mediante", "una", "nasolaringoendoscopia", "flexible", "se", "comprobaron", "las", "estructuras", "supraglóticas", "y", "las", "cuerdas", "vocales", "íntegras", ",", "sin", "alteraciones", "morfológicas", "ni", "movimientos", "anormales", ".", "El", "siguiente", "paso", "fue", "la", "realización", "de", "una", "serie", "fluoroscópica", "con", "contraste", "oral", ",", "que", "demostró", "una", "muesca", "en", "la", "pared", "posterior", "del", "tercio", "superior", "del", "esófago", ".", "Durante", "ese", "tiempo", "el", "paciente", "no", "mostró", "cambios", "en", "su", "sintomatología", ".", "Tras", "la", "cirugía", "de", "píloro", "no", "había", "vuelto", "a", "presentar", "vómitos", ".", "En", "ningún", "momento", "presentó", "datos", "de", "dificultad", "respiratoria", "asociados", "al", "estridor", ".", "\n", "Días", "después", "se", "realizó", "una", "broncoscopia", ",", "en", "la", "que", "se", "observó", "una", "compresión", "extrínseca", "2", "cm", "por", "encima", "de", "la", "carina", ",", "pulsátil", ",", "que", "obstruía", "más", "del", "50", "%", "de", "la", "luz", "de", "la", "tráquea", "y", "no", "se", "modificaba", "con", "presión", "positiva", ".", "Ante", "la", "fuerte", "sospecha", "de", "una", "malformación", "vascular", "que", "fuera", "responsable", "de", "la", "disminución", "del", "calibre", "traqueal", ",", "se", "realizó", "una", "angiografía", "por", "tomografía", "computarizada", "(", "angio", "-", "TC", ")", ",", "en", "la", "que", "se", "pudo", "identificar", "un", "doble", "arco", "aórtico", "completo", ",", "con", "predominancia", "del", "arco", "derecho", "como", "causa", "de", "la", "constricción", "traqueal", ".", "La", "ecocardiografía", "fue", "normal", ".", "\n", "El", "paciente", "fue", "operado", "por", "medio", "de", "una", "cirugía", "de", "abordaje", "torácico", "lateral", "izquierdo", "que", "se", "realizó", "sin", "contratiempos", ".", "\n", "En", "las", "primeras", "horas", "posquirúrgicas", "se", "notó", "una", "importante", "disminución", "en", "la", "intensidad", "del", "ruido", "inspiratorio", ".", "Fue", "dado", "de", "alta", "y", "durante", "las", "siguientes", "semanas", "el", "estridor", "residual", "continuó", "disminuyendo", ".", "No", "volvió", "a", "presentar", "síntomas", "respiratorios", "ni", "digestivos", ",", "y", "en", "una", "consulta", "de", "seguimiento", "a", "dos", "meses", "de", "la", "cirugía", "el", "estridor", "terminó", "por", "desaparecer", "del", "todo", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Jose", "Luis", "Fernandez", "Copado", ".", "Correo", "electrónico", ":", "a00799839@itesm.com", "\n" ]

[ "NOMBRE_PERSONAL_SANITARIO", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_SUJETO_ASISTENCIA", "EDAD_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "FAMILIARES_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA" ]

Daniel, Perea Dominguez, 7842356, Madrid, 28001, 30/03/2017, España, 26 dias, 25/04/2017, Jose Luis Fernandez Copado, 28 28 93020, Varón, 26 días, tres semanas, madre, Jose Luis Fernandez Copado, a00799839@itesm.com

470_task2

Sentence: Datos del paciente. Nombre: Daniel. Apellidos: Perea Dominguez. NHC: 7842356. Domicilio: Calle Conde Duque,19, 3A. Localidad/ Provincia: Madrid. CP: 28001. Datos asistenciales. Fecha de nacimiento: 30/03/2017. País: España. Edad: 26 dias Sexo: H. Fecha de Ingreso: 25/04/2017. Médico: Jose Luis Fernandez Copado. NºCol: 28 28 93020. Informe clínico del paciente:Varón de 26 días de vida sin antecedentes familiares, prenatales o perinatales de relevancia. Hacia las tres semanas de vida comienza a presentar vómitos, que fueron en aumento, y el día previo a su ingreso se presentaron con cada toma, abundantes y en proyectil. El paciente se mostraba ávido por comer y con buen estado general. Al presentarse en el Departamento de Urgencias, se tuvo la sospecha clínica de estenosis hipertrófica de píloro, apoyada por una gasometría que mostraba alcalosis metabólica y un ultrasonido con imagen en diana característica. El paciente fue intervenido de forma abierta mediante la técnica de Ramstedt, sin incidencias. Antes del procedimiento el paciente fue intubado sin complicaciones. A las 14 horas de la cirugía se escucha por primera vez estridor de predominio inspiratorio, que no se modificaba con el sueño, la posición ni con la alimentación. Se reinterrogó a la madre, que negó haberlo escuchado antes. El paciente no presentaba ningún dato de dificultad respiratoria ni desaturación del oxígeno en la pulsioximetría. Dado que se trataba de un paciente previamente sano al que no se le había escuchado estridor antes, se sospechó que la intubación operatoria y el edema postraumático asociado pudieran ser la causa. Se administró nebulización con adrenalina y una dosis de dexametasona intravenosa. Tras dos horas, el estridor no se había modificado, y al continuar el paciente sin signos de dificultad respiratoria, se inició el abordaje de este problema. En una radiografía simple de tórax no se observaron anormalidades en el parénquima pulmonar, estructuras del cuello o columna de aire traqueal. Posteriormente, mediante una nasolaringoendoscopia flexible se comprobaron las estructuras supraglóticas y las cuerdas vocales íntegras, sin alteraciones morfológicas ni movimientos anormales. El siguiente paso fue la realización de una serie fluoroscópica con contraste oral, que demostró una muesca en la pared posterior del tercio superior del esófago. Durante ese tiempo el paciente no mostró cambios en su sintomatología. Tras la cirugía de píloro no había vuelto a presentar vómitos. En ningún momento presentó datos de dificultad respiratoria asociados al estridor. Días después se realizó una broncoscopia, en la que se observó una compresión extrínseca 2 cm por encima de la carina, pulsátil, que obstruía más del 50% de la luz de la tráquea y no se modificaba con presión positiva. Ante la fuerte sospecha de una malformación vascular que fuera responsable de la disminución del calibre traqueal, se realizó una angiografía por tomografía computarizada (angio-TC), en la que se pudo identificar un doble arco aórtico completo, con predominancia del arco derecho como causa de la constricción traqueal. La ecocardiografía fue normal. El paciente fue operado por medio de una cirugía de abordaje torácico lateral izquierdo que se realizó sin contratiempos. En las primeras horas posquirúrgicas se notó una importante disminución en la intensidad del ruido inspiratorio. Fue dado de alta y durante las siguientes semanas el estridor residual continuó disminuyendo. No volvió a presentar síntomas respiratorios ni digestivos, y en una consulta de seguimiento a dos meses de la cirugía el estridor terminó por desaparecer del todo. Remitido por: Dr. Jose Luis Fernandez Copado. Correo electrónico: a00799839@itesm.com Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Datos del paciente. Nombre: Daniel. Apellidos: Perea Dominguez. NHC: 7842356. Domicilio: Calle Conde Duque,19, 3A. Localidad/ Provincia: Madrid. CP: 28001. Datos asistenciales. Fecha de nacimiento: 30/03/2017. País: España. Edad: 26 dias Sexo: H. Fecha de Ingreso: 25/04/2017. Médico: Jose Luis Fernandez Copado. NºCol: 28 28 93020. Informe clínico del paciente:Varón de 26 días de vida sin antecedentes familiares, prenatales o perinatales de relevancia. Hacia las tres semanas de vida comienza a presentar vómitos, que fueron en aumento, y el día previo a su ingreso se presentaron con cada toma, abundantes y en proyectil. El paciente se mostraba ávido por comer y con buen estado general. Al presentarse en el Departamento de Urgencias, se tuvo la sospecha clínica de estenosis hipertrófica de píloro, apoyada por una gasometría que mostraba alcalosis metabólica y un ultrasonido con imagen en diana característica. El paciente fue intervenido de forma abierta mediante la técnica de Ramstedt, sin incidencias. Antes del procedimiento el paciente fue intubado sin complicaciones. A las 14 horas de la cirugía se escucha por primera vez estridor de predominio inspiratorio, que no se modificaba con el sueño, la posición ni con la alimentación. Se reinterrogó a la madre, que negó haberlo escuchado antes. El paciente no presentaba ningún dato de dificultad respiratoria ni desaturación del oxígeno en la pulsioximetría. Dado que se trataba de un paciente previamente sano al que no se le había escuchado estridor antes, se sospechó que la intubación operatoria y el edema postraumático asociado pudieran ser la causa. Se administró nebulización con adrenalina y una dosis de dexametasona intravenosa. Tras dos horas, el estridor no se había modificado, y al continuar el paciente sin signos de dificultad respiratoria, se inició el abordaje de este problema. En una radiografía simple de tórax no se observaron anormalidades en el parénquima pulmonar, estructuras del cuello o columna de aire traqueal. Posteriormente, mediante una nasolaringoendoscopia flexible se comprobaron las estructuras supraglóticas y las cuerdas vocales íntegras, sin alteraciones morfológicas ni movimientos anormales. El siguiente paso fue la realización de una serie fluoroscópica con contraste oral, que demostró una muesca en la pared posterior del tercio superior del esófago. Durante ese tiempo el paciente no mostró cambios en su sintomatología. Tras la cirugía de píloro no había vuelto a presentar vómitos. En ningún momento presentó datos de dificultad respiratoria asociados al estridor. Días después se realizó una broncoscopia, en la que se observó una compresión extrínseca 2 cm por encima de la carina, pulsátil, que obstruía más del 50% de la luz de la tráquea y no se modificaba con presión positiva. Ante la fuerte sospecha de una malformación vascular que fuera responsable de la disminución del calibre traqueal, se realizó una angiografía por tomografía computarizada (angio-TC), en la que se pudo identificar un doble arco aórtico completo, con predominancia del arco derecho como causa de la constricción traqueal. La ecocardiografía fue normal. El paciente fue operado por medio de una cirugía de abordaje torácico lateral izquierdo que se realizó sin contratiempos. En las primeras horas posquirúrgicas se notó una importante disminución en la intensidad del ruido inspiratorio. Fue dado de alta y durante las siguientes semanas el estridor residual continuó disminuyendo. No volvió a presentar síntomas respiratorios ni digestivos, y en una consulta de seguimiento a dos meses de la cirugía el estridor terminó por desaparecer del todo. Remitido por: Dr. Jose Luis Fernandez Copado. Correo electrónico: a00799839@itesm.com

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", " ", "Daniel", ".", "\n", "Apellidos", ":", "Perea", "Dominguez", ".", "\n", "NHC", ":", "7842356", ".", "\n", "Domicilio", ":", "Calle", "Conde", "Duque,19", ",", "3A.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28001", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "30/03/2017", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "26", "dias", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "25/04/2017", ".", "\n", "Médico", ":", "Jose", "Luis", "Fernandez", "Copado", ".", "NºCol", ":", "28", "28", "93020", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Varón", "de", "26", "días", "de", "vida", "sin", "antecedentes", "familiares", ",", "prenatales", "o", "perinatales", "de", "relevancia", ".", "Hacia", "las", "tres", "semanas", "de", "vida", "comienza", "a", "presentar", "vómitos", ",", "que", "fueron", "en", "aumento", ",", "y", "el", "día", "previo", "a", "su", "ingreso", "se", "presentaron", "con", "cada", "toma", ",", "abundantes", "y", "en", "proyectil", ".", "El", "paciente", "se", "mostraba", "ávido", "por", "comer", "y", "con", "buen", "estado", "general", ".", "\n", "Al", "presentarse", "en", "el", "Departamento", "de", "Urgencias", ",", "se", "tuvo", "la", "sospecha", "clínica", "de", "estenosis", "hipertrófica", "de", "píloro", ",", "apoyada", "por", "una", "gasometría", "que", "mostraba", "alcalosis", "metabólica", "y", "un", "ultrasonido", "con", "imagen", "en", "diana", "característica", ".", "El", "paciente", "fue", "intervenido", "de", "forma", "abierta", "mediante", "la", "técnica", "de", "Ramstedt", ",", "sin", "incidencias", ".", "Antes", "del", "procedimiento", "el", "paciente", "fue", "intubado", "sin", "complicaciones", ".", "\n", "A", "las", "14", "horas", "de", "la", "cirugía", "se", "escucha", "por", "primera", "vez", "estridor", "de", "predominio", "inspiratorio", ",", "que", "no", "se", "modificaba", "con", "el", "sueño", ",", "la", "posición", "ni", "con", "la", "alimentación", ".", "Se", "reinterrogó", "a", "la", "madre", ",", "que", "negó", "haberlo", "escuchado", "antes", ".", "El", "paciente", "no", "presentaba", "ningún", "dato", "de", "dificultad", "respiratoria", "ni", "desaturación", "del", "oxígeno", "en", "la", "pulsioximetría", ".", "\n", "Dado", "que", "se", "trataba", "de", "un", "paciente", "previamente", "sano", "al", "que", "no", "se", "le", "había", "escuchado", "estridor", "antes", ",", "se", "sospechó", "que", "la", "intubación", "operatoria", "y", "el", "edema", "postraumático", "asociado", "pudieran", "ser", "la", "causa", ".", "Se", "administró", "nebulización", "con", "adrenalina", "y", "una", "dosis", "de", "dexametasona", "intravenosa", ".", "Tras", "dos", "horas", ",", "el", "estridor", "no", "se", "había", "modificado", ",", "y", "al", "continuar", "el", "paciente", "sin", "signos", "de", "dificultad", "respiratoria", ",", "se", "inició", "el", "abordaje", "de", "este", "problema", ".", "\n", "En", "una", "radiografía", "simple", "de", "tórax", "no", "se", "observaron", "anormalidades", "en", "el", "parénquima", "pulmonar", ",", "estructuras", "del", "cuello", "o", "columna", "de", "aire", "traqueal", ".", "Posteriormente", ",", "mediante", "una", "nasolaringoendoscopia", "flexible", "se", "comprobaron", "las", "estructuras", "supraglóticas", "y", "las", "cuerdas", "vocales", "íntegras", ",", "sin", "alteraciones", "morfológicas", "ni", "movimientos", "anormales", ".", "El", "siguiente", "paso", "fue", "la", "realización", "de", "una", "serie", "fluoroscópica", "con", "contraste", "oral", ",", "que", "demostró", "una", "muesca", "en", "la", "pared", "posterior", "del", "tercio", "superior", "del", "esófago", ".", "Durante", "ese", "tiempo", "el", "paciente", "no", "mostró", "cambios", "en", "su", "sintomatología", ".", "Tras", "la", "cirugía", "de", "píloro", "no", "había", "vuelto", "a", "presentar", "vómitos", ".", "En", "ningún", "momento", "presentó", "datos", "de", "dificultad", "respiratoria", "asociados", "al", "estridor", ".", "\n", "Días", "después", "se", "realizó", "una", "broncoscopia", ",", "en", "la", "que", "se", "observó", "una", "compresión", "extrínseca", "2", "cm", "por", "encima", "de", "la", "carina", ",", "pulsátil", ",", "que", "obstruía", "más", "del", "50", "%", "de", "la", "luz", "de", "la", "tráquea", "y", "no", "se", "modificaba", "con", "presión", "positiva", ".", "Ante", "la", "fuerte", "sospecha", "de", "una", "malformación", "vascular", "que", "fuera", "responsable", "de", "la", "disminución", "del", "calibre", "traqueal", ",", "se", "realizó", "una", "angiografía", "por", "tomografía", "computarizada", "(", "angio", "-", "TC", ")", ",", "en", "la", "que", "se", "pudo", "identificar", "un", "doble", "arco", "aórtico", "completo", ",", "con", "predominancia", "del", "arco", "derecho", "como", "causa", "de", "la", "constricción", "traqueal", ".", "La", "ecocardiografía", "fue", "normal", ".", "\n", "El", "paciente", "fue", "operado", "por", "medio", "de", "una", "cirugía", "de", "abordaje", "torácico", "lateral", "izquierdo", "que", "se", "realizó", "sin", "contratiempos", ".", "\n", "En", "las", "primeras", "horas", "posquirúrgicas", "se", "notó", "una", "importante", "disminución", "en", "la", "intensidad", "del", "ruido", "inspiratorio", ".", "Fue", "dado", "de", "alta", "y", "durante", "las", "siguientes", "semanas", "el", "estridor", "residual", "continuó", "disminuyendo", ".", "No", "volvió", "a", "presentar", "síntomas", "respiratorios", "ni", "digestivos", ",", "y", "en", "una", "consulta", "de", "seguimiento", "a", "dos", "meses", "de", "la", "cirugía", "el", "estridor", "terminó", "por", "desaparecer", "del", "todo", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Jose", "Luis", "Fernandez", "Copado", ".", "Correo", "electrónico", ":", "a00799839@itesm.com", "\n" ]

[ "NOMBRE_PERSONAL_SANITARIO", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_SUJETO_ASISTENCIA", "EDAD_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "FAMILIARES_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA" ]

noninvasive haemoglobin measurement is a Outcome_Other, pulse oximetry is a Intervention_Physical, oximetry haemoglobin is a Outcome_Physical, infusion experiments is a Intervention_Physical

57863_task0

Sentence: Accuracy of noninvasive haemoglobin measurement by pulse oximetry depends on the type of infusion fluid . CONTEXT Measurement of blood haemoglobin concentration by pulse oximetry could be of value in determining when erythrocytes should be transfused during surgery , but the effect of infusion fluids on the results is unclear . OBJECTIVE To study the effect of crystalloid and colloid fluid on the accuracy ( bias ) and precision of pulse oximetry haemoglobin estimation to indicate the venous haemoglobin concentration in volunteers . DESIGN Open interventional crossover study . SETTING Single university hospital . PARTICIPANTS Ten male volunteers aged 18-28 ( mean 22 ) years . INTERVENTIONS Each volunteer underwent three infusion experiments on separate days and in random order . The infusions were Ringer 's acetate ( 20 ml kg ) , hydroxyethyl starch 130/0.4 ( 10 ml kg ) and a combination of both . RESULTS At the end of the infusions of Ringer 's acetate , pulse oximetry haemoglobin concentration had decreased more than the true haemoglobin concentration ( 15 vs. 8 % ; P < 0.005 ; n = 10 ) whereas starch solution decreased pulse oximetry haemoglobin concentration less than true haemoglobin concentration ( 7 vs. 11 % ; P < 0.02 ; n = 20 ) . The same differences were seen when the fluids were infused separately and when they were combined . The overall difference between all 956 pairs of pulse oximetry haemoglobin concentration and true haemoglobin concentrations ( the bias ) averaged only -0.7 g l whereas the 95 % prediction interval was wide , ranging from -24.9 to 23.7 g l. In addition to the choice of infusion fluid , the bias was strongly dependent on the volunteer ( each factor , P < 0.001 ) . CONCLUSION The bias of measuring haemoglobin concentration by pulse oximetry is dependent on whether a crystalloid or a colloid fluid is infused . TRIAL REGISTRATION ClinicalTrials identifier : NCT01195025 . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Outcome_Other, Outcome_Physical

[ "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Accuracy of noninvasive haemoglobin measurement by pulse oximetry depends on the type of infusion fluid . CONTEXT Measurement of blood haemoglobin concentration by pulse oximetry could be of value in determining when erythrocytes should be transfused during surgery , but the effect of infusion fluids on the results is unclear . OBJECTIVE To study the effect of crystalloid and colloid fluid on the accuracy ( bias ) and precision of pulse oximetry haemoglobin estimation to indicate the venous haemoglobin concentration in volunteers . DESIGN Open interventional crossover study . SETTING Single university hospital . PARTICIPANTS Ten male volunteers aged 18-28 ( mean 22 ) years . INTERVENTIONS Each volunteer underwent three infusion experiments on separate days and in random order . The infusions were Ringer 's acetate ( 20 ml kg ) , hydroxyethyl starch 130/0.4 ( 10 ml kg ) and a combination of both . RESULTS At the end of the infusions of Ringer 's acetate , pulse oximetry haemoglobin concentration had decreased more than the true haemoglobin concentration ( 15 vs. 8 % ; P < 0.005 ; n = 10 ) whereas starch solution decreased pulse oximetry haemoglobin concentration less than true haemoglobin concentration ( 7 vs. 11 % ; P < 0.02 ; n = 20 ) . The same differences were seen when the fluids were infused separately and when they were combined . The overall difference between all 956 pairs of pulse oximetry haemoglobin concentration and true haemoglobin concentrations ( the bias ) averaged only -0.7 g l whereas the 95 % prediction interval was wide , ranging from -24.9 to 23.7 g l. In addition to the choice of infusion fluid , the bias was strongly dependent on the volunteer ( each factor , P < 0.001 ) . CONCLUSION The bias of measuring haemoglobin concentration by pulse oximetry is dependent on whether a crystalloid or a colloid fluid is infused . TRIAL REGISTRATION ClinicalTrials identifier : NCT01195025 .

[ "Accuracy", "of", "noninvasive", "haemoglobin", "measurement", "by", "pulse", "oximetry", "depends", "on", "the", "type", "of", "infusion", "fluid", ".", "CONTEXT", "Measurement", "of", "blood", "haemoglobin", "concentration", "by", "pulse", "oximetry", "could", "be", "of", "value", "in", "determining", "when", "erythrocytes", "should", "be", "transfused", "during", "surgery", ",", "but", "the", "effect", "of", "infusion", "fluids", "on", "the", "results", "is", "unclear", ".", "OBJECTIVE", "To", "study", "the", "effect", "of", "crystalloid", "and", "colloid", "fluid", "on", "the", "accuracy", "(", "bias", ")", "and", "precision", "of", "pulse", "oximetry", "haemoglobin", "estimation", "to", "indicate", "the", "venous", "haemoglobin", "concentration", "in", "volunteers", ".", "DESIGN", "Open", "interventional", "crossover", "study", ".", "SETTING", "Single", "university", "hospital", ".", "PARTICIPANTS", "Ten", "male", "volunteers", "aged", "18", "-", "28", "(", "mean", "22", ")", "years", ".", "INTERVENTIONS", "Each", "volunteer", "underwent", "three", "infusion", "experiments", "on", "separate", "days", "and", "in", "random", "order", ".", "The", "infusions", "were", "Ringer", "'", "s", "acetate", "(", "20", "ml", "kg", ")", ",", "hydroxyethyl", "starch", "130/0.4", "(", "10", "ml", "kg", ")", "and", "a", "combination", "of", "both", ".", "RESULTS", "At", "the", "end", "of", "the", "infusions", "of", "Ringer", "'", "s", "acetate", ",", "pulse", "oximetry", "haemoglobin", "concentration", "had", "decreased", "more", "than", "the", "true", "haemoglobin", "concentration", "(", "15", "vs", ".", "8", "%", ";", "P", "<", "0.005", ";", "n", "=", "10", ")", "whereas", "starch", "solution", "decreased", "pulse", "oximetry", "haemoglobin", "concentration", "less", "than", "true", "haemoglobin", "concentration", "(", "7", "vs", ".", "11", "%", ";", "P", "<", "0.02", ";", "n", "=", "20", ")", ".", "The", "same", "differences", "were", "seen", "when", "the", "fluids", "were", "infused", "separately", "and", "when", "they", "were", "combined", ".", "The", "overall", "difference", "between", "all", "956", "pairs", "of", "pulse", "oximetry", "haemoglobin", "concentration", "and", "true", "haemoglobin", "concentrations", "(", "the", "bias", ")", "averaged", "only", "-0.7", "g", "l", "whereas", "the", "95", "%", "prediction", "interval", "was", "wide", ",", "ranging", "from", "-24.9", "to", "23.7", "g", "l.", "In", "addition", "to", "the", "choice", "of", "infusion", "fluid", ",", "the", "bias", "was", "strongly", "dependent", "on", "the", "volunteer", "(", "each", "factor", ",", "P", "<", "0.001", ")", ".", "CONCLUSION", "The", "bias", "of", "measuring", "haemoglobin", "concentration", "by", "pulse", "oximetry", "is", "dependent", "on", "whether", "a", "crystalloid", "or", "a", "colloid", "fluid", "is", "infused", ".", "TRIAL", "REGISTRATION", "ClinicalTrials", "identifier", ":", "NCT01195025", "." ]

[ "Outcome_Other", "Intervention_Physical", "Outcome_Physical" ]

noninvasive haemoglobin measurement is a Outcome_Other, pulse oximetry is a Intervention_Physical, oximetry haemoglobin is a Outcome_Physical, infusion experiments is a Intervention_Physical

57863_task1

Sentence: Accuracy of noninvasive haemoglobin measurement by pulse oximetry depends on the type of infusion fluid . CONTEXT Measurement of blood haemoglobin concentration by pulse oximetry could be of value in determining when erythrocytes should be transfused during surgery , but the effect of infusion fluids on the results is unclear . OBJECTIVE To study the effect of crystalloid and colloid fluid on the accuracy ( bias ) and precision of pulse oximetry haemoglobin estimation to indicate the venous haemoglobin concentration in volunteers . DESIGN Open interventional crossover study . SETTING Single university hospital . PARTICIPANTS Ten male volunteers aged 18-28 ( mean 22 ) years . INTERVENTIONS Each volunteer underwent three infusion experiments on separate days and in random order . The infusions were Ringer 's acetate ( 20 ml kg ) , hydroxyethyl starch 130/0.4 ( 10 ml kg ) and a combination of both . RESULTS At the end of the infusions of Ringer 's acetate , pulse oximetry haemoglobin concentration had decreased more than the true haemoglobin concentration ( 15 vs. 8 % ; P < 0.005 ; n = 10 ) whereas starch solution decreased pulse oximetry haemoglobin concentration less than true haemoglobin concentration ( 7 vs. 11 % ; P < 0.02 ; n = 20 ) . The same differences were seen when the fluids were infused separately and when they were combined . The overall difference between all 956 pairs of pulse oximetry haemoglobin concentration and true haemoglobin concentrations ( the bias ) averaged only -0.7 g l whereas the 95 % prediction interval was wide , ranging from -24.9 to 23.7 g l. In addition to the choice of infusion fluid , the bias was strongly dependent on the volunteer ( each factor , P < 0.001 ) . CONCLUSION The bias of measuring haemoglobin concentration by pulse oximetry is dependent on whether a crystalloid or a colloid fluid is infused . TRIAL REGISTRATION ClinicalTrials identifier : NCT01195025 . Instructions: please typing these entity words according to sentence: noninvasive haemoglobin measurement, pulse oximetry, oximetry haemoglobin, infusion experiments Options: Intervention_Physical, Outcome_Other, Outcome_Physical

[ "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Accuracy of noninvasive haemoglobin measurement by pulse oximetry depends on the type of infusion fluid . CONTEXT Measurement of blood haemoglobin concentration by pulse oximetry could be of value in determining when erythrocytes should be transfused during surgery , but the effect of infusion fluids on the results is unclear . OBJECTIVE To study the effect of crystalloid and colloid fluid on the accuracy ( bias ) and precision of pulse oximetry haemoglobin estimation to indicate the venous haemoglobin concentration in volunteers . DESIGN Open interventional crossover study . SETTING Single university hospital . PARTICIPANTS Ten male volunteers aged 18-28 ( mean 22 ) years . INTERVENTIONS Each volunteer underwent three infusion experiments on separate days and in random order . The infusions were Ringer 's acetate ( 20 ml kg ) , hydroxyethyl starch 130/0.4 ( 10 ml kg ) and a combination of both . RESULTS At the end of the infusions of Ringer 's acetate , pulse oximetry haemoglobin concentration had decreased more than the true haemoglobin concentration ( 15 vs. 8 % ; P < 0.005 ; n = 10 ) whereas starch solution decreased pulse oximetry haemoglobin concentration less than true haemoglobin concentration ( 7 vs. 11 % ; P < 0.02 ; n = 20 ) . The same differences were seen when the fluids were infused separately and when they were combined . The overall difference between all 956 pairs of pulse oximetry haemoglobin concentration and true haemoglobin concentrations ( the bias ) averaged only -0.7 g l whereas the 95 % prediction interval was wide , ranging from -24.9 to 23.7 g l. In addition to the choice of infusion fluid , the bias was strongly dependent on the volunteer ( each factor , P < 0.001 ) . CONCLUSION The bias of measuring haemoglobin concentration by pulse oximetry is dependent on whether a crystalloid or a colloid fluid is infused . TRIAL REGISTRATION ClinicalTrials identifier : NCT01195025 .

[ "Accuracy", "of", "noninvasive", "haemoglobin", "measurement", "by", "pulse", "oximetry", "depends", "on", "the", "type", "of", "infusion", "fluid", ".", "CONTEXT", "Measurement", "of", "blood", "haemoglobin", "concentration", "by", "pulse", "oximetry", "could", "be", "of", "value", "in", "determining", "when", "erythrocytes", "should", "be", "transfused", "during", "surgery", ",", "but", "the", "effect", "of", "infusion", "fluids", "on", "the", "results", "is", "unclear", ".", "OBJECTIVE", "To", "study", "the", "effect", "of", "crystalloid", "and", "colloid", "fluid", "on", "the", "accuracy", "(", "bias", ")", "and", "precision", "of", "pulse", "oximetry", "haemoglobin", "estimation", "to", "indicate", "the", "venous", "haemoglobin", "concentration", "in", "volunteers", ".", "DESIGN", "Open", "interventional", "crossover", "study", ".", "SETTING", "Single", "university", "hospital", ".", "PARTICIPANTS", "Ten", "male", "volunteers", "aged", "18", "-", "28", "(", "mean", "22", ")", "years", ".", "INTERVENTIONS", "Each", "volunteer", "underwent", "three", "infusion", "experiments", "on", "separate", "days", "and", "in", "random", "order", ".", "The", "infusions", "were", "Ringer", "'", "s", "acetate", "(", "20", "ml", "kg", ")", ",", "hydroxyethyl", "starch", "130/0.4", "(", "10", "ml", "kg", ")", "and", "a", "combination", "of", "both", ".", "RESULTS", "At", "the", "end", "of", "the", "infusions", "of", "Ringer", "'", "s", "acetate", ",", "pulse", "oximetry", "haemoglobin", "concentration", "had", "decreased", "more", "than", "the", "true", "haemoglobin", "concentration", "(", "15", "vs", ".", "8", "%", ";", "P", "<", "0.005", ";", "n", "=", "10", ")", "whereas", "starch", "solution", "decreased", "pulse", "oximetry", "haemoglobin", "concentration", "less", "than", "true", "haemoglobin", "concentration", "(", "7", "vs", ".", "11", "%", ";", "P", "<", "0.02", ";", "n", "=", "20", ")", ".", "The", "same", "differences", "were", "seen", "when", "the", "fluids", "were", "infused", "separately", "and", "when", "they", "were", "combined", ".", "The", "overall", "difference", "between", "all", "956", "pairs", "of", "pulse", "oximetry", "haemoglobin", "concentration", "and", "true", "haemoglobin", "concentrations", "(", "the", "bias", ")", "averaged", "only", "-0.7", "g", "l", "whereas", "the", "95", "%", "prediction", "interval", "was", "wide", ",", "ranging", "from", "-24.9", "to", "23.7", "g", "l.", "In", "addition", "to", "the", "choice", "of", "infusion", "fluid", ",", "the", "bias", "was", "strongly", "dependent", "on", "the", "volunteer", "(", "each", "factor", ",", "P", "<", "0.001", ")", ".", "CONCLUSION", "The", "bias", "of", "measuring", "haemoglobin", "concentration", "by", "pulse", "oximetry", "is", "dependent", "on", "whether", "a", "crystalloid", "or", "a", "colloid", "fluid", "is", "infused", ".", "TRIAL", "REGISTRATION", "ClinicalTrials", "identifier", ":", "NCT01195025", "." ]

[ "Outcome_Other", "Intervention_Physical", "Outcome_Physical" ]